assays_ASI,assays_CURAB,assays_Ti,assays_ASSTI,assays_ASSCA,assays_Descr,assays_RELATT,assays_CONSC,assays_SRI,assays_SASSI,assays_CHI,assays_CI,assays_BAFO,assays_TII,assays_VAI
1,Autocuration,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,H,8,1,,CHEMBL615117,,BAO_0000019,,
2,Autocuration,22226,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,U,0,1,,CHEMBL615118,,BAO_0000219,,
3,Autocuration,22226,,,,U,0,1,,CHEMBL615119,,BAO_0000019,,
4,Autocuration,104729,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,H,4,1,,CHEMBL615120,,BAO_0000249,,
5,Intermediate,80001,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,1,1,,CHEMBL615121,163.0,BAO_0000219,,
6,Intermediate,80001,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,1,1,,CHEMBL615122,163.0,BAO_0000219,,
7,Intermediate,80001,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,N,1,1,,CHEMBL615123,163.0,BAO_0000219,,
8,Expert,80001,,,In vitro cell cytotoxicity was determined against 143B cell line,N,1,1,,CHEMBL615124,163.0,BAO_0000219,,
9,Intermediate,80001,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,N,1,1,,CHEMBL615125,163.0,BAO_0000219,,
10,Intermediate,80001,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,1,1,,CHEMBL615126,163.0,BAO_0000219,,
11,Intermediate,80001,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,1,1,,CHEMBL615127,163.0,BAO_0000219,,
12,Expert,80001,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,N,1,1,,CHEMBL615128,163.0,BAO_0000219,,
13,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,1,1,,CHEMBL857900,,BAO_0000218,,
14,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,1,1,,CHEMBL615129,,BAO_0000218,,
15,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,1,1,,CHEMBL615130,,BAO_0000218,,
16,Intermediate,50185,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,1,1,,CHEMBL615131,,BAO_0000218,,
17,Expert,100122,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,D,9,1,,CHEMBL884521,,BAO_0000357,,
18,Autocuration,12054,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),H,8,1,,CHEMBL615132,,BAO_0000357,,
19,Autocuration,12054,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,H,8,1,,CHEMBL615133,,BAO_0000019,,
20,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,8,1,,CHEMBL615134,,BAO_0000357,,
21,Autocuration,12054,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),H,8,1,,CHEMBL615135,,BAO_0000357,,
22,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,8,1,,CHEMBL615136,,BAO_0000357,,
23,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,8,1,,CHEMBL615137,,BAO_0000357,,
24,Autocuration,12054,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,8,1,,CHEMBL615138,,BAO_0000357,,
25,Autocuration,22226,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",U,0,1,,CHEMBL836324,,BAO_0000219,,
26,Autocuration,12054,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,H,8,1,,CHEMBL615139,,BAO_0000357,,
27,Autocuration,12054,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),H,8,1,,CHEMBL615140,,BAO_0000357,,
28,Autocuration,12426,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,H,8,1,,CHEMBL615141,,BAO_0000219,,
29,Autocuration,12054,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,H,8,1,,CHEMBL615142,,BAO_0000357,,
30,Autocuration,12054,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,H,8,1,,CHEMBL615143,,BAO_0000357,,
31,Autocuration,12054,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,H,8,1,,CHEMBL615144,,BAO_0000357,,
32,Autocuration,12054,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,H,8,1,,CHEMBL872867,,BAO_0000357,,
33,Autocuration,12054,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,H,8,1,,CHEMBL615145,,BAO_0000357,,
34,Autocuration,12054,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,H,8,1,,CHEMBL615146,,BAO_0000357,,
35,Autocuration,12054,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,H,8,1,,CHEMBL615147,,BAO_0000357,,
36,Autocuration,22226,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,U,0,1,,CHEMBL615148,,BAO_0000019,,
37,Autocuration,22226,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,U,0,1,,CHEMBL615149,,BAO_0000019,,
38,Autocuration,22226,,,Dissociation constant with dimeric 16S rRNA RNA construct B,U,0,1,,CHEMBL615150,,BAO_0000019,,
39,Intermediate,22222,,,Dissociation constant towards 16S rRNA construct A,M,3,1,,CHEMBL615151,,BAO_0000225,,
40,Intermediate,22222,,,Dissociation constant towards 16S rRNA construct B,M,3,1,,CHEMBL615152,,BAO_0000225,,
41,Expert,100263,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,M,3,1,,CHEMBL615153,,BAO_0000225,,
42,Expert,100263,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,M,3,1,,CHEMBL615154,,BAO_0000225,,
43,Autocuration,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,8,1,,CHEMBL615155,,BAO_0000019,,
44,Autocuration,13053,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,8,1,,CHEMBL615156,,BAO_0000019,,
45,Autocuration,20001,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,8,1,,CHEMBL615157,,BAO_0000019,,
46,Autocuration,20001,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,8,1,,CHEMBL615158,,BAO_0000019,,
47,Expert,12971,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,9,1,,CHEMBL615159,,BAO_0000019,,
48,Expert,12971,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,9,1,,CHEMBL615172,,BAO_0000019,,
49,Expert,12971,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,9,1,,CHEMBL615173,,BAO_0000019,,
50,Expert,12971,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,9,1,,CHEMBL615174,,BAO_0000019,,
51,Autocuration,13053,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,8,1,,CHEMBL884518,,BAO_0000019,,
52,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),H,8,1,,CHEMBL615175,,BAO_0000357,,
53,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,H,8,1,,CHEMBL615176,,BAO_0000357,,
54,Autocuration,11512,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,H,8,1,,CHEMBL615177,,BAO_0000357,,
55,Autocuration,104740,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,D,5,1,,CHEMBL615178,,BAO_0000249,,
56,Intermediate,80002,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,N,1,1,,CHEMBL615179,506.0,BAO_0000219,,
57,Autocuration,104835,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,D,7,1,,CHEMBL615180,,BAO_0000219,,
58,Autocuration,104821,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,D,7,1,,CHEMBL615181,,BAO_0000219,,
59,Autocuration,104848,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,D,7,1,,CHEMBL615182,,BAO_0000219,,
60,Expert,80002,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,N,1,1,,CHEMBL615183,506.0,BAO_0000219,,
61,Intermediate,80002,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,N,1,1,,CHEMBL615184,506.0,BAO_0000219,,
62,Intermediate,80002,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,N,1,1,,CHEMBL615185,506.0,BAO_0000219,,
63,Intermediate,80002,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,N,1,1,,CHEMBL615186,506.0,BAO_0000219,,
64,Intermediate,80002,,,Effective dose of compound against replication of 1A9 cell line was evaluated,N,1,1,,CHEMBL615187,506.0,BAO_0000219,,
65,Expert,80002,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,N,1,1,,CHEMBL885343,506.0,BAO_0000219,,
66,Intermediate,80002,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),N,1,1,,CHEMBL615188,506.0,BAO_0000219,,
67,Intermediate,80002,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,N,1,1,,CHEMBL615189,506.0,BAO_0000219,,
68,Intermediate,80002,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,N,1,1,,CHEMBL615190,506.0,BAO_0000219,,
69,Intermediate,80002,,,Inhibitory activity against Taxol resistant 1A9 cell lines,N,1,1,,CHEMBL615191,506.0,BAO_0000219,,
70,Expert,80002,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,N,1,1,,CHEMBL615192,506.0,BAO_0000219,,
71,Expert,80002,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,N,1,1,,CHEMBL827083,506.0,BAO_0000219,,
72,Expert,80002,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,N,1,1,,CHEMBL615193,506.0,BAO_0000219,,
73,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,N,1,1,,CHEMBL615194,506.0,BAO_0000219,,
74,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,N,1,1,,CHEMBL615195,506.0,BAO_0000219,,
75,Intermediate,80002,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,N,1,1,,CHEMBL615196,506.0,BAO_0000219,,
76,Intermediate,81072,,,Inhibitory concentration against Jurkat cells,N,1,1,,CHEMBL615197,503.0,BAO_0000219,,
77,Intermediate,22226,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,U,0,1,,CHEMBL615198,,BAO_0000019,,
78,Expert,100121,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,D,9,1,,CHEMBL615199,,BAO_0000357,,
79,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,8,1,,CHEMBL615200,,BAO_0000357,,
80,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,8,1,,CHEMBL615201,,BAO_0000357,,
81,Expert,11231,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",H,8,1,,CHEMBL615202,,BAO_0000357,,
82,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",H,8,1,,CHEMBL615203,,BAO_0000251,,
83,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",H,8,1,,CHEMBL615204,,BAO_0000251,,
84,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",H,8,1,,CHEMBL615205,,BAO_0000251,,
85,Autocuration,11231,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",H,8,1,,CHEMBL615206,,BAO_0000251,,
86,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",H,8,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,Autocuration,11231,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",H,8,1,,CHEMBL827084,,BAO_0000019,,
88,Autocuration,11231,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",H,8,1,,CHEMBL615208,,BAO_0000019,,
89,Autocuration,11231,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",H,8,1,,CHEMBL615209,,BAO_0000019,,
90,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",D,9,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,Autocuration,12083,Liver,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,9,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,Autocuration,12083,Liver,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,9,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,Expert,11377,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),H,8,1,,CHEMBL615213,,BAO_0000357,,
94,Expert,11377,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,H,8,1,,CHEMBL615273,,BAO_0000357,,
95,Expert,81020,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,1,1,,CHEMBL615274,726.0,BAO_0000219,,
96,Intermediate,81020,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,N,1,1,,CHEMBL615275,726.0,BAO_0000219,,
97,Intermediate,81020,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,N,1,1,,CHEMBL615276,726.0,BAO_0000219,,
98,Intermediate,81020,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,N,1,1,,CHEMBL615277,726.0,BAO_0000219,,
99,Intermediate,81020,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,N,1,1,,CHEMBL615326,726.0,BAO_0000219,,
100,Expert,50606,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,1,1,,CHEMBL883130,,BAO_0000218,,
101,Intermediate,81020,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,N,1,1,,CHEMBL884519,726.0,BAO_0000219,,
102,Intermediate,81020,,,Concentration required to inhibit 50% of 2.2.15 cell line,N,1,1,,CHEMBL615327,726.0,BAO_0000219,,
103,Intermediate,81020,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,N,1,1,,CHEMBL615328,726.0,BAO_0000219,,
104,Intermediate,50587,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,N,1,1,,CHEMBL615329,,BAO_0000218,,
105,Intermediate,50587,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,N,1,1,,CHEMBL615330,,BAO_0000218,,
106,Expert,50606,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",N,1,1,,CHEMBL615331,,BAO_0000218,,
107,Intermediate,50587,,,In vitro anti-HBV activity in 2.2.15 cells,N,1,1,,CHEMBL615332,,BAO_0000218,,
108,Intermediate,50587,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,N,1,1,,CHEMBL615333,,BAO_0000218,,
109,Intermediate,50587,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,N,1,1,,CHEMBL615334,,BAO_0000218,,
110,Intermediate,50587,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,N,1,1,,CHEMBL615335,,BAO_0000218,,
111,Intermediate,50587,,,Cytotoxicity in 2.2.15 cells,N,1,1,,CHEMBL615336,,BAO_0000218,,
112,Intermediate,50587,,,Cytotoxicity in 2.2.15 cells; Not determined,N,1,1,,CHEMBL615337,,BAO_0000218,,
113,Intermediate,50587,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,N,1,1,,CHEMBL615338,,BAO_0000218,,
114,Intermediate,50587,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,N,1,1,,CHEMBL615339,,BAO_0000218,,
115,Intermediate,50587,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,N,1,1,,CHEMBL615340,,BAO_0000218,,
116,Intermediate,81020,,,Antiviral activity against HBV was determined in 2.215 cell line,N,1,1,,CHEMBL615341,726.0,BAO_0000219,,
117,Autocuration,22226,,,Inhibition of 20-HETE synthesis in human renal microsomes,U,0,1,,CHEMBL615342,,BAO_0000251,,
118,Autocuration,22226,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,U,0,1,,CHEMBL615343,,BAO_0000019,,
119,Intermediate,80612,,,Inhibitory concentration against 2008 (ovarian) cells,N,1,1,,CHEMBL615344,388.0,BAO_0000219,,
120,Intermediate,80612,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,N,1,1,,CHEMBL615345,388.0,BAO_0000219,,
121,Intermediate,80612,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),N,1,1,,CHEMBL615346,388.0,BAO_0000219,,
122,Intermediate,80612,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,N,1,1,,CHEMBL615347,388.0,BAO_0000219,,
123,Intermediate,80612,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,N,1,1,,CHEMBL615348,388.0,BAO_0000219,,
124,Intermediate,80613,,,In vitro inhibition of 2008/R ovarian cancer cell line,N,1,1,,CHEMBL827085,561.0,BAO_0000219,,
125,Intermediate,80613,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,N,1,1,,CHEMBL615349,561.0,BAO_0000219,,
126,Intermediate,80614,,,In vitro inhibition of 2008/S ovarian cancer cell line,N,1,1,,CHEMBL615350,389.0,BAO_0000219,,
127,Intermediate,80614,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,N,1,1,,CHEMBL615351,389.0,BAO_0000219,,
128,Expert,100256,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,S,2,1,,CHEMBL615352,,BAO_0000220,,
129,Intermediate,100256,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,S,2,1,,CHEMBL615353,,BAO_0000220,,
130,Expert,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome,S,2,1,,CHEMBL615354,,BAO_0000220,,
131,Expert,100256,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,S,2,1,,CHEMBL615355,,BAO_0000220,,
132,Intermediate,100256,,,Inhibitory activity against 20S proteosome,S,2,1,,CHEMBL615356,,BAO_0000220,,
133,Autocuration,22226,,,Compound was tested for inhibitory activity against tryptase,U,0,1,,CHEMBL615357,,BAO_0000019,,
134,Intermediate,81020,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,N,1,1,,CHEMBL615358,726.0,BAO_0000219,,
135,Intermediate,81020,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,N,1,1,,CHEMBL827086,726.0,BAO_0000219,,
136,Autocuration,22226,,,Compound was tested for the inhibition of Alpha-glucosidase,U,0,1,,CHEMBL615359,,BAO_0000019,,
137,Autocuration,235,,,Inhibitory concentration against human neutrophil elastase (HNE),H,8,1,,CHEMBL615360,,BAO_0000357,,
138,Autocuration,22226,Heart,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,U,0,1,,CHEMBL615361,,BAO_0000218,948.0,
139,Autocuration,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,8,1,,CHEMBL615362,,BAO_0000019,,
140,Expert,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,8,1,,CHEMBL615363,,BAO_0000019,,
141,Autocuration,19640,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,8,1,,CHEMBL615364,,BAO_0000357,,
142,Expert,19640,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,8,1,,CHEMBL615365,,BAO_0000019,,
143,Intermediate,80360,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,N,1,1,,CHEMBL615366,524.0,BAO_0000219,,
144,Intermediate,80360,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,N,1,1,,CHEMBL615367,524.0,BAO_0000219,,
145,Intermediate,80384,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,N,1,1,,CHEMBL615368,554.0,BAO_0000219,,
146,Autocuration,22226,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,U,0,1,,CHEMBL615369,,BAO_0000019,,
147,Autocuration,22226,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,U,0,1,,CHEMBL615370,,BAO_0000019,,
148,Autocuration,191,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),H,8,1,,CHEMBL615673,,BAO_0000357,,
149,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,U,0,1,,CHEMBL615674,,BAO_0000019,,
150,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,U,0,1,,CHEMBL615675,,BAO_0000019,,
151,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,U,0,1,,CHEMBL615676,635.0,BAO_0000219,,
152,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,U,0,1,,CHEMBL615677,635.0,BAO_0000219,,
153,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,U,0,1,,CHEMBL615678,635.0,BAO_0000219,,
154,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,U,0,1,,CHEMBL615679,635.0,BAO_0000219,,
155,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,U,0,1,,CHEMBL615680,,BAO_0000019,,
156,Autocuration,22226,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,U,0,1,,CHEMBL615681,,BAO_0000019,,
157,Autocuration,104290,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,H,6,1,,CHEMBL857972,,BAO_0000249,,
158,Intermediate,50264,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,N,1,1,,CHEMBL857899,,BAO_0000218,,
159,Intermediate,50527,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),N,1,1,,CHEMBL615371,,BAO_0000218,,
160,Expert,50527,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,N,1,1,,CHEMBL615372,468.0,BAO_0000218,,
161,Intermediate,50527,,,Antiviral activity against 07/1 strain of VZV; ND: No data,N,1,1,,CHEMBL615373,,BAO_0000218,,
162,Intermediate,50527,,,Antiviral activity against 07/1 strain of VZV; ND=No data,N,1,1,,CHEMBL615374,,BAO_0000218,,
163,Intermediate,50145,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",N,1,1,,CHEMBL615375,,BAO_0000218,,
164,Autocuration,22226,,,Ratio of Ki at A2 to Ki at A1 receptors,U,0,1,,CHEMBL615376,,BAO_0000019,,
165,Expert,11143,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",H,8,1,,CHEMBL615377,,BAO_0000249,,
166,Expert,18077,,,"Inhibition of 1,3-beta-glucan synthase",H,8,1,,CHEMBL615378,,BAO_0000357,,
167,Intermediate,80609,,,Inhibition of growth of 1-87 human tumor cell line,N,1,1,,CHEMBL615379,832.0,BAO_0000219,,
168,Expert,12166,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,D,9,1,,CHEMBL615380,,BAO_0000219,,
169,Autocuration,100171,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),D,9,1,,CHEMBL615381,,BAO_0000357,,
170,Autocuration,100171,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,D,9,1,,CHEMBL615382,,BAO_0000357,,
171,Autocuration,100171,,,% inhibition against soybean 1-lipoxygenase (SLO),D,9,1,,CHEMBL615383,,BAO_0000357,,
172,Autocuration,100171,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,D,9,1,,CHEMBL615384,,BAO_0000357,,
173,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,D,9,1,,CHEMBL615385,,BAO_0000357,,
174,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,D,9,1,,CHEMBL615386,,BAO_0000357,,
175,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,D,9,1,,CHEMBL615387,,BAO_0000357,,
176,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,D,9,1,,CHEMBL615388,,BAO_0000357,,
177,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,D,9,1,,CHEMBL615214,,BAO_0000357,,
178,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,D,9,1,,CHEMBL827087,,BAO_0000357,,
179,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,D,9,1,,CHEMBL615215,,BAO_0000357,,
180,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,D,9,1,,CHEMBL615216,,BAO_0000357,,
181,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,D,9,1,,CHEMBL615217,,BAO_0000357,,
182,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,D,9,1,,CHEMBL615218,,BAO_0000357,,
183,Autocuration,100171,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,D,9,1,,CHEMBL615219,,BAO_0000357,,
184,Autocuration,22226,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,U,0,1,,CHEMBL615220,,BAO_0000019,,
185,Intermediate,80049,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),N,1,1,,CHEMBL615221,294.0,BAO_0000219,,
186,Intermediate,22226,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,U,0,1,,CHEMBL615222,,BAO_0000019,,
187,Autocuration,11489,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,8,1,,CHEMBL615223,,BAO_0000357,,
188,Autocuration,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,8,1,,CHEMBL615224,,BAO_0000357,,
189,Autocuration,11862,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,H,8,1,,CHEMBL615225,,BAO_0000357,,
190,Autocuration,11489,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,H,8,1,,CHEMBL615226,,BAO_0000357,,
191,Autocuration,11862,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,H,8,1,,CHEMBL615227,,BAO_0000357,,
192,Expert,12347,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,D,9,1,,CHEMBL615228,,BAO_0000019,,
193,Expert,100120,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,D,9,1,,CHEMBL615229,,BAO_0000357,,
194,Expert,100120,Adrenal gland,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,D,9,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,9,1,,CHEMBL615231,,BAO_0000357,,
196,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,9,1,,CHEMBL884520,,BAO_0000357,,
197,Expert,100120,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,D,9,1,,CHEMBL615232,,BAO_0000357,,
198,Autocuration,10328,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,H,8,1,,CHEMBL615233,,BAO_0000019,,
199,Autocuration,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,8,1,,CHEMBL827088,,BAO_0000357,,
200,Autocuration,11490,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,8,1,,CHEMBL615234,,BAO_0000357,,
201,Autocuration,11134,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,H,8,1,,CHEMBL615235,,BAO_0000019,,
202,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,8,1,,CHEMBL615236,,BAO_0000019,,
203,Autocuration,11134,,,Compound was tested in vitro for inhibition of 12-LO human platelet,H,8,1,,CHEMBL615237,,BAO_0000019,,
204,Autocuration,11134,,,Inhibitory concentration against human platelet 12-lipoxygenase,H,8,1,,CHEMBL615238,,BAO_0000019,,
205,Autocuration,11134,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,H,8,1,,CHEMBL615239,,BAO_0000019,,
206,Autocuration,11134,,,Inhibitory concentration against human platelet 12-lipoxygenase,D,9,1,,CHEMBL615240,,BAO_0000019,,
207,Expert,11835,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,H,8,1,,CHEMBL615241,,BAO_0000019,,
208,Expert,11601,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,H,8,1,,CHEMBL615242,,BAO_0000357,,
209,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),H,8,1,,CHEMBL615243,,BAO_0000019,,
210,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase,H,8,1,,CHEMBL615244,,BAO_0000019,,
211,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,H,8,1,,CHEMBL615245,,BAO_0000019,,
212,Autocuration,11134,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),H,8,1,,CHEMBL615246,,BAO_0000019,,
213,Autocuration,11134,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,H,8,1,,CHEMBL615247,,BAO_0000019,,
214,Autocuration,11134,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,H,8,1,,CHEMBL615248,,BAO_0000019,,
215,Autocuration,11601,,,Inhibitory activity towards porcine 12-lipoxygenase,H,8,1,,CHEMBL615249,,BAO_0000357,,
216,Autocuration,11601,,,Tested for inhibition against porcine 12-LO,H,8,1,,CHEMBL615250,,BAO_0000357,,
217,Autocuration,12052,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,H,8,1,,CHEMBL615251,,BAO_0000019,,
218,Autocuration,12052,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,H,8,1,,CHEMBL615252,,BAO_0000019,,
219,Expert,12052,,,In vitro inhibition of rat platelet 12-lipoxygenase,H,8,1,,CHEMBL828340,,BAO_0000019,,
220,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,8,1,,CHEMBL615253,,BAO_0000019,,
221,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,H,8,1,,CHEMBL615254,,BAO_0000019,,
222,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,H,8,1,,CHEMBL615255,,BAO_0000019,,
223,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,8,1,,CHEMBL615256,,BAO_0000019,,
224,Autocuration,12052,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,H,8,1,,CHEMBL615257,,BAO_0000019,,
225,Autocuration,12052,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,H,8,1,,CHEMBL615258,,BAO_0000019,,
226,Intermediate,80007,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,N,1,1,,CHEMBL615259,621.0,BAO_0000219,,
227,Expert,80007,,,In vitro antitumor activity against 41M cell line.,N,1,1,,CHEMBL615260,621.0,BAO_0000219,,
228,Intermediate,80007,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,N,1,1,,CHEMBL615261,621.0,BAO_0000219,,
229,Intermediate,80007,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,N,1,1,,CHEMBL615262,621.0,BAO_0000219,,
230,Expert,80007,,,In vitro antitumor activity against 41McisR cell line.,N,1,1,,CHEMBL615263,621.0,BAO_0000219,,
231,Expert,80007,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,N,1,1,,CHEMBL838393,621.0,BAO_0000219,,
232,Intermediate,80007,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,N,1,1,,CHEMBL615264,621.0,BAO_0000219,,
233,Expert,84,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),D,9,1,,CHEMBL615265,,BAO_0000357,,
234,Expert,68,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),D,9,1,,CHEMBL615266,,BAO_0000357,,
235,Expert,68,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),H,8,1,,CHEMBL615267,,BAO_0000357,,
236,Expert,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,8,1,,CHEMBL615268,,BAO_0000357,,
237,Expert,10201,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,H,8,1,,CHEMBL615269,,BAO_0000357,,
238,Expert,10201,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,8,1,,CHEMBL615270,,BAO_0000357,,
239,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,8,1,,CHEMBL615271,,BAO_0000357,,
240,Autocuration,11303,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,8,1,,CHEMBL615272,,BAO_0000357,,
241,Autocuration,11303,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,8,1,,CHEMBL615103,,BAO_0000357,,
242,Autocuration,11303,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",H,8,1,,CHEMBL615104,,BAO_0000357,,
243,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,8,1,,CHEMBL615105,,BAO_0000357,,
244,Autocuration,12220,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",H,8,1,,CHEMBL872866,,BAO_0000357,,
245,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,8,1,,CHEMBL615106,,BAO_0000357,,
246,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",H,8,1,,CHEMBL615107,,BAO_0000019,,
247,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",H,8,1,,CHEMBL615108,,BAO_0000357,,
248,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",H,8,1,,CHEMBL615109,,BAO_0000357,,
249,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,8,1,,CHEMBL615110,,BAO_0000357,,
250,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,8,1,,CHEMBL840105,,BAO_0000019,,
251,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",H,8,1,,CHEMBL615111,,BAO_0000019,,
252,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",H,8,1,,CHEMBL615112,,BAO_0000019,,
253,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",H,8,1,,CHEMBL615113,,BAO_0000019,,
254,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",H,8,1,,CHEMBL615114,,BAO_0000019,,
255,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,8,1,,CHEMBL615115,,BAO_0000357,,
256,Autocuration,11303,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,8,1,,CHEMBL615116,,BAO_0000019,,
257,Autocuration,11303,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",H,8,1,,CHEMBL615698,,BAO_0000357,,
258,Autocuration,22226,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",U,0,1,,CHEMBL615699,,BAO_0000019,,
259,Autocuration,22226,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",U,0,1,,CHEMBL615700,,BAO_0000019,,
260,Expert,100249,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,H,8,1,,CHEMBL615701,,BAO_0000357,,
261,Autocuration,22226,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,0,1,,CHEMBL615702,,BAO_0000019,,
262,Autocuration,22226,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,0,1,,CHEMBL615703,,BAO_0000019,,
263,Autocuration,22226,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",U,0,1,,CHEMBL615704,,BAO_0000019,,
264,Autocuration,104698,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,6,1,,CHEMBL615705,,BAO_0000019,,
265,Autocuration,104698,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,6,1,,CHEMBL615706,,BAO_0000019,,
266,Intermediate,20033,Ileum,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,D,9,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,Expert,10623,,,Stimulatory activity of intragastric pressure was tested in the rat,H,8,1,,CHEMBL615708,,BAO_0000019,,
268,Autocuration,121,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,H,8,1,,CHEMBL615709,,BAO_0000357,,
269,Autocuration,22226,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),U,0,1,,CHEMBL615710,,BAO_0000218,,
270,Autocuration,12688,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,8,1,,CHEMBL615711,,BAO_0000019,,
271,Expert,121,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,D,9,1,,CHEMBL615712,,BAO_0000357,,
272,Expert,121,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,D,9,1,,CHEMBL836325,,BAO_0000357,,
273,Autocuration,12198,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,H,8,1,,CHEMBL615713,,BAO_0000019,,
274,Autocuration,12198,,,Inhibition constant of high-affinity 5-HT uptake,H,8,1,,CHEMBL615714,,BAO_0000357,,
275,Autocuration,12198,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,H,8,1,,CHEMBL615715,,BAO_0000019,,
276,Autocuration,12198,,,Maximum rate was determined for high affinity transport of 5-HT,H,8,1,,CHEMBL615716,,BAO_0000019,,
277,Autocuration,104714,,,Compound was tested for agonistic activity against 5-HT uptake,H,4,1,,CHEMBL615717,,BAO_0000019,,
278,Expert,10577,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,H,8,1,,CHEMBL881818,,BAO_0000019,,
279,Expert,105,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,H,8,1,,CHEMBL884540,,BAO_0000357,,
280,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,D,5,1,,CHEMBL615718,,BAO_0000224,,
281,Autocuration,104744,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,H,4,1,,CHEMBL615719,,BAO_0000224,,
282,Autocuration,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,H,4,1,,CHEMBL615720,,BAO_0000249,,
283,Autocuration,104744,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,H,4,1,,CHEMBL615721,,BAO_0000249,,
284,Autocuration,104744,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,4,1,,CHEMBL615722,,BAO_0000019,,
285,Autocuration,51,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,H,8,1,,CHEMBL615723,,BAO_0000019,,
286,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),H,8,1,,CHEMBL615727,,BAO_0000218,,
290,Intermediate,105570,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,D,9,1,,CHEMBL615728,,BAO_0000019,,
291,Autocuration,279,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL857971,449.0,BAO_0000219,,
292,Autocuration,107,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL615729,,BAO_0000357,,
293,Expert,12687,,,Efficacy against 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL615730,,BAO_0000019,,
294,Expert,12687,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,H,8,1,,CHEMBL615731,,BAO_0000019,,
295,Expert,12687,,,Relative potency towards 5-HT2A receptor of rat tail artery,H,8,1,,CHEMBL615732,,BAO_0000019,,
296,Expert,12687,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,8,1,,CHEMBL615733,,BAO_0000019,,
297,Expert,12687,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,H,8,1,,CHEMBL615734,,BAO_0000019,,
298,Autocuration,12687,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,H,8,1,,CHEMBL615735,,BAO_0000019,,
299,Expert,12687,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,8,1,,CHEMBL615736,,BAO_0000019,,
300,Intermediate,20033,Ileum,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,9,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),D,9,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,Intermediate,20033,Ileum,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,9,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,Autocuration,10623,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,H,8,1,,CHEMBL615278,,BAO_0000357,,
304,Expert,10623,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,D,9,1,,CHEMBL615279,,BAO_0000019,,
305,Expert,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL615280,,BAO_0000357,,
306,Autocuration,22226,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,U,0,1,,CHEMBL615281,,BAO_0000019,,
307,Autocuration,22226,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,U,0,1,,CHEMBL615282,,BAO_0000019,,
308,Autocuration,22226,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,0,1,,CHEMBL615283,,BAO_0000019,,
309,Autocuration,80156,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,N,1,1,,CHEMBL615284,649.0,BAO_0000219,,
310,Autocuration,22226,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,U,0,1,,CHEMBL615285,,BAO_0000019,,
311,Autocuration,22226,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,0,1,,CHEMBL615286,,BAO_0000019,,
312,Autocuration,104703,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,D,7,1,,CHEMBL615287,,BAO_0000219,,
313,Intermediate,100256,,,Chymotryptic inhibitory activity against 26S proteasome,S,2,1,,CHEMBL615288,,BAO_0000220,,
314,Intermediate,100256,,,Inhibitory activity against 26S proteasome degradation of IkB,S,2,1,,CHEMBL615289,,BAO_0000220,,
315,Intermediate,81034,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,N,1,1,,CHEMBL615290,478.0,BAO_0000219,,
316,Intermediate,81034,,,In vitro inhibition of 2780/S ovarian cancer cell line,N,1,1,,CHEMBL884522,478.0,BAO_0000219,,
317,Autocuration,22226,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,U,0,1,,CHEMBL615291,,BAO_0000019,,
318,Intermediate,22222,,,Association constant for binding to AATT 28-mer AATT hairpin,M,3,1,,CHEMBL615292,,BAO_0000225,,
319,Intermediate,22222,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,M,3,1,,CHEMBL615293,,BAO_0000225,,
320,Intermediate,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,3,1,,CHEMBL615294,,BAO_0000225,,
321,Intermediate,22222,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,3,1,,CHEMBL615295,,BAO_0000225,,
322,Autocuration,22226,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),U,0,1,,CHEMBL825021,,BAO_0000019,,
323,Autocuration,22226,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),U,0,1,,CHEMBL615296,,BAO_0000019,,
324,Autocuration,22226,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,U,0,1,,CHEMBL615297,,BAO_0000019,,
325,Autocuration,22226,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,U,0,1,,CHEMBL615298,,BAO_0000019,,
326,Autocuration,22226,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,U,0,1,,CHEMBL615299,,BAO_0000019,,
327,Autocuration,22226,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,U,0,1,,CHEMBL615300,,BAO_0000019,,
328,Autocuration,241,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,H,8,1,,CHEMBL615301,,BAO_0000357,,
329,Expert,241,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,D,9,1,,CHEMBL615302,,BAO_0000357,,
330,Autocuration,22226,,,Selectivity ratio of ID50 in liver and heart,U,0,1,,CHEMBL615303,,BAO_0000019,,
331,Autocuration,12132,,,"Selectivity, ratio of relative ID50 in liver and heart",H,8,1,,CHEMBL615304,,BAO_0000019,,
332,Autocuration,12132,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,H,8,1,,CHEMBL615305,,BAO_0000019,,
333,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615306,,BAO_0000218,,
334,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615307,,BAO_0000218,,
335,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615308,,BAO_0000218,,
336,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615309,,BAO_0000218,,
337,Autocuration,22226,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",U,0,1,,CHEMBL615310,,BAO_0000019,,
338,Autocuration,12132,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,H,8,1,,CHEMBL615311,,BAO_0000019,,
339,Autocuration,22226,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",U,0,1,,CHEMBL615312,,BAO_0000019,,
340,Autocuration,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,8,1,,CHEMBL615313,,BAO_0000019,,
341,Autocuration,12132,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,8,1,,CHEMBL615314,,BAO_0000019,,
342,Autocuration,12132,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615315,,BAO_0000019,,
343,Autocuration,22226,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",U,0,1,,CHEMBL615316,,BAO_0000218,,
344,Autocuration,12132,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,H,8,1,,CHEMBL615317,,BAO_0000218,,
345,Autocuration,12132,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615318,,BAO_0000218,,
346,Autocuration,22226,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",U,0,1,,CHEMBL615319,,BAO_0000218,,
347,Autocuration,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615320,,BAO_0000019,,
348,Autocuration,12132,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,8,1,,CHEMBL615321,,BAO_0000019,,
349,Autocuration,22226,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",U,0,1,,CHEMBL615322,,BAO_0000019,,
350,Autocuration,19690,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,8,1,,CHEMBL615323,,BAO_0000357,,
351,Autocuration,19690,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,8,1,,CHEMBL615407,,BAO_0000357,,
352,Autocuration,19690,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,8,1,,CHEMBL857267,,BAO_0000357,,
353,Autocuration,19690,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,8,1,,CHEMBL615408,,BAO_0000357,,
354,Autocuration,19690,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,H,8,1,,CHEMBL615409,,BAO_0000357,,
355,Autocuration,19690,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,H,8,1,,CHEMBL615410,,BAO_0000357,,
356,Autocuration,19690,,,Inhibition constant against 3-dehydroquinate synthase,H,8,1,,CHEMBL615411,,BAO_0000357,,
357,Autocuration,19690,,,Association rate constant against 3-dehydroquinate synthase,H,8,1,,CHEMBL615412,,BAO_0000357,,
358,Autocuration,19690,,,Rate constant against 3-dehydroquinate synthase,H,8,1,,CHEMBL615413,,BAO_0000357,,
359,Autocuration,22226,,,Inhibitory activity against fuc-TVII,U,0,1,,CHEMBL615414,,BAO_0000019,,
360,Autocuration,12236,Liver,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,9,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,Autocuration,12236,Liver,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,9,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,Autocuration,12236,Liver,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,9,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,Autocuration,12236,Liver,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,9,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,Autocuration,12236,Liver,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,9,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,Autocuration,12236,Liver,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,D,9,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,D,9,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,D,9,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,D,9,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,D,9,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,Autocuration,12236,Liver,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,D,9,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,Autocuration,104832,,,Inhibitory activity against 3-phosphoglycerate kinase.,H,4,1,,CHEMBL825022,,BAO_0000224,,
372,Autocuration,104832,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,H,4,1,,CHEMBL615425,,BAO_0000224,,
373,Autocuration,104832,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",H,4,1,,CHEMBL615426,,BAO_0000224,,
374,Expert,10612,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,D,9,1,,CHEMBL615427,,BAO_0000357,,
375,Intermediate,80616,,,Cytotoxicity on 3677 melanoma cells,N,1,1,,CHEMBL615428,844.0,BAO_0000219,,
376,Intermediate,80616,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,N,1,1,,CHEMBL615429,844.0,BAO_0000219,,
377,Intermediate,80617,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,N,1,1,,CHEMBL615430,700.0,BAO_0000219,,
378,Intermediate,22226,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,U,0,1,,CHEMBL615431,,BAO_0000019,,
379,Autocuration,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,U,0,1,,CHEMBL615432,798.0,BAO_0000218,,
380,Autocuration,22226,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,U,0,1,,CHEMBL615433,798.0,BAO_0000218,,
381,Expert,12464,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,D,9,1,,CHEMBL615434,,BAO_0000019,,
382,Intermediate,50085,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,N,1,1,,CHEMBL615435,,BAO_0000218,,
383,Intermediate,50679,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,N,1,1,,CHEMBL615436,,BAO_0000218,,
384,Intermediate,50679,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,N,1,1,,CHEMBL615437,,BAO_0000218,,
385,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,9,1,,CHEMBL615438,,BAO_0000019,,
386,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,9,1,,CHEMBL615439,,BAO_0000019,,
387,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,9,1,,CHEMBL615440,,BAO_0000019,,
388,Expert,12464,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,D,9,1,,CHEMBL615441,,BAO_0000019,,
389,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,N,1,1,,CHEMBL615641,,BAO_0000218,,
390,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,N,1,1,,CHEMBL872065,,BAO_0000218,,
391,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,N,1,1,,CHEMBL825023,,BAO_0000218,,
392,Intermediate,50665,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,N,1,1,,CHEMBL615642,,BAO_0000218,,
393,Expert,12464,,,Inhibition of human rhinovirus 3C protease,H,8,1,,CHEMBL615643,,BAO_0000357,,
394,Autocuration,22226,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,U,0,1,,CHEMBL615644,,BAO_0000019,,
395,Intermediate,80619,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),N,1,1,,CHEMBL615645,833.0,BAO_0000218,,
396,Intermediate,80619,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),N,1,1,,CHEMBL615646,833.0,BAO_0000218,,
397,Intermediate,80619,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),N,1,1,,CHEMBL615647,833.0,BAO_0000218,,
398,Intermediate,80619,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),N,1,1,,CHEMBL615648,833.0,BAO_0000218,,
399,Intermediate,80619,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,N,1,1,,CHEMBL615649,833.0,BAO_0000218,,
400,Intermediate,80619,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,N,1,1,,CHEMBL615650,833.0,BAO_0000218,,
401,Intermediate,80620,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,1,1,,CHEMBL615651,847.0,BAO_0000218,,
402,Intermediate,80620,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,1,1,,CHEMBL615652,847.0,BAO_0000218,,
403,Expert,80620,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,N,1,1,,CHEMBL615653,847.0,BAO_0000218,,
404,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,N,1,1,,CHEMBL615654,847.0,BAO_0000219,,
405,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,N,1,1,,CHEMBL615655,847.0,BAO_0000219,,
406,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,N,1,1,,CHEMBL825024,847.0,BAO_0000219,,
407,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,N,1,1,,CHEMBL615656,847.0,BAO_0000219,,
408,Intermediate,80620,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,N,1,1,,CHEMBL615657,847.0,BAO_0000219,,
409,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,N,1,1,,CHEMBL615658,847.0,BAO_0000219,,
410,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,N,1,1,,CHEMBL615659,847.0,BAO_0000219,,
411,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,N,1,1,,CHEMBL615660,847.0,BAO_0000219,,
412,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,1,1,,CHEMBL615661,847.0,BAO_0000219,,
413,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,N,1,1,,CHEMBL615662,847.0,BAO_0000219,,
414,Intermediate,80620,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,N,1,1,,CHEMBL615663,847.0,BAO_0000219,,
415,Intermediate,80620,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,N,1,1,,CHEMBL615664,847.0,BAO_0000219,,
416,Intermediate,80620,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,N,1,1,,CHEMBL615665,847.0,BAO_0000219,,
417,Intermediate,80620,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,1,1,,CHEMBL615666,847.0,BAO_0000219,,
418,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,N,1,1,,CHEMBL615667,847.0,BAO_0000219,,
419,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,N,1,1,,CHEMBL615668,847.0,BAO_0000219,,
420,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,N,1,1,,CHEMBL615669,847.0,BAO_0000219,,
421,Intermediate,80620,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,N,1,1,,CHEMBL615670,847.0,BAO_0000219,,
422,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,N,1,1,,CHEMBL836739,847.0,BAO_0000219,,
423,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,N,1,1,,CHEMBL615671,847.0,BAO_0000219,,
424,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,N,1,1,,CHEMBL615672,847.0,BAO_0000219,,
425,Intermediate,80620,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,N,1,1,,CHEMBL615791,847.0,BAO_0000219,,
426,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,N,1,1,,CHEMBL615792,847.0,BAO_0000219,,
427,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,N,1,1,,CHEMBL615793,847.0,BAO_0000219,,
428,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,N,1,1,,CHEMBL615794,847.0,BAO_0000219,,
429,Intermediate,80620,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,N,1,1,,CHEMBL615795,847.0,BAO_0000219,,
430,Intermediate,80621,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,N,1,1,,CHEMBL615590,971.0,BAO_0000219,,
431,Autocuration,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,U,0,1,,CHEMBL615591,,BAO_0000218,,
432,Autocuration,22226,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,U,0,1,,CHEMBL615592,,BAO_0000218,,
433,Autocuration,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,U,0,1,,CHEMBL615593,,BAO_0000218,,
434,Autocuration,22226,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,U,0,1,,CHEMBL615594,,BAO_0000218,,
435,Intermediate,80951,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,1,1,,CHEMBL615595,723.0,BAO_0000219,,
436,Intermediate,80951,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,1,1,,CHEMBL615596,723.0,BAO_0000219,,
437,Expert,11169,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,H,8,1,,CHEMBL615597,723.0,BAO_0000219,,
438,Intermediate,80951,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,N,1,1,,CHEMBL615598,723.0,BAO_0000219,,
439,Intermediate,80951,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,N,1,1,,CHEMBL615599,723.0,BAO_0000219,,
440,Expert,80951,,,Effective dose against murine 3T3 fibroblasts cells,N,1,1,,CHEMBL615600,723.0,BAO_0000219,,
441,Expert,80951,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,N,1,1,,CHEMBL615601,723.0,BAO_0000219,,
442,Expert,80951,,,Cytotoxic effect on 3T3 cells,N,1,1,,CHEMBL615602,723.0,BAO_0000219,,
443,Expert,80951,,,Cytotoxic effect on 3T3 cells,N,1,1,,CHEMBL615603,723.0,BAO_0000219,,
444,Intermediate,80951,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,N,1,1,,CHEMBL615604,723.0,BAO_0000219,,
445,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,1,1,,CHEMBL615605,723.0,BAO_0000219,,
446,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,N,1,1,,CHEMBL615606,723.0,BAO_0000219,,
447,Expert,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,N,1,1,,CHEMBL884526,723.0,BAO_0000219,,
448,Expert,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,N,1,1,,CHEMBL615607,723.0,BAO_0000219,,
449,Intermediate,80951,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,N,1,1,,CHEMBL615608,723.0,BAO_0000219,,
450,Expert,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,N,1,1,,CHEMBL615609,723.0,BAO_0000219,,
451,Expert,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,N,1,1,,CHEMBL615682,723.0,BAO_0000219,,
452,Intermediate,80951,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,N,1,1,,CHEMBL615683,723.0,BAO_0000219,,
453,Expert,80951,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,N,1,1,,CHEMBL615684,723.0,BAO_0000218,,
454,Autocuration,104860,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,D,7,1,,CHEMBL615685,,BAO_0000219,,
455,Expert,80951,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,N,1,1,,CHEMBL615686,723.0,BAO_0000219,,
456,Intermediate,80951,,,Inhibitory activity against 3T3 cell line,N,1,1,,CHEMBL615687,723.0,BAO_0000219,,
457,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,N,1,1,,CHEMBL884523,723.0,BAO_0000219,,
458,Expert,11169,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,H,8,1,,CHEMBL615688,,BAO_0000019,,
459,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,N,1,1,,CHEMBL615689,723.0,BAO_0000219,,
460,Intermediate,80951,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,N,1,1,,CHEMBL615690,723.0,BAO_0000219,,
461,Expert,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,H,8,1,,CHEMBL615691,,BAO_0000019,,
462,Expert,11169,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,H,8,1,,CHEMBL615692,,BAO_0000019,,
463,Intermediate,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,1,1,,CHEMBL615693,723.0,BAO_0000219,,
464,Expert,80951,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,N,1,1,,CHEMBL615324,723.0,BAO_0000219,,
465,Expert,9,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,D,9,1,,CHEMBL615325,723.0,BAO_0000219,,
466,Expert,9,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),D,9,1,,CHEMBL615490,723.0,BAO_0000219,,
467,Expert,188,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,D,9,1,,CHEMBL615491,723.0,BAO_0000219,,
468,Expert,188,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),D,9,1,,CHEMBL615492,723.0,BAO_0000219,,
469,Intermediate,80951,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,N,1,1,,CHEMBL615493,723.0,BAO_0000219,,
470,Intermediate,80951,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,N,1,1,,CHEMBL615494,723.0,BAO_0000219,,
471,Intermediate,80951,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,N,1,1,,CHEMBL615495,723.0,BAO_0000219,,
472,Intermediate,80951,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,N,1,1,,CHEMBL615496,723.0,BAO_0000219,,
473,Intermediate,80951,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,N,1,1,,CHEMBL615497,723.0,BAO_0000219,,
474,Expert,80951,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,N,1,1,,CHEMBL615498,723.0,BAO_0000219,,
475,Intermediate,80951,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,N,1,1,,CHEMBL615499,723.0,BAO_0000219,,
476,Expert,80951,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,N,1,1,,CHEMBL835522,723.0,BAO_0000219,,
477,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,N,1,1,,CHEMBL615500,723.0,BAO_0000219,,
478,Intermediate,80951,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,1,1,,CHEMBL615501,723.0,BAO_0000219,,
479,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,1,1,,CHEMBL615502,723.0,BAO_0000219,,
480,Intermediate,80951,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,1,1,,CHEMBL615503,723.0,BAO_0000219,,
481,Intermediate,80951,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,1,1,,CHEMBL615504,723.0,BAO_0000219,,
482,Intermediate,80951,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,1,1,,CHEMBL615505,723.0,BAO_0000219,,
483,Expert,80951,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,N,1,1,,CHEMBL615506,723.0,BAO_0000219,,
484,Intermediate,80951,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,N,1,1,,CHEMBL615507,723.0,BAO_0000219,,
485,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,1,1,,CHEMBL615508,620.0,BAO_0000218,,
486,Intermediate,80006,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,N,1,1,,CHEMBL615509,620.0,BAO_0000219,,
487,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,N,1,1,,CHEMBL615510,620.0,BAO_0000219,,
488,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,N,1,1,,CHEMBL615511,620.0,BAO_0000219,,
489,Intermediate,80006,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,N,1,1,,CHEMBL615512,620.0,BAO_0000219,,
490,Intermediate,80006,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",N,1,1,,CHEMBL615513,620.0,BAO_0000218,,
491,Intermediate,80006,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",N,1,1,,CHEMBL615514,620.0,BAO_0000218,,
492,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,N,1,1,,CHEMBL615515,620.0,BAO_0000219,,
493,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,1,1,,CHEMBL615516,620.0,BAO_0000219,,
494,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,1,1,,CHEMBL615517,620.0,BAO_0000219,,
495,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,1,1,,CHEMBL615518,620.0,BAO_0000219,,
496,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,1,1,,CHEMBL615519,620.0,BAO_0000219,,
497,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,N,1,1,,CHEMBL615520,620.0,BAO_0000218,,
498,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,N,1,1,,CHEMBL615521,620.0,BAO_0000218,,
499,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,1,1,,CHEMBL615522,620.0,BAO_0000218,,
500,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,1,1,,CHEMBL615523,620.0,BAO_0000218,,
501,Expert,80006,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,1,1,,CHEMBL615524,620.0,BAO_0000218,,
502,Expert,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,1,1,,CHEMBL615525,620.0,BAO_0000218,,
503,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,1,1,,CHEMBL615526,620.0,BAO_0000218,,
504,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,1,1,,CHEMBL615527,620.0,BAO_0000218,,
505,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,N,1,1,,CHEMBL615528,620.0,BAO_0000218,,
506,Expert,80006,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,1,1,,CHEMBL615529,620.0,BAO_0000218,,
507,Expert,80006,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,1,1,,CHEMBL615530,620.0,BAO_0000218,,
508,Expert,80006,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,1,1,,CHEMBL615531,620.0,BAO_0000218,,
509,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,1,1,,CHEMBL615532,620.0,BAO_0000219,,
510,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,1,1,,CHEMBL615533,620.0,BAO_0000219,,
511,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,1,1,,CHEMBL615534,620.0,BAO_0000219,,
512,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,1,1,,CHEMBL615535,620.0,BAO_0000218,,
513,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,1,1,,CHEMBL615536,620.0,BAO_0000218,,
514,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,1,1,,CHEMBL615537,620.0,BAO_0000218,,
515,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,1,1,,CHEMBL615538,620.0,BAO_0000218,,
516,Intermediate,80006,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,1,1,,CHEMBL836166,620.0,BAO_0000218,,
517,Expert,11214,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,H,8,1,,CHEMBL615539,620.0,BAO_0000219,,
518,Intermediate,80006,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,N,1,1,,CHEMBL615540,620.0,BAO_0000219,,
519,Expert,11214,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,H,8,1,,CHEMBL615541,620.0,BAO_0000219,,
520,Expert,80006,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,N,1,1,,CHEMBL615542,620.0,BAO_0000219,,
521,Intermediate,80006,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,N,1,1,,CHEMBL615543,620.0,BAO_0000219,,
522,Expert,80006,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,N,1,1,,CHEMBL615544,620.0,BAO_0000219,,
523,Expert,80006,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,1,1,,CHEMBL615545,620.0,BAO_0000219,,
524,Expert,80006,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,1,1,,CHEMBL615546,620.0,BAO_0000219,,
525,Expert,80006,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,N,1,1,,CHEMBL615547,620.0,BAO_0000219,,
526,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,N,1,1,,CHEMBL615548,620.0,BAO_0000219,,
527,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,N,1,1,,CHEMBL615549,620.0,BAO_0000219,,
528,Expert,80006,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,N,1,1,,CHEMBL615550,620.0,BAO_0000219,,
529,Intermediate,80622,,,Inhibitory activity against rat fibroblast (3Y1) cell line,N,1,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,Expert,80622,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,N,1,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,Expert,80622,,,Cytotoxicity in 3Y1 cells.,N,1,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,Expert,80622,,,Cytostatic effect in 3Y1 cells.,N,1,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,Intermediate,80622,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",N,1,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,Expert,80622,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,N,1,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,Autocuration,22226,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,U,0,1,,CHEMBL615557,,BAO_0000019,,
536,Autocuration,22226,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,0,1,,CHEMBL615558,,BAO_0000019,,
537,Autocuration,22226,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,0,1,,CHEMBL872066,,BAO_0000019,,
538,Expert,11607,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,D,9,1,,CHEMBL615559,,BAO_0000019,,
539,Autocuration,11607,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,H,8,1,,CHEMBL615560,,BAO_0000019,,
540,Autocuration,11607,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,H,8,1,,CHEMBL615561,,BAO_0000019,,
541,Expert,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,H,8,1,,CHEMBL857062,,BAO_0000019,,
542,Expert,11607,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),H,8,1,,CHEMBL615562,,BAO_0000019,,
543,Autocuration,11607,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,H,8,1,,CHEMBL615563,,BAO_0000019,,
544,Autocuration,11607,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),H,8,1,,CHEMBL615564,,BAO_0000357,,
545,Autocuration,11607,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,H,8,1,,CHEMBL615565,,BAO_0000019,,
546,Autocuration,11607,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,H,8,1,,CHEMBL615566,,BAO_0000019,,
547,Expert,11607,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,D,9,1,,CHEMBL615567,,BAO_0000019,,
548,Autocuration,11607,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,H,8,1,,CHEMBL615568,,BAO_0000019,,
549,Autocuration,11607,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),H,8,1,,CHEMBL615569,,BAO_0000357,,
550,Autocuration,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,H,8,1,,CHEMBL615570,,BAO_0000019,,
551,Autocuration,11607,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),H,8,1,,CHEMBL615571,,BAO_0000019,,
552,Autocuration,104733,,,Binding affinity against melatonin (MT1) receptor (pC1),H,4,1,,CHEMBL615572,,BAO_0000224,,
553,Autocuration,22226,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,U,0,1,,CHEMBL615573,,BAO_0000019,,
554,Autocuration,22226,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,U,0,1,,CHEMBL615574,,BAO_0000019,,
555,Autocuration,22226,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,U,0,1,,CHEMBL615575,,BAO_0000019,,
556,Autocuration,10619,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,H,8,1,,CHEMBL615576,,BAO_0000357,,
557,Autocuration,10619,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL615577,,BAO_0000357,,
558,Autocuration,51,Hippocampus,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,H,8,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,Expert,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615579,,BAO_0000357,,
560,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615580,,BAO_0000357,,
561,Expert,51,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,H,8,1,,CHEMBL615581,,BAO_0000019,,
562,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,8,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,8,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,Autocuration,51,Hippocampus,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,Autocuration,51,Hippocampus,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,Autocuration,51,Hippocampus,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,Autocuration,51,Hippocampus,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,8,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,Autocuration,51,Hippocampus,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,D,9,1,,CHEMBL615589,,BAO_0000249,,
572,Expert,51,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,H,8,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,Autocuration,51,Hippocampus,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,H,8,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,Autocuration,51,Hippocampus,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,H,8,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,Expert,51,Hippocampus,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,H,8,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,Autocuration,51,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,H,8,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,H,8,1,,CHEMBL615447,449.0,BAO_0000219,,
578,Expert,51,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,8,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,Expert,51,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,8,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,8,1,,CHEMBL615450,449.0,BAO_0000219,,
581,Expert,51,Hippocampus,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,Autocuration,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,8,1,,CHEMBL615452,,BAO_0000357,,
583,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,Autocuration,51,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,8,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,Expert,51,Hippocampus,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,H,8,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,Expert,51,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,Expert,51,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",D,9,1,,CHEMBL615460,449.0,BAO_0000219,,
591,Autocuration,51,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,H,8,1,,CHEMBL615461,,BAO_0000019,,
592,Autocuration,51,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,H,8,1,,CHEMBL615462,,BAO_0000019,,
593,Autocuration,51,Hippocampus,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,H,8,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,Autocuration,51,Ileum,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,8,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,Autocuration,51,Ileum,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,8,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,8,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,8,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,8,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,Autocuration,51,Ileum,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,H,8,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615470,,BAO_0000357,,
601,Autocuration,51,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615471,,BAO_0000357,,
602,Autocuration,51,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615472,,BAO_0000357,,
603,Autocuration,106,Hippocampus,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,8,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,Autocuration,106,Hippocampus,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,8,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,Autocuration,11863,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,8,1,,CHEMBL615474,449.0,BAO_0000218,,
606,Autocuration,51,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615475,,BAO_0000357,,
607,Autocuration,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,H,8,1,,CHEMBL615476,308.0,BAO_0000219,,
608,Autocuration,51,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,H,8,1,,CHEMBL615477,308.0,BAO_0000219,,
609,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615478,,BAO_0000019,,
610,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615160,449.0,BAO_0000219,,
611,Expert,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615161,449.0,BAO_0000219,,
612,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,H,8,1,,CHEMBL615162,449.0,BAO_0000219,,
613,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,H,8,1,,CHEMBL615163,449.0,BAO_0000219,,
614,Expert,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL615164,449.0,BAO_0000219,,
615,Expert,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL615165,449.0,BAO_0000219,,
616,Autocuration,51,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,H,8,1,,CHEMBL615166,449.0,BAO_0000219,,
617,Autocuration,51,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,H,8,1,,CHEMBL615167,,BAO_0000219,,
618,Expert,51,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,9,1,,CHEMBL615168,308.0,BAO_0000219,,
619,Expert,51,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,D,9,1,,CHEMBL615169,308.0,BAO_0000219,,
620,Expert,51,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL615170,449.0,BAO_0000219,,
621,Expert,51,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,D,9,1,,CHEMBL615171,449.0,BAO_0000219,,
622,Autocuration,51,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615694,,BAO_0000019,,
623,Autocuration,51,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615695,,BAO_0000019,,
624,Autocuration,51,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL615696,,BAO_0000019,,
625,Autocuration,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,8,1,,CHEMBL615697,449.0,BAO_0000219,,
626,Expert,51,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,9,1,,CHEMBL859410,449.0,BAO_0000219,,
627,Autocuration,51,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,8,1,,CHEMBL615841,449.0,BAO_0000219,,
628,Expert,51,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,9,1,,CHEMBL615842,449.0,BAO_0000219,,
629,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,8,1,,CHEMBL835003,449.0,BAO_0000219,,
630,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),H,8,1,,CHEMBL615843,449.0,BAO_0000219,,
631,Expert,51,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,9,1,,CHEMBL615979,449.0,BAO_0000219,,
632,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,8,1,,CHEMBL615980,449.0,BAO_0000219,,
633,Expert,51,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,9,1,,CHEMBL615981,449.0,BAO_0000219,,
634,Expert,51,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,D,9,1,,CHEMBL615982,,BAO_0000019,,
635,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,9,1,,CHEMBL615983,,BAO_0000019,,
636,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",D,9,1,,CHEMBL615984,,BAO_0000019,,
637,Expert,51,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",D,9,1,,CHEMBL615985,,BAO_0000019,,
638,Autocuration,51,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,8,1,,CHEMBL615986,449.0,BAO_0000219,,
639,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,8,1,,CHEMBL615987,449.0,BAO_0000219,,
640,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,8,1,,CHEMBL615988,449.0,BAO_0000219,,
641,Expert,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,8,1,,CHEMBL615989,449.0,BAO_0000219,,
642,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,8,1,,CHEMBL615990,449.0,BAO_0000219,,
643,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,H,8,1,,CHEMBL615991,449.0,BAO_0000219,,
644,Autocuration,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,8,1,,CHEMBL615992,449.0,BAO_0000219,,
645,Autocuration,51,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,8,1,,CHEMBL615993,449.0,BAO_0000219,,
646,Expert,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,8,1,,CHEMBL615994,449.0,BAO_0000219,,
647,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,H,8,1,,CHEMBL615995,449.0,BAO_0000219,,
648,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,8,1,,CHEMBL615996,449.0,BAO_0000219,,
649,Autocuration,51,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,8,1,,CHEMBL615997,449.0,BAO_0000219,,
650,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,8,1,,CHEMBL615998,,BAO_0000019,,
651,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,8,1,,CHEMBL615999,,BAO_0000019,,
652,Autocuration,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,8,1,,CHEMBL616000,,BAO_0000019,,
653,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,8,1,,CHEMBL616001,722.0,BAO_0000219,,
654,Expert,51,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",D,9,1,,CHEMBL616002,,BAO_0000019,,
655,Expert,51,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",H,8,1,,CHEMBL616003,,BAO_0000019,,
656,Expert,51,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616004,,BAO_0000019,,
657,Expert,51,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,D,9,1,,CHEMBL616005,,BAO_0000019,,
658,Autocuration,51,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,8,1,,CHEMBL616006,,BAO_0000019,,
659,Expert,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",H,8,1,,CHEMBL616007,,BAO_0000019,,
660,Autocuration,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,8,1,,CHEMBL616008,,BAO_0000019,,
661,Autocuration,51,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,8,1,,CHEMBL616009,,BAO_0000019,,
662,Expert,51,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",H,8,1,,CHEMBL616010,,BAO_0000019,,
663,Expert,51,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",D,9,1,,CHEMBL616011,,BAO_0000019,,
664,Expert,51,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",D,9,1,,CHEMBL615740,,BAO_0000019,,
665,Autocuration,51,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL615741,,BAO_0000019,,
666,Expert,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,8,1,,CHEMBL615742,,BAO_0000019,,
667,Autocuration,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",H,8,1,,CHEMBL615743,,BAO_0000019,,
668,Autocuration,51,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,H,8,1,,CHEMBL615744,449.0,BAO_0000219,,
669,Expert,51,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,H,8,1,,CHEMBL615745,449.0,BAO_0000219,,
670,Autocuration,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL615746,,BAO_0000357,,
671,Autocuration,51,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL615747,,BAO_0000357,,
672,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,8,1,,CHEMBL615748,,BAO_0000019,,
673,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",H,8,1,,CHEMBL615749,,BAO_0000019,,
674,Autocuration,51,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,8,1,,CHEMBL615750,,BAO_0000019,,
675,Expert,51,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616259,,BAO_0000019,,
676,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,8,1,,CHEMBL616260,,BAO_0000019,,
677,Expert,51,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,D,9,1,,CHEMBL616261,,BAO_0000019,,
678,Expert,51,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,9,1,,CHEMBL616262,,BAO_0000019,,
679,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,9,1,,CHEMBL616263,,BAO_0000019,,
680,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,D,9,1,,CHEMBL616264,,BAO_0000019,,
681,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,D,9,1,,CHEMBL616265,,BAO_0000019,,
682,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,9,1,,CHEMBL616266,,BAO_0000019,,
683,Expert,51,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,9,1,,CHEMBL616267,,BAO_0000019,,
684,Expert,51,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,D,9,1,,CHEMBL616268,,BAO_0000019,,
685,Expert,51,,,Inhibition of human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616269,,BAO_0000357,,
686,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL884528,449.0,BAO_0000219,,
687,Expert,105,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,D,9,1,,CHEMBL616270,722.0,BAO_0000219,,
688,Autocuration,51,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,H,8,1,,CHEMBL616271,449.0,BAO_0000219,,
689,Autocuration,51,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616272,449.0,BAO_0000219,,
690,Expert,51,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,H,8,1,,CHEMBL616273,,BAO_0000357,,
691,Expert,51,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616274,,BAO_0000357,,
692,Autocuration,51,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL616275,449.0,BAO_0000219,,
693,Autocuration,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL616276,449.0,BAO_0000219,,
694,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,0,1,,CHEMBL616277,,BAO_0000218,,
695,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,U,0,1,,CHEMBL616278,,BAO_0000218,,
696,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,U,0,1,,CHEMBL616279,,BAO_0000218,,
697,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,0,1,,CHEMBL616280,,BAO_0000218,,
698,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,U,0,1,,CHEMBL616281,,BAO_0000218,,
699,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,0,1,,CHEMBL616282,,BAO_0000218,,
700,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,U,0,1,,CHEMBL616283,,BAO_0000218,,
701,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,U,0,1,,CHEMBL616284,,BAO_0000218,,
702,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,U,0,1,,CHEMBL616285,,BAO_0000218,,
703,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,U,0,1,,CHEMBL616286,,BAO_0000218,,
704,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,U,0,1,,CHEMBL616287,,BAO_0000218,,
705,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,U,0,1,,CHEMBL616288,,BAO_0000218,,
706,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,U,0,1,,CHEMBL616289,,BAO_0000218,,
707,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,U,0,1,,CHEMBL615610,,BAO_0000218,,
708,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,U,0,1,,CHEMBL615611,,BAO_0000218,,
709,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,U,0,1,,CHEMBL615612,,BAO_0000218,,
710,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,U,0,1,,CHEMBL615613,,BAO_0000218,,
711,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,U,0,1,,CHEMBL615614,,BAO_0000218,,
712,Autocuration,22226,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,0,1,,CHEMBL615615,,BAO_0000218,,
713,Autocuration,105093,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,H,4,1,,CHEMBL615616,,BAO_0000019,,
714,Autocuration,11923,Hypothalamus,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,H,8,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,Autocuration,10577,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,H,8,1,,CHEMBL615618,,BAO_0000019,,
716,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,H,8,1,,CHEMBL615619,,BAO_0000019,,
717,Expert,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,8,1,,CHEMBL615620,,BAO_0000019,,
718,Autocuration,55,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",H,8,1,,CHEMBL615621,,BAO_0000357,,
719,Autocuration,55,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",H,8,1,,CHEMBL615622,,BAO_0000357,,
720,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),H,8,1,,CHEMBL615623,,BAO_0000019,,
721,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,8,1,,CHEMBL615624,,BAO_0000019,,
722,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,8,1,,CHEMBL615625,,BAO_0000019,,
723,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,8,1,,CHEMBL767045,,BAO_0000019,,
724,Autocuration,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,H,8,1,,CHEMBL615626,,BAO_0000019,,
725,Autocuration,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,H,8,1,,CHEMBL615627,,BAO_0000019,,
726,Autocuration,55,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,H,8,1,,CHEMBL615628,,BAO_0000019,,
727,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,8,1,,CHEMBL615629,,BAO_0000357,,
728,Expert,55,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,D,9,1,,CHEMBL615630,,BAO_0000357,,
729,Autocuration,55,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL615631,,BAO_0000219,,
730,Autocuration,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,8,1,,CHEMBL615632,,BAO_0000218,,
731,Autocuration,17087,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,H,8,1,,CHEMBL615633,,BAO_0000357,,
732,Autocuration,17087,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,8,1,,CHEMBL615634,,BAO_0000218,,
733,Expert,55,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,8,1,,CHEMBL615635,,BAO_0000019,,
734,Expert,12166,,,In vitro inhibition of rat 5-Lipoxygenase,H,8,1,,CHEMBL615636,,BAO_0000357,,
735,Expert,12166,,,Inhibitory activity against 5-Lipoxygenase,D,9,1,,CHEMBL615637,,BAO_0000357,,
736,Expert,12166,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,H,8,1,,CHEMBL615638,702.0,BAO_0000219,,
737,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,8,1,,CHEMBL615639,702.0,BAO_0000219,,
738,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,H,8,1,,CHEMBL615640,702.0,BAO_0000219,,
739,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,H,8,1,,CHEMBL615796,,BAO_0000019,,
740,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL615845,,BAO_0000219,,
741,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,8,1,,CHEMBL615846,,BAO_0000357,,
742,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,8,1,,CHEMBL615847,702.0,BAO_0000219,,
743,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,H,8,1,,CHEMBL615848,,BAO_0000357,,
744,Autocuration,22226,,,Ratio of IC50 against 5-LO and COX,U,0,1,,CHEMBL615849,,BAO_0000019,,
745,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,8,1,,CHEMBL615850,,BAO_0000357,,
746,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,H,8,1,,CHEMBL615851,,BAO_0000357,,
747,Autocuration,12166,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,H,8,1,,CHEMBL615852,,BAO_0000219,,
748,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,H,8,1,,CHEMBL615853,,BAO_0000019,,
749,Autocuration,120,Prostate gland,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,H,8,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,U,0,1,,CHEMBL872871,,BAO_0000019,,
751,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,U,0,1,,CHEMBL615854,,BAO_0000019,,
752,Autocuration,22226,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,U,0,1,,CHEMBL767046,,BAO_0000019,,
753,Autocuration,10732,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,H,8,1,,CHEMBL615855,,BAO_0000357,,
754,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,D,9,1,,CHEMBL615856,,BAO_0000019,,
755,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,9,1,,CHEMBL615857,,BAO_0000019,,
756,Expert,12198,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,9,1,,CHEMBL615858,,BAO_0000019,,
757,Expert,10576,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,8,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,H,8,1,,CHEMBL615860,,BAO_0000357,,
759,Autocuration,22226,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,0,1,,CHEMBL615861,,BAO_0000019,,
760,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,0,1,,CHEMBL615862,,BAO_0000019,,
761,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,U,0,1,,CHEMBL615863,,BAO_0000019,,
762,Autocuration,22226,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,U,0,1,,CHEMBL615864,,BAO_0000019,,
763,Autocuration,104744,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,4,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,Autocuration,104744,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,4,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,Autocuration,104744,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,4,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,Autocuration,104744,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,H,4,1,,CHEMBL615868,,BAO_0000249,,
767,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,D,5,1,,CHEMBL615869,,BAO_0000249,,
768,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,D,5,1,,CHEMBL615870,,BAO_0000019,,
769,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,D,5,1,,CHEMBL615871,,BAO_0000019,,
770,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,H,4,1,,CHEMBL615872,,BAO_0000224,,
771,Autocuration,104744,Hippocampus,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,H,4,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,Autocuration,104744,Hippocampus,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,H,4,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,Autocuration,104744,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,H,4,1,,CHEMBL615479,,BAO_0000224,,
774,Autocuration,104744,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,H,4,1,,CHEMBL615480,,BAO_0000019,,
775,Autocuration,104744,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,D,5,1,,CHEMBL615481,,BAO_0000249,,
776,Autocuration,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,4,1,,CHEMBL872869,,BAO_0000019,,
777,Autocuration,104744,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,4,1,,CHEMBL615482,,BAO_0000019,,
778,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,4,1,,CHEMBL615483,,BAO_0000221,955.0,
779,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,4,1,,CHEMBL615484,,BAO_0000221,955.0,
780,Autocuration,104744,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,H,4,1,,CHEMBL615485,,BAO_0000019,,
781,Autocuration,104744,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,D,5,1,,CHEMBL615486,,BAO_0000224,,
782,Autocuration,104744,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,H,4,1,,CHEMBL615487,,BAO_0000224,,
783,Autocuration,104744,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,4,1,,CHEMBL615488,,BAO_0000224,,
784,Autocuration,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,4,1,,CHEMBL615489,,BAO_0000224,,
785,Autocuration,104744,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,4,1,,CHEMBL615389,,BAO_0000224,,
786,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,4,1,,CHEMBL615390,,BAO_0000019,,
787,Autocuration,104744,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,4,1,,CHEMBL615391,,BAO_0000019,,
788,Autocuration,104744,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,H,4,1,,CHEMBL615392,,BAO_0000224,,
789,Autocuration,22226,,,Affinity for 5-hydroxytryptamine 1 receptor,U,0,1,,CHEMBL615393,,BAO_0000019,,
790,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,H,4,1,,CHEMBL615394,,BAO_0000221,955.0,
791,Autocuration,104744,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,4,1,,CHEMBL615395,,BAO_0000221,955.0,
792,Autocuration,104744,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,H,4,1,,CHEMBL615396,,BAO_0000224,,
793,Autocuration,104744,Brain,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,H,4,1,,CHEMBL615397,,BAO_0000221,955.0,
794,Autocuration,104744,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,4,1,,CHEMBL615398,,BAO_0000019,,
795,Autocuration,22226,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,U,0,1,,CHEMBL615399,,BAO_0000019,,
796,Autocuration,104744,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,H,4,1,,CHEMBL615400,,BAO_0000019,,
797,Autocuration,104744,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,D,5,1,,CHEMBL615401,,BAO_0000019,,
798,Autocuration,22226,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,U,0,1,,CHEMBL615402,,BAO_0000019,,
799,Autocuration,104744,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,H,4,1,,CHEMBL615403,,BAO_0000019,,
800,Autocuration,104744,Brain,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,H,4,1,,CHEMBL615404,,BAO_0000221,955.0,
801,Autocuration,104744,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,H,4,1,,CHEMBL615781,,BAO_0000019,,
802,Autocuration,104744,Brain,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,H,4,1,,CHEMBL615782,,BAO_0000220,955.0,
803,Autocuration,104744,Brain,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,H,4,1,,CHEMBL615783,,BAO_0000221,955.0,
804,Autocuration,22226,,,Compound was tested for binding affinity against 5-HT1 receptor,U,0,1,,CHEMBL873481,,BAO_0000019,,
805,Autocuration,22226,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,U,0,1,,CHEMBL615784,,BAO_0000019,,
806,Expert,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,8,1,,CHEMBL615785,,BAO_0000357,,
807,Autocuration,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL615786,,BAO_0000249,,
808,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,8,1,,CHEMBL615787,,BAO_0000218,,
809,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,8,1,,CHEMBL615788,,BAO_0000218,,
810,Autocuration,10576,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL767044,,BAO_0000019,,
811,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,8,1,,CHEMBL615789,,BAO_0000218,,
812,Autocuration,10576,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,8,1,,CHEMBL615790,,BAO_0000218,,
813,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,H,8,1,,CHEMBL615813,,BAO_0000019,,
814,Autocuration,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,H,8,1,,CHEMBL615814,,BAO_0000219,,
815,Expert,51,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,H,8,1,,CHEMBL615815,,BAO_0000219,,
816,Autocuration,10576,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,H,8,1,,CHEMBL615816,,BAO_0000219,,
817,Expert,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,H,8,1,,CHEMBL615817,,BAO_0000249,,
818,Autocuration,10576,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,H,8,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,Autocuration,10576,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,H,8,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,H,8,1,,CHEMBL615820,,BAO_0000249,,
821,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,D,9,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,9,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,D,9,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,9,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,Expert,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615826,,BAO_0000357,,
827,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615827,,BAO_0000249,,
828,Expert,10576,Hippocampus,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,Expert,10576,Hippocampus,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,Autocuration,10576,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,Expert,10576,Hippocampus,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,H,8,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,Autocuration,10576,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615832,,BAO_0000357,,
833,Autocuration,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,H,8,1,,CHEMBL615833,,BAO_0000019,,
834,Autocuration,10576,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,H,8,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,Intermediate,10576,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,H,8,1,,CHEMBL615835,,BAO_0000249,,
836,Autocuration,10576,Hippocampus,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,H,8,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,D,9,1,,CHEMBL615837,,BAO_0000019,,
838,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,D,9,1,,CHEMBL615838,,BAO_0000019,,
839,Expert,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",H,8,1,,CHEMBL615839,,BAO_0000249,,
840,Autocuration,10576,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,H,8,1,,CHEMBL884525,,BAO_0000019,,
841,Autocuration,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,8,1,,CHEMBL615840,,BAO_0000249,,
842,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,8,1,,CHEMBL615406,,BAO_0000019,,
844,Expert,10576,Hippocampus,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,8,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,Expert,10576,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,H,8,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,Expert,10576,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,H,8,1,,CHEMBL615902,,BAO_0000357,,
847,Autocuration,10576,Hippocampus,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,8,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,Autocuration,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,H,8,1,,CHEMBL615904,,BAO_0000357,,
849,Expert,10576,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,8,1,,CHEMBL615905,,BAO_0000357,,
850,Autocuration,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,8,1,,CHEMBL615906,,BAO_0000019,,
851,Autocuration,10576,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,8,1,,CHEMBL615907,,BAO_0000019,,
852,Expert,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,8,1,,CHEMBL615908,,BAO_0000019,,
853,Autocuration,10576,Hippocampus,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,H,8,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",H,8,1,,CHEMBL615910,,BAO_0000019,,
855,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",H,8,1,,CHEMBL615911,,BAO_0000019,,
856,Autocuration,10576,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",H,8,1,,CHEMBL615912,,BAO_0000019,,
857,Expert,10576,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615913,,BAO_0000019,,
858,Expert,10576,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL615914,,BAO_0000357,,
859,Autocuration,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,8,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,Autocuration,10576,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,H,8,1,,CHEMBL615916,,BAO_0000357,,
861,Expert,10576,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,H,8,1,,CHEMBL615917,,BAO_0000357,,
862,Expert,10576,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615918,,BAO_0000357,,
863,Expert,10576,Hippocampus,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,H,8,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,Expert,10576,Hippocampus,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,D,9,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,Autocuration,10576,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615921,,BAO_0000357,,
866,Expert,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),H,8,1,,CHEMBL615922,,BAO_0000357,,
867,Expert,10576,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,9,1,,CHEMBL881290,,BAO_0000249,,
868,Autocuration,10576,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",H,8,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,Autocuration,10576,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,Autocuration,10576,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,Expert,10576,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL615926,,BAO_0000357,,
872,Expert,10576,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL615927,,BAO_0000019,,
873,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,8,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,Expert,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,D,9,1,,CHEMBL615929,,BAO_0000357,,
875,Autocuration,10576,Hippocampus,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,H,8,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,Autocuration,51,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,8,1,,CHEMBL615931,449.0,BAO_0000219,,
877,Autocuration,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615932,449.0,BAO_0000219,,
878,Autocuration,51,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615933,449.0,BAO_0000219,,
879,Autocuration,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615934,,BAO_0000357,,
880,Autocuration,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,H,8,1,,CHEMBL615935,,BAO_0000357,,
881,Autocuration,51,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,8,1,,CHEMBL615936,,BAO_0000019,,
882,Autocuration,51,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,H,8,1,,CHEMBL615937,449.0,BAO_0000219,,
883,Autocuration,51,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615938,,BAO_0000357,,
884,Autocuration,51,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),H,8,1,,CHEMBL615797,,BAO_0000357,,
885,Autocuration,51,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615798,,BAO_0000357,,
886,Autocuration,51,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,H,8,1,,CHEMBL872870,,BAO_0000357,,
887,Autocuration,51,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,H,8,1,,CHEMBL615799,,BAO_0000357,,
888,Autocuration,51,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615800,,BAO_0000357,,
889,Autocuration,51,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,8,1,,CHEMBL615801,722.0,BAO_0000219,,
890,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,H,8,1,,CHEMBL615802,,BAO_0000019,,
891,Autocuration,51,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,H,8,1,,CHEMBL615803,,BAO_0000357,,
892,Expert,51,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,8,1,,CHEMBL835002,,BAO_0000019,,
893,Autocuration,51,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",H,8,1,,CHEMBL615804,,BAO_0000019,,
894,Expert,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615805,308.0,BAO_0000219,,
895,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615806,449.0,BAO_0000219,,
896,Expert,51,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,D,9,1,,CHEMBL615807,,BAO_0000357,,
897,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,H,8,1,,CHEMBL615808,,BAO_0000357,,
898,Expert,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL615809,,BAO_0000357,,
899,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,H,8,1,,CHEMBL615810,308.0,BAO_0000219,,
900,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615811,,BAO_0000357,,
901,Autocuration,51,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,H,8,1,,CHEMBL615812,449.0,BAO_0000219,,
902,Autocuration,51,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,8,1,,CHEMBL615751,449.0,BAO_0000219,,
903,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615752,,BAO_0000357,,
904,Expert,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,H,8,1,,CHEMBL615753,449.0,BAO_0000219,,
905,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,H,8,1,,CHEMBL615754,449.0,BAO_0000219,,
906,Autocuration,51,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615755,,BAO_0000357,,
907,Expert,51,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,9,1,,CHEMBL615756,449.0,BAO_0000219,,
908,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615757,,BAO_0000019,,
909,Autocuration,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL615758,,BAO_0000357,,
910,Expert,51,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,8,1,,CHEMBL615759,,BAO_0000357,,
911,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615760,,BAO_0000357,,
912,Expert,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,H,8,1,,CHEMBL615761,308.0,BAO_0000219,,
913,Autocuration,51,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,H,8,1,,CHEMBL872104,,BAO_0000357,,
914,Autocuration,51,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615762,,BAO_0000357,,
915,Autocuration,51,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615763,,BAO_0000357,,
916,Autocuration,51,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL615764,,BAO_0000357,,
917,Autocuration,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),H,8,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,Autocuration,51,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),H,8,1,,CHEMBL615766,,BAO_0000019,,
919,Autocuration,51,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615767,,BAO_0000357,,
920,Expert,51,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615768,,BAO_0000357,,
921,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615769,,BAO_0000357,,
922,Expert,51,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,H,8,1,,CHEMBL615770,,BAO_0000357,,
923,Autocuration,51,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615771,,BAO_0000357,,
924,Expert,51,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,H,8,1,,CHEMBL615772,,BAO_0000357,,
925,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615773,,BAO_0000357,,
926,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615774,,BAO_0000357,,
927,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615775,,BAO_0000357,,
928,Autocuration,51,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL615776,,BAO_0000357,,
929,Expert,51,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615777,,BAO_0000357,,
930,Autocuration,51,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,H,8,1,,CHEMBL615778,,BAO_0000219,,
931,Expert,51,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,D,9,1,,CHEMBL615779,,BAO_0000357,,
932,Autocuration,51,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,8,1,,CHEMBL615780,,BAO_0000357,,
933,Autocuration,51,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616298,,BAO_0000357,,
934,Autocuration,51,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616299,,BAO_0000357,,
935,Autocuration,51,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,H,8,1,,CHEMBL616300,485.0,BAO_0000219,,
936,Expert,51,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,H,8,1,,CHEMBL616301,485.0,BAO_0000219,,
937,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616302,,BAO_0000019,,
938,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),H,8,1,,CHEMBL616117,,BAO_0000019,,
939,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),H,8,1,,CHEMBL616118,,BAO_0000019,,
940,Autocuration,51,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,H,8,1,,CHEMBL616119,,BAO_0000019,,
941,Expert,51,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,9,1,,CHEMBL616120,308.0,BAO_0000219,,
942,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616121,,BAO_0000357,,
943,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,H,8,1,,CHEMBL616122,,BAO_0000357,,
944,Autocuration,51,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616123,,BAO_0000357,,
945,Expert,51,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616124,,BAO_0000357,,
946,Expert,51,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,8,1,,CHEMBL616125,,BAO_0000357,,
947,Expert,51,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,H,8,1,,CHEMBL616126,,BAO_0000357,,
948,Autocuration,51,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616127,449.0,BAO_0000219,,
949,Expert,51,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616128,,BAO_0000019,,
950,Autocuration,51,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,8,1,,CHEMBL616129,,BAO_0000357,,
951,Expert,51,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616130,,BAO_0000357,,
952,Autocuration,51,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,H,8,1,,CHEMBL616131,,BAO_0000357,,
953,Autocuration,51,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,H,8,1,,CHEMBL616132,308.0,BAO_0000219,,
954,Expert,51,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,D,9,1,,CHEMBL616133,308.0,BAO_0000219,,
955,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616134,,BAO_0000357,,
956,Autocuration,51,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,H,8,1,,CHEMBL616135,,BAO_0000357,,
957,Expert,51,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,D,9,1,,CHEMBL616136,,BAO_0000357,,
958,Autocuration,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,H,8,1,,CHEMBL616137,,BAO_0000019,,
959,Autocuration,51,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,H,8,1,,CHEMBL872105,,BAO_0000019,,
960,Autocuration,51,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,H,8,1,,CHEMBL616138,,BAO_0000357,,
961,Expert,51,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616139,,BAO_0000357,,
962,Autocuration,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",H,8,1,,CHEMBL616140,,BAO_0000019,,
963,Expert,51,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,H,8,1,,CHEMBL616141,,BAO_0000019,,
964,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616142,,BAO_0000357,,
965,Autocuration,51,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,H,8,1,,CHEMBL616143,,BAO_0000357,,
966,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,8,1,,CHEMBL616144,308.0,BAO_0000219,,
967,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,H,8,1,,CHEMBL616145,308.0,BAO_0000219,,
968,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,8,1,,CHEMBL616012,308.0,BAO_0000219,,
969,Autocuration,51,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,8,1,,CHEMBL616013,308.0,BAO_0000219,,
970,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,8,1,,CHEMBL616014,,BAO_0000019,,
971,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,8,1,,CHEMBL616015,,BAO_0000019,,
972,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,8,1,,CHEMBL616016,,BAO_0000019,,
973,Autocuration,51,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,H,8,1,,CHEMBL616017,,BAO_0000218,,
974,Autocuration,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,H,8,1,,CHEMBL616018,,BAO_0000019,,
975,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,H,8,1,,CHEMBL616019,,BAO_0000019,,
976,Autocuration,51,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,H,8,1,,CHEMBL616020,,BAO_0000019,,
977,Autocuration,51,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL858018,,BAO_0000357,,
978,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,8,1,,CHEMBL616021,722.0,BAO_0000219,,
979,Expert,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",H,8,1,,CHEMBL616022,,BAO_0000019,,
980,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",H,8,1,,CHEMBL616023,,BAO_0000019,,
981,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",H,8,1,,CHEMBL616024,,BAO_0000019,,
982,Autocuration,51,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",H,8,1,,CHEMBL616025,,BAO_0000019,,
983,Autocuration,51,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,8,1,,CHEMBL616026,449.0,BAO_0000219,,
984,Autocuration,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",H,8,1,,CHEMBL616027,,BAO_0000019,,
985,Expert,51,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",D,9,1,,CHEMBL616028,,BAO_0000019,,
986,Expert,51,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,D,9,1,,CHEMBL616029,,BAO_0000019,,
987,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,H,8,1,,CHEMBL616030,449.0,BAO_0000219,,
988,Expert,51,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,H,8,1,,CHEMBL616031,,BAO_0000019,,
989,Expert,51,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,9,1,,CHEMBL616032,,BAO_0000019,,
990,Expert,51,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,9,1,,CHEMBL616033,,BAO_0000019,,
991,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,8,1,,CHEMBL616034,,BAO_0000019,,
992,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,8,1,,CHEMBL616035,,BAO_0000019,,
993,Autocuration,51,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616036,,BAO_0000019,,
994,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,8,1,,CHEMBL616037,,BAO_0000019,,
995,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,8,1,,CHEMBL616038,,BAO_0000019,,
996,Autocuration,51,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,8,1,,CHEMBL616039,,BAO_0000019,,
997,Autocuration,51,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616040,,BAO_0000019,,
998,Expert,51,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,9,1,,CHEMBL616041,308.0,BAO_0000219,,
999,Expert,51,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,9,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,Expert,51,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,9,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,Autocuration,51,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL616044,,BAO_0000019,,
1002,Autocuration,51,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL616045,,BAO_0000019,,
1003,Autocuration,51,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,8,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,Autocuration,51,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,8,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,Autocuration,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,H,8,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,Expert,51,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),D,9,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,Autocuration,51,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,8,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,Expert,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,H,8,1,,CHEMBL616051,,BAO_0000219,,
1009,Autocuration,51,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,H,8,1,,CHEMBL616212,,BAO_0000219,,
1010,Autocuration,51,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL616213,,BAO_0000019,,
1011,Expert,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,H,8,1,,CHEMBL616214,,BAO_0000219,,
1012,Expert,51,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,H,8,1,,CHEMBL616215,,BAO_0000219,,
1013,Autocuration,51,,,Binding activity radioligand.,H,8,1,,CHEMBL616216,,BAO_0000357,,
1014,Autocuration,51,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,8,1,,CHEMBL616217,,BAO_0000019,,
1015,Autocuration,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616218,,BAO_0000357,,
1016,Autocuration,51,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616219,,BAO_0000357,,
1017,Autocuration,51,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616220,,BAO_0000357,,
1018,Expert,51,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL833493,,BAO_0000357,,
1019,Autocuration,51,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616221,,BAO_0000357,,
1020,Expert,51,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,9,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,Autocuration,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616223,,BAO_0000019,,
1022,Autocuration,51,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,H,8,1,,CHEMBL616224,,BAO_0000019,,
1023,Expert,51,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,H,8,1,,CHEMBL616225,,BAO_0000019,,
1024,Expert,51,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,D,9,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,H,8,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,8,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,H,8,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,H,8,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616232,,BAO_0000357,,
1031,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,8,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,Autocuration,51,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,H,8,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,Autocuration,51,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,H,8,1,,CHEMBL616234,,BAO_0000219,,
1034,Autocuration,51,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616235,,BAO_0000357,,
1035,Expert,51,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,8,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,Expert,51,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,8,1,,CHEMBL616237,,BAO_0000019,,
1037,Autocuration,51,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,H,8,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,Autocuration,51,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,H,8,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,Autocuration,51,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,H,8,1,,CHEMBL616240,,BAO_0000219,,
1040,Expert,51,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,D,9,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,Autocuration,51,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,H,8,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,Autocuration,51,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,Expert,51,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616244,,BAO_0000357,,
1044,Autocuration,51,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616245,,BAO_0000357,,
1045,Autocuration,106,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,8,1,,CHEMBL616246,,BAO_0000357,,
1046,Autocuration,105,,,Binding affinity against 5-HT1D receptor,H,8,1,,CHEMBL616247,,BAO_0000357,,
1047,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616248,,BAO_0000357,,
1048,Autocuration,107,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL616249,,BAO_0000357,,
1049,Autocuration,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,8,1,,CHEMBL616250,,BAO_0000357,,
1050,Autocuration,51,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616251,,BAO_0000357,,
1051,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,H,8,1,,CHEMBL616252,,BAO_0000218,,
1052,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,H,8,1,,CHEMBL616253,,BAO_0000218,,
1053,Autocuration,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,H,8,1,,CHEMBL616254,,BAO_0000218,,
1054,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,D,9,1,,CHEMBL616255,,BAO_0000218,,
1055,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,D,9,1,,CHEMBL832872,,BAO_0000218,,
1056,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,D,9,1,,CHEMBL616256,,BAO_0000218,,
1057,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,D,9,1,,CHEMBL616257,,BAO_0000218,,
1058,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,D,9,1,,CHEMBL616258,,BAO_0000218,,
1059,Expert,11863,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,D,9,1,,CHEMBL616384,,BAO_0000218,,
1060,Autocuration,11863,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,H,8,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,Expert,11863,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,H,8,1,,CHEMBL616386,,BAO_0000357,,
1062,Expert,11863,Hippocampus,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,9,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,Autocuration,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,8,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,Expert,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,9,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,Autocuration,11863,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,8,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,Autocuration,11863,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,H,8,1,,CHEMBL616391,,BAO_0000357,,
1067,Expert,11863,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,D,9,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616393,,BAO_0000357,,
1069,Autocuration,51,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,H,8,1,,CHEMBL616394,,BAO_0000357,,
1070,Autocuration,51,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,H,8,1,,CHEMBL616395,,BAO_0000019,,
1071,Autocuration,51,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,H,8,1,,CHEMBL616396,,BAO_0000357,,
1072,Autocuration,51,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,8,1,,CHEMBL872907,,BAO_0000019,,
1073,Autocuration,51,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,8,1,,CHEMBL616397,,BAO_0000019,,
1074,Autocuration,51,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,H,8,1,,CHEMBL616398,,BAO_0000019,,
1075,Expert,51,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616399,,BAO_0000357,,
1076,Autocuration,51,,,Binding activity radioligand.,H,8,1,,CHEMBL857065,,BAO_0000357,,
1077,Expert,51,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,8,1,,CHEMBL616400,,BAO_0000019,,
1078,Autocuration,51,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,8,1,,CHEMBL616401,,BAO_0000019,,
1079,Expert,10624,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,H,8,1,,CHEMBL616402,,BAO_0000019,,
1080,Expert,51,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616403,,BAO_0000019,,
1081,Autocuration,51,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,H,8,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,Autocuration,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,H,8,1,,CHEMBL616405,,BAO_0000249,,
1083,Autocuration,51,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,H,8,1,,CHEMBL616406,,BAO_0000019,,
1084,Expert,51,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,H,8,1,,CHEMBL616407,,BAO_0000019,,
1085,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,H,8,1,,CHEMBL616408,,BAO_0000019,,
1086,Expert,10576,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,D,9,1,,CHEMBL616409,,BAO_0000249,,
1087,Expert,10576,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",D,9,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,Autocuration,10576,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,H,8,1,,CHEMBL616411,,BAO_0000357,,
1089,Expert,10576,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,9,1,,CHEMBL616412,,BAO_0000249,,
1090,Expert,10576,Hippocampus,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,9,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,Autocuration,10576,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,8,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,Expert,10576,Hippocampus,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,D,9,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,Autocuration,10576,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,H,8,1,,CHEMBL616416,,BAO_0000019,,
1094,Expert,10576,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616417,,BAO_0000357,,
1095,Autocuration,10576,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,8,1,,CHEMBL616418,,BAO_0000357,,
1096,Autocuration,10576,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,8,1,,CHEMBL616419,,BAO_0000219,,
1097,Autocuration,10576,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,H,8,1,,CHEMBL616420,,BAO_0000357,,
1098,Autocuration,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,8,1,,CHEMBL616421,,BAO_0000249,,
1099,Autocuration,10576,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,8,1,,CHEMBL616422,,BAO_0000249,,
1100,Expert,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,H,8,1,,CHEMBL616423,,BAO_0000249,,
1101,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,D,9,1,,CHEMBL616424,,BAO_0000357,,
1102,Expert,10576,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616425,,BAO_0000357,,
1103,Expert,10576,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,H,8,1,,CHEMBL616426,,BAO_0000357,,
1104,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,H,8,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,H,8,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,Autocuration,10576,Hippocampus,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,Expert,10576,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616052,,BAO_0000357,,
1108,Autocuration,10576,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616053,,BAO_0000357,,
1109,Autocuration,10576,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616054,,BAO_0000249,,
1110,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616055,,BAO_0000357,,
1111,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,H,8,1,,CHEMBL616056,,BAO_0000357,,
1112,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,8,1,,CHEMBL616057,,BAO_0000019,,
1113,Expert,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,D,9,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,Autocuration,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,8,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616060,,BAO_0000249,,
1116,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,D,9,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,H,8,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616063,,BAO_0000249,,
1119,Autocuration,10576,Striatum,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,8,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,D,9,1,,CHEMBL616065,,BAO_0000249,,
1121,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,D,9,1,,CHEMBL616066,,BAO_0000249,,
1122,Autocuration,10576,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,Autocuration,10576,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,H,8,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,Intermediate,10576,Hippocampus,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,Expert,10576,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,8,1,,CHEMBL616070,,BAO_0000249,,
1126,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,H,8,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,Autocuration,10576,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,H,8,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,Expert,10576,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,H,8,1,,CHEMBL616075,,BAO_0000019,,
1131,Autocuration,10576,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616076,,BAO_0000357,,
1132,Expert,10576,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,D,9,1,,CHEMBL616077,,BAO_0000019,,
1133,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,D,9,1,,CHEMBL616078,,BAO_0000019,,
1134,Expert,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,D,9,1,,CHEMBL616079,,BAO_0000019,,
1135,Expert,10576,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,9,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616081,,BAO_0000357,,
1137,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,D,9,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,Autocuration,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,H,8,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,8,1,,CHEMBL616084,,BAO_0000019,,
1140,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,H,8,1,,CHEMBL616085,,BAO_0000019,,
1141,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,H,8,1,,CHEMBL616086,,BAO_0000019,,
1142,Autocuration,10576,Hippocampus,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",H,8,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,Expert,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,H,8,1,,CHEMBL616088,,BAO_0000357,,
1144,Autocuration,10576,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,H,8,1,,CHEMBL616089,,BAO_0000019,,
1145,Expert,10576,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,D,9,1,,CHEMBL616090,,BAO_0000357,,
1146,Autocuration,10576,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,8,1,,CHEMBL616091,,BAO_0000357,,
1147,Autocuration,10576,Striatum,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,8,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,Autocuration,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),H,8,1,,CHEMBL616093,,BAO_0000357,,
1149,Autocuration,10576,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),H,8,1,,CHEMBL616094,,BAO_0000218,,
1150,Autocuration,10576,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,H,8,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616096,,BAO_0000357,,
1152,Expert,10576,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,H,8,1,,CHEMBL616097,,BAO_0000249,,
1153,Expert,10576,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,D,9,1,,CHEMBL616098,,BAO_0000249,,
1154,Autocuration,10576,Hippocampus,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,Autocuration,10576,Hippocampus,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,Expert,10576,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616101,,BAO_0000357,,
1157,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,H,8,1,,CHEMBL616102,,BAO_0000249,,
1158,Autocuration,10576,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616103,,BAO_0000357,,
1159,Expert,10576,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,H,8,1,,CHEMBL616104,,BAO_0000019,,
1160,Expert,10576,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL616105,,BAO_0000019,,
1161,Expert,10576,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616106,,BAO_0000019,,
1162,Autocuration,10576,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,H,8,1,,CHEMBL616107,,BAO_0000019,,
1163,Expert,10576,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,H,8,1,,CHEMBL616108,,BAO_0000357,,
1164,Expert,10576,Hippocampus,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,8,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,Autocuration,10576,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,H,8,1,,CHEMBL616110,,BAO_0000357,,
1166,Expert,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,H,8,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,H,8,1,,CHEMBL616112,,BAO_0000019,,
1168,Autocuration,10576,Hippocampus,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,H,8,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,Autocuration,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616114,,BAO_0000019,,
1170,Autocuration,10576,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616115,,BAO_0000019,,
1171,Autocuration,10576,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616116,,BAO_0000357,,
1172,Expert,10576,Brain,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,Expert,10576,Hippocampus,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,Expert,10576,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,H,8,1,,CHEMBL615940,,BAO_0000019,,
1175,Expert,10576,Hippocampus,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,H,8,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,H,8,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,H,8,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,H,8,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,H,8,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,H,8,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,H,8,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,H,8,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,H,8,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,H,8,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,H,8,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,H,8,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,H,8,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,H,8,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,Expert,10576,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,D,9,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,H,8,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,H,8,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,Expert,10576,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,H,8,1,,CHEMBL615958,,BAO_0000019,,
1193,Expert,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,H,8,1,,CHEMBL615959,,BAO_0000019,,
1194,Autocuration,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),H,8,1,,CHEMBL615960,,BAO_0000019,,
1195,Autocuration,10576,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),H,8,1,,CHEMBL615961,,BAO_0000019,,
1196,Expert,10576,Brain,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,8,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,Expert,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,H,8,1,,CHEMBL615963,,BAO_0000019,,
1198,Autocuration,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,H,8,1,,CHEMBL615964,,BAO_0000019,,
1199,Autocuration,10576,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,H,8,1,,CHEMBL615965,,BAO_0000019,,
1200,Expert,10576,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,H,8,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,Expert,10576,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,H,8,1,,CHEMBL615967,,BAO_0000249,,
1202,Expert,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL615968,,BAO_0000019,,
1203,Autocuration,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,8,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,Autocuration,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),H,8,1,,CHEMBL615970,,BAO_0000218,,
1205,Expert,10576,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,D,9,1,,CHEMBL615971,,BAO_0000357,,
1206,Expert,10576,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,8,1,,CHEMBL615972,,BAO_0000249,,
1207,Autocuration,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,H,8,1,,CHEMBL615973,,BAO_0000249,,
1208,Autocuration,10576,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,H,8,1,,CHEMBL615974,,BAO_0000249,,
1209,Expert,51,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,9,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,Expert,10576,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,H,8,1,,CHEMBL615976,,BAO_0000249,,
1211,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,D,9,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL615977,,BAO_0000357,,
1213,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,H,8,1,,CHEMBL615978,,BAO_0000357,,
1214,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,H,8,1,,CHEMBL616166,,BAO_0000357,,
1215,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,H,8,1,,CHEMBL616167,,BAO_0000357,,
1216,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,H,8,1,,CHEMBL616168,,BAO_0000357,,
1217,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,H,8,1,,CHEMBL616169,,BAO_0000357,,
1218,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,H,8,1,,CHEMBL616170,,BAO_0000357,,
1219,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,H,8,1,,CHEMBL616171,,BAO_0000357,,
1220,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,H,8,1,,CHEMBL616172,,BAO_0000357,,
1221,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,H,8,1,,CHEMBL616173,,BAO_0000357,,
1222,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,H,8,1,,CHEMBL616174,,BAO_0000357,,
1223,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,H,8,1,,CHEMBL616175,,BAO_0000357,,
1224,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,H,8,1,,CHEMBL616176,,BAO_0000357,,
1225,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,H,8,1,,CHEMBL616177,,BAO_0000357,,
1226,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,H,8,1,,CHEMBL616178,,BAO_0000357,,
1227,Autocuration,10576,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,H,8,1,,CHEMBL616179,,BAO_0000019,,
1228,Autocuration,10576,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616180,,BAO_0000357,,
1229,Autocuration,10576,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,H,8,1,,CHEMBL616181,,BAO_0000357,,
1230,Autocuration,10576,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,H,8,1,,CHEMBL616182,,BAO_0000019,,
1231,Autocuration,10576,Hippocampus,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,Expert,10576,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,H,8,1,,CHEMBL615874,,BAO_0000019,,
1233,Expert,10576,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,9,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,Autocuration,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,H,8,1,,CHEMBL615876,,BAO_0000019,,
1235,Autocuration,10576,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,H,8,1,,CHEMBL615877,,BAO_0000019,,
1236,Autocuration,10576,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),H,8,1,,CHEMBL615878,,BAO_0000357,,
1237,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,H,8,1,,CHEMBL615879,,BAO_0000357,,
1238,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,H,8,1,,CHEMBL615880,,BAO_0000357,,
1239,Autocuration,10576,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL615881,,BAO_0000019,,
1240,Expert,10576,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",D,9,1,,CHEMBL615882,,BAO_0000019,,
1241,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,H,8,1,,CHEMBL615883,,BAO_0000218,,
1242,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),H,8,1,,CHEMBL615884,,BAO_0000218,,
1243,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),H,8,1,,CHEMBL615885,,BAO_0000218,,
1244,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),H,8,1,,CHEMBL615886,,BAO_0000218,,
1245,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),H,8,1,,CHEMBL615887,,BAO_0000218,,
1246,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),H,8,1,,CHEMBL615888,,BAO_0000218,,
1247,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),H,8,1,,CHEMBL615889,,BAO_0000218,,
1248,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),H,8,1,,CHEMBL615890,,BAO_0000218,,
1249,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),H,8,1,,CHEMBL615891,,BAO_0000218,,
1250,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),H,8,1,,CHEMBL615892,,BAO_0000218,,
1251,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),H,8,1,,CHEMBL615893,,BAO_0000218,,
1252,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),H,8,1,,CHEMBL615894,,BAO_0000218,,
1253,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),H,8,1,,CHEMBL615895,,BAO_0000218,,
1254,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),H,8,1,,CHEMBL615896,,BAO_0000218,,
1255,Autocuration,10576,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,H,8,1,,CHEMBL615897,,BAO_0000218,,
1256,Expert,10576,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,9,1,,CHEMBL615898,,BAO_0000249,,
1257,Autocuration,10576,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,H,8,1,,CHEMBL615899,,BAO_0000019,,
1258,Autocuration,10576,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,8,1,,CHEMBL616291,,BAO_0000019,,
1259,Autocuration,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,H,8,1,,CHEMBL616292,,BAO_0000357,,
1260,Autocuration,10576,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,8,1,,CHEMBL616293,,BAO_0000249,,
1261,Expert,10576,Hippocampus,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,Autocuration,10576,Hippocampus,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,H,8,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,Autocuration,10576,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,H,8,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,8,1,,CHEMBL616297,,BAO_0000019,,
1265,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,H,8,1,,CHEMBL616605,,BAO_0000019,,
1266,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,H,8,1,,CHEMBL616606,,BAO_0000019,,
1267,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,8,1,,CHEMBL616607,,BAO_0000019,,
1268,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,8,1,,CHEMBL616608,,BAO_0000019,,
1269,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,H,8,1,,CHEMBL616609,,BAO_0000019,,
1270,Expert,10576,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,D,9,1,,CHEMBL616610,,BAO_0000019,,
1271,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,8,1,,CHEMBL616611,,BAO_0000019,,
1272,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,H,8,1,,CHEMBL616612,,BAO_0000019,,
1273,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,H,8,1,,CHEMBL616613,,BAO_0000019,,
1274,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,H,8,1,,CHEMBL616614,,BAO_0000019,,
1275,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,H,8,1,,CHEMBL616615,,BAO_0000019,,
1276,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,8,1,,CHEMBL616616,,BAO_0000019,,
1277,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,H,8,1,,CHEMBL616617,,BAO_0000019,,
1278,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,8,1,,CHEMBL616618,,BAO_0000019,,
1279,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,H,8,1,,CHEMBL616619,,BAO_0000019,,
1280,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,H,8,1,,CHEMBL616620,,BAO_0000019,,
1281,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,8,1,,CHEMBL616621,,BAO_0000019,,
1282,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,H,8,1,,CHEMBL616622,,BAO_0000019,,
1283,Expert,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,H,8,1,,CHEMBL616146,,BAO_0000019,,
1284,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,H,8,1,,CHEMBL832873,,BAO_0000019,,
1285,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,H,8,1,,CHEMBL616147,,BAO_0000019,,
1286,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,8,1,,CHEMBL872872,,BAO_0000019,,
1287,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,8,1,,CHEMBL616148,,BAO_0000019,,
1288,Autocuration,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,H,8,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,Expert,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,H,8,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,D,9,1,,CHEMBL616151,,BAO_0000249,,
1291,Expert,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,H,8,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,Autocuration,10576,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,H,8,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,Autocuration,10576,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,H,8,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,Expert,10576,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,9,1,,CHEMBL884861,,BAO_0000249,,
1295,Autocuration,10576,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,H,8,1,,CHEMBL616672,,BAO_0000357,,
1296,Autocuration,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,8,1,,CHEMBL616673,,BAO_0000019,,
1297,Expert,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616674,,BAO_0000019,,
1298,Autocuration,10576,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,8,1,,CHEMBL616675,,BAO_0000357,,
1299,Autocuration,10576,Hippocampus,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,H,8,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,Autocuration,10576,Hippocampus,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,8,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,Autocuration,10576,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,8,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,Expert,10576,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616679,,BAO_0000357,,
1303,Expert,10576,Hippocampus,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,H,8,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,Autocuration,10576,Hippocampus,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,Autocuration,10576,Hippocampus,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,Autocuration,10576,Hippocampus,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,Autocuration,10576,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,Autocuration,10576,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,H,8,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,Autocuration,10576,Brain,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,H,8,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,Autocuration,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,8,1,,CHEMBL616687,,BAO_0000357,,
1311,Autocuration,10576,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,8,1,,CHEMBL616688,,BAO_0000357,,
1312,Autocuration,10576,Hippocampus,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,H,8,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,Autocuration,10576,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,H,8,1,,CHEMBL616690,,BAO_0000357,,
1314,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,H,8,1,,CHEMBL616691,,BAO_0000357,,
1315,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,D,9,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,H,8,1,,CHEMBL616693,,BAO_0000249,,
1317,Expert,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",D,9,1,,CHEMBL616694,,BAO_0000019,,
1318,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,H,8,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,H,8,1,,CHEMBL616696,,BAO_0000357,,
1320,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL616697,,BAO_0000357,,
1321,Autocuration,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616698,,BAO_0000357,,
1322,Expert,10576,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616949,,BAO_0000019,,
1323,Autocuration,10576,Hippocampus,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,H,8,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,Autocuration,10576,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,8,1,,CHEMBL832875,,BAO_0000357,,
1325,Expert,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,8,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,Expert,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,8,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,Expert,10576,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,H,8,1,,CHEMBL616953,,BAO_0000357,,
1328,Autocuration,10576,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,H,8,1,,CHEMBL616954,,BAO_0000357,,
1329,Autocuration,106,,,GTPgammaS radioligand binding assay,H,8,1,,CHEMBL616955,,BAO_0000357,,
1330,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,8,1,,CHEMBL616956,,BAO_0000357,,
1331,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,H,8,1,,CHEMBL616957,,BAO_0000019,,
1332,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,H,8,1,,CHEMBL616958,,BAO_0000019,,
1333,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616959,,BAO_0000357,,
1334,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,8,1,,CHEMBL616960,,BAO_0000357,,
1335,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,H,8,1,,CHEMBL616961,,BAO_0000019,,
1336,Expert,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,H,8,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,Expert,106,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,D,9,1,,CHEMBL616524,,BAO_0000357,,
1339,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,H,8,1,,CHEMBL872908,,BAO_0000019,,
1341,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,H,8,1,,CHEMBL616526,,BAO_0000019,,
1342,Expert,106,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616527,,BAO_0000357,,
1343,Expert,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,8,1,,CHEMBL616528,,BAO_0000219,,
1344,Autocuration,106,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616529,,BAO_0000357,,
1345,Autocuration,106,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,H,8,1,,CHEMBL616530,,BAO_0000357,,
1346,Expert,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616531,,BAO_0000357,,
1347,Autocuration,106,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616532,,BAO_0000357,,
1348,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616533,,BAO_0000357,,
1349,Expert,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616534,,BAO_0000357,,
1350,Expert,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,H,8,1,,CHEMBL616535,,BAO_0000357,,
1351,Autocuration,106,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,H,8,1,,CHEMBL616536,,BAO_0000357,,
1352,Autocuration,106,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616537,,BAO_0000357,,
1353,Expert,106,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,H,8,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,Expert,106,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616539,,BAO_0000019,,
1355,Expert,106,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616540,,BAO_0000019,,
1356,Autocuration,106,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,8,1,,CHEMBL616429,,BAO_0000357,,
1357,Expert,106,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616430,,BAO_0000357,,
1358,Expert,106,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,D,9,1,,CHEMBL616431,,BAO_0000219,,
1359,Expert,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616432,,BAO_0000357,,
1360,Expert,106,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,D,9,1,,CHEMBL616433,,BAO_0000357,,
1361,Expert,106,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616434,,BAO_0000357,,
1362,Autocuration,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,H,8,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,Expert,106,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,H,8,1,,CHEMBL616436,,BAO_0000019,,
1364,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,8,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,Autocuration,106,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,H,8,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,Autocuration,106,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,8,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,D,9,1,,CHEMBL616440,,BAO_0000357,,
1368,Autocuration,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,H,8,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,Expert,106,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,H,8,1,,CHEMBL616442,,BAO_0000357,,
1370,Autocuration,106,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616443,,BAO_0000357,,
1371,Expert,106,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616445,,BAO_0000357,,
1373,Expert,106,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616446,,BAO_0000357,,
1374,Expert,106,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,D,9,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,H,8,1,,CHEMBL616448,,BAO_0000357,,
1376,Autocuration,106,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,H,8,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,Autocuration,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,H,8,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,Autocuration,106,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,H,8,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,8,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,Autocuration,106,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,H,8,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,Expert,106,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616455,,BAO_0000357,,
1384,Autocuration,106,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,8,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,Autocuration,106,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,H,8,1,,CHEMBL616457,,BAO_0000357,,
1386,Autocuration,106,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,8,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,Autocuration,106,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,Expert,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,H,8,1,,CHEMBL616460,,BAO_0000019,,
1389,Expert,106,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,H,8,1,,CHEMBL616461,,BAO_0000019,,
1390,Autocuration,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,8,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,Autocuration,106,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,8,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,Autocuration,105,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",H,8,1,,CHEMBL616464,,BAO_0000019,,
1393,Autocuration,105,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,H,8,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,Autocuration,17105,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL832874,,BAO_0000357,,
1395,Autocuration,106,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,H,8,1,,CHEMBL616184,,BAO_0000019,,
1396,Autocuration,106,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,H,8,1,,CHEMBL616185,,BAO_0000019,,
1397,Intermediate,106,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",H,8,1,,CHEMBL616186,,BAO_0000019,,
1398,Autocuration,106,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,H,8,1,,CHEMBL616187,,BAO_0000019,,
1399,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,H,8,1,,CHEMBL616188,,BAO_0000357,,
1400,Intermediate,10577,,,Binding affinity for 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL873475,,BAO_0000357,,
1401,Expert,10577,Striatum,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,D,9,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,Expert,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,8,1,,CHEMBL616190,,BAO_0000357,,
1403,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,H,8,1,,CHEMBL616191,,BAO_0000357,,
1404,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,H,8,1,,CHEMBL616192,,BAO_0000357,,
1405,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,H,8,1,,CHEMBL616193,,BAO_0000357,,
1406,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,H,8,1,,CHEMBL616194,,BAO_0000357,,
1407,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,H,8,1,,CHEMBL616195,,BAO_0000357,,
1408,Autocuration,10576,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,H,8,1,,CHEMBL616196,,BAO_0000357,,
1409,Autocuration,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,H,8,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,Intermediate,10576,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616198,,BAO_0000019,,
1411,Autocuration,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,8,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,Expert,10576,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,H,8,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,Expert,10576,Hippocampus,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,8,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,8,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,H,8,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,H,8,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,Expert,10576,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,H,8,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,Expert,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,8,1,,CHEMBL616207,,BAO_0000249,,
1420,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,H,8,1,,CHEMBL616208,,BAO_0000249,,
1421,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,H,8,1,,CHEMBL616209,,BAO_0000249,,
1422,Expert,10576,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,H,8,1,,CHEMBL616210,,BAO_0000357,,
1423,Expert,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,H,8,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,Autocuration,10576,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,H,8,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,Autocuration,10576,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616506,,BAO_0000019,,
1427,Autocuration,10576,Hippocampus,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,8,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,Expert,10576,Hippocampus,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,D,9,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,Autocuration,10576,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,H,8,1,,CHEMBL616303,,BAO_0000249,,
1430,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,H,8,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,Expert,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,8,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,Intermediate,10576,Hippocampus,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,Autocuration,10576,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616307,,BAO_0000357,,
1434,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,D,9,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,Expert,10576,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,H,8,1,,CHEMBL616308,,BAO_0000357,,
1436,Autocuration,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,H,8,1,,CHEMBL616309,,BAO_0000019,,
1437,Expert,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,H,8,1,,CHEMBL616310,,BAO_0000019,,
1438,Autocuration,10576,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,H,8,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,Expert,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616312,,BAO_0000357,,
1440,Autocuration,10576,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,H,8,1,,CHEMBL616313,,BAO_0000357,,
1441,Expert,10576,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,H,8,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,Autocuration,10576,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,H,8,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,Intermediate,10576,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,H,8,1,,CHEMBL616569,,BAO_0000019,,
1446,Expert,10576,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,H,8,1,,CHEMBL616570,,BAO_0000357,,
1447,Autocuration,10576,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,8,1,,CHEMBL616571,,BAO_0000357,,
1448,Autocuration,10576,Hippocampus,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,H,8,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,Expert,10576,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,H,8,1,,CHEMBL616573,,BAO_0000249,,
1450,Expert,10576,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,D,9,1,,CHEMBL616574,,BAO_0000357,,
1451,Expert,10576,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,H,8,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,Autocuration,10576,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,H,8,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,Autocuration,10576,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616576,,BAO_0000357,,
1454,Autocuration,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,H,8,1,,CHEMBL616577,,BAO_0000249,,
1455,Autocuration,10576,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,H,8,1,,CHEMBL616578,,BAO_0000249,,
1456,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,H,8,1,,CHEMBL616579,,BAO_0000357,,
1457,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,D,9,1,,CHEMBL616580,,BAO_0000019,,
1458,Autocuration,10576,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,8,1,,CHEMBL616581,,BAO_0000019,,
1459,Autocuration,10576,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,Expert,10576,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,8,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,Expert,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,D,9,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616585,,BAO_0000357,,
1463,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,D,9,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,Autocuration,10576,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,H,8,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,Autocuration,10576,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,H,8,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,Autocuration,10576,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,Expert,10576,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,Expert,10576,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",H,8,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,Expert,10576,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616592,,BAO_0000357,,
1470,Autocuration,10576,,,The inhibition activity of 5-HT1A at 1 uM,H,8,1,,CHEMBL616593,,BAO_0000357,,
1471,Expert,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",H,8,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,Expert,10576,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,H,8,1,,CHEMBL616595,,BAO_0000249,,
1473,Autocuration,10576,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,H,8,1,,CHEMBL616596,,BAO_0000357,,
1474,Autocuration,10576,Hippocampus,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,8,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,Expert,10576,Hippocampus,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,8,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,Expert,10576,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,D,9,1,,CHEMBL616599,,BAO_0000249,,
1477,Expert,10576,Hippocampus,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,9,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,H,8,1,,CHEMBL616601,,BAO_0000019,,
1479,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,H,8,1,,CHEMBL616602,,BAO_0000019,,
1480,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,H,8,1,,CHEMBL616603,,BAO_0000019,,
1481,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,H,8,1,,CHEMBL616604,,BAO_0000019,,
1482,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,H,8,1,,CHEMBL616316,,BAO_0000249,,
1483,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,H,8,1,,CHEMBL616317,,BAO_0000249,,
1484,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,D,9,1,,CHEMBL616318,,BAO_0000019,,
1485,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,H,8,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,Autocuration,10576,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,H,8,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,Expert,10576,Hippocampus,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,D,9,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,8,1,,CHEMBL616322,,BAO_0000019,,
1489,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,H,8,1,,CHEMBL616323,,BAO_0000019,,
1490,Autocuration,10576,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,H,8,1,,CHEMBL616324,,BAO_0000357,,
1491,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,8,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,8,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,Autocuration,10576,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,H,8,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,Autocuration,10576,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616328,,BAO_0000357,,
1495,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,8,1,,CHEMBL858110,,BAO_0000249,,
1496,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,8,1,,CHEMBL616329,,BAO_0000249,,
1497,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,8,1,,CHEMBL616330,,BAO_0000249,,
1498,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,8,1,,CHEMBL616331,,BAO_0000249,,
1499,Autocuration,10576,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,8,1,,CHEMBL616332,,BAO_0000249,,
1500,Autocuration,10576,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,8,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,Autocuration,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,H,8,1,,CHEMBL616333,,BAO_0000019,,
1502,Expert,10576,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616334,,BAO_0000019,,
1503,Autocuration,10576,Hippocampus,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,8,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,Autocuration,10576,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,H,8,1,,CHEMBL616336,,BAO_0000019,,
1505,Expert,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616337,,BAO_0000249,,
1506,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,H,8,1,,CHEMBL616338,,BAO_0000019,,
1507,Autocuration,10576,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,H,8,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,Autocuration,10576,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,H,8,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,Autocuration,10576,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL616341,,BAO_0000357,,
1510,Expert,10576,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616342,,BAO_0000357,,
1511,Expert,10576,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,D,9,1,,CHEMBL616343,,BAO_0000019,,
1512,Expert,10576,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,H,8,1,,CHEMBL616344,,BAO_0000019,,
1513,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616345,,BAO_0000357,,
1514,Expert,10576,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,H,8,1,,CHEMBL616346,,BAO_0000019,,
1515,Autocuration,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,8,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,Expert,10576,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,H,8,1,,CHEMBL616348,,BAO_0000019,,
1517,Expert,10576,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616349,,BAO_0000357,,
1518,Expert,10576,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,D,9,1,,CHEMBL616152,,BAO_0000249,,
1519,Autocuration,10576,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,8,1,,CHEMBL616153,,BAO_0000249,,
1520,Expert,10576,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",H,8,1,,CHEMBL616154,,BAO_0000019,,
1521,Autocuration,10576,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,8,1,,CHEMBL616155,,BAO_0000019,,
1522,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,D,9,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,Expert,10576,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,D,9,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,Autocuration,10576,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,H,8,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,Autocuration,10576,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,8,1,,CHEMBL616159,,BAO_0000357,,
1526,Expert,10576,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,H,8,1,,CHEMBL616160,,BAO_0000357,,
1527,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,H,8,1,,CHEMBL616161,,BAO_0000019,,
1528,Autocuration,10576,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,8,1,,CHEMBL616162,,BAO_0000019,,
1529,Expert,12687,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,9,1,,CHEMBL616163,,BAO_0000357,,
1530,Expert,10626,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,8,1,,CHEMBL616164,,BAO_0000249,,
1531,Autocuration,10576,Brain,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,H,8,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,Autocuration,51,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,H,8,1,,CHEMBL616355,,BAO_0000019,,
1533,Autocuration,10576,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,8,1,,CHEMBL616356,,BAO_0000019,,
1534,Autocuration,10576,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,8,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,Autocuration,10576,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",H,8,1,,CHEMBL616358,,BAO_0000019,,
1536,Autocuration,51,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616359,,BAO_0000357,,
1537,Expert,51,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,H,8,1,,CHEMBL616360,,BAO_0000357,,
1538,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616361,,BAO_0000357,,
1539,Autocuration,51,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616362,,BAO_0000357,,
1540,Autocuration,51,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,H,8,1,,CHEMBL616363,,BAO_0000249,,
1541,Autocuration,51,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,H,8,1,,CHEMBL616364,,BAO_0000357,,
1542,Autocuration,51,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616365,,BAO_0000357,,
1543,Expert,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616366,,BAO_0000357,,
1544,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL872906,,BAO_0000357,,
1545,Autocuration,51,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,H,8,1,,CHEMBL616367,,BAO_0000357,,
1546,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616368,,BAO_0000357,,
1547,Autocuration,51,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL616369,,BAO_0000357,,
1548,Expert,51,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,D,9,1,,CHEMBL616370,,BAO_0000357,,
1549,Expert,51,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,D,9,1,,CHEMBL616371,,BAO_0000357,,
1550,Autocuration,51,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,8,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,Expert,51,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,H,8,1,,CHEMBL616373,,BAO_0000219,,
1552,Autocuration,51,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616374,,BAO_0000218,,
1553,Autocuration,51,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,8,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,Autocuration,51,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL616376,,BAO_0000357,,
1555,Expert,51,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,H,8,1,,CHEMBL857064,,BAO_0000357,,
1556,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL616377,,BAO_0000357,,
1557,Autocuration,51,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,8,1,,CHEMBL616378,,BAO_0000357,,
1558,Autocuration,51,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616379,,BAO_0000357,,
1559,Autocuration,11863,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616380,,BAO_0000357,,
1560,Autocuration,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,H,8,1,,CHEMBL616381,,BAO_0000357,,
1561,Autocuration,11863,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616382,,BAO_0000357,,
1562,Autocuration,11863,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,H,8,1,,CHEMBL616383,,BAO_0000357,,
1563,Expert,11863,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,D,9,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,Autocuration,11863,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616351,,BAO_0000357,,
1565,Autocuration,11863,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,H,8,1,,CHEMBL616352,,BAO_0000357,,
1566,Autocuration,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616353,,BAO_0000357,,
1567,Autocuration,11863,,,Binding affinity against serotonergic 5-HT1a receptor,H,8,1,,CHEMBL616354,,BAO_0000357,,
1568,Autocuration,11863,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616508,,BAO_0000357,,
1569,Expert,11863,,,Binding affinity for 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616559,,BAO_0000357,,
1570,Autocuration,11863,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616560,,BAO_0000357,,
1571,Autocuration,11863,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",H,8,1,,CHEMBL616561,,BAO_0000357,,
1572,Autocuration,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,8,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,Autocuration,11863,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,8,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,Autocuration,11863,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616564,,BAO_0000357,,
1575,Autocuration,11863,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,H,8,1,,CHEMBL616565,,BAO_0000357,,
1576,Autocuration,11863,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616566,,BAO_0000218,,
1577,Autocuration,11863,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,H,8,1,,CHEMBL616989,,BAO_0000357,,
1578,Autocuration,11863,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL857975,,BAO_0000357,,
1579,Expert,11863,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,9,1,,CHEMBL616990,,BAO_0000357,,
1580,Autocuration,11863,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,8,1,,CHEMBL616991,,BAO_0000357,,
1581,Autocuration,11863,,,Tested against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616992,,BAO_0000357,,
1582,Autocuration,11863,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL616993,,BAO_0000357,,
1583,Expert,106,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,H,8,1,,CHEMBL616994,,BAO_0000019,,
1584,Autocuration,106,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,H,8,1,,CHEMBL616995,,BAO_0000019,,
1585,Intermediate,105571,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,D,9,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,Autocuration,106,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,8,1,,CHEMBL616997,,BAO_0000218,,
1587,Autocuration,106,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,8,1,,CHEMBL616998,,BAO_0000218,,
1588,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,H,8,1,,CHEMBL616999,,BAO_0000019,,
1589,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,H,8,1,,CHEMBL617000,,BAO_0000019,,
1590,Autocuration,106,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,H,8,1,,CHEMBL617001,,BAO_0000019,,
1591,Autocuration,106,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,H,8,1,,CHEMBL858111,,BAO_0000019,,
1592,Autocuration,106,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,H,8,1,,CHEMBL617002,,BAO_0000019,,
1593,Autocuration,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),H,8,1,,CHEMBL617003,,BAO_0000019,,
1594,Autocuration,106,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),H,8,1,,CHEMBL617004,,BAO_0000019,,
1595,Expert,106,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,D,9,1,,CHEMBL617005,,BAO_0000019,,
1596,Expert,106,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,D,9,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,Autocuration,106,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,H,8,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL883243,,BAO_0000357,,
1599,Autocuration,106,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,H,8,1,,CHEMBL616625,,BAO_0000019,,
1600,Expert,106,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",H,8,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,H,8,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,H,8,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,H,8,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,Autocuration,106,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,H,8,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,Expert,106,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",H,8,1,,CHEMBL616631,,BAO_0000019,,
1606,Autocuration,106,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",H,8,1,,CHEMBL616632,,BAO_0000019,,
1607,Expert,106,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616633,,BAO_0000357,,
1608,Expert,106,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,H,8,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,Autocuration,106,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL616635,,BAO_0000357,,
1610,Expert,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL885358,,BAO_0000357,,
1611,Expert,106,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,D,9,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,Expert,106,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,H,8,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,Autocuration,106,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616638,,BAO_0000357,,
1614,Expert,106,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,8,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,Expert,106,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,8,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,Expert,106,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,8,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,Expert,106,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,H,8,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,Expert,106,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,H,8,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,Autocuration,106,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),H,8,1,,CHEMBL616644,,BAO_0000357,,
1620,Autocuration,106,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,H,8,1,,CHEMBL616645,,BAO_0000357,,
1621,Autocuration,105,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,8,1,,CHEMBL616646,,BAO_0000019,,
1622,Expert,105,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,8,1,,CHEMBL616647,,BAO_0000019,,
1623,Autocuration,105,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),H,8,1,,CHEMBL616509,,BAO_0000357,,
1624,Autocuration,105,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),H,8,1,,CHEMBL616510,,BAO_0000357,,
1625,Autocuration,105,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616511,,BAO_0000357,,
1626,Expert,105,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,H,8,1,,CHEMBL616512,,BAO_0000357,,
1627,Autocuration,105,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,H,8,1,,CHEMBL616513,,BAO_0000357,,
1628,Autocuration,105,Striatum,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,8,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,Expert,105,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,H,8,1,,CHEMBL616515,,BAO_0000357,,
1630,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,H,8,1,,CHEMBL616516,,BAO_0000019,,
1631,Autocuration,105,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,8,1,,CHEMBL616517,,BAO_0000357,,
1632,Autocuration,105,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,8,1,,CHEMBL616518,,BAO_0000357,,
1633,Autocuration,105,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,8,1,,CHEMBL616519,,BAO_0000357,,
1634,Autocuration,105,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,8,1,,CHEMBL616520,,BAO_0000357,,
1635,Autocuration,105,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,H,8,1,,CHEMBL616521,,BAO_0000357,,
1636,Autocuration,105,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,H,8,1,,CHEMBL616522,,BAO_0000357,,
1637,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,8,1,,CHEMBL884531,,BAO_0000357,,
1638,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL616523,,BAO_0000357,,
1639,Autocuration,105,Striatum,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,8,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,Autocuration,105,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,H,8,1,,CHEMBL616732,,BAO_0000019,,
1641,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,H,8,1,,CHEMBL616733,,BAO_0000357,,
1642,Autocuration,105,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,8,1,,CHEMBL616734,,BAO_0000357,,
1643,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,H,8,1,,CHEMBL616735,,BAO_0000249,,
1644,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,H,8,1,,CHEMBL616736,,BAO_0000249,,
1645,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,8,1,,CHEMBL616737,,BAO_0000019,,
1646,Autocuration,105,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,H,8,1,,CHEMBL616738,,BAO_0000019,,
1647,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,8,1,,CHEMBL616739,,BAO_0000019,,
1648,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,8,1,,CHEMBL616740,,BAO_0000019,,
1649,Expert,105,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,8,1,,CHEMBL616741,,BAO_0000019,,
1650,Autocuration,105,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,H,8,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,Intermediate,105570,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,D,9,1,,CHEMBL616743,,BAO_0000019,,
1652,Intermediate,105570,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,D,9,1,,CHEMBL616744,,BAO_0000019,,
1653,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,D,9,1,,CHEMBL616745,,BAO_0000019,,
1654,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,9,1,,CHEMBL616746,,BAO_0000019,,
1655,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,D,9,1,,CHEMBL616747,,BAO_0000019,,
1656,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,D,9,1,,CHEMBL616748,,BAO_0000019,,
1657,Intermediate,105570,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,D,9,1,,CHEMBL616648,,BAO_0000019,,
1658,Intermediate,105570,,,Binding affinity against 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616649,,BAO_0000357,,
1659,Intermediate,105570,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,D,9,1,,CHEMBL616650,,BAO_0000357,,
1660,Intermediate,105570,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,9,1,,CHEMBL616651,,BAO_0000218,,
1661,Intermediate,105570,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,9,1,,CHEMBL616652,,BAO_0000218,,
1662,Intermediate,105570,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,9,1,,CHEMBL616653,,BAO_0000218,,
1663,Intermediate,105570,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,D,9,1,,CHEMBL616654,,BAO_0000218,,
1664,Intermediate,105570,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,D,9,1,,CHEMBL616655,,BAO_0000019,,
1665,Intermediate,105570,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616656,,BAO_0000357,,
1666,Autocuration,105,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,H,8,1,,CHEMBL616657,,BAO_0000019,,
1667,Intermediate,105570,Striatum,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,D,9,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,Intermediate,105570,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,D,9,1,,CHEMBL616659,,BAO_0000357,,
1669,Autocuration,51,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616660,,BAO_0000357,,
1670,Autocuration,106,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,H,8,1,,CHEMBL616661,,BAO_0000357,,
1671,Expert,105,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616662,,BAO_0000019,,
1672,Autocuration,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616663,,BAO_0000019,,
1673,Autocuration,105,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616664,,BAO_0000019,,
1674,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",D,9,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,Autocuration,105,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",H,8,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,Expert,105,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,Autocuration,105,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",H,8,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",D,9,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,Expert,105,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",H,8,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,Autocuration,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",H,8,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,Expert,105,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",H,8,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,Expert,105,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",H,8,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,Autocuration,105,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617044,,BAO_0000019,,
1685,Expert,105,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,9,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,9,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,Expert,105,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",H,8,1,,CHEMBL617048,,BAO_0000019,,
1689,Autocuration,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",H,8,1,,CHEMBL616897,,BAO_0000019,,
1690,Expert,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",D,9,1,,CHEMBL616898,,BAO_0000019,,
1691,Expert,105,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,D,9,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,Autocuration,105,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616899,,BAO_0000019,,
1693,Autocuration,105,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),H,8,1,,CHEMBL616900,,BAO_0000219,,
1694,Expert,105,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,H,8,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,Autocuration,105,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL616902,,BAO_0000357,,
1696,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,9,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,Expert,105,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,H,8,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,Autocuration,105,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616905,,BAO_0000357,,
1699,Expert,105,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,8,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,Expert,105,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,8,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,Expert,105,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,8,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,Expert,105,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,9,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,9,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,Expert,105,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,8,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,Expert,105,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,H,8,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,Autocuration,105,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),H,8,1,,CHEMBL616913,,BAO_0000357,,
1707,Expert,105,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,D,9,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,H,8,1,,CHEMBL616916,,BAO_0000019,,
1710,Expert,105,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616917,,BAO_0000357,,
1711,Autocuration,105,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",H,8,1,,CHEMBL616918,,BAO_0000357,,
1712,Expert,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,8,1,,CHEMBL616919,,BAO_0000219,,
1713,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,H,8,1,,CHEMBL616920,,BAO_0000357,,
1714,Autocuration,105,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL872914,,BAO_0000357,,
1715,Autocuration,105,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,H,8,1,,CHEMBL616921,,BAO_0000357,,
1716,Expert,105,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616922,,BAO_0000357,,
1717,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616923,,BAO_0000357,,
1718,Expert,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616924,,BAO_0000357,,
1719,Expert,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,H,8,1,,CHEMBL875909,,BAO_0000357,,
1720,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,H,8,1,,CHEMBL616925,,BAO_0000357,,
1721,Autocuration,105,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,H,8,1,,CHEMBL616926,,BAO_0000357,,
1722,Autocuration,105,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616927,,BAO_0000357,,
1723,Expert,105,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,H,8,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,Expert,105,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),D,9,1,,CHEMBL616929,,BAO_0000219,,
1725,Expert,105,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616930,,BAO_0000357,,
1726,Expert,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616931,,BAO_0000019,,
1727,Autocuration,105,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,8,1,,CHEMBL616932,,BAO_0000357,,
1728,Expert,105,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616933,,BAO_0000357,,
1729,Expert,105,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,D,9,1,,CHEMBL616934,,BAO_0000219,,
1730,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616935,,BAO_0000357,,
1731,Autocuration,105,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,H,8,1,,CHEMBL616936,,BAO_0000357,,
1732,Expert,105,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,D,9,1,,CHEMBL616937,,BAO_0000357,,
1733,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616938,,BAO_0000357,,
1734,Autocuration,105,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616939,,BAO_0000019,,
1735,Expert,105,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,H,8,1,,CHEMBL616940,,BAO_0000019,,
1736,Expert,105,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,D,9,1,,CHEMBL616941,,BAO_0000357,,
1737,Autocuration,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,H,8,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,Autocuration,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,H,8,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,Autocuration,104802,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,H,4,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,Autocuration,105,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",H,8,1,,CHEMBL616945,,BAO_0000019,,
1741,Autocuration,105,,,Binding activity radioligand.,H,8,1,,CHEMBL616946,,BAO_0000357,,
1742,Autocuration,105,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,8,1,,CHEMBL616947,,BAO_0000019,,
1743,Expert,105,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,Autocuration,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616851,,BAO_0000357,,
1745,Autocuration,105,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616852,,BAO_0000357,,
1746,Autocuration,105,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616853,,BAO_0000357,,
1747,Expert,105,,,Binding activity against human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616854,,BAO_0000357,,
1748,Expert,105,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,D,9,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,H,8,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616858,,BAO_0000357,,
1752,Autocuration,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,Autocuration,105,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,H,8,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,8,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,8,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,Autocuration,105,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,H,8,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,Autocuration,105,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,H,8,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,Expert,105,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL616544,,BAO_0000357,,
1759,Autocuration,105,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,H,8,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,Autocuration,105,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,H,8,1,,CHEMBL616546,,BAO_0000357,,
1761,Autocuration,105,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,H,8,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,Autocuration,105,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,Expert,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,H,8,1,,CHEMBL616549,,BAO_0000019,,
1764,Expert,105,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,H,8,1,,CHEMBL616550,,BAO_0000019,,
1765,Autocuration,108,,,Binding affinity against 5-HT2C receptor,H,8,1,,CHEMBL857066,,BAO_0000357,,
1766,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616551,,BAO_0000357,,
1767,Autocuration,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,8,1,,CHEMBL616552,,BAO_0000357,,
1768,Autocuration,10577,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,8,1,,CHEMBL832876,,BAO_0000019,,
1769,Expert,10577,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",H,8,1,,CHEMBL616553,,BAO_0000019,,
1770,Autocuration,10577,,,Binding affinity towards 5-HT1B was determined,H,8,1,,CHEMBL616554,,BAO_0000357,,
1771,Expert,10577,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,H,8,1,,CHEMBL616555,,BAO_0000019,,
1772,Expert,10577,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",H,8,1,,CHEMBL616556,,BAO_0000019,,
1773,Autocuration,10577,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",H,8,1,,CHEMBL616557,,BAO_0000019,,
1774,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,8,1,,CHEMBL616558,,BAO_0000019,,
1775,Expert,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,D,9,1,,CHEMBL616749,,BAO_0000019,,
1776,Autocuration,10577,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,8,1,,CHEMBL616750,,BAO_0000357,,
1777,Autocuration,10577,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",H,8,1,,CHEMBL616751,,BAO_0000357,,
1778,Autocuration,10577,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,8,1,,CHEMBL616752,,BAO_0000249,,
1779,Autocuration,10577,Striatum,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,H,8,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,Expert,10577,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616754,,BAO_0000357,,
1781,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,H,8,1,,CHEMBL616755,,BAO_0000019,,
1782,Autocuration,10577,Striatum,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,H,8,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,Autocuration,10577,Striatum,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,H,8,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,Autocuration,10577,Striatum,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,H,8,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,Autocuration,10577,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,8,1,,CHEMBL616759,,BAO_0000249,,
1786,Autocuration,10577,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,H,8,1,,CHEMBL616760,,BAO_0000357,,
1787,Autocuration,10577,Striatum,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,H,8,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,Autocuration,10577,Striatum,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,H,8,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,Autocuration,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,H,8,1,,CHEMBL616763,,BAO_0000019,,
1790,Expert,10577,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,H,8,1,,CHEMBL872909,,BAO_0000357,,
1791,Autocuration,10577,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616764,,BAO_0000357,,
1792,Expert,10577,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616765,,BAO_0000357,,
1793,Autocuration,10577,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,H,8,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,Autocuration,10577,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,H,8,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,Autocuration,10577,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616768,,BAO_0000357,,
1796,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL616769,,BAO_0000357,,
1797,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,H,8,1,,CHEMBL616770,,BAO_0000019,,
1798,Autocuration,10577,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,H,8,1,,CHEMBL616771,,BAO_0000019,,
1799,Autocuration,10577,Striatum,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,H,8,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,Expert,10577,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,H,8,1,,CHEMBL616773,,BAO_0000019,,
1801,Autocuration,10577,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,H,8,1,,CHEMBL616774,,BAO_0000019,,
1802,Autocuration,10577,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616775,,BAO_0000357,,
1803,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,8,1,,CHEMBL616776,,BAO_0000249,,
1804,Autocuration,10577,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,H,8,1,,CHEMBL616777,,BAO_0000357,,
1805,Autocuration,10577,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,H,8,1,,CHEMBL616778,,BAO_0000357,,
1806,Expert,10577,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,D,9,1,,CHEMBL616779,,BAO_0000249,,
1807,Expert,10577,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,D,9,1,,CHEMBL616780,,BAO_0000357,,
1808,Autocuration,10577,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,H,8,1,,CHEMBL616781,,BAO_0000019,,
1809,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,H,8,1,,CHEMBL616782,,BAO_0000357,,
1810,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616783,,BAO_0000357,,
1811,Expert,10577,Striatum,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,H,8,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,Autocuration,10577,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,H,8,1,,CHEMBL616785,,BAO_0000357,,
1813,Autocuration,10577,Brain,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,8,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,Autocuration,10577,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,H,8,1,,CHEMBL616786,,BAO_0000019,,
1815,Autocuration,10577,Brain,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,8,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,Autocuration,10577,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,H,8,1,,CHEMBL616788,,BAO_0000357,,
1817,Autocuration,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616789,,BAO_0000357,,
1818,Expert,10577,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,D,9,1,,CHEMBL616790,,BAO_0000019,,
1819,Expert,10577,,,Binding affinity at 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616791,,BAO_0000357,,
1820,Autocuration,10577,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,H,8,1,,CHEMBL616792,,BAO_0000019,,
1821,Expert,10577,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,D,9,1,,CHEMBL616793,,BAO_0000249,,
1822,Autocuration,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL616794,,BAO_0000357,,
1823,Autocuration,10577,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616795,,BAO_0000357,,
1824,Autocuration,104686,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,H,4,1,,CHEMBL616796,,BAO_0000019,,
1825,Autocuration,106,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616797,,BAO_0000357,,
1826,Autocuration,106,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,H,8,1,,CHEMBL616798,,BAO_0000249,,
1827,Autocuration,106,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,H,8,1,,CHEMBL616799,,BAO_0000357,,
1828,Autocuration,106,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,H,8,1,,CHEMBL616800,,BAO_0000357,,
1829,Autocuration,106,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616801,,BAO_0000357,,
1830,Autocuration,106,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,H,8,1,,CHEMBL616802,,BAO_0000357,,
1831,Autocuration,106,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,H,8,1,,CHEMBL616803,,BAO_0000357,,
1832,Expert,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,H,8,1,,CHEMBL857068,,BAO_0000357,,
1833,Autocuration,106,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,H,8,1,,CHEMBL616804,,BAO_0000357,,
1834,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,H,8,1,,CHEMBL616805,,BAO_0000357,,
1835,Autocuration,106,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616806,,BAO_0000357,,
1836,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1B receptor,H,8,1,,CHEMBL616807,,BAO_0000357,,
1837,Autocuration,106,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,H,8,1,,CHEMBL616808,,BAO_0000357,,
1838,Autocuration,106,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616809,,BAO_0000357,,
1839,Autocuration,106,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,H,8,1,,CHEMBL616810,,BAO_0000357,,
1840,Autocuration,104802,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,H,4,1,,CHEMBL616811,,BAO_0000224,,
1841,Autocuration,108,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,H,8,1,,CHEMBL616812,,BAO_0000357,,
1842,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL616813,,BAO_0000357,,
1843,Autocuration,108,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,H,8,1,,CHEMBL616814,,BAO_0000357,,
1844,Autocuration,108,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,8,1,,CHEMBL616815,,BAO_0000357,,
1845,Autocuration,108,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,8,1,,CHEMBL616816,,BAO_0000357,,
1846,Autocuration,108,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,H,8,1,,CHEMBL616817,,BAO_0000357,,
1847,Autocuration,108,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616818,,BAO_0000357,,
1848,Expert,108,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,H,8,1,,CHEMBL616819,,BAO_0000357,,
1849,Expert,108,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,H,8,1,,CHEMBL616820,,BAO_0000357,,
1850,Expert,108,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616821,,BAO_0000019,,
1851,Autocuration,108,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,H,8,1,,CHEMBL616822,,BAO_0000357,,
1852,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,8,1,,CHEMBL616823,,BAO_0000019,,
1853,Autocuration,12689,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,D,9,1,,CHEMBL616824,,BAO_0000357,,
1854,Autocuration,12689,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,9,1,,CHEMBL616825,,BAO_0000357,,
1855,Autocuration,12689,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,9,1,,CHEMBL616826,,BAO_0000357,,
1856,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,D,9,1,,CHEMBL616827,,BAO_0000019,,
1857,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,D,9,1,,CHEMBL616828,,BAO_0000357,,
1858,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,D,9,1,,CHEMBL616829,,BAO_0000357,,
1859,Autocuration,12689,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,D,9,1,,CHEMBL616830,,BAO_0000019,,
1860,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,D,9,1,,CHEMBL616831,,BAO_0000357,,
1861,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,9,1,,CHEMBL616832,,BAO_0000019,,
1862,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,9,1,,CHEMBL616833,,BAO_0000019,,
1863,Expert,12689,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,9,1,,CHEMBL616834,,BAO_0000019,,
1864,Autocuration,12689,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,9,1,,CHEMBL829595,,BAO_0000019,,
1865,Autocuration,12689,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,D,9,1,,CHEMBL616835,,BAO_0000357,,
1866,Autocuration,12689,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,D,9,1,,CHEMBL872910,,BAO_0000249,,
1867,Expert,12689,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,H,8,1,,CHEMBL616836,,BAO_0000357,,
1868,Autocuration,12689,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,D,9,1,,CHEMBL616837,,BAO_0000357,,
1869,Autocuration,12689,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,D,9,1,,CHEMBL616466,,BAO_0000019,,
1870,Autocuration,12689,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,D,9,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,Autocuration,108,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616468,,BAO_0000357,,
1872,Autocuration,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,8,1,,CHEMBL616469,,BAO_0000357,,
1873,Autocuration,108,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,8,1,,CHEMBL616470,,BAO_0000357,,
1874,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616471,,BAO_0000357,,
1875,Autocuration,12689,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616472,,BAO_0000357,,
1876,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,8,1,,CHEMBL616473,,BAO_0000357,,
1877,Autocuration,12689,,,Binding affinity against serotonergic 5-HT1c receptor,H,8,1,,CHEMBL616474,,BAO_0000357,,
1878,Autocuration,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,H,8,1,,CHEMBL616475,,BAO_0000357,,
1879,Autocuration,12689,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,H,8,1,,CHEMBL616476,,BAO_0000357,,
1880,Autocuration,105,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,8,1,,CHEMBL616477,,BAO_0000019,,
1881,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,H,4,1,,CHEMBL616478,,BAO_0000224,,
1882,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,H,4,1,,CHEMBL616479,,BAO_0000224,,
1883,Autocuration,104686,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,H,4,1,,CHEMBL616480,,BAO_0000019,,
1884,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,D,5,1,,CHEMBL616481,,BAO_0000019,,
1885,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,D,5,1,,CHEMBL616482,,BAO_0000249,,
1886,Autocuration,104686,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,D,5,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,H,4,1,,CHEMBL616483,,BAO_0000224,,
1888,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,H,4,1,,CHEMBL616484,,BAO_0000224,,
1889,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,H,4,1,,CHEMBL616485,,BAO_0000019,,
1890,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,4,1,,CHEMBL616486,,BAO_0000224,,
1891,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,H,4,1,,CHEMBL616487,,BAO_0000224,,
1892,Autocuration,104686,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,4,1,,CHEMBL616488,,BAO_0000224,,
1893,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616489,,BAO_0000019,,
1894,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616490,,BAO_0000019,,
1895,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,H,4,1,,CHEMBL616491,,BAO_0000019,,
1896,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,H,4,1,,CHEMBL616492,,BAO_0000019,,
1897,Autocuration,104686,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616493,,BAO_0000019,,
1898,Autocuration,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,H,4,1,,CHEMBL616494,,BAO_0000019,,
1899,Autocuration,104686,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,H,4,1,,CHEMBL616495,,BAO_0000019,,
1900,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,H,4,1,,CHEMBL616496,,BAO_0000019,,
1901,Autocuration,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616497,,BAO_0000019,,
1902,Autocuration,104686,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616498,,BAO_0000019,,
1903,Autocuration,104686,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,H,4,1,,CHEMBL616499,,BAO_0000019,,
1904,Autocuration,104686,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,H,4,1,,CHEMBL616500,,BAO_0000019,,
1905,Autocuration,104686,Brain,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,5,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,Autocuration,104686,Brain,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,H,4,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,4,1,,CHEMBL884529,,BAO_0000249,,
1908,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,4,1,,CHEMBL616503,,BAO_0000249,,
1909,Autocuration,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL616964,,BAO_0000224,,
1910,Autocuration,104686,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,4,1,,CHEMBL616965,,BAO_0000249,,
1911,Autocuration,104686,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,H,4,1,,CHEMBL616966,,BAO_0000224,,
1912,Autocuration,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,H,4,1,,CHEMBL616967,,BAO_0000224,,
1913,Autocuration,104686,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL616968,,BAO_0000224,,
1914,Autocuration,104686,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,H,4,1,,CHEMBL616969,,BAO_0000224,,
1915,Autocuration,104686,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,H,4,1,,CHEMBL884530,,BAO_0000019,,
1916,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL616970,,BAO_0000224,,
1917,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,4,1,,CHEMBL616971,,BAO_0000224,,
1918,Autocuration,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,4,1,,CHEMBL616972,,BAO_0000224,,
1919,Autocuration,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,H,4,1,,CHEMBL616973,,BAO_0000224,,
1920,Autocuration,104686,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,H,4,1,,CHEMBL616974,,BAO_0000224,,
1921,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,H,4,1,,CHEMBL616975,,BAO_0000019,,
1922,Autocuration,104686,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,H,4,1,,CHEMBL616976,,BAO_0000019,,
1923,Autocuration,104686,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,H,4,1,,CHEMBL616977,,BAO_0000224,,
1924,Autocuration,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,4,1,,CHEMBL616978,,BAO_0000224,,
1925,Autocuration,104686,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,H,4,1,,CHEMBL616979,,BAO_0000224,,
1926,Autocuration,104686,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL616980,,BAO_0000224,,
1927,Autocuration,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,H,4,1,,CHEMBL616981,,BAO_0000249,,
1928,Autocuration,104686,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,H,4,1,,CHEMBL616982,,BAO_0000249,,
1929,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,H,4,1,,CHEMBL616983,,BAO_0000224,,
1930,Autocuration,104686,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,H,4,1,,CHEMBL616984,,BAO_0000019,,
1931,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL616985,,BAO_0000224,,
1932,Autocuration,104686,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,4,1,,CHEMBL616986,,BAO_0000224,,
1933,Autocuration,104686,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,4,1,,CHEMBL616987,,BAO_0000224,,
1934,Autocuration,104686,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,H,4,1,,CHEMBL616988,,BAO_0000019,,
1935,Autocuration,104686,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,H,4,1,,CHEMBL617243,,BAO_0000019,,
1936,Autocuration,104686,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,H,4,1,,CHEMBL617244,,BAO_0000019,,
1937,Autocuration,104686,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,5,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,4,1,,CHEMBL617246,,BAO_0000249,,
1939,Autocuration,104686,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),H,4,1,,CHEMBL617546,,BAO_0000224,,
1940,Autocuration,104686,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),H,4,1,,CHEMBL617547,,BAO_0000249,,
1941,Autocuration,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,4,1,,CHEMBL617548,,BAO_0000219,,
1942,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617549,,BAO_0000224,,
1943,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,4,1,,CHEMBL617550,,BAO_0000224,,
1944,Autocuration,104686,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,4,1,,CHEMBL617551,,BAO_0000224,,
1945,Autocuration,104686,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,H,4,1,,CHEMBL617552,,BAO_0000249,,
1946,Autocuration,104686,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,H,4,1,,CHEMBL617553,,BAO_0000249,,
1947,Autocuration,104686,Thoracic aorta,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,H,4,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,Autocuration,104686,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617555,,BAO_0000019,,
1949,Autocuration,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,4,1,,CHEMBL617556,,BAO_0000224,,
1950,Autocuration,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,8,1,,CHEMBL617557,,BAO_0000357,,
1951,Autocuration,10624,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,8,1,,CHEMBL617558,,BAO_0000357,,
1952,Expert,17106,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,H,8,1,,CHEMBL617559,,BAO_0000357,,
1953,Expert,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor,D,9,1,,CHEMBL617560,,BAO_0000357,,
1954,Autocuration,17106,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,8,1,,CHEMBL617561,,BAO_0000249,,
1955,Autocuration,17106,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,8,1,,CHEMBL617562,,BAO_0000249,,
1956,Autocuration,17106,Striatum,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,H,8,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,Autocuration,17106,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617564,,BAO_0000019,,
1958,Expert,17106,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,H,8,1,,CHEMBL617565,,BAO_0000019,,
1959,Autocuration,17106,,,Binding activity radioligand.,H,8,1,,CHEMBL856076,,BAO_0000357,,
1960,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617566,,BAO_0000019,,
1961,Expert,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,8,1,,CHEMBL875911,,BAO_0000019,,
1962,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,8,1,,CHEMBL617567,,BAO_0000019,,
1963,Autocuration,17106,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,8,1,,CHEMBL617568,,BAO_0000249,,
1964,Expert,17106,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,H,8,1,,CHEMBL617569,,BAO_0000019,,
1965,Expert,17106,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,H,8,1,,CHEMBL617570,,BAO_0000249,,
1966,Autocuration,17106,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,H,8,1,,CHEMBL617571,,BAO_0000357,,
1967,Autocuration,105,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,H,8,1,,CHEMBL617572,,BAO_0000357,,
1968,Expert,105,,,The compound was tested for intrinsic activity against 5-HT1D receptor,H,8,1,,CHEMBL617573,,BAO_0000357,,
1969,Autocuration,105,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,H,8,1,,CHEMBL617574,,BAO_0000019,,
1970,Expert,105,,,The compound was tested for binding affinity against 5-HT1D receptor,H,8,1,,CHEMBL617575,,BAO_0000357,,
1971,Autocuration,10578,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,H,8,1,,CHEMBL617576,,BAO_0000357,,
1972,Autocuration,10578,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,H,8,1,,CHEMBL617577,,BAO_0000019,,
1973,Autocuration,10578,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617578,,BAO_0000019,,
1974,Autocuration,10578,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617579,,BAO_0000357,,
1975,Expert,10578,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,8,1,,CHEMBL617580,,BAO_0000019,,
1976,Autocuration,10578,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,8,1,,CHEMBL617581,,BAO_0000249,,
1977,Autocuration,10578,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,H,8,1,,CHEMBL617582,,BAO_0000357,,
1978,Expert,10578,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,H,8,1,,CHEMBL617583,,BAO_0000019,,
1979,Autocuration,105,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,H,8,1,,CHEMBL617584,,BAO_0000357,,
1980,Autocuration,105,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617585,,BAO_0000357,,
1981,Autocuration,105,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,H,8,1,,CHEMBL875912,,BAO_0000357,,
1982,Autocuration,105,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617586,,BAO_0000357,,
1983,Autocuration,105,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,H,8,1,,CHEMBL617587,,BAO_0000357,,
1984,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,H,8,1,,CHEMBL617588,,BAO_0000357,,
1985,Autocuration,105,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL857980,,BAO_0000357,,
1986,Autocuration,105,,,Tested against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL617589,,BAO_0000357,,
1987,Autocuration,105,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,H,8,1,,CHEMBL617590,,BAO_0000357,,
1988,Autocuration,105,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,Expert,105,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,D,9,1,,CHEMBL617592,,BAO_0000357,,
1990,Autocuration,105,,,,H,8,1,,CHEMBL617593,,BAO_0000357,,
1991,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,8,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,Autocuration,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,8,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,Autocuration,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,H,8,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,Autocuration,105,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,8,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,8,1,,CHEMBL617598,,BAO_0000019,,
1996,Autocuration,105,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,H,8,1,,CHEMBL872916,,BAO_0000357,,
1997,Expert,105,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,H,8,1,,CHEMBL617599,,BAO_0000357,,
1998,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,H,8,1,,CHEMBL617091,,BAO_0000357,,
1999,Expert,105,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",H,8,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,Autocuration,105,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,8,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,Autocuration,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,H,8,1,,CHEMBL617094,,BAO_0000019,,
2002,Autocuration,105,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,8,1,,CHEMBL617095,,BAO_0000019,,
2003,Autocuration,105,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,8,1,,CHEMBL617096,,BAO_0000019,,
2004,Autocuration,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,8,1,,CHEMBL617097,,BAO_0000019,,
2005,Autocuration,105,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,8,1,,CHEMBL617098,,BAO_0000019,,
2006,Autocuration,105,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,H,8,1,,CHEMBL617301,,BAO_0000357,,
2007,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,H,8,1,,CHEMBL617302,,BAO_0000357,,
2008,Autocuration,105,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617303,,BAO_0000357,,
2009,Expert,105,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617304,,BAO_0000357,,
2010,Expert,105,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",H,8,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,Autocuration,105,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,D,9,1,,CHEMBL617306,,BAO_0000219,,
2012,Autocuration,17106,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,H,8,1,,CHEMBL617307,,BAO_0000357,,
2013,Autocuration,105,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,H,8,1,,CHEMBL617308,,BAO_0000019,,
2014,Autocuration,105,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617309,,BAO_0000357,,
2015,Autocuration,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617310,,BAO_0000357,,
2016,Autocuration,105,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617311,,BAO_0000357,,
2017,Autocuration,105,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL617312,,BAO_0000357,,
2018,Autocuration,105,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617313,,BAO_0000357,,
2019,Expert,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,H,8,1,,CHEMBL617314,,BAO_0000357,,
2020,Autocuration,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,8,1,,CHEMBL617315,,BAO_0000019,,
2021,Autocuration,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,H,8,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,Autocuration,106,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,8,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,Autocuration,106,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,8,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,8,1,,CHEMBL617319,,BAO_0000019,,
2025,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,9,1,,CHEMBL617320,,BAO_0000357,,
2026,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,9,1,,CHEMBL617321,,BAO_0000357,,
2027,Expert,106,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,9,1,,CHEMBL617322,,BAO_0000357,,
2028,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616862,,BAO_0000357,,
2029,Autocuration,106,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,H,8,1,,CHEMBL616863,,BAO_0000357,,
2030,Autocuration,106,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,H,8,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,H,8,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,Autocuration,106,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,H,8,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,Autocuration,106,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,8,1,,CHEMBL616867,,BAO_0000019,,
2034,Expert,106,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",H,8,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,Expert,105,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,H,8,1,,CHEMBL616869,,BAO_0000357,,
2036,Expert,106,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,8,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,H,8,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,H,8,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,H,8,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,Autocuration,105,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,H,8,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,Autocuration,105,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,H,8,1,,CHEMBL616839,,BAO_0000357,,
2042,Autocuration,106,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,H,8,1,,CHEMBL616840,,BAO_0000019,,
2043,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,H,8,1,,CHEMBL616841,,BAO_0000357,,
2044,Autocuration,105,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,H,8,1,,CHEMBL616842,,BAO_0000357,,
2045,Expert,105,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,H,8,1,,CHEMBL857976,,BAO_0000357,,
2046,Autocuration,10618,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,H,8,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,Expert,10618,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,D,9,1,,CHEMBL616844,,BAO_0000357,,
2048,Autocuration,10618,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,H,8,1,,CHEMBL616845,,BAO_0000357,,
2049,Expert,10618,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,D,9,1,,CHEMBL616846,,BAO_0000357,,
2050,Autocuration,10618,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,H,8,1,,CHEMBL616847,,BAO_0000357,,
2051,Autocuration,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,H,8,1,,CHEMBL616848,,BAO_0000019,,
2052,Autocuration,10618,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL616849,,BAO_0000357,,
2053,Autocuration,10618,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL872911,,BAO_0000357,,
2054,Autocuration,10618,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL616850,,BAO_0000019,,
2055,Expert,10618,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,D,9,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,Autocuration,10618,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,H,8,1,,CHEMBL616700,,BAO_0000357,,
2057,Autocuration,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,Autocuration,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,Autocuration,10618,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,8,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,Autocuration,10618,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,H,8,1,,CHEMBL616704,,BAO_0000357,,
2061,Autocuration,10618,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,H,8,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,Autocuration,10618,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL616706,,BAO_0000357,,
2063,Autocuration,10618,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,H,8,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,Autocuration,10618,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,H,8,1,,CHEMBL616708,,BAO_0000357,,
2065,Autocuration,10618,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL616709,,BAO_0000357,,
2066,Autocuration,10618,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,H,8,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,Autocuration,10618,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,H,8,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,Autocuration,10618,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,Autocuration,10618,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,H,8,1,,CHEMBL616713,,BAO_0000357,,
2070,Autocuration,10618,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,H,8,1,,CHEMBL616714,,BAO_0000357,,
2071,Autocuration,10618,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL616715,,BAO_0000357,,
2072,Autocuration,10618,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,H,8,1,,CHEMBL616716,,BAO_0000357,,
2073,Autocuration,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",H,8,1,,CHEMBL616717,,BAO_0000019,,
2074,Expert,279,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",H,8,1,,CHEMBL616718,,BAO_0000019,,
2075,Autocuration,279,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL875905,,BAO_0000019,,
2076,Autocuration,279,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL616719,,BAO_0000019,,
2077,Expert,279,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",H,8,1,,CHEMBL616720,,BAO_0000019,,
2078,Autocuration,279,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL616721,,BAO_0000357,,
2079,Autocuration,279,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,H,8,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,Autocuration,279,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),H,8,1,,CHEMBL616723,,BAO_0000357,,
2081,Autocuration,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,H,8,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,Autocuration,279,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,H,8,1,,CHEMBL616725,,BAO_0000357,,
2083,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL616726,,BAO_0000357,,
2084,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,H,8,1,,CHEMBL616727,,BAO_0000357,,
2085,Autocuration,279,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,H,8,1,,CHEMBL616728,,BAO_0000357,,
2086,Autocuration,279,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL616729,,BAO_0000357,,
2087,Expert,279,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL616730,,BAO_0000019,,
2088,Autocuration,279,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL617125,,BAO_0000357,,
2089,Autocuration,279,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,H,8,1,,CHEMBL857977,,BAO_0000357,,
2090,Autocuration,279,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,Autocuration,279,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,H,8,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,Autocuration,279,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL617128,,BAO_0000357,,
2093,Autocuration,279,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,H,8,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,Autocuration,279,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,H,8,1,,CHEMBL617130,,BAO_0000357,,
2095,Autocuration,279,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,H,8,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,Autocuration,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,Autocuration,279,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,Autocuration,279,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,H,8,1,,CHEMBL617134,,BAO_0000357,,
2099,Autocuration,279,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,H,8,1,,CHEMBL617135,,BAO_0000357,,
2100,Autocuration,279,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,H,8,1,,CHEMBL617136,,BAO_0000357,,
2101,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",H,4,1,,CHEMBL617137,,BAO_0000019,,
2102,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,4,1,,CHEMBL617138,,BAO_0000019,,
2103,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,4,1,,CHEMBL617139,,BAO_0000019,,
2104,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617140,,BAO_0000019,,
2105,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",H,4,1,,CHEMBL617141,,BAO_0000218,,
2106,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL858112,,BAO_0000019,,
2107,Intermediate,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,H,8,1,,CHEMBL617142,,BAO_0000019,,
2108,Autocuration,22226,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",U,0,1,,CHEMBL617143,,BAO_0000019,,
2109,Autocuration,22226,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,U,0,1,,CHEMBL617144,,BAO_0000019,,
2110,Autocuration,22226,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,U,0,1,,CHEMBL617145,,BAO_0000019,,
2111,Autocuration,22226,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,U,0,1,,CHEMBL617146,,BAO_0000019,,
2112,Autocuration,104784,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,H,4,1,,CHEMBL617147,,BAO_0000019,,
2113,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,H,4,1,,CHEMBL617148,,BAO_0000019,,
2114,Autocuration,104784,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,H,4,1,,CHEMBL617149,,BAO_0000019,,
2115,Autocuration,104784,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,H,4,1,,CHEMBL617150,,BAO_0000224,,
2116,Autocuration,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,4,1,,CHEMBL617151,,BAO_0000224,,
2117,Autocuration,104784,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617201,,BAO_0000224,,
2118,Autocuration,10209,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,8,1,,CHEMBL617202,,BAO_0000357,,
2119,Autocuration,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,4,1,,CHEMBL617203,,BAO_0000218,,
2120,Autocuration,104826,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,H,4,1,,CHEMBL617204,,BAO_0000019,,
2121,Autocuration,104826,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,H,4,1,,CHEMBL617205,,BAO_0000224,,
2122,Autocuration,104826,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,D,5,1,,CHEMBL617206,,BAO_0000019,,
2123,Autocuration,104826,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,4,1,,CHEMBL617207,,BAO_0000218,,
2124,Autocuration,104826,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,D,5,1,,CHEMBL617208,,BAO_0000019,,
2125,Autocuration,104826,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617209,,BAO_0000224,,
2126,Autocuration,104826,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,H,4,1,,CHEMBL617210,,BAO_0000224,,
2127,Autocuration,104826,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,H,4,1,,CHEMBL617211,,BAO_0000224,,
2128,Autocuration,104826,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,D,5,1,,CHEMBL617212,,BAO_0000019,,
2129,Autocuration,104784,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,H,4,1,,CHEMBL617213,,BAO_0000224,,
2130,Autocuration,104784,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,H,4,1,,CHEMBL617214,,BAO_0000224,,
2131,Autocuration,22226,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,0,1,,CHEMBL617215,,BAO_0000221,,
2132,Autocuration,22226,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,0,1,,CHEMBL617216,,BAO_0000221,,
2133,Autocuration,17005,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617217,,BAO_0000357,,
2134,Autocuration,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617218,,BAO_0000019,,
2135,Autocuration,104686,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL872913,,BAO_0000019,,
2136,Autocuration,104826,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,H,4,1,,CHEMBL617219,,BAO_0000019,,
2137,Autocuration,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL873482,,BAO_0000224,,
2138,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,D,5,1,,CHEMBL617220,,BAO_0000019,,
2139,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,H,4,1,,CHEMBL617221,,BAO_0000019,,
2140,Autocuration,104686,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,H,4,1,,CHEMBL617222,,BAO_0000019,,
2141,Autocuration,104686,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,H,4,1,,CHEMBL875906,,BAO_0000019,,
2142,Autocuration,104686,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,H,4,1,,CHEMBL617223,,BAO_0000019,,
2143,Autocuration,104686,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617224,,BAO_0000224,,
2144,Autocuration,104686,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,D,5,1,,CHEMBL617225,,BAO_0000224,,
2145,Autocuration,104686,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,H,4,1,,CHEMBL617226,,BAO_0000224,,
2146,Autocuration,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,H,4,1,,CHEMBL617227,,BAO_0000224,,
2147,Autocuration,104686,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,H,4,1,,CHEMBL617228,,BAO_0000224,,
2148,Autocuration,104686,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,4,1,,CHEMBL617229,,BAO_0000224,,
2149,Autocuration,104686,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,4,1,,CHEMBL617230,,BAO_0000224,,
2150,Autocuration,104686,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,4,1,,CHEMBL617231,,BAO_0000224,,
2151,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,H,4,1,,CHEMBL617232,,BAO_0000224,,
2152,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617233,,BAO_0000224,,
2153,Autocuration,104686,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,H,4,1,,CHEMBL617234,,BAO_0000224,,
2154,Autocuration,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,H,4,1,,CHEMBL617235,,BAO_0000019,,
2155,Autocuration,104686,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,H,4,1,,CHEMBL617236,,BAO_0000019,,
2156,Autocuration,104686,Hippocampus,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,H,4,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,Autocuration,104686,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,H,4,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,Autocuration,104686,Brain,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,D,5,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,Autocuration,104686,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,H,4,1,,CHEMBL617240,,BAO_0000019,,
2160,Autocuration,104686,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,4,1,,CHEMBL617241,,BAO_0000249,,
2161,Autocuration,104686,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,4,1,,CHEMBL875907,,BAO_0000249,,
2162,Autocuration,104686,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,H,4,1,,CHEMBL617242,,BAO_0000019,,
2163,Autocuration,104686,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,H,4,1,,CHEMBL617152,,BAO_0000019,,
2164,Autocuration,104686,Brain,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,5,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,D,5,1,,CHEMBL617154,,BAO_0000249,,
2166,Autocuration,104686,Brain,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,Autocuration,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,4,1,,CHEMBL617156,,BAO_0000019,,
2168,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL617157,,BAO_0000019,,
2169,Autocuration,104686,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL617158,,BAO_0000019,,
2170,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,4,1,,CHEMBL617159,,BAO_0000019,,
2171,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,4,1,,CHEMBL617160,,BAO_0000019,,
2172,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL858113,,BAO_0000019,,
2173,Autocuration,104686,Brain,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,H,4,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617248,,BAO_0000019,,
2175,Autocuration,104686,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,4,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,H,4,1,,CHEMBL617250,,BAO_0000019,,
2177,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617251,,BAO_0000019,,
2178,Autocuration,104686,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617252,,BAO_0000019,,
2179,Autocuration,104686,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,H,4,1,,CHEMBL617006,,BAO_0000019,,
2180,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,H,4,1,,CHEMBL617007,,BAO_0000019,,
2181,Autocuration,104686,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",H,4,1,,CHEMBL617008,,BAO_0000019,,
2182,Autocuration,104686,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,H,4,1,,CHEMBL617009,,BAO_0000019,,
2183,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,D,5,1,,CHEMBL617010,,BAO_0000224,,
2184,Autocuration,104686,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL857978,,BAO_0000019,,
2185,Autocuration,104686,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617011,,BAO_0000019,,
2186,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,D,5,1,,CHEMBL617012,,BAO_0000019,,
2187,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,H,4,1,,CHEMBL617013,,BAO_0000224,,
2188,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,H,4,1,,CHEMBL617014,,BAO_0000249,,
2189,Autocuration,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617015,,BAO_0000019,,
2190,Autocuration,104686,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,H,4,1,,CHEMBL617016,,BAO_0000019,,
2191,Autocuration,104686,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,H,4,1,,CHEMBL617017,,BAO_0000224,,
2192,Autocuration,104686,Brain,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,H,4,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,Autocuration,104686,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,4,1,,CHEMBL617019,,BAO_0000019,,
2194,Autocuration,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617020,,BAO_0000019,,
2195,Autocuration,105075,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617021,,BAO_0000019,,
2196,Autocuration,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617022,,BAO_0000019,,
2197,Autocuration,105075,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617023,,BAO_0000019,,
2198,Autocuration,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617024,,BAO_0000019,,
2199,Autocuration,105075,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,4,1,,CHEMBL617025,,BAO_0000019,,
2200,Autocuration,105075,,,Hill coefficient of compound was determined,H,4,1,,CHEMBL617026,,BAO_0000224,,
2201,Autocuration,22226,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,U,0,1,,CHEMBL617027,,BAO_0000019,,
2202,Autocuration,104686,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,D,5,1,,CHEMBL617028,,BAO_0000019,,
2203,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,H,8,1,,CHEMBL617029,,BAO_0000019,,
2204,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,H,8,1,,CHEMBL875908,,BAO_0000019,,
2205,Autocuration,12687,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),H,8,1,,CHEMBL617030,,BAO_0000357,,
2206,Autocuration,12687,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),H,8,1,,CHEMBL617031,,BAO_0000019,,
2207,Autocuration,12687,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,H,8,1,,CHEMBL617032,,BAO_0000019,,
2208,Autocuration,104686,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,D,5,1,,CHEMBL617033,,BAO_0000224,,
2209,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",H,4,1,,CHEMBL617034,,BAO_0000224,,
2210,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,H,4,1,,CHEMBL617035,,BAO_0000224,,
2211,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,4,1,,CHEMBL617036,,BAO_0000019,,
2212,Autocuration,104784,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617037,,BAO_0000224,,
2213,Autocuration,22226,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,U,0,1,,CHEMBL617038,,BAO_0000219,,
2214,Autocuration,104784,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",H,4,1,,CHEMBL617039,,BAO_0000219,,
2215,Autocuration,104784,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617161,,BAO_0000224,,
2216,Autocuration,104784,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617162,,BAO_0000224,,
2217,Autocuration,104784,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617163,,BAO_0000224,,
2218,Autocuration,104784,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617164,,BAO_0000224,,
2219,Autocuration,104784,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,H,4,1,,CHEMBL617165,,BAO_0000249,,
2220,Autocuration,104784,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617166,,BAO_0000224,,
2221,Autocuration,104784,,,Binding affinity towards 5-HT2 receptor,H,4,1,,CHEMBL617167,,BAO_0000224,,
2222,Autocuration,104784,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL872912,,BAO_0000224,,
2223,Autocuration,104784,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,H,4,1,,CHEMBL617168,,BAO_0000224,,
2224,Autocuration,104686,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,H,4,1,,CHEMBL617169,,BAO_0000224,,
2225,Autocuration,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617170,,BAO_0000224,,
2226,Autocuration,104784,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,H,4,1,,CHEMBL617171,,BAO_0000224,,
2227,Autocuration,104784,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,H,4,1,,CHEMBL617172,,BAO_0000224,,
2228,Autocuration,104784,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617173,,BAO_0000224,,
2229,Autocuration,22226,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,U,0,1,,CHEMBL617174,,BAO_0000019,,
2230,Autocuration,104784,,,5-hydroxytryptamine 2 receptor binding affinity,H,4,1,,CHEMBL617175,,BAO_0000224,,
2231,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,H,8,1,,CHEMBL617176,,BAO_0000357,,
2232,Autocuration,17005,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617177,,BAO_0000357,,
2233,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,4,1,,CHEMBL617178,,BAO_0000224,,
2234,Autocuration,104784,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,H,4,1,,CHEMBL617179,,BAO_0000224,,
2235,Autocuration,104784,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,4,1,,CHEMBL617180,,BAO_0000224,,
2236,Autocuration,17005,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,H,8,1,,CHEMBL617181,,BAO_0000357,,
2237,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617182,,BAO_0000357,,
2238,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617183,,BAO_0000357,,
2239,Autocuration,17005,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617184,,BAO_0000357,,
2240,Autocuration,17005,,,Binding affinity against serotonergic 5-HT2 receptor,H,8,1,,CHEMBL617185,,BAO_0000357,,
2241,Autocuration,17005,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617186,,BAO_0000357,,
2242,Autocuration,17005,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,H,8,1,,CHEMBL617187,,BAO_0000357,,
2243,Autocuration,17005,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617188,,BAO_0000357,,
2244,Autocuration,17005,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617189,,BAO_0000218,,
2245,Autocuration,104784,,,Inhibitory activity against cloned human 5-HT2 receptor,D,5,1,,CHEMBL617190,,BAO_0000224,,
2246,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",D,5,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",D,5,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",D,5,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,Autocuration,104784,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",D,5,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,Autocuration,104784,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617195,,BAO_0000224,,
2251,Autocuration,104784,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,H,4,1,,CHEMBL881830,,BAO_0000224,,
2252,Autocuration,17005,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,8,1,,CHEMBL617196,,BAO_0000357,,
2253,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,H,4,1,,CHEMBL617197,,BAO_0000224,,
2254,Expert,17005,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617198,,BAO_0000357,,
2255,Expert,17005,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL873476,,BAO_0000357,,
2256,Expert,17005,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,H,8,1,,CHEMBL617199,,BAO_0000019,,
2257,Autocuration,107,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617200,,BAO_0000357,,
2258,Autocuration,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,8,1,,CHEMBL617484,,BAO_0000357,,
2259,Autocuration,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,8,1,,CHEMBL617485,,BAO_0000357,,
2260,Autocuration,51,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,8,1,,CHEMBL617486,,BAO_0000357,,
2261,Autocuration,107,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,H,8,1,,CHEMBL858022,,BAO_0000357,,
2262,Autocuration,107,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,8,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,Expert,107,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,D,9,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,Autocuration,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,8,1,,CHEMBL617051,,BAO_0000219,,
2265,Autocuration,107,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,H,8,1,,CHEMBL617052,,BAO_0000219,,
2266,Autocuration,107,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,8,1,,CHEMBL617053,,BAO_0000219,,
2267,Autocuration,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",H,8,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,Autocuration,107,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",H,8,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,Autocuration,107,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,H,8,1,,CHEMBL882924,,BAO_0000357,,
2270,Expert,107,,,Inhibition of human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617056,,BAO_0000357,,
2271,Autocuration,107,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,8,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,Expert,107,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,H,8,1,,CHEMBL617058,,BAO_0000219,,
2273,Autocuration,107,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),H,8,1,,CHEMBL617059,,BAO_0000357,,
2274,Autocuration,107,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,Expert,107,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,H,8,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,Expert,107,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,H,8,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,Expert,107,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,8,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,Autocuration,107,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,H,8,1,,CHEMBL617064,,BAO_0000019,,
2279,Autocuration,107,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL617065,,BAO_0000019,,
2280,Autocuration,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,8,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,Autocuration,107,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,H,8,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,Autocuration,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,H,8,1,,CHEMBL617068,,BAO_0000019,,
2283,Autocuration,107,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,H,8,1,,CHEMBL617069,,BAO_0000019,,
2284,Autocuration,107,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617070,,BAO_0000019,,
2285,Autocuration,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,H,8,1,,CHEMBL617071,,BAO_0000357,,
2286,Autocuration,107,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL872915,,BAO_0000357,,
2287,Autocuration,107,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,H,8,1,,CHEMBL617072,,BAO_0000357,,
2288,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,H,8,1,,CHEMBL617073,,BAO_0000357,,
2289,Autocuration,107,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,H,8,1,,CHEMBL617074,,BAO_0000357,,
2290,Expert,107,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,8,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,Autocuration,107,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617076,,BAO_0000357,,
2292,Expert,107,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,D,9,1,,CHEMBL617077,,BAO_0000019,,
2293,Expert,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,H,8,1,,CHEMBL617078,,BAO_0000357,,
2294,Expert,107,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617079,,BAO_0000357,,
2295,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL617080,,BAO_0000357,,
2296,Expert,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,H,8,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,Expert,107,,,Binding affinity towards human 5-HT2A receptor in BEK cells,H,8,1,,CHEMBL617082,,BAO_0000219,,
2298,Autocuration,107,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617083,,BAO_0000357,,
2299,Autocuration,107,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,8,1,,CHEMBL617084,,BAO_0000357,,
2300,Expert,107,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617085,,BAO_0000357,,
2301,Autocuration,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL617086,,BAO_0000357,,
2302,Autocuration,107,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,H,8,1,,CHEMBL617087,,BAO_0000219,,
2303,Autocuration,107,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617088,,BAO_0000357,,
2304,Autocuration,107,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617089,,BAO_0000357,,
2305,Expert,107,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",H,8,1,,CHEMBL617090,,BAO_0000019,,
2306,Autocuration,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617513,,BAO_0000357,,
2307,Autocuration,107,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,Autocuration,107,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617515,,BAO_0000019,,
2309,Autocuration,107,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,8,1,,CHEMBL617516,,BAO_0000357,,
2310,Expert,107,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,D,9,1,,CHEMBL617517,,BAO_0000357,,
2311,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,D,9,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,Autocuration,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617519,,BAO_0000357,,
2313,Expert,107,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617520,,BAO_0000357,,
2314,Autocuration,107,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,H,8,1,,CHEMBL617521,,BAO_0000357,,
2315,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617522,,BAO_0000357,,
2316,Autocuration,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL617523,,BAO_0000357,,
2317,Autocuration,107,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL617524,,BAO_0000357,,
2318,Autocuration,104686,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,H,4,1,,CHEMBL617525,,BAO_0000019,,
2319,Autocuration,104686,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,D,5,1,,CHEMBL617526,,BAO_0000019,,
2320,Autocuration,104686,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,H,4,1,,CHEMBL617527,,BAO_0000224,,
2321,Autocuration,104686,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,4,1,,CHEMBL617528,,BAO_0000019,,
2322,Autocuration,104686,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,4,1,,CHEMBL617529,,BAO_0000019,,
2323,Autocuration,104686,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,H,4,1,,CHEMBL617530,,BAO_0000224,,
2324,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,4,1,,CHEMBL617531,,BAO_0000019,,
2325,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,H,4,1,,CHEMBL617532,,BAO_0000019,,
2326,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617533,,BAO_0000019,,
2327,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,4,1,,CHEMBL617534,,BAO_0000019,,
2328,Autocuration,104686,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617535,,BAO_0000224,,
2329,Autocuration,104686,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,4,1,,CHEMBL617536,,BAO_0000224,,
2330,Autocuration,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617537,,BAO_0000224,,
2331,Autocuration,104686,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617538,,BAO_0000224,,
2332,Autocuration,104686,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,4,1,,CHEMBL617539,,BAO_0000219,,
2333,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617540,,BAO_0000224,,
2334,Autocuration,104686,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,D,5,1,,CHEMBL617541,,BAO_0000224,,
2335,Autocuration,104686,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617542,,BAO_0000224,,
2336,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,H,4,1,,CHEMBL617543,,BAO_0000224,,
2337,Autocuration,104686,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,5,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,Autocuration,104686,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,5,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,D,5,1,,CHEMBL617413,,BAO_0000019,,
2340,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,H,4,1,,CHEMBL617414,,BAO_0000019,,
2341,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,D,5,1,,CHEMBL617415,,BAO_0000019,,
2342,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617416,,BAO_0000224,,
2343,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,4,1,,CHEMBL617417,,BAO_0000224,,
2344,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",H,4,1,,CHEMBL617418,,BAO_0000019,,
2345,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,H,4,1,,CHEMBL617419,,BAO_0000019,,
2346,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,4,1,,CHEMBL617420,,BAO_0000224,,
2347,Autocuration,104686,,,Affinity for 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617421,,BAO_0000224,,
2348,Autocuration,104686,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,H,4,1,,CHEMBL617422,,BAO_0000224,,
2349,Autocuration,104686,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,H,4,1,,CHEMBL617423,,BAO_0000019,,
2350,Autocuration,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,H,4,1,,CHEMBL617424,,BAO_0000019,,
2351,Autocuration,104686,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,H,4,1,,CHEMBL617425,,BAO_0000019,,
2352,Autocuration,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),H,4,1,,CHEMBL617426,,BAO_0000224,,
2353,Autocuration,104686,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),H,4,1,,CHEMBL617427,,BAO_0000218,,
2354,Autocuration,104686,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,H,4,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,Autocuration,104686,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,H,4,1,,CHEMBL617429,,BAO_0000224,,
2356,Autocuration,104686,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,4,1,,CHEMBL617430,,BAO_0000019,,
2357,Autocuration,104686,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,4,1,,CHEMBL617431,,BAO_0000019,,
2358,Autocuration,104686,Frontal cortex,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,H,4,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,Autocuration,104686,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617433,,BAO_0000224,,
2360,Autocuration,104686,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617434,,BAO_0000224,,
2361,Autocuration,104686,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,D,5,1,,CHEMBL617435,,BAO_0000224,,
2362,Autocuration,104686,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,H,4,1,,CHEMBL617436,,BAO_0000019,,
2363,Autocuration,104686,Striatum,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,D,5,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,Autocuration,104686,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,4,1,,CHEMBL617438,,BAO_0000019,,
2365,Autocuration,104686,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,4,1,,CHEMBL617439,,BAO_0000019,,
2366,Autocuration,104686,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617440,,BAO_0000224,,
2367,Autocuration,104686,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617441,,BAO_0000224,,
2368,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,D,5,1,,CHEMBL872918,,BAO_0000019,,
2369,Autocuration,104686,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,D,5,1,,CHEMBL617442,,BAO_0000019,,
2370,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,4,1,,CHEMBL617443,,BAO_0000019,,
2371,Autocuration,104686,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,H,4,1,,CHEMBL617444,,BAO_0000019,,
2372,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,4,1,,CHEMBL617445,,BAO_0000019,,
2373,Autocuration,104686,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,H,4,1,,CHEMBL617446,,BAO_0000019,,
2374,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,H,4,1,,CHEMBL617447,,BAO_0000249,,
2375,Autocuration,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,H,4,1,,CHEMBL617448,,BAO_0000019,,
2376,Autocuration,104686,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,H,4,1,,CHEMBL617449,,BAO_0000019,,
2377,Autocuration,104686,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,H,4,1,,CHEMBL617450,,BAO_0000019,,
2378,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,H,4,1,,CHEMBL617451,,BAO_0000019,,
2379,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,H,4,1,,CHEMBL617452,,BAO_0000019,,
2380,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,H,4,1,,CHEMBL617453,,BAO_0000019,,
2381,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,H,4,1,,CHEMBL617660,,BAO_0000019,,
2382,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,H,4,1,,CHEMBL617661,,BAO_0000019,,
2383,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,H,4,1,,CHEMBL617662,,BAO_0000019,,
2384,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,H,4,1,,CHEMBL872919,,BAO_0000019,,
2385,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,H,4,1,,CHEMBL617663,,BAO_0000019,,
2386,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,H,4,1,,CHEMBL617664,,BAO_0000019,,
2387,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,H,4,1,,CHEMBL617665,,BAO_0000019,,
2388,Autocuration,104686,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,H,4,1,,CHEMBL617666,,BAO_0000019,,
2389,Autocuration,104686,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,H,4,1,,CHEMBL617667,,BAO_0000019,,
2390,Autocuration,104686,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,H,4,1,,CHEMBL617668,,BAO_0000249,,
2391,Autocuration,104686,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,H,4,1,,CHEMBL617669,,BAO_0000249,,
2392,Autocuration,104686,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617670,,BAO_0000224,,
2393,Autocuration,104686,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617671,,BAO_0000224,,
2394,Autocuration,104686,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617672,,BAO_0000224,,
2395,Autocuration,104686,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,H,4,1,,CHEMBL617673,,BAO_0000019,,
2396,Autocuration,104686,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,H,4,1,,CHEMBL617674,,BAO_0000224,,
2397,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,H,4,1,,CHEMBL617675,,BAO_0000019,,
2398,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,H,4,1,,CHEMBL617676,,BAO_0000019,,
2399,Autocuration,104686,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,H,4,1,,CHEMBL617677,,BAO_0000019,,
2400,Autocuration,104686,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617678,,BAO_0000019,,
2401,Autocuration,104686,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,H,4,1,,CHEMBL617679,,BAO_0000224,,
2402,Autocuration,104686,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,H,4,1,,CHEMBL617680,,BAO_0000224,,
2403,Autocuration,104686,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,H,4,1,,CHEMBL617681,,BAO_0000019,,
2404,Autocuration,104686,Brain,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,H,4,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,Autocuration,104686,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,H,4,1,,CHEMBL617683,,BAO_0000224,,
2406,Autocuration,104686,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,H,4,1,,CHEMBL617684,,BAO_0000224,,
2407,Autocuration,104686,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,D,5,1,,CHEMBL617685,,BAO_0000224,,
2408,Autocuration,104686,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,H,4,1,,CHEMBL617686,,BAO_0000019,,
2409,Autocuration,104686,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,H,4,1,,CHEMBL617687,,BAO_0000224,,
2410,Autocuration,104686,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,4,1,,CHEMBL617688,,BAO_0000224,,
2411,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL617689,,BAO_0000019,,
2412,Autocuration,104686,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,4,1,,CHEMBL617690,,BAO_0000019,,
2413,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,4,1,,CHEMBL617691,,BAO_0000218,,
2414,Autocuration,104686,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,4,1,,CHEMBL617692,,BAO_0000218,,
2415,Autocuration,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,4,1,,CHEMBL617693,,BAO_0000218,,
2416,Autocuration,104686,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,4,1,,CHEMBL617694,,BAO_0000218,,
2417,Expert,12687,Brain,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,H,8,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,Expert,12687,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,9,1,,CHEMBL617695,,BAO_0000019,,
2419,Autocuration,12687,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,H,8,1,,CHEMBL617696,,BAO_0000019,,
2420,Autocuration,12687,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617697,,BAO_0000357,,
2421,Expert,12687,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,D,9,1,,CHEMBL617257,,BAO_0000019,,
2422,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,D,9,1,,CHEMBL617258,,BAO_0000357,,
2423,Expert,12687,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,H,8,1,,CHEMBL617259,,BAO_0000019,,
2424,Autocuration,12687,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,H,8,1,,CHEMBL617260,,BAO_0000357,,
2425,Expert,12687,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617261,,BAO_0000357,,
2426,Autocuration,12687,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,H,8,1,,CHEMBL617262,,BAO_0000019,,
2427,Expert,12687,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,8,1,,CHEMBL617263,,BAO_0000019,,
2428,Autocuration,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,H,8,1,,CHEMBL617264,,BAO_0000019,,
2429,Expert,12687,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617265,,BAO_0000019,,
2430,Autocuration,12687,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617266,,BAO_0000249,,
2431,Autocuration,12687,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,H,8,1,,CHEMBL617267,,BAO_0000019,,
2432,Expert,12687,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,H,8,1,,CHEMBL617268,,BAO_0000019,,
2433,Autocuration,12687,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,H,8,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,Expert,12687,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,H,8,1,,CHEMBL617323,,BAO_0000357,,
2435,Autocuration,12687,,,Serotonergic activity of the compound.,H,8,1,,CHEMBL617324,,BAO_0000357,,
2436,Autocuration,12687,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,H,8,1,,CHEMBL617325,,BAO_0000249,,
2437,Expert,12687,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,D,9,1,,CHEMBL617326,,BAO_0000019,,
2438,Expert,12687,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,H,8,1,,CHEMBL617327,,BAO_0000249,,
2439,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,9,1,,CHEMBL617328,,BAO_0000019,,
2440,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,9,1,,CHEMBL617329,,BAO_0000019,,
2441,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,9,1,,CHEMBL617330,,BAO_0000019,,
2442,Autocuration,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617331,,BAO_0000357,,
2443,Autocuration,12687,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,H,8,1,,CHEMBL617332,,BAO_0000357,,
2444,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617333,,BAO_0000357,,
2445,Autocuration,107,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,H,8,1,,CHEMBL617334,,BAO_0000357,,
2446,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,H,8,1,,CHEMBL617335,,BAO_0000357,,
2447,Autocuration,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,H,8,1,,CHEMBL617336,,BAO_0000357,,
2448,Autocuration,107,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,H,8,1,,CHEMBL617337,,BAO_0000357,,
2449,Expert,107,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,D,9,1,,CHEMBL617338,,BAO_0000357,,
2450,Autocuration,107,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617339,,BAO_0000357,,
2451,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617340,,BAO_0000357,,
2452,Autocuration,107,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,H,8,1,,CHEMBL617341,,BAO_0000357,,
2453,Expert,107,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617342,,BAO_0000357,,
2454,Expert,107,,,Affinity for 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617343,,BAO_0000357,,
2455,Expert,107,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,H,8,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,H,8,1,,CHEMBL617345,,BAO_0000357,,
2457,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,H,8,1,,CHEMBL617346,,BAO_0000357,,
2458,Autocuration,107,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617347,,BAO_0000357,,
2459,Autocuration,107,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617348,,BAO_0000357,,
2460,Autocuration,107,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617349,,BAO_0000357,,
2461,Autocuration,107,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617350,,BAO_0000019,,
2462,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,H,8,1,,CHEMBL872339,,BAO_0000357,,
2463,Autocuration,107,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617351,,BAO_0000357,,
2464,Expert,107,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617352,,BAO_0000357,,
2465,Autocuration,107,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617353,,BAO_0000357,,
2466,Autocuration,107,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617354,,BAO_0000357,,
2467,Autocuration,107,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617355,,BAO_0000357,,
2468,Expert,107,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,H,8,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,Autocuration,107,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617357,,BAO_0000357,,
2470,Autocuration,107,,,Binding affinity at 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617358,,BAO_0000357,,
2471,Expert,107,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617359,,BAO_0000357,,
2472,Autocuration,107,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,H,8,1,,CHEMBL617360,,BAO_0000357,,
2473,Autocuration,107,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,H,8,1,,CHEMBL875913,,BAO_0000357,,
2474,Autocuration,107,,,Affinity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617361,,BAO_0000357,,
2475,Expert,107,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617362,,BAO_0000357,,
2476,Autocuration,107,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,8,1,,CHEMBL617363,,BAO_0000357,,
2477,Autocuration,107,,,Tested against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617364,,BAO_0000357,,
2478,Autocuration,105075,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,4,1,,CHEMBL617365,,BAO_0000224,,
2479,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,H,4,1,,CHEMBL617366,,BAO_0000224,,
2480,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,H,4,1,,CHEMBL617367,,BAO_0000224,,
2481,Autocuration,105075,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,4,1,,CHEMBL617368,,BAO_0000224,,
2482,Autocuration,107,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),H,8,1,,CHEMBL617369,,BAO_0000357,,
2483,Expert,227,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,D,9,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,Expert,227,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,D,9,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,Autocuration,227,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),H,8,1,,CHEMBL617372,,BAO_0000357,,
2486,Expert,227,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,D,9,1,,CHEMBL617373,,BAO_0000357,,
2487,Autocuration,227,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,H,8,1,,CHEMBL617374,,BAO_0000019,,
2488,Autocuration,227,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,H,8,1,,CHEMBL617375,,BAO_0000019,,
2489,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,H,8,1,,CHEMBL617376,,BAO_0000019,,
2490,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,H,8,1,,CHEMBL617377,,BAO_0000019,,
2491,Autocuration,227,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,H,8,1,,CHEMBL617378,,BAO_0000019,,
2492,Autocuration,227,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,8,1,,CHEMBL617379,,BAO_0000019,,
2493,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,H,8,1,,CHEMBL617380,,BAO_0000357,,
2494,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,H,8,1,,CHEMBL617381,,BAO_0000357,,
2495,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,8,1,,CHEMBL617382,,BAO_0000357,,
2496,Autocuration,107,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617383,,BAO_0000357,,
2497,Expert,107,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,H,8,1,,CHEMBL617384,,BAO_0000357,,
2498,Expert,107,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,H,8,1,,CHEMBL617385,,BAO_0000357,,
2499,Autocuration,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,H,8,1,,CHEMBL617386,,BAO_0000019,,
2500,Autocuration,107,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,H,8,1,,CHEMBL617387,,BAO_0000019,,
2501,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,8,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,Autocuration,107,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,H,8,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,Expert,107,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,9,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,Autocuration,104817,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,H,4,1,,CHEMBL617391,,BAO_0000224,,
2505,Autocuration,107,,,Binding activity radioligand.,H,8,1,,CHEMBL617392,,BAO_0000357,,
2506,Autocuration,107,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617393,,BAO_0000019,,
2507,Autocuration,107,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,8,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,Expert,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,8,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,Expert,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,H,8,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,Autocuration,107,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,H,8,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,Autocuration,107,,,Binding affinity against 5-HT2A receptor,H,8,1,,CHEMBL617398,,BAO_0000357,,
2512,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617399,,BAO_0000357,,
2513,Autocuration,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,Autocuration,107,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,Expert,107,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,D,9,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,9,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,H,8,1,,CHEMBL617404,,BAO_0000357,,
2518,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,9,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,9,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,Expert,107,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,D,9,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,Expert,107,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,H,8,1,,CHEMBL617254,,BAO_0000357,,
2522,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,H,8,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,Expert,107,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,D,9,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,Expert,107,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,H,8,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,Expert,107,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",H,8,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,Expert,107,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,D,9,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,Expert,107,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,H,8,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,Expert,107,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,H,8,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,Expert,107,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,9,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,8,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,Autocuration,107,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,8,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,Autocuration,107,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,H,8,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,Autocuration,107,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,H,8,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,Expert,107,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,H,8,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,Expert,107,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL616888,,BAO_0000357,,
2539,Autocuration,107,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,H,8,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,Autocuration,107,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,H,8,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,Expert,107,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,D,9,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,Autocuration,107,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,H,8,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,Autocuration,107,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",H,8,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,Autocuration,10620,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,H,8,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,Expert,107,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,H,8,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,Autocuration,10620,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL616896,,BAO_0000019,,
2547,Autocuration,10621,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617099,,BAO_0000357,,
2548,Autocuration,10621,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,H,8,1,,CHEMBL617100,,BAO_0000357,,
2549,Autocuration,107,,,Binding affinity against rabbit aorta 5-HT2A receptor,H,8,1,,CHEMBL884532,,BAO_0000357,,
2550,Expert,107,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,H,8,1,,CHEMBL617101,,BAO_0000357,,
2551,Expert,107,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,H,8,1,,CHEMBL617102,,BAO_0000357,,
2552,Autocuration,107,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,8,1,,CHEMBL617103,,BAO_0000019,,
2553,Expert,107,,,The compound was tested for binding affinity against 5-HT2A receptor,H,8,1,,CHEMBL617104,,BAO_0000357,,
2554,Autocuration,10576,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,H,8,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,H,8,1,,CHEMBL857502,,BAO_0000019,,
2556,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,8,1,,CHEMBL617105,,BAO_0000019,,
2557,Autocuration,12687,Stomach,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,H,8,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,Expert,12687,Stomach,,Binding affinity for 5-HT 2A in rat stomach fundus,D,9,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,Autocuration,12687,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,8,1,,CHEMBL617106,,BAO_0000019,,
2560,Expert,12687,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,Autocuration,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617108,,BAO_0000019,,
2562,Autocuration,12687,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617109,,BAO_0000019,,
2563,Autocuration,12687,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617110,,BAO_0000357,,
2564,Autocuration,12687,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,H,8,1,,CHEMBL617111,,BAO_0000357,,
2565,Expert,12687,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,D,9,1,,CHEMBL617112,,BAO_0000019,,
2566,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617113,,BAO_0000357,,
2567,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617114,,BAO_0000357,,
2568,Autocuration,12687,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617115,,BAO_0000357,,
2569,Autocuration,12687,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,8,1,,CHEMBL617116,,BAO_0000219,,
2570,Autocuration,12687,,,Efficacy at 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617117,,BAO_0000019,,
2571,Autocuration,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),H,8,1,,CHEMBL617118,,BAO_0000357,,
2572,Expert,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),D,9,1,,CHEMBL617119,,BAO_0000357,,
2573,Expert,12687,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),D,9,1,,CHEMBL617120,,BAO_0000357,,
2574,Expert,12687,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,D,9,1,,CHEMBL617121,,BAO_0000219,,
2575,Autocuration,12687,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,8,1,,CHEMBL617122,,BAO_0000219,,
2576,Autocuration,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617123,,BAO_0000019,,
2577,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,H,8,1,,CHEMBL617124,,BAO_0000019,,
2578,Expert,12687,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,H,8,1,,CHEMBL617600,,BAO_0000249,,
2579,Expert,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,H,8,1,,CHEMBL617601,,BAO_0000357,,
2580,Expert,12687,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,H,8,1,,CHEMBL882923,,BAO_0000019,,
2581,Autocuration,12687,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617602,,BAO_0000357,,
2582,Autocuration,12687,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,H,8,1,,CHEMBL617603,,BAO_0000019,,
2583,Autocuration,12687,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617604,,BAO_0000357,,
2584,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617605,,BAO_0000019,,
2585,Expert,12687,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617606,,BAO_0000019,,
2586,Expert,12687,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617607,,BAO_0000019,,
2587,Autocuration,12687,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL617455,,BAO_0000249,,
2588,Expert,12687,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,9,1,,CHEMBL617456,,BAO_0000019,,
2589,Expert,12687,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),H,8,1,,CHEMBL617457,,BAO_0000357,,
2590,Expert,12687,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617458,,BAO_0000357,,
2591,Expert,12687,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,D,9,1,,CHEMBL617459,,BAO_0000019,,
2592,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,H,8,1,,CHEMBL617460,,BAO_0000357,,
2593,Expert,12687,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",H,8,1,,CHEMBL617461,,BAO_0000357,,
2594,Expert,12687,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,D,9,1,,CHEMBL617462,,BAO_0000019,,
2595,Autocuration,12687,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,H,8,1,,CHEMBL617463,,BAO_0000357,,
2596,Autocuration,12687,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",H,8,1,,CHEMBL617464,,BAO_0000019,,
2597,Autocuration,12687,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",H,8,1,,CHEMBL617465,,BAO_0000019,,
2598,Expert,12687,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,H,8,1,,CHEMBL617466,,BAO_0000019,,
2599,Autocuration,12687,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,8,1,,CHEMBL617467,,BAO_0000019,,
2600,Expert,12687,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,H,8,1,,CHEMBL617468,,BAO_0000019,,
2601,Autocuration,12687,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,8,1,,CHEMBL617469,,BAO_0000019,,
2602,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617470,,BAO_0000019,,
2603,Autocuration,12687,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,H,8,1,,CHEMBL617471,,BAO_0000019,,
2604,Expert,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,H,8,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,Expert,12687,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,H,8,1,,CHEMBL617473,,BAO_0000357,,
2606,Expert,12687,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,9,1,,CHEMBL617474,,BAO_0000019,,
2607,Expert,12687,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,9,1,,CHEMBL617475,,BAO_0000019,,
2608,Autocuration,12687,Brain,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,H,8,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,Expert,12687,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617477,,BAO_0000357,,
2610,Expert,12687,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,Autocuration,12687,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",H,8,1,,CHEMBL617479,,BAO_0000221,,
2612,Autocuration,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,H,8,1,,CHEMBL617480,,BAO_0000357,,
2613,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617481,,BAO_0000357,,
2614,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,H,8,1,,CHEMBL617482,,BAO_0000019,,
2615,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617483,,BAO_0000019,,
2616,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL621528,,BAO_0000357,,
2617,Expert,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,D,9,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL621530,,BAO_0000357,,
2619,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL621531,,BAO_0000357,,
2620,Expert,12687,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL621532,,BAO_0000019,,
2621,Expert,12687,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL621533,,BAO_0000357,,
2622,Expert,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,8,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,Autocuration,12687,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,H,8,1,,CHEMBL621535,,BAO_0000019,,
2624,Autocuration,12687,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,8,1,,CHEMBL621536,,BAO_0000357,,
2625,Autocuration,12687,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL621537,,BAO_0000357,,
2626,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL621538,,BAO_0000357,,
2627,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,H,8,1,,CHEMBL621539,,BAO_0000019,,
2628,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,H,8,1,,CHEMBL621540,,BAO_0000019,,
2629,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,H,8,1,,CHEMBL621541,,BAO_0000019,,
2630,Autocuration,12687,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,H,8,1,,CHEMBL621542,,BAO_0000019,,
2631,Expert,12687,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,H,8,1,,CHEMBL621543,,BAO_0000357,,
2632,Expert,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,H,8,1,,CHEMBL621544,,BAO_0000357,,
2633,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,D,9,1,,CHEMBL621545,,BAO_0000357,,
2634,Autocuration,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL621546,,BAO_0000357,,
2635,Autocuration,12687,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,H,8,1,,CHEMBL621547,,BAO_0000357,,
2636,Expert,12687,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL618693,,BAO_0000357,,
2638,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL872922,,BAO_0000357,,
2639,Autocuration,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,H,8,1,,CHEMBL618694,,BAO_0000357,,
2640,Expert,12687,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,D,9,1,,CHEMBL618695,,BAO_0000357,,
2641,Autocuration,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,H,8,1,,CHEMBL618696,,BAO_0000357,,
2642,Expert,12687,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,H,8,1,,CHEMBL618697,,BAO_0000357,,
2643,Autocuration,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,H,8,1,,CHEMBL618892,,BAO_0000357,,
2644,Autocuration,12687,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,H,8,1,,CHEMBL618893,,BAO_0000357,,
2645,Autocuration,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL618894,,BAO_0000357,,
2646,Expert,12687,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,H,8,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,Expert,12687,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,9,1,,CHEMBL618896,,BAO_0000357,,
2648,Autocuration,12687,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,H,8,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,Autocuration,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,H,8,1,,CHEMBL618898,,BAO_0000357,,
2650,Autocuration,12687,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,H,8,1,,CHEMBL618899,,BAO_0000357,,
2651,Autocuration,12687,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,H,8,1,,CHEMBL618900,,BAO_0000357,,
2652,Autocuration,12687,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,H,8,1,,CHEMBL618901,,BAO_0000019,,
2653,Autocuration,12687,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL618902,,BAO_0000357,,
2654,Expert,12687,Hippocampus,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,Autocuration,12687,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL618904,,BAO_0000357,,
2656,Autocuration,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,H,8,1,,CHEMBL618905,,BAO_0000357,,
2657,Autocuration,12687,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,H,8,1,,CHEMBL618906,,BAO_0000357,,
2658,Expert,12687,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,H,8,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,Autocuration,12687,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,H,8,1,,CHEMBL618908,,BAO_0000019,,
2660,Autocuration,12687,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617909,,BAO_0000357,,
2661,Expert,12687,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,8,1,,CHEMBL617910,,BAO_0000019,,
2662,Autocuration,12687,Brain,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,H,8,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL872923,,BAO_0000249,,
2664,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL617912,,BAO_0000249,,
2665,Expert,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,D,9,1,,CHEMBL617913,,BAO_0000019,,
2666,Expert,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL617914,,BAO_0000249,,
2667,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL617915,,BAO_0000249,,
2668,Autocuration,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,8,1,,CHEMBL617916,,BAO_0000249,,
2669,Expert,12687,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,D,9,1,,CHEMBL617917,,BAO_0000019,,
2670,Expert,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617918,,BAO_0000019,,
2671,Autocuration,12687,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,H,8,1,,CHEMBL617919,,BAO_0000019,,
2672,Expert,12687,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,9,1,,CHEMBL617920,,BAO_0000019,,
2673,Expert,12687,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,D,9,1,,CHEMBL617921,,BAO_0000019,,
2674,Expert,105102,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",D,5,1,,CHEMBL617922,,BAO_0000224,,
2675,Autocuration,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL617923,,BAO_0000357,,
2676,Autocuration,12687,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,8,1,,CHEMBL617924,,BAO_0000357,,
2677,Autocuration,12687,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,H,8,1,,CHEMBL617925,,BAO_0000357,,
2678,Expert,12687,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,D,9,1,,CHEMBL617926,,BAO_0000357,,
2679,Autocuration,12687,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,H,8,1,,CHEMBL617927,,BAO_0000357,,
2680,Autocuration,12687,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,H,8,1,,CHEMBL617928,,BAO_0000357,,
2681,Expert,12687,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,9,1,,CHEMBL617929,,BAO_0000019,,
2682,Expert,12687,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,H,8,1,,CHEMBL617930,,BAO_0000019,,
2683,Autocuration,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,H,8,1,,CHEMBL617931,,BAO_0000019,,
2684,Autocuration,12687,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,H,8,1,,CHEMBL617932,,BAO_0000019,,
2685,Autocuration,12687,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,H,8,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,Autocuration,12687,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,8,1,,CHEMBL617934,,BAO_0000019,,
2687,Autocuration,12687,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,8,1,,CHEMBL617935,,BAO_0000019,,
2688,Autocuration,12687,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,H,8,1,,CHEMBL617936,,BAO_0000357,,
2689,Autocuration,12687,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,H,8,1,,CHEMBL617937,,BAO_0000019,,
2690,Autocuration,12687,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,H,8,1,,CHEMBL617938,,BAO_0000019,,
2691,Autocuration,12687,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,H,8,1,,CHEMBL617939,,BAO_0000218,,
2692,Autocuration,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,H,8,1,,CHEMBL617940,,BAO_0000218,,
2693,Autocuration,12687,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,H,8,1,,CHEMBL617941,,BAO_0000218,,
2694,Expert,12687,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,H,8,1,,CHEMBL617942,,BAO_0000357,,
2695,Expert,12687,,,Ratio of pKi of 5-HT2A to that of D2 receptor,H,8,1,,CHEMBL617943,,BAO_0000357,,
2696,Expert,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,4,1,,CHEMBL617944,,BAO_0000224,,
2697,Expert,105093,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,4,1,,CHEMBL617945,,BAO_0000224,,
2698,Expert,105075,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,H,4,1,,CHEMBL617946,,BAO_0000224,,
2699,Autocuration,12687,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,H,8,1,,CHEMBL617947,,BAO_0000357,,
2700,Expert,12687,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,H,8,1,,CHEMBL617948,,BAO_0000357,,
2701,Autocuration,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,H,8,1,,CHEMBL858116,,BAO_0000019,,
2702,Autocuration,12687,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,H,8,1,,CHEMBL617949,,BAO_0000019,,
2703,Autocuration,12687,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,H,8,1,,CHEMBL617950,,BAO_0000019,,
2704,Expert,12687,Thoracic aorta,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,H,8,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,Expert,12687,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,H,8,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,Autocuration,12687,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,H,8,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,Autocuration,12687,,,Binding activity radioligand.,H,8,1,,CHEMBL617954,,BAO_0000357,,
2708,Expert,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617955,,BAO_0000019,,
2709,Autocuration,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,8,1,,CHEMBL857071,,BAO_0000019,,
2710,Expert,12687,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,H,8,1,,CHEMBL617270,,BAO_0000019,,
2711,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,H,8,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,Autocuration,12687,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,H,8,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,Autocuration,12687,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,H,8,1,,CHEMBL617273,,BAO_0000019,,
2714,Expert,12687,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,D,9,1,,CHEMBL617274,,BAO_0000019,,
2715,Autocuration,108,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617275,,BAO_0000357,,
2716,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617276,,BAO_0000357,,
2717,Autocuration,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617277,,BAO_0000357,,
2718,Expert,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617278,,BAO_0000019,,
2719,Expert,108,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,H,8,1,,CHEMBL617279,,BAO_0000019,,
2720,Expert,108,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617280,,BAO_0000019,,
2721,Autocuration,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617281,,BAO_0000357,,
2722,Autocuration,108,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617282,,BAO_0000357,,
2723,Expert,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,H,8,1,,CHEMBL617283,,BAO_0000019,,
2724,Expert,108,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,H,8,1,,CHEMBL617284,,BAO_0000019,,
2725,Autocuration,108,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,Autocuration,108,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617286,,BAO_0000019,,
2727,Expert,108,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,D,9,1,,CHEMBL617287,,BAO_0000357,,
2728,Expert,108,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,H,8,1,,CHEMBL617288,,BAO_0000357,,
2729,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,H,8,1,,CHEMBL617289,,BAO_0000357,,
2730,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL872917,,BAO_0000357,,
2731,Autocuration,108,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL617290,,BAO_0000357,,
2732,Autocuration,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,8,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,Autocuration,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,H,8,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,Autocuration,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,8,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,Expert,108,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,9,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,Expert,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,8,1,,CHEMBL617295,,BAO_0000019,,
2737,Autocuration,108,,,Binding activity radioligand.,H,8,1,,CHEMBL617296,,BAO_0000357,,
2738,Autocuration,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617297,,BAO_0000019,,
2739,Expert,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,Expert,108,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,H,8,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,Autocuration,108,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,H,8,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,Autocuration,108,,,Binding affinity against 5-HT2C receptor,H,8,1,,CHEMBL617454,,BAO_0000357,,
2743,Autocuration,108,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,Expert,108,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,D,9,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,9,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,H,8,1,,CHEMBL617508,,BAO_0000357,,
2747,Expert,108,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,9,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,Expert,108,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,D,9,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,Expert,108,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,D,9,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,Autocuration,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,H,8,1,,CHEMBL617511,,BAO_0000357,,
2751,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,Autocuration,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,Autocuration,108,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,Expert,108,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,Autocuration,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",H,8,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,Expert,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",H,8,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,Expert,108,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,D,9,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,Autocuration,108,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",H,8,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,Expert,108,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,H,8,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,Expert,108,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,H,8,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,Autocuration,108,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,Autocuration,108,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,H,8,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,Expert,108,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,H,8,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL617762,,BAO_0000357,,
2766,Autocuration,108,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617763,,BAO_0000357,,
2767,Autocuration,108,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,H,8,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,Autocuration,108,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,H,8,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,Autocuration,108,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,H,8,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,Autocuration,108,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617766,,BAO_0000019,,
2771,Autocuration,108,Hippocampus,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,H,8,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,Autocuration,108,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,H,8,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,Autocuration,108,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",H,8,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,Autocuration,11864,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,H,8,1,,CHEMBL858023,,BAO_0000357,,
2775,Autocuration,11864,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,H,8,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,Autocuration,11864,Stomach,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,H,8,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,Autocuration,11864,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,H,8,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,8,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,H,8,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,Autocuration,11864,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,8,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,Autocuration,11864,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617852,,BAO_0000019,,
2782,Autocuration,12689,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,H,8,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,Expert,12689,Stomach,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,D,9,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,Expert,108,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,H,8,1,,CHEMBL617854,,BAO_0000357,,
2785,Expert,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL873477,,BAO_0000357,,
2786,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617855,,BAO_0000357,,
2787,Expert,108,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,H,8,1,,CHEMBL617856,,BAO_0000019,,
2788,Autocuration,108,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,H,8,1,,CHEMBL617857,,BAO_0000019,,
2789,Autocuration,108,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,H,8,1,,CHEMBL617858,,BAO_0000249,,
2790,Autocuration,108,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617859,,BAO_0000357,,
2791,Autocuration,108,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617860,,BAO_0000357,,
2792,Autocuration,108,,,Binding activity radioligand.,H,8,1,,CHEMBL617861,,BAO_0000357,,
2793,Expert,108,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617862,,BAO_0000019,,
2794,Autocuration,108,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,8,1,,CHEMBL617863,,BAO_0000019,,
2795,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,H,8,1,,CHEMBL617864,,BAO_0000249,,
2796,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,H,8,1,,CHEMBL617649,,BAO_0000249,,
2797,Expert,108,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,8,1,,CHEMBL617650,,BAO_0000019,,
2798,Expert,108,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,8,1,,CHEMBL617651,,BAO_0000019,,
2799,Autocuration,108,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,H,8,1,,CHEMBL617652,,BAO_0000357,,
2800,Autocuration,108,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,H,8,1,,CHEMBL857072,,BAO_0000019,,
2801,Autocuration,108,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617653,,BAO_0000357,,
2802,Autocuration,12687,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL617654,,BAO_0000019,,
2803,Autocuration,12689,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617655,,BAO_0000019,,
2804,Expert,12689,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617656,,BAO_0000357,,
2805,Autocuration,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617657,,BAO_0000357,,
2806,Autocuration,12689,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,H,8,1,,CHEMBL617658,,BAO_0000357,,
2807,Expert,12689,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL617659,,BAO_0000357,,
2808,Expert,12689,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL617838,,BAO_0000357,,
2809,Expert,12689,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,D,9,1,,CHEMBL617839,,BAO_0000249,,
2810,Autocuration,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,H,8,1,,CHEMBL617840,,BAO_0000357,,
2811,Autocuration,12689,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,H,8,1,,CHEMBL617841,,BAO_0000019,,
2812,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,H,8,1,,CHEMBL875915,,BAO_0000019,,
2813,Expert,12689,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,H,8,1,,CHEMBL617842,,BAO_0000219,,
2814,Expert,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,H,8,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,Expert,12689,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,H,8,1,,CHEMBL617844,,BAO_0000357,,
2816,Expert,12689,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617845,,BAO_0000357,,
2817,Expert,12689,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,Autocuration,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,H,8,1,,CHEMBL617847,,BAO_0000357,,
2819,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617848,,BAO_0000357,,
2820,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL617849,,BAO_0000357,,
2821,Expert,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL621507,,BAO_0000357,,
2822,Expert,12689,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,H,8,1,,CHEMBL621508,,BAO_0000357,,
2823,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,H,8,1,,CHEMBL621509,,BAO_0000019,,
2824,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,H,8,1,,CHEMBL621510,,BAO_0000019,,
2825,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,H,8,1,,CHEMBL621511,,BAO_0000019,,
2826,Expert,12689,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,Autocuration,12689,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL621513,,BAO_0000357,,
2828,Expert,12689,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,H,8,1,,CHEMBL621514,,BAO_0000357,,
2829,Expert,12689,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,H,8,1,,CHEMBL621515,,BAO_0000219,,
2830,Autocuration,12689,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,H,8,1,,CHEMBL621516,,BAO_0000219,,
2831,Autocuration,12689,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,H,8,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,Autocuration,12689,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,H,8,1,,CHEMBL621518,,BAO_0000357,,
2833,Autocuration,12689,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,H,8,1,,CHEMBL621519,,BAO_0000019,,
2834,Autocuration,12689,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621520,,BAO_0000357,,
2835,Autocuration,12689,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621521,,BAO_0000357,,
2836,Autocuration,12689,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621522,,BAO_0000357,,
2837,Expert,12689,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,H,8,1,,CHEMBL621523,,BAO_0000219,,
2838,Autocuration,12689,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621524,,BAO_0000357,,
2839,Expert,12689,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,D,9,1,,CHEMBL621525,,BAO_0000357,,
2840,Autocuration,12689,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,H,8,1,,CHEMBL872921,,BAO_0000357,,
2841,Autocuration,12689,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621526,,BAO_0000357,,
2842,Expert,12689,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,H,8,1,,CHEMBL621527,,BAO_0000219,,
2843,Expert,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,D,9,1,,CHEMBL617865,,BAO_0000019,,
2844,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617866,,BAO_0000357,,
2845,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,H,8,1,,CHEMBL617867,,BAO_0000019,,
2846,Autocuration,12689,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,H,8,1,,CHEMBL617487,,BAO_0000357,,
2847,Expert,12689,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617488,,BAO_0000357,,
2848,Autocuration,12689,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,H,8,1,,CHEMBL617489,,BAO_0000357,,
2849,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,H,8,1,,CHEMBL617490,,BAO_0000019,,
2850,Autocuration,12689,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,H,8,1,,CHEMBL617491,,BAO_0000019,,
2851,Autocuration,12689,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,H,8,1,,CHEMBL617492,,BAO_0000019,,
2852,Autocuration,12689,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,H,8,1,,CHEMBL617493,,BAO_0000019,,
2853,Autocuration,12689,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,H,8,1,,CHEMBL617494,,BAO_0000357,,
2854,Expert,12689,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,D,9,1,,CHEMBL617495,,BAO_0000019,,
2855,Autocuration,12689,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL617496,,BAO_0000357,,
2856,Autocuration,12689,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,H,8,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,Autocuration,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617498,,BAO_0000357,,
2858,Autocuration,12689,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,H,8,1,,CHEMBL617499,,BAO_0000357,,
2859,Autocuration,12689,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617500,,BAO_0000019,,
2860,Autocuration,108,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617501,,BAO_0000357,,
2861,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617502,,BAO_0000357,,
2862,Autocuration,227,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,H,8,1,,CHEMBL617503,,BAO_0000357,,
2863,Autocuration,227,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,H,8,1,,CHEMBL617504,,BAO_0000357,,
2864,Autocuration,227,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,H,8,1,,CHEMBL617406,,BAO_0000357,,
2865,Expert,227,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,D,9,1,,CHEMBL617407,,BAO_0000019,,
2866,Autocuration,227,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL617408,,BAO_0000357,,
2867,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617409,,BAO_0000357,,
2868,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617410,,BAO_0000357,,
2869,Autocuration,227,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617411,,BAO_0000357,,
2870,Autocuration,227,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617412,,BAO_0000019,,
2871,Expert,227,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,D,9,1,,CHEMBL617774,,BAO_0000357,,
2872,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,9,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,Expert,227,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,9,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,Expert,227,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,9,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,Expert,227,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,9,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,Autocuration,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,Expert,227,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,Autocuration,227,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",H,8,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,Expert,227,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,D,9,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,Expert,227,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,D,9,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,Autocuration,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,H,8,1,,CHEMBL617784,,BAO_0000357,,
2882,Autocuration,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,H,8,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,Expert,227,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,Expert,227,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,H,8,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,Expert,227,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,H,8,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,D,9,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,Expert,227,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,D,9,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,Autocuration,227,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,H,8,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,Expert,227,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,H,8,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,Expert,227,,,Binding affinity against 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617608,,BAO_0000357,,
2891,Autocuration,227,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,H,8,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,Autocuration,227,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,H,8,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,Autocuration,227,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,H,8,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,Autocuration,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,Autocuration,227,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,8,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,Autocuration,227,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,H,8,1,,CHEMBL617614,,BAO_0000019,,
2897,Expert,12688,Stomach,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,H,8,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,Expert,12688,Stomach,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,H,8,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,Autocuration,12688,Stomach,,Affinity against serotonergic receptor in the isolated rat stomach fundus,H,8,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,Expert,12688,Stomach,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,D,9,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,Expert,12688,,,Antagonistic against 5-hydroxytryptamine 2B receptor,D,9,1,,CHEMBL875914,,BAO_0000019,,
2902,Autocuration,12688,Stomach,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,H,8,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,Expert,12688,Stomach,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,D,9,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,H,8,1,,CHEMBL617620,,BAO_0000019,,
2905,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,H,8,1,,CHEMBL617621,,BAO_0000019,,
2906,Autocuration,12688,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,H,8,1,,CHEMBL617622,,BAO_0000019,,
2907,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,9,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,9,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,9,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,Expert,12688,Stomach,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,9,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,8,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,Expert,12688,Stomach,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,8,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,H,8,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,H,8,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,Expert,12688,Stomach,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,D,9,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,Autocuration,12688,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,H,8,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,Autocuration,12688,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,8,1,,CHEMBL617632,,BAO_0000357,,
2918,Expert,12688,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,H,8,1,,CHEMBL617633,,BAO_0000357,,
2919,Autocuration,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,8,1,,CHEMBL617634,,BAO_0000357,,
2920,Autocuration,12688,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,H,8,1,,CHEMBL617635,,BAO_0000357,,
2922,Autocuration,12688,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,D,9,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,Autocuration,227,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,8,1,,CHEMBL617638,,BAO_0000357,,
2924,Autocuration,227,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,H,8,1,,CHEMBL617639,,BAO_0000357,,
2925,Autocuration,227,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,H,8,1,,CHEMBL617640,,BAO_0000357,,
2926,Autocuration,227,,,Evaluated for the binding affinity to 5-HT 2B receptor,H,8,1,,CHEMBL617641,,BAO_0000357,,
2927,Autocuration,227,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617642,,BAO_0000357,,
2928,Autocuration,227,,,Binding affinities against 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617643,,BAO_0000357,,
2929,Autocuration,227,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,H,8,1,,CHEMBL617644,,BAO_0000357,,
2930,Autocuration,227,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL617645,,BAO_0000357,,
2931,Expert,108,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,8,1,,CHEMBL617646,,BAO_0000357,,
2932,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,8,1,,CHEMBL617647,,BAO_0000357,,
2933,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,H,8,1,,CHEMBL617648,,BAO_0000357,,
2934,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,H,8,1,,CHEMBL617875,,BAO_0000357,,
2935,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,H,8,1,,CHEMBL617876,,BAO_0000357,,
2936,Expert,108,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,H,8,1,,CHEMBL617877,,BAO_0000357,,
2937,Expert,108,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,8,1,,CHEMBL617878,,BAO_0000357,,
2938,Autocuration,108,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,8,1,,CHEMBL617879,,BAO_0000357,,
2939,Autocuration,108,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,H,8,1,,CHEMBL617880,,BAO_0000019,,
2940,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,D,9,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,Autocuration,51,,,Binding affinity against 5-HT1A receptor,H,8,1,,CHEMBL857073,,BAO_0000357,,
2942,Expert,108,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,H,8,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,Expert,108,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,D,9,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,Autocuration,108,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,H,8,1,,CHEMBL617884,,BAO_0000219,,
2945,Autocuration,108,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,H,8,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,Autocuration,108,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",H,8,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,Expert,108,,,Inhibition of human 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL617887,,BAO_0000357,,
2948,Autocuration,108,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),H,8,1,,CHEMBL617888,,BAO_0000357,,
2949,Autocuration,108,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,8,1,,CHEMBL617889,,BAO_0000019,,
2950,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617890,,BAO_0000357,,
2951,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,8,1,,CHEMBL617891,,BAO_0000357,,
2952,Autocuration,108,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,8,1,,CHEMBL617892,,BAO_0000357,,
2953,Expert,108,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,H,8,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,Expert,108,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,H,8,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,Expert,108,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,8,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,Autocuration,108,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,Expert,108,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,D,9,1,,CHEMBL617897,,BAO_0000357,,
2958,Autocuration,108,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,H,8,1,,CHEMBL617898,,BAO_0000019,,
2959,Autocuration,108,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,8,1,,CHEMBL617899,,BAO_0000019,,
2960,Expert,108,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,H,8,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,Autocuration,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,H,8,1,,CHEMBL617901,,BAO_0000019,,
2962,Autocuration,108,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,H,8,1,,CHEMBL617902,,BAO_0000019,,
2963,Autocuration,108,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL617903,,BAO_0000019,,
2964,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,H,8,1,,CHEMBL617904,,BAO_0000357,,
2965,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,H,8,1,,CHEMBL617905,,BAO_0000357,,
2966,Autocuration,108,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,H,8,1,,CHEMBL617906,,BAO_0000357,,
2967,Autocuration,108,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,H,8,1,,CHEMBL617907,,BAO_0000357,,
2968,Autocuration,108,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,H,8,1,,CHEMBL617908,,BAO_0000357,,
2969,Expert,108,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,8,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,Expert,108,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,D,9,1,,CHEMBL620618,,BAO_0000019,,
2971,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,H,8,1,,CHEMBL620619,,BAO_0000357,,
2972,Expert,108,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL620620,,BAO_0000357,,
2973,Autocuration,108,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,H,8,1,,CHEMBL620621,,BAO_0000357,,
2974,Autocuration,104698,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,D,7,1,,CHEMBL872920,,BAO_0000249,,
2975,Autocuration,104698,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,H,6,1,,CHEMBL620622,,BAO_0000223,,
2976,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,D,7,1,,CHEMBL620623,,BAO_0000019,,
2977,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,H,6,1,,CHEMBL620624,,BAO_0000019,,
2978,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,H,6,1,,CHEMBL620625,,BAO_0000019,,
2979,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,H,6,1,,CHEMBL620626,,BAO_0000219,,
2980,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,H,6,1,,CHEMBL621307,,BAO_0000019,,
2981,Autocuration,104698,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,H,6,1,,CHEMBL621308,,BAO_0000019,,
2982,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,H,6,1,,CHEMBL621309,,BAO_0000223,,
2983,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,H,6,1,,CHEMBL621310,,BAO_0000223,,
2984,Autocuration,104698,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,H,6,1,,CHEMBL621311,,BAO_0000223,,
2985,Autocuration,104698,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,6,1,,CHEMBL621502,,BAO_0000249,,
2986,Autocuration,104698,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,6,1,,CHEMBL621503,,BAO_0000249,,
2987,Autocuration,104698,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,H,6,1,,CHEMBL621504,,BAO_0000249,,
2988,Autocuration,104698,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL621505,,BAO_0000223,,
2989,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,6,1,,CHEMBL621506,,BAO_0000019,,
2990,Autocuration,104698,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,H,6,1,,CHEMBL619781,,BAO_0000223,,
2991,Autocuration,104698,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,H,6,1,,CHEMBL619782,,BAO_0000223,,
2992,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,H,6,1,,CHEMBL619783,,BAO_0000019,,
2993,Autocuration,104698,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,D,7,1,,CHEMBL619784,,BAO_0000019,,
2994,Autocuration,104698,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,6,1,,CHEMBL619785,,BAO_0000249,,
2995,Autocuration,104698,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL619786,,BAO_0000223,,
2996,Autocuration,104698,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,H,6,1,,CHEMBL619787,,BAO_0000019,,
2997,Autocuration,104698,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,H,6,1,,CHEMBL872925,,BAO_0000019,,
2998,Autocuration,104698,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,H,6,1,,CHEMBL619788,,BAO_0000019,,
2999,Autocuration,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,6,1,,CHEMBL619789,,BAO_0000249,,
3000,Autocuration,104698,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,6,1,,CHEMBL619790,,BAO_0000249,,
3001,Autocuration,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,6,1,,CHEMBL619791,,BAO_0000019,,
3002,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,6,1,,CHEMBL619792,,BAO_0000019,,
3003,Autocuration,104698,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,H,6,1,,CHEMBL619793,,BAO_0000249,,
3004,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL619794,,BAO_0000223,,
3005,Autocuration,104698,Brain,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,H,6,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,H,6,1,,CHEMBL619796,,BAO_0000019,,
3007,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,H,6,1,,CHEMBL620448,,BAO_0000223,,
3008,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,6,1,,CHEMBL620449,,BAO_0000223,,
3009,Autocuration,104698,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,H,6,1,,CHEMBL620450,,BAO_0000223,,
3010,Autocuration,104698,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,H,6,1,,CHEMBL620451,,BAO_0000223,,
3011,Autocuration,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,H,6,1,,CHEMBL620631,,BAO_0000223,,
3012,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,H,6,1,,CHEMBL620632,,BAO_0000019,,
3013,Autocuration,104698,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,H,6,1,,CHEMBL620633,,BAO_0000019,,
3014,Autocuration,104698,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,H,6,1,,CHEMBL620634,,BAO_0000223,,
3015,Autocuration,104698,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,6,1,,CHEMBL620635,,BAO_0000019,,
3016,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620636,,BAO_0000218,,
3017,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,H,6,1,,CHEMBL620637,,BAO_0000218,,
3018,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620638,,BAO_0000218,,
3019,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620639,,BAO_0000218,,
3020,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620640,,BAO_0000218,,
3021,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,H,6,1,,CHEMBL620641,,BAO_0000218,,
3022,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620642,,BAO_0000218,,
3023,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620643,,BAO_0000218,,
3024,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620644,,BAO_0000218,,
3025,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620645,,BAO_0000218,,
3026,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,H,6,1,,CHEMBL620646,,BAO_0000218,,
3027,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620647,,BAO_0000218,,
3028,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620648,,BAO_0000218,,
3029,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620649,,BAO_0000218,,
3030,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,H,6,1,,CHEMBL620650,,BAO_0000218,,
3031,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,H,6,1,,CHEMBL620651,,BAO_0000218,,
3032,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,H,6,1,,CHEMBL872875,,BAO_0000218,,
3033,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,H,6,1,,CHEMBL620652,,BAO_0000218,,
3034,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,H,6,1,,CHEMBL620653,,BAO_0000019,,
3035,Autocuration,104698,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,H,6,1,,CHEMBL857076,,BAO_0000019,,
3036,Autocuration,104698,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL620654,,BAO_0000019,,
3037,Autocuration,104698,,,Binding activity radioligand.,H,6,1,,CHEMBL620655,,BAO_0000223,,
3038,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,H,6,1,,CHEMBL620656,,BAO_0000249,,
3039,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,H,6,1,,CHEMBL620657,,BAO_0000249,,
3040,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,H,8,1,,CHEMBL620658,,BAO_0000357,,
3041,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,H,8,1,,CHEMBL620659,,BAO_0000357,,
3042,Autocuration,108,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,H,8,1,,CHEMBL620660,,BAO_0000357,,
3043,Autocuration,108,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620661,,BAO_0000357,,
3044,Autocuration,108,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620662,,BAO_0000357,,
3045,Expert,108,,,Affinity for 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620663,,BAO_0000357,,
3046,Autocuration,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,8,1,,CHEMBL620664,,BAO_0000357,,
3047,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,H,8,1,,CHEMBL620665,,BAO_0000357,,
3048,Autocuration,108,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,H,8,1,,CHEMBL620666,,BAO_0000357,,
3049,Autocuration,108,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,H,8,1,,CHEMBL620667,,BAO_0000357,,
3050,Expert,108,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,H,8,1,,CHEMBL620668,,BAO_0000357,,
3051,Autocuration,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,H,8,1,,CHEMBL620669,,BAO_0000357,,
3052,Expert,108,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620670,,BAO_0000357,,
3053,Autocuration,108,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620671,,BAO_0000357,,
3054,Autocuration,108,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,H,8,1,,CHEMBL620672,,BAO_0000357,,
3055,Autocuration,108,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,H,8,1,,CHEMBL620673,,BAO_0000357,,
3056,Autocuration,108,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620674,,BAO_0000357,,
3057,Autocuration,108,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL620675,,BAO_0000357,,
3058,Autocuration,108,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,H,8,1,,CHEMBL620676,,BAO_0000357,,
3059,Autocuration,108,,,Affinity against 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL621382,,BAO_0000357,,
3060,Expert,108,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,9,1,,CHEMBL621383,,BAO_0000357,,
3061,Autocuration,108,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,H,8,1,,CHEMBL621384,,BAO_0000357,,
3062,Autocuration,144,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,H,8,1,,CHEMBL621385,,BAO_0000357,,
3063,Autocuration,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,H,8,1,,CHEMBL617989,,BAO_0000357,,
3064,Expert,104714,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,H,4,1,,CHEMBL617990,,BAO_0000019,,
3065,Autocuration,104714,Ileum,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,4,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,Autocuration,104714,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,H,4,1,,CHEMBL617991,,BAO_0000019,,
3067,Autocuration,104714,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,H,4,1,,CHEMBL617992,,BAO_0000019,,
3068,Autocuration,104714,Ileum,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,4,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,Autocuration,104714,Ileum,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,H,4,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,H,4,1,,CHEMBL617995,,BAO_0000019,,
3071,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,H,4,1,,CHEMBL617996,,BAO_0000019,,
3072,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,H,4,1,,CHEMBL617997,,BAO_0000019,,
3073,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,H,4,1,,CHEMBL617998,,BAO_0000019,,
3074,Autocuration,104714,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,H,4,1,,CHEMBL617999,,BAO_0000019,,
3075,Autocuration,104714,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,H,4,1,,CHEMBL618000,,BAO_0000019,,
3076,Autocuration,104714,Ileum,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",H,4,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,Autocuration,104714,Ileum,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",H,4,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,Autocuration,104714,Ileum,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,H,4,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,Autocuration,104714,Ileum,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,H,4,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,Autocuration,104714,Ileum,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,H,4,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,Autocuration,104714,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,H,4,1,,CHEMBL617820,,BAO_0000223,,
3082,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,4,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,4,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,Autocuration,104714,Ileum,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),H,4,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,Autocuration,104714,Ileum,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,H,4,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,Autocuration,104714,Ileum,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,H,4,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,Autocuration,104714,Ileum,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,H,4,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,4,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,4,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,4,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,Autocuration,104714,Ileum,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,H,4,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,Autocuration,104714,Ileum,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,H,4,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,Autocuration,104714,Ileum,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,H,4,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,Autocuration,22226,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,U,0,1,,CHEMBL617833,,BAO_0000019,,
3095,Autocuration,51,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,H,8,1,,CHEMBL617834,,BAO_0000357,,
3096,Expert,104714,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,D,5,1,,CHEMBL617835,,BAO_0000223,,
3097,Autocuration,104714,,,Binding affinity towards 5-HT3 receptor,H,4,1,,CHEMBL617836,,BAO_0000223,,
3098,Autocuration,104714,,,Binding activity radioligand.,H,4,1,,CHEMBL617837,,BAO_0000223,,
3099,Autocuration,104714,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,H,4,1,,CHEMBL620392,,BAO_0000019,,
3100,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL620393,,BAO_0000223,,
3101,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL620394,,BAO_0000223,,
3102,Autocuration,104714,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,H,4,1,,CHEMBL620395,,BAO_0000223,,
3103,Autocuration,22226,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,U,0,1,,CHEMBL620396,,BAO_0000019,,
3104,Expert,105030,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,H,4,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,Autocuration,105030,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",H,4,1,,CHEMBL620583,,BAO_0000218,,
3106,Autocuration,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,4,1,,CHEMBL620584,,BAO_0000019,,
3107,Autocuration,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,H,4,1,,CHEMBL620585,,BAO_0000224,,
3108,Autocuration,105030,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,H,4,1,,CHEMBL620586,,BAO_0000224,,
3109,Autocuration,105030,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,4,1,,CHEMBL620587,,BAO_0000019,,
3110,Autocuration,105030,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,4,1,,CHEMBL620588,,BAO_0000019,,
3111,Autocuration,105030,,,5-hydroxytryptamine 3 receptor agonism in mouse,H,4,1,,CHEMBL620589,,BAO_0000218,,
3112,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,H,4,1,,CHEMBL620590,,BAO_0000219,,
3113,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,4,1,,CHEMBL617956,,BAO_0000019,,
3114,Autocuration,105030,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,4,1,,CHEMBL617957,,BAO_0000019,,
3115,Autocuration,105030,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,H,4,1,,CHEMBL617958,,BAO_0000224,,
3116,Autocuration,105030,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,4,1,,CHEMBL617959,,BAO_0000219,,
3117,Autocuration,105030,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,4,1,,CHEMBL617960,,BAO_0000219,,
3118,Autocuration,105030,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,4,1,,CHEMBL617961,,BAO_0000224,,
3119,Autocuration,105030,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,H,4,1,,CHEMBL617962,,BAO_0000219,,
3120,Autocuration,105030,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,H,4,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,Autocuration,11765,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,8,1,,CHEMBL617964,,BAO_0000019,,
3122,Autocuration,11765,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,H,8,1,,CHEMBL617965,,BAO_0000219,,
3123,Autocuration,10630,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,D,9,1,,CHEMBL617966,,BAO_0000357,,
3124,Autocuration,17106,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,8,1,,CHEMBL857074,,BAO_0000019,,
3125,Autocuration,144,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL617967,,BAO_0000357,,
3126,Autocuration,144,,,Binding activity radioligand.,H,8,1,,CHEMBL617968,,BAO_0000357,,
3127,Autocuration,104714,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,H,4,1,,CHEMBL617969,,BAO_0000223,,
3128,Autocuration,104714,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,4,1,,CHEMBL617970,,BAO_0000223,,
3129,Autocuration,104714,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,H,4,1,,CHEMBL617971,,BAO_0000223,,
3130,Autocuration,104714,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,4,1,,CHEMBL617972,,BAO_0000019,,
3131,Autocuration,104714,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,4,1,,CHEMBL617973,,BAO_0000019,,
3132,Autocuration,104714,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,4,1,,CHEMBL617974,,BAO_0000019,,
3133,Autocuration,104714,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,4,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,4,1,,CHEMBL617976,,BAO_0000019,,
3135,Autocuration,104714,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,4,1,,CHEMBL617977,,BAO_0000019,,
3136,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,4,1,,CHEMBL617978,,BAO_0000019,,
3137,Autocuration,104714,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,4,1,,CHEMBL617979,,BAO_0000019,,
3138,Autocuration,104714,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,H,4,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,Autocuration,104698,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL617981,,BAO_0000019,,
3140,Autocuration,12020,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),H,8,1,,CHEMBL617982,,BAO_0000019,,
3141,Autocuration,12020,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),H,8,1,,CHEMBL617983,,BAO_0000357,,
3142,Autocuration,104698,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,D,7,1,,CHEMBL617984,,BAO_0000019,,
3143,Autocuration,104698,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",H,6,1,,CHEMBL617985,,BAO_0000019,,
3144,Autocuration,104698,Heart,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,6,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,6,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,6,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",H,6,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,Autocuration,104698,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,6,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",H,6,1,,CHEMBL617794,,BAO_0000019,,
3150,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,6,1,,CHEMBL617795,,BAO_0000019,,
3151,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,6,1,,CHEMBL617796,,BAO_0000019,,
3152,Autocuration,104698,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",H,6,1,,CHEMBL617797,,BAO_0000019,,
3153,Autocuration,104698,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),D,7,1,,CHEMBL617798,,BAO_0000218,,
3154,Autocuration,104698,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),H,6,1,,CHEMBL617799,,BAO_0000218,,
3155,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,D,7,1,,CHEMBL617800,,BAO_0000218,,
3156,Autocuration,104698,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,D,7,1,,CHEMBL617801,,BAO_0000019,,
3157,Autocuration,104698,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,D,7,1,,CHEMBL617802,,BAO_0000218,,
3158,Autocuration,104698,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),D,7,1,,CHEMBL617803,,BAO_0000019,,
3159,Autocuration,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,6,1,,CHEMBL617804,,BAO_0000019,,
3160,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL617805,,BAO_0000019,,
3161,Autocuration,104698,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL617806,,BAO_0000223,,
3162,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,H,6,1,,CHEMBL617807,,BAO_0000019,,
3163,Autocuration,104698,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,H,6,1,,CHEMBL617808,,BAO_0000019,,
3164,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,H,6,1,,CHEMBL617809,,BAO_0000249,,
3165,Autocuration,104698,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,H,6,1,,CHEMBL617810,,BAO_0000019,,
3166,Autocuration,104698,Brain,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,H,6,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,Autocuration,104698,Brain,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,H,6,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,Autocuration,104698,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,6,1,,CHEMBL617813,,BAO_0000249,,
3169,Autocuration,104698,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,6,1,,CHEMBL617814,,BAO_0000249,,
3170,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,H,6,1,,CHEMBL617698,,BAO_0000019,,
3171,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,D,7,1,,CHEMBL617699,,BAO_0000019,,
3172,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,D,7,1,,CHEMBL617700,,BAO_0000019,,
3173,Autocuration,104698,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL617701,,BAO_0000223,,
3174,Autocuration,104698,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,6,1,,CHEMBL617702,,BAO_0000019,,
3175,Autocuration,104698,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",H,6,1,,CHEMBL617703,,BAO_0000249,,
3176,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,D,7,1,,CHEMBL617704,,BAO_0000019,,
3177,Autocuration,104698,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,6,1,,CHEMBL617705,,BAO_0000223,,
3178,Autocuration,104698,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL617706,,BAO_0000223,,
3179,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),H,6,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,H,6,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,H,6,1,,CHEMBL617709,,BAO_0000019,,
3182,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,H,6,1,,CHEMBL617710,,BAO_0000019,,
3183,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,H,6,1,,CHEMBL882925,,BAO_0000019,,
3184,Autocuration,104698,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,H,6,1,,CHEMBL617711,,BAO_0000019,,
3185,Autocuration,104698,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,H,6,1,,CHEMBL617712,,BAO_0000019,,
3186,Autocuration,104698,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,D,7,1,,CHEMBL617713,,BAO_0000019,,
3187,Autocuration,104698,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",H,6,1,,CHEMBL617714,,BAO_0000019,,
3188,Autocuration,104698,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,H,6,1,,CHEMBL617715,,BAO_0000218,,
3189,Autocuration,104698,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,H,6,1,,CHEMBL617716,,BAO_0000218,,
3190,Autocuration,104698,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,H,6,1,,CHEMBL617717,,BAO_0000218,,
3191,Autocuration,104698,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617718,,BAO_0000218,,
3192,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617719,,BAO_0000218,,
3193,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),H,6,1,,CHEMBL617720,,BAO_0000218,,
3194,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,D,7,1,,CHEMBL617721,,BAO_0000218,,
3195,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617722,,BAO_0000218,,
3196,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,H,6,1,,CHEMBL617723,,BAO_0000218,,
3197,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617724,,BAO_0000218,,
3198,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617725,,BAO_0000218,,
3199,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617726,,BAO_0000218,,
3200,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617727,,BAO_0000218,,
3201,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617728,,BAO_0000218,,
3202,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617729,,BAO_0000218,,
3203,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617730,,BAO_0000218,,
3204,Autocuration,104698,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617731,,BAO_0000218,,
3205,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617732,,BAO_0000218,,
3206,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617733,,BAO_0000218,,
3207,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617734,,BAO_0000218,,
3208,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,H,6,1,,CHEMBL872874,,BAO_0000218,,
3209,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,H,6,1,,CHEMBL617735,,BAO_0000218,,
3210,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,H,6,1,,CHEMBL617736,,BAO_0000218,,
3211,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,H,6,1,,CHEMBL617737,,BAO_0000218,,
3212,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,H,6,1,,CHEMBL617738,,BAO_0000218,,
3213,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617739,,BAO_0000218,,
3214,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617740,,BAO_0000218,,
3215,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617741,,BAO_0000218,,
3216,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617742,,BAO_0000218,,
3217,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617743,,BAO_0000218,,
3218,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617744,,BAO_0000218,,
3219,Autocuration,104698,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,H,6,1,,CHEMBL617745,,BAO_0000218,,
3220,Autocuration,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",H,6,1,,CHEMBL617746,,BAO_0000218,,
3221,Autocuration,104698,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",H,6,1,,CHEMBL617747,,BAO_0000218,,
3222,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,H,6,1,,CHEMBL617748,,BAO_0000218,,
3223,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,H,6,1,,CHEMBL618909,,BAO_0000218,,
3224,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,H,6,1,,CHEMBL618910,,BAO_0000218,,
3225,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,H,6,1,,CHEMBL618911,,BAO_0000218,,
3226,Autocuration,104698,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,H,6,1,,CHEMBL618912,,BAO_0000218,,
3227,Autocuration,104698,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),H,6,1,,CHEMBL618913,,BAO_0000218,,
3228,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,6,1,,CHEMBL618914,,BAO_0000019,,
3229,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,6,1,,CHEMBL618915,,BAO_0000019,,
3230,Autocuration,104698,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL618916,,BAO_0000223,,
3231,Autocuration,104698,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,H,6,1,,CHEMBL618917,,BAO_0000019,,
3232,Intermediate,104698,Hippocampus,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,D,7,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,Autocuration,104698,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,D,7,1,,CHEMBL618919,,BAO_0000019,,
3234,Autocuration,104698,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL618920,,BAO_0000019,,
3235,Autocuration,104698,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL618921,,BAO_0000223,,
3236,Autocuration,104698,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL618922,,BAO_0000019,,
3237,Autocuration,104698,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,H,6,1,,CHEMBL618923,,BAO_0000019,,
3238,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,H,6,1,,CHEMBL618924,,BAO_0000019,,
3239,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,H,6,1,,CHEMBL618925,,BAO_0000019,,
3240,Autocuration,104698,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,6,1,,CHEMBL618926,,BAO_0000019,,
3241,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,D,9,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,D,9,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",D,9,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",D,9,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,9,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,9,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",D,9,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,Intermediate,20033,Ileum,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,D,9,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,Intermediate,20033,Ileum,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,D,9,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,D,9,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,D,9,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,D,9,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",D,9,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",D,9,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",D,9,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,D,9,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,9,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,Intermediate,20033,Ileum,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,9,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,Intermediate,20033,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,9,1,,CHEMBL617869,,BAO_0000357,,
3260,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,9,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,Intermediate,20033,Striatum,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,9,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,Intermediate,20033,Striatum,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,D,9,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,9,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,9,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,Intermediate,20033,Striatum,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,9,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,D,9,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,D,9,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,9,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,D,9,1,,CHEMBL619070,,BAO_0000357,,
3270,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,D,9,1,,CHEMBL619071,,BAO_0000357,,
3271,Intermediate,20033,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619072,,BAO_0000019,,
3272,Intermediate,20033,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,D,9,1,,CHEMBL619073,,BAO_0000019,,
3273,Intermediate,20033,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619074,,BAO_0000019,,
3274,Intermediate,20033,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619075,,BAO_0000357,,
3275,Intermediate,20033,Striatum,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,Intermediate,20033,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,D,9,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,Intermediate,20033,Striatum,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,9,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,Intermediate,20033,Striatum,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,9,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,Intermediate,20033,Ileum,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,D,9,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,Expert,20033,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,D,9,1,,CHEMBL619081,,BAO_0000357,,
3281,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,9,1,,CHEMBL619082,,BAO_0000357,,
3282,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,D,9,1,,CHEMBL619083,,BAO_0000357,,
3283,Intermediate,20033,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,9,1,,CHEMBL619084,,BAO_0000357,,
3284,Intermediate,20033,Ileum,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,9,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,D,9,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,D,9,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,D,9,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,Intermediate,20033,Ileum,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,9,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,Intermediate,20033,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,D,9,1,,CHEMBL619089,,BAO_0000357,,
3290,Autocuration,168,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL619090,,BAO_0000357,,
3291,Intermediate,20033,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619091,,BAO_0000019,,
3292,Intermediate,20033,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619092,,BAO_0000357,,
3293,Intermediate,20033,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,D,9,1,,CHEMBL619093,,BAO_0000019,,
3294,Autocuration,168,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,H,8,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,Intermediate,20033,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,D,9,1,,CHEMBL619095,,BAO_0000019,,
3296,Intermediate,20033,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,D,9,1,,CHEMBL857988,,BAO_0000357,,
3297,Intermediate,20033,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,D,9,1,,CHEMBL619096,,BAO_0000357,,
3298,Intermediate,20033,Striatum,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,D,9,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,Intermediate,20033,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,D,9,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,Intermediate,20033,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,D,9,1,,CHEMBL619751,,BAO_0000357,,
3301,Intermediate,20033,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,D,9,1,,CHEMBL619752,,BAO_0000357,,
3302,Intermediate,20033,Ileum,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,9,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,Autocuration,108,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,H,8,1,,CHEMBL619004,,BAO_0000357,,
3304,Autocuration,168,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL619005,,BAO_0000357,,
3305,Autocuration,168,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL619006,,BAO_0000019,,
3306,Autocuration,168,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,H,8,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,Autocuration,168,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL619008,,BAO_0000357,,
3308,Autocuration,168,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL619009,,BAO_0000357,,
3309,Autocuration,168,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",H,8,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,Autocuration,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,H,8,1,,CHEMBL619011,,BAO_0000357,,
3311,Autocuration,10622,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,H,8,1,,CHEMBL619012,,BAO_0000357,,
3312,Autocuration,10622,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,H,8,1,,CHEMBL619013,,BAO_0000219,,
3313,Autocuration,10622,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,H,8,1,,CHEMBL619014,,BAO_0000357,,
3314,Autocuration,11249,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,H,8,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,Autocuration,11249,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,H,8,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,Autocuration,11249,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL619016,,BAO_0000357,,
3317,Autocuration,11249,Hippocampus,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,Autocuration,168,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,H,8,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,Autocuration,168,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,H,8,1,,CHEMBL619019,,BAO_0000019,,
3320,Expert,10623,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619020,,BAO_0000357,,
3321,Autocuration,10623,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,8,1,,CHEMBL619021,,BAO_0000019,,
3322,Autocuration,10623,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,H,8,1,,CHEMBL619022,,BAO_0000357,,
3323,Autocuration,10623,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,H,8,1,,CHEMBL619023,,BAO_0000357,,
3324,Autocuration,10623,,,lntrinsic activity relative to 5-HT receptor,H,8,1,,CHEMBL619024,,BAO_0000019,,
3325,Autocuration,10623,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,H,8,1,,CHEMBL619025,,BAO_0000019,,
3326,Expert,10623,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,H,8,1,,CHEMBL619026,,BAO_0000019,,
3327,Autocuration,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,H,8,1,,CHEMBL619027,,BAO_0000019,,
3328,Autocuration,10623,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,H,8,1,,CHEMBL619028,,BAO_0000019,,
3329,Autocuration,10623,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,H,8,1,,CHEMBL619029,,BAO_0000019,,
3330,Autocuration,10623,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,H,8,1,,CHEMBL619030,,BAO_0000019,,
3331,Expert,10623,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,H,8,1,,CHEMBL619031,,BAO_0000357,,
3332,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,H,8,1,,CHEMBL619032,,BAO_0000019,,
3333,Expert,10623,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL619033,,BAO_0000357,,
3334,Autocuration,10623,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,8,1,,CHEMBL619034,,BAO_0000357,,
3335,Autocuration,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,H,8,1,,CHEMBL619035,,BAO_0000357,,
3336,Autocuration,10623,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,H,8,1,,CHEMBL619036,,BAO_0000357,,
3337,Expert,10623,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,D,9,1,,CHEMBL619037,,BAO_0000019,,
3338,Autocuration,10623,Striatum,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,H,8,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,Autocuration,10623,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,H,8,1,,CHEMBL619039,,BAO_0000249,,
3340,Expert,10623,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,H,8,1,,CHEMBL619040,,BAO_0000249,,
3341,Expert,10623,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,D,9,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,Autocuration,10623,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,H,8,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,Expert,10623,Striatum,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,H,8,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,Expert,10623,Striatum,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,H,8,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,Expert,10623,Striatum,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,H,8,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,Expert,10623,Striatum,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,8,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,Expert,10623,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,H,8,1,,CHEMBL619047,,BAO_0000249,,
3348,Autocuration,10623,Brain,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,H,8,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,Autocuration,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,H,8,1,,CHEMBL859398,,BAO_0000019,,
3350,Autocuration,10623,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,H,8,1,,CHEMBL619049,,BAO_0000019,,
3351,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,H,8,1,,CHEMBL857886,,BAO_0000019,,
3352,Autocuration,10623,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,H,8,1,,CHEMBL619050,,BAO_0000019,,
3353,Autocuration,10623,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,H,8,1,,CHEMBL620591,,BAO_0000019,,
3354,Expert,10623,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,D,9,1,,CHEMBL620592,,BAO_0000357,,
3355,Expert,10623,Striatum,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,8,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,D,9,1,,CHEMBL620594,,BAO_0000019,,
3357,Expert,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,H,8,1,,CHEMBL875079,,BAO_0000019,,
3358,Expert,10623,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,8,1,,CHEMBL620595,,BAO_0000019,,
3359,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,D,9,1,,CHEMBL620596,,BAO_0000019,,
3360,Autocuration,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,H,8,1,,CHEMBL620597,,BAO_0000019,,
3361,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,H,8,1,,CHEMBL620598,,BAO_0000019,,
3362,Expert,10623,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),H,8,1,,CHEMBL620599,,BAO_0000218,,
3363,Autocuration,10623,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,8,1,,CHEMBL620600,,BAO_0000019,,
3364,Autocuration,168,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,H,8,1,,CHEMBL620601,,BAO_0000019,,
3365,Autocuration,168,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,H,8,1,,CHEMBL620602,,BAO_0000019,,
3366,Autocuration,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620603,,BAO_0000357,,
3367,Autocuration,168,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,H,8,1,,CHEMBL620604,,BAO_0000357,,
3368,Autocuration,168,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,H,8,1,,CHEMBL620605,,BAO_0000357,,
3369,Autocuration,168,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620606,,BAO_0000357,,
3370,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,8,1,,CHEMBL620607,,BAO_0000019,,
3371,Autocuration,168,,,In vitro binding affinity towards 5-HT4 receptor was determined,H,8,1,,CHEMBL620608,,BAO_0000357,,
3372,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,8,1,,CHEMBL620609,,BAO_0000019,,
3373,Autocuration,168,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620610,,BAO_0000019,,
3374,Autocuration,168,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620611,,BAO_0000357,,
3375,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,H,8,1,,CHEMBL620612,,BAO_0000357,,
3376,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,H,8,1,,CHEMBL620613,,BAO_0000357,,
3377,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,H,8,1,,CHEMBL620614,,BAO_0000357,,
3378,Expert,168,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620615,,BAO_0000357,,
3379,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,H,6,1,,CHEMBL857075,,BAO_0000249,,
3380,Autocuration,104698,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,H,6,1,,CHEMBL620616,,BAO_0000249,,
3381,Autocuration,104698,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,H,6,1,,CHEMBL619411,,BAO_0000249,,
3382,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,H,6,1,,CHEMBL619412,,BAO_0000019,,
3383,Autocuration,104698,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL619413,,BAO_0000019,,
3384,Autocuration,104698,Hippocampus,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,H,6,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,6,1,,CHEMBL619415,,BAO_0000019,,
3386,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,H,6,1,,CHEMBL619416,,BAO_0000019,,
3387,Autocuration,104698,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,H,6,1,,CHEMBL619417,,BAO_0000019,,
3388,Autocuration,104698,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL619418,,BAO_0000223,,
3389,Autocuration,104698,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,D,7,1,,CHEMBL619419,,BAO_0000223,,
3390,Autocuration,104698,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,H,6,1,,CHEMBL619420,,BAO_0000019,,
3391,Autocuration,104698,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,H,6,1,,CHEMBL619421,,BAO_0000249,,
3392,Autocuration,104698,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,D,7,1,,CHEMBL619422,,BAO_0000019,,
3393,Autocuration,104698,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,H,6,1,,CHEMBL619423,,BAO_0000019,,
3394,Autocuration,104698,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,H,6,1,,CHEMBL875080,,BAO_0000019,,
3395,Autocuration,104698,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,H,6,1,,CHEMBL619424,,BAO_0000019,,
3396,Autocuration,104698,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,H,6,1,,CHEMBL619425,,BAO_0000249,,
3397,Autocuration,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,H,6,1,,CHEMBL619426,,BAO_0000223,,
3398,Autocuration,104698,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,H,6,1,,CHEMBL619427,,BAO_0000223,,
3399,Autocuration,104698,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,D,7,1,,CHEMBL619645,,BAO_0000223,,
3400,Expert,10576,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",D,9,1,,CHEMBL619646,,BAO_0000249,,
3401,Autocuration,12020,Brain,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,H,8,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,Autocuration,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL619648,,BAO_0000019,,
3403,Autocuration,12020,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,H,8,1,,CHEMBL619165,,BAO_0000019,,
3404,Autocuration,12020,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL620719,,BAO_0000218,,
3405,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,8,1,,CHEMBL872924,,BAO_0000019,,
3406,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL620720,,BAO_0000357,,
3407,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,8,1,,CHEMBL620721,,BAO_0000019,,
3408,Autocuration,12020,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,H,8,1,,CHEMBL620722,,BAO_0000019,,
3409,Autocuration,104698,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",H,6,1,,CHEMBL620723,,BAO_0000019,,
3410,Autocuration,12020,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,8,1,,CHEMBL620724,,BAO_0000019,,
3411,Autocuration,104698,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,H,6,1,,CHEMBL620725,,BAO_0000249,,
3412,Autocuration,12020,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,D,9,1,,CHEMBL620726,,BAO_0000019,,
3413,Expert,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL620727,,BAO_0000357,,
3414,Autocuration,104714,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,H,4,1,,CHEMBL620728,,BAO_0000223,,
3415,Autocuration,22226,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,U,0,1,,CHEMBL620729,,BAO_0000019,,
3416,Autocuration,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,H,4,1,,CHEMBL858288,,BAO_0000019,,
3417,Autocuration,104714,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL620730,,BAO_0000223,,
3418,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL620731,,BAO_0000223,,
3419,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,H,4,1,,CHEMBL620732,,BAO_0000019,,
3420,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,4,1,,CHEMBL618042,,BAO_0000019,,
3421,Autocuration,104714,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,H,4,1,,CHEMBL618043,,BAO_0000019,,
3422,Autocuration,104714,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL618044,,BAO_0000223,,
3423,Autocuration,104714,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,H,4,1,,CHEMBL618045,,BAO_0000019,,
3424,Autocuration,104714,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,H,4,1,,CHEMBL618046,,BAO_0000223,,
3425,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,H,4,1,,CHEMBL618047,,BAO_0000019,,
3426,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,H,4,1,,CHEMBL875084,,BAO_0000019,,
3427,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,H,4,1,,CHEMBL618048,,BAO_0000019,,
3428,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,H,4,1,,CHEMBL618049,,BAO_0000223,,
3429,Autocuration,104714,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,H,4,1,,CHEMBL619764,,BAO_0000019,,
3430,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,H,4,1,,CHEMBL619765,,BAO_0000019,,
3431,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,H,4,1,,CHEMBL619766,,BAO_0000019,,
3432,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,H,4,1,,CHEMBL619767,,BAO_0000223,,
3433,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,H,4,1,,CHEMBL619768,,BAO_0000223,,
3434,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,H,4,1,,CHEMBL619769,,BAO_0000019,,
3435,Autocuration,104714,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,H,4,1,,CHEMBL619770,,BAO_0000223,,
3436,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL619771,,BAO_0000223,,
3437,Autocuration,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,H,4,1,,CHEMBL619772,,BAO_0000219,,
3438,Autocuration,104714,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,H,4,1,,CHEMBL619773,,BAO_0000223,,
3439,Autocuration,104714,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,H,4,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,Autocuration,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,H,4,1,,CHEMBL875083,,BAO_0000019,,
3441,Autocuration,104714,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,H,4,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,Autocuration,104714,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,4,1,,CHEMBL618127,,BAO_0000223,,
3443,Autocuration,104714,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,H,4,1,,CHEMBL618128,,BAO_0000223,,
3444,Autocuration,104714,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,H,4,1,,CHEMBL618129,,BAO_0000219,,
3445,Autocuration,104714,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,4,1,,CHEMBL618130,,BAO_0000223,,
3446,Autocuration,104714,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,H,4,1,,CHEMBL618131,,BAO_0000019,,
3447,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,H,4,1,,CHEMBL618132,,BAO_0000019,,
3448,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,H,4,1,,CHEMBL618133,,BAO_0000019,,
3449,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,H,4,1,,CHEMBL618134,,BAO_0000019,,
3450,Autocuration,104714,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,4,1,,CHEMBL618135,,BAO_0000019,,
3451,Autocuration,104714,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,H,4,1,,CHEMBL618136,,BAO_0000223,,
3452,Autocuration,104714,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL618137,,BAO_0000223,,
3453,Autocuration,104714,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,H,4,1,,CHEMBL618138,,BAO_0000223,,
3454,Autocuration,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,H,4,1,,CHEMBL618139,,BAO_0000223,,
3455,Autocuration,104714,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,H,4,1,,CHEMBL618140,,BAO_0000223,,
3456,Autocuration,104714,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,H,4,1,,CHEMBL618141,,BAO_0000223,,
3457,Expert,108,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,8,1,,CHEMBL873478,,BAO_0000357,,
3458,Autocuration,104698,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,6,1,,CHEMBL618142,,BAO_0000223,,
3459,Autocuration,144,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL618143,,BAO_0000357,,
3460,Autocuration,144,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL618144,,BAO_0000357,,
3461,Autocuration,144,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL618145,,BAO_0000357,,
3462,Autocuration,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,4,1,,CHEMBL618146,,BAO_0000223,,
3463,Autocuration,104714,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,H,4,1,,CHEMBL618147,,BAO_0000223,,
3464,Autocuration,104714,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,4,1,,CHEMBL618148,,BAO_0000223,,
3465,Autocuration,144,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,H,8,1,,CHEMBL618149,,BAO_0000019,,
3466,Autocuration,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL872927,,BAO_0000357,,
3467,Autocuration,144,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL618150,,BAO_0000357,,
3468,Autocuration,144,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,8,1,,CHEMBL618151,,BAO_0000357,,
3469,Autocuration,144,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,8,1,,CHEMBL875094,,BAO_0000357,,
3470,Autocuration,144,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,8,1,,CHEMBL618152,,BAO_0000019,,
3471,Autocuration,144,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,8,1,,CHEMBL618153,,BAO_0000357,,
3472,Autocuration,144,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,H,8,1,,CHEMBL618888,,BAO_0000357,,
3473,Autocuration,144,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,H,8,1,,CHEMBL618889,,BAO_0000019,,
3474,Autocuration,144,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,H,8,1,,CHEMBL618890,,BAO_0000357,,
3475,Autocuration,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,H,8,1,,CHEMBL618891,,BAO_0000019,,
3476,Autocuration,144,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,H,8,1,,CHEMBL619054,,BAO_0000019,,
3477,Autocuration,104714,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,H,4,1,,CHEMBL619055,,BAO_0000223,,
3478,Autocuration,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,8,1,,CHEMBL619056,,BAO_0000357,,
3479,Autocuration,144,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,H,8,1,,CHEMBL619057,,BAO_0000019,,
3480,Autocuration,144,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,8,1,,CHEMBL619058,,BAO_0000357,,
3481,Expert,12020,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,D,9,1,,CHEMBL619059,,BAO_0000219,,
3482,Expert,12020,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,D,9,1,,CHEMBL619060,,BAO_0000219,,
3483,Expert,12020,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,D,9,1,,CHEMBL875095,,BAO_0000219,,
3484,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,D,9,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,Intermediate,20033,Ileum,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,D,9,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,Intermediate,20033,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,D,9,1,,CHEMBL619063,,BAO_0000019,,
3487,Intermediate,20033,Ileum,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,D,9,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,Intermediate,20033,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,D,9,1,,CHEMBL619065,,BAO_0000357,,
3489,Intermediate,20033,Ileum,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,D,9,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,Autocuration,10209,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,8,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,Autocuration,10209,,,Affinity against 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619776,,BAO_0000357,,
3492,Autocuration,104841,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,4,1,,CHEMBL619777,,BAO_0000224,,
3493,Autocuration,104841,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,4,1,,CHEMBL619778,,BAO_0000224,,
3494,Autocuration,104841,Ileum,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,H,4,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,Autocuration,104841,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,4,1,,CHEMBL619780,,BAO_0000224,,
3496,Autocuration,104841,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,4,1,,CHEMBL619166,,BAO_0000224,,
3497,Autocuration,104841,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,4,1,,CHEMBL619167,,BAO_0000019,,
3498,Autocuration,104841,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,4,1,,CHEMBL619168,,BAO_0000019,,
3499,Expert,168,Cardiac atrium,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,D,9,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,Expert,168,Cardiac atrium,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,D,9,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,Autocuration,104841,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",D,5,1,,CHEMBL619171,,BAO_0000019,,
3502,Expert,168,Cardiac atrium,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",D,9,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,Autocuration,22226,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,U,0,1,,CHEMBL619173,,BAO_0000019,,
3504,Autocuration,22226,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,U,0,1,,CHEMBL619174,,BAO_0000019,,
3505,Autocuration,104705,,,5-hydroxytryptamine receptor binding affinity was determined in rats,H,4,1,,CHEMBL619175,,BAO_0000019,,
3506,Autocuration,104705,,,Binding affinity at rat 5-hydroxytryptamine receptor.,H,4,1,,CHEMBL619176,,BAO_0000224,,
3507,Autocuration,104705,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,H,4,1,,CHEMBL619177,,BAO_0000019,,
3508,Autocuration,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,H,4,1,,CHEMBL619178,,BAO_0000224,,
3509,Autocuration,104705,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,H,4,1,,CHEMBL619179,,BAO_0000224,,
3510,Autocuration,104705,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,H,4,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,Autocuration,104705,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,H,4,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,Autocuration,104705,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,4,1,,CHEMBL619182,,BAO_0000019,,
3513,Autocuration,104705,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,H,4,1,,CHEMBL619183,,BAO_0000224,,
3514,Autocuration,104705,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",H,4,1,,CHEMBL619184,,BAO_0000224,,
3515,Autocuration,10576,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,8,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,Expert,12198,,,Binding affinity for rat 5-hydroxytryptamine transporter.,H,8,1,,CHEMBL619186,,BAO_0000357,,
3517,Autocuration,104705,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,H,4,1,,CHEMBL619187,,BAO_0000019,,
3518,Autocuration,104705,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,D,5,1,,CHEMBL619188,,BAO_0000019,,
3519,Autocuration,104705,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,D,5,1,,CHEMBL619189,,BAO_0000224,,
3520,Expert,12198,Brain,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,D,9,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,Expert,12198,Cerebellum,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,D,9,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,Autocuration,104705,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,D,5,1,,CHEMBL619192,,BAO_0000019,,
3523,Autocuration,104705,,,Percent binding affinity against 5-hydroxytryptamine receptor,D,5,1,,CHEMBL619193,,BAO_0000224,,
3524,Autocuration,22226,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,U,0,1,,CHEMBL619194,,BAO_0000019,,
3525,Autocuration,104705,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,D,5,1,,CHEMBL619195,,BAO_0000224,,
3526,Autocuration,104705,,,Affinity against 5-hydroxytryptamine receptor was determined,D,5,1,,CHEMBL619196,,BAO_0000224,,
3527,Autocuration,104705,Stomach,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,D,5,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,Expert,121,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,9,1,,CHEMBL619198,,BAO_0000219,,
3529,Expert,121,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,9,1,,CHEMBL875081,,BAO_0000219,,
3530,Autocuration,18065,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,H,8,1,,CHEMBL884712,,BAO_0000357,,
3531,Expert,121,,,Inhibition of 5-hydroxytryptamine reuptake,H,8,1,,CHEMBL884710,,BAO_0000357,,
3532,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",H,8,1,,CHEMBL619199,,BAO_0000019,,
3533,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",H,8,1,,CHEMBL619200,,BAO_0000019,,
3534,Autocuration,18065,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",H,8,1,,CHEMBL619201,,BAO_0000019,,
3535,Autocuration,18065,,,Tested for 5-hydroxytryptamine receptor uptake,H,8,1,,CHEMBL619202,,BAO_0000019,,
3536,Expert,51,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,9,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,Expert,51,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,D,9,1,,CHEMBL619204,,BAO_0000019,,
3538,Autocuration,10576,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,H,8,1,,CHEMBL619205,,BAO_0000249,,
3539,Autocuration,10576,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,H,8,1,,CHEMBL619206,,BAO_0000357,,
3540,Expert,10576,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,H,8,1,,CHEMBL619207,,BAO_0000249,,
3541,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,H,8,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,H,8,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,H,8,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,H,8,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,H,8,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,H,8,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,H,8,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,H,8,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,H,8,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,H,8,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,Autocuration,10825,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,H,8,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,H,8,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,8,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,H,8,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,H,8,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,H,8,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,H,8,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,H,8,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,Expert,168,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620694,,BAO_0000357,,
3560,Autocuration,168,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,8,1,,CHEMBL857986,,BAO_0000019,,
3561,Autocuration,168,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,H,8,1,,CHEMBL620695,,BAO_0000357,,
3562,Expert,168,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620696,,BAO_0000357,,
3563,Autocuration,168,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,H,8,1,,CHEMBL620697,,BAO_0000357,,
3564,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,H,8,1,,CHEMBL620698,,BAO_0000357,,
3565,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,8,1,,CHEMBL620699,,BAO_0000357,,
3566,Autocuration,168,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,8,1,,CHEMBL620700,,BAO_0000357,,
3567,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,H,8,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,H,8,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,H,8,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,Autocuration,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,H,8,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,Autocuration,168,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,8,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,Expert,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,8,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,Expert,168,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,H,8,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,Expert,168,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,H,8,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,H,8,1,,CHEMBL620708,,BAO_0000357,,
3576,Autocuration,105,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,H,8,1,,CHEMBL620709,,BAO_0000357,,
3577,Expert,10624,,,Binding affinity against 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL620710,,BAO_0000357,,
3578,Autocuration,10624,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,H,8,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,Expert,10624,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,D,9,1,,CHEMBL620712,,BAO_0000357,,
3580,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL620713,,BAO_0000357,,
3581,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,D,9,1,,CHEMBL620714,,BAO_0000357,,
3582,Expert,10624,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL620715,,BAO_0000357,,
3583,Autocuration,10624,,,Binding affinity towards 5-HT5A receptor,H,8,1,,CHEMBL620716,,BAO_0000357,,
3584,Expert,10624,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,8,1,,CHEMBL620717,,BAO_0000357,,
3585,Autocuration,10624,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,H,8,1,,CHEMBL618072,,BAO_0000357,,
3586,Autocuration,10624,,,Binding affinity towards cloned human 5-HT5A receptor was determined,H,8,1,,CHEMBL857987,,BAO_0000357,,
3587,Autocuration,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,Autocuration,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,8,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,Autocuration,10624,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),H,8,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL618076,,BAO_0000357,,
3591,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,9,1,,CHEMBL618077,,BAO_0000357,,
3592,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,D,9,1,,CHEMBL618078,,BAO_0000357,,
3593,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,D,9,1,,CHEMBL881821,,BAO_0000357,,
3594,Expert,10625,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL618079,,BAO_0000357,,
3595,Expert,10625,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,8,1,,CHEMBL618080,,BAO_0000357,,
3596,Autocuration,10576,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,8,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,Autocuration,10626,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,8,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,Expert,10624,,,Binding affinity towards 5-HT5a receptor,H,8,1,,CHEMBL618083,,BAO_0000357,,
3599,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,D,9,1,,CHEMBL618084,,BAO_0000357,,
3600,Expert,10624,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,H,8,1,,CHEMBL618085,,BAO_0000357,,
3601,Expert,10624,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,H,8,1,,CHEMBL618086,,BAO_0000357,,
3602,Autocuration,10624,,,Binding affinities against 5-hydroxytryptamine 5A receptor,H,8,1,,CHEMBL875092,,BAO_0000357,,
3603,Autocuration,10624,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,H,8,1,,CHEMBL618087,,BAO_0000357,,
3604,Autocuration,10624,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,H,8,1,,CHEMBL872926,,BAO_0000357,,
3605,Autocuration,104714,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,H,4,1,,CHEMBL618088,,BAO_0000019,,
3606,Autocuration,104714,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,H,4,1,,CHEMBL618089,,BAO_0000223,,
3607,Expert,10627,,,Inhibition of human 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL618090,,BAO_0000357,,
3608,Expert,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,D,9,1,,CHEMBL618091,,BAO_0000357,,
3609,Autocuration,10627,,,Inhibition against human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL618092,,BAO_0000357,,
3610,Expert,10627,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,D,9,1,,CHEMBL618093,,BAO_0000357,,
3611,Expert,10627,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,H,8,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,Expert,10627,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL618095,,BAO_0000357,,
3613,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL875093,,BAO_0000357,,
3614,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,9,1,,CHEMBL618096,,BAO_0000357,,
3615,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,D,9,1,,CHEMBL618118,,BAO_0000357,,
3616,Expert,10627,,,Binding affinity against 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL618119,,BAO_0000357,,
3617,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL618120,,BAO_0000357,,
3618,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL618121,,BAO_0000357,,
3619,Expert,10627,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",H,8,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,H,8,1,,CHEMBL618123,,BAO_0000357,,
3621,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,H,8,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,Autocuration,10627,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL618125,,BAO_0000357,,
3623,Expert,10627,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,D,9,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,Expert,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,H,8,1,,CHEMBL618236,,BAO_0000019,,
3625,Expert,10627,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,8,1,,CHEMBL618237,,BAO_0000019,,
3626,Expert,10627,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,H,8,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,Expert,10627,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL618239,,BAO_0000357,,
3628,Autocuration,10627,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL618240,,BAO_0000019,,
3629,Autocuration,10627,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,H,8,1,,CHEMBL618241,,BAO_0000357,,
3630,Autocuration,10627,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,H,8,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,Autocuration,10627,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,H,8,1,,CHEMBL618242,,BAO_0000019,,
3632,Autocuration,10627,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL857991,,BAO_0000357,,
3633,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL619951,,BAO_0000357,,
3634,Expert,10627,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,D,9,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,Expert,10627,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,D,9,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,H,8,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,8,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,Autocuration,10627,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,8,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,8,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,8,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,H,8,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,8,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,Autocuration,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,H,8,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,Autocuration,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620630,,BAO_0000357,,
3645,Autocuration,10627,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,H,8,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,Autocuration,10627,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620783,,BAO_0000357,,
3647,Expert,10627,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620784,,BAO_0000357,,
3648,Expert,10627,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,H,8,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,Autocuration,10627,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),H,8,1,,CHEMBL857992,,BAO_0000357,,
3650,Autocuration,10627,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,H,8,1,,CHEMBL620786,,BAO_0000219,,
3651,Autocuration,10627,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,H,8,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",H,8,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",H,8,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,Autocuration,10627,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",H,8,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,Autocuration,10628,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,H,8,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,Autocuration,10628,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,H,8,1,,CHEMBL620792,,BAO_0000019,,
3657,Autocuration,10628,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620793,,BAO_0000357,,
3658,Autocuration,10628,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,H,8,1,,CHEMBL620794,,BAO_0000357,,
3659,Autocuration,10627,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,D,9,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620796,,BAO_0000357,,
3661,Autocuration,10627,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,H,8,1,,CHEMBL620797,,BAO_0000357,,
3662,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,D,9,1,,CHEMBL620798,,BAO_0000019,,
3663,Autocuration,10627,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,H,8,1,,CHEMBL620799,,BAO_0000357,,
3664,Expert,10627,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620800,,BAO_0000357,,
3665,Autocuration,10627,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,H,8,1,,CHEMBL620801,,BAO_0000357,,
3666,Autocuration,10627,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL875100,,BAO_0000357,,
3667,Autocuration,10627,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,H,8,1,,CHEMBL620802,,BAO_0000357,,
3668,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620803,,BAO_0000019,,
3669,Expert,10627,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,H,8,1,,CHEMBL620804,,BAO_0000019,,
3670,Autocuration,10627,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,H,8,1,,CHEMBL620805,,BAO_0000357,,
3671,Autocuration,10627,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620806,,BAO_0000357,,
3672,Autocuration,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,H,8,1,,CHEMBL620807,,BAO_0000357,,
3673,Autocuration,10627,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,H,8,1,,CHEMBL620808,,BAO_0000357,,
3674,Autocuration,10627,,,Binding affinities against 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620809,,BAO_0000357,,
3675,Autocuration,10627,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620810,,BAO_0000357,,
3676,Expert,10627,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,D,9,1,,CHEMBL620811,,BAO_0000357,,
3677,Autocuration,10627,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,H,8,1,,CHEMBL620812,,BAO_0000357,,
3678,Autocuration,10627,,,Affinity against 5-hydroxytryptamine 6 receptor,H,8,1,,CHEMBL620813,,BAO_0000357,,
3679,Autocuration,10627,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],H,8,1,,CHEMBL620814,,BAO_0000357,,
3680,Expert,10209,,,Inhibition of human 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL620815,,BAO_0000357,,
3681,Autocuration,10209,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,H,8,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,Autocuration,10209,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620817,,BAO_0000357,,
3683,Autocuration,10209,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),H,8,1,,CHEMBL620818,,BAO_0000357,,
3684,Expert,10209,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,H,8,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,Expert,10209,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,D,9,1,,CHEMBL620820,,BAO_0000357,,
3686,Autocuration,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,H,8,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL620822,,BAO_0000357,,
3688,Expert,10209,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL620823,,BAO_0000357,,
3689,Expert,10209,,,Binding affinity against 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL620824,,BAO_0000357,,
3690,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,H,8,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,Autocuration,10209,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,H,8,1,,CHEMBL872930,,BAO_0000357,,
3692,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620826,,BAO_0000357,,
3693,Autocuration,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL620827,,BAO_0000357,,
3694,Autocuration,10209,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620828,,BAO_0000357,,
3695,Autocuration,10209,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620829,,BAO_0000357,,
3696,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,H,8,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,Expert,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,H,8,1,,CHEMBL620831,,BAO_0000019,,
3698,Expert,10209,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,8,1,,CHEMBL620832,,BAO_0000019,,
3699,Expert,10209,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL621548,,BAO_0000357,,
3700,Autocuration,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL621549,,BAO_0000019,,
3701,Autocuration,10209,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,H,8,1,,CHEMBL621550,,BAO_0000357,,
3702,Autocuration,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,H,8,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,Autocuration,10209,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,H,8,1,,CHEMBL621552,,BAO_0000019,,
3704,Autocuration,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL857077,,BAO_0000357,,
3705,Autocuration,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,H,8,1,,CHEMBL618158,,BAO_0000357,,
3706,Expert,10209,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,D,9,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,Autocuration,10209,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,H,8,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,Expert,10209,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,D,9,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,Expert,10209,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,H,8,1,,CHEMBL618161,,BAO_0000357,,
3710,Expert,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,H,8,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,Expert,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,H,8,1,,CHEMBL618163,,BAO_0000357,,
3712,Autocuration,10209,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,H,8,1,,CHEMBL618164,,BAO_0000357,,
3713,Expert,10209,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,H,8,1,,CHEMBL618165,,BAO_0000219,,
3714,Autocuration,10209,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,H,8,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,8,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,8,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,8,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,Autocuration,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,H,8,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,Autocuration,10209,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,H,8,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,Autocuration,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),H,8,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,Expert,10209,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,D,9,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,Autocuration,10209,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),H,8,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,Intermediate,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,D,9,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,Intermediate,10209,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,D,9,1,,CHEMBL619896,,BAO_0000357,,
3725,Autocuration,10209,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,H,8,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,Autocuration,10209,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,H,8,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,Expert,10209,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,H,8,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,Autocuration,10209,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),H,8,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,Expert,10209,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,D,9,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,Autocuration,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,H,8,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,Autocuration,10209,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,H,8,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,Autocuration,10209,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",H,8,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,Autocuration,10209,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,D,9,1,,CHEMBL620734,,BAO_0000357,,
3734,Expert,10022,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,9,1,,CHEMBL620735,,BAO_0000357,,
3735,Autocuration,10209,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,H,8,1,,CHEMBL620736,,BAO_0000019,,
3736,Autocuration,11923,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,H,8,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,H,8,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,H,8,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,H,8,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,H,8,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,H,8,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,H,8,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,H,8,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,H,8,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,H,8,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,H,8,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,H,8,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,H,8,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,Expert,11923,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620750,,BAO_0000357,,
3750,Expert,11923,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,9,1,,CHEMBL620751,,BAO_0000357,,
3751,Expert,11923,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620752,,BAO_0000357,,
3752,Autocuration,11923,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,H,8,1,,CHEMBL872929,,BAO_0000019,,
3753,Expert,11923,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,D,9,1,,CHEMBL620753,,BAO_0000357,,
3754,Expert,11923,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL620754,,BAO_0000357,,
3755,Expert,11923,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,D,9,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,Autocuration,11923,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,8,1,,CHEMBL620756,,BAO_0000357,,
3757,Autocuration,11923,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL620757,,BAO_0000357,,
3758,Autocuration,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",H,8,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,Autocuration,11923,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",H,8,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,H,8,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,Autocuration,11923,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,H,8,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,8,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,8,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,Autocuration,11923,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,H,8,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,Expert,11923,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,D,9,1,,CHEMBL857990,,BAO_0000249,,
3766,Autocuration,11923,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,H,8,1,,CHEMBL620765,,BAO_0000357,,
3767,Expert,11923,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,H,8,1,,CHEMBL620766,,BAO_0000357,,
3768,Expert,11923,Hypothalamus,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,H,8,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,Autocuration,11923,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,H,8,1,,CHEMBL620768,,BAO_0000357,,
3770,Expert,11923,Hypothalamus,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,H,8,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,Expert,11923,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619052,,BAO_0000357,,
3772,Expert,11923,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,D,9,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,Expert,11923,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,D,9,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,Autocuration,11923,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,D,9,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,Expert,10209,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619851,,BAO_0000357,,
3776,Autocuration,10209,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,H,8,1,,CHEMBL619852,,BAO_0000357,,
3777,Autocuration,10209,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,H,8,1,,CHEMBL619853,,BAO_0000357,,
3778,Expert,10209,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,9,1,,CHEMBL619854,,BAO_0000357,,
3779,Expert,10209,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619855,,BAO_0000357,,
3780,Autocuration,10209,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,H,8,1,,CHEMBL619856,,BAO_0000357,,
3781,Autocuration,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,8,1,,CHEMBL619857,,BAO_0000357,,
3782,Expert,10209,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,H,8,1,,CHEMBL619858,,BAO_0000019,,
3783,Autocuration,10209,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,H,8,1,,CHEMBL619859,,BAO_0000357,,
3784,Autocuration,10209,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,8,1,,CHEMBL619860,,BAO_0000357,,
3785,Autocuration,10209,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619861,,BAO_0000357,,
3786,Expert,10209,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619862,,BAO_0000357,,
3787,Autocuration,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,H,8,1,,CHEMBL619863,,BAO_0000357,,
3788,Autocuration,10209,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,H,8,1,,CHEMBL619864,,BAO_0000357,,
3789,Autocuration,10209,,,Binding affinities against 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL872928,,BAO_0000357,,
3790,Autocuration,10209,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619865,,BAO_0000357,,
3791,Expert,10209,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,H,8,1,,CHEMBL619866,,BAO_0000357,,
3792,Autocuration,10209,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,H,8,1,,CHEMBL619867,,BAO_0000357,,
3793,Autocuration,10209,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,8,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,Autocuration,55,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,H,8,1,,CHEMBL619869,,BAO_0000019,,
3795,Expert,55,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,D,9,1,,CHEMBL619870,,BAO_0000019,,
3796,Autocuration,55,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,H,8,1,,CHEMBL619871,,BAO_0000357,,
3797,Autocuration,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme,H,8,1,,CHEMBL619872,,BAO_0000357,,
3798,Autocuration,55,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,H,8,1,,CHEMBL619873,,BAO_0000357,,
3799,Expert,55,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,H,8,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,Expert,55,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,H,8,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,H,8,1,,CHEMBL619876,,BAO_0000357,,
3802,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),H,8,1,,CHEMBL619877,,BAO_0000357,,
3803,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,H,8,1,,CHEMBL619878,,BAO_0000219,,
3804,Autocuration,55,Blood,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,H,8,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,Autocuration,55,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,H,8,1,,CHEMBL619880,,BAO_0000357,,
3806,Autocuration,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),H,8,1,,CHEMBL619881,,BAO_0000357,,
3807,Expert,55,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,H,8,1,,CHEMBL619882,,BAO_0000357,,
3808,Autocuration,55,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,H,8,1,,CHEMBL619883,,BAO_0000357,,
3809,Expert,55,Blood,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),D,9,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,Autocuration,55,,,In vitro potency against human 5-Lipoxygenase,H,8,1,,CHEMBL619885,,BAO_0000357,,
3811,Expert,55,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,D,9,1,,CHEMBL619886,,BAO_0000019,,
3812,Autocuration,55,Blood,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,H,8,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,Autocuration,55,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,8,1,,CHEMBL875097,,BAO_0000019,,
3814,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,H,8,1,,CHEMBL618001,,BAO_0000219,,
3815,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,H,8,1,,CHEMBL618002,,BAO_0000219,,
3816,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,H,8,1,,CHEMBL618003,,BAO_0000219,,
3817,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,H,8,1,,CHEMBL618004,,BAO_0000219,,
3818,Autocuration,55,,,Inhibition of human 5-lipoxygenase in human cells,H,8,1,,CHEMBL618005,,BAO_0000219,,
3819,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase,H,8,1,,CHEMBL618006,,BAO_0000357,,
3820,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,H,8,1,,CHEMBL875086,,BAO_0000019,,
3821,Expert,55,Blood,,Inhibition of 5-lipoxygenase from human whole blood,H,8,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,8,1,,CHEMBL618008,,BAO_0000357,,
3823,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,H,8,1,,CHEMBL618009,,BAO_0000219,,
3824,Expert,55,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,H,8,1,,CHEMBL618010,,BAO_0000357,,
3825,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,8,1,,CHEMBL618011,,BAO_0000357,,
3826,Expert,55,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,H,8,1,,CHEMBL618012,,BAO_0000357,,
3827,Autocuration,55,,,Tested against 5-lipoxygenase,H,8,1,,CHEMBL882927,,BAO_0000357,,
3828,Autocuration,55,,,Tested for activity against 5-Lipoxygenase (5-LO),H,8,1,,CHEMBL618013,,BAO_0000357,,
3829,Autocuration,55,,,Tested for activity against 5-lipoxygenase,H,8,1,,CHEMBL618014,,BAO_0000357,,
3830,Autocuration,55,,,Tested for inhibition of 5-HPETE production by human 5-LO,H,8,1,,CHEMBL618015,,BAO_0000357,,
3831,Autocuration,55,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,8,1,,CHEMBL618016,,BAO_0000019,,
3832,Expert,55,,,Inhibition of Human 5-lipoxygenase,H,8,1,,CHEMBL618017,,BAO_0000357,,
3833,Autocuration,55,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,H,8,1,,CHEMBL618018,,BAO_0000019,,
3834,Autocuration,55,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL875087,,BAO_0000219,,
3835,Autocuration,55,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL618019,,BAO_0000219,,
3836,Autocuration,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,H,8,1,,CHEMBL618020,,BAO_0000019,,
3837,Autocuration,55,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,H,8,1,,CHEMBL618021,,BAO_0000019,,
3838,Autocuration,55,Blood,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),H,8,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,Autocuration,55,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,H,8,1,,CHEMBL618023,,BAO_0000357,,
3840,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,8,1,,CHEMBL618024,,BAO_0000357,,
3841,Expert,55,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,H,8,1,,CHEMBL873950,,BAO_0000019,,
3842,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,8,1,,CHEMBL618025,,BAO_0000357,,
3843,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,H,8,1,,CHEMBL618026,,BAO_0000219,,
3844,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,H,8,1,,CHEMBL618027,,BAO_0000219,,
3845,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,H,8,1,,CHEMBL618028,,BAO_0000219,,
3846,Autocuration,55,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,H,8,1,,CHEMBL618029,,BAO_0000219,,
3847,Expert,55,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,H,8,1,,CHEMBL618030,,BAO_0000357,,
3848,Expert,55,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,H,8,1,,CHEMBL618031,,BAO_0000357,,
3849,Autocuration,55,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,H,8,1,,CHEMBL618032,,BAO_0000357,,
3850,Autocuration,55,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,8,1,,CHEMBL618033,,BAO_0000357,,
3851,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,H,8,1,,CHEMBL618034,,BAO_0000357,,
3852,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,8,1,,CHEMBL875088,,BAO_0000357,,
3853,Autocuration,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,H,8,1,,CHEMBL618035,,BAO_0000019,,
3854,Autocuration,55,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,H,8,1,,CHEMBL618036,,BAO_0000019,,
3855,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,H,8,1,,CHEMBL618037,,BAO_0000357,,
3856,Expert,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,8,1,,CHEMBL618038,,BAO_0000357,,
3857,Autocuration,55,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,8,1,,CHEMBL618761,,BAO_0000019,,
3858,Expert,55,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,H,8,1,,CHEMBL618762,,BAO_0000357,,
3859,Expert,55,,,Inhibition of lipoxygenase at the concentration of 1 uM,H,8,1,,CHEMBL618763,,BAO_0000357,,
3860,Autocuration,55,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,H,8,1,,CHEMBL618764,,BAO_0000357,,
3861,Expert,55,,,Inhibition of 5-Lipoxygenase (5-LOX),D,9,1,,CHEMBL618765,,BAO_0000357,,
3862,Expert,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,8,1,,CHEMBL618766,,BAO_0000357,,
3863,Expert,17087,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,8,1,,CHEMBL618767,,BAO_0000357,,
3864,Autocuration,17087,,,Inhibitory activity against lipoxygenase-2 in mice,H,8,1,,CHEMBL619380,,BAO_0000357,,
3865,Expert,17087,,,Inhibitory activity against murine lipoxygenase-2.,H,8,1,,CHEMBL619381,,BAO_0000357,,
3866,Expert,17087,,,Inhibition of 5-lipoxygenase from mouse macrophage,D,9,1,,CHEMBL619382,,BAO_0000357,,
3867,Autocuration,17087,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,H,8,1,,CHEMBL619383,,BAO_0000357,,
3868,Autocuration,55,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,8,1,,CHEMBL619384,,BAO_0000019,,
3869,Autocuration,55,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,H,8,1,,CHEMBL619385,,BAO_0000019,,
3870,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,H,8,1,,CHEMBL882928,,BAO_0000019,,
3871,Expert,12166,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,D,9,1,,CHEMBL619386,,BAO_0000019,,
3872,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",H,8,1,,CHEMBL619387,,BAO_0000019,,
3873,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,8,1,,CHEMBL619388,,BAO_0000019,,
3874,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",H,8,1,,CHEMBL619389,,BAO_0000019,,
3875,Expert,12166,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),H,8,1,,CHEMBL619390,,BAO_0000019,,
3876,Expert,12166,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",H,8,1,,CHEMBL619391,,BAO_0000019,,
3877,Autocuration,12166,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,H,8,1,,CHEMBL619392,,BAO_0000019,,
3878,Autocuration,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),H,8,1,,CHEMBL619393,,BAO_0000019,,
3879,Autocuration,12166,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,H,8,1,,CHEMBL619394,,BAO_0000019,,
3880,Autocuration,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,8,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,Autocuration,12166,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,8,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,Autocuration,12166,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),H,8,1,,CHEMBL619397,,BAO_0000357,,
3883,Autocuration,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",H,8,1,,CHEMBL619398,,BAO_0000357,,
3884,Autocuration,12166,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",H,8,1,,CHEMBL619399,,BAO_0000357,,
3885,Autocuration,12166,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,8,1,,CHEMBL619400,,BAO_0000357,,
3886,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,8,1,,CHEMBL619401,,BAO_0000019,,
3887,Autocuration,12166,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",H,8,1,,CHEMBL619402,,BAO_0000019,,
3888,Expert,12166,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,D,9,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,Autocuration,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,8,1,,CHEMBL619404,,BAO_0000357,,
3890,Autocuration,12166,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,H,8,1,,CHEMBL619405,,BAO_0000357,,
3891,Expert,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,H,8,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,Expert,12166,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,D,9,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),H,8,1,,CHEMBL619408,,BAO_0000357,,
3894,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,H,8,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,Expert,12166,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,H,8,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,8,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,Autocuration,12166,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,H,8,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,Expert,12166,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,H,8,1,,CHEMBL619903,,BAO_0000357,,
3899,Expert,12166,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",H,8,1,,CHEMBL619904,,BAO_0000357,,
3900,Expert,12166,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,H,8,1,,CHEMBL619905,,BAO_0000357,,
3901,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,H,8,1,,CHEMBL619906,,BAO_0000019,,
3902,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,H,8,1,,CHEMBL619907,,BAO_0000019,,
3903,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,H,8,1,,CHEMBL619908,,BAO_0000019,,
3904,Autocuration,12166,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,H,8,1,,CHEMBL619909,,BAO_0000019,,
3905,Expert,12166,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,H,8,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,Expert,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,H,8,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,Expert,12166,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,H,8,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,Autocuration,12166,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,H,8,1,,CHEMBL619912,,BAO_0000019,,
3909,Expert,12166,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,D,9,1,,CHEMBL619913,,BAO_0000357,,
3910,Expert,12166,,,In vitro inhibitory activity against RBL-1 5-LO,H,8,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,Autocuration,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),H,8,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,Autocuration,12166,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),H,8,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,Autocuration,12166,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,H,8,1,,CHEMBL619917,,BAO_0000218,,
3914,Autocuration,12166,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,H,8,1,,CHEMBL619918,,BAO_0000357,,
3915,Autocuration,12166,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,H,8,1,,CHEMBL619919,,BAO_0000218,,
3916,Autocuration,12166,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,H,8,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,Autocuration,12166,Blood,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,H,8,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,Expert,12166,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,H,8,1,,CHEMBL619921,,BAO_0000357,,
3919,Autocuration,12166,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,H,8,1,,CHEMBL619922,,BAO_0000019,,
3920,Autocuration,12166,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,H,8,1,,CHEMBL619923,,BAO_0000219,,
3921,Expert,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,H,8,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,Expert,12166,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,H,8,1,,CHEMBL619925,,BAO_0000357,,
3923,Expert,12166,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,H,8,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,Autocuration,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,H,8,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,Expert,12166,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,H,8,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase,H,8,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,H,8,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,H,8,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,H,8,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,H,8,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,H,8,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,H,8,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,H,8,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,H,8,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,H,8,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,H,8,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,H,8,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,H,8,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,H,8,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,H,8,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,H,8,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,H,8,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,H,8,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,H,8,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,H,8,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,H,8,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,H,8,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,H,8,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,H,8,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,H,8,1,,CHEMBL619950,,BAO_0000019,,
3951,Autocuration,12166,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,H,8,1,,CHEMBL618050,,BAO_0000019,,
3952,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,H,8,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,H,8,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,Expert,12166,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,D,9,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,H,8,1,,CHEMBL618053,,BAO_0000019,,
3956,Expert,12166,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),H,8,1,,CHEMBL618054,,BAO_0000019,,
3957,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,D,9,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,Expert,12166,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,H,8,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined,H,8,1,,CHEMBL618057,,BAO_0000357,,
3960,Autocuration,12166,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,H,8,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,Expert,12166,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,H,8,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,Expert,12166,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,D,9,1,,CHEMBL618060,,BAO_0000019,,
3963,Autocuration,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,H,8,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,Autocuration,12166,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,H,8,1,,CHEMBL618062,,BAO_0000019,,
3965,Expert,12166,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,H,8,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,Autocuration,12166,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,H,8,1,,CHEMBL618064,,BAO_0000357,,
3967,Expert,12166,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,D,9,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,Expert,12166,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,D,9,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,8,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,8,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,Expert,12166,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,D,9,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,Expert,12166,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,8,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,Autocuration,10825,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,H,8,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,Autocuration,10825,Limbic system,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,8,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,Autocuration,10825,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,H,8,1,,CHEMBL619248,,BAO_0000019,,
3976,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,8,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,Autocuration,10576,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,8,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,Autocuration,10577,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,8,1,,CHEMBL619251,,BAO_0000019,,
3979,Autocuration,55,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,H,8,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,Autocuration,55,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,H,8,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL619254,,BAO_0000219,,
3982,Expert,17140,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,H,8,1,,CHEMBL619255,,BAO_0000219,,
3983,Expert,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,H,8,1,,CHEMBL619256,,BAO_0000219,,
3984,Autocuration,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),H,8,1,,CHEMBL875418,,BAO_0000219,,
3985,Expert,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,8,1,,CHEMBL619257,,BAO_0000219,,
3986,Autocuration,17140,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,8,1,,CHEMBL619258,,BAO_0000219,,
3987,Expert,17140,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,H,8,1,,CHEMBL619259,,BAO_0000357,,
3988,Expert,17140,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,H,8,1,,CHEMBL619260,,BAO_0000357,,
3989,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,Autocuration,55,Blood,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",H,8,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",H,8,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,Autocuration,55,Blood,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,H,8,1,,CHEMBL619809,,BAO_0000218,,
4036,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,H,8,1,,CHEMBL619810,,BAO_0000218,,
4037,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,H,8,1,,CHEMBL619811,,BAO_0000218,,
4038,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,H,8,1,,CHEMBL620769,,BAO_0000218,,
4039,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,H,8,1,,CHEMBL620770,,BAO_0000218,,
4040,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,H,8,1,,CHEMBL620771,,BAO_0000218,,
4041,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,H,8,1,,CHEMBL620772,,BAO_0000218,,
4042,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,H,8,1,,CHEMBL620773,,BAO_0000218,,
4043,Autocuration,55,,,Ability to inhibit 5-lipoxygenase in guinea pig,H,8,1,,CHEMBL620774,,BAO_0000357,,
4044,Expert,55,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),H,8,1,,CHEMBL620775,,BAO_0000357,,
4045,Autocuration,55,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,H,8,1,,CHEMBL620776,,BAO_0000357,,
4046,Autocuration,55,Blood,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",H,8,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,Autocuration,55,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,H,8,1,,CHEMBL620778,,BAO_0000357,,
4048,Autocuration,55,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,H,8,1,,CHEMBL620779,,BAO_0000357,,
4049,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,H,8,1,,CHEMBL621500,,BAO_0000019,,
4050,Expert,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,8,1,,CHEMBL621501,,BAO_0000019,,
4051,Autocuration,55,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,8,1,,CHEMBL618098,,BAO_0000019,,
4052,Autocuration,55,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,8,1,,CHEMBL618099,,BAO_0000019,,
4053,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase,H,8,1,,CHEMBL618100,,BAO_0000357,,
4054,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,H,8,1,,CHEMBL618101,,BAO_0000357,,
4055,Autocuration,55,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,H,8,1,,CHEMBL618102,,BAO_0000357,,
4056,Autocuration,55,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,H,8,1,,CHEMBL618103,,BAO_0000357,,
4057,Autocuration,55,,,Inhibitory activity uM,H,8,1,,CHEMBL618104,,BAO_0000357,,
4058,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,H,8,1,,CHEMBL883712,,BAO_0000219,,
4059,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at 10 uM,H,8,1,,CHEMBL618105,,BAO_0000357,,
4060,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,8,1,,CHEMBL618106,,BAO_0000357,,
4061,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,H,8,1,,CHEMBL618107,,BAO_0000357,,
4062,Autocuration,55,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,8,1,,CHEMBL618108,,BAO_0000357,,
4063,Autocuration,55,,,Inhibitory activity uM,H,8,1,,CHEMBL618109,,BAO_0000357,,
4064,Autocuration,55,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,H,8,1,,CHEMBL618110,,BAO_0000357,,
4065,Expert,55,,,Inhibitory activity uM,H,8,1,,CHEMBL618111,,BAO_0000357,,
4066,Autocuration,55,,,Inhibitory activity uM,H,8,1,,CHEMBL618112,,BAO_0000019,,
4067,Autocuration,55,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,8,1,,CHEMBL618113,,BAO_0000019,,
4068,Autocuration,55,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,8,1,,CHEMBL618114,,BAO_0000357,,
4069,Expert,55,Ileum,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,H,8,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,8,1,,CHEMBL620872,,BAO_0000357,,
4071,Autocuration,55,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,8,1,,CHEMBL620873,,BAO_0000357,,
4072,Autocuration,55,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),H,8,1,,CHEMBL620874,,BAO_0000357,,
4073,Expert,55,,,In vitro inhibition of human 5-Lipoxygenase.,H,8,1,,CHEMBL620875,,BAO_0000357,,
4074,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,0,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,0,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,0,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,U,0,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,0,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,0,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,0,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,0,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,0,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,0,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,0,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,U,0,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,0,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,0,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,0,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,U,0,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,Autocuration,22226,Liver,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,0,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,Autocuration,22226,Liver,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,0,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,U,0,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,U,0,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,U,0,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,U,0,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,U,0,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,0,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,0,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,U,0,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,U,0,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,0,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,0,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,0,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,0,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,0,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,0,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,0,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,0,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,0,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,0,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,0,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,0,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,0,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,0,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,0,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,U,0,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,U,0,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,U,0,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,Autocuration,22226,Liver,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,U,0,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,Autocuration,22226,Liver,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,0,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,Autocuration,22226,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,U,0,1,,CHEMBL619976,,BAO_0000251,,
4122,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,0,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,0,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,Autocuration,22226,Liver,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",U,0,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,Autocuration,22226,Liver,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,0,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,Autocuration,22226,Liver,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,0,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,Intermediate,80433,,,In vitro inhibition of 7226/S myeloma cancer cell line,N,1,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,Intermediate,80698,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),N,1,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,Intermediate,80640,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,1,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,Intermediate,80640,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,1,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,Expert,81264,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,N,1,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,Expert,81264,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,N,1,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,N,1,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,N,1,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,N,1,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,N,1,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,N,1,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,Intermediate,80635,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,N,1,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,Intermediate,80640,,,In vitro antitumor activity against renal 786-0 tumor cell lines,N,1,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,Intermediate,80640,,,Cytotoxic activity against 786-0 Renal cancer cell line,N,1,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,Intermediate,80640,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,N,1,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,Intermediate,80640,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,N,1,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,Intermediate,80640,,,In vitro antitumor activity against human renal 786-0 cell line,N,1,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,Intermediate,80640,,,Inhibition of Renal cancer in 786-0 cancer cell lines,N,1,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,Intermediate,80640,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,N,1,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,Intermediate,80640,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,N,1,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,Intermediate,80640,,,inhibition of the growth of renal cancer(786-0) cell line,N,1,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,Intermediate,80640,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,Intermediate,80640,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,N,1,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,N,1,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,N,1,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,Intermediate,80640,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,N,1,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,Intermediate,80640,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,N,1,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,Intermediate,80640,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,N,1,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,Intermediate,80640,,,Compound was tested for growth inhibitory activity against 786-0 cell line,N,1,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,H,8,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,H,8,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,H,8,1,,CHEMBL619225,,BAO_0000019,,
4159,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,8,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,8,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,H,8,1,,CHEMBL619228,,BAO_0000357,,
4162,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,H,8,1,,CHEMBL619229,,BAO_0000219,,
4163,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,H,8,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,Autocuration,12166,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,H,8,1,,CHEMBL619231,,BAO_0000357,,
4165,Autocuration,12166,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",H,8,1,,CHEMBL619232,,BAO_0000357,,
4166,Expert,12166,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,H,8,1,,CHEMBL619233,,BAO_0000357,,
4167,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,H,8,1,,CHEMBL619234,,BAO_0000357,,
4168,Autocuration,12166,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),H,8,1,,CHEMBL619235,,BAO_0000357,,
4169,Expert,12166,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",D,9,1,,CHEMBL619236,,BAO_0000019,,
4170,Autocuration,12166,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,H,8,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,Autocuration,12166,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,H,8,1,,CHEMBL619238,,BAO_0000357,,
4172,Expert,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,H,8,1,,CHEMBL619239,,BAO_0000357,,
4173,Autocuration,12166,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,H,8,1,,CHEMBL619240,,BAO_0000357,,
4174,Autocuration,12166,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,8,1,,CHEMBL875417,,BAO_0000019,,
4175,Autocuration,12166,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),H,8,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,Expert,12166,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,8,1,,CHEMBL619242,,BAO_0000019,,
4177,Autocuration,12166,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,H,8,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,Autocuration,12166,,,Tested for its inhibitory activity against 5-lipoxygenase,H,8,1,,CHEMBL619243,,BAO_0000357,,
4179,Autocuration,12166,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,H,8,1,,CHEMBL619244,,BAO_0000357,,
4180,Expert,12166,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",H,8,1,,CHEMBL619245,,BAO_0000019,,
4181,Expert,12166,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,8,1,,CHEMBL619246,,BAO_0000019,,
4182,Expert,12166,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,8,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,H,8,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,8,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,Expert,12166,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,8,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,H,8,1,,CHEMBL619988,,BAO_0000218,,
4187,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,H,8,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,H,8,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL619991,,BAO_0000219,,
4190,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),H,8,1,,CHEMBL619992,,BAO_0000219,,
4191,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),H,8,1,,CHEMBL619993,,BAO_0000218,,
4192,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,H,8,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,H,8,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,Autocuration,12166,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],H,8,1,,CHEMBL619996,,BAO_0000019,,
4195,Autocuration,12166,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,H,8,1,,CHEMBL619997,,BAO_0000019,,
4196,Expert,12166,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,H,8,1,,CHEMBL619998,,BAO_0000019,,
4197,Expert,12166,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,H,8,1,,CHEMBL619999,,BAO_0000019,,
4198,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,H,8,1,,CHEMBL620000,,BAO_0000019,,
4199,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,H,8,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,Expert,12166,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,D,9,1,,CHEMBL620002,,BAO_0000357,,
4201,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,H,8,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,Expert,12166,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,H,8,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,Autocuration,12166,,,Compound was evaluated for the inhibition of 5-lipoxygenase,H,8,1,,CHEMBL874063,,BAO_0000357,,
4204,Autocuration,12166,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,H,8,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,H,8,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,Autocuration,12166,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,H,8,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,H,8,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,Expert,12166,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,D,9,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,8,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,H,8,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,H,8,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,H,8,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,H,8,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,Autocuration,12166,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,H,8,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,Expert,12166,,,Inhibitory activity against 5-lipoxygenase at 10 uM,D,9,1,,CHEMBL620838,,BAO_0000357,,
4216,Autocuration,12166,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,H,8,1,,CHEMBL620839,,BAO_0000357,,
4217,Expert,12166,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,H,8,1,,CHEMBL620840,,BAO_0000357,,
4218,Expert,12166,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,H,8,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,H,8,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,H,8,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,Autocuration,12166,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,H,8,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,Autocuration,12166,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,H,8,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,Autocuration,12166,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,H,8,1,,CHEMBL620846,,BAO_0000019,,
4224,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,8,1,,CHEMBL873951,,BAO_0000357,,
4225,Autocuration,12166,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,8,1,,CHEMBL620847,,BAO_0000357,,
4226,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,8,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,8,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,H,8,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,H,8,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,H,8,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,8,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,Expert,12166,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,D,9,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,H,8,1,,CHEMBL620854,,BAO_0000019,,
4234,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,8,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,Expert,12166,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,8,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,Autocuration,12166,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,8,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,Autocuration,12166,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,8,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,8,1,,CHEMBL620858,,BAO_0000019,,
4239,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,8,1,,CHEMBL620859,,BAO_0000019,,
4240,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,8,1,,CHEMBL620860,,BAO_0000019,,
4241,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,H,8,1,,CHEMBL620861,,BAO_0000019,,
4242,Expert,12166,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),H,8,1,,CHEMBL620862,,BAO_0000357,,
4243,Autocuration,12166,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,H,8,1,,CHEMBL620863,,BAO_0000357,,
4244,Autocuration,12166,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,8,1,,CHEMBL620864,,BAO_0000019,,
4245,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,H,8,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,H,8,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,H,8,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,8,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,Autocuration,12166,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,8,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,Autocuration,12166,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,H,8,1,,CHEMBL873952,,BAO_0000019,,
4251,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase,H,8,1,,CHEMBL875099,,BAO_0000357,,
4252,Autocuration,12166,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,H,8,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,H,8,1,,CHEMBL618261,,BAO_0000019,,
4254,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,H,8,1,,CHEMBL618262,,BAO_0000019,,
4255,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,H,8,1,,CHEMBL619428,,BAO_0000019,,
4256,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,8,1,,CHEMBL619429,,BAO_0000019,,
4257,Autocuration,12166,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,8,1,,CHEMBL619430,,BAO_0000019,,
4258,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,H,8,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,H,8,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,H,8,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,H,8,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,H,8,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,H,8,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,H,8,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,H,8,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,H,8,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,H,8,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,Autocuration,12166,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,H,8,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,Expert,12166,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,D,9,1,,CHEMBL620028,,BAO_0000019,,
4270,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,H,8,1,,CHEMBL620029,,BAO_0000357,,
4271,Autocuration,12166,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,H,8,1,,CHEMBL620030,,BAO_0000357,,
4272,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,H,8,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,Autocuration,12166,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,8,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,H,8,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,H,8,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,Autocuration,12166,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,H,8,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,Autocuration,12166,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,8,1,,CHEMBL618260,,BAO_0000019,,
4278,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,H,8,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,H,8,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,H,8,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,Autocuration,12166,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,H,8,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,Autocuration,12166,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,H,8,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,Autocuration,12166,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,H,8,1,,CHEMBL618394,,BAO_0000219,,
4284,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),H,8,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,Expert,12166,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),D,9,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,Expert,12166,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),D,9,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,Autocuration,12166,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,D,9,1,,CHEMBL618397,,BAO_0000019,,
4288,Autocuration,12054,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),H,8,1,,CHEMBL618398,,BAO_0000357,,
4289,Autocuration,22226,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",U,0,1,,CHEMBL618399,,BAO_0000019,,
4290,Expert,55,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,H,8,1,,CHEMBL618400,,BAO_0000357,,
4291,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,H,8,1,,CHEMBL618401,,BAO_0000357,,
4292,Autocuration,55,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,H,8,1,,CHEMBL618402,,BAO_0000357,,
4293,Autocuration,55,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,H,8,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,Expert,55,,,Inhibitory activity against 5-lipoxygenase.,H,8,1,,CHEMBL618403,,BAO_0000357,,
4295,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,H,8,1,,CHEMBL618404,,BAO_0000357,,
4296,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,H,8,1,,CHEMBL618405,,BAO_0000357,,
4297,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,H,8,1,,CHEMBL618406,,BAO_0000357,,
4298,Expert,55,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,H,8,1,,CHEMBL618407,,BAO_0000019,,
4299,Autocuration,55,,,Tested for the inhibitory activity against 5-lipoxygenase,H,8,1,,CHEMBL618408,,BAO_0000357,,
4300,Autocuration,55,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,H,8,1,,CHEMBL618409,,BAO_0000357,,
4301,Autocuration,55,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,H,8,1,,CHEMBL618410,,BAO_0000357,,
4302,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,H,8,1,,CHEMBL618411,,BAO_0000357,,
4303,Autocuration,55,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,H,8,1,,CHEMBL618412,,BAO_0000357,,
4304,Autocuration,12166,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,H,8,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,Autocuration,12166,,,,H,8,1,,CHEMBL618414,,BAO_0000357,,
4306,Autocuration,10102,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),H,8,1,,CHEMBL618415,,BAO_0000357,,
4307,Autocuration,10102,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,H,8,1,,CHEMBL618416,,BAO_0000019,,
4308,Autocuration,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,H,8,1,,CHEMBL876401,,BAO_0000357,,
4309,Expert,10102,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,H,8,1,,CHEMBL618417,,BAO_0000357,,
4310,Autocuration,10102,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,H,8,1,,CHEMBL618418,,BAO_0000357,,
4311,Autocuration,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",H,8,1,,CHEMBL618419,,BAO_0000357,,
4312,Autocuration,10102,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",H,8,1,,CHEMBL618420,,BAO_0000357,,
4313,Autocuration,10102,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,H,8,1,,CHEMBL618421,,BAO_0000357,,
4314,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,H,8,1,,CHEMBL618422,,BAO_0000019,,
4315,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),H,8,1,,CHEMBL618423,,BAO_0000019,,
4316,Autocuration,11238,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),H,8,1,,CHEMBL618424,,BAO_0000019,,
4317,Intermediate,100284,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,S,2,1,,CHEMBL618425,,BAO_0000220,,
4318,Autocuration,22226,,,The dark toxicity against 543 human galactophore carcinoma cells,U,0,1,,CHEMBL618426,,BAO_0000019,,
4319,Expert,80623,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,N,1,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,Expert,80008,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,N,1,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,Intermediate,80008,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,N,1,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,Intermediate,80008,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",N,1,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,Expert,80008,,,Growth inhibition against human 5637 cell lines,N,1,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,Expert,80008,,,Antitumor activity against human bladder carcinoma 5637 cells.,N,1,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,Intermediate,80008,,,Antitumor activity against human bladder carcinoma 5637 cells,N,1,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,Intermediate,80008,,,Antitumor activity against human bladder carcinoma 5637 cells,N,1,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,Expert,10443,,,In vitro inhibition of bovine trypsin(Trp).,D,9,1,,CHEMBL618434,,BAO_0000357,,
4328,Expert,240,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,H,8,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,Autocuration,10577,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,H,8,1,,CHEMBL876402,,BAO_0000357,,
4330,Autocuration,104698,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,H,6,1,,CHEMBL618436,,BAO_0000019,,
4331,Autocuration,22226,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,U,0,1,,CHEMBL618437,,BAO_0000218,,
4332,Intermediate,20033,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,D,9,1,,CHEMBL618438,,BAO_0000357,,
4333,Expert,17045,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,8,1,,CHEMBL883800,,BAO_0000251,,
4334,Expert,17045,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,8,1,,CHEMBL618439,,BAO_0000251,,
4335,Intermediate,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,0,1,,CHEMBL618440,,BAO_0000019,,
4336,Intermediate,22226,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,0,1,,CHEMBL618441,,BAO_0000019,,
4337,Expert,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,H,8,1,,CHEMBL618442,,BAO_0000019,,
4338,Autocuration,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,H,8,1,,CHEMBL618443,,BAO_0000019,,
4339,Expert,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,H,8,1,,CHEMBL619158,,BAO_0000019,,
4340,Autocuration,11938,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,H,8,1,,CHEMBL620974,,BAO_0000019,,
4341,Autocuration,11938,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,H,8,1,,CHEMBL620975,,BAO_0000357,,
4342,Intermediate,22226,,,Average inhibitory concentration against 60 human cell lines was reported,U,0,1,,CHEMBL620976,,BAO_0000019,,
4343,Expert,22226,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,U,0,1,,CHEMBL620977,,BAO_0000019,,
4344,Intermediate,80315,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,N,1,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,Intermediate,80315,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,N,1,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,Expert,80315,,,In vitro mean growth inhibitory activity against 60-cell panel,N,1,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,Expert,80315,,,In vitro mean growth lethal concentration against 60-cell panel,N,1,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,Expert,80315,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,N,1,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,Expert,80315,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,N,1,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,Autocuration,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,4,1,,CHEMBL620984,,BAO_0000019,,
4351,Autocuration,104775,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,4,1,,CHEMBL620985,,BAO_0000019,,
4352,Expert,275,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,H,8,1,,CHEMBL620986,,BAO_0000357,,
4353,Expert,50425,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,N,1,1,,CHEMBL620987,,BAO_0000218,,
4354,Expert,50425,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,N,1,1,,CHEMBL620988,,BAO_0000218,,
4355,Expert,50425,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,N,1,1,,CHEMBL620989,,BAO_0000218,,
4356,Expert,50425,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,N,1,1,,CHEMBL620990,,BAO_0000218,,
4357,Intermediate,50425,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,N,1,1,,CHEMBL620991,,BAO_0000218,,
4358,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,N,1,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,N,1,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,N,1,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,N,1,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,N,1,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,Intermediate,80628,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,N,1,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,U,0,1,,CHEMBL620997,,BAO_0000218,,
4365,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,U,0,1,,CHEMBL620998,,BAO_0000218,,
4366,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),U,0,1,,CHEMBL620999,,BAO_0000218,,
4367,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,U,0,1,,CHEMBL621000,,BAO_0000218,,
4368,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,U,0,1,,CHEMBL621001,,BAO_0000218,,
4369,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,U,0,1,,CHEMBL621002,,BAO_0000218,,
4370,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,U,0,1,,CHEMBL621003,,BAO_0000218,,
4371,Autocuration,22224,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",U,0,1,,CHEMBL621004,,BAO_0000218,,
4372,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),U,0,1,,CHEMBL621005,,BAO_0000218,,
4373,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),U,0,1,,CHEMBL621006,,BAO_0000218,,
4374,Autocuration,22224,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,U,0,1,,CHEMBL621007,,BAO_0000218,,
4375,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,U,0,1,,CHEMBL621008,,BAO_0000218,,
4376,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,U,0,1,,CHEMBL621009,,BAO_0000218,,
4377,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,U,0,1,,CHEMBL857705,,BAO_0000218,,
4378,Autocuration,22224,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,U,0,1,,CHEMBL619828,,BAO_0000218,,
4379,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,U,0,1,,CHEMBL619829,,BAO_0000218,,
4380,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,U,0,1,,CHEMBL619830,,BAO_0000218,,
4381,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,U,0,1,,CHEMBL619831,,BAO_0000218,,
4382,Autocuration,22224,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,U,0,1,,CHEMBL619832,,BAO_0000218,,
4383,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,U,0,1,,CHEMBL619833,,BAO_0000218,,
4384,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,U,0,1,,CHEMBL619834,,BAO_0000218,,
4385,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,U,0,1,,CHEMBL619835,,BAO_0000218,,
4386,Autocuration,22224,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,U,0,1,,CHEMBL619836,,BAO_0000218,,
4387,Intermediate,80628,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",N,1,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,Autocuration,22224,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,U,0,1,,CHEMBL619838,,BAO_0000218,,
4389,Intermediate,50594,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,N,1,1,,CHEMBL619839,,BAO_0000218,,
4390,Intermediate,80628,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,N,1,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,Intermediate,80628,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,N,1,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,Expert,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),N,1,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,Intermediate,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),N,1,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,Expert,80628,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),N,1,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,Autocuration,22226,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",U,0,1,,CHEMBL619844,,BAO_0000019,,
4396,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,U,0,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,0,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,U,0,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,U,0,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,U,0,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,U,0,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,U,0,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,U,0,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,0,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,0,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,0,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,Autocuration,22226,Liver,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,0,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,Autocuration,22224,Plasma,,The apparent total plasma clearance in monkey,U,0,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,Autocuration,22224,,,Compound was evaluated for Hepatic clearance in monkey,U,0,1,,CHEMBL620901,,BAO_0000218,,
4410,Autocuration,22224,,,Lower clearance in monkey (i.v.) at 0.5 mpk,U,0,1,,CHEMBL620902,,BAO_0000218,,
4411,Autocuration,22224,,,Plasma clearance in rhesus monkey,U,0,1,,CHEMBL620903,,BAO_0000218,,
4412,Autocuration,22224,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,U,0,1,,CHEMBL620904,,BAO_0000218,,
4413,Autocuration,22224,,,Plasma clearance of compound was determined in monkey,U,0,1,,CHEMBL620905,,BAO_0000218,,
4414,Autocuration,22224,,,Plasma clearance was calculated in rhesus monkey,U,0,1,,CHEMBL620906,,BAO_0000218,,
4415,Autocuration,22224,,,Plasma clearance in rhesus monkey,U,0,1,,CHEMBL875420,,BAO_0000218,,
4416,Autocuration,22224,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,0,1,,CHEMBL620907,,BAO_0000218,,
4417,Autocuration,22224,,,Plasma clearance was evaluated in rhesus,U,0,1,,CHEMBL620908,,BAO_0000218,,
4418,Autocuration,22224,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,U,0,1,,CHEMBL620909,,BAO_0000218,,
4419,Autocuration,22224,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,0,1,,CHEMBL620910,,BAO_0000218,,
4420,Autocuration,22224,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL620911,,BAO_0000218,,
4421,Autocuration,22224,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL620912,,BAO_0000218,,
4422,Autocuration,22224,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,U,0,1,,CHEMBL620913,,BAO_0000218,,
4423,Autocuration,22224,,,Cmax in monkey after administration of 1 mg/kg iv,U,0,1,,CHEMBL620914,,BAO_0000218,,
4424,Autocuration,22224,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,U,0,1,,CHEMBL620915,,BAO_0000218,,
4425,Autocuration,22224,,,Cmax in cynomolgus monkey by iv administration,U,0,1,,CHEMBL620916,,BAO_0000218,,
4426,Autocuration,22224,,,Cmax in cynomolgus monkey by po administration,U,0,1,,CHEMBL620917,,BAO_0000218,,
4427,Autocuration,22224,,,Cmax value evaluated in monkey,U,0,1,,CHEMBL620918,,BAO_0000218,,
4428,Autocuration,22224,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL620919,,BAO_0000218,,
4429,Autocuration,22224,Plasma,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,U,0,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,Autocuration,22224,Plasma,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,U,0,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,Autocuration,22224,Plasma,,Maximal plasma concentration in squirrel monkeys,U,0,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,Autocuration,22224,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,0,1,,CHEMBL620923,,BAO_0000218,,
4433,Autocuration,22224,Plasma,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,U,0,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,Autocuration,22224,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,0,1,,CHEMBL620925,,BAO_0000218,,
4435,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,0,1,,CHEMBL620926,,BAO_0000218,,
4436,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,0,1,,CHEMBL620927,,BAO_0000218,,
4437,Autocuration,22224,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,U,0,1,,CHEMBL620928,,BAO_0000218,,
4438,Autocuration,22224,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,U,0,1,,CHEMBL620929,,BAO_0000218,,
4439,Autocuration,22224,Plasma,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,U,0,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,Autocuration,22224,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,U,0,1,,CHEMBL620931,,BAO_0000218,,
4441,Autocuration,22224,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,U,0,1,,CHEMBL620932,,BAO_0000218,,
4442,Autocuration,22224,,,Absolute bioavailability was evaluated in monkey,U,0,1,,CHEMBL620933,,BAO_0000218,,
4443,Autocuration,22224,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,U,0,1,,CHEMBL620934,,BAO_0000218,,
4444,Autocuration,22224,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,U,0,1,,CHEMBL620935,,BAO_0000218,,
4445,Autocuration,22224,,,Bioavailability of compound was determined in rhesus monkey,U,0,1,,CHEMBL620936,,BAO_0000218,,
4446,Autocuration,22224,,,Bioavailability determined after oral administration in marmoset,U,0,1,,CHEMBL620937,,BAO_0000218,,
4447,Autocuration,22224,,,Oral bioavailability in cynomolgus monkey,U,0,1,,CHEMBL620938,,BAO_0000218,,
4448,Autocuration,22224,,,Bioavailability in monkey (p.o.) at 2.0 mpk,U,0,1,,CHEMBL620939,,BAO_0000218,,
4449,Autocuration,22224,,,Bioavailability was evaluated after oral administration in monkey,U,0,1,,CHEMBL620940,,BAO_0000218,,
4450,Autocuration,22224,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,0,1,,CHEMBL620941,,BAO_0000218,,
4451,Autocuration,22224,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL620942,,BAO_0000218,,
4452,Autocuration,22224,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL620943,,BAO_0000218,,
4453,Autocuration,22224,,,Bioavailability of the compound was determined in monkey,U,0,1,,CHEMBL620944,,BAO_0000218,,
4454,Autocuration,22224,,,Bioavailability in squirrel monkey (dose 5 mg/kg),U,0,1,,CHEMBL620945,,BAO_0000218,,
4455,Autocuration,22224,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,0,1,,CHEMBL620946,,BAO_0000218,,
4456,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL620947,,BAO_0000218,,
4457,Autocuration,22224,,,Compound was tested for bioavailability in squirrel monkey,U,0,1,,CHEMBL620948,,BAO_0000218,,
4458,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,U,0,1,,CHEMBL620949,,BAO_0000218,,
4459,Autocuration,22224,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),U,0,1,,CHEMBL620950,,BAO_0000218,,
4460,Autocuration,22224,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,U,0,1,,CHEMBL620951,,BAO_0000218,,
4461,Autocuration,22224,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,U,0,1,,CHEMBL620952,,BAO_0000218,,
4462,Autocuration,22224,,,Oral bioavailability in monkey (dose 5 mg/kg),U,0,1,,CHEMBL875421,,BAO_0000218,,
4463,Autocuration,22224,,,Oral bioavailability of compound at 5 mg/kg in monkey,U,0,1,,CHEMBL620953,,BAO_0000218,,
4464,Intermediate,50588,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,1,1,,CHEMBL873491,,BAO_0000218,,
4465,Intermediate,50588,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,N,1,1,,CHEMBL620954,,BAO_0000218,,
4466,Intermediate,50588,Plasma,,Plasma half life determined,N,1,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,Intermediate,50588,Plasma,,Plasma half life in dog,N,1,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,Intermediate,50588,Plasma,,Plasma half-life in Beagle dogs,N,1,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,Intermediate,50588,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,1,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,Intermediate,50588,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),N,1,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,Intermediate,50588,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,N,1,1,,CHEMBL618271,,BAO_0000218,,
4472,Intermediate,50588,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,N,1,1,,CHEMBL873493,,BAO_0000218,,
4473,Intermediate,50588,,,Tested for the half life period in dog,N,1,1,,CHEMBL621031,,BAO_0000218,,
4474,Intermediate,50588,,,Tested for the half life period in dog at dosage of 10 mpk,N,1,1,,CHEMBL621032,,BAO_0000218,,
4475,Intermediate,50588,,,The compound was tested for half life in dog,N,1,1,,CHEMBL621033,,BAO_0000218,,
4476,Intermediate,50588,Plasma,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",N,1,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,Intermediate,50588,,,The half life was determined,N,1,1,,CHEMBL621035,,BAO_0000218,,
4478,Intermediate,50588,Plasma,,The plasma half-life in dogs,N,1,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,Intermediate,50588,Plasma,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,N,1,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,Intermediate,50588,,,Half life in dog,N,1,1,,CHEMBL619812,,BAO_0000218,,
4481,Intermediate,50588,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,N,1,1,,CHEMBL619813,,BAO_0000218,,
4482,Intermediate,50588,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,N,1,1,,CHEMBL873335,,BAO_0000218,,
4483,Intermediate,50588,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619814,,BAO_0000218,,
4484,Expert,50506,,,Cmax in ferrets after 30 mg/kg oral dose,N,1,1,,CHEMBL619815,,BAO_0000218,,
4485,Expert,50506,,,Emesis in ferrets at 30 mg/kg oral dose,N,1,1,,CHEMBL619816,,BAO_0000218,,
4486,Autocuration,22224,,,Bioavailability in cynomolgus monkey,U,0,1,,CHEMBL619817,,BAO_0000218,,
4487,Intermediate,100710,,,Volume of distribution in cynomolgus,N,1,1,,CHEMBL619818,,BAO_0000218,,
4488,Autocuration,22224,Plasma,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,U,0,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,Autocuration,22224,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,0,1,,CHEMBL619820,,BAO_0000218,,
4490,Autocuration,22224,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",U,0,1,,CHEMBL875419,,BAO_0000218,,
4491,Autocuration,22224,Plasma,,AUC in guinea pig after 3mg/kg oral dose,U,0,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,Autocuration,22224,,,Bioavailability in guinea pig was tested,U,0,1,,CHEMBL619822,,BAO_0000218,,
4493,Autocuration,22224,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,U,0,1,,CHEMBL619823,,BAO_0000218,,
4494,Autocuration,22224,,,Tested for the oral bioavailability of the compound,U,0,1,,CHEMBL619824,,BAO_0000218,,
4495,Autocuration,22224,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,U,0,1,,CHEMBL619825,,BAO_0000218,,
4496,Autocuration,22224,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,U,0,1,,CHEMBL619826,,BAO_0000218,,
4497,Autocuration,22224,Lung,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,0,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,Autocuration,22224,,,Cmax in guinea pig after 3mg/kg oral dose,U,0,1,,CHEMBL618167,,BAO_0000218,,
4499,Autocuration,22224,Blood,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,Autocuration,22224,Brain,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,Autocuration,22224,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618170,,BAO_0000019,,
4502,Autocuration,22224,Intestine,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,Autocuration,22224,Kidney,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,Autocuration,22224,Liver,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,Autocuration,22224,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL618174,,BAO_0000019,,
4506,Autocuration,22224,Spleen,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,U,0,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,Autocuration,22224,,,Elimination T1/2 in Guinea pig (PO dose),U,0,1,,CHEMBL839827,,BAO_0000218,,
4508,Autocuration,22224,,,Partition coefficient was measured as -log (counts per min ),U,0,1,,CHEMBL618175,,BAO_0000019,,
4509,Autocuration,22224,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,0,1,,CHEMBL618176,,BAO_0000218,,
4510,Autocuration,22224,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,0,1,,CHEMBL618177,,BAO_0000218,,
4511,Autocuration,22224,,,Elimination T1/2 in Guinea pig (PO dose),U,0,1,,CHEMBL618178,,BAO_0000218,,
4512,Autocuration,22224,,,"Tested for the half life period of the compound, intravenously",U,0,1,,CHEMBL618179,,BAO_0000218,,
4513,Autocuration,22224,,,Half-life was measured,U,0,1,,CHEMBL873489,,BAO_0000019,,
4514,Autocuration,22224,,,The time required for onset of inotropy after addition of a single dose of delta F75,U,0,1,,CHEMBL618180,,BAO_0000019,,
4515,Autocuration,22224,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,U,0,1,,CHEMBL618181,,BAO_0000218,,
4516,Autocuration,22224,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,U,0,1,,CHEMBL618182,,BAO_0000218,,
4517,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,0,1,,CHEMBL618183,,BAO_0000218,,
4518,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL618184,,BAO_0000218,,
4519,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL618185,,BAO_0000218,,
4520,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL618186,,BAO_0000218,,
4521,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL618187,,BAO_0000218,,
4522,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,N,1,1,,CHEMBL618188,,BAO_0000218,,
4523,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL875409,,BAO_0000218,,
4524,Intermediate,50594,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL618189,,BAO_0000218,,
4525,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,Intermediate,50594,Blood,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,Intermediate,50594,Bone,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,Intermediate,50594,Brain,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,Intermediate,50594,Heart,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,Intermediate,50594,Intestine,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,Intermediate,50594,Kidney,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,Intermediate,50594,Liver,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,Intermediate,50594,Lung,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,N,1,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,Intermediate,50594,Muscle tissue,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,N,1,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,Intermediate,50594,Spleen,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,N,1,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,N,1,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,N,1,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,Intermediate,50594,Stomach,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,N,1,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,1,1,,CHEMBL619110,,BAO_0000218,,
4559,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,1,1,,CHEMBL619111,,BAO_0000218,,
4560,Intermediate,50594,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL619112,,BAO_0000218,,
4561,Intermediate,50594,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL619113,,BAO_0000218,,
4562,Intermediate,50594,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL619114,,BAO_0000218,,
4563,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,1,1,,CHEMBL619115,,BAO_0000218,,
4564,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,N,1,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,N,1,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,N,1,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,Intermediate,81034,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,N,1,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,1,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,1,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,1,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,1,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,1,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell line,N,1,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,Intermediate,81034,,,In vitro inhibitory activity against human tumor cell line A2780,N,1,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,N,1,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,1,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,1,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,Intermediate,81034,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,1,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,N,1,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,N,1,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,Intermediate,81034,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,N,1,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,1,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,1,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,Intermediate,81034,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,1,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,N,1,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,Intermediate,81034,,,Relative resistance factor in A2780 cisplatin-resistant line,N,1,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,Intermediate,81034,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,N,1,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,Intermediate,81034,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,N,1,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,1,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,Expert,81034,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,1,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,Intermediate,81034,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,N,1,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,Intermediate,81034,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,N,1,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,N,1,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,N,1,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,N,1,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,N,1,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,N,1,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,N,1,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,Intermediate,81034,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,N,1,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,Intermediate,81034,,,Antiproliferative effect of compound on A2780/DX cell line,N,1,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,Intermediate,81034,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,N,1,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),N,1,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),N,1,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,N,1,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,N,1,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,Intermediate,81034,,,In vitro cytotoxicity against A2780ADR cell line,N,1,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,Intermediate,81034,,,In vitro cytotoxicity against A2780CIS cell line,N,1,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,Intermediate,81034,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,N,1,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,Intermediate,81034,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,N,1,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",N,1,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",N,1,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,Autocuration,22224,,,Oral bioavailability of compound in rhesus macaques,U,0,1,,CHEMBL619798,,BAO_0000218,,
4613,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL619799,,BAO_0000218,,
4614,Autocuration,22224,,,Oral bioavailability evaluated in monkey,U,0,1,,CHEMBL619800,,BAO_0000218,,
4615,Autocuration,22224,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),U,0,1,,CHEMBL619801,,BAO_0000218,,
4616,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,U,0,1,,CHEMBL619802,,BAO_0000218,,
4617,Autocuration,22224,,,Oral bioavailability was calculated in rhesus monkey,U,0,1,,CHEMBL619803,,BAO_0000218,,
4618,Autocuration,22224,,,Oral bioavailability in cynomolgus monkey,U,0,1,,CHEMBL619965,,BAO_0000218,,
4619,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL619966,,BAO_0000218,,
4620,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL619967,,BAO_0000218,,
4621,Autocuration,22224,,,Oral bioavailability in monkey (dose 1 mg/kg),U,0,1,,CHEMBL620073,,BAO_0000218,,
4622,Autocuration,22224,,,Oral bioavailability in monkey (dose 5 mg/kg),U,0,1,,CHEMBL620074,,BAO_0000218,,
4623,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL620075,,BAO_0000218,,
4624,Autocuration,22224,,,Oral bioavailability in monkey,U,0,1,,CHEMBL620076,,BAO_0000218,,
4625,Autocuration,22224,,,Oral bioavailability in rhesus monkey,U,0,1,,CHEMBL620077,,BAO_0000218,,
4626,Autocuration,22224,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,U,0,1,,CHEMBL620078,,BAO_0000218,,
4627,Autocuration,22224,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,U,0,1,,CHEMBL620079,,BAO_0000218,,
4628,Autocuration,22224,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,0,1,,CHEMBL620080,,BAO_0000218,,
4629,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,U,0,1,,CHEMBL620081,,BAO_0000218,,
4630,Autocuration,22224,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),U,0,1,,CHEMBL620082,,BAO_0000218,,
4631,Autocuration,22224,,,Oral bioavailability in monkey at 10 mg/kg of the compound,U,0,1,,CHEMBL620083,,BAO_0000218,,
4632,Autocuration,22224,,,Bioavailability in Rhesus monkey,U,0,1,,CHEMBL620084,,BAO_0000218,,
4633,Autocuration,22224,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620085,,BAO_0000218,,
4634,Autocuration,22224,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL874595,,BAO_0000218,,
4635,Autocuration,22224,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,U,0,1,,CHEMBL873352,,BAO_0000218,,
4636,Autocuration,22224,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,U,0,1,,CHEMBL620086,,BAO_0000218,,
4637,Autocuration,22224,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,U,0,1,,CHEMBL620087,,BAO_0000218,,
4638,Autocuration,22224,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,0,1,,CHEMBL620088,,BAO_0000218,,
4639,Autocuration,22224,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,0,1,,CHEMBL620089,,BAO_0000218,,
4640,Autocuration,22224,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,0,1,,CHEMBL620090,,BAO_0000218,,
4641,Autocuration,22224,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,0,1,,CHEMBL620091,,BAO_0000218,,
4642,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),U,0,1,,CHEMBL620092,,BAO_0000251,,
4643,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),U,0,1,,CHEMBL620093,,BAO_0000251,,
4644,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),U,0,1,,CHEMBL620094,,BAO_0000251,,
4645,Autocuration,22224,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),U,0,1,,CHEMBL620095,,BAO_0000251,,
4646,Autocuration,22224,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620096,,BAO_0000218,,
4647,Autocuration,22224,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620097,,BAO_0000218,,
4648,Autocuration,22224,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,U,0,1,,CHEMBL620098,,BAO_0000019,,
4649,Autocuration,22224,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620099,,BAO_0000218,,
4650,Autocuration,22224,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620100,,BAO_0000218,,
4651,Autocuration,22224,,,Elimination Half-life of compound was determined in monkey,U,0,1,,CHEMBL620101,,BAO_0000019,,
4652,Autocuration,22224,,,Half life of compound was determined in rhesus monkey,U,0,1,,CHEMBL620102,,BAO_0000019,,
4653,Autocuration,22224,Plasma,,Half life in monkey plasma,U,0,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,Autocuration,22224,Plasma,,Half life in monkey plasma; Not detected,U,0,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,Autocuration,22224,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,0,1,,CHEMBL874596,,BAO_0000218,,
4656,Autocuration,22224,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,U,0,1,,CHEMBL873490,,BAO_0000218,,
4657,Autocuration,22224,,,Terminal half life of the compound.,U,0,1,,CHEMBL620105,,BAO_0000019,,
4658,Autocuration,22224,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,0,1,,CHEMBL620780,,BAO_0000218,,
4659,Autocuration,22224,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,0,1,,CHEMBL620781,,BAO_0000218,,
4660,Autocuration,22224,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,0,1,,CHEMBL620956,,BAO_0000218,,
4661,Autocuration,22224,Urine,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,Autocuration,22224,Urine,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,Autocuration,22224,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,U,0,1,,CHEMBL620959,,BAO_0000218,,
4664,Autocuration,22224,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,U,0,1,,CHEMBL620960,,BAO_0000218,,
4665,Autocuration,22224,,,Volume of distribution was evaluated in rhesus,U,0,1,,CHEMBL620961,,BAO_0000218,,
4666,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,0,1,,CHEMBL620962,,BAO_0000218,,
4667,Autocuration,22224,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,U,0,1,,CHEMBL620963,,BAO_0000218,,
4668,Autocuration,22224,,,Bioavailability in hamster was determined,U,0,1,,CHEMBL620964,,BAO_0000218,,
4669,Autocuration,22224,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,U,0,1,,CHEMBL620965,,BAO_0000218,,
4670,Autocuration,22224,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,U,0,1,,CHEMBL620966,,BAO_0000218,,
4671,Autocuration,22224,Blood,,Half life of compound was determined in hamster blood,U,0,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,Autocuration,22224,,,Michaelis-Menten constant of the compound.,U,0,1,,CHEMBL620968,,BAO_0000019,,
4673,Autocuration,22224,,,Vmax value was measured at 0 uM concentration of silyl ether.,U,0,1,,CHEMBL874597,,BAO_0000019,,
4674,Autocuration,22224,,,Vmax value was measured at 10 uM concentration of silyl ether.,U,0,1,,CHEMBL620969,,BAO_0000019,,
4675,Autocuration,22224,,,Vmax value was measured at 5 uM concentration of silyl ether.,U,0,1,,CHEMBL620970,,BAO_0000019,,
4676,Expert,235,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,D,9,1,,CHEMBL620971,,BAO_0000357,,
4677,Autocuration,22224,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,U,0,1,,CHEMBL620972,,BAO_0000218,,
4678,Autocuration,22224,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),U,0,1,,CHEMBL620973,,BAO_0000019,,
4679,Autocuration,22224,,,Active metabolite of ifosfamide determined in humans; A-Active,U,0,1,,CHEMBL618243,,BAO_0000019,,
4680,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,U,0,1,,CHEMBL618244,,BAO_0000019,,
4681,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,U,0,1,,CHEMBL618245,,BAO_0000019,,
4682,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,U,0,1,,CHEMBL618246,,BAO_0000019,,
4683,Autocuration,22224,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,U,0,1,,CHEMBL618247,,BAO_0000019,,
4684,Autocuration,22224,,,Compound was evaluated for oral bioavailability in human,U,0,1,,CHEMBL618248,,BAO_0000218,,
4685,Autocuration,22224,Urine,,Metabolite of ifosfamide determined in urine; NF-Not found,U,0,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),U,0,1,,CHEMBL618250,,BAO_0000019,,
4687,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,U,0,1,,CHEMBL874598,,BAO_0000019,,
4688,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,U,0,1,,CHEMBL618251,,BAO_0000019,,
4689,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,U,0,1,,CHEMBL618252,,BAO_0000019,,
4690,Autocuration,22224,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,U,0,1,,CHEMBL618253,,BAO_0000019,,
4691,Autocuration,22224,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),U,0,1,,CHEMBL618254,,BAO_0000019,,
4692,Autocuration,22224,,,Percent of compound in healthy individuals (Group D),U,0,1,,CHEMBL618255,,BAO_0000019,,
4693,Autocuration,22224,Liver,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,0,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,Autocuration,22224,,,Binding towards human plasma protein at 10 uM,U,0,1,,CHEMBL618984,,BAO_0000019,,
4695,Autocuration,22224,,,Binding towards human plasma protein at 100 uM,U,0,1,,CHEMBL618985,,BAO_0000019,,
4696,Autocuration,22224,,,Human plasma protein binding activity was determined,U,0,1,,CHEMBL618986,,BAO_0000019,,
4697,Autocuration,22224,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,0,1,,CHEMBL618987,,BAO_0000019,,
4698,Autocuration,22224,,,Percent binding of compound towards human plasma protein was determined,U,0,1,,CHEMBL618988,,BAO_0000019,,
4699,Autocuration,22224,Liver,,Plasma clearance in human liver microsomes,U,0,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,Autocuration,22224,Liver,,In vitro intrinsic clearance in human liver microsome,U,0,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,Autocuration,22224,Liver,,In vitro intrinsic clearance in human liver microsome,U,0,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined,U,0,1,,CHEMBL876725,,BAO_0000251,,
4703,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined; High,U,0,1,,CHEMBL618992,,BAO_0000251,,
4704,Autocuration,22224,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,U,0,1,,CHEMBL618993,,BAO_0000251,,
4705,Autocuration,22224,Liver,,Pharmacokinetic property (clearance) in human liver microsome,U,0,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,Autocuration,22224,Liver,,Plasma clearance in human liver microsomes,U,0,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,Autocuration,22224,Liver,,In vitro clearance in human liver microsomes,U,0,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,Autocuration,22224,Liver,,Intrinsic clearance in human liver microsomes was determined,U,0,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,Autocuration,22224,Liver,,Intrinsic clearance in human liver microsomes was determined,U,0,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,Autocuration,22224,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,U,0,1,,CHEMBL618999,,BAO_0000218,,
4711,Autocuration,22224,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,U,0,1,,CHEMBL620223,,BAO_0000218,,
4712,Autocuration,22224,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,U,0,1,,CHEMBL620224,,BAO_0000218,,
4713,Autocuration,22224,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,U,0,1,,CHEMBL620225,,BAO_0000019,,
4714,Autocuration,22224,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,U,0,1,,CHEMBL620226,,BAO_0000019,,
4715,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,1,1,,CHEMBL620230,,BAO_0000218,,
4720,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,1,1,,CHEMBL620231,,BAO_0000218,,
4721,Intermediate,50594,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,1,1,,CHEMBL620232,,BAO_0000218,,
4722,Intermediate,50594,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,N,1,1,,CHEMBL620233,,BAO_0000218,,
4723,Intermediate,50594,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),N,1,1,,CHEMBL620234,,BAO_0000218,,
4724,Intermediate,50594,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),N,1,1,,CHEMBL620235,,BAO_0000218,,
4725,Intermediate,50594,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),N,1,1,,CHEMBL620236,,BAO_0000218,,
4726,Intermediate,50594,Liver,,In vitro metabolic potential in mouse liver microsomes,N,1,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,Intermediate,50594,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,N,1,1,,CHEMBL620238,,BAO_0000218,,
4728,Intermediate,50594,Adrenal gland,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),N,1,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,Intermediate,50594,Brain,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,N,1,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,Intermediate,50594,Brain,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,N,1,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,Intermediate,50594,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),N,1,1,,CHEMBL876727,,BAO_0000218,,
4732,Intermediate,50594,Kidney,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),N,1,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,Intermediate,50594,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),N,1,1,,CHEMBL620243,,BAO_0000218,,
4734,Intermediate,50594,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,N,1,1,,CHEMBL620244,,BAO_0000218,,
4735,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,N,1,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,N,1,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,Intermediate,50594,Serum,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,N,1,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 24 mg/Kg,N,1,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 40 mg/Kg,N,1,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,Intermediate,50594,Plasma,,Half life of compound was determined in plasma of mice at 5 mg/Kg,N,1,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 18 uM/kg,N,1,1,,CHEMBL620250,,BAO_0000218,,
4742,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 23 uM/kg,N,1,1,,CHEMBL620251,,BAO_0000218,,
4743,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 25 uM/kg,N,1,1,,CHEMBL620252,,BAO_0000218,,
4744,Intermediate,50594,,,Half life after intraperitoneal administration in mice at 26 uM/kg,N,1,1,,CHEMBL620253,,BAO_0000218,,
4745,Intermediate,50594,,,Half life after intravenous administration in mice at 23 uM/kg,N,1,1,,CHEMBL620254,,BAO_0000218,,
4746,Intermediate,50594,,,Half life after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL620255,,BAO_0000218,,
4747,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,1,1,,CHEMBL620256,,BAO_0000218,,
4748,Intermediate,50594,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,N,1,1,,CHEMBL876728,,BAO_0000218,,
4749,Intermediate,50594,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,N,1,1,,CHEMBL620257,,BAO_0000218,,
4750,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,1,1,,CHEMBL620258,,BAO_0000218,,
4751,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",N,1,1,,CHEMBL620259,,BAO_0000218,,
4752,Intermediate,50594,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,N,1,1,,CHEMBL620260,,BAO_0000218,,
4753,Intermediate,50594,Blood,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,N,1,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,Intermediate,50594,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL620262,,BAO_0000218,,
4755,Intermediate,50594,,,Half life at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL620263,,BAO_0000218,,
4756,Intermediate,50594,,,Half life in ob/ob mice,N,1,1,,CHEMBL620264,,BAO_0000218,,
4757,Intermediate,50594,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,N,1,1,,CHEMBL620265,,BAO_0000218,,
4758,Intermediate,50594,,,Half-life was measured in mouse,N,1,1,,CHEMBL620266,,BAO_0000218,,
4759,Intermediate,50594,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,N,1,1,,CHEMBL620267,,BAO_0000218,,
4760,Intermediate,50594,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,N,1,1,,CHEMBL619364,,BAO_0000218,,
4761,Intermediate,50594,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,N,1,1,,CHEMBL619365,,BAO_0000218,,
4762,Intermediate,50594,Brain,,T2 in brain of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,Intermediate,50594,Kidney,,T2 in kidney of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,Intermediate,50594,Liver,,T2 in liver of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,Intermediate,50594,Lung,,T2 in lungs of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,Intermediate,50594,Spleen,,T2 in spleen of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,1,1,,CHEMBL619370,,BAO_0000218,,
4768,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",N,1,1,,CHEMBL619371,,BAO_0000218,,
4769,Intermediate,50594,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,N,1,1,,CHEMBL619372,,BAO_0000218,,
4770,Intermediate,50594,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,N,1,1,,CHEMBL620012,,BAO_0000218,,
4771,Intermediate,50594,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,N,1,1,,CHEMBL620013,,BAO_0000218,,
4772,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,1,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,1,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,1,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,1,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,1,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,Intermediate,81034,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,1,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,Intermediate,81034,,,In vitro cytotoxicity against A2780TAX cell line,N,1,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,Intermediate,80017,,,In vitro inhibitory activity against human tumor cell line A2780cis,N,1,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,Expert,81034,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,N,1,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,Intermediate,80017,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,N,1,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,1,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,Intermediate,81034,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,N,1,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,Intermediate,81034,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,N,1,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,Intermediate,81034,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,N,1,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,Expert,81034,,,In vitro antitumor activity against A2780cisR cell line.,N,1,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,Intermediate,81034,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),N,1,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,Expert,81034,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,N,1,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,Intermediate,80017,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,N,1,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,Expert,81034,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,N,1,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,D,9,1,,CHEMBL618336,,BAO_0000019,,
4792,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),H,8,1,,CHEMBL618337,,BAO_0000019,,
4793,Expert,11736,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),D,9,1,,CHEMBL618338,,BAO_0000019,,
4794,Expert,278,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,D,9,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,Expert,278,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,D,9,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,D,9,1,,CHEMBL618341,,BAO_0000019,,
4797,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),H,8,1,,CHEMBL618342,,BAO_0000019,,
4798,Expert,11831,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),D,9,1,,CHEMBL618343,,BAO_0000019,,
4799,Expert,280,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,H,8,1,,CHEMBL621038,,BAO_0000357,,
4800,Autocuration,22226,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),U,0,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,Autocuration,22226,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,U,0,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,Intermediate,80018,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,N,1,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,Intermediate,80018,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,N,1,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,Intermediate,80018,,,In vitro antitumor activity against A375cell line extracted form melanoma,N,1,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,Expert,80018,,,Inhibition of cell growth in (A375) melan cell line,N,1,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,Intermediate,80018,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,N,1,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,Intermediate,80018,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,N,1,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,Intermediate,80018,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,N,1,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,Intermediate,80019,,,Antiproliferative activity measured against A427 human lung carcinoma,N,1,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,Intermediate,80019,,,Antiproliferative activity measured against A427 human lung carcinoma,N,1,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,Intermediate,80019,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,N,1,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,Intermediate,80019,,,Inhibition of large cell lung carcinoma (A427),N,1,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,Intermediate,80019,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,N,1,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,Intermediate,80019,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,1,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,Intermediate,80019,,,Inhibitory concentration in human lung carcinoma A427 cell line,N,1,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,Intermediate,80019,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,N,1,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,Autocuration,22224,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,0,1,,CHEMBL621055,,BAO_0000218,,
4818,Autocuration,22224,,,Tested for volume of distribution upon iv administration to african green monkey,U,0,1,,CHEMBL876398,,BAO_0000218,,
4819,Autocuration,22224,,,Volume of distribution in monkey,U,0,1,,CHEMBL621056,,BAO_0000218,,
4820,Autocuration,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,0,1,,CHEMBL621057,,BAO_0000218,,
4821,Autocuration,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,0,1,,CHEMBL621058,,BAO_0000218,,
4822,Autocuration,22224,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,U,0,1,,CHEMBL621059,,BAO_0000218,,
4823,Autocuration,22224,,,The distribution volume after intravenous administration in cynomolgus monkeys,U,0,1,,CHEMBL621060,,BAO_0000218,,
4824,Autocuration,22224,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,U,0,1,,CHEMBL621061,,BAO_0000218,,
4825,Autocuration,22224,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,U,0,1,,CHEMBL621062,,BAO_0000218,,
4826,Autocuration,22224,,,Volume displacement was calculated in rhesus monkey,U,0,1,,CHEMBL621063,,BAO_0000218,,
4827,Autocuration,22224,,,Volume of distribution in steady state was determined in rhesus monkey,U,0,1,,CHEMBL621064,,BAO_0000218,,
4828,Autocuration,22224,,,Volume of distribution of compound was determined in monkey,U,0,1,,CHEMBL621065,,BAO_0000218,,
4829,Autocuration,22224,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL621066,,BAO_0000218,,
4830,Autocuration,22224,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL621067,,BAO_0000218,,
4831,Autocuration,22224,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,0,1,,CHEMBL621068,,BAO_0000218,,
4832,Autocuration,22224,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL876399,,BAO_0000218,,
4833,Autocuration,22224,,,Volume distribution in monkey after administration of 1 mg/kg iv,U,0,1,,CHEMBL621069,,BAO_0000218,,
4834,Autocuration,22224,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,0,1,,CHEMBL621070,,BAO_0000218,,
4835,Autocuration,22224,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,0,1,,CHEMBL621071,,BAO_0000218,,
4836,Autocuration,22224,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL621072,,BAO_0000218,,
4837,Autocuration,22224,,,Oral systemic bioavailability upon iv administration to african green monkey,U,0,1,,CHEMBL618209,,BAO_0000218,,
4838,Autocuration,22224,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,0,1,,CHEMBL618210,,BAO_0000218,,
4839,Autocuration,22224,,,Baboon plasma free fraction. ,U,0,1,,CHEMBL618211,,BAO_0000019,,
4840,Autocuration,22224,,,Area under the curve was calculated in rhesus monkey after iv administration,U,0,1,,CHEMBL618212,,BAO_0000218,,
4841,Autocuration,22224,,,Area under the curve was calculated in rhesus monkey after peroral administration,U,0,1,,CHEMBL618213,,BAO_0000019,,
4842,Autocuration,22224,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,U,0,1,,CHEMBL618214,,BAO_0000019,,
4843,Autocuration,22224,,,Half life period in monkey after 5 mg/kg dose,U,0,1,,CHEMBL873492,,BAO_0000218,,
4844,Autocuration,22224,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,U,0,1,,CHEMBL618272,,BAO_0000218,,
4845,Autocuration,22224,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,U,0,1,,CHEMBL618273,,BAO_0000218,,
4846,Autocuration,22224,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,0,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,Autocuration,22224,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,U,0,1,,CHEMBL618275,,BAO_0000218,,
4848,Autocuration,22224,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL618276,,BAO_0000218,,
4849,Autocuration,22224,,,Compound was evaluated for terminal half life in monkey,U,0,1,,CHEMBL618277,,BAO_0000019,,
4850,Autocuration,22224,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,U,0,1,,CHEMBL618278,,BAO_0000218,,
4851,Autocuration,22224,Plasma,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,0,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,Autocuration,22224,,,Half life of compound was determined in squirrel monkey,U,0,1,,CHEMBL618280,,BAO_0000019,,
4853,Autocuration,22224,,,Half life after iv administration in cynomolgus monkey,U,0,1,,CHEMBL618281,,BAO_0000218,,
4854,Autocuration,22224,Plasma,,Half life in monkey plasma after administration of 1 mg/kg iv,U,0,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,Autocuration,22224,,,Half life was calculated in rhesus monkey,U,0,1,,CHEMBL618283,,BAO_0000019,,
4856,Autocuration,22224,,,Half life in monkey,U,0,1,,CHEMBL618284,,BAO_0000019,,
4857,Autocuration,22224,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,0,1,,CHEMBL618285,,BAO_0000218,,
4858,Autocuration,22224,,,Half life was evaluated in rhesus,U,0,1,,CHEMBL618286,,BAO_0000019,,
4859,Autocuration,22224,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,U,0,1,,CHEMBL618287,,BAO_0000218,,
4860,Autocuration,22224,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,U,0,1,,CHEMBL618288,,BAO_0000218,,
4861,Autocuration,22224,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,0,1,,CHEMBL876393,,BAO_0000218,,
4862,Autocuration,22224,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,0,1,,CHEMBL618289,,BAO_0000218,,
4863,Autocuration,22224,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,U,0,1,,CHEMBL618290,,BAO_0000218,,
4864,Autocuration,22224,,,Half-life was calculated in monkey,U,0,1,,CHEMBL618291,,BAO_0000019,,
4865,Autocuration,22224,,,Half-life in Squirrel monkey,U,0,1,,CHEMBL618292,,BAO_0000019,,
4866,Autocuration,22224,,,Half-life in rhesus monkey,U,0,1,,CHEMBL618293,,BAO_0000019,,
4867,Autocuration,22224,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,U,0,1,,CHEMBL618294,,BAO_0000218,,
4868,Autocuration,22224,,,Half-life period after intravenous administration in cynomolgus monkeys,U,0,1,,CHEMBL618295,,BAO_0000218,,
4869,Autocuration,22224,,,Half-life period after oral administration in cynomolgus monkeys,U,0,1,,CHEMBL618296,,BAO_0000218,,
4870,Autocuration,22224,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,U,0,1,,CHEMBL618297,,BAO_0000218,,
4871,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,Autocuration,22224,Urine,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,0,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,0,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,0,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,0,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,Autocuration,22224,Urine,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,0,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,Autocuration,22224,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,U,0,1,,CHEMBL618305,,BAO_0000218,,
4880,Autocuration,22224,,,Oral bioavailability in human,U,0,1,,CHEMBL618306,,BAO_0000218,,
4881,Autocuration,22224,,,Compound was tested for human plasma protein binding,U,0,1,,CHEMBL618307,,BAO_0000019,,
4882,Autocuration,22224,,,Compound was tested for human plasma protein binding; Not determined,U,0,1,,CHEMBL618308,,BAO_0000019,,
4883,Autocuration,22224,,,Protein binding activity of compound in human plasma; % Free,U,0,1,,CHEMBL618309,,BAO_0000019,,
4884,Autocuration,22224,,,Unbound fraction (plasma),U,0,1,,CHEMBL618310,,BAO_0000019,,
4885,Autocuration,22224,Plasma,,Half life for the hydrolysis of compound in human blood serum,U,0,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,Autocuration,22224,Plasma,,Half life period in human plasma using phosphate buffer (0.08 M),U,0,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,Autocuration,22224,Plasma,,Half life period in human plasma using phosphate buffer (0.1 M),U,0,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,Autocuration,22224,Plasma,,Half-life in human plasma was determined,U,0,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,Autocuration,22224,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,U,0,1,,CHEMBL618314,,BAO_0000019,,
4890,Autocuration,22224,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),U,0,1,,CHEMBL618315,,BAO_0000019,,
4891,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,0,1,,CHEMBL618316,,BAO_0000019,,
4892,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,0,1,,CHEMBL618317,,BAO_0000019,,
4893,Autocuration,22224,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,0,1,,CHEMBL620138,,BAO_0000019,,
4894,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL858280,,BAO_0000019,,
4895,Autocuration,22224,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,U,0,1,,CHEMBL620139,,BAO_0000019,,
4896,Autocuration,22224,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,U,0,1,,CHEMBL620140,,BAO_0000251,,
4897,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),U,0,1,,CHEMBL620141,,BAO_0000019,,
4898,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),U,0,1,,CHEMBL620142,,BAO_0000019,,
4899,Autocuration,22224,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),U,0,1,,CHEMBL620143,,BAO_0000019,,
4900,Autocuration,22224,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),U,0,1,,CHEMBL620144,,BAO_0000251,,
4901,Autocuration,22224,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),U,0,1,,CHEMBL620145,,BAO_0000251,,
4902,Autocuration,22224,,,Metabolism of compound in human microsomes; Trace,U,0,1,,CHEMBL620146,,BAO_0000251,,
4903,Autocuration,22224,Liver,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,U,0,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,Autocuration,22224,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,U,0,1,,CHEMBL620148,,BAO_0000251,,
4905,Autocuration,22224,Liver,,In vitro metabolic potential in human liver microsomes,U,0,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,Autocuration,22224,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,U,0,1,,CHEMBL876412,,BAO_0000019,,
4907,Autocuration,22224,,,Tested for human plasma protein binding of the compound; Not tested,U,0,1,,CHEMBL619352,,BAO_0000019,,
4908,Autocuration,22224,,,Compound was tested for percent protein binding (PB) in human,U,0,1,,CHEMBL619353,,BAO_0000019,,
4909,Autocuration,22224,Plasma,,Protein binding in human plasma,U,0,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,Autocuration,22224,,,Permeability coefficient (B to A) in Caco-2 cell,U,0,1,,CHEMBL619355,,BAO_0000019,,
4911,Autocuration,22224,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,U,0,1,,CHEMBL619356,,BAO_0000019,,
4912,Autocuration,22224,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),U,0,1,,CHEMBL619357,,BAO_0000019,,
4913,Autocuration,22224,,,In vitro rate of absorption observed as Caco-2 permeability in humans,U,0,1,,CHEMBL619358,,BAO_0000019,,
4914,Autocuration,22224,,,Cellular permeability of compound was determined in Caco-2 cells; High,U,0,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,Autocuration,22224,,,Permeability in Caco-2 cells of compound,U,0,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,Autocuration,22224,,,Permeability coefficient (A to B) in Caco-2 cell,U,0,1,,CHEMBL619361,,BAO_0000019,,
4917,Autocuration,22224,,,Permeability coefficient (B to A) in Caco-2 cell,U,0,1,,CHEMBL619362,,BAO_0000019,,
4918,Autocuration,22224,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),U,0,1,,CHEMBL619363,,BAO_0000019,,
4919,Autocuration,22224,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,U,0,1,,CHEMBL618942,,BAO_0000019,,
4920,Autocuration,22224,,,Compound was tested for protein binding in human plasma,U,0,1,,CHEMBL618943,,BAO_0000019,,
4921,Autocuration,22224,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,U,0,1,,CHEMBL618944,,BAO_0000019,,
4922,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,U,0,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,Intermediate,50594,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,N,1,1,,CHEMBL618946,,BAO_0000218,,
4924,Intermediate,50594,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,1,1,,CHEMBL876413,,BAO_0000218,,
4925,Intermediate,50594,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,N,1,1,,CHEMBL618947,,BAO_0000218,,
4926,Intermediate,50594,Plasma,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,N,1,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,Intermediate,50594,Plasma,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,Intermediate,50594,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,N,1,1,,CHEMBL618950,,BAO_0000218,,
4929,Intermediate,50594,,,Tmax after oral administration at 30 mg/kg in ICR mouse,N,1,1,,CHEMBL618951,,BAO_0000218,,
4930,Intermediate,50594,,,Tmax after peroral administration in mice at 2.4 uM/kg,N,1,1,,CHEMBL618952,,BAO_0000218,,
4931,Intermediate,50594,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,N,1,1,,CHEMBL618953,,BAO_0000218,,
4932,Intermediate,50594,Brain,,Tmax in brain of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,Intermediate,50594,Kidney,,Tmax in kidney of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,Intermediate,50594,Liver,,Tmax in liver of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,Intermediate,50594,Lung,,Tmax in lungs of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,Intermediate,50594,,,Tmax in mice at 18 uM/kg i.p. administration,N,1,1,,CHEMBL618958,,BAO_0000218,,
4937,Intermediate,50594,,,Tmax in mice at 23 uM/kg i.v. administration,N,1,1,,CHEMBL618959,,BAO_0000218,,
4938,Intermediate,50594,,,Tmax in mice at 25 uM/kg i.p. administration,N,1,1,,CHEMBL618960,,BAO_0000218,,
4939,Intermediate,50594,,,Tmax in mice at 26 uM/kg i.p. administration,N,1,1,,CHEMBL876723,,BAO_0000218,,
4940,Intermediate,50594,Spleen,,Tmax in spleen of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,Intermediate,50594,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL618962,,BAO_0000218,,
4942,Intermediate,50594,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL618963,,BAO_0000218,,
4943,Intermediate,50594,,,Tmax value in IRC mice,N,1,1,,CHEMBL618964,,BAO_0000218,,
4944,Intermediate,50594,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL618965,,BAO_0000218,,
4945,Intermediate,50594,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL618966,,BAO_0000218,,
4946,Intermediate,50594,Urine,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),N,1,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,Intermediate,50594,Urine,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),N,1,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,Intermediate,50594,Urine,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),N,1,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,Intermediate,50594,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL618970,,BAO_0000218,,
4950,Intermediate,50594,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL618971,,BAO_0000218,,
4951,Intermediate,50594,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,1,1,,CHEMBL618972,,BAO_0000218,,
4952,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,N,1,1,,CHEMBL618973,,BAO_0000218,,
4953,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,N,1,1,,CHEMBL618974,,BAO_0000218,,
4954,Intermediate,50594,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,1,1,,CHEMBL618975,,BAO_0000218,,
4955,Intermediate,50594,,,Vd in mice,N,1,1,,CHEMBL618976,,BAO_0000218,,
4956,Intermediate,50594,,,Volume of distribution in mouse,N,1,1,,CHEMBL618977,,BAO_0000218,,
4957,Intermediate,50594,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL876724,,BAO_0000218,,
4958,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,N,1,1,,CHEMBL618978,,BAO_0000218,,
4959,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,N,1,1,,CHEMBL618979,,BAO_0000218,,
4960,Intermediate,50594,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,N,1,1,,CHEMBL618980,,BAO_0000218,,
4961,Intermediate,50594,,,Pharmacokinetic property (vdss) was measured in mouse,N,1,1,,CHEMBL618981,,BAO_0000218,,
4962,Intermediate,50594,,,Value distribution upon iv administration in mouse,N,1,1,,CHEMBL618982,,BAO_0000218,,
4963,Intermediate,50594,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL620150,,BAO_0000218,,
4964,Intermediate,50594,,,Volume of distribution was evaluated in mice after intravenous administration,N,1,1,,CHEMBL620151,,BAO_0000218,,
4965,Intermediate,50594,,,Volume of distribution was evaluated in mice after oral administration,N,1,1,,CHEMBL620152,,BAO_0000218,,
4966,Intermediate,50594,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,N,1,1,,CHEMBL620153,,BAO_0000218,,
4967,Intermediate,50594,,,Steady state volume of distribution was determined in mice,N,1,1,,CHEMBL876395,,BAO_0000218,,
4968,Intermediate,50594,,,Volume distribution (steady state) of compound was determined in mouse,N,1,1,,CHEMBL620154,,BAO_0000218,,
4969,Intermediate,50594,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL620155,,BAO_0000218,,
4970,Intermediate,50594,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL620156,,BAO_0000218,,
4971,Intermediate,50594,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,1,1,,CHEMBL620157,,BAO_0000218,,
4972,Intermediate,50594,Kidney,,Biodistribution of compound (oxidized form) in in kidney tissue,N,1,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,Intermediate,50594,Blood,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,1,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,Intermediate,50594,Blood,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,1,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,Intermediate,50594,Blood,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,Intermediate,80019,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,Expert,80852,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,N,1,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,Expert,80852,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,N,1,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,Expert,80852,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,N,1,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,Expert,80852,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,N,1,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,Expert,80852,,,Inhibition of A431 human carcinoma cell proliferation,N,1,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,Expert,80852,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,N,1,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,Intermediate,80852,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,N,1,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,Intermediate,80852,,,In vitro cytotoxicity against epidermoid carcinoma cell line,N,1,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,Expert,9,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",D,9,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,Intermediate,80852,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,N,1,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,Intermediate,80852,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,N,1,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,Intermediate,80852,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,N,1,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,Expert,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,H,8,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,Expert,80852,,,Tested for antiproliferative activity against human A431 cells,N,1,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,Expert,9,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,D,9,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,Expert,80852,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,N,1,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,Expert,80852,,,Inhibition of A431 cell proliferation,N,1,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,Expert,80852,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,N,1,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,Expert,80852,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),N,1,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,Intermediate,80852,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,N,1,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,Intermediate,80852,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,N,1,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,Intermediate,80852,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,N,1,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,Intermediate,80852,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,N,1,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,Expert,9,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,H,8,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,Intermediate,80852,,,In vivo antiproliferative activity against A431 cell line,N,1,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,Expert,9,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,D,9,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,Expert,80852,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,N,1,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,Expert,9,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,D,9,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,Intermediate,80852,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),N,1,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,Intermediate,80852,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),N,1,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,Intermediate,80852,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),N,1,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,Expert,9,,,Inhibition of EGFR overexpressing A431 cell proliferation,D,9,1,,CHEMBL621154,,BAO_0000019,,
5009,Expert,80852,,,Inhibition of A431 cell proliferation,N,1,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,Expert,9,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,D,9,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,Expert,9,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",D,9,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,Expert,9,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),H,8,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,Intermediate,80852,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,1,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,Intermediate,80852,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,1,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,N,1,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,N,1,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,Intermediate,80852,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,1,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,N,1,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,N,1,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,Autocuration,22224,,,Half-life period in cynomolgus monkey,U,0,1,,CHEMBL619159,,BAO_0000019,,
5021,Autocuration,22224,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",U,0,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,Autocuration,22224,,,Longer half-life in monkey (i.v.) at 0.5 mpk,U,0,1,,CHEMBL619161,,BAO_0000218,,
5023,Autocuration,22224,Plasma,,Plasma half life in monkey,U,0,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,Autocuration,22224,Plasma,,Plasma half-life in rhesus monkey,U,0,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,0,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,Autocuration,22224,,,Tested for half life upon iv administration to african green monkey,U,0,1,,CHEMBL619321,,BAO_0000218,,
5028,Autocuration,22224,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL873336,,BAO_0000218,,
5029,Autocuration,22224,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,0,1,,CHEMBL619322,,BAO_0000218,,
5030,Autocuration,22224,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,0,1,,CHEMBL619323,,BAO_0000218,,
5031,Autocuration,22224,,,The time for peak concentration value after oral administration in cynomolgus monkeys,U,0,1,,CHEMBL619324,,BAO_0000218,,
5032,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,U,0,1,,CHEMBL619325,,BAO_0000019,,
5033,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,U,0,1,,CHEMBL876411,,BAO_0000019,,
5034,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,U,0,1,,CHEMBL619326,,BAO_0000019,,
5035,Autocuration,22224,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,U,0,1,,CHEMBL619327,,BAO_0000019,,
5036,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,U,0,1,,CHEMBL619328,,BAO_0000019,,
5037,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,U,0,1,,CHEMBL619329,,BAO_0000019,,
5038,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,U,0,1,,CHEMBL619330,,BAO_0000019,,
5039,Autocuration,22224,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,U,0,1,,CHEMBL619331,,BAO_0000019,,
5040,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,U,0,1,,CHEMBL619332,,BAO_0000019,,
5041,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,U,0,1,,CHEMBL619333,,BAO_0000019,,
5042,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,U,0,1,,CHEMBL619334,,BAO_0000019,,
5043,Autocuration,22224,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,U,0,1,,CHEMBL619335,,BAO_0000019,,
5044,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,U,0,1,,CHEMBL619336,,BAO_0000019,,
5045,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,U,0,1,,CHEMBL619337,,BAO_0000019,,
5046,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,U,0,1,,CHEMBL619338,,BAO_0000019,,
5047,Autocuration,22224,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,U,0,1,,CHEMBL619339,,BAO_0000019,,
5048,Intermediate,50597,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,1,1,,CHEMBL619340,,BAO_0000218,,
5049,Intermediate,50597,Plasma,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,Intermediate,50597,Plasma,,AUC value in rat after IV administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,Intermediate,50597,Plasma,,AUC value in rat after oral administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,Intermediate,50597,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619343,,BAO_0000218,,
5053,Intermediate,50597,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619344,,BAO_0000218,,
5054,Intermediate,50597,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619345,,BAO_0000218,,
5055,Intermediate,50597,,,Vc value in rat after IV administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619346,,BAO_0000218,,
5056,Intermediate,50597,,,Half life period in rat after IV administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619347,,BAO_0000218,,
5057,Autocuration,22224,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,0,1,,CHEMBL619348,,BAO_0000019,,
5058,Autocuration,22224,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),U,0,1,,CHEMBL619349,,BAO_0000019,,
5059,Autocuration,22224,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),U,0,1,,CHEMBL619350,,BAO_0000019,,
5060,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,U,0,1,,CHEMBL619351,,BAO_0000019,,
5061,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,U,0,1,,CHEMBL875953,,BAO_0000019,,
5062,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,U,0,1,,CHEMBL621716,,BAO_0000019,,
5063,Autocuration,22224,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,U,0,1,,CHEMBL621717,,BAO_0000019,,
5064,Autocuration,22224,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,0,1,,CHEMBL621718,,BAO_0000019,,
5065,Autocuration,22224,,,Area under curve after 1 mpk peroral administration to beagles,U,0,1,,CHEMBL621719,,BAO_0000019,,
5066,Autocuration,22224,,,Area under curve after 2 mpk peroral administration to beagles,U,0,1,,CHEMBL621720,,BAO_0000019,,
5067,Autocuration,22224,,,Cmax value after 1 mpk peroral administration to beagles,U,0,1,,CHEMBL621721,,BAO_0000218,,
5068,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,U,0,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,U,0,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,U,0,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,U,0,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,U,0,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,U,0,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,Autocuration,22224,Urine,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,U,0,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,Autocuration,22224,Liver,,Metabolic stability observed at 30 min after administration in human liver microsomes,U,0,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,Autocuration,22224,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,U,0,1,,CHEMBL623448,,BAO_0000019,,
5077,Autocuration,22224,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,U,0,1,,CHEMBL623449,,BAO_0000019,,
5078,Autocuration,22224,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,U,0,1,,CHEMBL623450,,BAO_0000019,,
5079,Autocuration,22224,Liver,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",U,0,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,Autocuration,22224,,,Metabolic stability (% remaining at 30 mins) in human S9.,U,0,1,,CHEMBL623452,,BAO_0000019,,
5081,Autocuration,22224,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,U,0,1,,CHEMBL623453,,BAO_0000019,,
5082,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes,U,0,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,U,0,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,Autocuration,22224,Liver,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,U,0,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,Autocuration,22224,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,U,0,1,,CHEMBL624372,,BAO_0000218,,
5086,Autocuration,22224,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,U,0,1,,CHEMBL624373,,BAO_0000019,,
5087,Autocuration,22224,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,U,0,1,,CHEMBL624374,,BAO_0000019,,
5088,Autocuration,22224,,,The percent remaining in human plasma after 30 min was determined,U,0,1,,CHEMBL624556,,BAO_0000019,,
5089,Autocuration,22224,Plasma,,Conversion rate of the prodrug in human plasma,U,0,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,Autocuration,22224,Plasma,,Conversion rate of the prodrug in human plasma; ND means no data,U,0,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,Autocuration,22224,Blood,,Half life of compound was determined in human blood,U,0,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,Autocuration,22224,,,Half life of compound was determined in man with once daily dosing,U,0,1,,CHEMBL624560,,BAO_0000019,,
5093,Autocuration,22224,,,Half life in human microsomes,U,0,1,,CHEMBL624561,,BAO_0000251,,
5094,Autocuration,22224,Plasma,,Half life in human plasma,U,0,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,Autocuration,22224,Plasma,,Half life in human plasma; Not detected,U,0,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,Autocuration,22224,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,U,0,1,,CHEMBL624564,,BAO_0000218,,
5097,Autocuration,22224,Liver,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,U,0,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,Autocuration,22224,Plasma,,Half-life in human plasma,U,0,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,Autocuration,22224,Plasma,,Half-life of the parent prodrug in plasma,U,0,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,Autocuration,22224,Plasma,,In vitro half life in human plasma was determined,U,0,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,Autocuration,22224,Liver,,The compound was tested In Vitro for half life in human liver microsomes.,U,0,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,Autocuration,22224,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,U,0,1,,CHEMBL624568,,BAO_0000218,,
5103,Autocuration,22224,,,Observed volume of distribution,U,0,1,,CHEMBL624569,,BAO_0000218,,
5104,Autocuration,22224,,,Oral bioavailability in human,U,0,1,,CHEMBL624570,,BAO_0000218,,
5105,Autocuration,22224,,,Tested for human plasma protein binding of the compound,U,0,1,,CHEMBL624571,,BAO_0000019,,
5106,Autocuration,22224,,,"First order rate constant, k was determined in human plasma",U,0,1,,CHEMBL624572,,BAO_0000019,,
5107,Autocuration,22224,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,0,1,,CHEMBL624573,,BAO_0000019,,
5108,Autocuration,22224,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,0,1,,CHEMBL875153,,BAO_0000019,,
5109,Autocuration,22224,Liver,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,U,0,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,Autocuration,22224,,,The compound was tested for the plasma binding in human,U,0,1,,CHEMBL624575,,BAO_0000019,,
5111,Autocuration,22224,,,Plasma protein binding (human),U,0,1,,CHEMBL624576,,BAO_0000019,,
5112,Autocuration,22224,Liver,,Compound was evaluated for half-life in human liver microsomes,U,0,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,Autocuration,22224,Blood,,Half life measured in vitro for its stability in human blood,U,0,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,Autocuration,22224,Serum,,Half life in human serum,U,0,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,Autocuration,22224,Serum,,Half life in human serum; ND=not determined,U,0,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,Autocuration,22224,,,Half life were determined in CEM-SS cell extract in decomposition step 1,U,0,1,,CHEMBL622798,,BAO_0000019,,
5117,Autocuration,22224,,,Half life were determined in CEM-SS cell extract in decomposition step 2,U,0,1,,CHEMBL622799,,BAO_0000019,,
5118,Autocuration,22224,Plasma,,Half life of the in human plasma,U,0,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,Autocuration,22224,,,Half life period in human hepatic S9 fraction was determined,U,0,1,,CHEMBL622801,,BAO_0000220,,
5120,Autocuration,22224,Liver,,Half life period in human liver microsome was determined,U,0,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,Autocuration,22224,,,Half life period was determined; 6-7,U,0,1,,CHEMBL622803,,BAO_0000019,,
5122,Autocuration,22224,,,Half life period was evaluated in human,U,0,1,,CHEMBL875154,,BAO_0000019,,
5123,Autocuration,22224,Plasma,,Half life time in human plasma,U,0,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,Intermediate,50594,Brain,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,Intermediate,50594,Heart,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,Intermediate,50594,Heart,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,1,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,Intermediate,50594,Kidney,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,Intermediate,50594,Liver,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,Intermediate,50594,Liver,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,1,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,Intermediate,50594,Liver,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,Intermediate,50594,Spleen,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,1,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,Intermediate,50594,Spleen,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,1,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,Intermediate,50594,Spleen,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,Intermediate,50594,Brain,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,Intermediate,50594,Blood,,Biodistribution of compound (oxidized form) in blood tissue,N,1,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,Intermediate,50594,Blood,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,Intermediate,50594,Brain,,Biodistribution of compound (oxidized form) in brain tissue of mice,N,1,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,Intermediate,50594,Brain,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,Intermediate,50594,Heart,,Biodistribution of compound (oxidized form) in heart tissue of mice,N,1,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,Intermediate,50594,Heart,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,Intermediate,50594,Kidney,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,Intermediate,50594,Liver,,Biodistribution of compound (oxidized form) in liver tissue,N,1,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,N,1,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,Intermediate,80852,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,1,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",N,1,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",N,1,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,Expert,9,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,9,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,Intermediate,80852,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",N,1,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,Intermediate,80852,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,N,1,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,Expert,9,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,D,9,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,Expert,9,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,D,9,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",N,1,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,1,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,1,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",N,1,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",N,1,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,Expert,9,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",D,9,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,Expert,9,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,H,8,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",N,1,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,1,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,Expert,80852,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,1,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,Expert,80852,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",N,1,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,Expert,80852,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",N,1,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,Expert,80852,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,1,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,Expert,80852,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,1,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,Expert,80852,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,N,1,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,Intermediate,80852,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,N,1,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,Intermediate,80852,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,N,1,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,Intermediate,80852,,,Dose giving a 50% decrease in the living cell number (A437 cells),N,1,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,Expert,80682,,,In vitro inhibitory concentration against proliferation of A459 cell line.,N,1,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,Intermediate,80682,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,N,1,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,Intermediate,80682,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,N,1,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,Intermediate,80021,,,In vitro antitumor activity against renal A498 tumor cell lines,N,1,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,Intermediate,80021,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",N,1,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,Intermediate,80021,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",N,1,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,Intermediate,80021,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,N,1,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,Intermediate,80021,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,N,1,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,Intermediate,80021,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,N,1,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,Intermediate,80021,,,Cytotoxicity on kidney carcinoma (A-498) cell line,N,1,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,Intermediate,80021,,,Compound was evaluated against Human cell line renal A498,N,1,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,Intermediate,80021,,,Compound was tested for inhibition of A498 human renal cancer cell line,N,1,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,Intermediate,80021,,,Growth inhibitory activity against A498 human cancer cell line,N,1,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,Intermediate,80021,,,In vitro antitumor activity against human renal A498 cell line,N,1,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,Intermediate,80021,,,In vitro cytotoxic activity against renal (A498) cell line,N,1,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,Intermediate,80021,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,N,1,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,Intermediate,80021,,,Tested for cytostatic activity against renal A498 cell line,N,1,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,Intermediate,80021,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,N,1,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,Expert,80021,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,N,1,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,Autocuration,22224,,,Cmax value after 2 mpk peroral administration to beagles,U,0,1,,CHEMBL624629,,BAO_0000218,,
5210,Autocuration,22224,,,Bioavailability,U,0,1,,CHEMBL623551,,BAO_0000218,,
5211,Autocuration,22224,,,Bioavailability after 1 mpk peroral administration to beagles,U,0,1,,CHEMBL623552,,BAO_0000218,,
5212,Autocuration,22224,,,Bioavailability after 2 mpk peroral administration to beagles,U,0,1,,CHEMBL623553,,BAO_0000218,,
5213,Autocuration,22224,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,U,0,1,,CHEMBL623554,,BAO_0000019,,
5214,Autocuration,22224,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,U,0,1,,CHEMBL623555,,BAO_0000019,,
5215,Autocuration,22224,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,U,0,1,,CHEMBL623556,,BAO_0000019,,
5216,Autocuration,22224,,,Solubility against bovine alpha-chymotrypsin,U,0,1,,CHEMBL623557,,BAO_0000019,,
5217,Autocuration,22224,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,0,1,,CHEMBL623558,,BAO_0000019,,
5218,Autocuration,22224,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,0,1,,CHEMBL623559,,BAO_0000019,,
5219,Autocuration,22224,Spleen,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,U,0,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,Autocuration,22224,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,U,0,1,,CHEMBL623561,,BAO_0000019,,
5221,Autocuration,22224,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,U,0,1,,CHEMBL623562,,BAO_0000019,,
5222,Autocuration,22224,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,U,0,1,,CHEMBL623563,,BAO_0000019,,
5223,Autocuration,22224,Spleen,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,U,0,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,Autocuration,22224,,,Half life in presence of 2 mg/mL BSA at pH 8.8,U,0,1,,CHEMBL873806,,BAO_0000019,,
5225,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,U,0,1,,CHEMBL623565,,BAO_0000019,,
5226,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,U,0,1,,CHEMBL623566,,BAO_0000019,,
5227,Autocuration,22224,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,U,0,1,,CHEMBL623567,,BAO_0000019,,
5228,Autocuration,22224,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),U,0,1,,CHEMBL623568,,BAO_0000019,,
5229,Intermediate,50588,Plasma,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,N,1,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,Intermediate,50588,Plasma,,AUC after administration at 100 mg/kg/day in dogs,N,1,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,Intermediate,50588,Plasma,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,N,1,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,Intermediate,50588,Plasma,,AUC value after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,Intermediate,50588,Plasma,,AUC value after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,Intermediate,50588,Plasma,,AUC value after administration of 4 mg/Kg oral dose in dog,N,1,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,Intermediate,50588,Plasma,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,N,1,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,Intermediate,50588,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,N,1,1,,CHEMBL875277,,BAO_0000218,,
5237,Intermediate,50588,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,N,1,1,,CHEMBL622667,,BAO_0000218,,
5238,Intermediate,50588,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,N,1,1,,CHEMBL622668,,BAO_0000218,,
5239,Intermediate,50588,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,N,1,1,,CHEMBL622669,,BAO_0000218,,
5240,Intermediate,50588,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,N,1,1,,CHEMBL622670,,BAO_0000218,,
5241,Intermediate,50588,,,Area under curve determined in dogs after oral administration of 10 mg/kg,N,1,1,,CHEMBL622671,,BAO_0000218,,
5242,Intermediate,50588,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,1,1,,CHEMBL622672,,BAO_0000218,,
5243,Expert,50588,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL622673,,BAO_0000218,,
5244,Expert,50588,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL622674,,BAO_0000218,,
5245,Intermediate,50588,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,1,1,,CHEMBL622675,,BAO_0000218,,
5246,Intermediate,50588,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,N,1,1,,CHEMBL622676,,BAO_0000218,,
5247,Intermediate,50588,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,1,1,,CHEMBL622677,,BAO_0000218,,
5248,Intermediate,50588,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,N,1,1,,CHEMBL622678,,BAO_0000218,,
5249,Intermediate,50588,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,N,1,1,,CHEMBL622679,,BAO_0000218,,
5250,Intermediate,50588,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,1,1,,CHEMBL622680,,BAO_0000218,,
5251,Intermediate,50588,,,Area under curve was determine after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL622681,,BAO_0000218,,
5252,Intermediate,50588,,,Area under curve was determine after peroral administration at 5 mpk in dog,N,1,1,,CHEMBL875278,,BAO_0000218,,
5253,Intermediate,50588,,,Area under curve was determined,N,1,1,,CHEMBL622682,,BAO_0000218,,
5254,Intermediate,50588,,,Area under curve in dogs,N,1,1,,CHEMBL622683,,BAO_0000218,,
5255,Intermediate,50588,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,N,1,1,,CHEMBL622684,,BAO_0000218,,
5256,Intermediate,50588,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),N,1,1,,CHEMBL622685,,BAO_0000218,,
5257,Intermediate,50588,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,N,1,1,,CHEMBL622686,,BAO_0000218,,
5258,Intermediate,50588,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL618344,,BAO_0000218,,
5259,Intermediate,50588,,,Area under curve value in dog at a dose of 5 mg/kg,N,1,1,,CHEMBL875582,,BAO_0000218,,
5260,Intermediate,50588,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,N,1,1,,CHEMBL618345,,BAO_0000218,,
5261,Intermediate,50588,,,Area under curve was determined after 0.3 mg/kg po administration in dog,N,1,1,,CHEMBL618346,,BAO_0000218,,
5262,Intermediate,50588,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL618347,,BAO_0000218,,
5263,Intermediate,50588,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,N,1,1,,CHEMBL618348,,BAO_0000218,,
5264,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,U,0,1,,CHEMBL618349,,BAO_0000019,,
5265,Autocuration,22224,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,0,1,,CHEMBL618350,,BAO_0000019,,
5266,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,U,0,1,,CHEMBL618351,,BAO_0000019,,
5267,Autocuration,22224,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,U,0,1,,CHEMBL618352,,BAO_0000019,,
5268,Autocuration,22224,Blood,,Time taken to reduce 50% of the concentration of compound in blood plasma,U,0,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,Autocuration,22224,Plasma,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,0,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,Autocuration,22224,Plasma,,Half life in human plasma,U,0,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,Autocuration,22224,Plasma,,Half life in human plasma was reported,U,0,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,Autocuration,22224,Serum,,Half life in human serum,U,0,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,Autocuration,22224,Plasma,,Half life upon exposure to human plasma,U,0,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,Autocuration,22224,,,t1/2 in human microsomes,U,0,1,,CHEMBL618357,,BAO_0000251,,
5275,Autocuration,22224,Plasma,,Half life period in 80% human plasma at 37 degree Centigrade,U,0,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,Autocuration,22224,Zone of skin,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),U,0,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,Autocuration,22224,Plasma,,Half-life measured in in vitro Cathepsin B assay in human plasma,U,0,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,Autocuration,22224,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,U,0,1,,CHEMBL618361,,BAO_0000019,,
5279,Autocuration,22224,Liver,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,U,0,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,0,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,0,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,Autocuration,22224,Plasma,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,0,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,Autocuration,22224,,,Half-life in the CEM cell extracts,U,0,1,,CHEMBL618365,,BAO_0000019,,
5284,Autocuration,22224,Plasma,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,U,0,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,Autocuration,22224,Plasma,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,U,0,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,Autocuration,22224,,,Half-life was determined,U,0,1,,CHEMBL618367,,BAO_0000019,,
5287,Autocuration,22224,Blood,,Half-life (human blood stability),U,0,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,Autocuration,22224,Blood,,Half-life (human blood stability); no data,U,0,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,Autocuration,22224,Plasma,,Half-life in human plasma,U,0,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,Autocuration,22224,,,CYP3A4 metabolism half-life (t1/2),U,0,1,,CHEMBL618371,,BAO_0000019,,
5291,Autocuration,22224,Blood,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),U,0,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,Autocuration,22224,Plasma,,In vitro half life in human plasma,U,0,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,Autocuration,22224,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",U,0,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,Autocuration,22224,Plasma,,In vitro hydrolysis in human plasma,U,0,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,Autocuration,22224,Plasma,,In vitro hydrolysis in human plasma; no data,U,0,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,Autocuration,22224,Liver,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,U,0,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,Autocuration,22224,Plasma,,Plasma half life in human,U,0,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,Autocuration,22224,Plasma,,Stability after incubation with human plasma (at 37 degree C),U,0,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,Autocuration,22224,Plasma,,T1/2 was evaluated in human plasma,U,0,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,Autocuration,22224,Plasma,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,0,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,Autocuration,22224,Plasma,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",U,0,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,Autocuration,22224,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,0,1,,CHEMBL618383,,BAO_0000019,,
5303,Autocuration,22224,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,U,0,1,,CHEMBL618384,,BAO_0000019,,
5304,Autocuration,22224,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,U,0,1,,CHEMBL618385,,BAO_0000019,,
5305,Autocuration,22224,Plasma,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,U,0,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,Autocuration,22224,Plasma,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,U,0,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,Autocuration,22224,,,Time taken for 50% to be consumed by serum PON1 was determined,U,0,1,,CHEMBL619101,,BAO_0000019,,
5308,Autocuration,22224,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,U,0,1,,CHEMBL619102,,BAO_0000019,,
5309,Autocuration,22224,Liver,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,0,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL619268,,BAO_0000218,,
5311,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL619269,,BAO_0000218,,
5312,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL619270,,BAO_0000218,,
5313,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL619271,,BAO_0000218,,
5314,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL875585,,BAO_0000218,,
5315,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,0,1,,CHEMBL619272,,BAO_0000218,,
5316,Intermediate,80640,,,Compound tested for growth inhibition of renal cancer cell line 786-0,N,1,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,Intermediate,80640,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,N,1,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,Expert,80640,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,N,1,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",N,1,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",N,1,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,Intermediate,80640,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",N,1,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,Intermediate,80640,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,N,1,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,Intermediate,80640,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,N,1,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,Expert,80640,,,Cytotoxic effect on renal cancer line 786-0,N,1,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,Intermediate,80640,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,N,1,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,Intermediate,80640,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,Intermediate,80640,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",N,1,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,Intermediate,80640,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,N,1,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,Intermediate,80640,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,1,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,Intermediate,80640,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),N,1,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,Intermediate,80640,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,N,1,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,Intermediate,80640,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,1,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,Intermediate,80640,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),N,1,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,N,1,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),N,1,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,N,1,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),N,1,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),N,1,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,N,1,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),N,1,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),N,1,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),N,1,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,Intermediate,80641,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,N,1,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,Intermediate,80640,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,N,1,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,Intermediate,22226,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,U,0,1,,CHEMBL619299,,BAO_0000019,,
5346,Expert,80433,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,N,1,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,Expert,80433,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,N,1,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,Intermediate,80433,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,N,1,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,1,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,1,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,1,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,1,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,1,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,Intermediate,80433,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,Intermediate,80021,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,Intermediate,80021,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,N,1,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,Intermediate,80021,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),N,1,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,Intermediate,80021,,,In vitro inhibitory concentration against renal cancer cell line A498,N,1,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,Intermediate,80021,,,Cytotoxicity against A 498 tumor cell line,N,1,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,Intermediate,80021,,,In vitro antitumor activity against A498 human cancer cell line,N,1,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,Intermediate,80021,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),N,1,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,Intermediate,80021,,,Inhibitory dose required against A498 human tumor cell lines,N,1,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,Intermediate,80021,,,Anticancer activity against one renal cancer (A498 cell line),N,1,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,Intermediate,80021,,,In vitro cytotoxicity against melanoma A498 cell line,N,1,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,Intermediate,80021,,,Compound was tested for growth inhibitory activity against A498 cell line,N,1,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,Intermediate,80021,,,Compound tested for growth inhibition of renal cancer cell line A498,N,1,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,Intermediate,80021,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,N,1,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,Intermediate,80021,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,N,1,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,Intermediate,80021,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,N,1,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,Intermediate,80021,,,Tested for cytotoxicity against A498 cell lines in renal cancer,N,1,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,Intermediate,80021,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,N,1,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,Expert,80021,,,Cytotoxic effect on renal cancer lines A498,N,1,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,Intermediate,80021,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,N,1,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,Intermediate,80021,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,Intermediate,80021,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,N,1,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,Intermediate,80021,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,N,1,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,Intermediate,80021,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,N,1,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,Intermediate,80021,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,Expert,80682,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,N,1,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line,N,1,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,N,1,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,Intermediate,80682,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,N,1,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,Intermediate,80682,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",N,1,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,Expert,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,N,1,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,Intermediate,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,Expert,80682,,,In vitro cytotoxic activity against human lung A549 cell line,N,1,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),N,1,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line),N,1,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,Intermediate,80682,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,N,1,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,Expert,80682,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,N,1,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,Intermediate,80682,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",N,1,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,Intermediate,80682,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",N,1,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,Expert,80682,,,Inhibition of A549 human lung carcinoma cell proliferation,N,1,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,1,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,Intermediate,80682,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,N,1,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,Intermediate,80682,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,N,1,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,Intermediate,80682,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,N,1,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,Intermediate,80682,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,Intermediate,80682,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,N,1,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,Intermediate,80682,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,1,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,Expert,80682,,,Inhibition of A549 cancer cell proliferation,N,1,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,Expert,80682,,,Inhibition of A549 cancer cell proliferation (Not tested),N,1,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,Intermediate,80682,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,1,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,Intermediate,80682,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,N,1,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,Intermediate,80682,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,N,1,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,Intermediate,80682,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,N,1,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,Intermediate,80682,,,Cytotoxicity against Renal cell lines A549 was determined,N,1,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,Intermediate,50588,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,N,1,1,,CHEMBL620279,,BAO_0000218,,
5412,Intermediate,50588,,,Area under curve was determined in dog after oral administration at 1 mg/kg,N,1,1,,CHEMBL620280,,BAO_0000218,,
5413,Intermediate,50588,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL620281,,BAO_0000218,,
5414,Intermediate,50588,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL620282,,BAO_0000218,,
5415,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),N,1,1,,CHEMBL621134,,BAO_0000218,,
5416,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),N,1,1,,CHEMBL621135,,BAO_0000218,,
5417,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),N,1,1,,CHEMBL621136,,BAO_0000218,,
5418,Intermediate,50588,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),N,1,1,,CHEMBL621137,,BAO_0000218,,
5419,Intermediate,50588,Plasma,,Area under plasma concentration time curve in dog upon oral administration,N,1,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,Intermediate,50588,Plasma,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,N,1,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,Intermediate,50588,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,N,1,1,,CHEMBL621139,,BAO_0000218,,
5422,Intermediate,50588,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,N,1,1,,CHEMBL621140,,BAO_0000218,,
5423,Intermediate,50588,,,Area under the curve for the compound was obtained when tested in dog,N,1,1,,CHEMBL621141,,BAO_0000218,,
5424,Intermediate,50588,,,Area under the curve at a dose of 1 mg/kg,N,1,1,,CHEMBL621142,,BAO_0000218,,
5425,Intermediate,50588,,,Area under the curve at a dose of 1 mg/kg (oral),N,1,1,,CHEMBL621143,,BAO_0000218,,
5426,Intermediate,50588,,,Area under the curve at i.v. dose of 0.2 mg/kg,N,1,1,,CHEMBL621144,,BAO_0000218,,
5427,Intermediate,50588,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,N,1,1,,CHEMBL621145,,BAO_0000218,,
5428,Intermediate,50588,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL621146,,BAO_0000218,,
5429,Intermediate,50588,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,N,1,1,,CHEMBL622567,,BAO_0000218,,
5430,Intermediate,50588,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,N,1,1,,CHEMBL622568,,BAO_0000218,,
5431,Intermediate,50588,,,Compound was evaluated for area under the curve in dog blood.,N,1,1,,CHEMBL622569,,BAO_0000218,,
5432,Intermediate,50588,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,N,1,1,,CHEMBL622570,,BAO_0000218,,
5433,Intermediate,50588,Plasma,,AUC in dog after oral dose (1 mg/kg),N,1,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,Intermediate,50588,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,N,1,1,,CHEMBL622572,,BAO_0000218,,
5435,Intermediate,50588,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",N,1,1,,CHEMBL622573,,BAO_0000218,,
5436,Intermediate,50588,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,N,1,1,,CHEMBL622574,,BAO_0000218,,
5437,Intermediate,50588,,,Pharmacokinetic parameter AUC after oral administration to dogs,N,1,1,,CHEMBL622575,,BAO_0000218,,
5438,Intermediate,50588,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,N,1,1,,CHEMBL622576,,BAO_0000218,,
5439,Intermediate,50588,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,N,1,1,,CHEMBL622577,,BAO_0000218,,
5440,Intermediate,50588,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,N,1,1,,CHEMBL622578,,BAO_0000218,,
5441,Intermediate,50588,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,N,1,1,,CHEMBL622579,,BAO_0000218,,
5442,Intermediate,50588,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",N,1,1,,CHEMBL622580,,BAO_0000218,,
5443,Intermediate,50588,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",N,1,1,,CHEMBL622581,,BAO_0000218,,
5444,Intermediate,50588,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,1,1,,CHEMBL622582,,BAO_0000218,,
5445,Intermediate,50588,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,1,1,,CHEMBL622583,,BAO_0000218,,
5446,Intermediate,50588,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,1,1,,CHEMBL622584,,BAO_0000218,,
5447,Intermediate,50588,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,1,1,,CHEMBL622585,,BAO_0000218,,
5448,Intermediate,50588,,,Compound was evaluated for oral bioavailability in dog; 90-100,N,1,1,,CHEMBL622586,,BAO_0000218,,
5449,Intermediate,50588,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,N,1,1,,CHEMBL623281,,BAO_0000218,,
5450,Intermediate,50588,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,N,1,1,,CHEMBL623282,,BAO_0000218,,
5451,Intermediate,50588,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,N,1,1,,CHEMBL623283,,BAO_0000218,,
5452,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623284,,BAO_0000218,,
5453,Intermediate,50588,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,N,1,1,,CHEMBL623285,,BAO_0000218,,
5454,Intermediate,50588,Plasma,,Plasma protein binding towards dog plasma at 10 uM,N,1,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,Intermediate,50588,Plasma,,Plasma protein binding towards dog plasma at 100 uM,N,1,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,Intermediate,50588,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,1,1,,CHEMBL621705,,BAO_0000218,,
5457,Intermediate,50588,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,N,1,1,,CHEMBL621706,,BAO_0000218,,
5458,Intermediate,50588,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,N,1,1,,CHEMBL621707,,BAO_0000218,,
5459,Intermediate,50588,,,Bioavailability in dogs,N,1,1,,CHEMBL621708,,BAO_0000218,,
5460,Intermediate,50588,,,Bioavailability,N,1,1,,CHEMBL621709,,BAO_0000218,,
5461,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL621710,,BAO_0000218,,
5462,Intermediate,50588,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,N,1,1,,CHEMBL621711,,BAO_0000218,,
5463,Intermediate,50588,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),N,1,1,,CHEMBL621712,,BAO_0000218,,
5464,Intermediate,50588,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,N,1,1,,CHEMBL621713,,BAO_0000218,,
5465,Intermediate,50588,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,N,1,1,,CHEMBL621714,,BAO_0000218,,
5466,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL621715,,BAO_0000218,,
5467,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,0,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,Autocuration,22224,Liver,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL623720,,BAO_0000218,,
5471,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL623721,,BAO_0000218,,
5472,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,0,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,Autocuration,22224,Muscle tissue,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,Autocuration,22224,Spleen,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,Autocuration,22224,Spleen,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,0,1,,CHEMBL618545,,BAO_0000218,,
5478,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,0,1,,CHEMBL618546,,BAO_0000218,,
5479,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL623529,,BAO_0000218,,
5480,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,0,1,,CHEMBL623530,,BAO_0000218,,
5481,Autocuration,22224,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,0,1,,CHEMBL621764,,BAO_0000218,,
5482,Autocuration,22224,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,0,1,,CHEMBL621765,,BAO_0000019,,
5483,Autocuration,22224,Cerebellum,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,0,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,Autocuration,22224,Frontal cortex,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,0,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,Autocuration,22224,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),U,0,1,,CHEMBL621768,,BAO_0000019,,
5486,Autocuration,22224,Striatum,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),U,0,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,Autocuration,22224,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,0,1,,CHEMBL621770,,BAO_0000019,,
5488,Autocuration,22224,Cerebellum,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,0,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,Autocuration,22224,Frontal cortex,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,0,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,Autocuration,22224,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),U,0,1,,CHEMBL621773,,BAO_0000019,,
5491,Autocuration,22224,Striatum,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),U,0,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,Autocuration,22224,,,Compound was evaluated for oral bioavailability in rats,U,0,1,,CHEMBL621775,,BAO_0000218,,
5493,Autocuration,22224,Plasma,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,U,0,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,Autocuration,22224,,,Half life period was evaluated in monkey,U,0,1,,CHEMBL621777,,BAO_0000019,,
5495,Autocuration,22224,,,Half-life in rhesus monkeys by intravenous administration of dose,U,0,1,,CHEMBL875162,,BAO_0000218,,
5496,Intermediate,50594,Plasma,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,N,1,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,Intermediate,50594,Plasma,,AUC after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,Intermediate,50594,Plasma,,AUC value was determined after oral administration,N,1,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,Intermediate,50594,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,1,1,,CHEMBL622480,,BAO_0000218,,
5500,Intermediate,50594,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,1,1,,CHEMBL622481,,BAO_0000218,,
5501,Intermediate,50594,,,Area under curve by ioral administration in mouse,N,1,1,,CHEMBL622482,,BAO_0000218,,
5502,Intermediate,50594,,,Area under curve by iv administration in mouse,N,1,1,,CHEMBL622483,,BAO_0000218,,
5503,Intermediate,50594,,,Area under curve at 0-8 hr in IRC mice after peroral administration,N,1,1,,CHEMBL622484,,BAO_0000218,,
5504,Intermediate,50594,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,N,1,1,,CHEMBL622641,,BAO_0000218,,
5505,Intermediate,50594,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,N,1,1,,CHEMBL622642,,BAO_0000218,,
5506,Intermediate,50594,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,N,1,1,,CHEMBL622643,,BAO_0000218,,
5507,Intermediate,50594,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,N,1,1,,CHEMBL622644,,BAO_0000218,,
5508,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,1,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,1,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,1,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,1,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,Intermediate,80433,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,1,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,1,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,1,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,1,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,1,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,Intermediate,80433,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,1,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,Expert,80433,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,N,1,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,Intermediate,80433,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,N,1,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,Intermediate,80433,,,Cytotoxicity of compound against 8226/DOX1V cells,N,1,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,Intermediate,80433,,,Cytotoxicity of compound against 8226/S cells,N,1,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,Intermediate,80433,,,Inhibitory concentration against 8226 myeloma cancer cell line,N,1,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,Intermediate,80433,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,N,1,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,Intermediate,80647,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,N,1,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,Intermediate,80647,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',N,1,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,Expert,80647,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,N,1,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,Intermediate,80647,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,N,1,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,Autocuration,22226,,,Inhibitory activity against caspase-1,U,0,1,,CHEMBL620369,,BAO_0000019,,
5535,Autocuration,45,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,H,8,1,,CHEMBL620370,,BAO_0000357,,
5536,Intermediate,80648,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,N,1,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,Intermediate,80648,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,N,1,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,Intermediate,22226,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,U,0,1,,CHEMBL876492,,BAO_0000019,,
5539,Intermediate,22226,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,U,0,1,,CHEMBL620373,,BAO_0000019,,
5540,Intermediate,22226,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,U,0,1,,CHEMBL620374,,BAO_0000019,,
5541,Autocuration,22226,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,U,0,1,,CHEMBL620375,,BAO_0000019,,
5542,Autocuration,22226,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,0,1,,CHEMBL857902,,BAO_0000019,,
5543,Autocuration,22226,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,0,1,,CHEMBL620376,,BAO_0000019,,
5544,Autocuration,11922,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,H,8,1,,CHEMBL620377,,BAO_0000357,,
5545,Intermediate,81115,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,1,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,Intermediate,81115,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,1,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,Autocuration,22226,,,In vitro cytotoxicity of compound was tested against 9KB cells.,U,0,1,,CHEMBL620380,,BAO_0000219,,
5548,Intermediate,80653,,,Cytotoxic concentration against 9L cells was determined on day 3,N,1,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,Expert,80653,,,Tested in vitro for anticancer activity against 9L cells,N,1,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,Expert,80653,,,Tested in vitro for anticancer activity against 9L cells; Not determined,N,1,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,Intermediate,80682,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,N,1,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,N,1,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,N,1,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,Intermediate,80682,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,N,1,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,Expert,80682,,,Cytotoxicity against human lung carcinoma A549 cell line,N,1,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,Expert,25,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,D,9,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,Expert,25,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",D,9,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,Intermediate,80682,,,"In vitro growth inhibition of A549, lung carcinoma",N,1,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,Intermediate,80682,,,"In vitro growth inhibition of A549, lung carcinoma.",N,1,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,Intermediate,80682,,,Cytotoxic activity against human lung cancer A549 cell line was determined,N,1,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,Expert,80682,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,N,1,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,Intermediate,80682,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,N,1,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,Expert,80682,,,Cytotoxicity in A549 (human carcinoma) cell line.,N,1,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,Intermediate,80682,,,Cytotoxicity on lung carcinoma (A-549) cell line,N,1,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,Expert,80682,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,N,1,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,Intermediate,80682,,,Effective dose of compound against replication of A549 cell line was evaluated,N,1,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,Expert,80682,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,N,1,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,Intermediate,80682,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),N,1,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,Intermediate,80682,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,N,1,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,Intermediate,80682,,,The compound was evaluated for antiproliferative activity against A549 cell line,N,1,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,Intermediate,80682,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,N,1,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,Intermediate,80682,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,N,1,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,Intermediate,80682,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,N,1,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,Intermediate,80682,,,Growth inhibition against A549 cell line was evaluated,N,1,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,Intermediate,80682,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,N,1,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,Expert,80682,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,N,1,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,Intermediate,80682,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,N,1,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,Expert,80682,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,N,1,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,Intermediate,80682,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,N,1,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,Expert,80682,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,N,1,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,Intermediate,80682,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,N,1,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,Expert,80682,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,N,1,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,Intermediate,80682,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,N,1,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,Intermediate,80682,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,1,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,Expert,80682,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,N,1,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,Intermediate,80682,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),N,1,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,Intermediate,80682,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,N,1,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,Intermediate,80682,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,N,1,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,N,1,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,1,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,1,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,N,1,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,Intermediate,80682,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,N,1,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,Intermediate,80682,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,N,1,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,Intermediate,80682,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,N,1,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,Expert,80682,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,N,1,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,Intermediate,80682,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,1,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,Intermediate,50588,,,Oral bioavailability in dog (conscious),N,1,1,,CHEMBL621441,,BAO_0000218,,
5600,Intermediate,50588,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,N,1,1,,CHEMBL621442,,BAO_0000218,,
5601,Intermediate,50588,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,N,1,1,,CHEMBL621443,,BAO_0000218,,
5602,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621444,,BAO_0000218,,
5603,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL625133,,BAO_0000218,,
5604,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL625134,,BAO_0000218,,
5605,Intermediate,50588,,,Oral bioavailability in dog (fasted),N,1,1,,CHEMBL625135,,BAO_0000218,,
5606,Intermediate,50588,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL625136,,BAO_0000218,,
5607,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL625137,,BAO_0000218,,
5608,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL625138,,BAO_0000218,,
5609,Intermediate,50588,,,Percent bioavailability in dog,N,1,1,,CHEMBL625139,,BAO_0000218,,
5610,Intermediate,50588,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,N,1,1,,CHEMBL872264,,BAO_0000218,,
5611,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL625140,,BAO_0000218,,
5612,Intermediate,50588,,,The compound was evaluated for bioavailability in dogs; 34-44,N,1,1,,CHEMBL624436,,BAO_0000218,,
5613,Intermediate,50588,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,1,1,,CHEMBL624437,,BAO_0000218,,
5614,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL872261,,BAO_0000218,,
5615,Intermediate,50588,,,8 hour trough Blood level in dog was measured after administration of compound,N,1,1,,CHEMBL624438,,BAO_0000218,,
5616,Intermediate,50588,Plasma,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,N,1,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,Intermediate,50588,,,C24 after oral administration at 5 mg/kg,N,1,1,,CHEMBL624440,,BAO_0000218,,
5618,Intermediate,50588,,,Clearance after oral and iv dosing in dogs,N,1,1,,CHEMBL624441,,BAO_0000218,,
5619,Intermediate,50588,Plasma,,Clearance of the drug was measured in the plasma of dog,N,1,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,Intermediate,50588,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,N,1,1,,CHEMBL624443,,BAO_0000218,,
5621,Intermediate,50588,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,1,1,,CHEMBL624444,,BAO_0000218,,
5622,Intermediate,50588,,,Clearance of compound was determined in dogs,N,1,1,,CHEMBL624445,,BAO_0000218,,
5623,Intermediate,50588,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,N,1,1,,CHEMBL624446,,BAO_0000218,,
5624,Intermediate,50588,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,1,1,,CHEMBL624447,,BAO_0000218,,
5625,Intermediate,50588,,,Plasma clearance in dog was determined,N,1,1,,CHEMBL624448,,BAO_0000218,,
5626,Intermediate,50588,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,1,1,,CHEMBL624449,,BAO_0000218,,
5627,Intermediate,50588,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,N,1,1,,CHEMBL624450,,BAO_0000218,,
5628,Intermediate,50588,,,Plasma clearance in dog after administration of 1 mg/kg iv,N,1,1,,CHEMBL875942,,BAO_0000218,,
5629,Intermediate,50588,,,Plasma clearance in dogs,N,1,1,,CHEMBL624451,,BAO_0000218,,
5630,Intermediate,50588,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,N,1,1,,CHEMBL624452,,BAO_0000218,,
5631,Intermediate,50588,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,1,1,,CHEMBL624453,,BAO_0000218,,
5632,Intermediate,50588,,,Plasma clearance after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL624454,,BAO_0000218,,
5633,Intermediate,50588,,,Plasma clearance after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL624455,,BAO_0000218,,
5634,Intermediate,50588,,,Plasma administration to dogs,N,1,1,,CHEMBL624456,,BAO_0000218,,
5635,Intermediate,50588,,,Plasma clearance was determined,N,1,1,,CHEMBL624457,,BAO_0000218,,
5636,Intermediate,50588,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,N,1,1,,CHEMBL624458,,BAO_0000218,,
5637,Intermediate,50588,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,N,1,1,,CHEMBL624459,,BAO_0000218,,
5638,Intermediate,102164,Liver,,Intrinsic clearance in human liver microsomes,S,2,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,Intermediate,102164,Liver,,Intrinsic clearance in human liver microsomes,S,2,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,1,1,,CHEMBL875943,,BAO_0000218,,
5641,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,1,1,,CHEMBL624462,,BAO_0000218,,
5642,Intermediate,50588,,,Clearance in dog (dose 1 mg/kg i.v.),N,1,1,,CHEMBL624463,,BAO_0000218,,
5643,Intermediate,50588,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,N,1,1,,CHEMBL624464,,BAO_0000218,,
5644,Intermediate,50588,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,1,1,,CHEMBL624465,,BAO_0000218,,
5645,Intermediate,50588,,,Plasma clearance after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL624466,,BAO_0000218,,
5646,Intermediate,50588,,,Plasma clearance after peroral administration at 5 mpk in dog,N,1,1,,CHEMBL624467,,BAO_0000218,,
5647,Intermediate,50588,,,Plasma clearance after peroral administration at 5 mg/kg in dog,N,1,1,,CHEMBL624468,,BAO_0000218,,
5648,Intermediate,50588,,,Plasma clearance was measured in dog,N,1,1,,CHEMBL624469,,BAO_0000218,,
5649,Intermediate,50588,,,Plasma clearance was measured in dog,N,1,1,,CHEMBL624470,,BAO_0000218,,
5650,Intermediate,50588,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,N,1,1,,CHEMBL624471,,BAO_0000218,,
5651,Intermediate,50588,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,N,1,1,,CHEMBL624472,,BAO_0000218,,
5652,Intermediate,50588,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL622775,,BAO_0000218,,
5653,Intermediate,50588,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,N,1,1,,CHEMBL622776,,BAO_0000218,,
5654,Intermediate,50588,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,N,1,1,,CHEMBL622777,,BAO_0000218,,
5655,Intermediate,50588,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,N,1,1,,CHEMBL622778,,BAO_0000218,,
5656,Intermediate,50588,,,Clearance by intravenous administration of 1.2 mg/kg in dog,N,1,1,,CHEMBL622779,,BAO_0000218,,
5657,Intermediate,50588,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,N,1,1,,CHEMBL622780,,BAO_0000218,,
5658,Intermediate,50588,Plasma,,Clearance value was evaluated in dog plasma,N,1,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,Intermediate,50588,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,1,1,,CHEMBL622782,,BAO_0000218,,
5660,Intermediate,50588,Plasma,,Compound was tested for plasma clearance in dog,N,1,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,Intermediate,50588,,,Pharmacokinetic property (Plasma clearance) was measured in dog,N,1,1,,CHEMBL622784,,BAO_0000218,,
5662,Intermediate,50594,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,N,1,1,,CHEMBL622785,,BAO_0000218,,
5663,Intermediate,50594,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,N,1,1,,CHEMBL622786,,BAO_0000218,,
5664,Intermediate,50594,,,Area under curve value in mouse at a dose of 10 mg/kg,N,1,1,,CHEMBL622787,,BAO_0000218,,
5665,Intermediate,50594,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL875949,,BAO_0000218,,
5666,Intermediate,50594,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL622788,,BAO_0000218,,
5667,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,1,1,,CHEMBL622789,,BAO_0000218,,
5668,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,1,1,,CHEMBL622790,,BAO_0000218,,
5669,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,1,1,,CHEMBL622791,,BAO_0000218,,
5670,Intermediate,50594,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,1,1,,CHEMBL622792,,BAO_0000218,,
5671,Intermediate,50594,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL622793,,BAO_0000218,,
5672,Intermediate,50594,,,Area under curve was determined for the compound at 24 mg/Kg,N,1,1,,CHEMBL622794,,BAO_0000218,,
5673,Intermediate,50594,,,Area under curve was determined for the compound at 40 mg/Kg,N,1,1,,CHEMBL622795,,BAO_0000218,,
5674,Intermediate,50594,,,Area under curve was determined for the compound at 5 mg/Kg,N,1,1,,CHEMBL621803,,BAO_0000218,,
5675,Intermediate,50594,,,Area under the curve for the compound is obtained at dose 25 mg/kg,N,1,1,,CHEMBL621804,,BAO_0000218,,
5676,Intermediate,50594,,,Area under the curve for the compound was obtained when tested in mouse,N,1,1,,CHEMBL621805,,BAO_0000218,,
5677,Intermediate,50594,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,N,1,1,,CHEMBL621806,,BAO_0000218,,
5678,Intermediate,50594,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,N,1,1,,CHEMBL621807,,BAO_0000218,,
5679,Intermediate,50594,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,N,1,1,,CHEMBL621808,,BAO_0000218,,
5680,Intermediate,50594,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,N,1,1,,CHEMBL621809,,BAO_0000218,,
5681,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,1,1,,CHEMBL621810,,BAO_0000218,,
5682,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,1,1,,CHEMBL875164,,BAO_0000218,,
5683,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,1,1,,CHEMBL621811,,BAO_0000218,,
5684,Intermediate,50594,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",N,1,1,,CHEMBL621812,,BAO_0000218,,
5685,Intermediate,50594,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),N,1,1,,CHEMBL621813,,BAO_0000218,,
5686,Intermediate,50594,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),N,1,1,,CHEMBL621814,,BAO_0000218,,
5687,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,N,1,1,,CHEMBL621815,,BAO_0000218,,
5688,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,N,1,1,,CHEMBL621816,,BAO_0000218,,
5689,Intermediate,50594,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,1,1,,CHEMBL621817,,BAO_0000218,,
5690,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,N,1,1,,CHEMBL621818,,BAO_0000218,,
5691,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,N,1,1,,CHEMBL621819,,BAO_0000218,,
5692,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,N,1,1,,CHEMBL621820,,BAO_0000218,,
5693,Intermediate,50594,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,N,1,1,,CHEMBL621821,,BAO_0000218,,
5694,Intermediate,50594,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,N,1,1,,CHEMBL621822,,BAO_0000218,,
5695,Intermediate,50594,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,N,1,1,,CHEMBL619474,,BAO_0000218,,
5696,Intermediate,50594,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,1,1,,CHEMBL619475,,BAO_0000218,,
5697,Intermediate,50594,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,1,1,,CHEMBL619476,,BAO_0000218,,
5698,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",N,1,1,,CHEMBL619477,,BAO_0000218,,
5699,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",N,1,1,,CHEMBL619478,,BAO_0000218,,
5700,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",N,1,1,,CHEMBL619479,,BAO_0000218,,
5701,Intermediate,50594,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",N,1,1,,CHEMBL619480,,BAO_0000218,,
5702,Intermediate,50594,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,N,1,1,,CHEMBL619481,,BAO_0000218,,
5703,Intermediate,50594,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,N,1,1,,CHEMBL619482,,BAO_0000218,,
5704,Intermediate,50594,,,Area under the curve was evaluated in mice after intravenous administration,N,1,1,,CHEMBL619483,,BAO_0000218,,
5705,Intermediate,50594,,,Area under the curve was evaluated in mice after oral administration,N,1,1,,CHEMBL619484,,BAO_0000218,,
5706,Intermediate,50594,Plasma,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,Intermediate,50594,Plasma,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,1,1,,CHEMBL619487,,BAO_0000218,,
5709,Intermediate,50594,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL619488,,BAO_0000218,,
5710,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,Intermediate,80653,,,The compound was tested in vitro for anticancer activity against 9L cells,N,1,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,Autocuration,22226,,,Anti proliferation activity determined; Weak effect,U,0,1,,CHEMBL620283,,BAO_0000019,,
5713,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,U,0,1,,CHEMBL875176,,BAO_0000219,,
5714,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,U,0,1,,CHEMBL620284,,BAO_0000219,,
5715,Autocuration,22226,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,U,0,1,,CHEMBL623515,,BAO_0000219,,
5716,Autocuration,22226,,,The cytotoxic activity was in vitro tested by 9PS assay method,U,0,1,,CHEMBL623516,,BAO_0000019,,
5717,Autocuration,22226,,,The cytotoxic activity was in vitro tested by 9PS assay method.,U,0,1,,CHEMBL623517,,BAO_0000019,,
5718,Autocuration,22224,,,Partition coefficient (logD6.5),U,0,1,,CHEMBL857878,,BAO_0000019,,
5719,Expert,81034,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,N,1,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,Intermediate,80018,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),N,1,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,Expert,80852,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,N,1,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,Expert,9,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,9,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,Intermediate,80021,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,N,1,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,Intermediate,80021,,,in vitro cytotoxicity against A 498 cancer cell line,N,1,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,Intermediate,80021,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,N,1,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,Intermediate,80021,,,Cytotoxic activity against A 498 renal cancer cell lines.,N,1,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,Intermediate,80021,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,N,1,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,0,1,,CHEMBL621290,,BAO_0000019,,
5729,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,0,1,,CHEMBL621291,,BAO_0000019,,
5730,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,0,1,,CHEMBL621292,,BAO_0000019,,
5731,Autocuration,22226,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,0,1,,CHEMBL621293,,BAO_0000019,,
5732,Intermediate,80682,,,Inhibitory concentration required against A 549 lung cancer cell line,N,1,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,Intermediate,80682,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,N,1,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,Intermediate,80682,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,N,1,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,Intermediate,80682,,,In vitro cytotoxicity against lung cancer A 549 cell lines,N,1,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,Intermediate,80682,,,Compound was tested for its cytotoxicity against A 549 cell line,N,1,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,Expert,80682,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",N,1,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,Intermediate,80682,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",N,1,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,Expert,80682,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,N,1,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,Intermediate,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,1,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,Expert,80682,,,In vitro inhibition of A549 (human lung cancer) cell growth.,N,1,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,Intermediate,80682,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,N,1,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,Expert,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,1,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,Expert,80682,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),N,1,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,Autocuration,22226,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,U,0,1,,CHEMBL620404,,BAO_0000218,,
5746,Autocuration,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,H,4,1,,CHEMBL620405,,BAO_0000218,,
5747,Autocuration,104694,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,H,4,1,,CHEMBL620406,,BAO_0000218,,
5748,Autocuration,104694,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,H,4,1,,CHEMBL620407,,BAO_0000218,,
5749,Autocuration,104694,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,H,4,1,,CHEMBL620408,,BAO_0000218,,
5750,Autocuration,104694,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,H,4,1,,CHEMBL620409,,BAO_0000218,,
5751,Expert,80021,,,Inhibition of A-498 human Renal cell proliferation,N,1,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",U,0,1,,CHEMBL620411,,BAO_0000019,,
5753,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",U,0,1,,CHEMBL620412,,BAO_0000019,,
5754,Autocuration,22226,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",U,0,1,,CHEMBL876596,,BAO_0000019,,
5755,Expert,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,N,1,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,Intermediate,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,Intermediate,80012,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,Expert,80682,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,N,1,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,Intermediate,80682,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,N,1,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,Expert,80682,,,Cytotoxic activity evaluated against A549 tumor cells,N,1,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,Intermediate,80682,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,N,1,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,Intermediate,80682,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,N,1,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,Intermediate,80682,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,N,1,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,Intermediate,80682,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,N,1,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,Intermediate,80682,,,Cytotoxicity of compound against A549 cell line,N,1,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,Expert,80682,,,Cytotoxicity against human lung cell carcinoma A549 cell line,N,1,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,Intermediate,80682,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,N,1,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,Intermediate,80682,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,N,1,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,Intermediate,80682,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,N,1,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,Intermediate,80682,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,N,1,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,Intermediate,80682,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,N,1,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,Expert,80682,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,N,1,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,Intermediate,80682,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,N,1,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,Intermediate,80682,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,N,1,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,Intermediate,80682,,,In vitro cytotoxicity against A549 (human lung cancer),N,1,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,Expert,80682,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,Intermediate,80682,,,In vivo antiproliferative activity against A549 cell line,N,1,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,Intermediate,80682,,,Inhibition of non-small-cell lung adenocarcinoma (A549),N,1,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,Intermediate,80682,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,N,1,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,Intermediate,80682,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,N,1,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,Intermediate,80682,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),N,1,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,Intermediate,80682,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,1,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,Intermediate,80682,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,N,1,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,Intermediate,80682,,,Inhibitory activity against A549 lung cancer cell line,N,1,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,Intermediate,80682,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,N,1,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,Intermediate,80682,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,N,1,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,Intermediate,80682,,,Inhibitory concentration against A549 (lung cancer) cell line,N,1,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,Expert,80682,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,Intermediate,80682,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,N,1,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,Expert,80682,,,Activity against A549 cancer cell line.,N,1,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,Intermediate,80682,,,The compound was evaluated for cytotoxicity against A549 cell line,N,1,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,Intermediate,80682,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,N,1,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,Intermediate,80682,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,1,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,Intermediate,80682,,,Growth inhibitory activity was measured for human A549 tumor cell line.,N,1,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,Intermediate,80682,,,Inhibitory activity against A549 lung cancer cell line,N,1,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,Intermediate,80682,,,Inhibitory activity against A549 cell line; inactive,N,1,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,1,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,Expert,80682,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,1,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,Intermediate,80682,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,1,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),N,1,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),N,1,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),N,1,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),N,1,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,Intermediate,80682,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),N,1,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,Intermediate,80682,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,N,1,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,Intermediate,50588,,,Plasma clearance (in vivo) in mongrel dogs was determined,N,1,1,,CHEMBL621581,,BAO_0000218,,
5808,Intermediate,50588,,,Plasma clearance was measured in dog,N,1,1,,CHEMBL621582,,BAO_0000218,,
5809,Intermediate,50588,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,1,1,,CHEMBL621583,,BAO_0000218,,
5810,Intermediate,50588,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,1,1,,CHEMBL621584,,BAO_0000218,,
5811,Intermediate,50588,Plasma,,Tested for plasma clearance in dog,N,1,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,Intermediate,50588,,,The compound was tested for clearance in dog plasma.,N,1,1,,CHEMBL621586,,BAO_0000218,,
5813,Intermediate,50588,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",N,1,1,,CHEMBL875835,,BAO_0000218,,
5814,Intermediate,50588,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,N,1,1,,CHEMBL621587,,BAO_0000218,,
5815,Intermediate,50588,Plasma,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,1,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,Intermediate,50588,Liver,,In vitro clearance in dog liver microsomes,N,1,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,Intermediate,50588,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,1,1,,CHEMBL621590,,BAO_0000218,,
5818,Intermediate,50588,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,N,1,1,,CHEMBL621591,,BAO_0000218,,
5819,Intermediate,50588,,,Plasma clearance in dog,N,1,1,,CHEMBL621592,,BAO_0000218,,
5820,Intermediate,50588,,,Clearance rate in dog,N,1,1,,CHEMBL621593,,BAO_0000218,,
5821,Intermediate,50588,Plasma,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,1,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,Intermediate,50588,,,Clearance in dogs,N,1,1,,CHEMBL621595,,BAO_0000218,,
5823,Intermediate,50588,,,Plasma clearance in dogs,N,1,1,,CHEMBL621596,,BAO_0000218,,
5824,Intermediate,50588,,,Plasma clearance was determined,N,1,1,,CHEMBL621597,,BAO_0000218,,
5825,Intermediate,50588,,,Lower clearance in dog (i.v.) at 0.5 mpk,N,1,1,,CHEMBL621598,,BAO_0000218,,
5826,Intermediate,50588,,,Plasma clearance in Beagle dogs,N,1,1,,CHEMBL621599,,BAO_0000218,,
5827,Intermediate,50588,,,Plasma clearance (Clp) in dog,N,1,1,,CHEMBL875836,,BAO_0000218,,
5828,Intermediate,50588,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,N,1,1,,CHEMBL621600,,BAO_0000218,,
5829,Intermediate,50588,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,N,1,1,,CHEMBL621601,,BAO_0000218,,
5830,Intermediate,50588,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,N,1,1,,CHEMBL618474,,BAO_0000218,,
5831,Intermediate,50588,,,Plasma clearance of compound was determined in dog,N,1,1,,CHEMBL618475,,BAO_0000218,,
5832,Intermediate,50588,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL624524,,BAO_0000218,,
5833,Intermediate,50588,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,1,1,,CHEMBL624525,,BAO_0000218,,
5834,Intermediate,50588,,,Plasma clearance in dog was determined,N,1,1,,CHEMBL624526,,BAO_0000218,,
5835,Intermediate,50588,,,Plasma clearance was calculated in dog,N,1,1,,CHEMBL624527,,BAO_0000218,,
5836,Intermediate,50588,,,Plasma clearance at the dose of 2 mg/kg in dog,N,1,1,,CHEMBL624528,,BAO_0000218,,
5837,Intermediate,50588,,,Plasma clearance in dog,N,1,1,,CHEMBL624529,,BAO_0000218,,
5838,Intermediate,50588,,,Plasma clearance in dog,N,1,1,,CHEMBL624530,,BAO_0000218,,
5839,Intermediate,50588,,,Plasma clearance in dog; Unable to calculate,N,1,1,,CHEMBL624531,,BAO_0000218,,
5840,Intermediate,50588,,,Plasma clearance in rhesus monkey,N,1,1,,CHEMBL624532,,BAO_0000218,,
5841,Intermediate,50588,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,1,1,,CHEMBL624533,,BAO_0000218,,
5842,Intermediate,50588,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624534,,BAO_0000218,,
5843,Intermediate,50588,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624535,,BAO_0000218,,
5844,Intermediate,50588,,,Plasma clearance was evaluated in dog,N,1,1,,CHEMBL624536,,BAO_0000218,,
5845,Intermediate,50588,,,Plasma clearance was evaluated in dog; Not tested,N,1,1,,CHEMBL624537,,BAO_0000218,,
5846,Intermediate,50588,,,Plasma clearance was evaluated in rhesus,N,1,1,,CHEMBL624538,,BAO_0000218,,
5847,Intermediate,50588,,,Plasma clearance was evaluated in rhesus; Not tested,N,1,1,,CHEMBL624539,,BAO_0000218,,
5848,Intermediate,50588,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,N,1,1,,CHEMBL624540,,BAO_0000218,,
5849,Intermediate,50588,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL624541,,BAO_0000218,,
5850,Intermediate,50588,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL624542,,BAO_0000218,,
5851,Intermediate,50588,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL624543,,BAO_0000218,,
5852,Intermediate,50588,,,Clearance value at a dose of 0.2 mg/kg i.v.,N,1,1,,CHEMBL624544,,BAO_0000218,,
5853,Intermediate,50588,Plasma,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,N,1,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,Intermediate,50588,,,Cmax after oral dose of compound at 3 mg/kg in dogs,N,1,1,,CHEMBL624546,,BAO_0000218,,
5855,Intermediate,50588,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,N,1,1,,CHEMBL875957,,BAO_0000218,,
5856,Intermediate,50588,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,1,1,,CHEMBL624547,,BAO_0000218,,
5857,Intermediate,50588,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,N,1,1,,CHEMBL624548,,BAO_0000218,,
5858,Intermediate,50588,,,Cmax in dog after administration of 1 mg/kg iv,N,1,1,,CHEMBL624549,,BAO_0000218,,
5859,Intermediate,50588,Plasma,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,N,1,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,Intermediate,50588,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,N,1,1,,CHEMBL621613,,BAO_0000218,,
5861,Intermediate,50588,,,Cmax was determine after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL621614,,BAO_0000218,,
5862,Intermediate,50588,,,Cmax was determine after peroral administration at 5 mpk in dog,N,1,1,,CHEMBL623431,,BAO_0000218,,
5863,Intermediate,50588,,,Cmax was determine after peroral administration at 5 mg/kg in dog,N,1,1,,CHEMBL623432,,BAO_0000218,,
5864,Intermediate,50588,,,Cmax after 0.3 mg/kg po administration in dog,N,1,1,,CHEMBL623433,,BAO_0000218,,
5865,Intermediate,50588,,,Cmax after peroral administration in dogs at 2.4 uM/kg,N,1,1,,CHEMBL623434,,BAO_0000218,,
5866,Intermediate,50588,,,Cmax in dog after oral administration at 1 mg/kg,N,1,1,,CHEMBL623435,,BAO_0000218,,
5867,Intermediate,50588,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,N,1,1,,CHEMBL623436,,BAO_0000218,,
5868,Intermediate,50588,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,N,1,1,,CHEMBL875958,,BAO_0000218,,
5869,Intermediate,50588,,,Cmax value after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL623437,,BAO_0000218,,
5870,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,Intermediate,50594,Blood,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,Intermediate,50594,Bone,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623469,,BAO_0000218,,
5876,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623470,,BAO_0000218,,
5877,Intermediate,50594,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623471,,BAO_0000218,,
5878,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,Intermediate,50594,Heart,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,Intermediate,50594,Kidney,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,Intermediate,50594,Intestine,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,Intermediate,50594,Intestine,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,Intermediate,50594,Intestine,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,Intermediate,50594,Liver,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,Intermediate,50594,Lung,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,Intermediate,50594,Muscle tissue,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620287,,BAO_0000218,,
5897,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620288,,BAO_0000218,,
5898,Intermediate,50594,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620289,,BAO_0000218,,
5899,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,Intermediate,50594,Intestine,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,Intermediate,50594,Spleen,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,Expert,80012,,,Cytotoxicity against A-172 human tumor cell lines,N,1,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,Intermediate,80012,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,N,1,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,Intermediate,80014,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,N,1,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,Intermediate,81034,,,Tested for antiproliferative activity against A-2780 tumoral cell line,N,1,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,Intermediate,80018,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,N,1,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,Intermediate,80018,,,Tested in vitro against A-375 cell line human melanoma,N,1,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,Expert,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,N,1,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,Intermediate,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,Expert,80019,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,N,1,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,Intermediate,80019,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,1,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,Intermediate,80019,,,Antitumor activity on A-427 lung carcinoma cell lines,N,1,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,Intermediate,80019,,,Cytotoxic activity against human A-427 lung tumor cell line,N,1,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,Expert,80019,,,In vitro antitumor effects against human A-427 cell lines.,N,1,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,Expert,80019,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,N,1,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,Intermediate,80019,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,N,1,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,Intermediate,80019,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,N,1,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,Expert,80852,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,N,1,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,Intermediate,80021,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,N,1,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,Expert,80021,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,N,1,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,Intermediate,80021,,,Cytotoxicity against human kidney carcinoma A-498cell lines,N,1,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,Intermediate,80021,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,N,1,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,N,1,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,Intermediate,80021,,,Antitumor cytotoxic activity against A-498 cell line was determined,N,1,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,N,1,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,Intermediate,80021,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,N,1,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,Intermediate,80021,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,N,1,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,Intermediate,80021,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,N,1,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,Intermediate,80021,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",N,1,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,Intermediate,80682,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,N,1,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,Intermediate,80682,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,N,1,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,Intermediate,80682,,,In vitro antiproliferative activity against human A-549 NSCL cell line,N,1,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,Intermediate,80682,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,N,1,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,Intermediate,80682,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,N,1,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,N,1,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,N,1,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,N,1,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,N,1,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,N,1,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,Intermediate,80682,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,N,1,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,Expert,80682,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,N,1,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,Intermediate,80682,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,N,1,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,Intermediate,80682,,,Cytotoxic activity against A-549 cell line,N,1,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,Intermediate,80682,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,N,1,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,Intermediate,80682,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,N,1,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,Expert,80682,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",N,1,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,Intermediate,80682,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),N,1,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,Intermediate,80682,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),N,1,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,Intermediate,80682,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,N,1,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,Expert,80682,,,Cytotoxic activity towards A-549 cells,N,1,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.",N,1,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma",N,1,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.",N,1,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,Intermediate,80682,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",N,1,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,Intermediate,80682,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,N,1,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,Intermediate,80682,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,N,1,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,Intermediate,80682,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,N,1,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,1,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,1,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,1,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,1,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,1,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,Intermediate,80682,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",N,1,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,Intermediate,80682,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),N,1,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,Expert,80682,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,N,1,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,1,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,N,1,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,Intermediate,80682,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,1,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,Intermediate,80682,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,1,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,Intermediate,80682,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",N,1,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,N,1,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,N,1,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,N,1,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,N,1,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,Expert,80682,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,N,1,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,Intermediate,80682,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,N,1,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,Expert,80682,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,1,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,Expert,80682,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,N,1,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,Intermediate,80682,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,N,1,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,Intermediate,80682,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,N,1,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,Intermediate,80682,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,N,1,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,Intermediate,80682,,,In vitro antiproliferative activity against A549 cell line,N,1,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,Intermediate,80682,,,Synergism with indomethacin in A549 cells,N,1,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,Intermediate,80682,,,Synergism with tolmetin in A549 cells,N,1,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,Intermediate,80682,,,Synergism with sulindac in A549 cells,N,1,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,Intermediate,80682,,,Antagonism of indomethacin in A549 cells,N,1,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,Intermediate,80682,,,Antagonism of sulindac in A549 cells,N,1,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,Intermediate,80682,,,Antagonism of tolmetin in A549 cells,N,1,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,Intermediate,80682,,,Synergism with indomethacin in A549 cells,N,1,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,Intermediate,80682,,,Synergism with sulindac in A549 cells,N,1,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,Intermediate,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,N,1,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,Intermediate,50588,,,Cmax value after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL621656,,BAO_0000218,,
5998,Intermediate,50588,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,1,1,,CHEMBL621657,,BAO_0000218,,
5999,Intermediate,50588,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,N,1,1,,CHEMBL621658,,BAO_0000218,,
6000,Intermediate,50588,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,1,1,,CHEMBL621659,,BAO_0000218,,
6001,Intermediate,50588,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,N,1,1,,CHEMBL621660,,BAO_0000218,,
6002,Intermediate,50588,,,Cmax value after administration of 4 mg/Kg oral dose in dog,N,1,1,,CHEMBL621661,,BAO_0000218,,
6003,Intermediate,50588,,,Cmax value in dog,N,1,1,,CHEMBL621662,,BAO_0000218,,
6004,Intermediate,50588,,,Cmax value in dogs after oral administration at 1 mg/kg,N,1,1,,CHEMBL621663,,BAO_0000218,,
6005,Intermediate,50588,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,N,1,1,,CHEMBL621664,,BAO_0000218,,
6006,Intermediate,50588,Plasma,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,N,1,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,Intermediate,50588,Plasma,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,N,1,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,Intermediate,50588,,,Concentration maxima after oral dosing in dogs,N,1,1,,CHEMBL621667,,BAO_0000218,,
6009,Intermediate,50588,,,Concentration maxima after oral dosing in dogs; not available,N,1,1,,CHEMBL876738,,BAO_0000218,,
6010,Intermediate,50588,,,Concentration maxima after oral dosing in dogs; not available,N,1,1,,CHEMBL621668,,BAO_0000218,,
6011,Intermediate,50588,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,N,1,1,,CHEMBL621669,,BAO_0000218,,
6012,Intermediate,50588,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,N,1,1,,CHEMBL621670,,BAO_0000218,,
6013,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,N,1,1,,CHEMBL621671,,BAO_0000218,,
6014,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,N,1,1,,CHEMBL622360,,BAO_0000218,,
6015,Intermediate,50588,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,N,1,1,,CHEMBL622361,,BAO_0000218,,
6016,Intermediate,50588,Plasma,,Cmax in dog plasma after oral dose (1 mg/kg),N,1,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,Intermediate,50588,Plasma,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,N,1,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,Intermediate,50588,Plasma,,Maximal plasma concentration at a dose of 1 mg/kg,N,1,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,Intermediate,50588,Plasma,,Maximal plasma concentration at a dose of 1 mg/kg (oral),N,1,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,Intermediate,50588,Plasma,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,N,1,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,Intermediate,50588,,,Maximum concentration of compound in dog was evaluated.,N,1,1,,CHEMBL622534,,BAO_0000218,,
6022,Intermediate,50588,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,N,1,1,,CHEMBL622535,,BAO_0000218,,
6023,Intermediate,50588,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,N,1,1,,CHEMBL876739,,BAO_0000218,,
6024,Intermediate,50588,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,1,1,,CHEMBL622536,,BAO_0000218,,
6025,Intermediate,50588,Plasma,,Maximum concentration obtained in dog plasma was determined,N,1,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,Intermediate,50588,,,Maximum concentration was determined,N,1,1,,CHEMBL622538,,BAO_0000218,,
6027,Intermediate,50588,,,Maximum concentration at the dose of 2 mg/kg in dog,N,1,1,,CHEMBL627867,,BAO_0000218,,
6028,Intermediate,50588,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL627868,,BAO_0000218,,
6029,Intermediate,50588,Plasma,,Maximum concentration was evaluated in dog plasma,N,1,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,Intermediate,50588,,,Maximum concentration was evaluated after 75 min after administration in dog,N,1,1,,CHEMBL627870,,BAO_0000218,,
6031,Intermediate,50588,Plasma,,Maximum plasma concentration determined in dog after oral administration of 17b,N,1,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,Intermediate,50588,Plasma,,Maximum plasma concentration determined in dog after oral administration of 2b,N,1,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,Intermediate,50588,Plasma,,Maximum plasma concentration in dog,N,1,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,N,1,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,N,1,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,N,1,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,Intermediate,50588,Plasma,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,N,1,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,Intermediate,50588,Plasma,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,Intermediate,50588,Plasma,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,N,1,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,Intermediate,50588,Plasma,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,1,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,Intermediate,50588,Plasma,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,1,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,Intermediate,50588,Plasma,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,1,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,Intermediate,50588,Plasma,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,N,1,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,Intermediate,50588,Plasma,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,N,1,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,N,1,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,N,1,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,N,1,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,N,1,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,Expert,50588,Plasma,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,Intermediate,50588,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,N,1,1,,CHEMBL625245,,BAO_0000218,,
6053,Intermediate,50588,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,N,1,1,,CHEMBL625246,,BAO_0000218,,
6054,Intermediate,50594,Stomach,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,1,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,N,1,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,Intermediate,50594,Urine,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,N,1,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,Intermediate,50594,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,N,1,1,,CHEMBL625251,,BAO_0000218,,
6059,Intermediate,50594,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,N,1,1,,CHEMBL875356,,BAO_0000218,,
6060,Intermediate,50594,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),N,1,1,,CHEMBL625252,,BAO_0000218,,
6061,Intermediate,50594,Blood,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,1,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,Intermediate,50594,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),N,1,1,,CHEMBL625254,,BAO_0000218,,
6063,Intermediate,50594,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),N,1,1,,CHEMBL625255,,BAO_0000218,,
6064,Intermediate,50594,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),N,1,1,,CHEMBL625256,,BAO_0000218,,
6065,Intermediate,50594,Blood,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,1,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,Intermediate,50594,Blood,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),N,1,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,Intermediate,50594,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),N,1,1,,CHEMBL625259,,BAO_0000218,,
6068,Intermediate,50594,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,N,1,1,,CHEMBL625260,,BAO_0000218,,
6069,Intermediate,50594,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,1,1,,CHEMBL625261,,BAO_0000218,,
6070,Intermediate,50594,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,1,1,,CHEMBL625262,,BAO_0000218,,
6071,Intermediate,50594,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,1,1,,CHEMBL622639,,BAO_0000218,,
6072,Intermediate,50594,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,N,1,1,,CHEMBL622640,,BAO_0000218,,
6073,Intermediate,50594,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,N,1,1,,CHEMBL622812,,BAO_0000218,,
6074,Intermediate,50594,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,N,1,1,,CHEMBL622813,,BAO_0000218,,
6075,Intermediate,50594,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,N,1,1,,CHEMBL622814,,BAO_0000218,,
6076,Intermediate,50594,,,Time at maximum activity in mice (Radiolabeled compound),N,1,1,,CHEMBL622815,,BAO_0000218,,
6077,Intermediate,50594,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,N,1,1,,CHEMBL625342,,BAO_0000218,,
6078,Intermediate,50594,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,N,1,1,,CHEMBL625343,,BAO_0000218,,
6079,Intermediate,50594,,,Binding towards mouse plasma protein at 10 uM,N,1,1,,CHEMBL877591,,BAO_0000218,,
6080,Intermediate,50594,,,Binding towards mouse plasma protein at 100 uM,N,1,1,,CHEMBL625344,,BAO_0000218,,
6081,Intermediate,50594,,,Bioavailability was evaluated in mice after intravenous administration,N,1,1,,CHEMBL625345,,BAO_0000218,,
6082,Intermediate,50594,,,Bioavailability was evaluated in mice after oral administration,N,1,1,,CHEMBL625346,,BAO_0000218,,
6083,Intermediate,50594,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,N,1,1,,CHEMBL625347,,BAO_0000218,,
6084,Intermediate,50594,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,N,1,1,,CHEMBL625348,,BAO_0000218,,
6085,Intermediate,50594,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL625349,,BAO_0000218,,
6086,Intermediate,50594,,,Oral bioavailability in mouse,N,1,1,,CHEMBL625350,,BAO_0000218,,
6087,Intermediate,50594,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL882952,,BAO_0000218,,
6088,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,Intermediate,50594,Brain,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,Intermediate,80682,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),N,1,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,Expert,80682,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,N,1,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,Intermediate,80682,,,Cytotoxicity against human lung carcinoma A-549 cell lines,N,1,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,Intermediate,80682,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,N,1,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,N,1,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,N,1,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,N,1,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,N,1,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,N,1,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,N,1,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,N,1,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,Intermediate,80682,,,In vitro cytotoxicity against A-549 human lung cancer cells,N,1,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,N,1,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,Intermediate,80682,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,N,1,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,Expert,80682,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,1,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,Intermediate,80682,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,N,1,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,Intermediate,80682,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,N,1,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,Expert,80682,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,N,1,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,Intermediate,80682,,,Antitumor cytotoxic activity against A-549 cell line was determined,N,1,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,Intermediate,80682,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",N,1,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,Intermediate,80682,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,1,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,Expert,80682,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,Intermediate,80682,,,Antitumoral activity was assayed against A-549 cell line,N,1,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,Intermediate,80682,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,N,1,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,Intermediate,80682,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,1,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,Expert,80682,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,Intermediate,80682,,,Compound was tested for inhibition of cell growth of A-549 cells,N,1,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,Intermediate,80682,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,N,1,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,Intermediate,80682,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,N,1,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,Expert,80682,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,N,1,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,Expert,80682,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,N,1,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,Intermediate,80682,,,Cytotoxic activity against A-549 cell lines.,N,1,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,Expert,80682,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,N,1,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,Intermediate,80682,,,Cytotoxicity against human A549 non small cell lung cell lines,N,1,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,Expert,80682,,,Inhibition of cell growth in (A-549) lung cell line,N,1,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,Intermediate,80682,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,N,1,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,Intermediate,80682,,,In vitro antitumor activity against A-549 tumor cells.,N,1,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,Expert,80682,,,In vitro antitumor effects against human A-549 cell lines.,N,1,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,Intermediate,80682,,,In vitro cytotoxic activity of compound against A-549 cell line,N,1,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,Intermediate,80682,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,N,1,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,Intermediate,80682,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,N,1,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,Intermediate,80682,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,N,1,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,Expert,80682,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,N,1,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,Intermediate,80682,,,Inhibitory concentration of compound against A-549 cell line,N,1,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,Intermediate,80682,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,N,1,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,Intermediate,80682,,,cytotoxic activity against leukemia (A-549) cancer cell line,N,1,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,Expert,80682,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,1,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,Intermediate,80682,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,N,1,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),N,1,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),N,1,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),N,1,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),N,1,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,Intermediate,80682,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,N,1,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,Intermediate,80682,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,N,1,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,Intermediate,80682,,,Cytotoxicity against A549 cells; No cytotoxicity,N,1,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,Expert,80682,,,Cytotoxicity against human lung carcinoma (A549) cell lines,N,1,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,Expert,80682,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,N,1,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,Intermediate,80682,,,In vitro anticancer activity against human lung (A549) cell line,N,1,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,Intermediate,80682,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,N,1,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,N,1,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,N,1,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,N,1,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,N,1,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,Intermediate,80682,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,1,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,Expert,80682,,,Inhibition of A549 human lung tumor cell proliferation,N,1,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,Intermediate,80682,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",N,1,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,Expert,80682,,,In vitro cytotoxicity against human tumor cell line A549,N,1,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,Intermediate,80682,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,N,1,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,Intermediate,80682,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,N,1,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,Intermediate,80682,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,N,1,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,Intermediate,80682,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,N,1,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,Intermediate,80682,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,N,1,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,1,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,1,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,1,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,Intermediate,80682,,,In vitro anticancer activity against human lung (A549) cell line,N,1,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,N,1,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,N,1,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,N,1,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,Intermediate,80682,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,N,1,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,Intermediate,80682,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,N,1,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,Expert,80682,,,Percentage inhibition of human lung carcinoma (A549) cell lines,N,1,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,Intermediate,80682,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,N,1,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",N,1,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,Intermediate,80682,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,1,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,Intermediate,80682,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,1,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",N,1,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",N,1,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",N,1,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",N,1,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,Intermediate,80682,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",N,1,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,Intermediate,80682,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,N,1,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,Intermediate,80682,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,N,1,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,Intermediate,80682,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,1,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,N,1,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,N,1,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,N,1,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,N,1,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,Intermediate,50588,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,N,1,1,,CHEMBL619606,,BAO_0000218,,
6197,Intermediate,50588,,,Pharmacokinetic activity (Cmax) in dog,N,1,1,,CHEMBL876032,,BAO_0000218,,
6198,Intermediate,50588,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,1,1,,CHEMBL619607,,BAO_0000218,,
6199,Intermediate,50588,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,N,1,1,,CHEMBL619608,,BAO_0000218,,
6200,Intermediate,50588,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,N,1,1,,CHEMBL619609,,BAO_0000218,,
6201,Intermediate,50588,Plasma,,Cmax in dog plasma after 30mg/kg oral dose,N,1,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,Intermediate,50588,Blood,,Tested for the peak blood level in dog,N,1,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,Intermediate,50588,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",N,1,1,,CHEMBL619612,,BAO_0000218,,
6204,Intermediate,50588,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",N,1,1,,CHEMBL619613,,BAO_0000218,,
6205,Intermediate,50588,Blood,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,N,1,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,Intermediate,50588,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL619615,,BAO_0000218,,
6207,Intermediate,50588,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,N,1,1,,CHEMBL619616,,BAO_0000218,,
6208,Intermediate,50588,Plasma,,Final plasma concentration in dogs after oral administration at 1 mg/kg,N,1,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,N,1,1,,CHEMBL619618,,BAO_0000218,,
6210,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,N,1,1,,CHEMBL876033,,BAO_0000218,,
6211,Intermediate,50588,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,N,1,1,,CHEMBL619619,,BAO_0000218,,
6212,Intermediate,50588,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,N,1,1,,CHEMBL619620,,BAO_0000218,,
6213,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,N,1,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,N,1,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,Intermediate,50588,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,N,1,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,Intermediate,50588,,,Absolute bioavailability was evaluated in dog,N,1,1,,CHEMBL618875,,BAO_0000218,,
6217,Intermediate,50588,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,N,1,1,,CHEMBL618876,,BAO_0000218,,
6218,Intermediate,50588,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,N,1,1,,CHEMBL618877,,BAO_0000218,,
6219,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL618878,,BAO_0000218,,
6220,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL618879,,BAO_0000218,,
6221,Intermediate,50588,,,Bioavailability after intravenous administration in dogs,N,1,1,,CHEMBL618880,,BAO_0000218,,
6222,Intermediate,50588,,,Bioavailability after peroral administration in dogs,N,1,1,,CHEMBL618881,,BAO_0000218,,
6223,Intermediate,50588,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,1,1,,CHEMBL618882,,BAO_0000218,,
6224,Intermediate,50588,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,N,1,1,,CHEMBL624226,,BAO_0000218,,
6225,Intermediate,50588,Plasma,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,N,1,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,Intermediate,50588,,,Bioavailability,N,1,1,,CHEMBL624228,,BAO_0000218,,
6227,Intermediate,50588,,,Bioavailability,N,1,1,,CHEMBL624229,,BAO_0000218,,
6228,Intermediate,50588,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,N,1,1,,CHEMBL624230,,BAO_0000218,,
6229,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL624231,,BAO_0000218,,
6230,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL624232,,BAO_0000218,,
6231,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL625127,,BAO_0000218,,
6232,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL625128,,BAO_0000218,,
6233,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL621675,,BAO_0000218,,
6234,Intermediate,50588,,,Bioavailability in dog (p.o.) at 2.0 mpk,N,1,1,,CHEMBL621676,,BAO_0000218,,
6235,Intermediate,50588,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),N,1,1,,CHEMBL621677,,BAO_0000218,,
6236,Intermediate,50588,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,1,1,,CHEMBL621678,,BAO_0000218,,
6237,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL621679,,BAO_0000218,,
6238,Intermediate,50588,,,Bioavailability was evaluated after oral administration in dog,N,1,1,,CHEMBL621680,,BAO_0000218,,
6239,Intermediate,50588,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL621681,,BAO_0000218,,
6240,Intermediate,50588,,,Bioavailability was evaluated in dog,N,1,1,,CHEMBL876740,,BAO_0000218,,
6241,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL621682,,BAO_0000218,,
6242,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL621683,,BAO_0000218,,
6243,Intermediate,50588,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,1,1,,CHEMBL621684,,BAO_0000218,,
6244,Intermediate,50588,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,1,1,,CHEMBL621685,,BAO_0000218,,
6245,Intermediate,50588,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,1,1,,CHEMBL621686,,BAO_0000218,,
6246,Intermediate,50588,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL621687,,BAO_0000218,,
6247,Intermediate,50588,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,N,1,1,,CHEMBL621688,,BAO_0000218,,
6248,Intermediate,50588,,,Bioavailability of compound in dog was determined after peroral administration,N,1,1,,CHEMBL621689,,BAO_0000218,,
6249,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621690,,BAO_0000218,,
6250,Intermediate,50588,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,N,1,1,,CHEMBL621691,,BAO_0000218,,
6251,Intermediate,50588,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,N,1,1,,CHEMBL875941,,BAO_0000218,,
6252,Intermediate,50588,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,N,1,1,,CHEMBL621692,,BAO_0000218,,
6253,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL621693,,BAO_0000218,,
6254,Intermediate,50588,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),N,1,1,,CHEMBL621694,,BAO_0000218,,
6255,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,Intermediate,50594,Heart,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,Intermediate,50594,Kidney,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,Intermediate,50594,Liver,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,Intermediate,50594,Lung,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,1,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,Intermediate,50594,Brain,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,N,1,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,N,1,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),N,1,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,Intermediate,80682,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),N,1,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,Expert,80682,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,N,1,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,N,1,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,N,1,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,N,1,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,Expert,80682,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,N,1,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,N,1,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,N,1,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,N,1,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,N,1,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,Intermediate,80682,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,N,1,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,Intermediate,80682,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,N,1,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,Expert,80682,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,N,1,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,Intermediate,80682,,,Cytotoxic activity of compound against A-549 tumor cell line.,N,1,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,N,1,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,N,1,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,Intermediate,80682,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,N,1,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,Intermediate,80682,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,N,1,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,Intermediate,80682,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),N,1,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,Expert,80682,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,N,1,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,Intermediate,80682,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,N,1,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,Intermediate,80682,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,N,1,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,Intermediate,80682,,,Cytotoxic concentration against A-549 tumor cells.,N,1,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,Intermediate,80682,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,N,1,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,Intermediate,80682,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",N,1,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,Expert,50191,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,N,1,1,,CHEMBL619457,,BAO_0000218,,
6323,Intermediate,50192,,,Activity against Acinetobacter calcoaceticus (AC54),N,1,1,,CHEMBL619458,,BAO_0000218,,
6324,Expert,50274,,,In vitro antifungal activity against Aspergillus flavus CM74,N,1,1,,CHEMBL619459,,BAO_0000218,,
6325,Expert,50274,,,In vitro antifungal activity against Aspergillus flavus CM74,N,1,1,,CHEMBL619460,,BAO_0000218,,
6326,Intermediate,50416,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,N,1,1,,CHEMBL619461,,BAO_0000218,,
6327,Intermediate,50416,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),N,1,1,,CHEMBL619462,,BAO_0000218,,
6328,Intermediate,50416,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,1,1,,CHEMBL620388,,BAO_0000218,,
6329,Intermediate,50416,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,1,1,,CHEMBL620389,,BAO_0000218,,
6330,Intermediate,50416,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),N,1,1,,CHEMBL620390,,BAO_0000218,,
6331,Expert,50416,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,1,1,,CHEMBL620391,,BAO_0000218,,
6332,Expert,50416,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,1,1,,CHEMBL621073,,BAO_0000218,,
6333,Intermediate,50296,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,N,1,1,,CHEMBL621074,,BAO_0000218,,
6334,Intermediate,50366,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,N,1,1,,CHEMBL621075,,BAO_0000218,,
6335,Intermediate,50535,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,1,1,,CHEMBL619554,,BAO_0000218,,
6336,Intermediate,50535,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,1,1,,CHEMBL619555,,BAO_0000218,,
6337,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,N,1,1,,CHEMBL619556,,BAO_0000218,,
6338,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,N,1,1,,CHEMBL619557,,BAO_0000218,,
6339,Intermediate,50169,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,N,1,1,,CHEMBL619558,,BAO_0000218,,
6340,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,1,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,Intermediate,80682,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,N,1,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,1,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,1,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,Intermediate,80682,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,1,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,Intermediate,80682,,,GI values against A549 cells (lung cancer),N,1,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,Intermediate,80682,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,N,1,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,Intermediate,80682,,,Inhibitory activity against A549 human adenocarcinoma,N,1,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,Intermediate,80682,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,N,1,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,Intermediate,80682,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,N,1,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,1,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,Intermediate,80682,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,N,1,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,Intermediate,80682,,,Cytotoxicity against human A549 lung cells,N,1,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,Intermediate,80682,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,N,1,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,Expert,80682,,,Growth inhibition of A549 (human lung carcinoma) cell line.,N,1,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,Expert,80682,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,N,1,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,Intermediate,80682,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,N,1,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,Intermediate,80682,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,N,1,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,Expert,80682,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,N,1,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,Intermediate,80682,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,N,1,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,Intermediate,80682,,,In vitro inhibitory activity against A549 tumor cell culture,N,1,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,Intermediate,80682,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,N,1,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,Intermediate,80682,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),N,1,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,Intermediate,80682,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,N,1,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,Intermediate,80682,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,N,1,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,Intermediate,80682,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,N,1,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,Intermediate,80682,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,N,1,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,Intermediate,80682,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,N,1,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,Intermediate,80682,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,N,1,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,Intermediate,80682,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,1,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,Intermediate,80682,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,1,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,Intermediate,80682,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,1,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,Intermediate,80682,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,N,1,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,Intermediate,80682,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,N,1,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,Intermediate,80682,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,1,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,Intermediate,80682,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),N,1,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,Intermediate,80682,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,N,1,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,Intermediate,80682,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,N,1,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,Intermediate,80682,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,N,1,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,Intermediate,80682,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,N,1,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,Intermediate,80682,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,N,1,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,Intermediate,80682,,,Antitumor activity against A549/ATCC cell line,N,1,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,Intermediate,80682,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,N,1,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,Expert,80682,,,In vitro cytotoxicity against A549/ATCC cell line.,N,1,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,Intermediate,80682,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,N,1,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,Intermediate,80682,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,N,1,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,Intermediate,80682,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,N,1,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,Intermediate,80682,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,Autocuration,22226,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,U,0,1,,CHEMBL622475,,BAO_0000219,,
6389,Intermediate,22224,,,Compound was tested for oral bioavailability in dogs,U,0,1,,CHEMBL622476,,BAO_0000218,,
6390,Intermediate,50588,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,N,1,1,,CHEMBL875831,,BAO_0000218,,
6391,Intermediate,50588,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,N,1,1,,CHEMBL622477,,BAO_0000218,,
6392,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL622478,,BAO_0000218,,
6393,Intermediate,50588,,,Compound was tested for the oral bioavailability in dog; No availability,N,1,1,,CHEMBL623172,,BAO_0000218,,
6394,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),N,1,1,,CHEMBL623173,,BAO_0000218,,
6395,Intermediate,50588,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,1,1,,CHEMBL623174,,BAO_0000218,,
6396,Intermediate,50588,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,1,1,,CHEMBL623175,,BAO_0000218,,
6397,Intermediate,50588,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),N,1,1,,CHEMBL623340,,BAO_0000218,,
6398,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),N,1,1,,CHEMBL623341,,BAO_0000218,,
6399,Intermediate,50588,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),N,1,1,,CHEMBL623342,,BAO_0000218,,
6400,Intermediate,50588,,,Oral bioavailability of active FTIs in dogs,N,1,1,,CHEMBL623343,,BAO_0000218,,
6401,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,1,1,,CHEMBL623344,,BAO_0000218,,
6402,Expert,50588,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL623345,,BAO_0000218,,
6403,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL875832,,BAO_0000218,,
6404,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623346,,BAO_0000218,,
6405,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623347,,BAO_0000218,,
6406,Intermediate,50588,,,Oral bioavailability of compound was determined in dog; Not tested,N,1,1,,CHEMBL623348,,BAO_0000218,,
6407,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623349,,BAO_0000218,,
6408,Intermediate,50588,,,Oral bioavailability (10 mg/kg) was determined in dog,N,1,1,,CHEMBL623350,,BAO_0000218,,
6409,Intermediate,50588,,,Oral bioavailability,N,1,1,,CHEMBL623351,,BAO_0000218,,
6410,Intermediate,50588,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),N,1,1,,CHEMBL623352,,BAO_0000218,,
6411,Intermediate,50588,,,Oral bioavailability administered in solution in rats,N,1,1,,CHEMBL623353,,BAO_0000218,,
6412,Intermediate,50588,,,Oral bioavailability after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL875833,,BAO_0000218,,
6413,Intermediate,50588,,,Oral bioavailability at a dose of 1 mg/kg in dogs,N,1,1,,CHEMBL623354,,BAO_0000218,,
6414,Intermediate,50588,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),N,1,1,,CHEMBL623355,,BAO_0000218,,
6415,Intermediate,50588,,,Oral bioavailability in Dog; ND = not determined,N,1,1,,CHEMBL623356,,BAO_0000218,,
6416,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623357,,BAO_0000218,,
6417,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623358,,BAO_0000218,,
6418,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623359,,BAO_0000218,,
6419,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623360,,BAO_0000218,,
6420,Intermediate,50588,,,Oral bioavailability in dogs; No data,N,1,1,,CHEMBL623361,,BAO_0000218,,
6421,Intermediate,50588,,,Oral bioavailability measured in dogs,N,1,1,,CHEMBL623362,,BAO_0000218,,
6422,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623363,,BAO_0000218,,
6423,Intermediate,50588,,,Oral bioavailability was calculated in dog,N,1,1,,CHEMBL623364,,BAO_0000218,,
6424,Intermediate,50588,,,Oral bioavailability after 0.3 mg/kg po administration in dog,N,1,1,,CHEMBL875834,,BAO_0000218,,
6425,Intermediate,50588,,,Oral bioavailability in dog (i.v. dosing),N,1,1,,CHEMBL623365,,BAO_0000218,,
6426,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623366,,BAO_0000218,,
6427,Intermediate,50588,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,N,1,1,,CHEMBL623367,,BAO_0000218,,
6428,Intermediate,50588,,,Oral bioavailability in Beagle dogs,N,1,1,,CHEMBL623368,,BAO_0000218,,
6429,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623369,,BAO_0000218,,
6430,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623370,,BAO_0000218,,
6431,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623371,,BAO_0000218,,
6432,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL623372,,BAO_0000218,,
6433,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621351,,BAO_0000218,,
6434,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621352,,BAO_0000218,,
6435,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621353,,BAO_0000218,,
6436,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621354,,BAO_0000218,,
6437,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621355,,BAO_0000218,,
6438,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621356,,BAO_0000218,,
6439,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621357,,BAO_0000218,,
6440,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621358,,BAO_0000218,,
6441,Intermediate,50588,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),N,1,1,,CHEMBL621359,,BAO_0000218,,
6442,Intermediate,50588,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,1,1,,CHEMBL621360,,BAO_0000218,,
6443,Intermediate,50588,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,1,1,,CHEMBL621361,,BAO_0000218,,
6444,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621362,,BAO_0000218,,
6445,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621363,,BAO_0000218,,
6446,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621364,,BAO_0000218,,
6447,Intermediate,50588,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),N,1,1,,CHEMBL621166,,BAO_0000218,,
6448,Intermediate,50588,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),N,1,1,,CHEMBL621167,,BAO_0000218,,
6449,Intermediate,50588,,,Oral bioavailability (F) in dogs,N,1,1,,CHEMBL621168,,BAO_0000218,,
6450,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL621169,,BAO_0000218,,
6451,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL875950,,BAO_0000218,,
6452,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL621170,,BAO_0000218,,
6453,Intermediate,50588,,,Oral bioavailability after peroral administration at 5 mpk in Dog,N,1,1,,CHEMBL621171,,BAO_0000218,,
6454,Intermediate,50588,,,Oral bioavailability in dog (dose 5 mg/kg),N,1,1,,CHEMBL621172,,BAO_0000218,,
6455,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL621173,,BAO_0000218,,
6456,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,Intermediate,50594,Kidney,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,Intermediate,50594,Spleen,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,Intermediate,50594,Heart,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,Intermediate,50594,Liver,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,1,1,,CHEMBL857901,,BAO_0000218,,
6501,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,1,1,,CHEMBL875274,,BAO_0000218,,
6502,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,1,1,,CHEMBL624379,,BAO_0000218,,
6503,Intermediate,50067,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,1,1,,CHEMBL624380,,BAO_0000218,,
6504,Intermediate,50192,,,Activity against Acinetobacter calcoaceticus (AC54),N,1,1,,CHEMBL624381,,BAO_0000218,,
6505,Intermediate,50714,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,N,1,1,,CHEMBL624382,,BAO_0000218,,
6506,Intermediate,50714,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,N,1,1,,CHEMBL624383,,BAO_0000218,,
6507,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,N,1,1,,CHEMBL624384,,BAO_0000218,,
6508,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,N,1,1,,CHEMBL624385,,BAO_0000218,,
6509,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,N,1,1,,CHEMBL624386,,BAO_0000218,,
6510,Intermediate,50296,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,N,1,1,,CHEMBL624387,,BAO_0000218,,
6511,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii 631,N,1,1,,CHEMBL624388,,BAO_0000218,,
6512,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii N/9,N,1,1,,CHEMBL624389,,BAO_0000218,,
6513,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii B74,N,1,1,,CHEMBL624390,,BAO_0000218,,
6514,Intermediate,50296,,,Plaque bactericidal index against Actinomyces naeslundii N/3,N,1,1,,CHEMBL875275,,BAO_0000218,,
6515,Intermediate,50056,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,N,1,1,,CHEMBL624391,,BAO_0000218,,
6516,Intermediate,50056,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",N,1,1,,CHEMBL623636,,BAO_0000218,,
6517,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,1,1,,CHEMBL623637,,BAO_0000218,,
6518,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,1,1,,CHEMBL623638,,BAO_0000218,,
6519,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,1,1,,CHEMBL623639,,BAO_0000218,,
6520,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,1,1,,CHEMBL623640,,BAO_0000218,,
6521,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,1,1,,CHEMBL623641,,BAO_0000218,,
6522,Intermediate,50532,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,N,1,1,,CHEMBL623642,,BAO_0000218,,
6523,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,1,1,,CHEMBL623643,,BAO_0000218,,
6524,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,1,1,,CHEMBL623644,,BAO_0000218,,
6525,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,1,1,,CHEMBL623645,,BAO_0000218,,
6526,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,1,1,,CHEMBL623646,,BAO_0000218,,
6527,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,1,1,,CHEMBL623647,,BAO_0000218,,
6528,Intermediate,50532,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,N,1,1,,CHEMBL623648,,BAO_0000218,,
6529,Intermediate,50366,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,1,1,,CHEMBL623649,,BAO_0000218,,
6530,Intermediate,50366,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,1,1,,CHEMBL623650,,BAO_0000218,,
6531,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,N,1,1,,CHEMBL623651,,BAO_0000218,,
6532,Expert,50366,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,N,1,1,,CHEMBL623652,,BAO_0000218,,
6533,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,N,1,1,,CHEMBL623653,,BAO_0000218,,
6534,Intermediate,50366,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,N,1,1,,CHEMBL623654,,BAO_0000218,,
6535,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus 8A06,N,1,1,,CHEMBL623655,,BAO_0000218,,
6536,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus M-100,N,1,1,,CHEMBL623656,,BAO_0000218,,
6537,Expert,50366,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,N,1,1,,CHEMBL623657,,BAO_0000218,,
6538,Intermediate,50366,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,1,1,,CHEMBL623658,,BAO_0000218,,
6539,Intermediate,50366,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,1,1,,CHEMBL623659,,BAO_0000218,,
6540,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus 626,N,1,1,,CHEMBL623660,,BAO_0000218,,
6541,Intermediate,50366,,,Plaque bactericidal index against Actinomyces viscosus T14V,N,1,1,,CHEMBL623661,,BAO_0000218,,
6542,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,N,1,1,,CHEMBL875281,,BAO_0000218,,
6543,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,N,1,1,,CHEMBL623662,,BAO_0000218,,
6544,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,N,1,1,,CHEMBL623663,,BAO_0000218,,
6545,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,N,1,1,,CHEMBL623664,,BAO_0000218,,
6546,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,N,1,1,,CHEMBL623665,,BAO_0000218,,
6547,Intermediate,80023,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,Intermediate,80661,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,Autocuration,22226,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,U,0,1,,CHEMBL620433,,BAO_0000219,,
6550,Intermediate,80024,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,1,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,Intermediate,80024,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,1,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,Intermediate,80024,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,N,1,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,Intermediate,80024,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,N,1,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,Expert,81037,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,N,1,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,Expert,80024,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",N,1,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,Expert,80024,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,N,1,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,Expert,80024,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,N,1,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,N,1,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,N,1,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,Expert,10649,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",H,8,1,,CHEMBL619660,,BAO_0000019,,
6561,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,N,1,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,Intermediate,80024,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,N,1,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,Intermediate,80663,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,N,1,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,Autocuration,22226,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,U,0,1,,CHEMBL619664,,BAO_0000219,,
6565,Autocuration,22226,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",U,0,1,,CHEMBL619665,,BAO_0000219,,
6566,Intermediate,80662,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),N,1,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,Intermediate,80662,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),N,1,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,Intermediate,80662,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,N,1,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,Intermediate,80566,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,N,1,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,Intermediate,80578,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,N,1,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,Expert,80089,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",N,1,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,Intermediate,80089,,,Average intracellular compound concentration when the hypoxic SER=1.6,N,1,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,Intermediate,80089,,,Average intracellular compound concentration when the hypoxic SER=1.6.,N,1,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,Intermediate,80089,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,N,1,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,Intermediate,80089,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,N,1,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,Intermediate,80089,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,N,1,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,Intermediate,80089,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",N,1,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,Intermediate,80089,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",N,1,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,Intermediate,80089,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,N,1,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,1,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,1,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,Intermediate,80089,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,N,1,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,Expert,80089,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,N,1,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,Intermediate,80089,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,N,1,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,Expert,80089,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,N,1,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,Intermediate,80089,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,N,1,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,Expert,80089,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,N,1,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,Expert,80089,,,Aerobic growth inhibition in Chinese hamster cell line AA8,N,1,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,Expert,80089,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,N,1,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,Expert,80089,,,Inhibition of growth under aerobic conditions in AA8 cells,N,1,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL621463,,BAO_0000218,,
6592,Intermediate,50588,,,Oral bioavailability in dog at 10 mg/kg of the compound,N,1,1,,CHEMBL621464,,BAO_0000218,,
6593,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),N,1,1,,CHEMBL621465,,BAO_0000218,,
6594,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),N,1,1,,CHEMBL621466,,BAO_0000218,,
6595,Intermediate,50588,,,Oral bioavailability in dog (mongrel),N,1,1,,CHEMBL621467,,BAO_0000218,,
6596,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL621468,,BAO_0000218,,
6597,Intermediate,50588,,,Oral bioavailability in dog (dose 10 mg/kg),N,1,1,,CHEMBL876734,,BAO_0000218,,
6598,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL618476,,BAO_0000218,,
6599,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,1,1,,CHEMBL618477,,BAO_0000218,,
6600,Intermediate,50588,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),N,1,1,,CHEMBL618478,,BAO_0000218,,
6601,Intermediate,50588,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,N,1,1,,CHEMBL618479,,BAO_0000218,,
6602,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL618480,,BAO_0000218,,
6603,Intermediate,50588,,,Bioavailability in dog (dose 3-10 mg/kg),N,1,1,,CHEMBL618481,,BAO_0000218,,
6604,Intermediate,50588,Plasma,,The compound was tested for bioavailability of compound in plasma of dog; Complete,N,1,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL618483,,BAO_0000218,,
6606,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL618484,,BAO_0000218,,
6607,Intermediate,50588,,,Bioavailability in dog,N,1,1,,CHEMBL618485,,BAO_0000218,,
6608,Intermediate,50588,,,oral bioavailability was measured in dogs,N,1,1,,CHEMBL618486,,BAO_0000218,,
6609,Intermediate,50588,,,Compound was tested for plasma protein binding in dog; Not determined,N,1,1,,CHEMBL618487,,BAO_0000218,,
6610,Intermediate,50588,,,Compound was tested for plasma protein binding of dog,N,1,1,,CHEMBL618488,,BAO_0000218,,
6611,Intermediate,50588,,,Compound was tested for plasma protein binding of dog; Not determined,N,1,1,,CHEMBL876735,,BAO_0000218,,
6612,Intermediate,50588,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,N,1,1,,CHEMBL618489,,BAO_0000218,,
6613,Intermediate,50588,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,N,1,1,,CHEMBL618490,,BAO_0000218,,
6614,Intermediate,50588,,,Half life was determined,N,1,1,,CHEMBL618491,,BAO_0000218,,
6615,Intermediate,50588,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,N,1,1,,CHEMBL618492,,BAO_0000218,,
6616,Intermediate,50588,,,Half life was evaluated in dog,N,1,1,,CHEMBL873354,,BAO_0000218,,
6617,Intermediate,50588,,,Half life was determined,N,1,1,,CHEMBL618493,,BAO_0000218,,
6618,Intermediate,50588,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618494,,BAO_0000218,,
6619,Intermediate,50588,Heart,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,Intermediate,50588,Kidney,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,Intermediate,50588,Liver,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,Intermediate,50588,Lung,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,Intermediate,50588,Spleen,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,1,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,Intermediate,50588,,,LogP in dog,N,1,1,,CHEMBL876736,,BAO_0000218,,
6625,Intermediate,50588,,,Partition coefficient (logP),N,1,1,,CHEMBL618500,,BAO_0000218,,
6626,Intermediate,50588,,,Partition coefficient in dog,N,1,1,,CHEMBL857831,,BAO_0000218,,
6627,Intermediate,50588,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL618501,,BAO_0000218,,
6628,Intermediate,50588,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),N,1,1,,CHEMBL618502,,BAO_0000218,,
6629,Intermediate,50588,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,N,1,1,,CHEMBL618503,,BAO_0000218,,
6630,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),N,1,1,,CHEMBL618504,,BAO_0000218,,
6631,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),N,1,1,,CHEMBL618505,,BAO_0000218,,
6632,Intermediate,50588,,,Metabolism of compound in dog S9 microsomes; Trace,N,1,1,,CHEMBL618506,,BAO_0000218,,
6633,Intermediate,50588,Liver,,In vitro metabolic potential in dog liver microsomes,N,1,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,Intermediate,50588,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,N,1,1,,CHEMBL876737,,BAO_0000218,,
6635,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL618508,,BAO_0000218,,
6636,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL618509,,BAO_0000218,,
6637,Intermediate,50588,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL618510,,BAO_0000218,,
6638,Intermediate,50588,,,The compound was tested for bioavailability in dogs,N,1,1,,CHEMBL618511,,BAO_0000218,,
6639,Intermediate,50588,,,The compound was tested for oral bioavailability in dogs,N,1,1,,CHEMBL618512,,BAO_0000218,,
6640,Intermediate,50588,,,Oral bioavailability in dog,N,1,1,,CHEMBL618513,,BAO_0000218,,
6641,Intermediate,50588,,,Compound was tested for percent protein binding (PB) in dog,N,1,1,,CHEMBL618514,,BAO_0000218,,
6642,Intermediate,50588,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,N,1,1,,CHEMBL620052,,BAO_0000218,,
6643,Intermediate,50588,Plasma,,Compound was evaluated for plasma clearance.,N,1,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,Intermediate,50588,Plasma,,The compound was tested for plasma clearance in dog,N,1,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,Intermediate,50588,Plasma,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,N,1,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,Intermediate,50588,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL620056,,BAO_0000218,,
6647,Intermediate,50588,Liver,,In vitro relative rate of metabolism was determined in dog liver microsomes,N,1,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,Intermediate,50588,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,N,1,1,,CHEMBL618939,,BAO_0000218,,
6649,Intermediate,50588,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,1,1,,CHEMBL618940,,BAO_0000218,,
6650,Intermediate,50588,,,Half life after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL618941,,BAO_0000218,,
6651,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,Intermediate,50594,Lung,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,N,1,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,N,1,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,N,1,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,N,1,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,Intermediate,50594,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,N,1,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,Intermediate,50594,Brain,,C2 in brain of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,Intermediate,50594,Kidney,,C2 in kidney of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,Intermediate,50594,Liver,,C2 in liver of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,Intermediate,50594,Lung,,C2 in lungs of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,Intermediate,50594,Spleen,,C2 in spleen of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,Intermediate,50594,,,Plasma clearance in mouse,N,1,1,,CHEMBL623487,,BAO_0000218,,
6665,Intermediate,50594,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,N,1,1,,CHEMBL623488,,BAO_0000218,,
6666,Intermediate,50594,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,N,1,1,,CHEMBL623489,,BAO_0000218,,
6667,Intermediate,50594,,,Clearance was evaluated in mice after intravenous administration,N,1,1,,CHEMBL875157,,BAO_0000218,,
6668,Intermediate,50594,,,Clearance was evaluated in mice after oral administration,N,1,1,,CHEMBL623490,,BAO_0000218,,
6669,Intermediate,50594,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,N,1,1,,CHEMBL623491,,BAO_0000218,,
6670,Intermediate,50594,,,Plasma clearance of compound was determined at 40 mg/Kg,N,1,1,,CHEMBL623492,,BAO_0000218,,
6671,Intermediate,50594,,,Plasma clearance of at 24 mg/Kg,N,1,1,,CHEMBL623493,,BAO_0000218,,
6672,Intermediate,50594,,,Plasma clearance at 24 mg/Kg,N,1,1,,CHEMBL623494,,BAO_0000218,,
6673,Intermediate,50594,,,Plasma clearance at 5 mg/Kg,N,1,1,,CHEMBL623495,,BAO_0000218,,
6674,Intermediate,50594,,,Plasma clearance in mice,N,1,1,,CHEMBL623496,,BAO_0000218,,
6675,Intermediate,50594,,,Plasma clearance value upon iv administration in mouse,N,1,1,,CHEMBL623497,,BAO_0000218,,
6676,Intermediate,50594,Plasma,,Total plasma clearance in mice,N,1,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,Intermediate,50594,,,Clearance in mouse,N,1,1,,CHEMBL623499,,BAO_0000218,,
6678,Intermediate,50594,,,Clearance value was determined,N,1,1,,CHEMBL623500,,BAO_0000218,,
6679,Intermediate,50594,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL623501,,BAO_0000218,,
6680,Intermediate,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL875158,,BAO_0000100,,
6681,Intermediate,50594,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,N,1,1,,CHEMBL623502,,BAO_0000218,,
6682,Intermediate,50594,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL623503,,BAO_0000218,,
6683,Intermediate,50594,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL623504,,BAO_0000218,,
6684,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,N,1,1,,CHEMBL623505,,BAO_0000218,,
6685,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,N,1,1,,CHEMBL623506,,BAO_0000218,,
6686,Intermediate,50594,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,1,1,,CHEMBL623507,,BAO_0000218,,
6687,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,N,1,1,,CHEMBL623508,,BAO_0000218,,
6688,Intermediate,50594,,,Cmax after oral administration at 30 mg/kg in ICR mouse,N,1,1,,CHEMBL623509,,BAO_0000218,,
6689,Intermediate,50594,,,Cmax after peroral administration in mice at 2.4 uM/kg,N,1,1,,CHEMBL875159,,BAO_0000218,,
6690,Intermediate,50594,Brain,,Cmax in brain of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,Intermediate,50594,Kidney,,Cmax in kidney of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,Intermediate,50594,Liver,,Cmax in liver of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,Intermediate,50594,Lung,,Cmax in lungs of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,Intermediate,50594,,,Cmax in mice at 18 uM/kg i.p. administration,N,1,1,,CHEMBL623514,,BAO_0000218,,
6695,Intermediate,50594,,,Cmax in mice at 23 uM/kg i.v. administration,N,1,1,,CHEMBL622609,,BAO_0000218,,
6696,Intermediate,50594,,,Cmax in mice at 24 uM/kg i.p. administration,N,1,1,,CHEMBL622610,,BAO_0000218,,
6697,Intermediate,50594,,,Cmax in mice at 25 uM/kg i.p. administration,N,1,1,,CHEMBL621823,,BAO_0000218,,
6698,Intermediate,50594,,,Cmax in mice at 26 uM/kg i.p. administration,N,1,1,,CHEMBL621824,,BAO_0000218,,
6699,Intermediate,50594,Spleen,,Cmax in spleen of mice at the oral dose of 50 mg/kg,N,1,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,Intermediate,50594,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,N,1,1,,CHEMBL621826,,BAO_0000218,,
6701,Intermediate,50594,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,N,1,1,,CHEMBL621827,,BAO_0000218,,
6702,Intermediate,50594,,,Cmax value was determined,N,1,1,,CHEMBL621828,,BAO_0000218,,
6703,Intermediate,50594,,,Cmax value in IRC mice,N,1,1,,CHEMBL621829,,BAO_0000218,,
6704,Intermediate,50594,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL621830,,BAO_0000218,,
6705,Intermediate,50594,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,1,1,,CHEMBL621831,,BAO_0000218,,
6706,Intermediate,50594,Plasma,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,1,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,Intermediate,50594,Plasma,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",N,1,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,Intermediate,50594,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,N,1,1,,CHEMBL624580,,BAO_0000218,,
6709,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,N,1,1,,CHEMBL624581,,BAO_0000218,,
6710,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,N,1,1,,CHEMBL624582,,BAO_0000218,,
6711,Intermediate,50535,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,N,1,1,,CHEMBL624583,,BAO_0000218,,
6712,Intermediate,80018,,,Inhibitory activity against human tumor cell line A0375 melanoma.,N,1,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,Expert,12512,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,D,9,1,,CHEMBL624585,,BAO_0000249,,
6714,Expert,114,,,Forskolin-induced cAMP production at human A1 adenosine receptor,D,9,1,,CHEMBL875165,,BAO_0000019,,
6715,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,H,8,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,H,8,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,H,8,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,H,8,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,H,8,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,Expert,114,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,D,9,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,H,8,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,H,8,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,H,8,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,H,8,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,8,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,H,8,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,H,8,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,Autocuration,114,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,H,8,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,Expert,114,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,8,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,Intermediate,80013,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,N,1,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,Autocuration,22226,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,U,0,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,Autocuration,22226,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,U,0,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,Intermediate,80013,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,N,1,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,Intermediate,80013,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,N,1,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,Intermediate,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,N,1,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,Intermediate,80089,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,N,1,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,Intermediate,80089,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,N,1,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,Intermediate,80089,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,N,1,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,Intermediate,80089,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,N,1,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,Intermediate,80089,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,N,1,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,Intermediate,80089,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",N,1,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,Intermediate,80089,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),N,1,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,Expert,80089,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",N,1,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,Expert,80089,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,N,1,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,Intermediate,80089,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,N,1,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,Intermediate,80089,,,Inhibitory activity against aerobic growth of AA8 cells.,N,1,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,Intermediate,80089,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,1,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,Expert,80089,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,1,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,Intermediate,80089,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,1,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,Expert,80089,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,N,1,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,Expert,80089,,,Cytotoxicity against AA8 cell line,N,1,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,Intermediate,80089,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),N,1,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,1,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,1,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,Intermediate,80089,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,1,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,Intermediate,80089,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,N,1,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,Intermediate,80089,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,1,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,Intermediate,80089,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,1,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,Autocuration,22224,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),U,0,1,,CHEMBL622734,,BAO_0000218,,
6765,Expert,80089,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,N,1,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,U,0,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,U,0,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,U,0,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,U,0,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,U,0,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,Autocuration,22224,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,U,0,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,Autocuration,22224,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,U,0,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,Expert,80089,,,Concentration required to reduce AA8 cell survival by 10%,N,1,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,Autocuration,22224,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",U,0,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,Autocuration,22224,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,0,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,0,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,U,0,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,Autocuration,22224,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,U,0,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,Autocuration,22224,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,U,0,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,Autocuration,22224,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,U,0,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,Autocuration,22224,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",U,0,1,,CHEMBL618841,,BAO_0000019,,
6782,Autocuration,22224,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,U,0,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,Autocuration,22224,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,U,0,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,Intermediate,50588,,,Half life period after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL618844,,BAO_0000218,,
6785,Intermediate,50588,,,Half life period after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL618845,,BAO_0000218,,
6786,Intermediate,50588,,,Half life was measured after oral 2b administration (tested in 6 dogs),N,1,1,,CHEMBL618846,,BAO_0000218,,
6787,Intermediate,50588,,,Half life was measured in dog after oral 17b administration,N,1,1,,CHEMBL618847,,BAO_0000218,,
6788,Intermediate,50588,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,N,1,1,,CHEMBL618848,,BAO_0000218,,
6789,Intermediate,50588,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,N,1,1,,CHEMBL618849,,BAO_0000218,,
6790,Intermediate,50588,,,Tmax value after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL618850,,BAO_0000218,,
6791,Intermediate,50588,,,Tmax value after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL618851,,BAO_0000218,,
6792,Intermediate,50588,,,Compound was evaluated for its half life when administered intravenously in dog,N,1,1,,CHEMBL873815,,BAO_0000218,,
6793,Intermediate,50588,Plasma,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,1,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,Intermediate,50588,,,Elimination Half-life of compound was determined in dog,N,1,1,,CHEMBL618853,,BAO_0000218,,
6795,Intermediate,50588,,,Half life of compound in dog following oral administration,N,1,1,,CHEMBL618854,,BAO_0000218,,
6796,Intermediate,50588,,,Half life of compound was determined in dog,N,1,1,,CHEMBL618855,,BAO_0000218,,
6797,Intermediate,50588,Blood,,Half life of compound was determined in dog blood,N,1,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,Intermediate,50588,,,Half life after oral and iv dosing in dogs,N,1,1,,CHEMBL875827,,BAO_0000218,,
6799,Intermediate,50588,,,Half life in dogs in hours,N,1,1,,CHEMBL618857,,BAO_0000218,,
6800,Intermediate,50588,,,Half life on i.v. administration of 2 mg/kg was measured in dog,N,1,1,,CHEMBL618858,,BAO_0000218,,
6801,Intermediate,50588,,,t1/2 in dog after oral dose (1 mg/kg),N,1,1,,CHEMBL618859,,BAO_0000218,,
6802,Intermediate,50588,,,Half life was evaluated in dog,N,1,1,,CHEMBL618860,,BAO_0000218,,
6803,Intermediate,50588,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,N,1,1,,CHEMBL618861,,BAO_0000218,,
6804,Intermediate,50588,,,Half life period of compound was determined after peroral administration at 2 mg/kg,N,1,1,,CHEMBL622539,,BAO_0000218,,
6805,Intermediate,50588,,,Half life period (10 mg/kg) was determined in dog,N,1,1,,CHEMBL622540,,BAO_0000218,,
6806,Intermediate,50588,,,Half life period (10 mg/kg) was determined in dog,N,1,1,,CHEMBL873803,,BAO_0000218,,
6807,Intermediate,50588,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,N,1,1,,CHEMBL873804,,BAO_0000218,,
6808,Intermediate,50588,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,N,1,1,,CHEMBL624311,,BAO_0000218,,
6809,Intermediate,50588,,,Half life period in dog,N,1,1,,CHEMBL624312,,BAO_0000218,,
6810,Intermediate,50588,,,Half life period in dogs after oral administration at 1 mg/kg,N,1,1,,CHEMBL624313,,BAO_0000218,,
6811,Intermediate,50588,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL624314,,BAO_0000218,,
6812,Intermediate,50588,,,Half-life of compound was determined in dogs,N,1,1,,CHEMBL624315,,BAO_0000218,,
6813,Intermediate,50588,Plasma,,Half-life in dog plasma,N,1,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,Intermediate,50588,,,Half-life in mongrel dogs was determined,N,1,1,,CHEMBL624317,,BAO_0000218,,
6815,Intermediate,50588,,,Half-life in dog upon oral administration,N,1,1,,CHEMBL624318,,BAO_0000218,,
6816,Intermediate,50588,,,Half-life in dog upon oral administration; Unable to calculate,N,1,1,,CHEMBL624319,,BAO_0000218,,
6817,Intermediate,50588,,,Half-life was measured in dog,N,1,1,,CHEMBL624496,,BAO_0000218,,
6818,Intermediate,50588,,,Half-life was measured in dog,N,1,1,,CHEMBL624497,,BAO_0000218,,
6819,Intermediate,50588,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,N,1,1,,CHEMBL624498,,BAO_0000218,,
6820,Intermediate,50588,,,Oral half life was determined,N,1,1,,CHEMBL624499,,BAO_0000218,,
6821,Intermediate,50588,Plasma,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,N,1,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,Intermediate,50588,Plasma,,Plasma half life was evaluated,N,1,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,Intermediate,50588,Plasma,,Plasma half life was evaluated in Dog,N,1,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,Intermediate,50588,Plasma,,Plasma half life was evaluated in dog,N,1,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,Intermediate,50588,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,N,1,1,,CHEMBL623668,,BAO_0000218,,
6826,Intermediate,50588,,,Tested for the half life value in dog,N,1,1,,CHEMBL623669,,BAO_0000218,,
6827,Intermediate,50588,,,Maximum time at the dose of 2 mg/kg in dog,N,1,1,,CHEMBL623670,,BAO_0000218,,
6828,Intermediate,50588,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL623671,,BAO_0000218,,
6829,Intermediate,50588,Blood,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,Intermediate,50588,Blood,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,Intermediate,50588,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,N,1,1,,CHEMBL623673,,BAO_0000218,,
6832,Intermediate,50588,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,1,1,,CHEMBL623674,,BAO_0000218,,
6833,Intermediate,50588,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,N,1,1,,CHEMBL623675,,BAO_0000218,,
6834,Intermediate,50588,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",N,1,1,,CHEMBL872526,,BAO_0000218,,
6835,Intermediate,50588,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",N,1,1,,CHEMBL623676,,BAO_0000218,,
6836,Intermediate,50588,Plasma,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,1,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,Intermediate,50588,Plasma,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,1,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,Intermediate,50588,Plasma,,Time taken for maximum plasma concentration in dog,N,1,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,Intermediate,50588,,,Time to reach Cmax after oral administration to dogs,N,1,1,,CHEMBL623680,,BAO_0000218,,
6840,Intermediate,50588,Plasma,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,Intermediate,50588,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,N,1,1,,CHEMBL623682,,BAO_0000218,,
6842,Intermediate,50588,,,Tmax after peroral administration (1 mg/kg) was determined in dog,N,1,1,,CHEMBL623683,,BAO_0000218,,
6843,Expert,50588,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL623684,,BAO_0000218,,
6844,Intermediate,50588,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,N,1,1,,CHEMBL622745,,BAO_0000218,,
6845,Intermediate,50588,,,Tmax after peroral administration in dogs at 2.4 uM/kg,N,1,1,,CHEMBL622746,,BAO_0000218,,
6846,Intermediate,50594,,,In vivo Cmax in mice at dose of 100 mg/kg,N,1,1,,CHEMBL622747,,BAO_0000218,,
6847,Intermediate,50594,,,In vivo Cmax in mice at dose of 50 mg/kg,N,1,1,,CHEMBL622748,,BAO_0000218,,
6848,Intermediate,50594,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,N,1,1,,CHEMBL622749,,BAO_0000218,,
6849,Intermediate,50594,Plasma,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,1,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,Intermediate,50594,Plasma,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,Intermediate,50594,Plasma,,Maximum concentration obtained in mouse plasma was determined,N,1,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,Intermediate,50594,Plasma,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,N,1,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,Intermediate,50594,Plasma,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,Intermediate,50594,Plasma,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,N,1,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,Intermediate,50594,Plasma,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,N,1,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,Intermediate,50594,Plasma,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,N,1,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,N,1,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,N,1,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,Intermediate,50594,Plasma,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,N,1,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,Intermediate,50594,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,N,1,1,,CHEMBL622816,,BAO_0000218,,
6861,Intermediate,50594,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,N,1,1,,CHEMBL623313,,BAO_0000218,,
6862,Intermediate,50594,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,N,1,1,,CHEMBL623314,,BAO_0000218,,
6863,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,N,1,1,,CHEMBL876788,,BAO_0000218,,
6864,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,N,1,1,,CHEMBL623315,,BAO_0000218,,
6865,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,N,1,1,,CHEMBL623316,,BAO_0000218,,
6866,Intermediate,50594,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,N,1,1,,CHEMBL623317,,BAO_0000218,,
6868,Intermediate,50594,,,Cmax in male mice after 2 mg/kg oral dose,N,1,1,,CHEMBL623319,,BAO_0000218,,
6869,Intermediate,50594,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,N,1,1,,CHEMBL623320,,BAO_0000218,,
6870,Intermediate,50594,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,N,1,1,,CHEMBL623321,,BAO_0000218,,
6871,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,N,1,1,,CHEMBL623322,,BAO_0000218,,
6872,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,N,1,1,,CHEMBL623323,,BAO_0000218,,
6873,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,N,1,1,,CHEMBL623324,,BAO_0000218,,
6874,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,N,1,1,,CHEMBL623325,,BAO_0000218,,
6875,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,N,1,1,,CHEMBL623326,,BAO_0000218,,
6876,Intermediate,50594,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,N,1,1,,CHEMBL623327,,BAO_0000218,,
6877,Intermediate,50594,Plasma,,Maximum concentration in plasma upon oral administration in mouse,N,1,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,Intermediate,50594,Plasma,,Maximum plasma concentration was evaluated in mice after oral administration,N,1,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,Intermediate,50594,Plasma,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,N,1,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,Intermediate,50594,,,Dose at which the compound induced fecal excretion in mice,N,1,1,,CHEMBL876789,,BAO_0000218,,
6893,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,N,1,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,N,1,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,N,1,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,Expert,80013,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,N,1,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,Intermediate,80013,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),N,1,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,Intermediate,80655,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,N,1,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,Intermediate,80655,,,Anticancer activity against human ovarian carcinoma A121 cells,N,1,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,Intermediate,80655,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,N,1,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,Intermediate,80655,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,N,1,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,Expert,80655,,,Growth inhibition of human ovarian carcinoma (A121) cell line,N,1,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,Expert,80655,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,N,1,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,Intermediate,80655,,,Cytotoxicity against human A121 ovarian cells,N,1,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,Intermediate,80655,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,N,1,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,Intermediate,80655,,,In vitro cytotoxicity against human ovarian carcinoma A21,N,1,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,Intermediate,80655,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,N,1,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,Intermediate,80655,,,Inhibitory activity of compound against human A121 ovarian cell line.,N,1,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,Intermediate,80655,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,N,1,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,Intermediate,80655,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,N,1,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,Intermediate,80012,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,N,1,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,Expert,80012,,,In vitro cytotoxicity against A172 human tumor cell lines.,N,1,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,Intermediate,80012,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,N,1,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,Intermediate,80012,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,N,1,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,Intermediate,80012,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,N,1,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,Autocuration,104729,,,Association constant against A2 adenosine receptor,H,4,1,,CHEMBL624725,,BAO_0000224,,
6917,Intermediate,80656,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,N,1,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,Autocuration,104713,,,Ratio of Ki for adenosine A2 and A1 receptor binding,D,5,1,,CHEMBL857535,,BAO_0000224,,
6919,Expert,80014,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,N,1,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,Expert,80014,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,N,1,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,Intermediate,80015,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,N,1,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,Intermediate,80657,,,Growth inhibition against Human squamous cell line(A 253),N,1,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,Intermediate,80657,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,N,1,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,Intermediate,80657,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,N,1,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,Intermediate,80657,,,Growth inhibition of A253 cell lines.,N,1,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),N,1,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,1,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,Intermediate,80657,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,1,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,Intermediate,81034,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,N,1,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,Intermediate,81034,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,N,1,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,Expert,81034,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,N,1,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,Intermediate,81034,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),N,1,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,Expert,81034,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,N,1,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,Intermediate,81034,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,N,1,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,1,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,Expert,81034,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,N,1,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,Expert,81034,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,N,1,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,Expert,81034,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,N,1,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,N,1,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,N,1,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,N,1,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,Autocuration,22224,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,U,0,1,,CHEMBL623826,,BAO_0000019,,
6943,Autocuration,22224,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,U,0,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,U,0,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,U,0,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,Autocuration,22224,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),U,0,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,Autocuration,22224,,,Growth inhibition against CHO-derived cell line AA8,U,0,1,,CHEMBL623831,,BAO_0000019,,
6948,Autocuration,22224,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],U,0,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,Expert,80089,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,N,1,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,Expert,80089,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,N,1,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,Autocuration,22224,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,U,0,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,Autocuration,22224,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,U,0,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,Autocuration,22224,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,U,0,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,Expert,80089,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,N,1,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,Autocuration,12675,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,H,8,1,,CHEMBL623839,,BAO_0000019,,
6956,Autocuration,12675,,,Number of binding sites (n) of isolated serum protein AAG,H,8,1,,CHEMBL623840,,BAO_0000019,,
6957,Intermediate,22222,,,Association constant for binding to AATT duplex,M,3,1,,CHEMBL623841,,BAO_0000225,,
6958,Expert,100090,,,Inhibition of ABAE human fibroblast cell proliferation,N,1,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,Intermediate,80668,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",N,1,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,Expert,102444,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,D,9,1,,CHEMBL618669,,BAO_0000218,,
6961,Expert,102444,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,D,9,1,,CHEMBL618670,,BAO_0000218,,
6962,Autocuration,69,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,H,8,1,,CHEMBL618671,,BAO_0000357,,
6963,Autocuration,69,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,H,8,1,,CHEMBL618672,,BAO_0000357,,
6964,Intermediate,80669,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,N,1,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,Intermediate,80669,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),N,1,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,U,0,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),U,0,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,Autocuration,22224,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),U,0,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,Intermediate,80025,,,Inhibition of growth of renal cancer ACHN cell line,N,1,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,Intermediate,80025,,,Inhibition of growth of ACHN renal cancer cell line,N,1,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,Intermediate,80025,,,Inhibitory concentration required against ACHN renal cancer cell line,N,1,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,Expert,80025,,,Concentration required to inhibit growth of human renal (ACHN) cell line,N,1,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,Intermediate,80025,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,N,1,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,Intermediate,80025,,,Cytotoxic activity against ACHN Renal cancer cell line,N,1,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,Intermediate,80025,,,Cytotoxicity evaluation against ACHN renal cancer cells,N,1,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,Intermediate,80025,,,In vitro antitumor activity against human renal ACHN cell line,N,1,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,Intermediate,80025,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,1,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,Intermediate,80025,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,1,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,Intermediate,80025,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",N,1,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,Intermediate,80025,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,1,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,Expert,80025,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,1,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,Intermediate,80025,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,N,1,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,Intermediate,80025,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,N,1,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,Intermediate,80025,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,Intermediate,80025,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",N,1,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,Intermediate,80025,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,N,1,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,Intermediate,80025,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,N,1,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,Intermediate,80025,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,N,1,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,Intermediate,80025,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,N,1,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,Intermediate,80025,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,N,1,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,Intermediate,50588,,,Tmax value after administration of 4 mg/Kg oral dose in dog,N,1,1,,CHEMBL872527,,BAO_0000218,,
6992,Intermediate,50588,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",N,1,1,,CHEMBL876500,,BAO_0000218,,
6993,Intermediate,50588,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL619379,,BAO_0000218,,
6994,Intermediate,50588,,,Volume distribution after 15 mg/kg iv dose in Dogs,N,1,1,,CHEMBL619538,,BAO_0000218,,
6995,Intermediate,50588,,,Volume distribution after 30 mg/kg po dose in Dogs,N,1,1,,CHEMBL619539,,BAO_0000218,,
6996,Intermediate,50588,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,N,1,1,,CHEMBL619540,,BAO_0000218,,
6997,Intermediate,50588,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,N,1,1,,CHEMBL619541,,BAO_0000218,,
6998,Intermediate,50588,,,Volume of distribution was evaluated in dog,N,1,1,,CHEMBL619542,,BAO_0000218,,
6999,Intermediate,50588,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,1,1,,CHEMBL619543,,BAO_0000218,,
7000,Expert,50588,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619544,,BAO_0000218,,
7001,Intermediate,50588,,,The compound was tested for volume of distribution in dog,N,1,1,,CHEMBL619545,,BAO_0000218,,
7002,Intermediate,50588,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,N,1,1,,CHEMBL619546,,BAO_0000218,,
7003,Intermediate,50588,,,Vd (1 mg/kg) was determined in dog (in vivo),N,1,1,,CHEMBL619547,,BAO_0000218,,
7004,Intermediate,50588,,,Vd in dog,N,1,1,,CHEMBL619548,,BAO_0000218,,
7005,Intermediate,50588,,,Volume distribution was determined,N,1,1,,CHEMBL619549,,BAO_0000218,,
7006,Intermediate,50588,,,Volume of distribution in dog,N,1,1,,CHEMBL619550,,BAO_0000218,,
7007,Intermediate,50588,,,Volume of distribution by as 4 fold increase by iv administration in dogs,N,1,1,,CHEMBL876501,,BAO_0000218,,
7008,Intermediate,50588,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,1,1,,CHEMBL619551,,BAO_0000218,,
7009,Intermediate,50588,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL619552,,BAO_0000218,,
7010,Intermediate,50588,,,Volume distribution at the dose of 2 mg/kg in dog,N,1,1,,CHEMBL619553,,BAO_0000218,,
7011,Intermediate,50588,,,Steady state volume of distribution was determined,N,1,1,,CHEMBL618722,,BAO_0000218,,
7012,Intermediate,50588,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,N,1,1,,CHEMBL618723,,BAO_0000218,,
7013,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,1,1,,CHEMBL618724,,BAO_0000218,,
7014,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,1,1,,CHEMBL618725,,BAO_0000218,,
7015,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,1,1,,CHEMBL618726,,BAO_0000218,,
7016,Intermediate,50588,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,1,1,,CHEMBL618727,,BAO_0000218,,
7017,Intermediate,50588,,,Pharmacokinetic property (vdss) was measured in dog,N,1,1,,CHEMBL624233,,BAO_0000218,,
7018,Intermediate,50588,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL624234,,BAO_0000218,,
7019,Intermediate,50588,,,Vdss was determined after iv 0.1 mg/kg administration in dog,N,1,1,,CHEMBL624235,,BAO_0000218,,
7020,Intermediate,50588,,,Volume displacement was calculated in dog,N,1,1,,CHEMBL624236,,BAO_0000218,,
7021,Intermediate,50588,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,1,1,,CHEMBL624237,,BAO_0000218,,
7022,Intermediate,50588,,,Volume distribution constant was determined,N,1,1,,CHEMBL624238,,BAO_0000218,,
7023,Intermediate,50588,,,Volume distribution at a dose of 1 uM/kg in dog was determined,N,1,1,,CHEMBL624239,,BAO_0000218,,
7024,Intermediate,50588,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,1,1,,CHEMBL875829,,BAO_0000218,,
7025,Intermediate,50588,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,1,1,,CHEMBL624240,,BAO_0000218,,
7026,Intermediate,50588,,,Volume distribution (Vdss) was measured in dog,N,1,1,,CHEMBL624241,,BAO_0000218,,
7027,Intermediate,50588,,,Volume distribution (Vdss) was measured in dog,N,1,1,,CHEMBL624242,,BAO_0000218,,
7028,Intermediate,50588,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL624243,,BAO_0000218,,
7029,Intermediate,50588,,,Volume of distribution in steady state was determined in dog,N,1,1,,CHEMBL624244,,BAO_0000218,,
7030,Intermediate,50588,,,Volume of distribution of compound was determined in dog,N,1,1,,CHEMBL624245,,BAO_0000218,,
7031,Intermediate,50588,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,N,1,1,,CHEMBL624246,,BAO_0000218,,
7032,Intermediate,50588,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,1,1,,CHEMBL624247,,BAO_0000218,,
7033,Intermediate,50588,,,Volume of distribution (Vdss) was measured in dog,N,1,1,,CHEMBL624248,,BAO_0000218,,
7034,Intermediate,50588,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,1,1,,CHEMBL624249,,BAO_0000218,,
7035,Intermediate,50588,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624250,,BAO_0000218,,
7036,Intermediate,50588,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624251,,BAO_0000218,,
7037,Intermediate,50588,,,Maximum rate of depolarization of the upstroke of the action potential,N,1,1,,CHEMBL624252,,BAO_0000218,,
7038,Intermediate,50588,,,Steady state volume distribution in dog,N,1,1,,CHEMBL624253,,BAO_0000218,,
7039,Intermediate,50588,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,N,1,1,,CHEMBL624950,,BAO_0000218,,
7040,Intermediate,50588,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,N,1,1,,CHEMBL624951,,BAO_0000218,,
7041,Intermediate,50588,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,N,1,1,,CHEMBL875830,,BAO_0000218,,
7042,Intermediate,50588,,,Volume distribution in dog after administration of 1 mg/kg iv,N,1,1,,CHEMBL624952,,BAO_0000218,,
7043,Intermediate,50588,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,N,1,1,,CHEMBL624953,,BAO_0000218,,
7044,Intermediate,50588,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,N,1,1,,CHEMBL624954,,BAO_0000218,,
7045,Intermediate,50588,,,Vss on i.v. administration of 2 mg/kg was measured in dog,N,1,1,,CHEMBL624955,,BAO_0000218,,
7046,Intermediate,50588,,,Vss was determined,N,1,1,,CHEMBL624956,,BAO_0000218,,
7047,Intermediate,50588,,,Vss in dog,N,1,1,,CHEMBL625129,,BAO_0000218,,
7048,Intermediate,50588,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,1,1,,CHEMBL625130,,BAO_0000218,,
7049,Intermediate,50588,,,Volume distribution in dogs,N,1,1,,CHEMBL625131,,BAO_0000218,,
7050,Intermediate,50588,,,Volume of distribution in dog,N,1,1,,CHEMBL625132,,BAO_0000218,,
7051,Intermediate,50588,,,Tested for the oral bioavailability in dog,N,1,1,,CHEMBL872263,,BAO_0000218,,
7060,Intermediate,50594,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,N,1,1,,CHEMBL624336,,BAO_0000218,,
7061,Intermediate,50594,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,N,1,1,,CHEMBL624337,,BAO_0000218,,
7062,Intermediate,50594,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,N,1,1,,CHEMBL624338,,BAO_0000218,,
7063,Intermediate,50594,,,Bioavailability was measured in mouse,N,1,1,,CHEMBL624339,,BAO_0000218,,
7064,Intermediate,50594,,,Bioavailability in mouse,N,1,1,,CHEMBL624340,,BAO_0000218,,
7065,Intermediate,50594,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL624341,,BAO_0000218,,
7066,Intermediate,50594,,,Bioavailability in mouse,N,1,1,,CHEMBL624342,,BAO_0000218,,
7067,Intermediate,50594,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,N,1,1,,CHEMBL624343,,BAO_0000218,,
7068,Intermediate,50594,,,Oral bioavailability in mouse,N,1,1,,CHEMBL624344,,BAO_0000218,,
7069,Intermediate,50594,,,Oral availability at 50 mg/kg po in male mice,N,1,1,,CHEMBL624345,,BAO_0000218,,
7070,Intermediate,50594,,,Oral bioavailability in mouse (dose 10 mg/kg),N,1,1,,CHEMBL624346,,BAO_0000218,,
7071,Expert,50594,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL624347,,BAO_0000218,,
7072,Intermediate,50594,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",N,1,1,,CHEMBL624348,,BAO_0000218,,
7074,Intermediate,50594,,,Oral bioavailability in mouse,N,1,1,,CHEMBL622754,,BAO_0000218,,
7075,Intermediate,50594,,,Oral bioavailability in vivo in mice;ND=Not determined,N,1,1,,CHEMBL622755,,BAO_0000218,,
7076,Intermediate,50594,,,Oral bioavailability in mouse at 10 mg/kg of the compound,N,1,1,,CHEMBL622756,,BAO_0000218,,
7077,Intermediate,50594,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),N,1,1,,CHEMBL622757,,BAO_0000218,,
7078,Intermediate,50594,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),N,1,1,,CHEMBL622758,,BAO_0000218,,
7079,Intermediate,50594,,,Tested for bioavailability of the compound,N,1,1,,CHEMBL622759,,BAO_0000218,,
7080,Intermediate,50594,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,N,1,1,,CHEMBL622760,,BAO_0000218,,
7081,Intermediate,50594,Plasma,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,N,1,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by human plasma. ,N,1,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,N,1,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,N,1,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,Intermediate,50594,Plasma,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,N,1,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,N,1,1,,CHEMBL622766,,BAO_0000218,,
7087,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,N,1,1,,CHEMBL622767,,BAO_0000218,,
7088,Intermediate,50594,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,N,1,1,,CHEMBL622768,,BAO_0000218,,
7089,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,Intermediate,50594,Blood,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,1,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,Intermediate,81034,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,N,1,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,Expert,81034,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,N,1,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,Intermediate,81034,,,Compound was evaluated for cytotoxicity against A2780 cell line,N,1,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,Expert,81034,,,Inhibition of A2780 cell clonogenic assay,N,1,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,Expert,81034,,,Cytotoxic effect on ovarian cancer cell line (A2780),N,1,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,Intermediate,81034,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,N,1,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,Intermediate,81034,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",N,1,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,Expert,81034,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,N,1,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,Expert,81034,,,Antiproliferative activity against human A2780 cells,N,1,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,Expert,81034,,,Inhibition of human A2780 cell proliferation,N,1,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,Expert,81034,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,N,1,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,Expert,81034,,,Inhibition of human A2780 cell proliferation (No data),N,1,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,Intermediate,81034,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,N,1,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,Intermediate,81034,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,N,1,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,Expert,81034,,,Growth inhibition against A2780 wild-type ovarian cell lines,N,1,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,Intermediate,81034,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,N,1,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,Autocuration,104766,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,D,5,1,,CHEMBL622599,,BAO_0000019,,
7115,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,1,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,1,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,1,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,Intermediate,81034,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,1,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,Intermediate,81034,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,1,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,Intermediate,81034,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,1,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,Expert,81034,,,In vitro inhibition of human ovarian cell line A2780,N,1,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,Expert,81034,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",N,1,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,Intermediate,81034,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),N,1,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,Expert,81034,,,Concentration required to inhibit A2780-cell growth by 50%,N,1,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,Expert,81034,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,N,1,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,Expert,81034,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,N,1,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,Intermediate,81034,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,N,1,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,Expert,81034,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,N,1,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,Expert,81034,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,1,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,Intermediate,81034,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,1,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,Intermediate,81034,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,N,1,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,Intermediate,81034,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",N,1,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,Intermediate,81034,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",N,1,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,Intermediate,81034,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",N,1,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,Intermediate,81034,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",N,1,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,Intermediate,81034,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,N,1,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,Intermediate,81034,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,1,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,Intermediate,81034,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,1,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,Intermediate,81034,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",N,1,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,Intermediate,81034,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,N,1,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,Intermediate,81034,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,N,1,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,Expert,81034,,,In vitro antitumor activity against A2780 cell line.,N,1,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,Intermediate,81034,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,N,1,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,Expert,81034,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,N,1,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,Intermediate,80025,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,N,1,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,Intermediate,80025,,,The IC50 value was measured on ACHN cell line in renal tumor type.,N,1,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,Intermediate,80025,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,N,1,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,Expert,80025,,,In vitro lethal concentration against most sensitive ACHN cell line,N,1,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,Intermediate,80025,,,Tested for cytotoxic activity against renal cancer ACHN cell line,N,1,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,Intermediate,80025,,,Compound tested for growth inhibition of renal cancer cell line ACHN,N,1,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,Intermediate,80025,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,N,1,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,Intermediate,80025,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,N,1,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,Intermediate,80025,,,In vitro anticancer activity against ACHN renal cancer cell line,N,1,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,Intermediate,80025,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,N,1,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,Intermediate,80025,,,Percent selectivity was evaluated in renal ACHN cell lines,N,1,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,Intermediate,80025,,,In vitro inhibitory activity against renal ACHN cancer cell line,N,1,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,Intermediate,80025,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,N,1,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,Intermediate,80025,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,N,1,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,Intermediate,80025,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,1,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,Intermediate,80025,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,N,1,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,Expert,80025,,,Cytotoxic effect on renal cancer line ACHN,N,1,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,Intermediate,80025,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,N,1,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,Intermediate,80025,,,In vitro inhibition of Renal Cancer ACHN cell lines,N,1,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,Intermediate,80025,,,Antitumor activity against human renal adenocarcinoma ACHN cells,N,1,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,Expert,80025,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,N,1,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,Intermediate,80025,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,N,1,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,Intermediate,80025,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,1,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,Intermediate,80025,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",N,1,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,Intermediate,80025,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,N,1,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,Intermediate,80025,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,1,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,Intermediate,80025,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,N,1,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,Intermediate,80025,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,N,1,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,Autocuration,22224,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,0,1,,CHEMBL621840,,BAO_0000019,,
7174,Autocuration,10647,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,H,8,1,,CHEMBL621841,,BAO_0000019,,
7175,Expert,50529,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,N,1,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,Intermediate,50529,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,N,1,1,,CHEMBL876595,,BAO_0000218,,
7177,Autocuration,12159,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),H,8,1,,CHEMBL620221,,BAO_0000357,,
7178,Autocuration,12159,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),H,8,1,,CHEMBL620222,,BAO_0000357,,
7179,Intermediate,80670,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,N,1,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,Intermediate,80671,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,N,1,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,Intermediate,80671,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,N,1,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,Intermediate,80671,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",N,1,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,Intermediate,80671,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,N,1,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,Intermediate,80671,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,N,1,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,Intermediate,80671,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,N,1,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,Autocuration,22224,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,U,0,1,,CHEMBL620513,,BAO_0000019,,
7187,Autocuration,22224,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,U,0,1,,CHEMBL620514,,BAO_0000019,,
7188,Autocuration,22224,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,U,0,1,,CHEMBL620515,,BAO_0000019,,
7189,Autocuration,22224,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),U,0,1,,CHEMBL620516,,BAO_0000218,,
7190,Intermediate,50588,Plasma,,AUC value in dog after IV administration at a dose of 5 mg/kg,N,1,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,Intermediate,50588,Plasma,,AUC value in dog after oral administration at a dose of 5 mg/kg,N,1,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,Intermediate,50588,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,N,1,1,,CHEMBL620519,,BAO_0000218,,
7193,Intermediate,50588,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,N,1,1,,CHEMBL621386,,BAO_0000218,,
7194,Intermediate,50588,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,N,1,1,,CHEMBL621387,,BAO_0000218,,
7195,Intermediate,50588,,,Compound was evaluated for its clearance when administered intravenously in dog,N,1,1,,CHEMBL621388,,BAO_0000218,,
7196,Intermediate,50588,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL621389,,BAO_0000218,,
7197,Intermediate,50588,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,1,1,,CHEMBL621390,,BAO_0000218,,
7198,Intermediate,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL621391,,BAO_0000100,,
7199,Intermediate,50588,,,Half life in dog,N,1,1,,CHEMBL621392,,BAO_0000218,,
7200,Intermediate,50588,,,Time taken for EC90 was determined when tested in dog,N,1,1,,CHEMBL621393,,BAO_0000218,,
7201,Intermediate,50588,,,Half life (iv) was determined,N,1,1,,CHEMBL621394,,BAO_0000218,,
7202,Intermediate,50588,Liver,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,N,1,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,Intermediate,50588,,,Area under the curve was calculated in dog after iv administration,N,1,1,,CHEMBL621396,,BAO_0000218,,
7204,Intermediate,50588,,,Area under the curve was calculated in dog after peroral administration,N,1,1,,CHEMBL621397,,BAO_0000218,,
7205,Intermediate,50588,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,N,1,1,,CHEMBL621398,,BAO_0000218,,
7206,Intermediate,50588,,,pKa was evaluated in dog,N,1,1,,CHEMBL618818,,BAO_0000218,,
7207,Intermediate,50588,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,N,1,1,,CHEMBL618819,,BAO_0000218,,
7208,Intermediate,50588,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL618820,,BAO_0000218,,
7209,Intermediate,50588,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL873810,,BAO_0000218,,
7210,Intermediate,50588,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,1,1,,CHEMBL876606,,BAO_0000218,,
7211,Intermediate,50588,,,Compound was evaluated for the half-life (t 1/2) in hours,N,1,1,,CHEMBL618821,,BAO_0000218,,
7212,Intermediate,50588,Blood,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,Intermediate,50588,Blood,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,1,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,Intermediate,50588,,,Half life after intravenous administration of 1 mg/kg in dog,N,1,1,,CHEMBL618824,,BAO_0000218,,
7215,Intermediate,50588,,,Half life was measured in dog,N,1,1,,CHEMBL618825,,BAO_0000218,,
7216,Intermediate,50588,,,Half life period in dog after 5 mg/kg dose,N,1,1,,CHEMBL618826,,BAO_0000218,,
7217,Intermediate,50588,,,Half life period was evaluated in dog; 4-4.8,N,1,1,,CHEMBL618827,,BAO_0000218,,
7218,Intermediate,50588,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,1,1,,CHEMBL618828,,BAO_0000218,,
7219,Intermediate,50588,,,Half-life was determined in dog after a3 mg/kg of iv dose,N,1,1,,CHEMBL618829,,BAO_0000218,,
7220,Intermediate,50588,,,Half-life was determined,N,1,1,,CHEMBL618830,,BAO_0000218,,
7221,Intermediate,50588,,,Half life in dogs,N,1,1,,CHEMBL618831,,BAO_0000218,,
7222,Intermediate,50588,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,N,1,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,Intermediate,50588,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,N,1,1,,CHEMBL619649,,BAO_0000218,,
7224,Intermediate,50588,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,N,1,1,,CHEMBL876607,,BAO_0000218,,
7225,Intermediate,50588,,,Compound was evaluated for the half life period after oral administration in conscious dog.,N,1,1,,CHEMBL619650,,BAO_0000218,,
7226,Intermediate,50588,,,Compound was tested for half life in dog,N,1,1,,CHEMBL619651,,BAO_0000218,,
7227,Intermediate,50588,,,Compound was tested for its half life in dog,N,1,1,,CHEMBL619652,,BAO_0000218,,
7228,Intermediate,50588,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,1,1,,CHEMBL619653,,BAO_0000218,,
7229,Intermediate,50588,,,Half life of compound in dog was determined,N,1,1,,CHEMBL619654,,BAO_0000218,,
7230,Intermediate,50588,,,Half life (iv) was determined,N,1,1,,CHEMBL619655,,BAO_0000218,,
7231,Intermediate,50588,Blood,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),N,1,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,Intermediate,50588,Plasma,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,1,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,Intermediate,50588,Plasma,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,1,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,Intermediate,50588,,,Half life in dog,N,1,1,,CHEMBL621366,,BAO_0000218,,
7235,Intermediate,50588,Plasma,,Half life in dog plasma,N,1,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,Intermediate,50588,Plasma,,Half life in dog plasma after administration of 0.25 mg/kg iv,N,1,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,Intermediate,50588,Plasma,,Half life in dog plasma after administration of 1 mg/kg iv,N,1,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,Intermediate,50588,Plasma,,Half life in dog plasma was determined at dose 10 mg/kg,N,1,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,Intermediate,50588,,,Half life in dog was determined,N,1,1,,CHEMBL621371,,BAO_0000218,,
7240,Intermediate,50588,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,1,1,,CHEMBL621372,,BAO_0000218,,
7241,Intermediate,50588,Plasma,,Half life upon exposure to human plasma,N,1,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,Intermediate,50588,,,Half life was calculated in dog,N,1,1,,CHEMBL621374,,BAO_0000218,,
7243,Intermediate,50588,,,Half life was determined,N,1,1,,CHEMBL621375,,BAO_0000218,,
7244,Intermediate,50588,,,Half life was determined,N,1,1,,CHEMBL621376,,BAO_0000218,,
7245,Intermediate,50588,,,Half life by intravenous administration of 1.2 mg/kg in dog,N,1,1,,CHEMBL619624,,BAO_0000218,,
7246,Intermediate,50588,,,Half life in dog,N,1,1,,CHEMBL875840,,BAO_0000218,,
7247,Intermediate,50588,,,Half life in dog after intra venous administration of the compound,N,1,1,,CHEMBL619625,,BAO_0000218,,
7248,Intermediate,50588,,,Half life in dog after intra venous administration of the compound; ND means Not determined,N,1,1,,CHEMBL619626,,BAO_0000218,,
7249,Intermediate,50588,,,Half life in dog after po administration of the compound,N,1,1,,CHEMBL619627,,BAO_0000218,,
7250,Intermediate,50588,,,Half life in dog after po administration of the compound; ND means Not determined,N,1,1,,CHEMBL873817,,BAO_0000218,,
7251,Intermediate,50588,,,Half life in dog at the single oral dose of 1 mg/kg,N,1,1,,CHEMBL619628,,BAO_0000218,,
7252,Intermediate,50588,,,Half life in dogs,N,1,1,,CHEMBL619629,,BAO_0000218,,
7253,Intermediate,50588,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,N,1,1,,CHEMBL619630,,BAO_0000218,,
7254,Intermediate,50588,,,Half life in rat,N,1,1,,CHEMBL619631,,BAO_0000218,,
7255,Intermediate,50588,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,1,1,,CHEMBL619632,,BAO_0000218,,
7256,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,Intermediate,50594,Bone,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,Intermediate,50594,Gut,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,Intermediate,50594,Heart,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,1,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,Intermediate,50594,Kidney,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,Intermediate,50594,Liver,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,Intermediate,81034,,,In vitro cytotoxicity against A2780 (human ovarian cancer),N,1,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,Intermediate,81034,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,N,1,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,Intermediate,81034,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,N,1,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,Intermediate,81034,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,N,1,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,Expert,81034,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,N,1,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,Expert,81034,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,N,1,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,Expert,81034,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,N,1,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,Intermediate,81034,,,In vitro cytotoxicity against A2780 cell line,N,1,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,Intermediate,81034,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,N,1,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,Intermediate,81034,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,N,1,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,Intermediate,81034,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,N,1,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,Intermediate,81034,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",N,1,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,Intermediate,81034,,,Inhibition of tubulin polymerization in analogy of ca.,N,1,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,Intermediate,81034,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,N,1,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,Expert,81034,,,Cytotoxic effect in ovarian cancer cell line (A2780),N,1,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,Intermediate,81034,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,N,1,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,Intermediate,81034,,,Tested for the cytotoxicity in A2780 ovarian cell line,N,1,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,1,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,Intermediate,81034,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,N,1,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,N,1,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,1,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,N,1,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,Intermediate,80017,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),N,1,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,Intermediate,81034,,,In vivo log of cells killed after administration of compound in A2780 cell line,N,1,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,Intermediate,81034,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,N,1,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,N,1,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,N,1,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,N,1,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,N,1,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,Intermediate,81034,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),N,1,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,Intermediate,81034,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,N,1,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,Expert,81034,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,N,1,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,Expert,81034,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,1,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,N,1,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,Intermediate,81034,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,N,1,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,Intermediate,81034,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,N,1,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,Intermediate,81034,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",N,1,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,Intermediate,81034,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),N,1,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,Expert,81034,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",N,1,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,Intermediate,81034,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,1,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,Intermediate,81034,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,1,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,Intermediate,81034,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,1,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,Intermediate,81034,,,In vitro antiproliferative activity against A2780 cell line,N,1,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,Expert,81034,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,N,1,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,N,1,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,Intermediate,81034,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,N,1,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,Intermediate,50588,,,Vc value in dog after IV administration at a dose of 5 mg/kg,N,1,1,,CHEMBL621869,,BAO_0000218,,
7337,Intermediate,50588,,,Half life period in dog after IV administration at a dose of 5 mg/kg,N,1,1,,CHEMBL621870,,BAO_0000218,,
7338,Autocuration,22224,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,U,0,1,,CHEMBL621871,,BAO_0000019,,
7339,Autocuration,22224,Plasma,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,Autocuration,22224,Plasma,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,Autocuration,22224,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,0,1,,CHEMBL621245,,BAO_0000218,,
7342,Autocuration,22224,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,U,0,1,,CHEMBL621246,,BAO_0000218,,
7343,Autocuration,22224,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,U,0,1,,CHEMBL621247,,BAO_0000218,,
7344,Autocuration,22224,,,Oral Bioavailability in rat,U,0,1,,CHEMBL618386,,BAO_0000218,,
7345,Autocuration,22224,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,0,1,,CHEMBL618387,,BAO_0000218,,
7346,Autocuration,22224,,,Area under curve value in monkey at a dose of 5 mg/kg,U,0,1,,CHEMBL618388,,BAO_0000218,,
7347,Autocuration,22224,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,U,0,1,,CHEMBL618389,,BAO_0000218,,
7348,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,U,0,1,,CHEMBL618574,,BAO_0000019,,
7349,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,U,0,1,,CHEMBL618575,,BAO_0000019,,
7350,Autocuration,22224,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,U,0,1,,CHEMBL618576,,BAO_0000019,,
7351,Autocuration,22224,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,U,0,1,,CHEMBL618577,,BAO_0000218,,
7352,Autocuration,22224,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,U,0,1,,CHEMBL876487,,BAO_0000218,,
7353,Autocuration,22224,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,U,0,1,,CHEMBL618578,,BAO_0000218,,
7354,Autocuration,22224,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL618579,,BAO_0000218,,
7355,Autocuration,22224,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL618580,,BAO_0000019,,
7356,Autocuration,22224,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,U,0,1,,CHEMBL618581,,BAO_0000218,,
7357,Autocuration,22224,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,U,0,1,,CHEMBL618582,,BAO_0000218,,
7358,Autocuration,22224,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,U,0,1,,CHEMBL618583,,BAO_0000218,,
7359,Autocuration,22224,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,U,0,1,,CHEMBL618584,,BAO_0000218,,
7360,Autocuration,22224,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),U,0,1,,CHEMBL618585,,BAO_0000218,,
7361,Autocuration,22224,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),U,0,1,,CHEMBL618586,,BAO_0000218,,
7362,Autocuration,22224,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL618587,,BAO_0000218,,
7363,Autocuration,22224,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,0,1,,CHEMBL618588,,BAO_0000218,,
7364,Autocuration,22224,,,Binding towards monkey plasma protein at 10 uM,U,0,1,,CHEMBL618589,,BAO_0000019,,
7365,Autocuration,22224,,,Binding towards monkey plasma protein at 100 uM,U,0,1,,CHEMBL618590,,BAO_0000019,,
7366,Autocuration,22224,,,Apparent bioavailability in squirrel monkey was determined,U,0,1,,CHEMBL872262,,BAO_0000218,,
7367,Autocuration,22224,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,0,1,,CHEMBL618591,,BAO_0000218,,
7368,Autocuration,22224,,,Bioavailability in monkey (dose 2 mg/kg),U,0,1,,CHEMBL618592,,BAO_0000218,,
7369,Autocuration,22224,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,U,0,1,,CHEMBL876488,,BAO_0000218,,
7370,Autocuration,22224,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL618593,,BAO_0000218,,
7371,Autocuration,22224,,,Bioavailability in monkey (i.d. dosing),U,0,1,,CHEMBL618594,,BAO_0000218,,
7372,Autocuration,22224,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,U,0,1,,CHEMBL618595,,BAO_0000218,,
7373,Autocuration,22224,,,Clearance of the drug was measured in cynomolgus,U,0,1,,CHEMBL621469,,BAO_0000019,,
7374,Autocuration,22224,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,U,0,1,,CHEMBL621470,,BAO_0000218,,
7375,Autocuration,22224,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,0,1,,CHEMBL621471,,BAO_0000218,,
7376,Autocuration,22224,Plasma,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,0,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,Autocuration,22224,,,Plasma clearance in rhesus monkey was determined,U,0,1,,CHEMBL621473,,BAO_0000218,,
7378,Autocuration,22224,,,Plasma clearance in monkey after administration of 1 mg/kg iv,U,0,1,,CHEMBL621474,,BAO_0000218,,
7379,Autocuration,22224,,,Plasma clearance in cynomolgus monkey,U,0,1,,CHEMBL621475,,BAO_0000218,,
7380,Autocuration,22224,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,U,0,1,,CHEMBL621476,,BAO_0000218,,
7381,Autocuration,22224,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,U,0,1,,CHEMBL624290,,BAO_0000218,,
7382,Autocuration,22224,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,U,0,1,,CHEMBL624291,,BAO_0000218,,
7383,Autocuration,22224,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,0,1,,CHEMBL624292,,BAO_0000218,,
7384,Autocuration,22224,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,0,1,,CHEMBL624293,,BAO_0000218,,
7385,Autocuration,22224,,,Tested for Clearance upon iv administration to african green monkey,U,0,1,,CHEMBL624294,,BAO_0000218,,
7386,Autocuration,22224,,,Clearance in monkey,U,0,1,,CHEMBL624295,,BAO_0000218,,
7387,Intermediate,50588,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624296,,BAO_0000218,,
7388,Intermediate,50588,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,1,1,,CHEMBL624297,,BAO_0000218,,
7389,Intermediate,50588,,,Half life was evaluated after intravenous administration to dogs,N,1,1,,CHEMBL624298,,BAO_0000218,,
7390,Intermediate,50588,,,Half life was evaluated in dog,N,1,1,,CHEMBL624299,,BAO_0000218,,
7391,Intermediate,50588,,,Half life was evaluated in dog,N,1,1,,CHEMBL624300,,BAO_0000218,,
7392,Intermediate,50588,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,1,1,,CHEMBL624301,,BAO_0000218,,
7393,Intermediate,50588,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),N,1,1,,CHEMBL624302,,BAO_0000218,,
7394,Intermediate,50588,,,Half life period after intravenous administration in dog,N,1,1,,CHEMBL876026,,BAO_0000218,,
7395,Intermediate,50588,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,N,1,1,,CHEMBL624303,,BAO_0000218,,
7396,Intermediate,50588,,,Half life period at a dose of 1 uM/kg in dog was determined,N,1,1,,CHEMBL624304,,BAO_0000218,,
7397,Intermediate,50588,,,Half life period was determine after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL624305,,BAO_0000218,,
7398,Intermediate,50588,,,Half life period was determine after peroral administration at 5 mpk in dog,N,1,1,,CHEMBL624306,,BAO_0000218,,
7399,Intermediate,50588,,,Half life period was determined,N,1,1,,CHEMBL624307,,BAO_0000218,,
7400,Intermediate,50588,,,Half life period was determined,N,1,1,,CHEMBL624308,,BAO_0000218,,
7401,Intermediate,50588,,,Half life period by iv administration in dog at a dose of 6 mg/kg,N,1,1,,CHEMBL624309,,BAO_0000218,,
7402,Intermediate,50588,,,Half life period was evaluated in dog,N,1,1,,CHEMBL624310,,BAO_0000218,,
7403,Intermediate,50588,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL625003,,BAO_0000218,,
7404,Intermediate,50588,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,1,1,,CHEMBL625004,,BAO_0000218,,
7405,Intermediate,50588,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,N,1,1,,CHEMBL625005,,BAO_0000218,,
7406,Intermediate,50588,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,N,1,1,,CHEMBL873813,,BAO_0000218,,
7407,Intermediate,50588,,,Half-life after oral dose of compound at 3 mg/kg in dogs,N,1,1,,CHEMBL625006,,BAO_0000218,,
7408,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,N,1,1,,CHEMBL625007,,BAO_0000218,,
7409,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,N,1,1,,CHEMBL876027,,BAO_0000218,,
7410,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,N,1,1,,CHEMBL625008,,BAO_0000218,,
7411,Intermediate,50588,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,N,1,1,,CHEMBL625009,,BAO_0000218,,
7412,Intermediate,50588,Plasma,,Half-life of compound in plasma of dog was determined,N,1,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,Intermediate,50588,,,Half-life of compound was determined in dogs,N,1,1,,CHEMBL625011,,BAO_0000218,,
7414,Intermediate,50588,,,Half-life after administration of 4 mg/Kg oral dose in dog,N,1,1,,CHEMBL621553,,BAO_0000218,,
7415,Intermediate,50588,,,Half-life after intravenous administration of 1 mg/kg/h in dog,N,1,1,,CHEMBL621554,,BAO_0000218,,
7416,Intermediate,50588,,,Half-life in Dog,N,1,1,,CHEMBL621555,,BAO_0000218,,
7417,Intermediate,50588,,,Half-life in Dog,N,1,1,,CHEMBL621556,,BAO_0000218,,
7418,Intermediate,50588,,,Half-life in dog,N,1,1,,CHEMBL621557,,BAO_0000218,,
7419,Intermediate,50588,,,Half-life in dog after oral administration at 1 mg/kg,N,1,1,,CHEMBL621558,,BAO_0000218,,
7420,Intermediate,50588,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,N,1,1,,CHEMBL621559,,BAO_0000218,,
7421,Intermediate,50588,,,Half-life in dogs,N,1,1,,CHEMBL621560,,BAO_0000218,,
7422,Intermediate,50588,,,Half-life in dogs; ND indicates not determined,N,1,1,,CHEMBL876028,,BAO_0000218,,
7423,Intermediate,50588,Plasma,,Half-life in plasma of dog,N,1,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,Intermediate,50588,Plasma,,Half-life in plasma of dog at dose of 3-10 mgkg,N,1,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,Intermediate,50588,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,1,1,,CHEMBL621563,,BAO_0000218,,
7426,Intermediate,50588,,,Half-life was measured in dog after an iv dose of 1 mg/kg,N,1,1,,CHEMBL621564,,BAO_0000218,,
7427,Intermediate,50588,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,N,1,1,,CHEMBL621565,,BAO_0000218,,
7428,Intermediate,50588,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,1,1,,CHEMBL621566,,BAO_0000218,,
7429,Intermediate,50588,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,1,1,,CHEMBL621567,,BAO_0000218,,
7430,Intermediate,50588,,,Half-life of the compound after 0.3 mg/kg po administration in dog,N,1,1,,CHEMBL622978,,BAO_0000218,,
7431,Intermediate,50588,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,N,1,1,,CHEMBL873814,,BAO_0000218,,
7432,Intermediate,50588,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,N,1,1,,CHEMBL623219,,BAO_0000218,,
7433,Intermediate,50588,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,N,1,1,,CHEMBL624477,,BAO_0000218,,
7434,Intermediate,50588,,,t1/2 in dog,N,1,1,,CHEMBL624478,,BAO_0000218,,
7435,Intermediate,50588,,,Half-life period measured in dogs,N,1,1,,CHEMBL624479,,BAO_0000218,,
7436,Intermediate,50588,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,1,1,,CHEMBL624480,,BAO_0000218,,
7437,Intermediate,50588,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,1,1,,CHEMBL623595,,BAO_0000218,,
7438,Intermediate,50588,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL623596,,BAO_0000218,,
7439,Intermediate,50588,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",N,1,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,Intermediate,50588,,,In vivo half life period was calculated at 1 mg/kg in dog,N,1,1,,CHEMBL623598,,BAO_0000218,,
7441,Intermediate,50588,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,N,1,1,,CHEMBL623599,,BAO_0000218,,
7442,Intermediate,50588,,,Longer half-life in dog (i.v.) at 0.5 mpk,N,1,1,,CHEMBL623600,,BAO_0000218,,
7443,Intermediate,50588,,,Oral bioavailability in dog (dose 5 uM/kg),N,1,1,,CHEMBL623601,,BAO_0000218,,
7444,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,1,1,,CHEMBL623602,,BAO_0000218,,
7445,Intermediate,50588,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,1,1,,CHEMBL623603,,BAO_0000218,,
7446,Intermediate,50588,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,1,1,,CHEMBL623604,,BAO_0000218,,
7447,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,1,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,Intermediate,50594,Lung,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,1,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,Intermediate,50594,Muscle tissue,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,Intermediate,50594,Zone of skin,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,Intermediate,50594,Spleen,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,1,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,1,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,1,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,1,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,1,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,1,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,Intermediate,50594,Stomach,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,1,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL624594,,BAO_0000218,,
7482,Intermediate,50597,,,Tested for the bioavailability in rat,N,1,1,,CHEMBL624595,,BAO_0000218,,
7483,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,1,1,,CHEMBL624596,,BAO_0000218,,
7484,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL624597,,BAO_0000218,,
7485,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL624598,,BAO_0000218,,
7486,Intermediate,50597,,,Bioavailability in rat (dose 3-10 mg/kg),N,1,1,,CHEMBL624599,,BAO_0000218,,
7487,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL875166,,BAO_0000218,,
7488,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,Intermediate,50597,,,Half life after oral administration was determined in rats at 6 mg/kg,N,1,1,,CHEMBL624602,,BAO_0000218,,
7491,Intermediate,50597,,,Half life was determined,N,1,1,,CHEMBL624603,,BAO_0000218,,
7492,Intermediate,50597,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,N,1,1,,CHEMBL624604,,BAO_0000218,,
7493,Intermediate,50597,Plasma,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,N,1,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL624606,,BAO_0000218,,
7495,Intermediate,50597,Blood,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,N,1,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,Intermediate,50597,,,Hill coefficient of the compound,N,1,1,,CHEMBL624608,,BAO_0000218,,
7497,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,N,1,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,N,1,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,N,1,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,N,1,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,N,1,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,Intermediate,50597,Blood,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,N,1,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,Intermediate,50597,Blood,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",N,1,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,Intermediate,50597,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,1,1,,CHEMBL624392,,BAO_0000218,,
7505,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,Intermediate,50597,Thyroid gland,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,N,1,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,Intermediate,50597,Blood,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,Intermediate,50597,Bone,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,Intermediate,50597,Heart,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL618647,,BAO_0000218,2113.0,
7525,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL618648,,BAO_0000218,2113.0,
7526,Intermediate,50597,Kidney,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL618649,,BAO_0000218,2113.0,
7527,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL618650,,BAO_0000218,2107.0,
7528,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL618651,,BAO_0000218,2107.0,
7529,Intermediate,50597,Liver,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL876497,,BAO_0000218,2107.0,
7530,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL618652,,BAO_0000218,2048.0,
7531,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL618653,,BAO_0000218,2048.0,
7532,Intermediate,50597,Lung,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL618654,,BAO_0000218,2048.0,
7533,Intermediate,50597,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,N,1,1,,CHEMBL618655,,BAO_0000218,,
7534,Intermediate,50597,,,Compound was tested for solubility in water,N,1,1,,CHEMBL618656,,BAO_0000218,,
7535,Intermediate,22229,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),U,0,1,,CHEMBL618657,,BAO_0000100,,
7536,Intermediate,50597,,,Solubility was determined,N,1,1,,CHEMBL618658,,BAO_0000218,,
7537,Intermediate,50597,,,solubility in water (ug/mL) at 37 degree C.,N,1,1,,CHEMBL618659,,BAO_0000218,,
7538,Intermediate,50597,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,N,1,1,,CHEMBL618660,,BAO_0000218,,
7539,Intermediate,50597,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,N,1,1,,CHEMBL618661,,BAO_0000218,,
7540,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL873807,,BAO_0000218,,
7541,Intermediate,50597,,,Half life in Dawley rat,N,1,1,,CHEMBL618662,,BAO_0000218,,
7542,Intermediate,50597,,,Half life period after 3 mg/kg iv administration,N,1,1,,CHEMBL618663,,BAO_0000218,,
7543,Intermediate,50597,,,Half life period after 3 mg/kg iv administration in rat,N,1,1,,CHEMBL618664,,BAO_0000218,,
7544,Intermediate,50597,,,Half life period after 3 mg/kg iv administration in the rat,N,1,1,,CHEMBL618665,,BAO_0000218,,
7545,Intermediate,50597,,,Half life period in female Sprague-Dawley rats,N,1,1,,CHEMBL876498,,BAO_0000218,,
7546,Intermediate,50597,,,Half life period in rat,N,1,1,,CHEMBL618666,,BAO_0000218,,
7547,Intermediate,50597,,,Half-life in rats was determined,N,1,1,,CHEMBL620440,,BAO_0000218,,
7548,Intermediate,50597,,,Half-life in rats with metabolic oxidation,N,1,1,,CHEMBL620441,,BAO_0000218,,
7549,Intermediate,50597,,,Half-life in rats,N,1,1,,CHEMBL620442,,BAO_0000218,,
7550,Intermediate,50597,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,1,1,,CHEMBL620443,,BAO_0000218,,
7551,Intermediate,50597,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,1,1,,CHEMBL620444,,BAO_0000218,,
7552,Intermediate,50597,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,1,1,,CHEMBL620445,,BAO_0000218,,
7553,Intermediate,50597,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,1,1,,CHEMBL620446,,BAO_0000218,,
7554,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat,N,1,1,,CHEMBL620447,,BAO_0000218,1969.0,
7555,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat; 22-25,N,1,1,,CHEMBL621129,,BAO_0000218,1969.0,
7556,Intermediate,50597,Plasma,,Biological half-life measured in plasma of rat; 9-16,N,1,1,,CHEMBL621130,,BAO_0000218,1969.0,
7557,Intermediate,50597,,,Compound was evaluated for its half life when administered intravenously in rat,N,1,1,,CHEMBL873808,,BAO_0000218,,
7558,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,N,1,1,,CHEMBL876598,,BAO_0000218,,
7559,Intermediate,50597,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,N,1,1,,CHEMBL621131,,BAO_0000218,,
7560,Intermediate,50597,,,Half life (T1/2) after oral administration in rat,N,1,1,,CHEMBL621132,,BAO_0000218,,
7561,Intermediate,50597,,,Half life of compound after iv administration of 20 mg/kg dose in rat,N,1,1,,CHEMBL621133,,BAO_0000218,,
7562,Expert,50597,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL621312,,BAO_0000218,,
7563,Intermediate,50597,,,Half life of compound was determined in rat,N,1,1,,CHEMBL621313,,BAO_0000218,,
7564,Intermediate,50597,Blood,,Half life of compound was determined in rat blood,N,1,1,,CHEMBL621314,,BAO_0000218,178.0,
7565,Intermediate,50597,,,Half life at 1 mg/kg was determined in rat,N,1,1,,CHEMBL621315,,BAO_0000218,,
7566,Intermediate,50597,,,Half life at 10 mg/kg was determined in rat,N,1,1,,CHEMBL621316,,BAO_0000218,,
7567,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL621317,,BAO_0000218,,
7568,Intermediate,50597,,,Half life in rats in hours,N,1,1,,CHEMBL621318,,BAO_0000218,,
7569,Intermediate,50597,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,1,1,,CHEMBL621319,,BAO_0000218,,
7570,Intermediate,50597,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,N,1,1,,CHEMBL621377,,BAO_0000218,,
7571,Intermediate,50597,,,Half life was determined,N,1,1,,CHEMBL621378,,BAO_0000218,,
7572,Intermediate,50597,,,Half life after i.v. administration,N,1,1,,CHEMBL876599,,BAO_0000218,,
7573,Intermediate,50597,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,N,1,1,,CHEMBL621379,,BAO_0000218,,
7574,Intermediate,50597,Plasma,,Half life in rat plasma,N,1,1,,CHEMBL621380,,BAO_0000218,1969.0,
7575,Intermediate,50597,Plasma,,Half life in rat plasma; Not detected,N,1,1,,CHEMBL621381,,BAO_0000218,1969.0,
7576,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL618515,,BAO_0000218,,
7577,Intermediate,50597,,,Half life period of compound was determined after peroral administration,N,1,1,,CHEMBL618516,,BAO_0000218,,
7578,Intermediate,50597,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,N,1,1,,CHEMBL618517,,BAO_0000218,,
7579,Intermediate,50597,,,Half life period in rat,N,1,1,,CHEMBL618518,,BAO_0000218,,
7580,Intermediate,50597,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,1,1,,CHEMBL618519,,BAO_0000218,,
7581,Intermediate,50597,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL618698,,BAO_0000218,,
7582,Intermediate,50597,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,N,1,1,,CHEMBL618862,,BAO_0000218,,
7583,Intermediate,50597,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL618863,,BAO_0000218,,
7584,Intermediate,50597,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL618864,,BAO_0000218,,
7585,Intermediate,50597,,,Half life time in rat the dose of 2 mg/kg,N,1,1,,CHEMBL618865,,BAO_0000218,,
7586,Intermediate,50597,,,Half-life 24 hr after 10 mg/kg iv administration in rats,N,1,1,,CHEMBL618866,,BAO_0000218,,
7587,Intermediate,50597,,,Half-life 24 hr after 2 mg/kg iv administration in rats,N,1,1,,CHEMBL618867,,BAO_0000218,,
7588,Intermediate,50597,,,Half-life consistent with the observed metabolic steady state in rats,N,1,1,,CHEMBL875828,,BAO_0000218,,
7589,Intermediate,50597,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,1,1,,CHEMBL618868,,BAO_0000218,,
7590,Intermediate,50597,,,Half-life for oxidative metabolic stability was determined using male human,N,1,1,,CHEMBL618869,,BAO_0000218,,
7591,Intermediate,50597,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",N,1,1,,CHEMBL618870,,BAO_0000218,,
7592,Intermediate,50597,Plasma,,Half-life in rat plasma,N,1,1,,CHEMBL618871,,BAO_0000218,1969.0,
7593,Intermediate,50597,Plasma,,Half-life in rat plasma was determined,N,1,1,,CHEMBL618872,,BAO_0000218,1969.0,
7594,Intermediate,50597,,,Half-life in rats was determined,N,1,1,,CHEMBL873816,,BAO_0000218,,
7595,Autocuration,22224,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,U,0,1,,CHEMBL618873,,BAO_0000218,,
7596,Autocuration,22224,,,Area under curve after oral dose of 0.1 mg//kg,U,0,1,,CHEMBL621602,,BAO_0000019,,
7597,Autocuration,22224,,,Area under curve after oral dose of 0.3 mg/kg,U,0,1,,CHEMBL621603,,BAO_0000218,,
7598,Autocuration,22224,,,Area under curve after oral dose of 1 mg/kg,U,0,1,,CHEMBL621604,,BAO_0000218,,
7599,Autocuration,22224,,,Area under curve after oral dose of 10 mg/kg,U,0,1,,CHEMBL621605,,BAO_0000218,,
7600,Autocuration,22224,,,Area under curve after oral dose of 23.4 mg/kg,U,0,1,,CHEMBL621606,,BAO_0000218,,
7601,Autocuration,22224,,,Area under curve after oral dose of 3 mg/kg,U,0,1,,CHEMBL621607,,BAO_0000218,,
7602,Autocuration,22224,,,Area under curve after oral dose of 3.87 mg/kg,U,0,1,,CHEMBL621608,,BAO_0000218,,
7603,Autocuration,22224,,,Area under curve was determined,U,0,1,,CHEMBL621609,,BAO_0000019,,
7604,Autocuration,22224,,,Area under curve at a dose of 10 mg/kg,U,0,1,,CHEMBL621610,,BAO_0000218,,
7605,Intermediate,50597,,,Area under curve was determined; ND=No data,N,1,1,,CHEMBL621611,,BAO_0000218,,
7606,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL621612,,BAO_0000218,,
7607,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,1,1,,CHEMBL622308,,BAO_0000218,,
7608,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622309,,BAO_0000218,,
7609,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,N,1,1,,CHEMBL622310,,BAO_0000218,,
7610,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622311,,BAO_0000218,,
7611,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,N,1,1,,CHEMBL622312,,BAO_0000218,,
7612,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622931,,BAO_0000218,,
7613,Intermediate,50597,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,N,1,1,,CHEMBL622932,,BAO_0000218,,
7614,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622736,,BAO_0000218,1969.0,
7615,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,1,1,,CHEMBL622737,,BAO_0000218,1969.0,
7616,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622738,,BAO_0000218,1969.0,
7617,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,N,1,1,,CHEMBL622739,,BAO_0000218,1969.0,
7618,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622740,,BAO_0000218,1969.0,
7619,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,N,1,1,,CHEMBL622741,,BAO_0000218,1969.0,
7620,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,1,1,,CHEMBL622742,,BAO_0000218,1969.0,
7621,Intermediate,50597,Plasma,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,N,1,1,,CHEMBL622743,,BAO_0000218,1969.0,
7622,Intermediate,50594,Plasma,,AUC in mice,N,1,1,,CHEMBL622744,,BAO_0000218,1969.0,
7623,Autocuration,22224,,,Area under curve was measured from the graph obtained from concentration Vs time,U,0,1,,CHEMBL624134,,BAO_0000019,,
7624,Autocuration,22224,,,Area under curve value of compound per hour after oral administration,U,0,1,,CHEMBL624135,,BAO_0000019,,
7625,Intermediate,50597,,,Area under curve was determined after oral administration in rats,N,1,1,,CHEMBL624136,,BAO_0000218,,
7626,Intermediate,50597,,,Area under curve was determined after oral administration in rats; No data,N,1,1,,CHEMBL624137,,BAO_0000218,,
7627,Intermediate,50597,,,Area under curve was determined after oral administration in rats;No data,N,1,1,,CHEMBL624320,,BAO_0000218,,
7628,Intermediate,50588,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,1,1,,CHEMBL624321,,BAO_0000218,,
7629,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,N,1,1,,CHEMBL624322,,BAO_0000218,,
7630,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,N,1,1,,CHEMBL624323,,BAO_0000218,,
7631,Intermediate,50597,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,N,1,1,,CHEMBL624324,,BAO_0000218,,
7632,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,N,1,1,,CHEMBL624325,,BAO_0000218,,
7633,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,N,1,1,,CHEMBL624326,,BAO_0000218,,
7634,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,N,1,1,,CHEMBL624327,,BAO_0000218,,
7635,Intermediate,50597,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,N,1,1,,CHEMBL624328,,BAO_0000218,,
7636,Intermediate,50588,,,Area under curve was determined in Dogs after peroral administration,N,1,1,,CHEMBL627848,,BAO_0000218,,
7637,Intermediate,50597,,,Area under curve was determined in Rats after peroral administration,N,1,1,,CHEMBL627849,,BAO_0000218,,
7638,Intermediate,50597,,,Area under curve was determined in carotid blood of rat when administered intradermally,N,1,1,,CHEMBL627850,,BAO_0000218,,
7639,Intermediate,50597,,,Area under curve was determined in portal blood of rat when administered intradermally,N,1,1,,CHEMBL627851,,BAO_0000218,,
7640,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627852,,BAO_0000218,,
7641,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627853,,BAO_0000218,,
7642,Intermediate,50594,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,1,1,,CHEMBL627854,,BAO_0000218,,
7643,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627855,,BAO_0000218,,
7644,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),N,1,1,,CHEMBL627856,,BAO_0000218,,
7645,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL875339,,BAO_0000218,,
7646,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),N,1,1,,CHEMBL627857,,BAO_0000218,,
7647,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,N,1,1,,CHEMBL627858,,BAO_0000218,2106.0,
7648,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,N,1,1,,CHEMBL627859,,BAO_0000218,178.0,
7649,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,N,1,1,,CHEMBL627860,,BAO_0000218,955.0,
7650,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,N,1,1,,CHEMBL627019,,BAO_0000218,948.0,
7651,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,N,1,1,,CHEMBL627020,,BAO_0000218,2107.0,
7652,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,N,1,1,,CHEMBL627021,,BAO_0000218,2048.0,
7653,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,N,1,1,,CHEMBL627022,,BAO_0000218,2385.0,
7654,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,N,1,1,,CHEMBL627023,,BAO_0000218,,
7655,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,N,1,1,,CHEMBL627024,,BAO_0000218,2106.0,
7656,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,N,1,1,,CHEMBL627025,,BAO_0000218,2046.0,
7657,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,N,1,1,,CHEMBL627026,,BAO_0000218,2113.0,
7658,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,N,1,1,,CHEMBL627027,,BAO_0000218,178.0,
7659,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,N,1,1,,CHEMBL627028,,BAO_0000218,955.0,
7660,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,N,1,1,,CHEMBL627029,,BAO_0000218,948.0,
7661,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,N,1,1,,CHEMBL627030,,BAO_0000218,2113.0,
7662,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,N,1,1,,CHEMBL627031,,BAO_0000218,2107.0,
7663,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,N,1,1,,CHEMBL627032,,BAO_0000218,2048.0,
7664,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,N,1,1,,CHEMBL627033,,BAO_0000218,2385.0,
7665,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,N,1,1,,CHEMBL627034,,BAO_0000218,,
7666,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,N,1,1,,CHEMBL627035,,BAO_0000218,2106.0,
7667,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,N,1,1,,CHEMBL627036,,BAO_0000218,2046.0,
7668,Intermediate,50597,Blood,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,N,1,1,,CHEMBL875340,,BAO_0000218,178.0,
7669,Intermediate,50597,Heart,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,N,1,1,,CHEMBL627037,,BAO_0000218,948.0,
7670,Intermediate,50597,Kidney,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,N,1,1,,CHEMBL627038,,BAO_0000218,2113.0,
7671,Intermediate,50597,Liver,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,N,1,1,,CHEMBL627039,,BAO_0000218,2107.0,
7672,Intermediate,50597,Muscle tissue,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,N,1,1,,CHEMBL627040,,BAO_0000218,2385.0,
7673,Intermediate,50597,Spleen,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,N,1,1,,CHEMBL624663,,BAO_0000218,2106.0,
7674,Intermediate,50597,Thyroid gland,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,N,1,1,,CHEMBL625963,,BAO_0000218,2046.0,
7675,Intermediate,50597,Brain,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,N,1,1,,CHEMBL876799,,BAO_0000218,955.0,
7676,Intermediate,50597,Lung,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,N,1,1,,CHEMBL626133,,BAO_0000218,2048.0,
7677,Intermediate,50597,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,N,1,1,,CHEMBL626134,,BAO_0000218,,
7678,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL626135,,BAO_0000218,,
7679,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL626136,,BAO_0000218,,
7680,Intermediate,50597,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,N,1,1,,CHEMBL626137,,BAO_0000218,,
7681,Intermediate,50597,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL626138,,BAO_0000218,,
7682,Intermediate,50597,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL626139,,BAO_0000218,,
7683,Intermediate,50597,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,1,1,,CHEMBL626140,,BAO_0000218,,
7684,Intermediate,50597,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,1,1,,CHEMBL626141,,BAO_0000218,,
7685,Intermediate,50597,,,C24h in rat p.o. at 20 mg/kg concentration,N,1,1,,CHEMBL626142,,BAO_0000218,,
7686,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL627930,,BAO_0000218,2385.0,
7687,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL627931,,BAO_0000218,2385.0,
7688,Intermediate,50597,Muscle tissue,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL627932,,BAO_0000218,2385.0,
7689,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,1,1,,CHEMBL627933,,BAO_0000218,2106.0,
7690,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,N,1,1,,CHEMBL627934,,BAO_0000218,2106.0,
7691,Intermediate,50597,Spleen,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,N,1,1,,CHEMBL627935,,BAO_0000218,2106.0,
7692,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,1,1,,CHEMBL627936,,BAO_0000218,178.0,
7693,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL627937,,BAO_0000218,178.0,
7694,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,1,1,,CHEMBL627938,,BAO_0000218,178.0,
7695,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL627939,,BAO_0000218,178.0,
7696,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,N,1,1,,CHEMBL627940,,BAO_0000218,178.0,
7697,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,1,1,,CHEMBL627941,,BAO_0000218,178.0,
7698,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,1,1,,CHEMBL876800,,BAO_0000218,178.0,
7699,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL627942,,BAO_0000218,178.0,
7700,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,1,1,,CHEMBL627943,,BAO_0000218,178.0,
7701,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,N,1,1,,CHEMBL627944,,BAO_0000218,178.0,
7702,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL627945,,BAO_0000218,178.0,
7703,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,N,1,1,,CHEMBL628584,,BAO_0000218,178.0,
7704,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,N,1,1,,CHEMBL628585,,BAO_0000218,178.0,
7705,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,N,1,1,,CHEMBL628586,,BAO_0000218,178.0,
7706,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,N,1,1,,CHEMBL628587,,BAO_0000218,178.0,
7707,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,N,1,1,,CHEMBL628588,,BAO_0000218,178.0,
7708,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,N,1,1,,CHEMBL628589,,BAO_0000218,178.0,
7709,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,N,1,1,,CHEMBL625304,,BAO_0000218,178.0,
7710,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,N,1,1,,CHEMBL625305,,BAO_0000218,178.0,
7711,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,N,1,1,,CHEMBL625306,,BAO_0000218,178.0,
7712,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,N,1,1,,CHEMBL625307,,BAO_0000218,178.0,
7713,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,N,1,1,,CHEMBL625308,,BAO_0000218,178.0,
7714,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,N,1,1,,CHEMBL627740,,BAO_0000218,178.0,
7715,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,N,1,1,,CHEMBL627741,,BAO_0000218,178.0,
7716,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,1,1,,CHEMBL627742,,BAO_0000218,178.0,
7717,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL627743,,BAO_0000218,178.0,
7718,Intermediate,50597,Blood,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL627744,,BAO_0000218,178.0,
7719,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL627745,,BAO_0000218,10000001.0,
7720,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,1,1,,CHEMBL627746,,BAO_0000218,10000001.0,
7721,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,1,1,,CHEMBL627747,,BAO_0000218,10000001.0,
7722,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL876810,,BAO_0000218,10000001.0,
7723,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,N,1,1,,CHEMBL627748,,BAO_0000218,10000001.0,
7724,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,1,1,,CHEMBL627749,,BAO_0000218,10000001.0,
7725,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,1,1,,CHEMBL627750,,BAO_0000218,10000001.0,
7726,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL618728,,BAO_0000218,10000001.0,
7727,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,1,1,,CHEMBL618729,,BAO_0000218,10000001.0,
7728,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,N,1,1,,CHEMBL618730,,BAO_0000218,10000001.0,
7729,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,N,1,1,,CHEMBL618731,,BAO_0000218,10000001.0,
7730,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,N,1,1,,CHEMBL618732,,BAO_0000218,10000001.0,
7731,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,N,1,1,,CHEMBL618733,,BAO_0000218,10000001.0,
7732,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,N,1,1,,CHEMBL618734,,BAO_0000218,10000001.0,
7733,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,N,1,1,,CHEMBL618735,,BAO_0000218,10000001.0,
7734,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,N,1,1,,CHEMBL876602,,BAO_0000218,10000001.0,
7735,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,N,1,1,,CHEMBL618736,,BAO_0000218,10000001.0,
7736,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,N,1,1,,CHEMBL618737,,BAO_0000218,10000001.0,
7737,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,N,1,1,,CHEMBL618738,,BAO_0000218,10000001.0,
7738,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,N,1,1,,CHEMBL618739,,BAO_0000218,10000001.0,
7739,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,N,1,1,,CHEMBL618740,,BAO_0000218,10000001.0,
7740,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,1,1,,CHEMBL618741,,BAO_0000218,10000001.0,
7741,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL618742,,BAO_0000218,10000001.0,
7742,Intermediate,50597,Bone,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL618743,,BAO_0000218,10000001.0,
7743,Intermediate,50597,Plasma,,Half-life from rat plasma at a single oral dose of 25 mg/kg,N,1,1,,CHEMBL618744,,BAO_0000218,1969.0,
7744,Intermediate,50597,,,Half-life in male rat,N,1,1,,CHEMBL618745,,BAO_0000218,,
7745,Intermediate,50597,,,Half-life in rat after peroral administration at 10 mg/kg concentration,N,1,1,,CHEMBL620479,,BAO_0000218,,
7746,Intermediate,50597,,,Half-life in rat after peroral administration at 5 mg/kg concentration,N,1,1,,CHEMBL620480,,BAO_0000218,,
7747,Intermediate,50597,,,Half-life in rat at a dose of 3 mg/kg,N,1,1,,CHEMBL620481,,BAO_0000218,,
7748,Intermediate,50597,,,Half-life was evaluated in rats,N,1,1,,CHEMBL620482,,BAO_0000218,,
7749,Intermediate,50597,,,Half-life was measured in rat,N,1,1,,CHEMBL876603,,BAO_0000218,,
7750,Intermediate,50597,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,N,1,1,,CHEMBL620483,,BAO_0000218,,
7751,Intermediate,50597,,,Half-life period in rats after intravenous administration at 5 mg/kg,N,1,1,,CHEMBL620484,,BAO_0000218,,
7752,Intermediate,50597,,,Half-life period in rat at 10 mg/kg,N,1,1,,CHEMBL620485,,BAO_0000218,,
7753,Intermediate,50597,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",N,1,1,,CHEMBL620486,,BAO_0000218,,
7754,Intermediate,50597,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",N,1,1,,CHEMBL620487,,BAO_0000218,,
7755,Intermediate,50597,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",N,1,1,,CHEMBL620488,,BAO_0000218,,
7756,Intermediate,50597,,,Half-life time in rat the dose of 2 mg/kg,N,1,1,,CHEMBL620489,,BAO_0000218,,
7757,Intermediate,50597,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,N,1,1,,CHEMBL620490,,BAO_0000218,,
7758,Intermediate,50597,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,N,1,1,,CHEMBL620491,,BAO_0000218,,
7759,Intermediate,50597,Plasma,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,1,1,,CHEMBL876604,,BAO_0000218,1969.0,
7760,Intermediate,50597,,,Oral half life was determined,N,1,1,,CHEMBL620492,,BAO_0000218,,
7761,Intermediate,50597,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL620493,,BAO_0000218,,
7762,Intermediate,50597,,,Pharmacokinetic property (t1/2) in rat,N,1,1,,CHEMBL620494,,BAO_0000218,,
7763,Intermediate,50597,Plasma,,Plasma elimination half-life was determined,N,1,1,,CHEMBL620495,,BAO_0000218,1969.0,
7764,Intermediate,50597,Plasma,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,1,1,,CHEMBL620496,,BAO_0000218,1969.0,
7765,Intermediate,50597,Plasma,,Plasma half life was observed after intravenous administration in rat,N,1,1,,CHEMBL620497,,BAO_0000218,1969.0,
7766,Intermediate,50597,Plasma,,Plasma half-life was determined,N,1,1,,CHEMBL620498,,BAO_0000218,1969.0,
7767,Intermediate,50597,Plasma,,Plasma half-life following oral administration in Fisher rats,N,1,1,,CHEMBL620499,,BAO_0000218,1969.0,
7768,Intermediate,50597,Plasma,,Plasma half-life in rat,N,1,1,,CHEMBL620500,,BAO_0000218,1969.0,
7769,Intermediate,50597,Plasma,,Plasmatic Half-life after intravenous administration to rat,N,1,1,,CHEMBL873809,,BAO_0000218,1969.0,
7770,Intermediate,50597,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,1,1,,CHEMBL620501,,BAO_0000218,,
7771,Intermediate,50597,,,Terminal half life after intravenous administration (1 mg/kg) in rat,N,1,1,,CHEMBL620502,,BAO_0000218,,
7772,Intermediate,50597,,,Terminal half life in Rat at a oral dose of 5 mg/kg,N,1,1,,CHEMBL620503,,BAO_0000218,,
7773,Intermediate,50597,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,1,1,,CHEMBL620504,,BAO_0000218,,
7774,Intermediate,50597,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,N,1,1,,CHEMBL876605,,BAO_0000218,,
7775,Intermediate,50597,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,N,1,1,,CHEMBL620505,,BAO_0000218,,
7776,Intermediate,50597,Plasma,,plasma half life was observed after intravenous administration in rat,N,1,1,,CHEMBL873811,,BAO_0000218,1969.0,
7777,Expert,50597,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL624016,,BAO_0000218,,
7778,Intermediate,50597,,,Half life of compound determined in rat,N,1,1,,CHEMBL624017,,BAO_0000218,,
7779,Intermediate,50597,,,Mean residence time determined in rat,N,1,1,,CHEMBL624018,,BAO_0000218,,
7780,Intermediate,50597,,,Plasma half life determined in rat,N,1,1,,CHEMBL624019,,BAO_0000218,,
7781,Intermediate,50597,Brain,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,N,1,1,,CHEMBL624020,,BAO_0000218,955.0,
7782,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter maximum time period,N,1,1,,CHEMBL624201,,BAO_0000218,,
7783,Intermediate,50597,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,1,1,,CHEMBL872528,,BAO_0000218,,
7784,Intermediate,50597,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624202,,BAO_0000218,,
7785,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624203,,BAO_0000218,,
7786,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624350,,BAO_0000218,,
7787,Intermediate,50597,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL621320,,BAO_0000218,,
7788,Intermediate,50597,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,1,1,,CHEMBL621321,,BAO_0000218,,
7789,Intermediate,50597,,,Maximum time (Tmax) required to reach Cmax in rats,N,1,1,,CHEMBL621322,,BAO_0000218,,
7790,Intermediate,50597,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL621323,,BAO_0000218,,
7791,Intermediate,50597,,,Maximum time of clearance of compound in rats after peroral administration,N,1,1,,CHEMBL621324,,BAO_0000218,,
7792,Intermediate,50597,,,Maximum time at the dose of 2 mg/kg in rat,N,1,1,,CHEMBL621325,,BAO_0000218,,
7793,Intermediate,50597,Plasma,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,N,1,1,,CHEMBL875837,,BAO_0000218,1969.0,
7794,Intermediate,50597,Plasma,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,N,1,1,,CHEMBL621326,,BAO_0000218,1969.0,
7795,Intermediate,50597,,,Tmax in Guinea pig (PO dose),N,1,1,,CHEMBL621327,,BAO_0000218,,
7796,Intermediate,50597,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL621328,,BAO_0000218,,
7797,Intermediate,50597,,,Pharmacokinetic parameter (Tmax) in rat,N,1,1,,CHEMBL621329,,BAO_0000218,,
7798,Intermediate,50597,,,Pharmacokinetic parameter (Tmax) was estimated,N,1,1,,CHEMBL621330,,BAO_0000218,,
7799,Intermediate,50597,,,Pharmacokinetic property (Tmax) in rat,N,1,1,,CHEMBL621331,,BAO_0000218,,
7800,Intermediate,50597,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,1,1,,CHEMBL621332,,BAO_0000218,,
7801,Intermediate,50597,,,T max in Rat at a oral dose of 5 mg/kg,N,1,1,,CHEMBL621333,,BAO_0000218,,
7802,Intermediate,50597,,,T max was determined at 10 mg/kg po dose in rats,N,1,1,,CHEMBL621334,,BAO_0000218,,
7803,Intermediate,50594,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),N,1,1,,CHEMBL621335,,BAO_0000218,,
7804,Intermediate,50588,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,N,1,1,,CHEMBL621336,,BAO_0000218,,
7805,Intermediate,50597,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,N,1,1,,CHEMBL621337,,BAO_0000218,,
7806,Intermediate,50588,,,Area under curve was measured after i.v. administration into Beagle dog.,N,1,1,,CHEMBL621338,,BAO_0000218,,
7807,Intermediate,50588,,,Area under curve was measured after iv administration into Beagle dog,N,1,1,,CHEMBL875838,,BAO_0000218,,
7808,Intermediate,50588,,,Area under curve was measured after po administration into Beagle dog,N,1,1,,CHEMBL621339,,BAO_0000218,,
7809,Intermediate,50588,,,Area under curve was measured after po administration into Beagle dog.,N,1,1,,CHEMBL621340,,BAO_0000218,,
7810,Autocuration,22224,,,Area under curve was measured at peroral dose of 3 mg/kg,U,0,1,,CHEMBL621341,,BAO_0000218,,
7811,Autocuration,22224,,,Area under curve was measured by using concentration Vs time,U,0,1,,CHEMBL621342,,BAO_0000019,,
7812,Autocuration,22224,,,Area under curve was measured by using concentration Vs time; not tested,U,0,1,,CHEMBL621343,,BAO_0000019,,
7813,Intermediate,50594,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),N,1,1,,CHEMBL621344,,BAO_0000218,,
7814,Intermediate,50594,,,Area under curve(AUC) was measured in mice after oral administration.,N,1,1,,CHEMBL621345,,BAO_0000218,,
7815,Autocuration,22224,,,Area under curve(AUC) value of the compound,U,0,1,,CHEMBL621346,,BAO_0000019,,
7816,Autocuration,22224,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,U,0,1,,CHEMBL621347,,BAO_0000218,,
7817,Intermediate,50588,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,N,1,1,,CHEMBL621348,,BAO_0000218,,
7818,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood,U,0,1,,CHEMBL621349,,BAO_0000019,178.0,
7819,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,U,0,1,,CHEMBL621350,,BAO_0000019,178.0,
7820,Autocuration,22224,Blood,,Area under curve(carotid artery) was determined by the availability in blood; No data,U,0,1,,CHEMBL875839,,BAO_0000019,178.0,
7821,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood,U,0,1,,CHEMBL620211,,BAO_0000019,178.0,
7822,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,U,0,1,,CHEMBL620212,,BAO_0000019,178.0,
7823,Autocuration,22224,Blood,,Area under curve(portal vein) was determined by the availability in blood; No data,U,0,1,,CHEMBL620213,,BAO_0000019,178.0,
7824,Intermediate,50797,Plasma,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,1,1,,CHEMBL620214,,BAO_0000218,1969.0,
7825,Intermediate,50797,Plasma,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,1,1,,CHEMBL620215,,BAO_0000218,1969.0,
7826,Intermediate,50797,Plasma,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,N,1,1,,CHEMBL620216,,BAO_0000218,1969.0,
7827,Intermediate,50588,Plasma,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",N,1,1,,CHEMBL620888,,BAO_0000218,1969.0,
7828,Intermediate,50588,Plasma,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",N,1,1,,CHEMBL620889,,BAO_0000218,1969.0,
7829,Autocuration,22224,Plasma,,Area under plasma concentration vs time curve observed in rats for 0-3 h,U,0,1,,CHEMBL620890,,BAO_0000019,1969.0,
7830,Intermediate,50597,Plasma,,Area under plasma time curve determined in male rat,N,1,1,,CHEMBL620891,,BAO_0000218,1969.0,
7831,Autocuration,22224,,,Area under the MAP curve measured over 5 min.,U,0,1,,CHEMBL620892,,BAO_0000019,,
7832,Intermediate,50594,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,N,1,1,,CHEMBL621079,,BAO_0000218,,
7833,Intermediate,50594,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,N,1,1,,CHEMBL621080,,BAO_0000218,,
7834,Intermediate,50588,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,N,1,1,,CHEMBL621081,,BAO_0000218,,
7835,Intermediate,100712,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,N,1,1,,CHEMBL621082,,BAO_0000218,,
7836,Intermediate,50597,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,N,1,1,,CHEMBL621083,,BAO_0000218,,
7837,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,N,1,1,,CHEMBL621084,,BAO_0000218,,
7838,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,N,1,1,,CHEMBL621085,,BAO_0000218,,
7839,Intermediate,50588,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,N,1,1,,CHEMBL621086,,BAO_0000218,,
7840,Intermediate,50588,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,1,1,,CHEMBL621087,,BAO_0000218,,
7841,Intermediate,50588,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),N,1,1,,CHEMBL622607,,BAO_0000218,,
7842,Intermediate,50588,,,Serum AUC in marmosets (IV dose),N,1,1,,CHEMBL622608,,BAO_0000218,,
7843,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,U,0,1,,CHEMBL624481,,BAO_0000019,,
7844,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,U,0,1,,CHEMBL624482,,BAO_0000019,,
7845,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,U,0,1,,CHEMBL624483,,BAO_0000019,,
7846,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,U,0,1,,CHEMBL624484,,BAO_0000019,,
7847,Autocuration,22224,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,U,0,1,,CHEMBL624485,,BAO_0000019,,
7848,Intermediate,50597,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,N,1,1,,CHEMBL624486,,BAO_0000218,,
7849,Autocuration,22224,,,Area under the curve for the compound was calculated.,U,0,1,,CHEMBL624487,,BAO_0000019,,
7850,Autocuration,22224,,,Area under the curve in concentration/ time,U,0,1,,CHEMBL624488,,BAO_0000019,,
7851,Intermediate,50597,,,Area under the curve administered intraintestinal in rats.,N,1,1,,CHEMBL624489,,BAO_0000218,,
7852,Intermediate,50597,,,Area under the curve administered intravenously in rats.,N,1,1,,CHEMBL625184,,BAO_0000218,,
7853,Autocuration,22224,,,Area under the curve during intravenous administration,U,0,1,,CHEMBL625185,,BAO_0000019,,
7854,Autocuration,22224,,,Area under the curve during intravenous administration; Not determined,U,0,1,,CHEMBL875954,,BAO_0000019,,
7855,Autocuration,22224,,,Area under the curve during systemic administration,U,0,1,,CHEMBL625186,,BAO_0000019,,
7856,Autocuration,22224,,,Area under the curve during systemic administration; Not determined,U,0,1,,CHEMBL625187,,BAO_0000019,,
7857,Autocuration,22224,,,Area under the curve was calculated for the compound.,U,0,1,,CHEMBL625188,,BAO_0000019,,
7858,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,N,1,1,,CHEMBL625189,,BAO_0000218,,
7859,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,N,1,1,,CHEMBL625190,,BAO_0000218,,
7860,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,N,1,1,,CHEMBL621733,,BAO_0000218,,
7861,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,N,1,1,,CHEMBL621734,,BAO_0000218,,
7862,Intermediate,50597,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,N,1,1,,CHEMBL621735,,BAO_0000218,,
7863,Intermediate,50597,Plasma,,Clearance of the drug was measured in the plasma of rat; No data,N,1,1,,CHEMBL621736,,BAO_0000218,1969.0,
7864,Intermediate,50597,Plasma,,The pharmacokinetic parameter plasma clearance in vivo in rats,N,1,1,,CHEMBL621737,,BAO_0000218,1969.0,
7865,Intermediate,50597,,,Plasma clearance at the dose of 2 mg/kg in rat,N,1,1,,CHEMBL621738,,BAO_0000218,,
7866,Intermediate,50597,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,1,1,,CHEMBL622806,,BAO_0000218,,
7867,Intermediate,50597,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,1,1,,CHEMBL623519,,BAO_0000218,,
7868,Intermediate,50597,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,1,1,,CHEMBL623520,,BAO_0000218,,
7869,Intermediate,50597,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,1,1,,CHEMBL623521,,BAO_0000218,,
7870,Intermediate,50597,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,1,1,,CHEMBL623522,,BAO_0000218,,
7871,Intermediate,50597,,,Clearance rate in rat,N,1,1,,CHEMBL623523,,BAO_0000218,,
7872,Intermediate,50597,,,Clearance rate in rat,N,1,1,,CHEMBL623690,,BAO_0000218,,
7873,Intermediate,50597,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL623691,,BAO_0000218,,
7874,Intermediate,50597,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL623692,,BAO_0000218,,
7875,Intermediate,50597,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL623693,,BAO_0000218,,
7876,Intermediate,50597,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL623694,,BAO_0000218,,
7877,Intermediate,50597,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,N,1,1,,CHEMBL623695,,BAO_0000218,,
7878,Intermediate,50597,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,N,1,1,,CHEMBL623696,,BAO_0000218,,
7879,Intermediate,50597,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,N,1,1,,CHEMBL623697,,BAO_0000218,,
7880,Intermediate,22224,Plasma,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,0,1,,CHEMBL623698,,BAO_0000218,1969.0,
7881,Intermediate,22224,Plasma,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,U,0,1,,CHEMBL623699,,BAO_0000218,1969.0,
7882,Intermediate,50597,,,Mean (%CV) PK parameters for CL(mL/min/kg).,N,1,1,,CHEMBL623700,,BAO_0000218,,
7883,Intermediate,50597,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,N,1,1,,CHEMBL623701,,BAO_0000218,,
7884,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,N,1,1,,CHEMBL623702,,BAO_0000218,1969.0,
7885,Intermediate,50597,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,N,1,1,,CHEMBL623703,,BAO_0000218,,
7886,Intermediate,50597,,,Plasma clearance in rat was determined,N,1,1,,CHEMBL623704,,BAO_0000218,,
7887,Intermediate,50597,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL623705,,BAO_0000218,,
7888,Intermediate,50597,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL623706,,BAO_0000218,,
7889,Intermediate,50597,,,Plasma clearance was determined,N,1,1,,CHEMBL623707,,BAO_0000218,,
7890,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL623708,,BAO_0000218,,
7891,Intermediate,50597,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,N,1,1,,CHEMBL623709,,BAO_0000218,,
7892,Intermediate,50597,,,Plasma clearance in rat by iv administration,N,1,1,,CHEMBL623710,,BAO_0000218,,
7893,Intermediate,50597,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,N,1,1,,CHEMBL623711,,BAO_0000218,,
7894,Intermediate,50597,,,Plasma clearance in rat p.o.,N,1,1,,CHEMBL623712,,BAO_0000218,,
7895,Intermediate,50597,,,Plasma clearance in rats,N,1,1,,CHEMBL623713,,BAO_0000218,,
7896,Intermediate,50597,,,Plasma clearance was determined; ND denotes no data,N,1,1,,CHEMBL623714,,BAO_0000218,,
7897,Intermediate,50597,,,Plasma clearance was determined; ND denotes not determined,N,1,1,,CHEMBL623715,,BAO_0000218,,
7898,Intermediate,50597,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,1,1,,CHEMBL623716,,BAO_0000218,,
7899,Intermediate,50597,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,1,1,,CHEMBL622980,,BAO_0000218,,
7900,Intermediate,50597,,,Plasma administration to rats,N,1,1,,CHEMBL622981,,BAO_0000218,,
7901,Intermediate,50597,,,Plasma clearance of the compound in female Sprague-Dawley rats,N,1,1,,CHEMBL622982,,BAO_0000218,,
7902,Intermediate,50597,,,Plasma clearance was observed after intravenous administration in rat,N,1,1,,CHEMBL622983,,BAO_0000218,,
7903,Intermediate,50597,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,N,1,1,,CHEMBL622984,,BAO_0000218,,
7904,Intermediate,50597,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,N,1,1,,CHEMBL622985,,BAO_0000218,,
7905,Intermediate,50597,Plasma,,plasma clearance was observed after intravenous administration in rat,N,1,1,,CHEMBL623631,,BAO_0000218,1969.0,
7906,Intermediate,50597,,,In vivo CL/F determined,N,1,1,,CHEMBL623632,,BAO_0000218,,
7907,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,N,1,1,,CHEMBL623633,,BAO_0000218,1969.0,
7908,Intermediate,50597,Plasma,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,N,1,1,,CHEMBL623634,,BAO_0000218,1969.0,
7909,Intermediate,50597,,,Compound was tested for the lower blood clearance in rat,N,1,1,,CHEMBL623635,,BAO_0000218,,
7910,Intermediate,50597,,,Evaluated for the low clearance in rat (in vivo),N,1,1,,CHEMBL621195,,BAO_0000218,,
7911,Intermediate,50597,,,Pharmacokinetic property (CLb)of the compound was determined in rat,N,1,1,,CHEMBL621196,,BAO_0000218,,
7912,Intermediate,50597,,,Rapid clearance after intravenous administration in rat was determined,N,1,1,,CHEMBL875287,,BAO_0000218,,
7913,Intermediate,50597,,,Clearance measured in rat,N,1,1,,CHEMBL621197,,BAO_0000218,,
7914,Intermediate,50597,Plasma,,Compound was evaluated for plasma clearance in rat,N,1,1,,CHEMBL621198,,BAO_0000218,1969.0,
7915,Intermediate,50597,Plasma,,Low plasma clearance was calculated in rat,N,1,1,,CHEMBL621199,,BAO_0000218,1969.0,
7916,Intermediate,50597,,,Pharmacokinetic property (Clp) in rat,N,1,1,,CHEMBL621200,,BAO_0000218,,
7917,Intermediate,50597,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,N,1,1,,CHEMBL621201,,BAO_0000218,,
7918,Intermediate,50597,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,N,1,1,,CHEMBL621202,,BAO_0000218,,
7919,Intermediate,50597,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,N,1,1,,CHEMBL621203,,BAO_0000218,,
7920,Intermediate,50597,,,Plasma clearance after IV dosing at 1 mg/kg in rat,N,1,1,,CHEMBL621204,,BAO_0000218,,
7921,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,N,1,1,,CHEMBL621205,,BAO_0000218,948.0,
7922,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL621206,,BAO_0000218,948.0,
7923,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,1,1,,CHEMBL621207,,BAO_0000218,948.0,
7924,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,N,1,1,,CHEMBL621208,,BAO_0000218,948.0,
7925,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL621209,,BAO_0000218,948.0,
7926,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,N,1,1,,CHEMBL876484,,BAO_0000218,948.0,
7927,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,1,1,,CHEMBL621210,,BAO_0000218,948.0,
7928,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL621211,,BAO_0000218,948.0,
7929,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,1,1,,CHEMBL621212,,BAO_0000218,948.0,
7930,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,N,1,1,,CHEMBL621213,,BAO_0000218,948.0,
7931,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,N,1,1,,CHEMBL621214,,BAO_0000218,948.0,
7932,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,N,1,1,,CHEMBL621215,,BAO_0000218,948.0,
7933,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,N,1,1,,CHEMBL621216,,BAO_0000218,948.0,
7934,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,N,1,1,,CHEMBL621217,,BAO_0000218,948.0,
7935,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,N,1,1,,CHEMBL621218,,BAO_0000218,948.0,
7936,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,N,1,1,,CHEMBL621219,,BAO_0000218,948.0,
7937,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,N,1,1,,CHEMBL621220,,BAO_0000218,948.0,
7938,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,N,1,1,,CHEMBL621221,,BAO_0000218,948.0,
7939,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,N,1,1,,CHEMBL621222,,BAO_0000218,948.0,
7940,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,N,1,1,,CHEMBL621223,,BAO_0000218,948.0,
7941,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,N,1,1,,CHEMBL876485,,BAO_0000218,948.0,
7942,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,1,1,,CHEMBL621224,,BAO_0000218,948.0,
7943,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL621225,,BAO_0000218,948.0,
7944,Intermediate,50597,Heart,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL621226,,BAO_0000218,948.0,
7945,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL621227,,BAO_0000218,2113.0,
7946,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,1,1,,CHEMBL621228,,BAO_0000218,2113.0,
7947,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,1,1,,CHEMBL621229,,BAO_0000218,2113.0,
7948,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL621230,,BAO_0000218,2113.0,
7949,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,1,1,,CHEMBL621231,,BAO_0000218,2113.0,
7950,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,1,1,,CHEMBL621232,,BAO_0000218,2113.0,
7951,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,1,1,,CHEMBL621233,,BAO_0000218,2113.0,
7952,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL621234,,BAO_0000218,2113.0,
7953,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,1,1,,CHEMBL621235,,BAO_0000218,2113.0,
7954,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,1,1,,CHEMBL621236,,BAO_0000218,2113.0,
7955,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL621237,,BAO_0000218,2113.0,
7956,Intermediate,50597,Kidney,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL876486,,BAO_0000218,2113.0,
7957,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,N,1,1,,CHEMBL622436,,BAO_0000218,160.0,
7958,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL622437,,BAO_0000218,160.0,
7959,Intermediate,50597,Intestine,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,N,1,1,,CHEMBL622438,,BAO_0000218,160.0,
7960,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,N,1,1,,CHEMBL622439,,BAO_0000218,2107.0,
7961,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL622440,,BAO_0000218,2107.0,
7962,Intermediate,50597,Liver,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL622441,,BAO_0000218,2107.0,
7963,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,1,1,,CHEMBL622442,,BAO_0000218,2107.0,
7964,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL622443,,BAO_0000218,2107.0,
7965,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,1,1,,CHEMBL622444,,BAO_0000218,2107.0,
7966,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,N,1,1,,CHEMBL622445,,BAO_0000218,2107.0,
7967,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,1,1,,CHEMBL622446,,BAO_0000218,2107.0,
7968,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,1,1,,CHEMBL622447,,BAO_0000218,2107.0,
7969,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL622448,,BAO_0000218,2107.0,
7970,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,1,1,,CHEMBL622449,,BAO_0000218,2107.0,
7971,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL622450,,BAO_0000218,2107.0,
7972,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,N,1,1,,CHEMBL622451,,BAO_0000218,2107.0,
7973,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,N,1,1,,CHEMBL622452,,BAO_0000218,2107.0,
7974,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,N,1,1,,CHEMBL622453,,BAO_0000218,2107.0,
7975,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,N,1,1,,CHEMBL622454,,BAO_0000218,2107.0,
7976,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,N,1,1,,CHEMBL622455,,BAO_0000218,2107.0,
7977,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,N,1,1,,CHEMBL876024,,BAO_0000218,2107.0,
7978,Intermediate,50597,,,T max was determined at 3 mg/kg po dose in rats,N,1,1,,CHEMBL622456,,BAO_0000218,,
7979,Intermediate,50597,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622457,,BAO_0000218,,
7980,Intermediate,50597,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622458,,BAO_0000218,,
7981,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,N,1,1,,CHEMBL622459,,BAO_0000218,,
7982,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,N,1,1,,CHEMBL873343,,BAO_0000218,,
7983,Intermediate,50597,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,N,1,1,,CHEMBL622460,,BAO_0000218,,
7984,Intermediate,50597,Plasma,,Time for maximum plasma concentration determined in rat,N,1,1,,CHEMBL622461,,BAO_0000218,1969.0,
7985,Intermediate,50597,Plasma,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,1,1,,CHEMBL622462,,BAO_0000218,1969.0,
7986,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,N,1,1,,CHEMBL622463,,BAO_0000218,,
7987,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,N,1,1,,CHEMBL622464,,BAO_0000218,,
7988,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,N,1,1,,CHEMBL622465,,BAO_0000218,,
7989,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,N,1,1,,CHEMBL622466,,BAO_0000218,,
7990,Intermediate,50597,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,N,1,1,,CHEMBL622467,,BAO_0000218,,
7991,Intermediate,50597,Plasma,,Time of maximum plasma concentration in rat,N,1,1,,CHEMBL622468,,BAO_0000218,1969.0,
7992,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,1,1,,CHEMBL876025,,BAO_0000218,1969.0,
7993,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,1,1,,CHEMBL622469,,BAO_0000218,1969.0,
7994,Intermediate,50597,Plasma,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,1,1,,CHEMBL622470,,BAO_0000218,1969.0,
7995,Intermediate,50597,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,N,1,1,,CHEMBL622471,,BAO_0000218,,
7996,Intermediate,50597,Plasma,,Time required to reach maximum concentration in rat plasma,N,1,1,,CHEMBL622472,,BAO_0000218,1969.0,
7997,Intermediate,50597,Plasma,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,1,1,,CHEMBL622473,,BAO_0000218,1969.0,
7998,Intermediate,50597,Plasma,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,1,1,,CHEMBL624282,,BAO_0000218,1969.0,
7999,Intermediate,50597,Plasma,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,1,1,,CHEMBL624283,,BAO_0000218,1969.0,
8000,Intermediate,50597,Plasma,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,1,1,,CHEMBL624284,,BAO_0000218,1969.0,
8001,Intermediate,50597,Plasma,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL624285,,BAO_0000218,1969.0,
8002,Intermediate,50597,,,Time to reach Cmax after oral administration to rats,N,1,1,,CHEMBL624286,,BAO_0000218,,
8003,Intermediate,50597,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,N,1,1,,CHEMBL624287,,BAO_0000218,,
8004,Intermediate,50597,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,N,1,1,,CHEMBL624288,,BAO_0000218,,
8005,Intermediate,50597,Plasma,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,N,1,1,,CHEMBL624289,,BAO_0000218,1969.0,
8006,Intermediate,50597,Plasma,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,N,1,1,,CHEMBL873344,,BAO_0000218,1969.0,
8007,Intermediate,50597,,,Tmax after peroral administration (10 mg/kg) was determined in rat,N,1,1,,CHEMBL619623,,BAO_0000218,,
8008,Expert,50597,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL621399,,BAO_0000218,,
8009,Intermediate,50597,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,N,1,1,,CHEMBL621400,,BAO_0000218,,
8010,Intermediate,50597,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",N,1,1,,CHEMBL621401,,BAO_0000218,,
8011,Intermediate,50597,,,Tmax was determined,N,1,1,,CHEMBL621402,,BAO_0000218,,
8012,Intermediate,50597,,,Tmax was determined,N,1,1,,CHEMBL621403,,BAO_0000218,,
8013,Intermediate,50597,,,Tmax after oral administration in rat,N,1,1,,CHEMBL621121,,BAO_0000218,,
8014,Intermediate,50597,,,Tmax after peroral administration in rats at 2.4 uM/kg,N,1,1,,CHEMBL872525,,BAO_0000218,,
8015,Intermediate,50597,,,Tmax in male rat,N,1,1,,CHEMBL621122,,BAO_0000218,,
8016,Intermediate,50597,,,Tmax in rat at 10 mg/kg,N,1,1,,CHEMBL621123,,BAO_0000218,,
8017,Intermediate,50597,,,Tmax in rat by po administration at a dose of 40 mg/kg,N,1,1,,CHEMBL621124,,BAO_0000218,,
8018,Intermediate,50597,,,Tmax in rats,N,1,1,,CHEMBL621125,,BAO_0000218,,
8019,Intermediate,50597,,,Tmax was measured in rats after peroral administration at 5 mg/kg,N,1,1,,CHEMBL621126,,BAO_0000218,,
8020,Intermediate,50597,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,N,1,1,,CHEMBL621127,,BAO_0000218,,
8021,Intermediate,50597,,,Tmax value after administration of 20 mg/Kg oral dose in rat,N,1,1,,CHEMBL621128,,BAO_0000218,,
8022,Intermediate,50597,,,Tmax value at a dose of 10 mg/kg in male SD rats,N,1,1,,CHEMBL618263,,BAO_0000218,,
8023,Intermediate,50597,,,Tmax value at a dose of 100 mg/kg in male SD rats,N,1,1,,CHEMBL618264,,BAO_0000218,,
8024,Intermediate,50597,,,Tmax value at a dose of 50 mg/kg in male SD rats,N,1,1,,CHEMBL618265,,BAO_0000218,,
8025,Intermediate,50597,Plasma,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL618266,,BAO_0000218,1969.0,
8026,Intermediate,50597,,,time required to reach maximum concentration (Cmax) after oral administration in rat,N,1,1,,CHEMBL618267,,BAO_0000218,,
8027,Intermediate,50597,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),N,1,1,,CHEMBL618450,,BAO_0000218,1088.0,
8028,Intermediate,50597,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),N,1,1,,CHEMBL618451,,BAO_0000218,1088.0,
8029,Intermediate,50597,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL618452,,BAO_0000218,,
8030,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,N,1,1,,CHEMBL618453,,BAO_0000218,1088.0,
8031,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,N,1,1,,CHEMBL618454,,BAO_0000218,1088.0,
8032,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,N,1,1,,CHEMBL618455,,BAO_0000218,1088.0,
8033,Intermediate,50597,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,N,1,1,,CHEMBL618456,,BAO_0000218,,
8034,Intermediate,50597,,,Compound distribution in rat tissues was determined,N,1,1,,CHEMBL618457,,BAO_0000218,,
8035,Intermediate,50597,,,Volume of distribution was evaluated in rat,N,1,1,,CHEMBL618458,,BAO_0000218,,
8036,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,N,1,1,,CHEMBL618459,,BAO_0000218,,
8037,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,N,1,1,,CHEMBL876733,,BAO_0000218,,
8038,Intermediate,50588,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,N,1,1,,CHEMBL618460,,BAO_0000218,,
8039,Intermediate,50597,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,N,1,1,,CHEMBL618461,,BAO_0000218,,
8040,Autocuration,22224,,,Area under the curve was determined after oral administration (300 uM/Kg),U,0,1,,CHEMBL618462,,BAO_0000019,,
8041,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,N,1,1,,CHEMBL618463,,BAO_0000218,,
8042,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,N,1,1,,CHEMBL618464,,BAO_0000218,,
8043,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,N,1,1,,CHEMBL618465,,BAO_0000218,,
8044,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,N,1,1,,CHEMBL618466,,BAO_0000218,,
8045,Intermediate,50597,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,N,1,1,,CHEMBL618467,,BAO_0000218,,
8046,Intermediate,50597,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,N,1,1,,CHEMBL618468,,BAO_0000218,,
8047,Intermediate,50588,Plasma,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,N,1,1,,CHEMBL618469,,BAO_0000218,1969.0,
8048,Intermediate,50588,Plasma,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,N,1,1,,CHEMBL618470,,BAO_0000218,1969.0,
8049,Autocuration,22224,,,Plasma drug AUC in rat (PO dose),U,0,1,,CHEMBL618471,,BAO_0000218,,
8050,Intermediate,50594,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,N,1,1,,CHEMBL618472,,BAO_0000218,,
8051,Autocuration,22224,,,Area under was determined at a dose of 30 mg/kg,U,0,1,,CHEMBL618473,,BAO_0000218,,
8052,Intermediate,50506,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,N,1,1,,CHEMBL621699,,BAO_0000218,,
8053,Intermediate,50597,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,N,1,1,,CHEMBL621700,,BAO_0000218,,
8054,Intermediate,50597,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,N,1,1,,CHEMBL621701,,BAO_0000218,,
8055,Intermediate,50506,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,N,1,1,,CHEMBL621702,,BAO_0000218,,
8056,Intermediate,50588,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,N,1,1,,CHEMBL621703,,BAO_0000218,,
8057,Intermediate,50588,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,N,1,1,,CHEMBL621704,,BAO_0000218,,
8058,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",N,1,1,,CHEMBL624259,,BAO_0000218,,
8059,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",N,1,1,,CHEMBL624260,,BAO_0000218,,
8060,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",N,1,1,,CHEMBL624430,,BAO_0000218,,
8061,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",N,1,1,,CHEMBL624431,,BAO_0000218,,
8062,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",N,1,1,,CHEMBL624432,,BAO_0000218,,
8063,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",N,1,1,,CHEMBL624433,,BAO_0000218,,
8064,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",N,1,1,,CHEMBL624434,,BAO_0000218,,
8065,Intermediate,50597,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",N,1,1,,CHEMBL624435,,BAO_0000218,,
8066,Intermediate,50594,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,N,1,1,,CHEMBL618570,,BAO_0000218,,
8067,Intermediate,50594,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,1,1,,CHEMBL618571,,BAO_0000218,,
8068,Intermediate,50594,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,N,1,1,,CHEMBL618572,,BAO_0000218,,
8069,Intermediate,50594,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,1,1,,CHEMBL618573,,BAO_0000218,,
8070,Intermediate,50594,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,N,1,1,,CHEMBL619267,,BAO_0000218,,
8071,Intermediate,50594,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,1,1,,CHEMBL619431,,BAO_0000218,,
8072,Intermediate,50594,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,N,1,1,,CHEMBL619432,,BAO_0000218,,
8073,Intermediate,50594,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,1,1,,CHEMBL619433,,BAO_0000218,,
8074,Autocuration,22224,Plasma,,AUC in mice after oral dose (50 mg/kg),U,0,1,,CHEMBL619434,,BAO_0000218,1969.0,
8075,Intermediate,50594,Serum,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,N,1,1,,CHEMBL619435,,BAO_0000218,1977.0,
8076,Autocuration,22224,Plasma,,AUC (0-4 hr) ug/ml/h,U,0,1,,CHEMBL619436,,BAO_0000019,1969.0,
8077,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,N,1,1,,CHEMBL619437,,BAO_0000218,,
8078,Autocuration,22224,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,U,0,1,,CHEMBL619438,,BAO_0000218,,
8079,Intermediate,50594,,,Compound was evaluated for Area under curve in mice,N,1,1,,CHEMBL619439,,BAO_0000218,,
8080,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,1,1,,CHEMBL619440,,BAO_0000218,,
8081,Autocuration,22224,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,U,0,1,,CHEMBL619441,,BAO_0000218,,
8082,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,1,1,,CHEMBL619442,,BAO_0000218,,
8083,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,U,0,1,,CHEMBL875156,,BAO_0000019,,
8084,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,U,0,1,,CHEMBL619443,,BAO_0000019,,
8085,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,U,0,1,,CHEMBL619444,,BAO_0000019,,
8086,Autocuration,22224,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,U,0,1,,CHEMBL623464,,BAO_0000019,,
8087,Intermediate,50594,,,Compound was evaluated for area under curve when administered through oral route in mouse,N,1,1,,CHEMBL623465,,BAO_0000218,,
8088,Intermediate,50597,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,N,1,1,,CHEMBL623466,,BAO_0000218,,
8089,Intermediate,50597,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,N,1,1,,CHEMBL623467,,BAO_0000218,,
8090,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL623468,,BAO_0000218,,
8091,Intermediate,50597,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,1,1,,CHEMBL622660,,BAO_0000218,,
8092,Intermediate,50597,,,Plasma clearance rate in Sprague-Dawley rats,N,1,1,,CHEMBL622661,,BAO_0000218,,
8093,Intermediate,50597,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL622662,,BAO_0000218,,
8094,Intermediate,50597,,,Pharmacokinetic property (total body clearance) in rat,N,1,1,,CHEMBL622663,,BAO_0000218,,
8095,Intermediate,50597,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,N,1,1,,CHEMBL622664,,BAO_0000218,,
8096,Intermediate,50597,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL622665,,BAO_0000218,,
8097,Intermediate,50597,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,1,1,,CHEMBL622666,,BAO_0000218,,
8098,Intermediate,50597,,,Cl in rat i.v. at 2 mg/kg concentration,N,1,1,,CHEMBL621615,,BAO_0000218,,
8099,Intermediate,50597,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL621616,,BAO_0000218,,
8100,Intermediate,50597,,,Clearance was determined,N,1,1,,CHEMBL621617,,BAO_0000218,,
8101,Intermediate,50597,,,Clearance by intravenous administration of 3.4 mg/kg in rat,N,1,1,,CHEMBL621618,,BAO_0000218,,
8102,Intermediate,50597,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,1,1,,CHEMBL621619,,BAO_0000218,,
8103,Intermediate,50597,,,Clearance rate after i.v. administration in rats,N,1,1,,CHEMBL621620,,BAO_0000218,,
8104,Intermediate,50597,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL621786,,BAO_0000218,,
8105,Intermediate,50597,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,1,1,,CHEMBL621787,,BAO_0000218,,
8106,Intermediate,50597,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,N,1,1,,CHEMBL621788,,BAO_0000218,,
8107,Intermediate,50597,,,Clearance (Cl) after oral administration in rat,N,1,1,,CHEMBL621789,,BAO_0000218,,
8108,Intermediate,50597,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,N,1,1,,CHEMBL621790,,BAO_0000218,,
8109,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat,N,1,1,,CHEMBL621791,,BAO_0000218,1969.0,
8110,Intermediate,50597,,,In vitro microsome metabolism clearance in rat was determined,N,1,1,,CHEMBL621792,,BAO_0000218,,
8111,Intermediate,50597,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,N,1,1,,CHEMBL621793,,BAO_0000218,,
8112,Intermediate,50597,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL621794,,BAO_0000218,,
8113,Intermediate,50597,Plasma,,In vivo plasma clearance was determined,N,1,1,,CHEMBL621795,,BAO_0000218,1969.0,
8114,Intermediate,50597,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,N,1,1,,CHEMBL621796,,BAO_0000218,,
8115,Intermediate,50597,Liver,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,N,1,1,,CHEMBL621797,401.0,BAO_0000218,2107.0,
8116,Intermediate,50597,,,Pharmacokinetic property (Plasma clearance) was measured in rat,N,1,1,,CHEMBL621798,,BAO_0000218,,
8117,Intermediate,50597,,,Pharmacokinetic property (clearance) in rat i.v.,N,1,1,,CHEMBL621799,,BAO_0000218,,
8118,Intermediate,50597,,,"Plasma Clearance was evaluated in rats, iv",N,1,1,,CHEMBL621800,,BAO_0000218,,
8119,Intermediate,50597,,,Plasma clearance (in vivo) in rats was determined,N,1,1,,CHEMBL621801,,BAO_0000218,,
8120,Intermediate,50597,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,N,1,1,,CHEMBL621802,,BAO_0000218,,
8121,Intermediate,50597,,,Plasma clearance was determined,N,1,1,,CHEMBL618596,,BAO_0000218,,
8122,Intermediate,50597,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,N,1,1,,CHEMBL618597,,BAO_0000218,,
8123,Intermediate,50597,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,N,1,1,,CHEMBL618598,,BAO_0000218,,
8124,Intermediate,50597,,,Plasma clearance in rats,N,1,1,,CHEMBL618599,,BAO_0000218,,
8125,Intermediate,50597,,,Plasma clearance rate determined in rat,N,1,1,,CHEMBL618600,,BAO_0000218,,
8126,Intermediate,50597,,,Plasma clearance was determined in rat,N,1,1,,CHEMBL618601,,BAO_0000218,,
8127,Intermediate,50597,,,Plasma clearance was determined,N,1,1,,CHEMBL618602,,BAO_0000218,,
8128,Intermediate,50597,,,Plasma clearance value in rat,N,1,1,,CHEMBL618603,,BAO_0000218,,
8129,Intermediate,50597,Liver,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,1,1,,CHEMBL618604,,BAO_0000218,2107.0,
8130,Intermediate,50597,,,Clearance in rat,N,1,1,,CHEMBL618605,,BAO_0000218,,
8131,Intermediate,50597,,,Total body clearance in rat i.v. at 2 mg/kg concentration,N,1,1,,CHEMBL618606,,BAO_0000218,,
8132,Intermediate,50597,,,Clearance of compound in rats after intravenous administration,N,1,1,,CHEMBL618607,,BAO_0000218,,
8133,Intermediate,50597,,,Clearance after iv administration to rats,N,1,1,,CHEMBL618608,,BAO_0000218,,
8134,Intermediate,50597,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,1,1,,CHEMBL618609,,BAO_0000218,,
8135,Intermediate,50597,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,1,1,,CHEMBL618610,,BAO_0000218,,
8136,Intermediate,50597,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,N,1,1,,CHEMBL618611,,BAO_0000218,,
8137,Intermediate,50597,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,1,1,,CHEMBL618612,,BAO_0000218,,
8138,Intermediate,50597,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,1,1,,CHEMBL618613,,BAO_0000218,,
8139,Intermediate,50597,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,1,1,,CHEMBL621076,,BAO_0000218,,
8140,Intermediate,50597,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,1,1,,CHEMBL621077,,BAO_0000218,,
8141,Intermediate,50597,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",N,1,1,,CHEMBL621078,,BAO_0000218,,
8142,Intermediate,50597,,,Clearance in rat,N,1,1,,CHEMBL621251,,BAO_0000218,,
8143,Intermediate,50597,,,Clearance in rat after oral administration at 10 mg/kg,N,1,1,,CHEMBL621252,,BAO_0000218,,
8144,Intermediate,50597,,,Clearance in rat.,N,1,1,,CHEMBL621253,,BAO_0000218,,
8145,Intermediate,50597,,,Clearance rate following an oral dose of 20 mg/kg in rats,N,1,1,,CHEMBL621254,,BAO_0000218,,
8146,Intermediate,50597,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,N,1,1,,CHEMBL621255,,BAO_0000218,,
8147,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,N,1,1,,CHEMBL621256,,BAO_0000218,1969.0,
8148,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,N,1,1,,CHEMBL621257,,BAO_0000218,2107.0,
8149,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,N,1,1,,CHEMBL621258,,BAO_0000218,2107.0,
8150,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,N,1,1,,CHEMBL621259,,BAO_0000218,2107.0,
8151,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,N,1,1,,CHEMBL621260,,BAO_0000218,2107.0,
8152,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,N,1,1,,CHEMBL876494,,BAO_0000218,2107.0,
8153,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,N,1,1,,CHEMBL621261,,BAO_0000218,2107.0,
8154,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,N,1,1,,CHEMBL621262,,BAO_0000218,2107.0,
8155,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,1,1,,CHEMBL621263,,BAO_0000218,2107.0,
8156,Intermediate,50597,Liver,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL621264,,BAO_0000218,2107.0,
8157,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL621265,,BAO_0000218,2385.0,
8158,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,N,1,1,,CHEMBL621266,,BAO_0000218,2385.0,
8159,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,N,1,1,,CHEMBL621267,,BAO_0000218,2385.0,
8160,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL621268,,BAO_0000218,2385.0,
8161,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,N,1,1,,CHEMBL621269,,BAO_0000218,2385.0,
8162,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,N,1,1,,CHEMBL621270,,BAO_0000218,2385.0,
8163,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,N,1,1,,CHEMBL621271,,BAO_0000218,2385.0,
8164,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,N,1,1,,CHEMBL621272,,BAO_0000218,2385.0,
8165,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,N,1,1,,CHEMBL621273,,BAO_0000218,2385.0,
8166,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,N,1,1,,CHEMBL621274,,BAO_0000218,2385.0,
8167,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,N,1,1,,CHEMBL876495,,BAO_0000218,2385.0,
8168,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,N,1,1,,CHEMBL621275,,BAO_0000218,2385.0,
8169,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL621276,,BAO_0000218,2385.0,
8170,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL621277,,BAO_0000218,2385.0,
8171,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL621278,,BAO_0000218,160.0,
8172,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,N,1,1,,CHEMBL621279,,BAO_0000218,160.0,
8173,Intermediate,50597,Intestine,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),N,1,1,,CHEMBL621280,,BAO_0000218,160.0,
8174,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,N,1,1,,CHEMBL621281,,BAO_0000218,2106.0,
8175,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,N,1,1,,CHEMBL621282,,BAO_0000218,2106.0,
8176,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,1,1,,CHEMBL621283,,BAO_0000218,2106.0,
8177,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,N,1,1,,CHEMBL621284,,BAO_0000218,2106.0,
8178,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,N,1,1,,CHEMBL621285,,BAO_0000218,2106.0,
8179,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL621286,,BAO_0000218,2106.0,
8180,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,N,1,1,,CHEMBL623220,,BAO_0000218,2106.0,
8181,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,N,1,1,,CHEMBL623221,,BAO_0000218,2106.0,
8182,Intermediate,50597,Spleen,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,N,1,1,,CHEMBL876029,,BAO_0000218,2106.0,
8183,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,N,1,1,,CHEMBL623222,,BAO_0000218,945.0,
8184,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,N,1,1,,CHEMBL623223,,BAO_0000218,945.0,
8185,Intermediate,50597,Stomach,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,N,1,1,,CHEMBL621445,,BAO_0000218,945.0,
8186,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621446,,BAO_0000218,178.0,
8187,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621447,,BAO_0000218,178.0,
8188,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619681,,BAO_0000218,178.0,
8189,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619682,,BAO_0000218,178.0,
8190,Intermediate,50597,Blood,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619683,,BAO_0000218,178.0,
8191,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619684,,BAO_0000218,955.0,
8192,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619685,,BAO_0000218,955.0,
8193,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619686,,BAO_0000218,955.0,
8194,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619687,,BAO_0000218,955.0,
8195,Intermediate,50597,Brain,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619688,,BAO_0000218,955.0,
8196,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619689,,BAO_0000218,948.0,
8197,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619690,,BAO_0000218,948.0,
8198,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619691,,BAO_0000218,948.0,
8199,Intermediate,50597,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,1,1,,CHEMBL619692,,BAO_0000218,,
8200,Expert,50597,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL619693,,BAO_0000218,,
8201,Intermediate,50597,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,N,1,1,,CHEMBL619694,,BAO_0000218,,
8202,Intermediate,50597,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,N,1,1,,CHEMBL619695,,BAO_0000218,,
8203,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,N,1,1,,CHEMBL619696,,BAO_0000218,,
8204,Intermediate,50597,,,Compound was evaluated for volume of distribution in rat,N,1,1,,CHEMBL619697,,BAO_0000218,,
8205,Intermediate,50597,,,Steady state volume distribution was determined; steady state(ss),N,1,1,,CHEMBL619698,,BAO_0000218,,
8206,Intermediate,50597,,,Steady state volume of distribution after iv administration to rats,N,1,1,,CHEMBL619699,,BAO_0000218,,
8207,Intermediate,50597,,,Steady state volume of distribution dosing at 3 mg/kg iv,N,1,1,,CHEMBL619700,,BAO_0000218,,
8208,Intermediate,50597,,,The compound was evaluated for volume of distribution in rat,N,1,1,,CHEMBL619701,,BAO_0000218,,
8209,Intermediate,50597,,,The compound was tested for volume of distribution in rat,N,1,1,,CHEMBL619702,,BAO_0000218,,
8210,Intermediate,50597,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,N,1,1,,CHEMBL620335,,BAO_0000218,,
8211,Intermediate,50597,,,Volume distribution (VD) after oral administration in rat,N,1,1,,CHEMBL620336,,BAO_0000218,,
8212,Intermediate,50597,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,1,1,,CHEMBL620337,,BAO_0000218,,
8213,Intermediate,50597,,,Volume distribution in rat,N,1,1,,CHEMBL620520,,BAO_0000218,,
8214,Intermediate,50597,,,Volume distribution in rat,N,1,1,,CHEMBL620521,,BAO_0000218,,
8215,Intermediate,50597,,,Volume distribution in rat after peroral administration at 10 mg/kg,N,1,1,,CHEMBL875825,,BAO_0000218,,
8216,Intermediate,50597,,,Volume distribution in rat after peroral administration at 5 mg/kg,N,1,1,,CHEMBL620522,,BAO_0000218,,
8217,Intermediate,50597,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,1,1,,CHEMBL620523,,BAO_0000218,,
8218,Intermediate,50597,,,Volume of distribution in rat.,N,1,1,,CHEMBL620524,,BAO_0000218,,
8219,Intermediate,50597,,,Volume of distribution in rat,N,1,1,,CHEMBL620525,,BAO_0000218,,
8220,Intermediate,50597,,,Volume of distribution in rat,N,1,1,,CHEMBL620526,,BAO_0000218,,
8221,Intermediate,50597,,,Volume of distribution in rat by iv administration,N,1,1,,CHEMBL620527,,BAO_0000218,,
8222,Intermediate,50597,,,Volume of distribution in rats,N,1,1,,CHEMBL620528,,BAO_0000218,,
8223,Intermediate,50597,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,1,1,,CHEMBL620529,,BAO_0000218,,
8224,Intermediate,50597,,,Volume distribution at the dose of 2 mg/kg in rat,N,1,1,,CHEMBL620530,,BAO_0000218,,
8225,Intermediate,50597,,,Steady state volume of distribution was determined,N,1,1,,CHEMBL620531,,BAO_0000218,,
8226,Intermediate,22224,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,0,1,,CHEMBL620532,,BAO_0000218,,
8227,Intermediate,22224,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,U,0,1,,CHEMBL620533,,BAO_0000218,,
8228,Intermediate,22224,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,U,0,1,,CHEMBL620534,,BAO_0000218,,
8229,Intermediate,50597,,,Mean (%CV) PK parameters for Vdss(mL/kg).,N,1,1,,CHEMBL620535,,BAO_0000218,,
8230,Intermediate,50597,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,N,1,1,,CHEMBL875826,,BAO_0000218,,
8231,Intermediate,50597,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,N,1,1,,CHEMBL620536,,BAO_0000218,,
8232,Intermediate,50597,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL620537,,BAO_0000218,,
8233,Intermediate,50597,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,N,1,1,,CHEMBL618526,,BAO_0000218,,
8234,Intermediate,50597,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,N,1,1,,CHEMBL618527,,BAO_0000218,,
8235,Intermediate,50597,,,Pharmacokinetic property (Vdss) in rat,N,1,1,,CHEMBL618528,,BAO_0000218,,
8236,Intermediate,50597,,,Pharmacokinetic property (vdss) was measured in rat,N,1,1,,CHEMBL618529,,BAO_0000218,,
8237,Intermediate,50597,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL618530,,BAO_0000218,,
8238,Intermediate,50597,,,Volume of distribution in rat,N,1,1,,CHEMBL618531,,BAO_0000218,,
8239,Intermediate,50597,,,The pharmacokinetic parameter volume of distribution in vivo in rats,N,1,1,,CHEMBL618532,,BAO_0000218,,
8240,Intermediate,50597,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL618533,,BAO_0000218,,
8241,Intermediate,50597,,,Vdss in rat i.v. at 2 mg/kg concentration,N,1,1,,CHEMBL618534,,BAO_0000218,,
8242,Intermediate,50597,,,Volume distribution after intravenous administration (1 mg/kg) in rat,N,1,1,,CHEMBL618535,,BAO_0000218,,
8243,Intermediate,50597,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,1,1,,CHEMBL618536,,BAO_0000218,,
8244,Intermediate,50597,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,1,1,,CHEMBL618537,,BAO_0000218,,
8245,Intermediate,50597,,,Volume distribution at a dose of 10 uM/kg in rat was determined,N,1,1,,CHEMBL618538,,BAO_0000218,,
8246,Intermediate,50597,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,1,1,,CHEMBL618539,,BAO_0000218,,
8247,Intermediate,50597,,,Volume distribution was calculated in rat,N,1,1,,CHEMBL618540,,BAO_0000218,,
8248,Intermediate,50597,,,Volume distribution was determined,N,1,1,,CHEMBL618541,,BAO_0000218,,
8249,Intermediate,50597,,,Volume of distribution after intravenous administration was evaluated in rat,N,1,1,,CHEMBL618542,,BAO_0000218,,
8250,Intermediate,50597,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL622544,,BAO_0000218,,
8251,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",N,1,1,,CHEMBL622545,,BAO_0000218,,
8252,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,1,1,,CHEMBL622546,,BAO_0000218,,
8253,Intermediate,50597,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",N,1,1,,CHEMBL622547,,BAO_0000218,,
8254,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,N,1,1,,CHEMBL622548,,BAO_0000218,,
8255,Intermediate,50597,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,N,1,1,,CHEMBL622549,,BAO_0000218,,
8256,Intermediate,50597,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,1,1,,CHEMBL622550,,BAO_0000218,,
8257,Intermediate,50594,,,Compound was evaluated for area under curve when administered through oral route to mouse,N,1,1,,CHEMBL622551,,BAO_0000218,,
8258,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,1,1,,CHEMBL622552,,BAO_0000218,,
8259,Intermediate,50597,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,1,1,,CHEMBL622553,,BAO_0000218,,
8260,Autocuration,22224,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,U,0,1,,CHEMBL622554,,BAO_0000218,,
8261,Intermediate,50588,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,N,1,1,,CHEMBL622555,,BAO_0000218,,
8262,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,1,1,,CHEMBL622556,,BAO_0000218,,
8263,Intermediate,50594,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,1,1,,CHEMBL622557,,BAO_0000218,,
8264,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,N,1,1,,CHEMBL622558,,BAO_0000218,178.0,
8265,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,N,1,1,,CHEMBL622559,,BAO_0000218,178.0,
8266,Intermediate,50588,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,N,1,1,,CHEMBL622560,,BAO_0000218,,
8267,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,1,1,,CHEMBL622561,,BAO_0000218,,
8268,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,N,1,1,,CHEMBL622562,,BAO_0000218,,
8269,Intermediate,50597,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,1,1,,CHEMBL622563,,BAO_0000218,,
8270,Autocuration,22224,,,Concentration of compound in Central nervous system,U,0,1,,CHEMBL622564,,BAO_0000019,,
8271,Autocuration,22224,,,Concentration of compound in Central nervous system; Not detectable,U,0,1,,CHEMBL622565,,BAO_0000019,,
8272,Intermediate,50594,,,"Concentration of diester in the blood, following oral administration in mice",N,1,1,,CHEMBL622566,,BAO_0000218,,
8273,Intermediate,50594,,,"Concentration of monoester in the blood, following oral administration in mice",N,1,1,,CHEMBL624515,,BAO_0000218,,
8274,Intermediate,50594,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,N,1,1,,CHEMBL624516,,BAO_0000218,,
8275,Autocuration,22224,,,Evaluated for Pharmacokinetic property: Area under the curve,U,0,1,,CHEMBL624517,,BAO_0000019,,
8276,Intermediate,50594,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,N,1,1,,CHEMBL624518,,BAO_0000218,,
8277,Intermediate,100710,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,N,1,1,,CHEMBL624519,,BAO_0000218,,
8278,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL624520,,BAO_0000218,,
8279,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL624521,,BAO_0000218,,
8280,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL624522,,BAO_0000218,,
8281,Intermediate,100710,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL624523,,BAO_0000218,,
8282,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,1,1,,CHEMBL624409,,BAO_0000218,,
8283,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",N,1,1,,CHEMBL624410,,BAO_0000218,,
8284,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,1,1,,CHEMBL624411,,BAO_0000218,,
8285,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",N,1,1,,CHEMBL623531,,BAO_0000218,,
8286,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",N,1,1,,CHEMBL623532,,BAO_0000218,,
8287,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",N,1,1,,CHEMBL623533,,BAO_0000218,,
8288,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,1,1,,CHEMBL623534,,BAO_0000218,,
8289,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623535,,BAO_0000218,,
8290,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623536,,BAO_0000218,,
8291,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623537,,BAO_0000218,,
8292,Intermediate,50594,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623538,,BAO_0000218,,
8293,Intermediate,50594,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623539,,BAO_0000218,,
8294,Intermediate,50594,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,N,1,1,,CHEMBL623540,,BAO_0000218,,
8295,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",N,1,1,,CHEMBL623541,,BAO_0000218,,
8296,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",N,1,1,,CHEMBL623542,,BAO_0000218,,
8297,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",N,1,1,,CHEMBL623543,,BAO_0000218,,
8298,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",N,1,1,,CHEMBL623544,,BAO_0000218,,
8299,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",N,1,1,,CHEMBL623545,,BAO_0000218,,
8300,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",N,1,1,,CHEMBL623546,,BAO_0000218,,
8301,Intermediate,50597,Plasma,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL623547,,BAO_0000218,1969.0,
8302,Intermediate,50597,,,High i.v. clearance in Dawley rats,N,1,1,,CHEMBL623548,,BAO_0000218,,
8303,Intermediate,50597,Liver,,In vitro clearance in rat liver microsomes,N,1,1,,CHEMBL623549,,BAO_0000218,2107.0,
8304,Intermediate,50597,Liver,,Intrinsic clearance in rat liver microsomes was determined,N,1,1,,CHEMBL623550,,BAO_0000218,2107.0,
8305,Intermediate,50597,Liver,,Intrinsic clearance in rat hepatocytes was determined,N,1,1,,CHEMBL875276,401.0,BAO_0000218,2107.0,
8306,Intermediate,50597,,,Plasma Clearance was determined,N,1,1,,CHEMBL621872,,BAO_0000218,,
8307,Intermediate,50597,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,N,1,1,,CHEMBL621873,,BAO_0000218,,
8308,Intermediate,50597,,,Plasma clearance in rat.,N,1,1,,CHEMBL621874,,BAO_0000218,,
8309,Intermediate,50597,,,Plasma clearance in rats,N,1,1,,CHEMBL621875,,BAO_0000218,,
8310,Intermediate,50597,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,N,1,1,,CHEMBL621876,,BAO_0000218,,
8311,Intermediate,50597,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,N,1,1,,CHEMBL621877,,BAO_0000218,,
8312,Intermediate,50597,,,Plasma clearance was measured in rat,N,1,1,,CHEMBL621878,,BAO_0000218,,
8313,Intermediate,50597,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,1,1,,CHEMBL621879,,BAO_0000218,,
8314,Intermediate,50597,Plasma,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",N,1,1,,CHEMBL621880,,BAO_0000218,1969.0,
8315,Intermediate,50597,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,N,1,1,,CHEMBL621881,,BAO_0000218,,
8316,Intermediate,50597,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,1,1,,CHEMBL621882,,BAO_0000218,,
8317,Intermediate,50597,,,Total clearance at 1 mg/kg was determined in rat,N,1,1,,CHEMBL875283,,BAO_0000218,,
8318,Intermediate,50597,,,Total clearance at 10 mg/kg was determined in rat,N,1,1,,CHEMBL621883,,BAO_0000218,,
8319,Intermediate,50597,,,Clearance in rat,N,1,1,,CHEMBL621884,,BAO_0000218,,
8320,Intermediate,50597,,,Plasma clearance rate determined in rats,N,1,1,,CHEMBL621885,,BAO_0000218,,
8321,Intermediate,50597,,,Clearance of compound in rat was evaluated,N,1,1,,CHEMBL621886,,BAO_0000218,,
8322,Intermediate,50597,Plasma,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,1,1,,CHEMBL621887,,BAO_0000218,1969.0,
8323,Intermediate,50597,,,Pharmacokinetic property (blood clearance) in rat,N,1,1,,CHEMBL621888,,BAO_0000218,,
8324,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL621889,,BAO_0000218,,
8325,Intermediate,50597,,,Plasma clearance in rats,N,1,1,,CHEMBL621890,,BAO_0000218,,
8326,Intermediate,50597,Liver,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,N,1,1,,CHEMBL621891,,BAO_0000218,2107.0,
8327,Intermediate,50597,,,Clearance in Dawley rat,N,1,1,,CHEMBL621892,,BAO_0000218,,
8328,Intermediate,50597,,,Clearance rat,N,1,1,,CHEMBL621893,,BAO_0000218,,
8329,Intermediate,50597,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),N,1,1,,CHEMBL621894,,BAO_0000218,,
8330,Intermediate,50597,,,Clearance rat; Not determined,N,1,1,,CHEMBL621895,,BAO_0000218,,
8331,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,N,1,1,,CHEMBL875284,,BAO_0000218,,
8332,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,1,1,,CHEMBL618699,,BAO_0000218,,
8333,Intermediate,50597,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,1,1,,CHEMBL618700,,BAO_0000218,,
8334,Intermediate,50597,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,1,1,,CHEMBL618701,,BAO_0000218,,
8335,Intermediate,50597,Plasma,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,1,1,,CHEMBL876600,,BAO_0000218,1969.0,
8336,Intermediate,50597,,,Clearance of compound in rat after 1 mg/kg i.v. administration,N,1,1,,CHEMBL618702,,BAO_0000218,,
8337,Intermediate,50597,,,Compound was evaluated for Hepatic clearance in rat,N,1,1,,CHEMBL618703,,BAO_0000218,,
8338,Intermediate,50597,,,In vivo clearance after 5 mg/kg dose,N,1,1,,CHEMBL618704,,BAO_0000218,,
8339,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rats,N,1,1,,CHEMBL618705,,BAO_0000218,1969.0,
8340,Intermediate,50597,,,Hepatic clearance after intravenous administration was evaluated in rat,N,1,1,,CHEMBL618706,,BAO_0000218,,
8341,Intermediate,50597,,,Lower clearance in rat (i.v.) at 0.5 mpk,N,1,1,,CHEMBL618707,,BAO_0000218,,
8342,Intermediate,50597,Plasma,,Pharmacokinetic parameter expressed as plasma clearance in rat,N,1,1,,CHEMBL618708,,BAO_0000218,1969.0,
8343,Intermediate,50597,,,Pharmacokinetic property (Clp) in rat,N,1,1,,CHEMBL618709,,BAO_0000218,,
8344,Intermediate,50597,,,Plasma clearance in Sprague-Dawley rats,N,1,1,,CHEMBL618710,,BAO_0000218,,
8345,Intermediate,50597,,,Plasma clearance (Clp) in rat,N,1,1,,CHEMBL618711,,BAO_0000218,,
8346,Intermediate,50597,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,N,1,1,,CHEMBL618712,,BAO_0000218,,
8347,Intermediate,50597,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,N,1,1,,CHEMBL618713,,BAO_0000218,,
8348,Intermediate,50597,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL618714,,BAO_0000218,,
8349,Intermediate,50597,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,1,1,,CHEMBL618715,,BAO_0000218,,
8350,Intermediate,50597,,,Plasma clearance in rat was determined,N,1,1,,CHEMBL618716,,BAO_0000218,,
8351,Intermediate,50597,,,Plasma clearance measured in rat,N,1,1,,CHEMBL876601,,BAO_0000218,,
8352,Intermediate,50597,,,Plasma clearance was calculated in rat,N,1,1,,CHEMBL618717,,BAO_0000218,,
8353,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL618718,,BAO_0000218,,
8354,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL618719,,BAO_0000218,,
8355,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL618720,,BAO_0000218,,
8356,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL618721,,BAO_0000218,,
8357,Intermediate,50597,,,Plasma clearance in rats,N,1,1,,CHEMBL621477,,BAO_0000218,,
8358,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL621478,,BAO_0000218,,
8359,Intermediate,50597,,,Plasma clearance was evaluated in rat,N,1,1,,CHEMBL621479,,BAO_0000218,,
8360,Intermediate,50597,,,Plasma clearance was evaluated in rat; Not tested,N,1,1,,CHEMBL621480,,BAO_0000218,,
8361,Intermediate,50597,,,Plasma clearance rate was determined for the compound in rat,N,1,1,,CHEMBL621481,,BAO_0000218,,
8362,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",N,1,1,,CHEMBL621482,,BAO_0000218,,
8363,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,1,1,,CHEMBL621483,,BAO_0000218,,
8364,Intermediate,50597,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",N,1,1,,CHEMBL621484,,BAO_0000218,,
8365,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621485,,BAO_0000218,948.0,
8366,Intermediate,50597,Heart,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621486,,BAO_0000218,948.0,
8367,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621487,,BAO_0000218,160.0,
8368,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621488,,BAO_0000218,160.0,
8369,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621489,,BAO_0000218,160.0,
8370,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621490,,BAO_0000218,160.0,
8371,Intermediate,50597,Intestine,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621491,,BAO_0000218,160.0,
8372,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621492,,BAO_0000218,2113.0,
8373,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621493,,BAO_0000218,2113.0,
8374,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621494,,BAO_0000218,2113.0,
8375,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621495,,BAO_0000218,2113.0,
8376,Intermediate,50597,Kidney,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621496,,BAO_0000218,2113.0,
8377,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621497,,BAO_0000218,2107.0,
8378,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621498,,BAO_0000218,2107.0,
8379,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL621499,,BAO_0000218,2107.0,
8380,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL618634,,BAO_0000218,2107.0,
8381,Intermediate,50597,Liver,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL618635,,BAO_0000218,2107.0,
8382,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL618636,,BAO_0000218,2048.0,
8383,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619737,,BAO_0000218,2048.0,
8384,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL619738,,BAO_0000218,2048.0,
8385,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624329,,BAO_0000218,2048.0,
8386,Intermediate,50597,Lung,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624330,,BAO_0000218,2048.0,
8387,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624331,,BAO_0000218,2385.0,
8388,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624332,,BAO_0000218,2385.0,
8389,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624333,,BAO_0000218,2385.0,
8390,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624334,,BAO_0000218,2385.0,
8391,Intermediate,50597,Muscle tissue,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL624335,,BAO_0000218,2385.0,
8392,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620016,,BAO_0000218,2106.0,
8393,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620169,,BAO_0000218,2106.0,
8394,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620170,,BAO_0000218,2106.0,
8395,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620171,,BAO_0000218,2106.0,
8396,Intermediate,50597,Spleen,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620172,,BAO_0000218,2106.0,
8397,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620173,,BAO_0000218,945.0,
8398,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620174,,BAO_0000218,945.0,
8399,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620175,,BAO_0000218,945.0,
8400,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620176,,BAO_0000218,945.0,
8401,Intermediate,50597,Stomach,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620177,,BAO_0000218,945.0,
8402,Intermediate,50597,Cerebellum,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620178,,BAO_0000218,2037.0,
8403,Intermediate,50597,Cerebellum,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620179,,BAO_0000218,2037.0,
8404,Intermediate,50597,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620180,,BAO_0000218,,
8405,Intermediate,50597,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,N,1,1,,CHEMBL620181,,BAO_0000218,,
8406,Intermediate,50597,,,Volume of distribution of compound in rats after intravenous administration,N,1,1,,CHEMBL620182,,BAO_0000218,,
8407,Intermediate,50597,,,Volume of distribution in rat,N,1,1,,CHEMBL620183,,BAO_0000218,,
8408,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,N,1,1,,CHEMBL620184,,BAO_0000218,,
8409,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,1,1,,CHEMBL620185,,BAO_0000218,,
8410,Intermediate,50597,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,1,1,,CHEMBL620186,,BAO_0000218,,
8411,Intermediate,50597,,,Volume of distribution was determined in Dawley rat,N,1,1,,CHEMBL620187,,BAO_0000218,,
8412,Intermediate,50597,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL620188,,BAO_0000218,,
8413,Intermediate,50597,,,Volume of distribution was reported in Sprague-Dawley rat,N,1,1,,CHEMBL620189,,BAO_0000218,,
8414,Intermediate,50597,,,Volumes of distribution in rat after peroral administration,N,1,1,,CHEMBL620190,,BAO_0000218,,
8415,Intermediate,50597,,,Volumes of distribution in rat after po administration,N,1,1,,CHEMBL620191,,BAO_0000218,,
8416,Intermediate,50597,,,Volumes of distribution in rat after po administration; Not determined,N,1,1,,CHEMBL620192,,BAO_0000218,,
8417,Intermediate,50597,,,Pharmacokinetic property (Volume) in rat i.v.,N,1,1,,CHEMBL620193,,BAO_0000218,,
8418,Intermediate,50597,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,N,1,1,,CHEMBL620194,,BAO_0000218,,
8419,Intermediate,50597,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",N,1,1,,CHEMBL876730,,BAO_0000218,,
8420,Intermediate,50597,,,Volume distribution in rat after oral administration at 10 mg/kg,N,1,1,,CHEMBL620195,,BAO_0000218,,
8421,Intermediate,50597,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL620196,,BAO_0000218,,
8422,Intermediate,50597,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,1,1,,CHEMBL620197,,BAO_0000218,,
8423,Intermediate,50597,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,N,1,1,,CHEMBL620198,,BAO_0000218,,
8424,Intermediate,50597,,,Volume of distribution in rats,N,1,1,,CHEMBL620199,,BAO_0000218,,
8425,Intermediate,50597,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,N,1,1,,CHEMBL620200,,BAO_0000218,,
8426,Intermediate,50597,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,N,1,1,,CHEMBL620201,,BAO_0000218,,
8427,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL620202,,BAO_0000218,,
8428,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL620203,,BAO_0000218,,
8429,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,N,1,1,,CHEMBL620204,,BAO_0000218,,
8430,Intermediate,50597,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL620205,,BAO_0000218,,
8431,Intermediate,50597,,,Pharmacokinetic parameter (Vss) in rat,N,1,1,,CHEMBL624664,,BAO_0000218,,
8432,Intermediate,50597,,,Pharmacokinetic property (Volume) in rat i.v.,N,1,1,,CHEMBL624665,,BAO_0000218,,
8433,Intermediate,50597,,,Pharmacokinetic property (Vss) in rat,N,1,1,,CHEMBL624666,,BAO_0000218,,
8434,Intermediate,50597,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,1,1,,CHEMBL624667,,BAO_0000218,,
8435,Intermediate,50597,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL624668,,BAO_0000218,,
8436,Intermediate,50597,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL624669,,BAO_0000218,,
8437,Intermediate,50597,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL624670,,BAO_0000218,,
8438,Intermediate,50597,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL624671,,BAO_0000218,,
8439,Intermediate,50597,,,Steady state volume distribution in rat,N,1,1,,CHEMBL624672,,BAO_0000218,,
8440,Intermediate,50597,Plasma,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",N,1,1,,CHEMBL624673,,BAO_0000218,1969.0,
8441,Intermediate,50597,,,Steady state volume of distribution determined in rat,N,1,1,,CHEMBL624674,,BAO_0000218,,
8442,Intermediate,50597,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,1,1,,CHEMBL624675,,BAO_0000218,,
8443,Intermediate,50597,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,N,1,1,,CHEMBL621728,,BAO_0000218,,
8444,Intermediate,50597,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,N,1,1,,CHEMBL621729,,BAO_0000218,,
8445,Intermediate,50597,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,N,1,1,,CHEMBL621730,,BAO_0000218,,
8446,Intermediate,50597,,,Volume distribution in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL621731,,BAO_0000218,,
8447,Intermediate,50597,,,Volume distribution in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL621732,,BAO_0000218,,
8448,Intermediate,50597,,,Volume in steady state distribution value was determined,N,1,1,,CHEMBL621908,,BAO_0000218,,
8449,Intermediate,50597,,,Volume in steady state distribution value was determined; ND denotes no data,N,1,1,,CHEMBL875347,,BAO_0000218,,
8450,Intermediate,50597,,,Volume in steady state distribution value was determined; ND denotes not determined,N,1,1,,CHEMBL621909,,BAO_0000218,,
8451,Intermediate,50597,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,1,1,,CHEMBL621910,,BAO_0000218,,
8452,Intermediate,50597,,,Volume of distribution at steady state was evaluated in rats,N,1,1,,CHEMBL621911,,BAO_0000218,,
8453,Intermediate,50597,,,Volume of distribution at steady state was observed after intravenous administration in rat,N,1,1,,CHEMBL621912,,BAO_0000218,,
8454,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,N,1,1,,CHEMBL621913,,BAO_0000218,,
8455,Intermediate,50597,,,Volume of distribution in steady state was determined in rat,N,1,1,,CHEMBL621914,,BAO_0000218,,
8456,Intermediate,50597,,,Volume of distribution after i.v. administration,N,1,1,,CHEMBL621915,,BAO_0000218,,
8457,Intermediate,50597,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,1,1,,CHEMBL621916,,BAO_0000218,,
8458,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL621917,,BAO_0000218,2107.0,
8459,Intermediate,50594,Liver,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL621918,,BAO_0000218,2107.0,
8460,Intermediate,50594,Spleen,,Biodistribution of compound (oxidized form) in spleen tissue,N,1,1,,CHEMBL621919,,BAO_0000218,2106.0,
8461,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL621920,,BAO_0000218,2106.0,
8462,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL621921,,BAO_0000218,2106.0,
8463,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622401,,BAO_0000218,2106.0,
8464,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,1,1,,CHEMBL875348,,BAO_0000218,2106.0,
8465,Intermediate,50594,Spleen,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,1,1,,CHEMBL622402,,BAO_0000218,2106.0,
8466,Intermediate,50594,Blood,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,N,1,1,,CHEMBL622403,,BAO_0000218,178.0,
8467,Intermediate,50594,Blood,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622404,,BAO_0000218,178.0,
8468,Intermediate,50594,Brain,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,N,1,1,,CHEMBL622405,,BAO_0000218,955.0,
8469,Intermediate,50594,Brain,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,1,1,,CHEMBL622406,,BAO_0000218,955.0,
8470,Intermediate,50594,Brain,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622407,,BAO_0000218,955.0,
8471,Intermediate,50594,Heart,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,N,1,1,,CHEMBL622408,,BAO_0000218,948.0,
8472,Intermediate,50594,Heart,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,1,1,,CHEMBL622409,,BAO_0000218,948.0,
8473,Intermediate,50594,Heart,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL622410,,BAO_0000218,948.0,
8474,Intermediate,50594,Kidney,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,N,1,1,,CHEMBL622411,,BAO_0000218,2113.0,
8475,Intermediate,50594,Kidney,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,1,1,,CHEMBL627864,,BAO_0000218,2113.0,
8476,Intermediate,50594,Kidney,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL627865,,BAO_0000218,2113.0,
8477,Intermediate,50594,Liver,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,N,1,1,,CHEMBL627866,,BAO_0000218,2107.0,
8478,Intermediate,50594,Liver,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL627751,,BAO_0000218,2107.0,
8479,Intermediate,50594,Spleen,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,N,1,1,,CHEMBL627752,,BAO_0000218,2106.0,
8480,Intermediate,50594,Spleen,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,1,1,,CHEMBL627753,,BAO_0000218,2106.0,
8481,Intermediate,50594,Spleen,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,1,1,,CHEMBL627754,,BAO_0000218,2106.0,
8482,Intermediate,50594,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,N,1,1,,CHEMBL627755,,BAO_0000218,,
8483,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627756,,BAO_0000218,955.0,
8484,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627757,,BAO_0000218,955.0,
8485,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627758,,BAO_0000218,955.0,
8486,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627759,,BAO_0000218,955.0,
8487,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627760,,BAO_0000218,955.0,
8488,Intermediate,50594,Brain,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627761,,BAO_0000218,955.0,
8489,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL876811,,BAO_0000218,948.0,
8490,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627762,,BAO_0000218,948.0,
8491,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627763,,BAO_0000218,948.0,
8492,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627764,,BAO_0000218,948.0,
8493,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627765,,BAO_0000218,948.0,
8494,Intermediate,50594,Heart,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627766,,BAO_0000218,948.0,
8495,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627767,,BAO_0000218,2113.0,
8496,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627768,,BAO_0000218,2113.0,
8497,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL628422,,BAO_0000218,2113.0,
8498,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL628423,,BAO_0000218,2113.0,
8499,Intermediate,50597,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,N,1,1,,CHEMBL628424,,BAO_0000218,,
8500,Intermediate,50597,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,N,1,1,,CHEMBL628425,,BAO_0000218,,
8501,Intermediate,50597,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,N,1,1,,CHEMBL628426,,BAO_0000218,,
8502,Intermediate,50597,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL628427,,BAO_0000218,,
8503,Intermediate,50597,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL626938,,BAO_0000218,,
8504,Intermediate,50597,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,1,1,,CHEMBL626939,,BAO_0000218,,
8505,Intermediate,50597,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL626940,,BAO_0000218,,
8506,Intermediate,50597,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL626941,,BAO_0000218,,
8507,Intermediate,50597,,,Plasma clearance was reported in Sprague-Dawley rat,N,1,1,,CHEMBL626942,,BAO_0000218,,
8508,Intermediate,50597,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,N,1,1,,CHEMBL876812,,BAO_0000218,,
8509,Intermediate,50597,,,Plasma clearance of compound in rats was evaluated,N,1,1,,CHEMBL626943,,BAO_0000218,,
8510,Intermediate,50597,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,N,1,1,,CHEMBL626944,,BAO_0000218,,
8511,Intermediate,50597,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,N,1,1,,CHEMBL626945,,BAO_0000218,,
8512,Intermediate,50597,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,1,1,,CHEMBL626946,,BAO_0000218,,
8513,Intermediate,50597,,,Plasma clearance rate in Sprague-Dawley rats,N,1,1,,CHEMBL626856,,BAO_0000218,,
8514,Intermediate,50597,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),N,1,1,,CHEMBL626857,,BAO_0000218,,
8515,Intermediate,50597,Plasma,,The compound was evaluated for plasma clearance in rat,N,1,1,,CHEMBL626858,,BAO_0000218,1969.0,
8516,Intermediate,50597,Plasma,,Total plasma clearance in rat,N,1,1,,CHEMBL627018,,BAO_0000218,1969.0,
8517,Intermediate,50597,Blood,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,N,1,1,,CHEMBL625331,,BAO_0000218,178.0,
8518,Intermediate,50597,Blood,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,N,1,1,,CHEMBL625332,,BAO_0000218,178.0,
8519,Intermediate,50597,,,C max was determined at 10 mg/kg po dose in rats,N,1,1,,CHEMBL877590,,BAO_0000218,,
8520,Intermediate,50597,,,C max was determined at 3 mg/kg po dose in rats,N,1,1,,CHEMBL625333,,BAO_0000218,,
8521,Intermediate,50597,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,N,1,1,,CHEMBL625334,,BAO_0000218,,
8522,Intermediate,50597,,,Cmax after single intravenous bolus of 1 mg/kg in rats,N,1,1,,CHEMBL625335,,BAO_0000218,,
8523,Intermediate,50597,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,N,1,1,,CHEMBL625336,,BAO_0000218,,
8524,Intermediate,50597,,,Cmax 24 hr after 10 mg/kg oral administration in rats,N,1,1,,CHEMBL625337,,BAO_0000218,,
8525,Intermediate,50597,,,Cmax 24 hr after 2 mg/kg oral administration in rats,N,1,1,,CHEMBL625338,,BAO_0000218,,
8526,Intermediate,50597,Plasma,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,N,1,1,,CHEMBL625339,,BAO_0000218,1969.0,
8527,Intermediate,50597,,,Cmax in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL625340,,BAO_0000218,,
8528,Intermediate,50597,,,Cmax in rat after administration of 2 mg/kg iv,N,1,1,,CHEMBL625341,,BAO_0000218,,
8529,Intermediate,50597,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,N,1,1,,CHEMBL622687,,BAO_0000218,,
8530,Intermediate,50597,Plasma,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,N,1,1,,CHEMBL622688,,BAO_0000218,1969.0,
8531,Intermediate,50597,Blood,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,N,1,1,,CHEMBL622689,,BAO_0000218,178.0,
8532,Intermediate,50597,Blood,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,N,1,1,,CHEMBL620295,,BAO_0000218,178.0,
8533,Intermediate,50597,,,Cmax after 10 mg/kg oral administration in rat,N,1,1,,CHEMBL620296,,BAO_0000218,,
8534,Intermediate,50597,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,N,1,1,,CHEMBL620297,,BAO_0000218,,
8535,Intermediate,50597,,,Cmax after IV dosing at 1 mg/kg in rat; no data,N,1,1,,CHEMBL620298,,BAO_0000218,,
8536,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats,N,1,1,,CHEMBL620299,,BAO_0000218,,
8537,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats; Not performed.,N,1,1,,CHEMBL620300,,BAO_0000218,,
8538,Intermediate,50597,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,N,1,1,,CHEMBL620301,,BAO_0000218,,
8539,Intermediate,50597,,,Cmax after oral administration in rat,N,1,1,,CHEMBL620302,,BAO_0000218,,
8540,Intermediate,50597,,,Cmax after oral administration at a dose of 2 mg/kg in rat,N,1,1,,CHEMBL620303,,BAO_0000218,,
8541,Intermediate,50597,,,Cmax after oral administration at a dose of 4 mg/kg in rat,N,1,1,,CHEMBL620304,,BAO_0000218,,
8542,Intermediate,50597,,,Cmax in rats after 20 mg/kg oral dose,N,1,1,,CHEMBL620305,,BAO_0000218,,
8543,Intermediate,50597,,,Cmax after peroral administration in rats at 2.4 uM/kg,N,1,1,,CHEMBL620306,,BAO_0000218,,
8544,Intermediate,50597,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,N,1,1,,CHEMBL620307,,BAO_0000218,,
8545,Intermediate,50597,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,N,1,1,,CHEMBL620308,,BAO_0000218,,
8546,Intermediate,50597,,,Cmax by administering at 20 mg/kg p.o. in rats,N,1,1,,CHEMBL620309,,BAO_0000218,,
8547,Intermediate,50597,,,Cmax in male rat,N,1,1,,CHEMBL620310,,BAO_0000218,,
8548,Intermediate,50597,,,Cmax in rat,N,1,1,,CHEMBL620311,,BAO_0000218,,
8549,Intermediate,50597,,,Cmax in rat,N,1,1,,CHEMBL620312,,BAO_0000218,,
8550,Intermediate,50597,,,Cmax in rat,N,1,1,,CHEMBL620313,,BAO_0000218,,
8551,Intermediate,50597,,,Cmax in rat at 10 mg/kg,N,1,1,,CHEMBL620314,,BAO_0000218,,
8552,Intermediate,50597,,,Cmax in rat at the dose of 1 mg/kg i.v.,N,1,1,,CHEMBL620315,,BAO_0000218,,
8553,Intermediate,50597,,,Cmax in rat by po administration at a dose of 40 mg/kg,N,1,1,,CHEMBL620316,,BAO_0000218,,
8554,Intermediate,50597,,,Cmax in rat p.o. at 20 mg/kg concentration,N,1,1,,CHEMBL620317,,BAO_0000218,,
8555,Intermediate,50597,,,Cmax in rats,N,1,1,,CHEMBL620318,,BAO_0000218,,
8556,Intermediate,50597,,,Cmax in rats,N,1,1,,CHEMBL620319,,BAO_0000218,,
8557,Intermediate,50597,,,Cmax was evaluated after 20 uM/kg of peroral administration,N,1,1,,CHEMBL620320,,BAO_0000218,,
8558,Intermediate,50597,,,Cmax was measured in rats after peroral administration at 3 mg/kg,N,1,1,,CHEMBL620321,,BAO_0000218,,
8559,Intermediate,50597,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,N,1,1,,CHEMBL620322,,BAO_0000218,,
8560,Intermediate,50597,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620323,,BAO_0000218,,
8561,Intermediate,50597,Frontal cortex,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620324,,BAO_0000218,1870.0,
8562,Intermediate,50597,Frontal cortex,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620325,,BAO_0000218,1870.0,
8563,Intermediate,50597,Hippocampus,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620326,,BAO_0000218,10000000.0,
8564,Intermediate,50597,Hippocampus,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620327,,BAO_0000218,10000000.0,
8565,Intermediate,50597,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620328,,BAO_0000218,,
8566,Intermediate,50597,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620329,,BAO_0000218,,
8567,Intermediate,50597,Midbrain,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620330,,BAO_0000218,1891.0,
8568,Intermediate,50597,Midbrain,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL875286,,BAO_0000218,1891.0,
8569,Intermediate,50597,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620331,,BAO_0000218,,
8570,Intermediate,50597,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620332,,BAO_0000218,,
8571,Intermediate,50597,Striatum,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620333,,BAO_0000218,2435.0,
8572,Intermediate,50597,Striatum,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,1,1,,CHEMBL620334,,BAO_0000218,2435.0,
8573,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL621015,,BAO_0000218,178.0,
8574,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL621016,,BAO_0000218,178.0,
8575,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL621191,,BAO_0000218,178.0,
8576,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL621192,,BAO_0000218,178.0,
8577,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL621193,,BAO_0000218,178.0,
8578,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL621194,,BAO_0000218,178.0,
8579,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL624204,,BAO_0000218,178.0,
8580,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL624205,,BAO_0000218,178.0,
8581,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL624206,,BAO_0000218,178.0,
8582,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL624207,,BAO_0000218,178.0,
8583,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL624208,,BAO_0000218,178.0,
8584,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL624209,,BAO_0000218,178.0,
8585,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL624210,,BAO_0000218,178.0,
8586,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL624211,,BAO_0000218,178.0,
8587,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL624212,,BAO_0000218,178.0,
8588,Intermediate,50597,Blood,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL624213,,BAO_0000218,178.0,
8589,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL876611,,BAO_0000218,178.0,
8590,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL624214,,BAO_0000218,178.0,
8591,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL624215,,BAO_0000218,178.0,
8592,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL624216,,BAO_0000218,178.0,
8593,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL624217,,BAO_0000218,178.0,
8594,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL624218,,BAO_0000218,178.0,
8595,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL624219,,BAO_0000218,178.0,
8596,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL624220,,BAO_0000218,178.0,
8597,Intermediate,50597,Blood,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL624221,,BAO_0000218,178.0,
8598,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL624222,,BAO_0000218,,
8599,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL624223,,BAO_0000218,,
8600,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL624224,,BAO_0000218,,
8601,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL624225,,BAO_0000218,,
8602,Intermediate,50597,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL622420,,BAO_0000218,,
8603,Intermediate,50597,,,Volume of steady state distribution after i.v. administration in rats,N,1,1,,CHEMBL622421,,BAO_0000218,,
8604,Intermediate,50597,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,N,1,1,,CHEMBL622422,,BAO_0000218,,
8605,Intermediate,50597,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,1,1,,CHEMBL622423,,BAO_0000218,,
8606,Intermediate,50597,,,Vss was determined,N,1,1,,CHEMBL622424,,BAO_0000218,,
8607,Intermediate,50597,,,Vss in rat,N,1,1,,CHEMBL622425,,BAO_0000218,,
8608,Intermediate,50597,,,Vss was evaluated after 10 uM/kg of intra arterial administration,N,1,1,,CHEMBL876612,,BAO_0000218,,
8609,Intermediate,50597,,,volume of distribution at steady state was observed after intravenous administration in rat,N,1,1,,CHEMBL622426,,BAO_0000218,,
8610,Intermediate,50597,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,1,1,,CHEMBL622427,,BAO_0000218,,
8611,Intermediate,50597,,,Pharmacokinetic (PK) parameter Vz in rat,N,1,1,,CHEMBL622428,,BAO_0000218,,
8612,Intermediate,50597,,,Volume distribution in rats,N,1,1,,CHEMBL622429,,BAO_0000218,,
8613,Intermediate,50597,,,Volume of distribution in rat; No data,N,1,1,,CHEMBL622430,,BAO_0000218,,
8614,Intermediate,50597,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL622431,,BAO_0000218,,
8615,Intermediate,50597,Ileum,,% absorption predicted from in vitro rat ileum transport studies,N,1,1,,CHEMBL622432,,BAO_0000218,2116.0,
8616,Intermediate,50597,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,1,1,,CHEMBL622433,,BAO_0000218,,
8617,Intermediate,50597,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,1,1,,CHEMBL622434,,BAO_0000218,,
8618,Intermediate,50597,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,N,1,1,,CHEMBL622435,,BAO_0000218,,
8619,Intermediate,50597,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),N,1,1,,CHEMBL618748,,BAO_0000218,,
8620,Intermediate,50597,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,1,1,,CHEMBL618749,,BAO_0000218,,
8621,Intermediate,50597,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,1,1,,CHEMBL618750,,BAO_0000218,,
8622,Intermediate,50597,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,1,1,,CHEMBL618751,,BAO_0000218,,
8623,Intermediate,50597,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,1,1,,CHEMBL618752,,BAO_0000218,,
8624,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618753,,BAO_0000218,,
8625,Intermediate,50597,Plasma,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,N,1,1,,CHEMBL618754,,BAO_0000218,1969.0,
8626,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618755,,BAO_0000218,,
8627,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618756,,BAO_0000218,,
8628,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618757,,BAO_0000218,,
8629,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL618758,,BAO_0000218,,
8630,Intermediate,50597,,,Oral bioavailability in rat (dose 30 mg/kg),N,1,1,,CHEMBL621088,,BAO_0000218,,
8631,Intermediate,50597,,,Pharmacokinetic property (cLogP) in rat,N,1,1,,CHEMBL621089,,BAO_0000218,,
8632,Intermediate,50597,Blood,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,N,1,1,,CHEMBL621090,,BAO_0000218,178.0,
8633,Intermediate,50597,Blood,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,N,1,1,,CHEMBL621091,,BAO_0000218,178.0,
8634,Intermediate,50597,,,Clearance in rat.,N,1,1,,CHEMBL876731,,BAO_0000218,,
8635,Intermediate,50597,,,Compound was evaluated for its clearance when administered intravenously in rat,N,1,1,,CHEMBL621092,,BAO_0000218,,
8636,Intermediate,50597,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL621093,,BAO_0000218,,
8637,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat,N,1,1,,CHEMBL621094,,BAO_0000218,,
8638,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,N,1,1,,CHEMBL621095,,BAO_0000218,,
8639,Intermediate,50597,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,N,1,1,,CHEMBL621096,,BAO_0000218,,
8640,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL621097,,BAO_0000218,2113.0,
8641,Intermediate,50597,,,Percent dose excreted in 0-48 hours administered ip to male rat,N,1,1,,CHEMBL621098,,BAO_0000218,,
8642,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621099,,BAO_0000218,2037.0,
8643,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621100,,BAO_0000218,2037.0,
8644,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL621101,,BAO_0000218,2037.0,
8645,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621102,,BAO_0000218,2037.0,
8646,Intermediate,50597,Cerebellum,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL876732,,BAO_0000218,2037.0,
8647,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621103,,BAO_0000218,,
8648,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621104,,BAO_0000218,,
8649,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL621105,,BAO_0000218,,
8650,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621106,,BAO_0000218,,
8651,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621107,,BAO_0000218,,
8652,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621108,,BAO_0000218,,
8653,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621109,,BAO_0000218,,
8654,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL621110,,BAO_0000218,2113.0,
8655,Intermediate,50594,Kidney,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL621111,,BAO_0000218,2113.0,
8656,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL622541,,BAO_0000218,2107.0,
8657,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL622542,,BAO_0000218,2107.0,
8658,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL622543,,BAO_0000218,2107.0,
8659,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624412,,BAO_0000218,2107.0,
8660,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624413,,BAO_0000218,2107.0,
8661,Intermediate,50594,Liver,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624414,,BAO_0000218,2107.0,
8662,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624415,,BAO_0000218,2048.0,
8663,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624416,,BAO_0000218,2048.0,
8664,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624417,,BAO_0000218,2048.0,
8665,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624418,,BAO_0000218,2048.0,
8666,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624419,,BAO_0000218,2048.0,
8667,Intermediate,50594,Lung,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624420,,BAO_0000218,2048.0,
8668,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624421,,BAO_0000218,2385.0,
8669,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624422,,BAO_0000218,2385.0,
8670,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL624423,,BAO_0000218,2385.0,
8671,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL625123,,BAO_0000218,2385.0,
8672,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL625124,,BAO_0000218,2385.0,
8673,Intermediate,50594,Muscle tissue,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL625125,,BAO_0000218,2385.0,
8674,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL625126,,BAO_0000218,14.0,
8675,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626947,,BAO_0000218,14.0,
8676,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626948,,BAO_0000218,14.0,
8677,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626949,,BAO_0000218,14.0,
8678,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626950,,BAO_0000218,14.0,
8679,Intermediate,50594,Zone of skin,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626951,,BAO_0000218,14.0,
8680,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626952,,BAO_0000218,2106.0,
8681,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626953,,BAO_0000218,2106.0,
8682,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626954,,BAO_0000218,2106.0,
8683,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626955,,BAO_0000218,2106.0,
8684,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626956,,BAO_0000218,2106.0,
8685,Intermediate,50594,Spleen,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626957,,BAO_0000218,2106.0,
8686,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626958,,BAO_0000218,178.0,
8687,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626959,,BAO_0000218,178.0,
8688,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626960,,BAO_0000218,178.0,
8689,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL626961,,BAO_0000218,178.0,
8690,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627589,,BAO_0000218,178.0,
8691,Intermediate,50594,Blood,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),N,1,1,,CHEMBL627590,,BAO_0000218,178.0,
8692,Intermediate,50594,,,Time taken for EC90 was determined when tested in mouse,N,1,1,,CHEMBL627591,,BAO_0000218,,
8693,Intermediate,50594,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,N,1,1,,CHEMBL627592,,BAO_0000218,,
8694,Intermediate,50594,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,1,1,,CHEMBL627593,,BAO_0000218,,
8695,Intermediate,50594,,,Half life in mice,N,1,1,,CHEMBL627594,,BAO_0000218,,
8696,Intermediate,50594,,,Half life period in mouse after 10 mg/Kg dose,N,1,1,,CHEMBL876813,,BAO_0000218,,
8697,Intermediate,50594,,,Half life period in mouse after 10 mg/kg dose,N,1,1,,CHEMBL627595,,BAO_0000218,,
8698,Intermediate,50594,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,1,1,,CHEMBL627596,,BAO_0000218,,
8699,Intermediate,50597,,,Cmax value at 5 mg/kg po was determined in rat,N,1,1,,CHEMBL627597,,BAO_0000218,,
8700,Intermediate,50597,,,Cmax value evaluated in rat,N,1,1,,CHEMBL627598,,BAO_0000218,,
8701,Intermediate,50597,Brain,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,N,1,1,,CHEMBL627599,,BAO_0000218,955.0,
8702,Intermediate,50597,,,Cmax value after administration of 20 mg/Kg oral dose in rat,N,1,1,,CHEMBL627600,,BAO_0000218,,
8703,Intermediate,50597,,,Cmax value at 1 mg/kg po in rat,N,1,1,,CHEMBL627601,,BAO_0000218,,
8704,Intermediate,50597,,,Cmax value at 5 mg/kg po in rat,N,1,1,,CHEMBL627776,,BAO_0000218,,
8705,Intermediate,50597,,,Cmax value at a dose of 10 mg/kg in male SD rats,N,1,1,,CHEMBL627777,,BAO_0000218,,
8706,Intermediate,50597,,,Cmax value at a dose of 100 mg/kg in male SD rats,N,1,1,,CHEMBL627778,,BAO_0000218,,
8707,Intermediate,50597,,,Cmax value at a dose of 50 mg/kg in male SD rats,N,1,1,,CHEMBL627779,,BAO_0000218,,
8708,Intermediate,50597,,,Cmax value in rats at 10 mg/kg,N,1,1,,CHEMBL876814,,BAO_0000218,,
8709,Intermediate,50597,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,N,1,1,,CHEMBL627780,,BAO_0000218,,
8710,Intermediate,50597,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,N,1,1,,CHEMBL627781,,BAO_0000218,,
8711,Intermediate,50597,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,1,1,,CHEMBL627782,,BAO_0000218,,
8712,Intermediate,50597,Plasma,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,N,1,1,,CHEMBL627783,,BAO_0000218,1969.0,
8713,Intermediate,50597,Plasma,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,N,1,1,,CHEMBL627784,,BAO_0000218,1969.0,
8714,Intermediate,50597,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,N,1,1,,CHEMBL627785,,BAO_0000218,,
8715,Intermediate,50597,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,N,1,1,,CHEMBL627786,,BAO_0000218,,
8716,Intermediate,50597,Plasma,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,N,1,1,,CHEMBL627787,,BAO_0000218,1969.0,
8717,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,N,1,1,,CHEMBL627788,,BAO_0000218,1969.0,
8718,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,N,1,1,,CHEMBL626579,,BAO_0000218,1969.0,
8719,Intermediate,50597,Plasma,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,N,1,1,,CHEMBL626580,,BAO_0000218,1969.0,
8720,Intermediate,50597,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,N,1,1,,CHEMBL876815,,BAO_0000218,,
8721,Intermediate,50597,Plasma,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,N,1,1,,CHEMBL626581,,BAO_0000218,1969.0,
8722,Intermediate,50597,Plasma,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,N,1,1,,CHEMBL626582,,BAO_0000218,1969.0,
8723,Intermediate,50597,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,N,1,1,,CHEMBL626583,,BAO_0000218,,
8724,Intermediate,50597,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL626205,,BAO_0000218,,
8725,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL626206,,BAO_0000218,,
8726,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL626207,,BAO_0000218,,
8727,Intermediate,50597,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL623882,,BAO_0000218,,
8728,Intermediate,50597,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,N,1,1,,CHEMBL623883,,BAO_0000218,,
8729,Intermediate,50597,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,N,1,1,,CHEMBL623884,,BAO_0000218,,
8730,Intermediate,50597,Plasma,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,1,1,,CHEMBL623885,,BAO_0000218,1969.0,
8731,Intermediate,50597,Plasma,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,N,1,1,,CHEMBL623886,,BAO_0000218,1969.0,
8732,Intermediate,50597,,,Maximal concentration in rat was determined,N,1,1,,CHEMBL623887,,BAO_0000218,,
8733,Intermediate,50597,,,Maximal concentration after i.v. administration,N,1,1,,CHEMBL623888,,BAO_0000218,,
8734,Intermediate,50597,Plasma,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,N,1,1,,CHEMBL623889,,BAO_0000218,1969.0,
8735,Intermediate,50597,Plasma,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,N,1,1,,CHEMBL623890,,BAO_0000218,1969.0,
8736,Intermediate,50597,Plasma,,Cmax in rat plasma after oral dose (50 mg/Kg),N,1,1,,CHEMBL623891,,BAO_0000218,1969.0,
8737,Intermediate,50597,Plasma,,Maximal plasma concentration was determined.,N,1,1,,CHEMBL623892,,BAO_0000218,1969.0,
8738,Intermediate,50597,Plasma,,Maximal plasma drug concentration was determined,N,1,1,,CHEMBL623893,,BAO_0000218,1969.0,
8739,Intermediate,50597,,,Maximal concentration in rats after peroral administration,N,1,1,,CHEMBL877616,,BAO_0000218,,
8740,Intermediate,50597,,,Maximum concentration in rat after 2 mg/kg peroral administration,N,1,1,,CHEMBL623894,,BAO_0000218,,
8741,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,N,1,1,,CHEMBL623895,,BAO_0000218,1969.0,
8742,Intermediate,50597,,,Maximum concentration of compound in rat was evaluated.,N,1,1,,CHEMBL623896,,BAO_0000218,,
8743,Intermediate,50597,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL623897,,BAO_0000218,,
8744,Intermediate,50597,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL623898,,BAO_0000218,,
8745,Intermediate,50597,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,N,1,1,,CHEMBL623899,,BAO_0000218,,
8746,Intermediate,50597,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL623900,,BAO_0000218,,
8747,Intermediate,50597,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,N,1,1,,CHEMBL623901,,BAO_0000218,,
8748,Intermediate,50597,,,Maximum concentration was evaluated in rats,N,1,1,,CHEMBL623902,,BAO_0000218,,
8749,Intermediate,50597,Cerebrospinal fluid,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,N,1,1,,CHEMBL623903,,BAO_0000218,1359.0,
8750,Intermediate,50597,Plasma,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,N,1,1,,CHEMBL623904,,BAO_0000218,1969.0,
8751,Intermediate,50597,Plasma,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,1,1,,CHEMBL877617,,BAO_0000218,1969.0,
8752,Intermediate,50597,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,N,1,1,,CHEMBL623905,,BAO_0000218,,
8753,Intermediate,50597,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,N,1,1,,CHEMBL623906,,BAO_0000218,,
8754,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL623907,,BAO_0000218,1969.0,
8755,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL623908,,BAO_0000218,,
8756,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL623909,,BAO_0000218,,
8757,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL623910,,BAO_0000218,,
8758,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL623911,,BAO_0000218,,
8759,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL623912,,BAO_0000218,,
8760,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL624616,,BAO_0000218,,
8761,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL624617,,BAO_0000218,,
8762,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL624618,,BAO_0000218,,
8763,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL624619,,BAO_0000218,,
8764,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL624794,,BAO_0000218,,
8765,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL624795,,BAO_0000218,,
8766,Intermediate,50597,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL623921,,BAO_0000218,,
8767,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL623922,,BAO_0000218,,
8768,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL623923,,BAO_0000218,,
8769,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL623924,,BAO_0000218,,
8770,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL623925,,BAO_0000218,,
8771,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL623926,,BAO_0000218,,
8772,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL623927,,BAO_0000218,,
8773,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL623928,,BAO_0000218,,
8774,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL623929,,BAO_0000218,,
8775,Intermediate,50597,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL623930,,BAO_0000218,,
8776,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL623931,,BAO_0000218,955.0,
8777,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL622165,,BAO_0000218,955.0,
8778,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL621249,,BAO_0000218,955.0,
8779,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL621250,,BAO_0000218,955.0,
8780,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL621448,,BAO_0000218,955.0,
8781,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL621449,,BAO_0000218,955.0,
8782,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL621450,,BAO_0000218,955.0,
8783,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL621451,,BAO_0000218,955.0,
8784,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL621452,,BAO_0000218,955.0,
8785,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL621453,,BAO_0000218,955.0,
8786,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL621454,,BAO_0000218,955.0,
8787,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL621455,,BAO_0000218,955.0,
8788,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL621456,,BAO_0000218,955.0,
8789,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL625145,,BAO_0000218,955.0,
8790,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL875847,,BAO_0000218,955.0,
8791,Intermediate,50597,Brain,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL625146,,BAO_0000218,955.0,
8792,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL625147,,BAO_0000218,955.0,
8793,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL625148,,BAO_0000218,955.0,
8794,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL625149,,BAO_0000218,955.0,
8795,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL625150,,BAO_0000218,955.0,
8796,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL625151,,BAO_0000218,955.0,
8797,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL625152,,BAO_0000218,955.0,
8798,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL625153,,BAO_0000218,955.0,
8799,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL625154,,BAO_0000218,955.0,
8800,Intermediate,50597,Brain,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL625155,,BAO_0000218,955.0,
8801,Intermediate,50597,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL625156,,BAO_0000218,,
8802,Intermediate,50597,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624354,,BAO_0000218,,
8803,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624355,,BAO_0000218,10000000.0,
8804,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624356,,BAO_0000218,10000000.0,
8805,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624357,,BAO_0000218,10000000.0,
8806,Intermediate,50597,Hippocampus,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624358,,BAO_0000218,10000000.0,
8807,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624359,,BAO_0000218,2435.0,
8808,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624360,,BAO_0000218,2435.0,
8809,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL624361,,BAO_0000218,2435.0,
8810,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624362,,BAO_0000218,2435.0,
8811,Intermediate,50597,Striatum,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624363,,BAO_0000218,2435.0,
8812,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624364,,BAO_0000218,178.0,
8813,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624365,,BAO_0000218,178.0,
8814,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624366,,BAO_0000218,178.0,
8815,Intermediate,50597,Blood,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624367,,BAO_0000218,178.0,
8816,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624368,,BAO_0000218,955.0,
8817,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL624369,,BAO_0000218,955.0,
8818,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL624370,,BAO_0000218,955.0,
8819,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625069,,BAO_0000218,955.0,
8820,Intermediate,50597,Brain,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625070,,BAO_0000218,955.0,
8821,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626051,,BAO_0000218,948.0,
8822,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626052,,BAO_0000218,948.0,
8823,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL626053,,BAO_0000218,948.0,
8824,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626054,,BAO_0000218,948.0,
8825,Intermediate,50597,Heart,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626055,,BAO_0000218,948.0,
8826,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626056,,BAO_0000218,2113.0,
8827,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626057,,BAO_0000218,2113.0,
8828,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625193,,BAO_0000218,2113.0,
8829,Intermediate,50597,Kidney,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625194,,BAO_0000218,2113.0,
8830,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625195,,BAO_0000218,2107.0,
8831,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625196,,BAO_0000218,2107.0,
8832,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL625197,,BAO_0000218,2107.0,
8833,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625198,,BAO_0000218,2107.0,
8834,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL627929,,BAO_0000218,2107.0,
8835,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL627074,,BAO_0000218,2048.0,
8836,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL627075,,BAO_0000218,2048.0,
8837,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL627076,,BAO_0000218,2048.0,
8838,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL627077,,BAO_0000218,2048.0,
8839,Intermediate,50597,Lung,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL627078,,BAO_0000218,2048.0,
8840,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL627079,,BAO_0000218,2385.0,
8841,Intermediate,50594,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,1,1,,CHEMBL873824,,BAO_0000218,,
8842,Intermediate,50594,Plasma,,Half life in mouse plasma was determined at dose 25 mg/kg,N,1,1,,CHEMBL627080,,BAO_0000218,1969.0,
8843,Intermediate,50594,,,Half life was determined,N,1,1,,CHEMBL627081,,BAO_0000218,,
8844,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,1,1,,CHEMBL627082,,BAO_0000218,,
8845,Intermediate,50594,,,Half-life in male mice after 1 mg/kg intravenous dose,N,1,1,,CHEMBL627083,,BAO_0000218,,
8847,Intermediate,50594,Plasma,,Half life in mice plasma,N,1,1,,CHEMBL627085,,BAO_0000218,1969.0,
8848,Intermediate,50594,,,Half life in mouse,N,1,1,,CHEMBL627086,,BAO_0000218,,
8849,Intermediate,50594,Plasma,,Half life in mouse plasma at dose 25 mg/kg,N,1,1,,CHEMBL627087,,BAO_0000218,1969.0,
8850,Intermediate,50594,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,N,1,1,,CHEMBL627088,,BAO_0000218,,
8851,Intermediate,50594,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,N,1,1,,CHEMBL627089,,BAO_0000218,,
8852,Intermediate,50594,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,N,1,1,,CHEMBL627090,,BAO_0000218,,
8853,Intermediate,50594,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,1,1,,CHEMBL627091,,BAO_0000218,,
8854,Intermediate,50594,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",N,1,1,,CHEMBL627092,,BAO_0000218,,
8855,Intermediate,50594,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",N,1,1,,CHEMBL876785,,BAO_0000218,,
8856,Intermediate,50594,,,Half-life by iv administration in mouse,N,1,1,,CHEMBL627093,,BAO_0000218,,
8857,Intermediate,50594,,,Half-life by oral administration in mouse,N,1,1,,CHEMBL627094,,BAO_0000218,,
8858,Intermediate,50594,,,Half-life in mice,N,1,1,,CHEMBL627095,,BAO_0000218,,
8859,Intermediate,50594,Brain,,Half-life using mouse brain homogenate,N,1,1,,CHEMBL627096,,BAO_0000218,955.0,
8860,Intermediate,50594,,,Half-life was measured in mice,N,1,1,,CHEMBL627097,,BAO_0000218,,
8861,Intermediate,50594,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,N,1,1,,CHEMBL627098,,BAO_0000218,,
8862,Intermediate,50594,Blood,,Half-life period was determined in mouse blood,N,1,1,,CHEMBL627099,,BAO_0000218,178.0,
8863,Intermediate,50594,Brain,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",N,1,1,,CHEMBL627100,,BAO_0000218,955.0,
8864,Intermediate,50594,Plasma,,Plasma half life in mouse,N,1,1,,CHEMBL627101,,BAO_0000218,1969.0,
8865,Intermediate,50594,,,Stability of the peptide in the presence of mouse serum,N,1,1,,CHEMBL627102,,BAO_0000218,,
8866,Intermediate,50594,,,Terminal half life of compound was determined in mouse,N,1,1,,CHEMBL627103,,BAO_0000218,,
8867,Intermediate,50594,,,Terminal half life was evaluated in mice after intravenous administration,N,1,1,,CHEMBL627104,,BAO_0000218,,
8868,Intermediate,50594,,,Terminal half life was evaluated in mice after oral administration,N,1,1,,CHEMBL627105,,BAO_0000218,,
8869,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,N,1,1,,CHEMBL876786,,BAO_0000218,,
8870,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,N,1,1,,CHEMBL873825,,BAO_0000218,,
8871,Intermediate,50594,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,N,1,1,,CHEMBL627106,,BAO_0000218,,
8872,Intermediate,50594,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,N,1,1,,CHEMBL626336,,BAO_0000218,,
8873,Intermediate,50594,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",N,1,1,,CHEMBL877462,,BAO_0000218,,
8874,Intermediate,50594,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",N,1,1,,CHEMBL626337,,BAO_0000218,,
8875,Intermediate,50594,,,Half life after intraperitoneal administration of 100 mg/kg in mice,N,1,1,,CHEMBL626338,,BAO_0000218,,
8876,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,N,1,1,,CHEMBL626339,,BAO_0000218,,
8877,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,1,1,,CHEMBL626340,,BAO_0000218,,
8878,Intermediate,50594,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,N,1,1,,CHEMBL625377,,BAO_0000218,,
8879,Intermediate,50594,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,N,1,1,,CHEMBL625378,,BAO_0000218,,
8880,Intermediate,50594,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,N,1,1,,CHEMBL625379,,BAO_0000218,,
8881,Autocuration,22224,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),U,0,1,,CHEMBL625380,,BAO_0000251,,
8882,Autocuration,22224,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),U,0,1,,CHEMBL625381,,BAO_0000251,,
8883,Autocuration,22224,,,Stability to porcine renal DHP-I,U,0,1,,CHEMBL625382,,BAO_0000019,,
8884,Autocuration,22224,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,U,0,1,,CHEMBL873828,,BAO_0000218,,
8885,Autocuration,22224,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,U,0,1,,CHEMBL625383,,BAO_0000218,,
8886,Autocuration,22224,,,Half-life of the parent prodrug in porcine esterase solution,U,0,1,,CHEMBL625384,,BAO_0000019,,
8887,Autocuration,22224,,,"First order rate constant, k was determined in in pig liver Esterase",U,0,1,,CHEMBL625385,,BAO_0000019,,
8888,Autocuration,22224,Liver,,Half life of the in pig liver Esterase,U,0,1,,CHEMBL625386,,BAO_0000221,2107.0,
8889,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,U,0,1,,CHEMBL623571,,BAO_0000221,2107.0,
8890,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,U,0,1,,CHEMBL623572,,BAO_0000221,2107.0,
8891,Autocuration,22224,Liver,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,U,0,1,,CHEMBL623573,,BAO_0000221,2107.0,
8892,Autocuration,22224,Liver,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,U,0,1,,CHEMBL623574,,BAO_0000221,2107.0,
8893,Autocuration,22224,Liver,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,U,0,1,,CHEMBL623575,,BAO_0000221,2107.0,
8894,Autocuration,22224,Liver,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,U,0,1,,CHEMBL623749,,BAO_0000221,2107.0,
8895,Autocuration,22224,Liver,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,U,0,1,,CHEMBL623750,,BAO_0000221,2107.0,
8896,Autocuration,22224,Liver,,Half-life in vitro in pig liver,U,0,1,,CHEMBL623751,,BAO_0000221,2107.0,
8897,Autocuration,22224,Liver,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,U,0,1,,CHEMBL623752,,BAO_0000221,2107.0,
8898,Intermediate,50597,Plasma,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL623753,,BAO_0000218,1969.0,
8899,Intermediate,50597,Plasma,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,1,1,,CHEMBL623754,,BAO_0000218,1969.0,
8900,Intermediate,50597,Plasma,,Maximum concentration in rat plasma was determined,N,1,1,,CHEMBL623755,,BAO_0000218,1969.0,
8901,Intermediate,50597,,,Maximum concentration in rats,N,1,1,,CHEMBL623756,,BAO_0000218,,
8902,Intermediate,50597,,,Maximum concentration in rats at 1-2 hours,N,1,1,,CHEMBL623757,,BAO_0000218,,
8903,Intermediate,50597,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,N,1,1,,CHEMBL623758,,BAO_0000218,,
8904,Intermediate,50597,Brain,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,N,1,1,,CHEMBL623759,,BAO_0000218,955.0,
8905,Intermediate,50597,,,Maximum concentration at the dose of 2 mg/kg in rat,N,1,1,,CHEMBL623760,,BAO_0000218,,
8906,Intermediate,50597,,,Maximum concentration was evaluated in rats,N,1,1,,CHEMBL623761,,BAO_0000218,,
8907,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,N,1,1,,CHEMBL623762,,BAO_0000218,1969.0,
8908,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,N,1,1,,CHEMBL877594,,BAO_0000218,1969.0,
8909,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,N,1,1,,CHEMBL623763,,BAO_0000218,1969.0,
8910,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,N,1,1,,CHEMBL623764,,BAO_0000218,1969.0,
8911,Intermediate,50597,Plasma,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,N,1,1,,CHEMBL623765,,BAO_0000218,1969.0,
8912,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,N,1,1,,CHEMBL623766,,BAO_0000218,178.0,
8913,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,N,1,1,,CHEMBL623767,,BAO_0000218,178.0,
8914,Intermediate,50597,Blood,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,N,1,1,,CHEMBL623768,,BAO_0000218,178.0,
8915,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623769,,BAO_0000218,1969.0,
8916,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623770,,BAO_0000218,1969.0,
8917,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623771,,BAO_0000218,1969.0,
8918,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623772,,BAO_0000218,1969.0,
8919,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623773,,BAO_0000218,1969.0,
8920,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623774,,BAO_0000218,1969.0,
8921,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,N,1,1,,CHEMBL623775,,BAO_0000218,1969.0,
8922,Intermediate,50597,,,Cmax in rat (PO dose),N,1,1,,CHEMBL623776,,BAO_0000218,,
8923,Intermediate,50597,Plasma,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL622191,,BAO_0000218,1969.0,
8924,Intermediate,50597,Plasma,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL622192,,BAO_0000218,1969.0,
8925,Intermediate,50597,Plasma,,Maximum plasma concentration determined in rat,N,1,1,,CHEMBL622193,,BAO_0000218,1969.0,
8926,Intermediate,50597,Plasma,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,1,1,,CHEMBL622194,,BAO_0000218,1969.0,
8927,Intermediate,50597,Plasma,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,1,1,,CHEMBL622195,,BAO_0000218,1969.0,
8928,Intermediate,50597,Plasma,,Maximum plasma concentration in rat,N,1,1,,CHEMBL622196,,BAO_0000218,1969.0,
8929,Intermediate,50597,Plasma,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,1,1,,CHEMBL622197,,BAO_0000218,1969.0,
8930,Intermediate,50597,Plasma,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,N,1,1,,CHEMBL622198,,BAO_0000218,1969.0,
8931,Intermediate,50597,Plasma,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,N,1,1,,CHEMBL622199,,BAO_0000218,1969.0,
8932,Intermediate,50597,Plasma,,Maximum plasma concentration of compound was measured in rat,N,1,1,,CHEMBL622200,,BAO_0000218,1969.0,
8933,Intermediate,50597,Plasma,,Maximum plasma concentration after 20 mg/kg oral administration in rat,N,1,1,,CHEMBL622201,,BAO_0000218,1969.0,
8934,Intermediate,50597,Plasma,,Maximum plasma concentration after oral administration to rats,N,1,1,,CHEMBL623990,,BAO_0000218,1969.0,
8935,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL623991,,BAO_0000218,1969.0,
8936,Intermediate,50597,Plasma,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",N,1,1,,CHEMBL623992,,BAO_0000218,1969.0,
8937,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL623993,,BAO_0000218,1969.0,
8938,Intermediate,50597,Plasma,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,N,1,1,,CHEMBL623994,,BAO_0000218,1969.0,
8939,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL623995,,BAO_0000218,1969.0,
8940,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL623996,,BAO_0000218,1969.0,
8941,Intermediate,50597,Plasma,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL623997,,BAO_0000218,1969.0,
8942,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats,N,1,1,,CHEMBL623998,,BAO_0000218,1969.0,
8943,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats after 6 hours,N,1,1,,CHEMBL623999,,BAO_0000218,1969.0,
8944,Intermediate,50597,Plasma,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,N,1,1,,CHEMBL624000,,BAO_0000218,1969.0,
8945,Intermediate,50597,Plasma,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,1,1,,CHEMBL624001,,BAO_0000218,1969.0,
8946,Intermediate,50597,Plasma,,Maximum plasma concentration in rat after po administration,N,1,1,,CHEMBL624002,,BAO_0000218,1969.0,
8947,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",N,1,1,,CHEMBL624003,,BAO_0000218,1969.0,
8948,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",N,1,1,,CHEMBL624004,,BAO_0000218,1969.0,
8949,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL624005,,BAO_0000218,948.0,
8950,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL624006,,BAO_0000218,948.0,
8951,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL624007,,BAO_0000218,948.0,
8952,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL624008,,BAO_0000218,948.0,
8953,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL624009,,BAO_0000218,948.0,
8954,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL874387,,BAO_0000218,948.0,
8955,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL624010,,BAO_0000218,948.0,
8956,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL624011,,BAO_0000218,948.0,
8957,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL624012,,BAO_0000218,948.0,
8958,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL624013,,BAO_0000218,948.0,
8959,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL624736,,BAO_0000218,948.0,
8960,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL624737,,BAO_0000218,948.0,
8961,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL624738,,BAO_0000218,948.0,
8962,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL624739,,BAO_0000218,948.0,
8963,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL624740,,BAO_0000218,948.0,
8964,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL624896,,BAO_0000218,948.0,
8965,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL624897,,BAO_0000218,948.0,
8966,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL624108,,BAO_0000218,948.0,
8967,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL624109,,BAO_0000218,948.0,
8968,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL624110,,BAO_0000218,948.0,
8969,Intermediate,50597,Heart,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL624111,,BAO_0000218,948.0,
8970,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL624112,,BAO_0000218,948.0,
8971,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL624113,,BAO_0000218,948.0,
8972,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL619709,,BAO_0000218,948.0,
8973,Intermediate,50597,Heart,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL619710,,BAO_0000218,948.0,
8974,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL619711,,BAO_0000218,2113.0,
8975,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL619712,,BAO_0000218,2113.0,
8976,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL619713,,BAO_0000218,2113.0,
8977,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL619714,,BAO_0000218,2113.0,
8978,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL619715,,BAO_0000218,2113.0,
8979,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL619716,,BAO_0000218,2113.0,
8980,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL619717,,BAO_0000218,2113.0,
8981,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL619718,,BAO_0000218,2113.0,
8982,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL619719,,BAO_0000218,2113.0,
8983,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL875329,,BAO_0000218,2113.0,
8984,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL619720,,BAO_0000218,2113.0,
8985,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL619721,,BAO_0000218,2113.0,
8986,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL619722,,BAO_0000218,2113.0,
8987,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL619723,,BAO_0000218,2113.0,
8988,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL619724,,BAO_0000218,2113.0,
8989,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL619725,,BAO_0000218,2113.0,
8990,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL619726,,BAO_0000218,2113.0,
8991,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL619727,,BAO_0000218,2113.0,
8992,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL619728,,BAO_0000218,2113.0,
8993,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL619729,,BAO_0000218,2113.0,
8994,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL619730,,BAO_0000218,2385.0,
8995,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL619731,,BAO_0000218,2385.0,
8996,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL619732,,BAO_0000218,2385.0,
8997,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL619733,,BAO_0000218,2385.0,
8998,Intermediate,50597,Muscle tissue,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL619734,,BAO_0000218,2385.0,
8999,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL619735,,BAO_0000218,14.0,
9000,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL875330,,BAO_0000218,14.0,
9001,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL628465,,BAO_0000218,14.0,
9002,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628466,,BAO_0000218,14.0,
9003,Intermediate,50597,Zone of skin,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628467,,BAO_0000218,14.0,
9004,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628468,,BAO_0000218,2106.0,
9005,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628469,,BAO_0000218,2106.0,
9006,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL628470,,BAO_0000218,2106.0,
9007,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628471,,BAO_0000218,2106.0,
9008,Intermediate,50597,Spleen,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL628472,,BAO_0000218,2106.0,
9009,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625191,,BAO_0000218,2046.0,
9010,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL625192,,BAO_0000218,2046.0,
9011,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,1,1,,CHEMBL875337,,BAO_0000218,2046.0,
9012,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626341,,BAO_0000218,2046.0,
9013,Intermediate,50597,Thyroid gland,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL626342,,BAO_0000218,2046.0,
9014,Intermediate,50597,Liver,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,1,1,,CHEMBL621943,,BAO_0000218,2107.0,
9015,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL621944,,BAO_0000218,,
9016,Intermediate,50597,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,N,1,1,,CHEMBL621945,,BAO_0000218,,
9017,Intermediate,50597,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),N,1,1,,CHEMBL621946,,BAO_0000218,,
9018,Intermediate,50597,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,1,1,,CHEMBL621947,,BAO_0000218,,
9019,Intermediate,50597,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),N,1,1,,CHEMBL621948,,BAO_0000218,,
9020,Intermediate,50597,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,1,1,,CHEMBL621949,,BAO_0000218,,
9021,Intermediate,50597,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),N,1,1,,CHEMBL621950,,BAO_0000218,,
9022,Intermediate,50597,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,N,1,1,,CHEMBL621951,,BAO_0000218,,
9023,Intermediate,50597,Blood,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,N,1,1,,CHEMBL621952,,BAO_0000218,178.0,
9024,Intermediate,50597,Liver,,Stability (%) in rat liver microsomes,N,1,1,,CHEMBL621953,,BAO_0000218,2107.0,
9025,Intermediate,50597,,,Area under curve was calculated after intravenous administration,N,1,1,,CHEMBL621954,,BAO_0000218,,
9026,Intermediate,50597,,,Area under the curve was calculated after iv administration in rat,N,1,1,,CHEMBL621955,,BAO_0000218,,
9027,Intermediate,50597,,,Area under the curve was calculated in rat after peroral administration,N,1,1,,CHEMBL621956,,BAO_0000218,,
9028,Intermediate,50597,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,1,1,,CHEMBL621957,,BAO_0000218,,
9029,Intermediate,50597,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,N,1,1,,CHEMBL621958,,BAO_0000218,,
9030,Intermediate,50597,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,N,1,1,,CHEMBL621959,,BAO_0000218,,
9031,Intermediate,50597,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,N,1,1,,CHEMBL621960,,BAO_0000218,,
9032,Intermediate,50597,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,N,1,1,,CHEMBL621961,,BAO_0000218,,
9033,Intermediate,50597,,,p value of the compound,N,1,1,,CHEMBL621962,,BAO_0000218,,
9034,Intermediate,50597,,,p value of the compound,N,1,1,,CHEMBL876787,,BAO_0000218,,
9035,Intermediate,50597,,,p value of the compound,N,1,1,,CHEMBL621963,,BAO_0000218,,
9036,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL622637,,BAO_0000218,945.0,
9037,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL622638,,BAO_0000218,945.0,
9038,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL626561,,BAO_0000218,945.0,
9039,Autocuration,22224,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),U,0,1,,CHEMBL626562,,BAO_0000019,,
9040,Autocuration,22224,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),U,0,1,,CHEMBL626563,,BAO_0000218,,
9041,Autocuration,22224,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),U,0,1,,CHEMBL626564,,BAO_0000218,,
9042,Autocuration,22224,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,0,1,,CHEMBL626565,,BAO_0000218,,
9043,Autocuration,22224,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,0,1,,CHEMBL626566,,BAO_0000218,,
9044,Autocuration,22224,,,Clearance rate in rabbits,U,0,1,,CHEMBL626567,,BAO_0000218,,
9045,Autocuration,22224,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,0,1,,CHEMBL626568,,BAO_0000218,,
9046,Autocuration,22224,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,0,1,,CHEMBL626569,,BAO_0000218,,
9047,Autocuration,22224,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,0,1,,CHEMBL626570,,BAO_0000218,,
9048,Autocuration,22224,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,0,1,,CHEMBL626571,,BAO_0000218,,
9049,Autocuration,22224,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,U,0,1,,CHEMBL626572,,BAO_0000218,,
9050,Autocuration,22224,Plasma,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,0,1,,CHEMBL626573,,BAO_0000218,1969.0,
9051,Autocuration,22224,Liver,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,U,0,1,,CHEMBL626574,,BAO_0000251,2107.0,
9052,Autocuration,22224,Liver,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,U,0,1,,CHEMBL626575,,BAO_0000251,2107.0,
9053,Autocuration,22224,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,U,0,1,,CHEMBL626576,,BAO_0000218,,
9054,Autocuration,22224,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,U,0,1,,CHEMBL626577,,BAO_0000218,,
9055,Autocuration,22224,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,U,0,1,,CHEMBL626578,,BAO_0000218,,
9056,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,0,1,,CHEMBL625263,,BAO_0000218,,
9057,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,0,1,,CHEMBL625264,,BAO_0000218,,
9058,Autocuration,22224,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,0,1,,CHEMBL625265,,BAO_0000218,,
9059,Autocuration,22224,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),U,0,1,,CHEMBL625266,,BAO_0000251,,
9060,Autocuration,22224,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),U,0,1,,CHEMBL876796,,BAO_0000251,,
9061,Autocuration,22224,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,U,0,1,,CHEMBL625267,,BAO_0000218,,
9062,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,0,1,,CHEMBL625268,,BAO_0000218,1969.0,
9063,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,0,1,,CHEMBL625269,,BAO_0000218,1969.0,
9064,Autocuration,22224,Plasma,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,0,1,,CHEMBL624689,,BAO_0000218,1969.0,
9065,Autocuration,22224,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,U,0,1,,CHEMBL624690,,BAO_0000218,,
9066,Autocuration,22224,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),U,0,1,,CHEMBL624691,,BAO_0000218,1088.0,
9067,Autocuration,22224,Urine,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),U,0,1,,CHEMBL624692,,BAO_0000218,1088.0,
9068,Autocuration,22224,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,U,0,1,,CHEMBL624693,,BAO_0000218,,
9069,Autocuration,22224,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,U,0,1,,CHEMBL624694,,BAO_0000218,,
9070,Autocuration,22224,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,U,0,1,,CHEMBL877596,,BAO_0000221,,
9071,Autocuration,22224,,,Time within which only 10% of the drug was degraded,U,0,1,,CHEMBL624695,,BAO_0000019,,
9072,Autocuration,22224,Liver,,Half life period in rabbit liver homogenate,U,0,1,,CHEMBL624696,,BAO_0000221,2107.0,
9073,Autocuration,22224,,,Half life value in rabbits,U,0,1,,CHEMBL624697,,BAO_0000019,,
9074,Autocuration,22224,Blood,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,0,1,,CHEMBL624698,,BAO_0000218,178.0,
9075,Autocuration,22224,Blood,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,0,1,,CHEMBL624699,,BAO_0000218,178.0,
9076,Autocuration,22224,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,U,0,1,,CHEMBL624700,,BAO_0000218,,
9077,Intermediate,50597,Plasma,,AUC 0-8 hr value in rats at 10 mg/kg,N,1,1,,CHEMBL622903,,BAO_0000218,1969.0,
9078,Intermediate,50597,Plasma,,AUC after administration at 2000 mg/kg/day in rats,N,1,1,,CHEMBL622904,,BAO_0000218,1969.0,
9079,Intermediate,50597,Plasma,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,N,1,1,,CHEMBL622905,,BAO_0000218,1969.0,
9080,Intermediate,50597,Plasma,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,1,1,,CHEMBL622906,,BAO_0000218,1969.0,
9081,Intermediate,50597,Plasma,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,1,1,,CHEMBL622907,,BAO_0000218,1969.0,
9082,Intermediate,50597,Plasma,,AUC in rat after oral administration at 10.5 mg/kg dose,N,1,1,,CHEMBL622908,,BAO_0000218,1969.0,
9083,Intermediate,50597,Plasma,,AUC in rat after oral administration at 11.2 mg/kg dose,N,1,1,,CHEMBL622909,,BAO_0000218,1969.0,
9084,Intermediate,50597,Plasma,,AUC in rat after oral administration at 9.7 mg/kg dose,N,1,1,,CHEMBL622910,,BAO_0000218,1969.0,
9085,Intermediate,50597,Brain,,AUC in rat brain after oral administration at 10 mg/kg,N,1,1,,CHEMBL622911,,BAO_0000218,955.0,
9086,Intermediate,50597,Plasma,,AUC in rat p.o.,N,1,1,,CHEMBL622912,,BAO_0000218,1969.0,
9087,Intermediate,50597,Plasma,,AUC in rat p.o. at 20 mg/kg concentration,N,1,1,,CHEMBL622913,,BAO_0000218,1969.0,
9088,Intermediate,50597,Plasma,,AUC in rat plasma after oral administration at 10 mg/kg,N,1,1,,CHEMBL622914,,BAO_0000218,1969.0,
9089,Intermediate,50597,Plasma,,AUC in rats,N,1,1,,CHEMBL622915,,BAO_0000218,1969.0,
9090,Intermediate,50597,Plasma,,AUC value after IV dose at a dose of 5 mg/kg in rats.,N,1,1,,CHEMBL622916,,BAO_0000218,1969.0,
9091,Intermediate,50597,Plasma,,AUC value after oral dose at a dose of 10 mg/kg in rats.,N,1,1,,CHEMBL622917,,BAO_0000218,1969.0,
9092,Intermediate,50597,Plasma,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,1,1,,CHEMBL622918,,BAO_0000218,1969.0,
9093,Intermediate,50597,Plasma,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,N,1,1,,CHEMBL622919,,BAO_0000218,1969.0,
9094,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rat,N,1,1,,CHEMBL622920,,BAO_0000218,1969.0,
9095,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,1,1,,CHEMBL622921,,BAO_0000218,1969.0,
9096,Intermediate,50597,Plasma,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,1,1,,CHEMBL622922,,BAO_0000218,1969.0,
9097,Intermediate,50597,Plasma,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,1,1,,CHEMBL622923,,BAO_0000218,1969.0,
9098,Intermediate,50597,Plasma,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL877604,,BAO_0000218,1969.0,
9099,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,N,1,1,,CHEMBL622924,,BAO_0000218,1969.0,
9100,Intermediate,50597,Plasma,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,N,1,1,,CHEMBL622925,,BAO_0000218,1969.0,
9101,Intermediate,50597,Plasma,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,N,1,1,,CHEMBL622926,,BAO_0000218,1969.0,
9102,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,N,1,1,,CHEMBL623625,,BAO_0000218,1969.0,
9103,Expert,50597,Plasma,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL623626,,BAO_0000218,1969.0,
9104,Intermediate,50597,Plasma,,Maximum plasma drug concentration was determined,N,1,1,,CHEMBL623627,,BAO_0000218,1969.0,
9105,Intermediate,50597,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,N,1,1,,CHEMBL623628,,BAO_0000218,,
9106,Intermediate,50597,Plasma,,Mean peak plasma concentration was observed after intravenous administration in rat,N,1,1,,CHEMBL623629,,BAO_0000218,1969.0,
9107,Intermediate,50597,Plasma,,Mean peak plasma concentration was observed after oral administration in rat,N,1,1,,CHEMBL623630,,BAO_0000218,1969.0,
9108,Intermediate,50597,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,N,1,1,,CHEMBL623804,,BAO_0000218,,
9109,Intermediate,50597,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL623805,,BAO_0000218,,
9110,Intermediate,50597,Plasma,,Peak oral plasma concentration was determined in rats by oral administration,N,1,1,,CHEMBL623806,,BAO_0000218,1969.0,
9111,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) was determined,N,1,1,,CHEMBL623807,,BAO_0000218,1969.0,
9112,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,N,1,1,,CHEMBL623808,,BAO_0000218,1969.0,
9113,Intermediate,50597,Plasma,,Peak plasma concentration (Cmax) in rats,N,1,1,,CHEMBL623809,,BAO_0000218,1969.0,
9114,Intermediate,50597,Plasma,,Peak plasma concentration at 1 mg/kg peroral administration,N,1,1,,CHEMBL623810,,BAO_0000218,1969.0,
9115,Intermediate,50597,Plasma,,Peak plasma concentration in rat,N,1,1,,CHEMBL623811,,BAO_0000218,1969.0,
9116,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL623812,,BAO_0000218,1969.0,
9117,Intermediate,50597,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,N,1,1,,CHEMBL877605,,BAO_0000218,,
9118,Intermediate,50597,,,Pharmacokinetic property (Cmax) in rat,N,1,1,,CHEMBL623813,,BAO_0000218,,
9119,Intermediate,50597,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,1,1,,CHEMBL623814,,BAO_0000218,,
9120,Intermediate,50597,,,Cmax in rat after 3mg/kg oral dose,N,1,1,,CHEMBL623815,,BAO_0000218,,
9121,Intermediate,50597,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,N,1,1,,CHEMBL623816,,BAO_0000218,,
9122,Intermediate,50597,,,Cmax in rats after 20 mg/kg oral dose,N,1,1,,CHEMBL623145,,BAO_0000218,,
9123,Intermediate,50597,Plasma,,Cmax in rat plasma after 30mg/kg oral dose,N,1,1,,CHEMBL623146,,BAO_0000218,1969.0,
9124,Intermediate,50597,Plasma,,Plasma concentration after oral administration of 100 mg/kg to rats,N,1,1,,CHEMBL623147,,BAO_0000218,1969.0,
9125,Intermediate,50597,Brain,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,1,1,,CHEMBL623042,,BAO_0000218,955.0,
9126,Intermediate,50597,,,Tested for the Cmax in rat at 10 mg/kg per orally,N,1,1,,CHEMBL623043,,BAO_0000218,,
9127,Intermediate,50597,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL623044,,BAO_0000218,,
9128,Intermediate,50597,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL623045,,BAO_0000218,,
9129,Intermediate,50597,,,Bioavailability as oral Cmax in rats at 30 mins,N,1,1,,CHEMBL623046,,BAO_0000218,,
9130,Intermediate,50597,,,Bioavailability as oral Cmax in rats at 6hr,N,1,1,,CHEMBL623226,,BAO_0000218,,
9131,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,N,1,1,,CHEMBL623227,,BAO_0000218,,
9132,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,N,1,1,,CHEMBL623228,,BAO_0000218,,
9133,Intermediate,50597,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,N,1,1,,CHEMBL623229,,BAO_0000218,,
9134,Intermediate,50597,Plasma,,The maximum plasma levels for the compounds were determined by LC-MS.,N,1,1,,CHEMBL623230,,BAO_0000218,1969.0,
9135,Intermediate,50597,Plasma,,mean peak plasma concentration was observed after intravenous administration in rat,N,1,1,,CHEMBL623231,,BAO_0000218,1969.0,
9136,Intermediate,50597,Plasma,,mean peak plasma concentration was observed after oral administration in rat,N,1,1,,CHEMBL623232,,BAO_0000218,1969.0,
9137,Intermediate,50597,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL623233,,BAO_0000218,,
9138,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,N,1,1,,CHEMBL623234,,BAO_0000218,,
9139,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,N,1,1,,CHEMBL623235,,BAO_0000218,,
9140,Intermediate,50597,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,N,1,1,,CHEMBL623236,,BAO_0000218,,
9141,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,N,1,1,,CHEMBL623237,,BAO_0000218,,
9142,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,N,1,1,,CHEMBL623238,,BAO_0000218,,
9143,Intermediate,50597,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,N,1,1,,CHEMBL623239,,BAO_0000218,,
9144,Intermediate,22224,Plasma,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,U,0,1,,CHEMBL623240,,BAO_0000218,1969.0,
9145,Intermediate,50597,Hypothalamus,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",N,1,1,,CHEMBL623241,,BAO_0000218,1898.0,
9146,Intermediate,50597,Hypothalamus,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",N,1,1,,CHEMBL623242,,BAO_0000218,1898.0,
9147,Intermediate,50597,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",N,1,1,,CHEMBL874394,,BAO_0000218,,
9148,Intermediate,50597,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",N,1,1,,CHEMBL623243,,BAO_0000218,,
9149,Intermediate,50597,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL623244,,BAO_0000218,,
9150,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL623245,,BAO_0000218,2113.0,
9151,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL623246,,BAO_0000218,2113.0,
9152,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL623247,,BAO_0000218,2113.0,
9153,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL623248,,BAO_0000218,2113.0,
9154,Intermediate,50597,Kidney,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL623249,,BAO_0000218,2113.0,
9155,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL625072,,BAO_0000218,2107.0,
9156,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL625073,,BAO_0000218,2107.0,
9157,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL625074,,BAO_0000218,2107.0,
9158,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL625075,,BAO_0000218,2107.0,
9159,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL625076,,BAO_0000218,2107.0,
9160,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL625077,,BAO_0000218,2107.0,
9161,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL625078,,BAO_0000218,2107.0,
9162,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL874395,,BAO_0000218,2107.0,
9163,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL625079,,BAO_0000218,2107.0,
9164,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL625080,,BAO_0000218,2107.0,
9165,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL625081,,BAO_0000218,2107.0,
9166,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL625082,,BAO_0000218,2107.0,
9167,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL625083,,BAO_0000218,2107.0,
9168,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL625084,,BAO_0000218,2107.0,
9169,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL625085,,BAO_0000218,2107.0,
9170,Intermediate,50597,Liver,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL625086,,BAO_0000218,2107.0,
9171,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL625087,,BAO_0000218,2107.0,
9172,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL625088,,BAO_0000218,2107.0,
9173,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL622205,,BAO_0000218,2107.0,
9174,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL622206,,BAO_0000218,2107.0,
9175,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL622207,,BAO_0000218,2107.0,
9176,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL622366,,BAO_0000218,2107.0,
9177,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL622367,,BAO_0000218,2107.0,
9178,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL875331,,BAO_0000218,2107.0,
9179,Intermediate,50597,Liver,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL622368,,BAO_0000218,2107.0,
9180,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL622369,,BAO_0000218,2048.0,
9181,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL622370,,BAO_0000218,2048.0,
9182,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL622371,,BAO_0000218,2048.0,
9183,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL622372,,BAO_0000218,2048.0,
9184,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL622373,,BAO_0000218,2048.0,
9185,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL622374,,BAO_0000218,2048.0,
9186,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL622375,,BAO_0000218,2048.0,
9187,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL622376,,BAO_0000218,2048.0,
9188,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL622377,,BAO_0000218,2048.0,
9189,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL622378,,BAO_0000218,2048.0,
9190,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL622379,,BAO_0000218,2048.0,
9191,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL622380,,BAO_0000218,2048.0,
9192,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL622381,,BAO_0000218,2048.0,
9193,Intermediate,50597,Lung,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL622382,,BAO_0000218,2048.0,
9194,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL622383,,BAO_0000218,2048.0,
9195,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL875332,,BAO_0000218,945.0,
9196,Intermediate,50597,Stomach,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL622384,,BAO_0000218,945.0,
9197,Intermediate,50597,Stomach,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL622385,,BAO_0000218,945.0,
9198,Intermediate,50597,Stomach,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,1,1,,CHEMBL622386,,BAO_0000218,945.0,
9199,Intermediate,50597,,,The compound was tested for the plasma binding in rat,N,1,1,,CHEMBL622387,,BAO_0000218,,
9200,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",N,1,1,,CHEMBL622388,,BAO_0000218,,
9201,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",N,1,1,,CHEMBL622389,,BAO_0000218,,
9202,Intermediate,50597,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",N,1,1,,CHEMBL622390,,BAO_0000218,,
9203,Intermediate,50597,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),N,1,1,,CHEMBL622391,,BAO_0000218,,
9204,Intermediate,50597,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),N,1,1,,CHEMBL622392,,BAO_0000218,,
9205,Intermediate,50597,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),N,1,1,,CHEMBL622393,,BAO_0000218,,
9206,Intermediate,50597,,,Plasma level at 2 hr after administration of the compound,N,1,1,,CHEMBL622394,,BAO_0000218,,
9207,Intermediate,50597,,,plasma level at 2 hr after administration of the compound,N,1,1,,CHEMBL622395,,BAO_0000218,,
9208,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 1 min,N,1,1,,CHEMBL622396,,BAO_0000218,1977.0,
9209,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 10 min,N,1,1,,CHEMBL624894,,BAO_0000218,1977.0,
9210,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 10 mins,N,1,1,,CHEMBL624895,,BAO_0000218,1977.0,
9211,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 2 hr,N,1,1,,CHEMBL624058,,BAO_0000218,1977.0,
9212,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 3 min,N,1,1,,CHEMBL624059,,BAO_0000218,1977.0,
9213,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 3 mins,N,1,1,,CHEMBL624060,,BAO_0000218,1977.0,
9214,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 5 min,N,1,1,,CHEMBL624061,,BAO_0000218,1977.0,
9215,Intermediate,50597,Serum,,Stability in rat serum measured as % recovery at 5 mins,N,1,1,,CHEMBL624062,,BAO_0000218,1977.0,
9216,Intermediate,50597,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL624063,,BAO_0000218,,
9217,Intermediate,50597,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL624064,,BAO_0000218,,
9218,Intermediate,50597,Plasma,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,N,1,1,,CHEMBL624065,,BAO_0000218,1969.0,
9219,Intermediate,50597,Plasma,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,N,1,1,,CHEMBL624066,,BAO_0000218,1969.0,
9220,Intermediate,50597,,,Half life tested in mature male rat at a dose of 30 mg/kg,N,1,1,,CHEMBL877490,,BAO_0000218,,
9221,Intermediate,50597,,,Half life after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL874442,,BAO_0000218,,
9222,Intermediate,50597,,,Half life period after administration (30 mg/kg) in rat,N,1,1,,CHEMBL626890,,BAO_0000218,,
9223,Intermediate,50597,,,Half life period in rat after 5 mg/Kg dose,N,1,1,,CHEMBL626891,,BAO_0000218,,
9224,Intermediate,50597,,,Half life period in rat after 5 mg/kg dose,N,1,1,,CHEMBL626892,,BAO_0000218,,
9225,Intermediate,50597,,,Half life period was determined,N,1,1,,CHEMBL626893,,BAO_0000218,,
9226,Intermediate,50597,,,Half life period was evaluated in rat,N,1,1,,CHEMBL626894,,BAO_0000218,,
9227,Intermediate,50597,,,Half life period was evaluated in rat; 0.5-1.0,N,1,1,,CHEMBL626895,,BAO_0000218,,
9228,Intermediate,50597,,,Half life period was evaluated in rat; 5.9-7.5,N,1,1,,CHEMBL626896,,BAO_0000218,,
9229,Intermediate,50597,Plasma,,Half-life in rat plasma,N,1,1,,CHEMBL626897,,BAO_0000218,1969.0,
9230,Intermediate,50597,,,Half-life time in rat was determined,N,1,1,,CHEMBL626898,,BAO_0000218,,
9231,Intermediate,50597,,,Terminal half-life after iv administration to rats,N,1,1,,CHEMBL626899,,BAO_0000218,,
9232,Intermediate,50597,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,N,1,1,,CHEMBL626900,,BAO_0000218,,
9233,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,N,1,1,,CHEMBL626901,,BAO_0000218,,
9234,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),N,1,1,,CHEMBL626902,,BAO_0000218,,
9235,Intermediate,50597,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),N,1,1,,CHEMBL626903,,BAO_0000218,,
9236,Intermediate,50597,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,N,1,1,,CHEMBL874443,,BAO_0000218,,
9237,Intermediate,50597,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL626904,,BAO_0000218,,
9238,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL626905,,BAO_0000218,,
9239,Intermediate,50597,Plasma,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,1,1,,CHEMBL873830,,BAO_0000218,1969.0,
9240,Intermediate,50597,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,N,1,1,,CHEMBL626906,,BAO_0000218,,
9241,Intermediate,50597,Plasma,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL631076,,BAO_0000218,1969.0,
9242,Intermediate,50597,Plasma,,Biological half-life was measured in plasma of rats,N,1,1,,CHEMBL631077,,BAO_0000218,1969.0,
9243,Intermediate,50597,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,1,1,,CHEMBL631078,,BAO_0000218,,
9244,Intermediate,50597,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,N,1,1,,CHEMBL631079,,BAO_0000218,,
9245,Intermediate,50597,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,N,1,1,,CHEMBL631080,,BAO_0000218,,
9246,Intermediate,50597,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,N,1,1,,CHEMBL631081,,BAO_0000218,,
9247,Intermediate,50597,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,N,1,1,,CHEMBL631239,,BAO_0000218,,
9248,Intermediate,50597,Plasma,,Compound was evaluated for plasma half life in rat,N,1,1,,CHEMBL631240,,BAO_0000218,1969.0,
9249,Intermediate,50597,Plasma,,AUC value at a dose of 5 mg/kg (p.o.) in rats,N,1,1,,CHEMBL631241,,BAO_0000218,1969.0,
9250,Intermediate,50597,Plasma,,AUC value after administration of 20 mg/Kg oral dose in rat,N,1,1,,CHEMBL631242,,BAO_0000218,1969.0,
9251,Intermediate,50597,Plasma,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,N,1,1,,CHEMBL631243,,BAO_0000218,1969.0,
9252,Intermediate,50597,Plasma,,AUC0-96 after administration at 50 mg/kg,N,1,1,,CHEMBL874444,,BAO_0000218,1969.0,
9253,Intermediate,50597,Plasma,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,N,1,1,,CHEMBL631244,,BAO_0000218,1969.0,
9254,Intermediate,50597,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",N,1,1,,CHEMBL631245,,BAO_0000218,,
9255,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,N,1,1,,CHEMBL627162,,BAO_0000218,,
9256,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,N,1,1,,CHEMBL627163,,BAO_0000218,,
9257,Intermediate,50597,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,N,1,1,,CHEMBL627164,,BAO_0000218,,
9258,Intermediate,50597,Kidney,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,N,1,1,,CHEMBL627165,,BAO_0000218,2113.0,
9259,Intermediate,50597,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,N,1,1,,CHEMBL627166,,BAO_0000218,,
9260,Intermediate,50597,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,N,1,1,,CHEMBL627167,,BAO_0000218,,
9261,Intermediate,50597,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,N,1,1,,CHEMBL627822,,BAO_0000218,,
9262,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL627823,,BAO_0000218,,
9263,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,N,1,1,,CHEMBL627824,,BAO_0000218,,
9264,Intermediate,50597,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,1,1,,CHEMBL627825,,BAO_0000218,,
9265,Intermediate,50597,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,N,1,1,,CHEMBL627826,,BAO_0000218,,
9266,Intermediate,50597,,,Area under curve (Pharmacokinetic property) was determined,N,1,1,,CHEMBL627827,,BAO_0000218,,
9267,Intermediate,50597,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,N,1,1,,CHEMBL627828,,BAO_0000218,,
9268,Intermediate,50597,,,Area under curve after intravenous administration (1 mg/kg) in rat,N,1,1,,CHEMBL627829,,BAO_0000218,,
9269,Intermediate,50597,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,N,1,1,,CHEMBL627830,,BAO_0000218,,
9270,Intermediate,50597,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,N,1,1,,CHEMBL627831,,BAO_0000218,,
9271,Intermediate,50597,,,Area under curve in male SD rats was observed after oral administration in rat,N,1,1,,CHEMBL627832,,BAO_0000218,,
9272,Intermediate,50597,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,N,1,1,,CHEMBL627833,,BAO_0000218,,
9273,Expert,50597,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL627834,,BAO_0000218,,
9274,Expert,50597,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL628004,,BAO_0000218,,
9275,Intermediate,50597,,,Area under curve at 5 mg/kg po was determined in rat,N,1,1,,CHEMBL628005,,BAO_0000218,,
9276,Intermediate,50597,,,Area under curve in Rat at a oral dose of 5 mg/kg,N,1,1,,CHEMBL628006,,BAO_0000218,,
9277,Intermediate,50597,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,1,1,,CHEMBL628007,,BAO_0000218,,
9278,Intermediate,50597,,,Area under curve was determined,N,1,1,,CHEMBL625676,,BAO_0000218,,
9279,Intermediate,50597,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,N,1,1,,CHEMBL631309,,BAO_0000218,,
9280,Intermediate,50597,,,Area under curve after intravenous administration at 3 mg/kg,N,1,1,,CHEMBL631310,,BAO_0000218,,
9281,Intermediate,50597,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,N,1,1,,CHEMBL631311,,BAO_0000218,,
9282,Intermediate,50597,,,Area under curve at 4 hr in rat,N,1,1,,CHEMBL631312,,BAO_0000218,,
9283,Intermediate,50597,,,Area under curve at a dose of 30 mg/kg,N,1,1,,CHEMBL631313,,BAO_0000218,,
9284,Intermediate,50597,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,N,1,1,,CHEMBL631314,,BAO_0000218,,
9285,Intermediate,50597,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,N,1,1,,CHEMBL631315,,BAO_0000218,,
9286,Intermediate,50597,,,Area under curve for a 2-mpk po dose in SD rats,N,1,1,,CHEMBL631316,,BAO_0000218,,
9287,Intermediate,50597,,,Area under curve in SD rats,N,1,1,,CHEMBL631317,,BAO_0000218,,
9288,Intermediate,50597,,,Area under curve in rat after oral administration at 13 mg/kg dose,N,1,1,,CHEMBL874471,,BAO_0000218,,
9289,Intermediate,50597,,,Area under curve in rat by po administration at 0-24 hr,N,1,1,,CHEMBL631318,,BAO_0000218,,
9290,Intermediate,50597,Plasma,,Area under curve in rat plasma,N,1,1,,CHEMBL631319,,BAO_0000218,1969.0,
9291,Intermediate,50597,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,N,1,1,,CHEMBL631320,,BAO_0000218,,
9292,Intermediate,50597,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,N,1,1,,CHEMBL631321,,BAO_0000218,,
9293,Intermediate,50597,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,N,1,1,,CHEMBL631322,,BAO_0000218,,
9294,Intermediate,50597,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,N,1,1,,CHEMBL631323,,BAO_0000218,,
9295,Intermediate,50597,,,Area under curve value in rat at a dose of 5 mg/kg,N,1,1,,CHEMBL631324,,BAO_0000218,,
9296,Intermediate,50597,,,Area under curve was determined after oral administration in rats,N,1,1,,CHEMBL631325,,BAO_0000218,,
9297,Intermediate,50597,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL631326,,BAO_0000218,,
9298,Intermediate,50597,,,Area under curve was determined after peroral administration in rat,N,1,1,,CHEMBL631327,,BAO_0000218,,
9299,Intermediate,50597,,,Area under curve was determined at a dose 30 mpk administered orally.,N,1,1,,CHEMBL631328,,BAO_0000218,,
9300,Intermediate,50597,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL631329,,BAO_0000218,,
9301,Intermediate,50597,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,N,1,1,,CHEMBL627217,,BAO_0000218,,
9302,Intermediate,50597,,,Area under curve was determined in male rat,N,1,1,,CHEMBL626352,,BAO_0000218,,
9303,Intermediate,50597,,,Area under curve was determined in rat after PO administration,N,1,1,,CHEMBL626353,,BAO_0000218,,
9304,Intermediate,50597,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,N,1,1,,CHEMBL626354,,BAO_0000218,,
9305,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,N,1,1,,CHEMBL626355,,BAO_0000218,,
9306,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,N,1,1,,CHEMBL626356,,BAO_0000218,,
9307,Intermediate,50597,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,N,1,1,,CHEMBL626357,,BAO_0000218,,
9308,Intermediate,50597,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL626358,,BAO_0000218,,
9309,Intermediate,50597,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL626359,,BAO_0000218,,
9310,Intermediate,50597,Plasma,,Peak plasma concentration in rat at a dose of 3 mg/kg,N,1,1,,CHEMBL626360,,BAO_0000218,1969.0,
9311,Intermediate,50597,,,Plasma concentration at 2 hr in rats was evaluated.,N,1,1,,CHEMBL626361,,BAO_0000218,,
9312,Intermediate,50597,,,Plasma concentration at 2 hr in rats was evaluated; Not available,N,1,1,,CHEMBL626362,,BAO_0000218,,
9313,Intermediate,50597,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL626363,,BAO_0000218,,
9314,Intermediate,50597,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL626970,,BAO_0000218,,
9315,Intermediate,50597,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL626971,,BAO_0000218,,
9316,Intermediate,50597,Plasma,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL626972,,BAO_0000218,1969.0,
9317,Intermediate,50597,Plasma,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL626973,,BAO_0000218,1969.0,
9318,Intermediate,50597,Plasma,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL626974,,BAO_0000218,1969.0,
9319,Intermediate,50597,Plasma,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL874592,,BAO_0000218,1969.0,
9320,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,N,1,1,,CHEMBL626975,,BAO_0000218,,
9321,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,N,1,1,,CHEMBL626976,,BAO_0000218,,
9322,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,N,1,1,,CHEMBL626977,,BAO_0000218,,
9323,Intermediate,50597,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,N,1,1,,CHEMBL626978,,BAO_0000218,,
9324,Intermediate,50597,,,PK study was carried to determine the relative absorption ranking in rat.,N,1,1,,CHEMBL626979,,BAO_0000218,,
9325,Intermediate,50597,Plasma,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,N,1,1,,CHEMBL626980,,BAO_0000218,1969.0,
9326,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",N,1,1,,CHEMBL626981,,BAO_0000218,178.0,
9327,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",N,1,1,,CHEMBL626982,,BAO_0000218,178.0,
9328,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",N,1,1,,CHEMBL626983,,BAO_0000218,178.0,
9329,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",N,1,1,,CHEMBL622522,,BAO_0000218,178.0,
9330,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",N,1,1,,CHEMBL622523,,BAO_0000218,178.0,
9331,Intermediate,50597,Blood,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",N,1,1,,CHEMBL622524,,BAO_0000218,178.0,
9332,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",N,1,1,,CHEMBL622525,,BAO_0000218,955.0,
9333,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",N,1,1,,CHEMBL622526,,BAO_0000218,955.0,
9334,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",N,1,1,,CHEMBL619849,,BAO_0000218,955.0,
9335,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",N,1,1,,CHEMBL619850,,BAO_0000218,955.0,
9336,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",N,1,1,,CHEMBL623864,,BAO_0000218,955.0,
9337,Intermediate,50597,Brain,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",N,1,1,,CHEMBL623865,,BAO_0000218,955.0,
9338,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",N,1,1,,CHEMBL623866,,BAO_0000218,948.0,
9339,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",N,1,1,,CHEMBL623867,,BAO_0000218,948.0,
9340,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",N,1,1,,CHEMBL877615,,BAO_0000218,948.0,
9341,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",N,1,1,,CHEMBL623868,,BAO_0000218,948.0,
9342,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",N,1,1,,CHEMBL623869,,BAO_0000218,948.0,
9343,Intermediate,50597,Heart,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",N,1,1,,CHEMBL623870,,BAO_0000218,948.0,
9344,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL623871,,BAO_0000218,2048.0,
9345,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL623872,,BAO_0000218,2048.0,
9346,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL622129,,BAO_0000218,2048.0,
9347,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL622130,,BAO_0000218,2048.0,
9348,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL622131,,BAO_0000218,2048.0,
9349,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL622132,,BAO_0000218,2048.0,
9350,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL622133,,BAO_0000218,2048.0,
9351,Intermediate,50597,Lung,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL622134,,BAO_0000218,2048.0,
9352,Intermediate,50597,Lung,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL622135,,BAO_0000218,2048.0,
9353,Intermediate,50597,Lung,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL622136,,BAO_0000218,2048.0,
9354,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL622137,,BAO_0000218,2385.0,
9355,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL622138,,BAO_0000218,2385.0,
9356,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL623017,,BAO_0000218,2385.0,
9357,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL623018,,BAO_0000218,2385.0,
9358,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL623019,,BAO_0000218,2385.0,
9359,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL623020,,BAO_0000218,2385.0,
9360,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL623021,,BAO_0000218,2385.0,
9361,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL623022,,BAO_0000218,2385.0,
9362,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL623023,,BAO_0000218,2385.0,
9363,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL623024,,BAO_0000218,2385.0,
9364,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL623025,,BAO_0000218,2385.0,
9365,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL620545,,BAO_0000218,2385.0,
9366,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL620546,,BAO_0000218,2385.0,
9367,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL620547,,BAO_0000218,2385.0,
9368,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL620548,,BAO_0000218,2385.0,
9369,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL620549,,BAO_0000218,2385.0,
9370,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL620550,,BAO_0000218,2385.0,
9371,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL620551,,BAO_0000218,2385.0,
9372,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL620552,,BAO_0000218,2385.0,
9373,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL620553,,BAO_0000218,2385.0,
9374,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL620554,,BAO_0000218,2385.0,
9375,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL875845,,BAO_0000218,2385.0,
9376,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL620555,,BAO_0000218,2385.0,
9377,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL620556,,BAO_0000218,2385.0,
9378,Intermediate,50597,Muscle tissue,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL620557,,BAO_0000218,2385.0,
9379,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL620558,,BAO_0000218,,
9380,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL620559,,BAO_0000218,,
9381,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL622939,,BAO_0000218,,
9382,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL622940,,BAO_0000218,,
9383,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL622941,,BAO_0000218,,
9384,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL622942,,BAO_0000218,,
9385,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL622943,,BAO_0000218,,
9386,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL622944,,BAO_0000218,,
9387,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL622945,,BAO_0000218,,
9388,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL622946,,BAO_0000218,,
9389,Intermediate,50597,,,Compound was evaluated for terminal half life in rat,N,1,1,,CHEMBL622947,,BAO_0000218,,
9390,Intermediate,50597,Plasma,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,N,1,1,,CHEMBL622948,,BAO_0000218,1969.0,
9391,Intermediate,50597,Plasma,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,N,1,1,,CHEMBL622949,,BAO_0000218,1969.0,
9392,Intermediate,50597,,,Compound was tested for its half life in rat,N,1,1,,CHEMBL622950,,BAO_0000218,,
9393,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,0,1,,CHEMBL622951,,BAO_0000218,1969.0,
9394,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in Sprague Dawley rats,U,0,1,,CHEMBL622952,,BAO_0000366,1969.0,
9395,Intermediate,22224,Plasma,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,U,0,1,,CHEMBL622953,,BAO_0000366,1969.0,
9396,Intermediate,50597,Plasma,,Compound was tested for plasma half-life period in rat,N,1,1,,CHEMBL873818,,BAO_0000218,1969.0,
9397,Intermediate,50597,,,Elimination half life after i.v. administration of compound in rats,N,1,1,,CHEMBL622954,,BAO_0000218,,
9398,Intermediate,50597,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,N,1,1,,CHEMBL622955,,BAO_0000218,,
9399,Intermediate,50597,,,Elimination half-life after IV dosing at 1 mg/kg in rat,N,1,1,,CHEMBL875229,,BAO_0000218,,
9400,Intermediate,50597,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,N,1,1,,CHEMBL622956,,BAO_0000218,,
9401,Intermediate,50597,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,N,1,1,,CHEMBL622957,,BAO_0000218,,
9402,Intermediate,50597,Brain,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,1,1,,CHEMBL622958,,BAO_0000218,955.0,
9403,Intermediate,50597,Plasma,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,1,1,,CHEMBL622959,,BAO_0000218,1969.0,
9404,Intermediate,50597,Brain,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,1,1,,CHEMBL622960,,BAO_0000218,955.0,
9405,Intermediate,50597,Plasma,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,1,1,,CHEMBL622961,,BAO_0000218,1969.0,
9406,Intermediate,50597,,,Evaluated for the half life in rat (in vivo),N,1,1,,CHEMBL622962,,BAO_0000218,,
9407,Intermediate,50597,,,Hafl life in rat,N,1,1,,CHEMBL622963,,BAO_0000218,,
9408,Intermediate,50597,,,Hafl life rat,N,1,1,,CHEMBL622964,,BAO_0000218,,
9409,Intermediate,50597,,,Hafl life rat,N,1,1,,CHEMBL622965,,BAO_0000218,,
9410,Intermediate,50597,,,Hafl life rat; Not determined,N,1,1,,CHEMBL622966,,BAO_0000218,,
9411,Intermediate,50597,,,Hafl life rat; Not determined,N,1,1,,CHEMBL622967,,BAO_0000218,,
9412,Intermediate,50597,Kidney,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL622968,,BAO_0000218,2113.0,
9413,Intermediate,50597,Liver,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL622969,,BAO_0000218,2107.0,
9414,Intermediate,50597,Lung,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL875327,,BAO_0000218,2048.0,
9415,Intermediate,50597,,,Half life in rat after 1 mg/kg i.v. administration,N,1,1,,CHEMBL628638,,BAO_0000218,,
9416,Intermediate,50597,,,Half life in rat after 2 mg/kg peroral administration,N,1,1,,CHEMBL628639,,BAO_0000218,,
9417,Intermediate,50597,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL625840,,BAO_0000218,,
9418,Intermediate,50597,,,Half life of 10 mg/kg oral dose determined in rats,N,1,1,,CHEMBL625841,,BAO_0000218,,
9419,Intermediate,50597,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL625842,,BAO_0000218,,
9420,Intermediate,50597,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL625843,,BAO_0000218,,
9421,Intermediate,50597,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL625844,,BAO_0000218,,
9422,Intermediate,50597,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL873822,,BAO_0000218,,
9423,Intermediate,50597,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL625845,,BAO_0000218,,
9424,Intermediate,50597,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL627059,,BAO_0000218,,
9425,Intermediate,50597,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL627060,,BAO_0000218,,
9426,Intermediate,50597,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL627061,,BAO_0000218,,
9427,Intermediate,50597,,,Half life of compound at 5 mg/kg after po administration was determined in rat,N,1,1,,CHEMBL627709,,BAO_0000218,,
9428,Intermediate,50597,,,Half life of compound determined after intravenous administration to rat,N,1,1,,CHEMBL627710,,BAO_0000218,,
9429,Intermediate,50597,,,Half life of compound was determined in rat,N,1,1,,CHEMBL627711,,BAO_0000218,,
9430,Intermediate,50597,Plasma,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL627712,,BAO_0000218,1969.0,
9431,Intermediate,50597,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL627713,,BAO_0000218,,
9432,Intermediate,50597,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL627714,,BAO_0000218,,
9433,Intermediate,22224,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,0,1,,CHEMBL627889,,BAO_0000218,,
9434,Intermediate,22224,,,Half life determined in rat by intravenous administration,U,0,1,,CHEMBL627890,,BAO_0000218,,
9435,Intermediate,50597,,,Half life determined in rats after iv administration,N,1,1,,CHEMBL627891,,BAO_0000218,,
9436,Intermediate,50597,Plasma,,Half life in rat plasma after administration of 2 mg/kg iv,N,1,1,,CHEMBL627892,,BAO_0000218,1969.0,
9437,Intermediate,50597,Plasma,,Half life in rat plasma after administration of 2 mg/kg iv,N,1,1,,CHEMBL627893,,BAO_0000218,1969.0,
9438,Intermediate,50597,Plasma,,Half life in rat plasma was determined,N,1,1,,CHEMBL627894,,BAO_0000218,1969.0,
9439,Intermediate,50597,Plasma,,Half life in rat plasma was determined; NA means not applicable,N,1,1,,CHEMBL627895,,BAO_0000218,1969.0,
9440,Intermediate,50597,,,Half life in rat was tested,N,1,1,,CHEMBL627896,,BAO_0000218,,
9441,Intermediate,50597,Plasma,,Half life measured in rat plasma,N,1,1,,CHEMBL627897,,BAO_0000218,1969.0,
9442,Intermediate,50597,,,Half life recorded in rats,N,1,1,,CHEMBL627898,,BAO_0000218,,
9443,Intermediate,50597,,,Half life was calculated,N,1,1,,CHEMBL627899,,BAO_0000218,,
9444,Intermediate,50597,,,Half life was calculated in rat,N,1,1,,CHEMBL873823,,BAO_0000218,,
9445,Intermediate,50597,,,Half life was determined,N,1,1,,CHEMBL627900,,BAO_0000218,,
9446,Intermediate,50597,,,Half life after 10 mg/kg oral administration in rat,N,1,1,,CHEMBL627901,,BAO_0000218,,
9447,Intermediate,50597,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,N,1,1,,CHEMBL627902,,BAO_0000218,,
9448,Intermediate,50597,,,Half life after administering orally a dose of 30 mg/kg,N,1,1,,CHEMBL627903,,BAO_0000218,,
9449,Intermediate,50597,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,N,1,1,,CHEMBL627904,,BAO_0000218,,
9450,Intermediate,50597,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,N,1,1,,CHEMBL627905,,BAO_0000218,,
9451,Intermediate,50597,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,N,1,1,,CHEMBL627906,,BAO_0000218,,
9452,Intermediate,50597,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,N,1,1,,CHEMBL627907,,BAO_0000218,,
9453,Intermediate,50597,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,N,1,1,,CHEMBL876783,,BAO_0000218,,
9454,Intermediate,50597,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,N,1,1,,CHEMBL627908,,BAO_0000218,,
9455,Intermediate,50597,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,1,1,,CHEMBL627909,,BAO_0000218,,
9456,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,N,1,1,,CHEMBL627910,,BAO_0000218,,
9457,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),N,1,1,,CHEMBL627911,,BAO_0000218,,
9458,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),N,1,1,,CHEMBL627912,,BAO_0000218,,
9459,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),N,1,1,,CHEMBL627913,,BAO_0000218,,
9460,Intermediate,50597,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),N,1,1,,CHEMBL627914,,BAO_0000218,,
9461,Intermediate,50597,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,N,1,1,,CHEMBL627915,,BAO_0000218,,
9462,Intermediate,50597,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,N,1,1,,CHEMBL627916,,BAO_0000218,,
9463,Intermediate,50597,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,N,1,1,,CHEMBL627917,,BAO_0000218,,
9464,Intermediate,50597,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,N,1,1,,CHEMBL627918,,BAO_0000218,,
9465,Intermediate,50597,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,N,1,1,,CHEMBL627919,,BAO_0000218,,
9466,Intermediate,50597,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,N,1,1,,CHEMBL627920,,BAO_0000218,,
9467,Intermediate,50597,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,N,1,1,,CHEMBL627921,,BAO_0000218,,
9468,Intermediate,50597,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL627922,,BAO_0000218,,
9469,Intermediate,50597,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL876784,,BAO_0000218,,
9470,Intermediate,50597,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL627923,,BAO_0000218,,
9471,Intermediate,50597,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL626208,,BAO_0000218,,
9472,Intermediate,50597,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL626209,,BAO_0000218,,
9473,Intermediate,50597,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL626210,,BAO_0000218,,
9474,Intermediate,50597,Plasma,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,1,1,,CHEMBL627994,,BAO_0000218,1969.0,
9475,Intermediate,50597,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL627995,,BAO_0000218,,
9476,Intermediate,50597,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,N,1,1,,CHEMBL627996,,BAO_0000218,,
9477,Intermediate,50597,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,N,1,1,,CHEMBL627997,,BAO_0000218,,
9478,Intermediate,50597,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,N,1,1,,CHEMBL627998,,BAO_0000218,,
9479,Intermediate,50597,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,N,1,1,,CHEMBL628640,,BAO_0000218,,
9480,Intermediate,50597,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,N,1,1,,CHEMBL628641,,BAO_0000218,,
9481,Intermediate,50597,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,N,1,1,,CHEMBL628642,,BAO_0000218,,
9482,Intermediate,50597,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),N,1,1,,CHEMBL628643,,BAO_0000218,,
9483,Intermediate,50597,,,Compound was tested for area under curve in rat,N,1,1,,CHEMBL628644,,BAO_0000218,,
9484,Intermediate,50597,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,N,1,1,,CHEMBL628645,,BAO_0000218,,
9485,Intermediate,50597,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,1,1,,CHEMBL628646,,BAO_0000218,,
9486,Intermediate,50597,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),N,1,1,,CHEMBL628647,,BAO_0000218,,
9487,Intermediate,50597,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,1,1,,CHEMBL628648,,BAO_0000218,,
9488,Intermediate,50597,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,1,1,,CHEMBL625358,,BAO_0000218,,
9489,Intermediate,50597,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,1,1,,CHEMBL625359,,BAO_0000218,,
9490,Intermediate,50597,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,1,1,,CHEMBL625360,,BAO_0000218,,
9491,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),N,1,1,,CHEMBL625361,,BAO_0000218,,
9492,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),N,1,1,,CHEMBL625362,,BAO_0000218,,
9493,Intermediate,50597,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),N,1,1,,CHEMBL625363,,BAO_0000218,,
9494,Intermediate,50597,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,1,1,,CHEMBL625364,,BAO_0000218,,
9495,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625365,,BAO_0000218,,
9496,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625366,,BAO_0000218,,
9497,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625367,,BAO_0000218,,
9498,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",N,1,1,,CHEMBL625368,,BAO_0000218,2113.0,
9499,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",N,1,1,,CHEMBL625369,,BAO_0000218,2113.0,
9500,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",N,1,1,,CHEMBL625370,,BAO_0000218,2113.0,
9501,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",N,1,1,,CHEMBL625371,,BAO_0000218,2113.0,
9502,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",N,1,1,,CHEMBL625372,,BAO_0000218,2113.0,
9503,Intermediate,50597,Kidney,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",N,1,1,,CHEMBL625373,,BAO_0000218,2113.0,
9504,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",N,1,1,,CHEMBL625374,,BAO_0000218,2107.0,
9505,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",N,1,1,,CHEMBL877593,,BAO_0000218,2107.0,
9506,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",N,1,1,,CHEMBL625375,,BAO_0000218,2107.0,
9507,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",N,1,1,,CHEMBL625376,,BAO_0000218,2107.0,
9508,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",N,1,1,,CHEMBL621973,,BAO_0000218,2107.0,
9509,Intermediate,50597,Liver,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",N,1,1,,CHEMBL621974,,BAO_0000218,2107.0,
9510,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",N,1,1,,CHEMBL621975,,BAO_0000218,2048.0,
9511,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",N,1,1,,CHEMBL622166,,BAO_0000218,2048.0,
9512,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",N,1,1,,CHEMBL622167,,BAO_0000218,2048.0,
9513,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",N,1,1,,CHEMBL622168,,BAO_0000218,2048.0,
9514,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",N,1,1,,CHEMBL622169,,BAO_0000218,2048.0,
9515,Intermediate,50597,Lung,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",N,1,1,,CHEMBL622170,,BAO_0000218,2048.0,
9516,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",N,1,1,,CHEMBL622171,,BAO_0000218,2046.0,
9517,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",N,1,1,,CHEMBL622172,,BAO_0000218,2046.0,
9518,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",N,1,1,,CHEMBL622173,,BAO_0000218,2046.0,
9519,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",N,1,1,,CHEMBL622174,,BAO_0000218,2046.0,
9520,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",N,1,1,,CHEMBL622175,,BAO_0000218,2046.0,
9521,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",N,1,1,,CHEMBL622176,,BAO_0000218,2046.0,
9522,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",N,1,1,,CHEMBL622177,,BAO_0000218,2046.0,
9523,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",N,1,1,,CHEMBL622178,,BAO_0000218,2046.0,
9524,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",N,1,1,,CHEMBL622179,,BAO_0000218,2046.0,
9525,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",N,1,1,,CHEMBL622180,,BAO_0000218,2046.0,
9526,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL622181,,BAO_0000218,,
9527,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL622182,,BAO_0000218,,
9528,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL622183,,BAO_0000218,,
9529,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL622184,,BAO_0000218,,
9530,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL622185,,BAO_0000218,,
9531,Intermediate,50597,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL622186,,BAO_0000218,,
9532,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL622187,,BAO_0000218,,
9533,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL625002,,BAO_0000218,,
9534,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL622090,,BAO_0000218,,
9535,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL622091,,BAO_0000218,,
9536,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL622092,,BAO_0000218,,
9537,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL622093,,BAO_0000218,,
9538,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL622094,,BAO_0000218,,
9539,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL622095,,BAO_0000218,,
9540,Intermediate,50597,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL622264,,BAO_0000218,,
9541,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL622265,,BAO_0000218,2106.0,
9542,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL622266,,BAO_0000218,2106.0,
9543,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL622267,,BAO_0000218,2106.0,
9544,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL622268,,BAO_0000218,2106.0,
9545,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL622269,,BAO_0000218,2106.0,
9546,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL625071,,BAO_0000218,2106.0,
9547,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL621621,,BAO_0000218,2106.0,
9548,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL621622,,BAO_0000218,2106.0,
9549,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL621623,,BAO_0000218,2106.0,
9550,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL621624,,BAO_0000218,2106.0,
9551,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL621625,,BAO_0000218,2106.0,
9552,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL621626,,BAO_0000218,2106.0,
9553,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL621627,,BAO_0000218,2106.0,
9554,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL621628,,BAO_0000218,2106.0,
9555,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL875328,,BAO_0000218,2106.0,
9556,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL621629,,BAO_0000218,2106.0,
9557,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL621630,,BAO_0000218,2106.0,
9558,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL621631,,BAO_0000218,2106.0,
9559,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL621632,,BAO_0000218,2106.0,
9560,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL621633,,BAO_0000218,2106.0,
9561,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL621634,,BAO_0000218,2106.0,
9562,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL621635,,BAO_0000218,2106.0,
9563,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL621636,,BAO_0000218,2106.0,
9564,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL621637,,BAO_0000218,2106.0,
9565,Intermediate,50597,Spleen,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL621638,,BAO_0000218,2106.0,
9566,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL618883,,BAO_0000218,,
9567,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,1,1,,CHEMBL618884,,BAO_0000218,,
9568,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL628627,,BAO_0000218,,
9569,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL628628,,BAO_0000218,,
9570,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,1,1,,CHEMBL628629,,BAO_0000218,,
9571,Intermediate,50597,,,Half life after administering orally a dose of 3 mg/kg,N,1,1,,CHEMBL628630,,BAO_0000218,,
9572,Intermediate,50597,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,N,1,1,,CHEMBL628631,,BAO_0000218,,
9573,Intermediate,50597,,,Half life after administering intravenously a dose of 1 mg/kg,N,1,1,,CHEMBL628632,,BAO_0000218,,
9574,Intermediate,50597,,,Half life after oral dosing in rats,N,1,1,,CHEMBL628633,,BAO_0000218,,
9575,Intermediate,50597,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,N,1,1,,CHEMBL628634,,BAO_0000218,,
9576,Intermediate,50597,,,Half life by intravenous administration of 3.4 mg/kg in rat,N,1,1,,CHEMBL627789,,BAO_0000218,,
9577,Intermediate,50597,,,Half life in rat,N,1,1,,CHEMBL627790,,BAO_0000218,,
9578,Intermediate,50597,,,Half life in rat,N,1,1,,CHEMBL627791,,BAO_0000218,,
9579,Intermediate,50597,,,Half life in rat,N,1,1,,CHEMBL627792,,BAO_0000218,,
9580,Intermediate,50597,,,Half life in rat after intravenous administration of the compound,N,1,1,,CHEMBL627793,,BAO_0000218,,
9581,Intermediate,50597,Plasma,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,N,1,1,,CHEMBL627794,,BAO_0000218,1969.0,
9582,Intermediate,50597,,,Half life in rat after po administration of the compound,N,1,1,,CHEMBL627795,,BAO_0000218,,
9583,Intermediate,50597,,,Half life in rat after po administration of the compound; ND means Not determined,N,1,1,,CHEMBL627796,,BAO_0000218,,
9584,Intermediate,50597,Plasma,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,N,1,1,,CHEMBL875335,,BAO_0000218,1969.0,
9585,Intermediate,50597,Plasma,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,N,1,1,,CHEMBL627797,,BAO_0000218,1969.0,
9586,Intermediate,50597,,,Half life in rat i.v.,N,1,1,,CHEMBL627798,,BAO_0000218,,
9587,Intermediate,50597,,,Half life in rat i.v. at 2 mg/kg concentration,N,1,1,,CHEMBL627799,,BAO_0000218,,
9588,Intermediate,50597,,,Half life in rats,N,1,1,,CHEMBL627800,,BAO_0000218,,
9589,Intermediate,50597,,,Half life in rats after intravenous administration,N,1,1,,CHEMBL627801,,BAO_0000218,,
9590,Intermediate,50597,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,N,1,1,,CHEMBL627802,,BAO_0000218,,
9591,Expert,50597,,,Half life in rat,N,1,1,,CHEMBL627803,,BAO_0000218,,
9592,Intermediate,50597,,,Half life was evaluated after intravenous administration to rats,N,1,1,,CHEMBL873820,,BAO_0000218,,
9593,Intermediate,50597,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),N,1,1,,CHEMBL627804,,BAO_0000218,,
9594,Intermediate,50597,,,Half life was evaluated in rat,N,1,1,,CHEMBL627805,,BAO_0000218,,
9595,Intermediate,50597,,,Half life was evaluated in rat,N,1,1,,CHEMBL627806,,BAO_0000218,,
9596,Intermediate,50597,,,Half life was evaluated in rat; Not tested,N,1,1,,CHEMBL627107,,BAO_0000218,,
9597,Intermediate,50597,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,N,1,1,,CHEMBL627108,,BAO_0000218,,
9598,Intermediate,50597,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,N,1,1,,CHEMBL627109,,BAO_0000218,,
9599,Intermediate,50597,Blood,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,N,1,1,,CHEMBL627110,,BAO_0000218,178.0,
9600,Intermediate,22224,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,0,1,,CHEMBL627111,,BAO_0000218,,
9601,Intermediate,22224,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,0,1,,CHEMBL627112,,BAO_0000218,,
9602,Intermediate,22224,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,U,0,1,,CHEMBL627113,,BAO_0000218,,
9603,Intermediate,22224,,,Half life was measured in rat at dose of 30 mg/kg by po administration,U,0,1,,CHEMBL627114,,BAO_0000218,,
9604,Intermediate,50597,,,Half life (t1/2) was determined,N,1,1,,CHEMBL627115,,BAO_0000218,,
9605,Intermediate,50597,,,Half life period at a dose of 10 uM/kg in rat was determined,N,1,1,,CHEMBL627116,,BAO_0000218,,
9606,Intermediate,50597,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,N,1,1,,CHEMBL627117,,BAO_0000218,,
9607,Intermediate,50597,,,Half life period was determined,N,1,1,,CHEMBL627118,,BAO_0000218,,
9608,Intermediate,50597,,,Half life period after intravenous administration at 20 mpk in rats,N,1,1,,CHEMBL627119,,BAO_0000218,,
9609,Intermediate,50597,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,N,1,1,,CHEMBL627120,,BAO_0000218,,
9610,Intermediate,50597,,,Half life period after intravenous administration in rat,N,1,1,,CHEMBL626922,,BAO_0000218,,
9611,Intermediate,50597,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,1,1,,CHEMBL626923,,BAO_0000218,,
9612,Intermediate,50597,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,1,1,,CHEMBL626924,,BAO_0000218,,
9613,Intermediate,50597,Plasma,,Half life period in 80% rat plasma at 37 degree Centigrade,N,1,1,,CHEMBL626925,,BAO_0000218,1969.0,
9614,Intermediate,50597,,,Half life period in SD rats,N,1,1,,CHEMBL626926,,BAO_0000218,,
9615,Intermediate,50597,Plasma,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),N,1,1,,CHEMBL626927,,BAO_0000218,1969.0,
9616,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),N,1,1,,CHEMBL626928,,BAO_0000218,1969.0,
9617,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,1,1,,CHEMBL626929,,BAO_0000218,1969.0,
9618,Intermediate,50597,Plasma,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,1,1,,CHEMBL626930,,BAO_0000218,1969.0,
9619,Intermediate,50597,,,Half life period in rat,N,1,1,,CHEMBL626931,,BAO_0000218,,
9620,Intermediate,50597,,,Half life period in rat,N,1,1,,CHEMBL626932,,BAO_0000218,,
9621,Intermediate,50597,,,Half life period in rat,N,1,1,,CHEMBL626933,,BAO_0000218,,
9622,Intermediate,50597,,,Half life period in rat after oral administration at 10.5 mg/kg dose,N,1,1,,CHEMBL873826,,BAO_0000218,,
9623,Intermediate,50597,,,Half life period in rat after oral administration at 11.2 mg/kg dose,N,1,1,,CHEMBL626934,,BAO_0000218,,
9624,Intermediate,50597,,,Half life period in rat after oral administration at 13 mg/kg dose,N,1,1,,CHEMBL626935,,BAO_0000218,,
9625,Intermediate,50597,,,Half life period in rat after oral administration at 9.7 mg/kg dose,N,1,1,,CHEMBL626936,,BAO_0000218,,
9626,Intermediate,50597,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL626937,,BAO_0000218,,
9627,Intermediate,50597,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,1,1,,CHEMBL625906,,BAO_0000218,,
9628,Intermediate,50597,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,1,1,,CHEMBL625907,,BAO_0000218,,
9629,Intermediate,50597,,,PK study was carried to determine AUC (area under curve) value in rat,N,1,1,,CHEMBL625908,,BAO_0000218,,
9630,Intermediate,50597,,,Pharmacokinetic parameter AUC after intravenous administration to rats,N,1,1,,CHEMBL625909,,BAO_0000218,,
9631,Intermediate,50597,,,Pharmacokinetic parameter AUC after oral administration to rats,N,1,1,,CHEMBL625910,,BAO_0000218,,
9632,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,N,1,1,,CHEMBL625911,,BAO_0000218,,
9633,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,N,1,1,,CHEMBL625912,,BAO_0000218,,
9634,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,N,1,1,,CHEMBL626538,,BAO_0000218,,
9635,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,N,1,1,,CHEMBL876794,,BAO_0000218,,
9636,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,N,1,1,,CHEMBL626539,,BAO_0000218,,
9637,Intermediate,50597,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,N,1,1,,CHEMBL626540,,BAO_0000218,,
9638,Intermediate,50597,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,N,1,1,,CHEMBL626541,,BAO_0000218,,
9639,Intermediate,50597,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,N,1,1,,CHEMBL626542,,BAO_0000218,,
9640,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,N,1,1,,CHEMBL626543,,BAO_0000218,,
9641,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,N,1,1,,CHEMBL626544,,BAO_0000218,,
9642,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,N,1,1,,CHEMBL626545,,BAO_0000218,,
9643,Intermediate,50597,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,N,1,1,,CHEMBL626546,,BAO_0000218,,
9644,Intermediate,50597,,,Pharmacokinetic parameter area under curve was reported,N,1,1,,CHEMBL626547,,BAO_0000218,,
9645,Intermediate,50597,,,Pharmacokinetic property (AUC) in rat,N,1,1,,CHEMBL626548,,BAO_0000218,,
9646,Intermediate,50597,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,N,1,1,,CHEMBL626549,,BAO_0000218,,
9647,Intermediate,50597,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,N,1,1,,CHEMBL626550,,BAO_0000218,,
9648,Intermediate,50597,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,N,1,1,,CHEMBL626551,,BAO_0000218,,
9649,Intermediate,50597,,,Pharmacokinetic property was determined,N,1,1,,CHEMBL623777,,BAO_0000218,,
9650,Intermediate,50597,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,N,1,1,,CHEMBL623778,,BAO_0000218,,
9651,Intermediate,50597,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,N,1,1,,CHEMBL623779,,BAO_0000218,,
9652,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,1,1,,CHEMBL623780,,BAO_0000218,1969.0,
9653,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,N,1,1,,CHEMBL622015,,BAO_0000218,1969.0,
9654,Intermediate,50597,Plasma,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,N,1,1,,CHEMBL622016,,BAO_0000218,1969.0,
9655,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",N,1,1,,CHEMBL622017,,BAO_0000218,,
9656,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",N,1,1,,CHEMBL622018,,BAO_0000218,,
9657,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",N,1,1,,CHEMBL622019,,BAO_0000218,,
9658,Intermediate,50597,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",N,1,1,,CHEMBL622020,,BAO_0000218,,
9659,Intermediate,50597,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,N,1,1,,CHEMBL622021,,BAO_0000218,,
9660,Intermediate,50597,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,N,1,1,,CHEMBL622022,,BAO_0000218,,
9661,Intermediate,50597,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,N,1,1,,CHEMBL622023,,BAO_0000218,,
9662,Intermediate,50597,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,N,1,1,,CHEMBL622024,,BAO_0000218,,
9663,Intermediate,50597,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),N,1,1,,CHEMBL622693,,BAO_0000218,,
9664,Intermediate,50597,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),N,1,1,,CHEMBL622694,,BAO_0000218,,
9665,Intermediate,50597,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,1,1,,CHEMBL622695,,BAO_0000218,,
9666,Intermediate,50597,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,1,1,,CHEMBL622696,,BAO_0000218,,
9667,Intermediate,50597,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",N,1,1,,CHEMBL622697,,BAO_0000218,,
9668,Intermediate,50597,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",N,1,1,,CHEMBL622874,,BAO_0000218,,
9669,Intermediate,50597,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",N,1,1,,CHEMBL622875,,BAO_0000218,,
9670,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,1,1,,CHEMBL622876,,BAO_0000218,,
9671,Intermediate,50597,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,1,1,,CHEMBL622877,,BAO_0000218,,
9672,Intermediate,50597,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,1,1,,CHEMBL622878,,BAO_0000218,,
9673,Intermediate,50597,Plasma,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,N,1,1,,CHEMBL622879,,BAO_0000218,1969.0,
9674,Intermediate,50597,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,N,1,1,,CHEMBL877602,,BAO_0000218,,
9675,Intermediate,50597,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622880,,BAO_0000218,,
9676,Intermediate,50597,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622881,,BAO_0000218,,
9677,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622882,,BAO_0000218,,
9678,Intermediate,50597,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL622883,,BAO_0000218,,
9679,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",N,1,1,,CHEMBL622884,,BAO_0000218,2046.0,
9680,Intermediate,50597,Thyroid gland,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",N,1,1,,CHEMBL622885,,BAO_0000218,2046.0,
9681,Intermediate,50597,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,1,1,,CHEMBL622886,,BAO_0000218,,
9682,Intermediate,50597,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,1,1,,CHEMBL622887,,BAO_0000218,,
9683,Intermediate,50597,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,1,1,,CHEMBL622888,,BAO_0000218,1088.0,
9684,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622889,,BAO_0000218,178.0,
9685,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622890,,BAO_0000218,178.0,
9686,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622891,,BAO_0000218,178.0,
9687,Intermediate,50597,Blood,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL877603,,BAO_0000218,178.0,
9688,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622892,,BAO_0000218,955.0,
9689,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622893,,BAO_0000218,955.0,
9690,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622894,,BAO_0000218,955.0,
9691,Intermediate,50597,Brain,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622895,,BAO_0000218,955.0,
9692,Intermediate,50597,Brain,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,N,1,1,,CHEMBL622896,,BAO_0000218,955.0,
9693,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622897,,BAO_0000218,948.0,
9694,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622898,,BAO_0000218,948.0,
9695,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622899,,BAO_0000218,948.0,
9696,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622900,,BAO_0000218,2113.0,
9697,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624114,,BAO_0000218,2113.0,
9698,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624115,,BAO_0000218,2113.0,
9699,Intermediate,50597,Kidney,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624116,,BAO_0000218,2113.0,
9700,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624117,,BAO_0000218,2107.0,
9701,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624118,,BAO_0000218,2107.0,
9702,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624119,,BAO_0000218,2107.0,
9703,Intermediate,50597,Liver,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624120,,BAO_0000218,2107.0,
9704,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624121,,BAO_0000218,2048.0,
9705,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624122,,BAO_0000218,2048.0,
9706,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624123,,BAO_0000218,2048.0,
9707,Intermediate,50597,Lung,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624124,,BAO_0000218,2048.0,
9708,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624125,,BAO_0000218,2385.0,
9709,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624126,,BAO_0000218,2385.0,
9710,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624127,,BAO_0000218,2385.0,
9711,Intermediate,50597,Muscle tissue,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624128,,BAO_0000218,2385.0,
9712,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL624129,,BAO_0000218,14.0,
9713,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL624130,,BAO_0000218,14.0,
9714,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622340,,BAO_0000218,14.0,
9715,Intermediate,50597,Zone of skin,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622341,,BAO_0000218,14.0,
9716,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622342,,BAO_0000218,160.0,
9717,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622343,,BAO_0000218,160.0,
9718,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622344,,BAO_0000218,160.0,
9719,Intermediate,50597,Intestine,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622345,,BAO_0000218,160.0,
9720,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622346,,BAO_0000218,2106.0,
9721,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622347,,BAO_0000218,2106.0,
9722,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622348,,BAO_0000218,2106.0,
9723,Intermediate,50597,Spleen,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622349,,BAO_0000218,2106.0,
9724,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,1,1,,CHEMBL622350,,BAO_0000218,,
9725,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,1,1,,CHEMBL622351,,BAO_0000218,,
9726,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,1,1,,CHEMBL622352,,BAO_0000218,,
9727,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,1,1,,CHEMBL622353,,BAO_0000218,,
9728,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,1,1,,CHEMBL622354,,BAO_0000218,,
9729,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,1,1,,CHEMBL622355,,BAO_0000218,,
9730,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,1,1,,CHEMBL622356,,BAO_0000218,,
9731,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,1,1,,CHEMBL622357,,BAO_0000218,,
9732,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,1,1,,CHEMBL622358,,BAO_0000218,,
9733,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,1,1,,CHEMBL622359,,BAO_0000218,,
9734,Intermediate,50597,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,1,1,,CHEMBL874393,,BAO_0000218,,
9735,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL622872,,BAO_0000218,,
9736,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL622873,,BAO_0000218,,
9737,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL623047,,BAO_0000218,,
9738,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL623048,,BAO_0000218,,
9739,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL623049,,BAO_0000218,,
9740,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL623050,,BAO_0000218,,
9741,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL623051,,BAO_0000218,,
9742,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL623052,,BAO_0000218,,
9743,Intermediate,50597,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL626343,,BAO_0000218,,
9744,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,1,1,,CHEMBL626344,,BAO_0000218,,
9745,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,1,1,,CHEMBL626345,,BAO_0000218,,
9746,Intermediate,50597,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,1,1,,CHEMBL626346,,BAO_0000218,,
9747,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,1,1,,CHEMBL626347,,BAO_0000218,,
9748,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,1,1,,CHEMBL626348,,BAO_0000218,,
9749,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,1,1,,CHEMBL626349,,BAO_0000218,,
9750,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,1,1,,CHEMBL626350,,BAO_0000218,,
9751,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,1,1,,CHEMBL626351,,BAO_0000218,,
9752,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,1,1,,CHEMBL627650,,BAO_0000218,,
9753,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,1,1,,CHEMBL627651,,BAO_0000218,,
9754,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,1,1,,CHEMBL627652,,BAO_0000218,,
9755,Intermediate,50597,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,1,1,,CHEMBL627653,,BAO_0000218,,
9756,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,N,1,1,,CHEMBL627654,,BAO_0000218,,
9757,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,N,1,1,,CHEMBL627835,,BAO_0000218,,
9758,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,N,1,1,,CHEMBL627836,,BAO_0000218,,
9759,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,N,1,1,,CHEMBL627837,,BAO_0000218,,
9760,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,N,1,1,,CHEMBL627838,,BAO_0000218,,
9761,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,N,1,1,,CHEMBL875338,,BAO_0000218,,
9762,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,N,1,1,,CHEMBL627839,,BAO_0000218,,
9763,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,N,1,1,,CHEMBL627840,,BAO_0000218,,
9764,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,N,1,1,,CHEMBL627841,,BAO_0000218,,
9765,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,N,1,1,,CHEMBL627842,,BAO_0000218,,
9766,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,N,1,1,,CHEMBL627843,,BAO_0000218,,
9767,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,N,1,1,,CHEMBL627844,,BAO_0000218,,
9768,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,N,1,1,,CHEMBL627845,,BAO_0000218,,
9769,Intermediate,50597,,,Half life period in rat by iv administration at a dose of 3 mg/kg,N,1,1,,CHEMBL627846,,BAO_0000218,,
9770,Intermediate,50597,Plasma,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),N,1,1,,CHEMBL627847,,BAO_0000218,1969.0,
9771,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),N,1,1,,CHEMBL873821,,BAO_0000218,1969.0,
9772,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,1,1,,CHEMBL626079,,BAO_0000218,1969.0,
9773,Intermediate,50597,Plasma,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,1,1,,CHEMBL626080,,BAO_0000218,1969.0,
9774,Intermediate,50597,Plasma,,Half life period was evaluated in rat plasma,N,1,1,,CHEMBL626081,,BAO_0000218,1969.0,
9775,Intermediate,50597,Plasma,,Half life period was evaluated in rat plasma; Not tested,N,1,1,,CHEMBL875344,,BAO_0000218,1969.0,
9776,Intermediate,50597,,,Half life period was evaluated in rats,N,1,1,,CHEMBL626082,,BAO_0000218,,
9777,Intermediate,50597,,,"Half life period was evaluated in rats, iv",N,1,1,,CHEMBL626250,,BAO_0000218,,
9778,Intermediate,50597,,,Half life period after intravenous administration at 5 mg/kg in rat,N,1,1,,CHEMBL626251,,BAO_0000218,,
9779,Intermediate,50597,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,1,1,,CHEMBL626252,,BAO_0000218,,
9780,Intermediate,50597,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,N,1,1,,CHEMBL626253,,BAO_0000218,,
9781,Intermediate,50597,Plasma,,Half life stability of compound was evaluated in rat plasma,N,1,1,,CHEMBL626254,,BAO_0000218,1969.0,
9782,Intermediate,50597,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,N,1,1,,CHEMBL626255,,BAO_0000218,,
9783,Intermediate,50597,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,1,1,,CHEMBL626256,,BAO_0000218,,
9784,Intermediate,50597,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,1,1,,CHEMBL626257,,BAO_0000218,,
9785,Intermediate,50597,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,N,1,1,,CHEMBL626258,,BAO_0000218,,
9786,Intermediate,50597,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,N,1,1,,CHEMBL626259,,BAO_0000218,,
9787,Intermediate,50597,,,Half in rat i.v.,N,1,1,,CHEMBL626260,,BAO_0000218,,
9788,Intermediate,50597,,,Half period in rat after intravenous administration,N,1,1,,CHEMBL875345,,BAO_0000218,,
9789,Intermediate,50597,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,N,1,1,,CHEMBL626261,,BAO_0000218,,
9790,Intermediate,50597,Liver,,Half-life measured in in vitro Cathepsin B assay in rat liver,N,1,1,,CHEMBL626262,,BAO_0000218,2107.0,
9791,Intermediate,50597,,,Half-life of compound was determined in rats,N,1,1,,CHEMBL626263,,BAO_0000218,,
9792,Intermediate,50597,,,Half-life at 10 mg/kg in rat upon intravenous administration,N,1,1,,CHEMBL625270,,BAO_0000218,,
9793,Intermediate,50597,,,Half-life determined in rat,N,1,1,,CHEMBL625271,,BAO_0000218,,
9794,Intermediate,50597,,,Half-life determined in rat,N,1,1,,CHEMBL625272,,BAO_0000218,,
9795,Intermediate,50597,Brain,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,N,1,1,,CHEMBL625273,,BAO_0000218,955.0,
9796,Intermediate,50597,Plasma,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",N,1,1,,CHEMBL625274,,BAO_0000218,1969.0,
9797,Intermediate,50597,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,1,1,,CHEMBL625275,,BAO_0000218,,
9798,Intermediate,50597,Plasma,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,N,1,1,,CHEMBL625276,,BAO_0000218,1969.0,
9799,Intermediate,50597,Plasma,,Half-life in rat plasma,N,1,1,,CHEMBL625277,,BAO_0000218,1969.0,
9800,Intermediate,50597,Plasma,,Half-life in rat plasma was determined,N,1,1,,CHEMBL625278,,BAO_0000218,1969.0,
9801,Intermediate,50597,Plasma,,Half-life in rat plasma; Not tested,N,1,1,,CHEMBL625279,,BAO_0000218,1969.0,
9802,Intermediate,50597,Serum,,Half-life in rat serum,N,1,1,,CHEMBL625280,,BAO_0000218,1977.0,
9803,Intermediate,50597,Serum,,Half-life in rat serum; na is not available,N,1,1,,CHEMBL876797,,BAO_0000218,1977.0,
9804,Intermediate,50597,,,Half-life was calculated in rat,N,1,1,,CHEMBL625281,,BAO_0000218,,
9805,Intermediate,50597,Plasma,,Half-life was calculated in rat plasma,N,1,1,,CHEMBL873827,,BAO_0000218,1969.0,
9806,Intermediate,50597,,,Half-life was determined,N,1,1,,CHEMBL625282,,BAO_0000218,,
9807,Intermediate,50597,,,Half-life was determined,N,1,1,,CHEMBL625283,,BAO_0000218,,
9808,Intermediate,50597,,,Half-life after administration of 20 mg/Kg oral dose in rat,N,1,1,,CHEMBL625284,,BAO_0000218,,
9809,Intermediate,50597,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,N,1,1,,CHEMBL625285,,BAO_0000218,,
9810,Intermediate,50597,,,Half-life after intravenous administration in female rat,N,1,1,,CHEMBL625286,,BAO_0000218,,
9811,Intermediate,50597,,,Half-life after intravenous administration in male rat,N,1,1,,CHEMBL625287,,BAO_0000218,,
9812,Intermediate,50597,,,Half-life after intravenous dose in rat,N,1,1,,CHEMBL625288,,BAO_0000218,,
9813,Intermediate,50597,Liver,,Half-life in a rat liver homogenate preparation,N,1,1,,CHEMBL625289,,BAO_0000218,2107.0,
9814,Intermediate,50597,Plasma,,Half-life in plasma of rat,N,1,1,,CHEMBL625290,,BAO_0000218,1969.0,
9815,Intermediate,50597,Plasma,,Half-life in plasma of rat at dose of 3-10 mgkg,N,1,1,,CHEMBL876798,,BAO_0000218,1969.0,
9816,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL625291,,BAO_0000218,,
9817,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL625292,,BAO_0000218,,
9818,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL625293,,BAO_0000218,,
9819,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL622832,,BAO_0000218,,
9820,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL622833,,BAO_0000218,,
9821,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL622834,,BAO_0000218,,
9822,Intermediate,50597,,,Half-life in rat after oral administration at 10 mg/kg,N,1,1,,CHEMBL622835,,BAO_0000218,,
9823,Intermediate,50597,,,Half-life in rat after po administration at a dose of 10 mg/kg,N,1,1,,CHEMBL622836,,BAO_0000218,,
9824,Intermediate,50597,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,1,1,,CHEMBL622837,,BAO_0000218,,
9825,Intermediate,50597,,,Half-life in rat at 3 mg/kg dose administered intravenously,N,1,1,,CHEMBL622838,,BAO_0000218,,
9826,Intermediate,50597,Brain,,Half-life in rat brain homogenate,N,1,1,,CHEMBL622839,,BAO_0000218,955.0,
9827,Intermediate,50597,Plasma,,Half-life in rat plasma,N,1,1,,CHEMBL622840,,BAO_0000218,1969.0,
9828,Intermediate,50597,,,Half-life in rats,N,1,1,,CHEMBL622841,,BAO_0000218,,
9829,Intermediate,50597,,,Half-life in Dawley rats,N,1,1,,CHEMBL622842,,BAO_0000218,,
9830,Intermediate,50597,Plasma,,Half-life in vitro in rat plasma,N,1,1,,CHEMBL622843,,BAO_0000218,1969.0,
9831,Intermediate,50597,Plasma,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,N,1,1,,CHEMBL622844,,BAO_0000218,1969.0,
9832,Intermediate,50597,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",N,1,1,,CHEMBL622845,,BAO_0000218,,
9833,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 100 umol/kg,N,1,1,,CHEMBL622846,,BAO_0000218,,
9834,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 300 umol/kg,N,1,1,,CHEMBL622847,,BAO_0000218,,
9835,Intermediate,50597,,,The area under the curve of compound was measured at the dose of 30 umol/kg,N,1,1,,CHEMBL622848,,BAO_0000218,,
9836,Intermediate,50597,,,Bioavailability as oral AUC in rats,N,1,1,,CHEMBL622849,,BAO_0000218,,
9837,Intermediate,50597,Plasma,,The plasma concentration versus time curve (AUC) was determined,N,1,1,,CHEMBL622850,,BAO_0000218,1969.0,
9838,Intermediate,50597,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL876807,,BAO_0000218,,
9839,Intermediate,50597,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL622851,,BAO_0000218,,
9840,Intermediate,50597,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL622852,,BAO_0000218,,
9841,Intermediate,50597,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,N,1,1,,CHEMBL622853,,BAO_0000218,,
9842,Intermediate,50597,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,N,1,1,,CHEMBL622854,,BAO_0000218,,
9843,Intermediate,50597,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,1,1,,CHEMBL622855,,BAO_0000218,,
9844,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL622856,,BAO_0000218,1969.0,
9845,Intermediate,50597,Plasma,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL622857,,BAO_0000218,1969.0,
9846,Intermediate,50597,Plasma,,AUC in rat after po administration at a dose of 10 mg/kg,N,1,1,,CHEMBL622858,,BAO_0000218,1969.0,
9847,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,N,1,1,,CHEMBL622859,,BAO_0000218,1969.0,
9848,Intermediate,50597,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,N,1,1,,CHEMBL622860,,BAO_0000218,,
9849,Intermediate,50597,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,N,1,1,,CHEMBL622861,,BAO_0000218,,
9850,Intermediate,50597,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,N,1,1,,CHEMBL622862,,BAO_0000218,,
9851,Intermediate,50597,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,N,1,1,,CHEMBL622863,,BAO_0000218,,
9852,Intermediate,50597,,,Area under curve value 6 hr after po administration in rat,N,1,1,,CHEMBL623817,,BAO_0000218,,
9853,Intermediate,50597,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL623818,,BAO_0000218,,
9854,Intermediate,50597,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",N,1,1,,CHEMBL623819,,BAO_0000218,,
9855,Intermediate,50597,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL623820,,BAO_0000218,,
9856,Intermediate,50597,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,N,1,1,,CHEMBL623821,,BAO_0000218,,
9857,Intermediate,50597,Plasma,,AUC normalized for dose (AUCN) in rat,N,1,1,,CHEMBL623822,,BAO_0000218,1969.0,
9858,Intermediate,50597,,,Area under curve in rat after p.o. administration,N,1,1,,CHEMBL623823,,BAO_0000218,,
9859,Intermediate,50597,,,Area under curve in rat after p.o. administration,N,1,1,,CHEMBL623824,,BAO_0000218,,
9860,Intermediate,50597,,,Area under curve in rat after p.o. administration; Not determined,N,1,1,,CHEMBL623825,,BAO_0000218,,
9861,Intermediate,50597,,,Area under curve in rat after peroral administration,N,1,1,,CHEMBL622070,,BAO_0000218,,
9862,Intermediate,50597,,,Area under curve (carotid artery) value of the compound,N,1,1,,CHEMBL622071,,BAO_0000218,,
9863,Intermediate,50597,,,Bioavailability expressed as the area under curve of rat carotid artery,N,1,1,,CHEMBL622072,,BAO_0000218,,
9864,Intermediate,50597,,,Area under curve in male SD rats was observed after intravenous administration in rat,N,1,1,,CHEMBL622073,,BAO_0000218,,
9865,Intermediate,50597,,,Area under curve of the compound was determined,N,1,1,,CHEMBL622074,,BAO_0000218,,
9866,Intermediate,50597,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,N,1,1,,CHEMBL622075,,BAO_0000218,,
9867,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,N,1,1,,CHEMBL622076,,BAO_0000218,1969.0,
9868,Intermediate,50597,Plasma,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,N,1,1,,CHEMBL622077,,BAO_0000218,1969.0,
9869,Intermediate,50597,,,Area under curve (portal vein) value of the compound,N,1,1,,CHEMBL622078,,BAO_0000218,,
9870,Intermediate,50597,,,Bioavailability expressed as the area under curve of rat portal vein,N,1,1,,CHEMBL622079,,BAO_0000218,,
9871,Intermediate,50597,Plasma,,Area Under plasma concentration time curve in rat upon peroral administration,N,1,1,,CHEMBL622080,,BAO_0000218,1969.0,
9872,Intermediate,50597,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,N,1,1,,CHEMBL877612,,BAO_0000218,,
9873,Intermediate,50597,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,N,1,1,,CHEMBL622081,,BAO_0000218,,
9874,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats,N,1,1,,CHEMBL622082,,BAO_0000218,,
9875,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats after iv administration,N,1,1,,CHEMBL622083,,BAO_0000218,,
9876,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 30-80,N,1,1,,CHEMBL622084,,BAO_0000218,,
9877,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 50-60,N,1,1,,CHEMBL622085,,BAO_0000218,,
9878,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; no data,N,1,1,,CHEMBL622086,,BAO_0000218,,
9879,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; peptide,N,1,1,,CHEMBL622087,,BAO_0000218,,
9880,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",N,1,1,,CHEMBL622088,,BAO_0000218,178.0,
9881,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",N,1,1,,CHEMBL622089,,BAO_0000218,178.0,
9882,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",N,1,1,,CHEMBL623685,,BAO_0000218,178.0,
9883,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",N,1,1,,CHEMBL623686,,BAO_0000218,178.0,
9884,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL623687,,BAO_0000218,945.0,
9885,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL623688,,BAO_0000218,945.0,
9886,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL623689,,BAO_0000218,945.0,
9887,Intermediate,50597,Stomach,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622485,,BAO_0000218,945.0,
9888,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622486,,BAO_0000218,2046.0,
9889,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL877613,,BAO_0000218,2046.0,
9890,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622487,,BAO_0000218,2046.0,
9891,Intermediate,50597,Thyroid gland,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622488,,BAO_0000218,2046.0,
9892,Intermediate,50597,Heart,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,1,1,,CHEMBL622489,,BAO_0000218,948.0,
9893,Intermediate,50597,Urine,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,1,1,,CHEMBL622490,,BAO_0000218,1088.0,
9894,Intermediate,50597,Urine,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,1,1,,CHEMBL622491,,BAO_0000218,1088.0,
9895,Intermediate,50597,Liver,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,N,1,1,,CHEMBL622492,,BAO_0000218,2107.0,
9896,Intermediate,50597,Urine,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,1,1,,CHEMBL622493,,BAO_0000218,1088.0,
9897,Intermediate,50597,Urine,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,1,1,,CHEMBL622494,,BAO_0000218,1088.0,
9898,Intermediate,50597,Muscle tissue,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,1,1,,CHEMBL622495,,BAO_0000218,2385.0,
9899,Intermediate,50597,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,N,1,1,,CHEMBL622496,,BAO_0000218,,
9900,Intermediate,50597,Urine,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,1,1,,CHEMBL622497,,BAO_0000218,1088.0,
9901,Intermediate,50597,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,N,1,1,,CHEMBL622498,,BAO_0000218,,
9902,Intermediate,50597,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,N,1,1,,CHEMBL624918,,BAO_0000218,1088.0,
9903,Intermediate,50597,Urine,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,N,1,1,,CHEMBL624919,,BAO_0000218,1088.0,
9904,Intermediate,50597,Blood,,Biodistribution of compound in rat blood after 5 min of administration,N,1,1,,CHEMBL624920,,BAO_0000218,178.0,
9905,Intermediate,50597,Blood,,Biodistribution of compound in rat blood after 5 min of administration.,N,1,1,,CHEMBL624921,,BAO_0000218,178.0,
9906,Intermediate,50597,Brain,,Biodistribution of compound in rat brain after 5 min of administration,N,1,1,,CHEMBL624922,,BAO_0000218,955.0,
9907,Intermediate,50597,Heart,,Biodistribution of compound in rat heart after 5 min of administration,N,1,1,,CHEMBL624923,,BAO_0000218,948.0,
9908,Intermediate,50597,Heart,,Biodistribution of compound in rat heart after 5 min of administration.,N,1,1,,CHEMBL624924,,BAO_0000218,948.0,
9909,Intermediate,50597,Kidney,,Biodistribution of compound in rat kidney after 5 min of administration,N,1,1,,CHEMBL624925,,BAO_0000218,2113.0,
9910,Intermediate,50597,Kidney,,Biodistribution of compound in rat kidney after 5 min of administration.,N,1,1,,CHEMBL624926,,BAO_0000218,2113.0,
9911,Intermediate,50597,Liver,,Biodistribution of compound in rat liver after 5 min of administration,N,1,1,,CHEMBL624927,,BAO_0000218,2107.0,
9912,Intermediate,50597,Liver,,Biodistribution of compound in rat liver after 5 min of administration.,N,1,1,,CHEMBL874402,,BAO_0000218,2107.0,
9913,Intermediate,50597,Lung,,Biodistribution of compound in rat lung after 5 min of administration,N,1,1,,CHEMBL624928,,BAO_0000218,2048.0,
9914,Intermediate,50597,Lung,,Biodistribution of compound in rat lung after 5 min of administration.,N,1,1,,CHEMBL624929,,BAO_0000218,2048.0,
9915,Intermediate,50597,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration,N,1,1,,CHEMBL624930,,BAO_0000218,2385.0,
9916,Intermediate,50597,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration.,N,1,1,,CHEMBL624931,,BAO_0000218,2385.0,
9917,Intermediate,50597,Heart,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624932,,BAO_0000218,948.0,
9918,Intermediate,50597,Heart,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624933,,BAO_0000218,948.0,
9919,Intermediate,50597,Liver,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624934,,BAO_0000218,2107.0,
9920,Intermediate,50597,Liver,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624935,,BAO_0000218,2107.0,
9921,Intermediate,50597,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624936,,BAO_0000218,,
9922,Intermediate,50597,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624937,,BAO_0000218,,
9923,Intermediate,50597,Spleen,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624938,,BAO_0000218,2106.0,
9924,Intermediate,50597,Spleen,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624939,,BAO_0000218,2106.0,
9925,Intermediate,50597,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL624940,,BAO_0000218,,
9926,Intermediate,50597,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,1,1,,CHEMBL874403,,BAO_0000218,,
9927,Intermediate,50597,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,N,1,1,,CHEMBL624941,,BAO_0000218,,
9928,Intermediate,50597,Urine,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,N,1,1,,CHEMBL624942,,BAO_0000218,1088.0,
9929,Intermediate,50597,Urine,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,N,1,1,,CHEMBL624943,,BAO_0000218,1088.0,
9930,Intermediate,50597,,,% Bioavailability after 1 day of the drug administration in rats,N,1,1,,CHEMBL624944,,BAO_0000218,,
9931,Intermediate,50597,,,% Bioavailability after 4 day of the drug administration in rats,N,1,1,,CHEMBL624945,,BAO_0000218,,
9932,Intermediate,50597,,,Absolute bioavailability was evaluated in rat,N,1,1,,CHEMBL624946,,BAO_0000218,,
9933,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,N,1,1,,CHEMBL624947,,BAO_0000218,,
9934,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,N,1,1,,CHEMBL624948,,BAO_0000218,,
9935,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,N,1,1,,CHEMBL624949,,BAO_0000218,,
9936,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,N,1,1,,CHEMBL622025,,BAO_0000218,2113.0,
9937,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,N,1,1,,CHEMBL622026,,BAO_0000218,2113.0,
9938,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,N,1,1,,CHEMBL622027,,BAO_0000218,2113.0,
9939,Intermediate,50597,Kidney,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,N,1,1,,CHEMBL622028,,BAO_0000218,2113.0,
9940,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,N,1,1,,CHEMBL622029,,BAO_0000218,2107.0,
9941,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,N,1,1,,CHEMBL622208,,BAO_0000218,2107.0,
9942,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,N,1,1,,CHEMBL622209,,BAO_0000218,2107.0,
9943,Intermediate,50597,Liver,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,N,1,1,,CHEMBL622210,,BAO_0000218,2107.0,
9944,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,N,1,1,,CHEMBL622211,,BAO_0000218,,
9945,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,N,1,1,,CHEMBL622212,,BAO_0000218,,
9946,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,N,1,1,,CHEMBL622213,,BAO_0000218,,
9947,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,N,1,1,,CHEMBL874404,,BAO_0000218,,
9948,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,N,1,1,,CHEMBL620452,,BAO_0000218,2385.0,
9949,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,N,1,1,,CHEMBL620453,,BAO_0000218,2385.0,
9950,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,N,1,1,,CHEMBL620454,,BAO_0000218,2385.0,
9951,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,N,1,1,,CHEMBL624067,,BAO_0000218,2385.0,
9952,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,N,1,1,,CHEMBL624068,,BAO_0000218,,
9953,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,N,1,1,,CHEMBL624069,,BAO_0000218,992.0,
9954,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,N,1,1,,CHEMBL624070,,BAO_0000218,992.0,
9955,Intermediate,50597,Female gonad,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,N,1,1,,CHEMBL624071,,BAO_0000218,992.0,
9956,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,N,1,1,,CHEMBL624072,,BAO_0000218,995.0,
9957,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,N,1,1,,CHEMBL624073,,BAO_0000218,995.0,
9958,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,N,1,1,,CHEMBL624788,,BAO_0000218,995.0,
9959,Intermediate,50597,Uterus,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,N,1,1,,CHEMBL624789,,BAO_0000218,995.0,
9960,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,N,1,1,,CHEMBL624790,,BAO_0000218,,
9961,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,N,1,1,,CHEMBL624791,,BAO_0000218,,
9962,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,N,1,1,,CHEMBL624792,,BAO_0000218,,
9963,Intermediate,50597,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,N,1,1,,CHEMBL624793,,BAO_0000218,,
9964,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,N,1,1,,CHEMBL877491,,BAO_0000218,2385.0,
9965,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,N,1,1,,CHEMBL624957,,BAO_0000218,2385.0,
9966,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,N,1,1,,CHEMBL624958,,BAO_0000218,2385.0,
9967,Intermediate,50597,Muscle tissue,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,N,1,1,,CHEMBL624959,,BAO_0000218,2385.0,
9968,Intermediate,50597,,,Dissociation constant was determined,N,1,1,,CHEMBL624960,,BAO_0000218,,
9969,Intermediate,50597,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",N,1,1,,CHEMBL624961,,BAO_0000218,,
9970,Intermediate,50597,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL624962,,BAO_0000218,,
9971,Intermediate,50597,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL624963,,BAO_0000218,,
9972,Intermediate,50597,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,N,1,1,,CHEMBL624964,,BAO_0000218,,
9973,Intermediate,50597,,,LogP value was evaluated in the in situ rat gut perfusion assay,N,1,1,,CHEMBL624965,,BAO_0000218,,
9974,Intermediate,50597,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,1,1,,CHEMBL624966,,BAO_0000218,,
9975,Intermediate,50597,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,N,1,1,,CHEMBL624967,,BAO_0000218,,
9976,Intermediate,50597,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL624968,,BAO_0000218,,
9977,Intermediate,50597,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL624969,,BAO_0000218,,
9978,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,N,1,1,,CHEMBL624970,,BAO_0000218,,
9979,Intermediate,50597,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,N,1,1,,CHEMBL624971,,BAO_0000218,,
9980,Intermediate,50597,,,Half-life was evaluated after 20 uM/kg of peroral administration,N,1,1,,CHEMBL624972,,BAO_0000218,,
9981,Intermediate,50597,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,1,1,,CHEMBL624973,,BAO_0000218,,
9982,Intermediate,50597,Plasma,,Half-life was evaluated in plasma of rat,N,1,1,,CHEMBL624974,,BAO_0000218,1969.0,
9983,Intermediate,50597,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,N,1,1,,CHEMBL624975,,BAO_0000218,,
9984,Intermediate,50597,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,N,1,1,,CHEMBL877492,,BAO_0000218,,
9985,Intermediate,50597,,,Half-life was measured in rat after an iv dose of 1 mg/kg,N,1,1,,CHEMBL624976,,BAO_0000218,,
9986,Intermediate,50597,,,Half-life period of compound in rats after peroral administration,N,1,1,,CHEMBL624977,,BAO_0000218,,
9987,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma.,N,1,1,,CHEMBL626848,,BAO_0000218,1969.0,
9988,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma; ND is not determined,N,1,1,,CHEMBL626849,,BAO_0000218,1969.0,
9989,Intermediate,50597,Plasma,,Half-life period of compound was measured in rat plasma; not determined,N,1,1,,CHEMBL626850,,BAO_0000218,1969.0,
9990,Intermediate,50597,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,1,1,,CHEMBL626851,,BAO_0000218,,
9991,Intermediate,50597,,,Half-life period in rat by iv administration,N,1,1,,CHEMBL626852,,BAO_0000218,,
9992,Intermediate,50597,,,Half-life period in rats following intravenous administration at 2 mg/kg,N,1,1,,CHEMBL626853,,BAO_0000218,,
9993,Intermediate,50597,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL626854,,BAO_0000218,,
9994,Intermediate,50597,,,Half-life period was determined for the compound in rat,N,1,1,,CHEMBL627486,,BAO_0000218,,
9995,Intermediate,50597,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",N,1,1,,CHEMBL627487,,BAO_0000218,,
9996,Intermediate,50597,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",N,1,1,,CHEMBL627488,,BAO_0000218,,
9997,Intermediate,50597,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,N,1,1,,CHEMBL627489,,BAO_0000218,,
9998,Intermediate,50597,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,1,1,,CHEMBL627490,,BAO_0000218,,
9999,Intermediate,50597,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),N,1,1,,CHEMBL873829,,BAO_0000218,,
10000,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.,N,1,1,,CHEMBL627655,,BAO_0000218,,
10001,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,1,1,,CHEMBL625994,,BAO_0000218,,
10002,Intermediate,50597,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,1,1,,CHEMBL625995,,BAO_0000218,,
10003,Intermediate,50597,,,Half-life in rat,N,1,1,,CHEMBL625996,,BAO_0000218,,
10004,Intermediate,50597,Plasma,,In vitro half life in rat plasma,N,1,1,,CHEMBL625850,,BAO_0000218,1969.0,
10005,Intermediate,50597,Plasma,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",N,1,1,,CHEMBL625851,,BAO_0000218,1969.0,
10006,Intermediate,50597,,,In vitro half life in rat,N,1,1,,CHEMBL625852,,BAO_0000218,,
10007,Intermediate,50597,,,In vivo half life period after intravenous administration in rat,N,1,1,,CHEMBL625853,,BAO_0000218,,
10008,Intermediate,50597,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,1,1,,CHEMBL625854,,BAO_0000218,,
10009,Intermediate,50597,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,1,1,,CHEMBL874450,,BAO_0000218,,
10010,Intermediate,50597,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625855,,BAO_0000218,,
10011,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625856,,BAO_0000218,,
10012,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL625857,,BAO_0000218,,
10013,Intermediate,50597,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL873831,,BAO_0000218,,
10014,Intermediate,50597,,,Longer half-life in rat (i.v.) at 0.5 mpk,N,1,1,,CHEMBL625858,,BAO_0000218,,
10015,Intermediate,50597,,,Longer half-life in rat (p.o.) at 2.0 mpk,N,1,1,,CHEMBL625859,,BAO_0000218,,
10016,Intermediate,50597,,,Pharmacokinetic property (half life) in rat,N,1,1,,CHEMBL625860,,BAO_0000218,,
10017,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,N,1,1,,CHEMBL625861,,BAO_0000218,,
10018,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,N,1,1,,CHEMBL625862,,BAO_0000218,,
10019,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,N,1,1,,CHEMBL625863,,BAO_0000218,,
10020,Intermediate,50597,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,N,1,1,,CHEMBL625864,,BAO_0000218,,
10021,Intermediate,50597,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,N,1,1,,CHEMBL625865,,BAO_0000218,,
10022,Intermediate,50597,,,Pharmacokinetic half time was determined intravenously in rats.,N,1,1,,CHEMBL625866,,BAO_0000218,,
10023,Intermediate,50597,Plasma,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,N,1,1,,CHEMBL625867,,BAO_0000218,1969.0,
10024,Intermediate,50597,Plasma,,Plasma half life of hydrolysis of the compound,N,1,1,,CHEMBL625868,,BAO_0000218,1969.0,
10025,Intermediate,50597,Plasma,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,N,1,1,,CHEMBL625869,,BAO_0000218,1969.0,
10026,Intermediate,50597,Plasma,,Plasma half life period was calculated in rat,N,1,1,,CHEMBL874451,,BAO_0000218,1969.0,
10027,Intermediate,50597,Plasma,,Plasma half-life in Sprague-Dawley rats,N,1,1,,CHEMBL625870,,BAO_0000218,1969.0,
10028,Intermediate,50597,Plasma,,Plasma half-life in Sprague-Dawley rats; Not determined,N,1,1,,CHEMBL625871,,BAO_0000218,1969.0,
10029,Intermediate,50597,Plasma,,Plasma half-life in rats,N,1,1,,CHEMBL625872,,BAO_0000218,1969.0,
10030,Intermediate,50597,Plasma,,Plasma half-life in rats; <MQL,N,1,1,,CHEMBL625873,,BAO_0000218,1969.0,
10031,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was determined,N,1,1,,CHEMBL625874,,BAO_0000218,1969.0,
10032,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,N,1,1,,CHEMBL625875,,BAO_0000218,1969.0,
10033,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL625876,,BAO_0000218,1969.0,
10034,Intermediate,50597,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,1,1,,CHEMBL631258,,BAO_0000218,1969.0,
10035,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,N,1,1,,CHEMBL631259,,BAO_0000218,1969.0,
10036,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,N,1,1,,CHEMBL631260,,BAO_0000218,1969.0,
10037,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",N,1,1,,CHEMBL631261,,BAO_0000218,178.0,
10038,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",N,1,1,,CHEMBL631262,,BAO_0000218,178.0,
10039,Intermediate,50597,Blood,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",N,1,1,,CHEMBL631263,,BAO_0000218,178.0,
10040,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",N,1,1,,CHEMBL631264,,BAO_0000218,,
10041,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",N,1,1,,CHEMBL631265,,BAO_0000218,,
10042,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",N,1,1,,CHEMBL631266,,BAO_0000218,,
10043,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",N,1,1,,CHEMBL631267,,BAO_0000218,,
10044,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",N,1,1,,CHEMBL631268,,BAO_0000218,,
10045,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",N,1,1,,CHEMBL631269,,BAO_0000218,,
10046,Intermediate,50597,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",N,1,1,,CHEMBL631270,,BAO_0000218,,
10047,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,1,1,,CHEMBL631271,,BAO_0000218,948.0,
10048,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",N,1,1,,CHEMBL631272,,BAO_0000218,948.0,
10049,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",N,1,1,,CHEMBL631273,,BAO_0000218,948.0,
10050,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",N,1,1,,CHEMBL631274,,BAO_0000218,948.0,
10051,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",N,1,1,,CHEMBL631275,,BAO_0000218,948.0,
10052,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",N,1,1,,CHEMBL626984,,BAO_0000218,948.0,
10053,Intermediate,50597,Heart,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",N,1,1,,CHEMBL626985,,BAO_0000218,948.0,
10054,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,1,1,,CHEMBL626986,,BAO_0000218,2107.0,
10055,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",N,1,1,,CHEMBL626987,,BAO_0000218,2107.0,
10056,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",N,1,1,,CHEMBL626988,,BAO_0000218,2107.0,
10057,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",N,1,1,,CHEMBL626989,,BAO_0000218,2107.0,
10058,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",N,1,1,,CHEMBL626990,,BAO_0000218,2107.0,
10059,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",N,1,1,,CHEMBL626991,,BAO_0000218,2107.0,
10060,Intermediate,50597,Liver,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",N,1,1,,CHEMBL626992,,BAO_0000218,2107.0,
10061,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",N,1,1,,CHEMBL626993,,BAO_0000218,2048.0,
10062,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",N,1,1,,CHEMBL874593,,BAO_0000218,2048.0,
10063,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",N,1,1,,CHEMBL626994,,BAO_0000218,2048.0,
10064,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",N,1,1,,CHEMBL626995,,BAO_0000218,2048.0,
10065,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",N,1,1,,CHEMBL626190,,BAO_0000218,2048.0,
10066,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",N,1,1,,CHEMBL626191,,BAO_0000218,2048.0,
10067,Intermediate,50597,Lung,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",N,1,1,,CHEMBL626364,,BAO_0000218,2048.0,
10068,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",N,1,1,,CHEMBL626365,,BAO_0000218,2046.0,
10069,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",N,1,1,,CHEMBL626366,,BAO_0000218,2046.0,
10070,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",N,1,1,,CHEMBL626367,,BAO_0000218,2046.0,
10071,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",N,1,1,,CHEMBL626368,,BAO_0000218,2046.0,
10072,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",N,1,1,,CHEMBL626369,,BAO_0000218,2046.0,
10073,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",N,1,1,,CHEMBL626370,,BAO_0000218,2046.0,
10074,Intermediate,50597,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",N,1,1,,CHEMBL626371,,BAO_0000218,,
10075,Intermediate,50597,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",N,1,1,,CHEMBL626372,,BAO_0000218,,
10076,Intermediate,50597,,,Bioavailability after a dose of 10 mg/kg p.o.,N,1,1,,CHEMBL626373,,BAO_0000218,,
10077,Intermediate,50597,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,N,1,1,,CHEMBL626374,,BAO_0000218,,
10078,Intermediate,50597,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,N,1,1,,CHEMBL626375,,BAO_0000218,,
10079,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),N,1,1,,CHEMBL626376,,BAO_0000218,,
10080,Intermediate,50597,,,Bioavailability in rat po was determined,N,1,1,,CHEMBL626377,,BAO_0000218,,
10081,Intermediate,50597,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,N,1,1,,CHEMBL626378,,BAO_0000218,,
10082,Intermediate,50597,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,N,1,1,,CHEMBL626379,,BAO_0000218,,
10083,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,1,1,,CHEMBL626380,,BAO_0000218,,
10084,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,1,1,,CHEMBL626381,,BAO_0000218,,
10085,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626382,,BAO_0000218,,
10086,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (female),N,1,1,,CHEMBL626383,,BAO_0000218,,
10087,Intermediate,50597,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,1,1,,CHEMBL874652,,BAO_0000218,,
10088,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),N,1,1,,CHEMBL626384,,BAO_0000218,,
10089,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,N,1,1,,CHEMBL626385,,BAO_0000218,,
10090,Intermediate,50597,,,Bioavailability in rat at an oral dose of 2 mg/kg,N,1,1,,CHEMBL626386,,BAO_0000218,,
10091,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626387,,BAO_0000218,,
10092,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626388,,BAO_0000218,,
10093,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626389,,BAO_0000218,,
10094,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626390,,BAO_0000218,,
10095,Intermediate,50597,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,N,1,1,,CHEMBL626391,,BAO_0000218,,
10096,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL626392,,BAO_0000218,,
10097,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL626393,,BAO_0000218,,
10098,Intermediate,50597,,,Bioavailability was determined in rat,N,1,1,,CHEMBL623026,,BAO_0000218,,
10099,Intermediate,50597,,,Bioavailability,N,1,1,,CHEMBL623027,,BAO_0000218,,
10100,Intermediate,50597,,,Bioavailability,N,1,1,,CHEMBL623028,,BAO_0000218,,
10101,Intermediate,50597,,,Bioavailability in rat after 1 day dosing,N,1,1,,CHEMBL623029,,BAO_0000218,,
10102,Intermediate,50597,,,Bioavailability in rat after 4 day dosing,N,1,1,,CHEMBL623030,,BAO_0000218,,
10103,Intermediate,50597,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,N,1,1,,CHEMBL623031,,BAO_0000218,,
10104,Intermediate,50597,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,N,1,1,,CHEMBL623032,,BAO_0000218,,
10105,Intermediate,50597,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,N,1,1,,CHEMBL623033,,BAO_0000218,,
10106,Intermediate,50597,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,N,1,1,,CHEMBL623034,,BAO_0000218,,
10107,Intermediate,50597,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,N,1,1,,CHEMBL623035,,BAO_0000218,,
10108,Intermediate,50597,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,1,1,,CHEMBL623036,,BAO_0000218,,
10109,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,1,1,,CHEMBL623037,,BAO_0000218,,
10110,Intermediate,50597,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,N,1,1,,CHEMBL623038,,BAO_0000218,,
10111,Intermediate,50597,Plasma,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,N,1,1,,CHEMBL874385,,BAO_0000218,1969.0,
10112,Intermediate,50597,,,Bioavailability in rat (Fisher) (fasted),N,1,1,,CHEMBL623039,,BAO_0000218,,
10113,Intermediate,22224,,,Bioavailability in monkey after po administration of 10 mg/kg dose,U,0,1,,CHEMBL623040,,BAO_0000218,,
10114,Intermediate,22224,,,Oral bioavailability in monkey (dose 10 mg/kg),U,0,1,,CHEMBL623041,,BAO_0000218,,
10115,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623741,,BAO_0000218,,
10116,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623742,,BAO_0000218,,
10117,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623743,,BAO_0000218,,
10118,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623744,,BAO_0000218,,
10119,Intermediate,50597,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),N,1,1,,CHEMBL623745,,BAO_0000218,,
10120,Intermediate,50597,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),N,1,1,,CHEMBL623746,,BAO_0000218,,
10121,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),N,1,1,,CHEMBL623747,,BAO_0000218,,
10122,Intermediate,22224,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,0,1,,CHEMBL623748,,BAO_0000218,,
10123,Intermediate,22224,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,0,1,,CHEMBL623916,,BAO_0000218,,
10124,Intermediate,50597,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,1,1,,CHEMBL623917,,BAO_0000218,,
10125,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg i.v.),N,1,1,,CHEMBL623918,,BAO_0000218,,
10126,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL874386,,BAO_0000218,,
10127,Intermediate,50597,Plasma,,Bioavailability in rat; Only traces detected in rat plasma,N,1,1,,CHEMBL623919,,BAO_0000218,1969.0,
10128,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623920,,BAO_0000218,,
10129,Intermediate,50597,,,Bioavailability upon oral administration of compound,N,1,1,,CHEMBL623148,,BAO_0000218,,
10130,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),N,1,1,,CHEMBL623149,,BAO_0000218,,
10131,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL623150,,BAO_0000218,,
10132,Intermediate,50597,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",N,1,1,,CHEMBL623151,,BAO_0000218,,
10133,Intermediate,50597,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",N,1,1,,CHEMBL623152,,BAO_0000218,,
10134,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,N,1,1,,CHEMBL623153,,BAO_0000218,,
10135,Expert,50597,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,N,1,1,,CHEMBL623154,,BAO_0000218,,
10136,Intermediate,50597,,,In vitro and metabolic stability was determined,N,1,1,,CHEMBL623155,,BAO_0000218,,
10137,Intermediate,50597,,,In vitro metabolic stability in rat hepatocytes,N,1,1,,CHEMBL623156,,BAO_0000218,,
10138,Intermediate,50597,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,N,1,1,,CHEMBL623157,,BAO_0000218,,
10139,Intermediate,50597,Liver,,Metabolic rate for compound was observed in rat hepatocytes,N,1,1,,CHEMBL623158,401.0,BAO_0000218,2107.0,
10140,Intermediate,50597,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,N,1,1,,CHEMBL623159,,BAO_0000218,,
10141,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),N,1,1,,CHEMBL874390,,BAO_0000218,,
10142,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),N,1,1,,CHEMBL623160,,BAO_0000218,,
10143,Intermediate,50597,,,Metabolism of compound in rat S9 microsomes; Trace,N,1,1,,CHEMBL623161,,BAO_0000218,,
10144,Intermediate,50597,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,N,1,1,,CHEMBL623162,,BAO_0000218,,
10145,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,N,1,1,,CHEMBL623163,,BAO_0000218,,
10146,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,N,1,1,,CHEMBL623164,,BAO_0000218,,
10147,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,N,1,1,,CHEMBL623165,,BAO_0000218,,
10148,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,N,1,1,,CHEMBL623166,,BAO_0000218,,
10149,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,N,1,1,,CHEMBL624983,,BAO_0000218,,
10150,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,N,1,1,,CHEMBL624984,,BAO_0000218,,
10151,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,N,1,1,,CHEMBL624985,,BAO_0000218,,
10152,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,N,1,1,,CHEMBL622970,,BAO_0000218,,
10153,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,N,1,1,,CHEMBL622971,,BAO_0000218,,
10154,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,N,1,1,,CHEMBL622972,,BAO_0000218,,
10155,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,N,1,1,,CHEMBL622973,,BAO_0000218,,
10156,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,N,1,1,,CHEMBL622974,,BAO_0000218,,
10157,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,N,1,1,,CHEMBL622975,,BAO_0000218,,
10158,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,N,1,1,,CHEMBL622976,,BAO_0000218,,
10159,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,N,1,1,,CHEMBL622977,,BAO_0000218,,
10160,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,1,1,,CHEMBL624351,,BAO_0000218,,
10161,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,N,1,1,,CHEMBL624352,,BAO_0000218,,
10162,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,1,1,,CHEMBL624353,,BAO_0000218,,
10163,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,N,1,1,,CHEMBL622397,,BAO_0000218,,
10164,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,N,1,1,,CHEMBL622398,,BAO_0000218,,
10165,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,N,1,1,,CHEMBL622399,,BAO_0000218,,
10166,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,1,1,,CHEMBL622400,,BAO_0000218,,
10167,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,1,1,,CHEMBL628428,,BAO_0000218,,
10168,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,N,1,1,,CHEMBL628590,,BAO_0000218,,
10169,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,1,1,,CHEMBL628591,,BAO_0000218,,
10170,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,N,1,1,,CHEMBL628592,,BAO_0000218,,
10171,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,1,1,,CHEMBL628593,,BAO_0000218,,
10172,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,N,1,1,,CHEMBL875333,,BAO_0000218,,
10173,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,1,1,,CHEMBL628594,,BAO_0000218,,
10174,Intermediate,50597,Plasma,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,N,1,1,,CHEMBL628595,,BAO_0000218,1969.0,
10175,Intermediate,50597,Plasma,,Stability in rat plasma was determined,N,1,1,,CHEMBL628596,,BAO_0000218,1969.0,
10176,Intermediate,50597,Plasma,,Stability in rat plasma was determined; ND= no data,N,1,1,,CHEMBL628597,,BAO_0000218,1969.0,
10177,Intermediate,50597,Plasma,,Tested for plasma half life period in rat (0-8 hr),N,1,1,,CHEMBL628598,,BAO_0000218,1969.0,
10178,Intermediate,50597,Plasma,,Tested for plasma half life period in rat (0-8 hr); Not determined,N,1,1,,CHEMBL628599,,BAO_0000218,1969.0,
10179,Intermediate,50597,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,N,1,1,,CHEMBL628600,,BAO_0000218,,
10180,Intermediate,50597,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,N,1,1,,CHEMBL628601,,BAO_0000218,,
10181,Intermediate,50597,,,Tested for the half life in rat,N,1,1,,CHEMBL628602,,BAO_0000218,,
10182,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,N,1,1,,CHEMBL628603,,BAO_0000218,,
10183,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,N,1,1,,CHEMBL628604,,BAO_0000218,,
10184,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,N,1,1,,CHEMBL628605,,BAO_0000218,,
10185,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,N,1,1,,CHEMBL628606,,BAO_0000218,,
10186,Intermediate,50597,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,N,1,1,,CHEMBL628607,,BAO_0000218,,
10187,Intermediate,50597,,,The biological half life the compound was measured at the dose of 100 umol/kg,N,1,1,,CHEMBL628608,,BAO_0000218,,
10188,Intermediate,50597,,,The biological half life the compound was measured at the dose of 30 umol/kg,N,1,1,,CHEMBL628609,,BAO_0000218,,
10189,Intermediate,50597,Plasma,,The compound was evaluated for plasma half life period in rat,N,1,1,,CHEMBL628610,,BAO_0000218,1969.0,
10190,Intermediate,50597,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL873819,,BAO_0000218,,
10191,Intermediate,50597,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL628611,,BAO_0000218,,
10192,Intermediate,50597,,,The pharmacokinetic parameter half-life period in vivo in rats,N,1,1,,CHEMBL628612,,BAO_0000218,,
10193,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined",N,1,1,,CHEMBL628613,,BAO_0000218,,
10194,Intermediate,50597,,,"The pharmacokinetic property, Half-life in rat in vivo",N,1,1,,CHEMBL628614,,BAO_0000218,,
10195,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",N,1,1,,CHEMBL628615,,BAO_0000218,,
10196,Intermediate,50597,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",N,1,1,,CHEMBL628616,,BAO_0000218,,
10197,Intermediate,50597,Plasma,,The plasma half life period in rats,N,1,1,,CHEMBL627924,,BAO_0000218,1969.0,
10198,Intermediate,50597,Liver,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,N,1,1,,CHEMBL627925,,BAO_0000218,2107.0,
10199,Intermediate,50597,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,1,1,,CHEMBL627926,,BAO_0000218,,
10200,Intermediate,50597,,,t1/2 (apparent elimination)of the compound was determined,N,1,1,,CHEMBL627927,,BAO_0000218,,
10201,Intermediate,50597,,,t1/2 value in rat,N,1,1,,CHEMBL627928,,BAO_0000218,,
10202,Intermediate,50597,,,Half life in rat,N,1,1,,CHEMBL627539,,BAO_0000218,,
10203,Intermediate,50597,Plasma,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,1,1,,CHEMBL876790,,BAO_0000218,1969.0,
10204,Intermediate,50597,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,N,1,1,,CHEMBL858186,,BAO_0000218,,
10205,Intermediate,50597,,,Half-life period in fasted rats,N,1,1,,CHEMBL627540,,BAO_0000218,,
10206,Intermediate,50597,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,N,1,1,,CHEMBL627541,,BAO_0000218,,
10207,Intermediate,50597,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,N,1,1,,CHEMBL627715,,BAO_0000218,,
10208,Intermediate,50597,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,1,1,,CHEMBL627716,,BAO_0000218,,
10209,Intermediate,50597,,,Maximum time required to achieve Cmax was determined in rat,N,1,1,,CHEMBL627717,,BAO_0000218,,
10210,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL627718,,BAO_0000218,,
10211,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,1,1,,CHEMBL627719,,BAO_0000218,,
10212,Intermediate,50597,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,N,1,1,,CHEMBL627720,,BAO_0000218,,
10213,Intermediate,50597,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,N,1,1,,CHEMBL627721,,BAO_0000218,,
10214,Intermediate,50597,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,N,1,1,,CHEMBL627722,,BAO_0000218,,
10215,Intermediate,50597,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL627723,,BAO_0000218,,
10216,Intermediate,50597,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL626058,,BAO_0000218,,
10217,Intermediate,50597,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL626059,,BAO_0000218,,
10218,Intermediate,50597,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL626060,,BAO_0000218,,
10219,Intermediate,50597,Plasma,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL626061,,BAO_0000218,1969.0,
10220,Intermediate,50597,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL876791,,BAO_0000218,,
10221,Intermediate,50597,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,1,1,,CHEMBL626062,,BAO_0000218,,
10222,Intermediate,50597,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,N,1,1,,CHEMBL626063,,BAO_0000218,,
10223,Intermediate,50597,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,N,1,1,,CHEMBL626064,,BAO_0000218,,
10224,Intermediate,50597,Plasma,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL626065,,BAO_0000218,1969.0,
10225,Intermediate,50597,Plasma,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,N,1,1,,CHEMBL626066,,BAO_0000218,1969.0,
10226,Intermediate,50597,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,N,1,1,,CHEMBL626067,,BAO_0000218,,
10227,Intermediate,50597,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,N,1,1,,CHEMBL626068,,BAO_0000218,,
10228,Intermediate,50597,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,N,1,1,,CHEMBL626069,,BAO_0000218,,
10229,Intermediate,50597,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,N,1,1,,CHEMBL626070,,BAO_0000218,,
10230,Intermediate,50597,,,Percent total excretion of N-methoxyacetaminophen glucuronide,N,1,1,,CHEMBL626071,,BAO_0000218,,
10231,Intermediate,50597,,,Percent total excretion of N-methoxyacetaminophen sulfate,N,1,1,,CHEMBL626072,,BAO_0000218,,
10232,Intermediate,50597,,,Percent total excretion of acetaminophen,N,1,1,,CHEMBL626073,,BAO_0000218,,
10233,Intermediate,50597,Thyroid gland,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",N,1,1,,CHEMBL626741,,BAO_0000218,2046.0,
10234,Intermediate,50597,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",N,1,1,,CHEMBL626742,,BAO_0000218,,
10235,Intermediate,50597,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,N,1,1,,CHEMBL626743,,BAO_0000218,,
10236,Intermediate,50597,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,1,1,,CHEMBL876792,,BAO_0000218,,
10237,Intermediate,50597,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,1,1,,CHEMBL626744,,BAO_0000218,,
10238,Intermediate,50597,,,Compound was tested for antidiuretic activity in rats,N,1,1,,CHEMBL626745,,BAO_0000218,,
10239,Intermediate,50597,Plasma,,AUC in rat after 3mg/kg oral dose,N,1,1,,CHEMBL626746,,BAO_0000218,1969.0,
10240,Intermediate,50597,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,N,1,1,,CHEMBL626747,,BAO_0000218,,
10241,Intermediate,50597,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,N,1,1,,CHEMBL626748,,BAO_0000218,,
10242,Intermediate,50597,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,N,1,1,,CHEMBL626749,,BAO_0000218,,
10243,Intermediate,50597,,,Oral Bioavailability was determined,N,1,1,,CHEMBL626750,,BAO_0000218,,
10244,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL626751,,BAO_0000218,,
10245,Intermediate,50597,,,Oral bioavailability in rat; Not performed.,N,1,1,,CHEMBL626913,,BAO_0000218,,
10246,Intermediate,50597,,,Bioavailability,N,1,1,,CHEMBL626914,,BAO_0000218,,
10247,Intermediate,50597,,,Bioavailability was determined; ND denotes no data,N,1,1,,CHEMBL626915,,BAO_0000218,,
10248,Intermediate,50597,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,N,1,1,,CHEMBL626916,,BAO_0000218,,
10249,Intermediate,50597,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,N,1,1,,CHEMBL626917,,BAO_0000218,,
10250,Intermediate,50597,,,Binding towards rat plasma protein at 10 uM,N,1,1,,CHEMBL626918,,BAO_0000218,,
10251,Intermediate,50597,,,Binding towards rat plasma protein at 100 uM,N,1,1,,CHEMBL626919,,BAO_0000218,,
10252,Intermediate,50597,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,1,1,,CHEMBL626920,,BAO_0000218,,
10253,Intermediate,50597,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,1,1,,CHEMBL621976,,BAO_0000218,,
10254,Intermediate,50597,,,Bioavailability in rat after 5 mg/kg oral gavage,N,1,1,,CHEMBL877599,,BAO_0000218,,
10255,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL621977,,BAO_0000218,,
10256,Intermediate,50597,,,Bioavailability in rat (dose 1 mg/kg i.v.),N,1,1,,CHEMBL621978,,BAO_0000218,,
10257,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg p.o.),N,1,1,,CHEMBL621979,,BAO_0000218,,
10258,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL621980,,BAO_0000218,,
10259,Intermediate,50597,,,Bioavailability of the compound in rats after administration of 30 mg/kg,N,1,1,,CHEMBL621981,,BAO_0000218,,
10260,Intermediate,50597,,,Bioavailability after administration of 10 mg/kg in rats,N,1,1,,CHEMBL621982,,BAO_0000218,,
10261,Intermediate,50597,,,Bioavailability after administration of 2 mg/kg in rats,N,1,1,,CHEMBL882953,,BAO_0000218,,
10262,Intermediate,50597,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,N,1,1,,CHEMBL621983,,BAO_0000218,,
10263,Intermediate,50597,,,Bioavailability in dogs was determined; high,N,1,1,,CHEMBL621984,,BAO_0000218,,
10264,Intermediate,50597,,,Bioavailability in monkey after intravenous administration at 1 mpk,N,1,1,,CHEMBL621985,,BAO_0000218,,
10265,Intermediate,50597,,,Bioavailability in monkey after peroral administration at 10 mpk,N,1,1,,CHEMBL621986,,BAO_0000218,,
10266,Intermediate,50597,,,Bioavailability in rat after intravenous administration at 1 mpk,N,1,1,,CHEMBL621987,,BAO_0000218,,
10267,Intermediate,50597,,,Bioavailability in rat after intravenous administration at 2 mpk,N,1,1,,CHEMBL877600,,BAO_0000218,,
10268,Intermediate,50597,,,Bioavailability in rat after peroral administration at 30 mpk,N,1,1,,CHEMBL621988,,BAO_0000218,,
10269,Intermediate,50597,,,Bioavailability in rat after peroral administration at at 100 mpk,N,1,1,,CHEMBL621989,,BAO_0000218,,
10270,Intermediate,50597,,,Bioavailability in rats was evaluated,N,1,1,,CHEMBL621990,,BAO_0000218,,
10271,Intermediate,50597,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,N,1,1,,CHEMBL621991,,BAO_0000218,,
10272,Intermediate,50597,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,N,1,1,,CHEMBL621992,,BAO_0000218,,
10273,Intermediate,50597,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,N,1,1,,CHEMBL621993,,BAO_0000218,,
10274,Intermediate,50597,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,N,1,1,,CHEMBL621994,,BAO_0000218,,
10275,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL621995,,BAO_0000218,,
10276,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL621996,,BAO_0000218,,
10277,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),N,1,1,,CHEMBL621997,,BAO_0000218,,
10278,Intermediate,50597,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,1,1,,CHEMBL621998,,BAO_0000218,,
10279,Intermediate,50597,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,N,1,1,,CHEMBL621999,,BAO_0000218,,
10280,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622000,,BAO_0000218,,
10281,Intermediate,50597,,,Bioavailability was measured in rat after oral administration; 2-4,N,1,1,,CHEMBL622001,,BAO_0000218,,
10282,Intermediate,50597,,,Bioavailability was measured in rat after oral administration; 3-7,N,1,1,,CHEMBL622002,,BAO_0000218,,
10283,Intermediate,50597,,,Bioavailability in rat (intraduodenal administration),N,1,1,,CHEMBL622003,,BAO_0000218,,
10284,Intermediate,50597,,,Bioavailability in rat (intraduodenal administration),N,1,1,,CHEMBL877601,,BAO_0000218,,
10285,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL624871,,BAO_0000218,,
10286,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622004,,BAO_0000218,,
10287,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),N,1,1,,CHEMBL882954,,BAO_0000218,,
10288,Intermediate,50597,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,N,1,1,,CHEMBL622005,,BAO_0000218,,
10289,Intermediate,50597,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,N,1,1,,CHEMBL622006,,BAO_0000218,,
10290,Intermediate,50597,,,Bioavailability was measured in rat,N,1,1,,CHEMBL622007,,BAO_0000218,,
10291,Intermediate,50597,,,Bioavailability was reported,N,1,1,,CHEMBL622008,,BAO_0000218,,
10292,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,1,1,,CHEMBL622009,,BAO_0000218,,
10293,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,1,1,,CHEMBL622010,,BAO_0000218,,
10294,Intermediate,50597,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,1,1,,CHEMBL622011,,BAO_0000218,,
10295,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),N,1,1,,CHEMBL622012,,BAO_0000218,,
10296,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),N,1,1,,CHEMBL622013,,BAO_0000218,,
10297,Intermediate,50597,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,1,1,,CHEMBL622014,,BAO_0000218,,
10298,Intermediate,50597,,,Bioavailability was determined at 3 mg/kg po dose in rats,N,1,1,,CHEMBL624749,,BAO_0000218,,
10299,Intermediate,50597,,,Oral bioavailability in rat (dose 2 mg/kg),N,1,1,,CHEMBL624750,,BAO_0000218,,
10300,Intermediate,50597,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",N,1,1,,CHEMBL624751,,BAO_0000218,,
10301,Intermediate,50597,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,1,1,,CHEMBL624752,,BAO_0000218,,
10302,Intermediate,50597,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,1,1,,CHEMBL624753,,BAO_0000218,,
10303,Intermediate,50597,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,N,1,1,,CHEMBL624754,,BAO_0000218,,
10304,Intermediate,50597,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,1,1,,CHEMBL624755,,BAO_0000218,,
10305,Intermediate,50597,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,1,1,,CHEMBL624756,,BAO_0000218,,
10306,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL624757,,BAO_0000218,,
10307,Intermediate,50597,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,1,1,,CHEMBL624758,,BAO_0000218,,
10308,Intermediate,50597,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,1,1,,CHEMBL622270,,BAO_0000218,,
10309,Intermediate,50597,,,Bioavailability in rat (Sprague-Dawley),N,1,1,,CHEMBL622271,,BAO_0000218,,
10310,Intermediate,50597,,,Bioavailability in rat at the dose of 2 mg/kg,N,1,1,,CHEMBL622272,,BAO_0000218,,
10311,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622273,,BAO_0000218,,
10312,Intermediate,50597,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,1,1,,CHEMBL622274,,BAO_0000218,,
10313,Intermediate,50597,,,Bioavailability value of compound in rats was determined after peroral administration,N,1,1,,CHEMBL622275,,BAO_0000218,,
10314,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg),N,1,1,,CHEMBL622276,,BAO_0000218,,
10315,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622277,,BAO_0000218,,
10316,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg),N,1,1,,CHEMBL622278,,BAO_0000218,,
10317,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622279,,BAO_0000218,,
10318,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622280,,BAO_0000218,,
10319,Intermediate,50597,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,N,1,1,,CHEMBL624083,,BAO_0000218,,
10320,Intermediate,50597,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,N,1,1,,CHEMBL624084,,BAO_0000218,,
10321,Intermediate,50597,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),N,1,1,,CHEMBL624085,,BAO_0000218,,
10322,Intermediate,50597,,,Compound was tested for bioavailability in rats,N,1,1,,CHEMBL624086,,BAO_0000218,,
10323,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL624087,,BAO_0000218,,
10324,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL624088,,BAO_0000218,,
10325,Intermediate,22224,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,U,0,1,,CHEMBL624089,,BAO_0000218,,
10326,Intermediate,22224,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),U,0,1,,CHEMBL624090,,BAO_0000218,,
10327,Intermediate,50597,,,Evaluated for the bioavailability in rat (in vivo),N,1,1,,CHEMBL624091,,BAO_0000218,,
10328,Intermediate,50597,,,F value of compound in rats was determined after peroral administration,N,1,1,,CHEMBL624092,,BAO_0000218,,
10329,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624093,,BAO_0000218,,
10330,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624094,,BAO_0000218,,
10331,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624095,,BAO_0000218,,
10332,Intermediate,50597,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,1,1,,CHEMBL624096,,BAO_0000218,,
10333,Intermediate,50597,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",N,1,1,,CHEMBL624097,,BAO_0000218,,
10334,Intermediate,50597,,,Maximum fall in carotid flow in rat,N,1,1,,CHEMBL624098,,BAO_0000218,,
10335,Intermediate,50597,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,N,1,1,,CHEMBL874392,,BAO_0000218,,
10336,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg),N,1,1,,CHEMBL624099,,BAO_0000218,,
10337,Intermediate,50597,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,1,1,,CHEMBL624100,,BAO_0000218,,
10338,Intermediate,50597,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,1,1,,CHEMBL624101,,BAO_0000218,,
10339,Intermediate,50597,,,Oral bioavailability in rat (male Wistar),N,1,1,,CHEMBL624102,,BAO_0000218,,
10340,Intermediate,50597,,,Oral bioavailability after administration (30 mg/kg) in rat; good,N,1,1,,CHEMBL624103,,BAO_0000218,,
10341,Intermediate,50597,,,Oral bioavailability at the dose of 2 mg/kg in rat,N,1,1,,CHEMBL624104,,BAO_0000218,,
10342,Intermediate,50597,,,Oral bioavailability determined in rats,N,1,1,,CHEMBL624105,,BAO_0000218,,
10343,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),N,1,1,,CHEMBL624106,,BAO_0000218,,
10344,Intermediate,50597,,,Oral bioavailability in rat (dose single 10 mg/kg),N,1,1,,CHEMBL624107,,BAO_0000218,,
10345,Intermediate,50597,,,Oral bioavailability in rat (dose single 10 mg/kg),N,1,1,,CHEMBL623943,,BAO_0000218,,
10346,Intermediate,50597,,,Oral bioavailability in rat (dose 5 mg/kg,N,1,1,,CHEMBL623944,,BAO_0000218,,
10347,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,N,1,1,,CHEMBL623945,,BAO_0000218,,
10348,Intermediate,50597,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,N,1,1,,CHEMBL623946,,BAO_0000218,,
10349,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,N,1,1,,CHEMBL623947,,BAO_0000218,,
10350,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,N,1,1,,CHEMBL623948,,BAO_0000218,,
10351,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,N,1,1,,CHEMBL623949,,BAO_0000218,,
10352,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,N,1,1,,CHEMBL623950,,BAO_0000218,,
10353,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,N,1,1,,CHEMBL874398,,BAO_0000218,,
10354,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,N,1,1,,CHEMBL623951,,BAO_0000218,,
10355,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,N,1,1,,CHEMBL623952,,BAO_0000218,,
10356,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,N,1,1,,CHEMBL623953,,BAO_0000218,,
10357,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,N,1,1,,CHEMBL623954,,BAO_0000218,,
10358,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,N,1,1,,CHEMBL623955,,BAO_0000218,,
10359,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,N,1,1,,CHEMBL623956,,BAO_0000218,,
10360,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,N,1,1,,CHEMBL627807,,BAO_0000218,,
10361,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,N,1,1,,CHEMBL627808,,BAO_0000218,,
10362,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,N,1,1,,CHEMBL627809,,BAO_0000218,,
10363,Intermediate,50597,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,N,1,1,,CHEMBL627810,,BAO_0000218,,
10364,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",N,1,1,,CHEMBL627811,,BAO_0000218,,
10365,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",N,1,1,,CHEMBL627812,,BAO_0000218,,
10366,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",N,1,1,,CHEMBL627813,,BAO_0000218,,
10367,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",N,1,1,,CHEMBL627814,,BAO_0000218,,
10368,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",N,1,1,,CHEMBL875336,,BAO_0000218,,
10369,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",N,1,1,,CHEMBL627815,,BAO_0000218,,
10370,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",N,1,1,,CHEMBL627816,,BAO_0000218,,
10371,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",N,1,1,,CHEMBL627817,,BAO_0000218,,
10372,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",N,1,1,,CHEMBL627818,,BAO_0000218,,
10373,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",N,1,1,,CHEMBL627819,,BAO_0000218,,
10374,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",N,1,1,,CHEMBL627820,,BAO_0000218,,
10375,Intermediate,50597,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",N,1,1,,CHEMBL627821,,BAO_0000218,,
10376,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,1,1,,CHEMBL628464,,BAO_0000218,,
10377,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,N,1,1,,CHEMBL626239,,BAO_0000218,,
10378,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,N,1,1,,CHEMBL626240,,BAO_0000218,,
10379,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,N,1,1,,CHEMBL626241,,BAO_0000218,,
10380,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,N,1,1,,CHEMBL626242,,BAO_0000218,,
10381,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,N,1,1,,CHEMBL626243,,BAO_0000218,,
10382,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,1,1,,CHEMBL626244,,BAO_0000218,,
10383,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,N,1,1,,CHEMBL626907,,BAO_0000218,,
10384,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,1,1,,CHEMBL626908,,BAO_0000218,,
10385,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,1,1,,CHEMBL626909,,BAO_0000218,,
10386,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,1,1,,CHEMBL626910,,BAO_0000218,,
10387,Intermediate,50597,,,Percent total excretion of acetaminophen cysteine conjugate,N,1,1,,CHEMBL875342,,BAO_0000218,,
10388,Intermediate,50597,,,Percent total excretion of acetaminophen glucuronide,N,1,1,,CHEMBL626911,,BAO_0000218,,
10389,Intermediate,50597,,,Percent total excretion of acetaminophen sulfate,N,1,1,,CHEMBL626912,,BAO_0000218,,
10390,Intermediate,50597,,,Percent total excretion of acetaminophen-mercapturic acid,N,1,1,,CHEMBL627065,,BAO_0000218,,
10391,Intermediate,50597,Urine,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,N,1,1,,CHEMBL627066,,BAO_0000218,1088.0,
10392,Intermediate,50597,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,1,1,,CHEMBL627067,,BAO_0000218,,
10393,Autocuration,22224,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration,U,0,1,,CHEMBL627068,,BAO_0000218,2385.0,
10394,Autocuration,22224,Muscle tissue,,Biodistribution of compound in rat muscle after 5 min of administration.,U,0,1,,CHEMBL627069,,BAO_0000218,2385.0,
10395,Autocuration,22224,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL627070,,BAO_0000218,,
10396,Autocuration,22224,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL627071,,BAO_0000218,,
10397,Autocuration,22224,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL627072,,BAO_0000218,,
10398,Autocuration,22224,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL627073,,BAO_0000218,,
10399,Autocuration,22224,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL625387,,BAO_0000218,,
10400,Autocuration,22224,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL625388,,BAO_0000218,,
10401,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL625389,,BAO_0000218,1969.0,
10402,Autocuration,22224,Plasma,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,0,1,,CHEMBL875343,,BAO_0000218,1969.0,
10403,Intermediate,50497,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),N,1,1,,CHEMBL876795,,BAO_0000218,,
10404,Intermediate,50497,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,N,1,1,,CHEMBL626552,,BAO_0000218,,
10405,Intermediate,50497,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,N,1,1,,CHEMBL626553,,BAO_0000218,,
10406,Autocuration,22224,Plasma,,The human biological plasma half life of the compound,U,0,1,,CHEMBL626554,,BAO_0000366,1969.0,
10407,Intermediate,50597,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,1,1,,CHEMBL626555,,BAO_0000218,1088.0,
10408,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,N,1,1,,CHEMBL626556,,BAO_0000218,,
10409,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,N,1,1,,CHEMBL626557,,BAO_0000218,,
10410,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,N,1,1,,CHEMBL626558,,BAO_0000218,,
10411,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,N,1,1,,CHEMBL626559,,BAO_0000218,,
10412,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,N,1,1,,CHEMBL626560,,BAO_0000218,,
10413,Intermediate,50597,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,N,1,1,,CHEMBL876803,,BAO_0000218,,
10414,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,N,1,1,,CHEMBL627964,,BAO_0000218,,
10415,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,N,1,1,,CHEMBL627965,,BAO_0000218,,
10416,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,N,1,1,,CHEMBL627966,,BAO_0000218,,
10417,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,N,1,1,,CHEMBL627967,,BAO_0000218,,
10418,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,N,1,1,,CHEMBL627968,,BAO_0000218,,
10419,Intermediate,50597,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,N,1,1,,CHEMBL627969,,BAO_0000218,,
10420,Intermediate,50597,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,N,1,1,,CHEMBL627970,,BAO_0000218,,
10421,Intermediate,50597,Blood,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,N,1,1,,CHEMBL627971,,BAO_0000218,178.0,
10422,Intermediate,50597,Blood,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,N,1,1,,CHEMBL627972,,BAO_0000218,178.0,
10423,Expert,180,,,Dissociation constant against binding to human cyclophilin A,D,9,1,,CHEMBL856029,,BAO_0000357,,
10424,Expert,11591,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,H,8,1,,CHEMBL627973,,BAO_0000019,,
10425,Autocuration,22224,,,-Log C was determined by performing the electroshock minimum test,U,0,1,,CHEMBL627974,,BAO_0000019,,
10426,Autocuration,22224,,,-Log C was determined by performing the foot shock test,U,0,1,,CHEMBL627975,,BAO_0000019,,
10427,Autocuration,22224,,,-Log C was determined by performing the incl screen test,U,0,1,,CHEMBL627976,,BAO_0000019,,
10428,Autocuration,22224,,,-Log C was determined by performing the maximum electroshock test,U,0,1,,CHEMBL627977,,BAO_0000019,,
10429,Autocuration,22224,,,-Log C was determined by performing the pentylenetetrazole test,U,0,1,,CHEMBL627978,,BAO_0000019,,
10430,Autocuration,22224,,,Tested for experimental arotinoid inhibitory dose,U,0,1,,CHEMBL627979,,BAO_0000019,,
10431,Autocuration,22224,,,Negative log transformed activity,U,0,1,,CHEMBL876804,,BAO_0000019,,
10432,Autocuration,22224,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",U,0,1,,CHEMBL627980,,BAO_0000019,,
10433,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,N,1,1,,CHEMBL627981,,BAO_0000218,,
10434,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,N,1,1,,CHEMBL627982,,BAO_0000218,,
10435,Intermediate,50512,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,N,1,1,,CHEMBL627983,,BAO_0000218,,
10436,Intermediate,50512,Ileum,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,N,1,1,,CHEMBL627984,,BAO_0000218,2116.0,
10437,Autocuration,22229,,,Solubility in water was determined; values expressed as -log,U,0,1,,CHEMBL627985,,BAO_0000100,,
10438,Autocuration,22224,,,Ratio of Kcat to that of Km was determined,U,0,1,,CHEMBL627986,,BAO_0000019,,
10439,Autocuration,22224,,,Observed first order rate constant,U,0,1,,CHEMBL627987,,BAO_0000019,,
10440,Autocuration,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,U,0,1,,CHEMBL627988,,BAO_0000019,,
10441,Intermediate,50597,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,N,1,1,,CHEMBL627989,,BAO_0000218,,
10442,Intermediate,50597,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,N,1,1,,CHEMBL627990,,BAO_0000218,,
10443,Intermediate,50597,,,Oral Bioavailability after administration of 10 mg/kg in male rat,N,1,1,,CHEMBL876805,,BAO_0000218,,
10444,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),N,1,1,,CHEMBL627991,,BAO_0000218,,
10445,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL627992,,BAO_0000218,,
10446,Intermediate,50597,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,1,1,,CHEMBL627993,,BAO_0000218,,
10447,Intermediate,50597,,,Oral bioavailability at 1 mg/kg was determined in rat,N,1,1,,CHEMBL622817,,BAO_0000218,,
10448,Intermediate,50597,,,Oral bioavailability at 10 mg/kg was determined in rat,N,1,1,,CHEMBL622818,,BAO_0000218,,
10449,Intermediate,50597,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",N,1,1,,CHEMBL622819,,BAO_0000218,,
10450,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL872267,,BAO_0000218,,
10451,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622820,,BAO_0000218,,
10452,Intermediate,50597,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,N,1,1,,CHEMBL622821,,BAO_0000218,,
10453,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622822,,BAO_0000218,,
10454,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622823,,BAO_0000218,,
10455,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622824,,BAO_0000218,,
10456,Intermediate,50597,,,Oral bioavailability in rat at a dose of 3 mg/kg,N,1,1,,CHEMBL622825,,BAO_0000218,,
10457,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 10 mg/kg,N,1,1,,CHEMBL622901,,BAO_0000218,,
10458,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622902,,BAO_0000218,,
10459,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL621844,,BAO_0000218,,
10460,Intermediate,50597,,,Oral bioavailability in Dawley rats,N,1,1,,CHEMBL621845,,BAO_0000218,,
10461,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL621846,,BAO_0000218,,
10462,Intermediate,50597,,,Oral bioavailability in rat (dose 30 mg/kg),N,1,1,,CHEMBL621847,,BAO_0000218,,
10463,Intermediate,50597,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,1,1,,CHEMBL877609,,BAO_0000218,,
10464,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,1,1,,CHEMBL621848,,BAO_0000218,,
10465,Intermediate,50597,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,1,1,,CHEMBL621849,,BAO_0000218,,
10466,Intermediate,50597,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,1,1,,CHEMBL622030,,BAO_0000218,,
10467,Intermediate,50597,,,Percent oral bioavailability determined in rats,N,1,1,,CHEMBL622031,,BAO_0000218,,
10468,Intermediate,50597,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,1,1,,CHEMBL622032,,BAO_0000218,,
10469,Intermediate,50597,,,The compound was evaluated for bioavailability in rats; 32-51,N,1,1,,CHEMBL622033,,BAO_0000218,,
10470,Intermediate,50597,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,1,1,,CHEMBL622034,,BAO_0000218,,
10471,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622035,,BAO_0000218,,
10472,Intermediate,50597,,,Bioavailability percent in rat at the dose of 2 mg/kg,N,1,1,,CHEMBL882966,,BAO_0000218,,
10473,Intermediate,50597,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,N,1,1,,CHEMBL622036,,BAO_0000218,,
10474,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622037,,BAO_0000218,,
10475,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622038,,BAO_0000218,,
10476,Intermediate,50597,,,Bioavailability in rats,N,1,1,,CHEMBL622039,,BAO_0000218,,
10477,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,N,1,1,,CHEMBL622040,,BAO_0000218,178.0,
10478,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622041,,BAO_0000218,178.0,
10479,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622042,,BAO_0000218,178.0,
10480,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622043,,BAO_0000218,178.0,
10481,Intermediate,50597,Blood,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622044,,BAO_0000218,178.0,
10482,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622045,,BAO_0000218,10000001.0,
10483,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622046,,BAO_0000218,10000001.0,
10484,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622047,,BAO_0000218,10000001.0,
10485,Intermediate,50597,Bone,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL877610,,BAO_0000218,10000001.0,
10486,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622048,,BAO_0000218,955.0,
10487,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622049,,BAO_0000218,955.0,
10488,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622050,,BAO_0000218,955.0,
10489,Intermediate,50597,Brain,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622051,,BAO_0000218,955.0,
10490,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622052,,BAO_0000218,,
10491,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622053,,BAO_0000218,,
10492,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622054,,BAO_0000218,,
10493,Intermediate,50597,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622055,,BAO_0000218,,
10494,Intermediate,50597,,,Oral bioavailability in rats was determined; High,N,1,1,,CHEMBL622056,,BAO_0000218,,
10495,Intermediate,50597,,,Oral bioavailability in the rat was determined,N,1,1,,CHEMBL622057,,BAO_0000218,,
10496,Intermediate,50597,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,N,1,1,,CHEMBL628008,,BAO_0000218,,
10497,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),N,1,1,,CHEMBL622058,,BAO_0000218,,
10498,Intermediate,50597,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL622059,,BAO_0000218,,
10499,Intermediate,50597,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL622060,,BAO_0000218,,
10500,Intermediate,50597,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL622061,,BAO_0000218,,
10501,Intermediate,50597,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,1,1,,CHEMBL622062,,BAO_0000218,,
10502,Intermediate,50597,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,N,1,1,,CHEMBL622063,,BAO_0000218,,
10503,Expert,50597,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,N,1,1,,CHEMBL877611,,BAO_0000218,,
10504,Intermediate,50597,,,Oral bioavailability of compound in Sprague Dawley rats,N,1,1,,CHEMBL622064,,BAO_0000218,,
10505,Intermediate,50597,,,Oral bioavailability of compound in rat,N,1,1,,CHEMBL622065,,BAO_0000218,,
10506,Intermediate,50597,,,Oral bioavailability in rat (dose 2 mg/kg),N,1,1,,CHEMBL622066,,BAO_0000218,,
10507,Intermediate,50597,,,Oral bioavailability of compound in rat was determined,N,1,1,,CHEMBL622067,,BAO_0000218,,
10508,Intermediate,50597,,,Oral bioavailability of compound in rats,N,1,1,,CHEMBL622068,,BAO_0000218,,
10509,Intermediate,50597,,,Oral bioavailability of compound was determined in rats,N,1,1,,CHEMBL622069,,BAO_0000218,,
10510,Intermediate,50597,,,Oral bioavailability at a dose of 30 mg/kg in rats,N,1,1,,CHEMBL624796,,BAO_0000218,,
10511,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),N,1,1,,CHEMBL624797,,BAO_0000218,,
10512,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg),N,1,1,,CHEMBL623053,,BAO_0000218,,
10513,Intermediate,50597,,,Oral bioavailability evaluated in rat,N,1,1,,CHEMBL623054,,BAO_0000218,,
10514,Intermediate,50597,,,Oral bioavailability in fasted rat,N,1,1,,CHEMBL623055,,BAO_0000218,,
10515,Intermediate,50597,,,Oral bioavailability in fed rat,N,1,1,,CHEMBL623056,,BAO_0000218,,
10516,Intermediate,50597,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),N,1,1,,CHEMBL623057,,BAO_0000218,,
10517,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623058,,BAO_0000218,,
10518,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,1,1,,CHEMBL623059,,BAO_0000218,,
10519,Intermediate,50597,,,Oral bioavailability in rat after administration of 10 mg/kg po,N,1,1,,CHEMBL623060,,BAO_0000218,,
10520,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623061,,BAO_0000218,,
10521,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623062,,BAO_0000218,,
10522,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623063,,BAO_0000218,,
10523,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623064,,BAO_0000218,,
10524,Intermediate,50597,,,Oral bioavailability in ratrs,N,1,1,,CHEMBL623065,,BAO_0000218,,
10525,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623066,,BAO_0000218,,
10526,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623067,,BAO_0000218,,
10527,Intermediate,50597,,,Oral bioavailability in rats was determined; High,N,1,1,,CHEMBL623068,,BAO_0000218,,
10528,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623069,,BAO_0000218,,
10529,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623070,,BAO_0000218,,
10530,Intermediate,50597,,,Oral bioavailability was calculated in rat,N,1,1,,CHEMBL623071,,BAO_0000218,,
10531,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL623072,,BAO_0000218,,
10532,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL623073,,BAO_0000218,,
10533,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL623074,,BAO_0000218,,
10534,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL623075,,BAO_0000218,,
10535,Intermediate,50597,,,Oral bioavailability after i.v. administration,N,1,1,,CHEMBL623076,,BAO_0000218,,
10536,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,1,1,,CHEMBL623077,,BAO_0000218,,
10537,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley),N,1,1,,CHEMBL623078,,BAO_0000218,,
10538,Intermediate,50597,,,Oral bioavailability in Sprague-Dawley rats,N,1,1,,CHEMBL623079,,BAO_0000218,,
10539,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,1,1,,CHEMBL623080,,BAO_0000218,,
10540,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,1,1,,CHEMBL623081,,BAO_0000218,,
10541,Intermediate,50597,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,N,1,1,,CHEMBL623082,,BAO_0000218,,
10542,Intermediate,50597,,,Oral bioavailability in fasted rat,N,1,1,,CHEMBL874400,,BAO_0000218,,
10543,Intermediate,50597,,,Oral bioavailability in fed rat,N,1,1,,CHEMBL623083,,BAO_0000218,,
10544,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623084,,BAO_0000218,,
10545,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623085,,BAO_0000218,,
10546,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623086,,BAO_0000218,,
10547,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623087,,BAO_0000218,,
10548,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623088,,BAO_0000218,,
10549,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623089,,BAO_0000218,,
10550,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623090,,BAO_0000218,,
10551,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623091,,BAO_0000218,,
10552,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623092,,BAO_0000218,,
10553,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623093,,BAO_0000218,,
10554,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL874401,,BAO_0000218,,
10555,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623094,,BAO_0000218,,
10556,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL623095,,BAO_0000218,,
10557,Intermediate,50597,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,N,1,1,,CHEMBL623096,,BAO_0000218,,
10558,Intermediate,50597,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,N,1,1,,CHEMBL624913,,BAO_0000218,,
10559,Intermediate,50597,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),N,1,1,,CHEMBL624914,,BAO_0000218,,
10560,Intermediate,50597,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,N,1,1,,CHEMBL624915,,BAO_0000218,,
10561,Intermediate,50597,,,Oral bioavailability in rat; Not measured,N,1,1,,CHEMBL624916,,BAO_0000218,,
10562,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL624917,,BAO_0000218,,
10563,Intermediate,50597,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,N,1,1,,CHEMBL625157,,BAO_0000218,,
10564,Intermediate,50597,Liver,,In vitro metabolic potential in rat liver microsomes,N,1,1,,CHEMBL625158,,BAO_0000218,2107.0,
10565,Intermediate,50597,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",N,1,1,,CHEMBL625159,,BAO_0000218,,
10566,Intermediate,50597,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",N,1,1,,CHEMBL625160,,BAO_0000218,,
10567,Intermediate,50597,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,N,1,1,,CHEMBL625161,,BAO_0000218,,
10568,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL625162,,BAO_0000218,,
10569,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL625163,,BAO_0000218,,
10570,Intermediate,50597,,,Oral bioavailability in rats at 10 mg/kg,N,1,1,,CHEMBL625164,,BAO_0000218,,
10571,Intermediate,50597,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,1,1,,CHEMBL625165,,BAO_0000218,,
10572,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL625166,,BAO_0000218,,
10573,Intermediate,50597,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,N,1,1,,CHEMBL625167,,BAO_0000218,,
10574,Intermediate,50597,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,N,1,1,,CHEMBL625168,,BAO_0000218,,
10575,Intermediate,50597,,,Plasma clearance of the compound,N,1,1,,CHEMBL625169,,BAO_0000218,,
10576,Intermediate,50597,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,N,1,1,,CHEMBL626264,,BAO_0000218,,
10577,Intermediate,50597,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,N,1,1,,CHEMBL626265,,BAO_0000218,,
10578,Intermediate,50597,Plasma,,The compound was tested for plasma clearance in rat,N,1,1,,CHEMBL626266,,BAO_0000218,1969.0,
10579,Intermediate,50597,Plasma,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,N,1,1,,CHEMBL626267,,BAO_0000218,1969.0,
10580,Intermediate,50597,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,N,1,1,,CHEMBL626268,,BAO_0000218,,
10581,Intermediate,50597,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,N,1,1,,CHEMBL626269,,BAO_0000218,,
10582,Intermediate,50597,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,N,1,1,,CHEMBL626270,,BAO_0000218,,
10583,Intermediate,50597,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,N,1,1,,CHEMBL626271,,BAO_0000218,,
10584,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",N,1,1,,CHEMBL626272,,BAO_0000218,,
10585,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,1,1,,CHEMBL626273,,BAO_0000218,,
10586,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,1,1,,CHEMBL875346,,BAO_0000218,,
10587,Intermediate,50597,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",N,1,1,,CHEMBL626274,,BAO_0000218,,
10588,Intermediate,50597,,,Compound was tested for protein binding in rat plasma,N,1,1,,CHEMBL626275,,BAO_0000218,,
10589,Intermediate,50597,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,N,1,1,,CHEMBL624646,,BAO_0000218,,
10590,Intermediate,50597,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,N,1,1,,CHEMBL624647,,BAO_0000218,,
10591,Intermediate,50597,Liver,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,N,1,1,,CHEMBL624648,,BAO_0000218,2107.0,
10592,Intermediate,50597,,,Area under curve ratio was determined (po/iv) in rat,N,1,1,,CHEMBL624649,,BAO_0000218,,
10593,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,N,1,1,,CHEMBL624650,,BAO_0000218,,
10594,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,N,1,1,,CHEMBL624651,,BAO_0000218,,
10595,Intermediate,50597,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,N,1,1,,CHEMBL624652,,BAO_0000218,,
10596,Intermediate,50597,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,N,1,1,,CHEMBL624653,,BAO_0000218,,
10597,Intermediate,50597,,,Ratio of AUCbrain to AUCplasma,N,1,1,,CHEMBL624654,,BAO_0000218,,
10598,Intermediate,50597,,,Ratio of brain to plasma,N,1,1,,CHEMBL624655,,BAO_0000218,,
10599,Intermediate,50597,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,N,1,1,,CHEMBL624656,,BAO_0000218,,
10600,Intermediate,50597,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,1,1,,CHEMBL624657,,BAO_0000218,,
10601,Intermediate,50597,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,1,1,,CHEMBL624658,,BAO_0000218,,
10602,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,N,1,1,,CHEMBL624659,,BAO_0000218,,
10603,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,N,1,1,,CHEMBL624660,,BAO_0000218,,
10604,Intermediate,50597,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,N,1,1,,CHEMBL624661,,BAO_0000218,,
10605,Intermediate,50597,,,Steady state brain :blood ratio was determined,N,1,1,,CHEMBL624662,,BAO_0000218,,
10606,Intermediate,50597,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL625199,,BAO_0000218,,
10607,Intermediate,50597,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,1,1,,CHEMBL625200,,BAO_0000218,,
10608,Intermediate,50597,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,1,1,,CHEMBL625201,,BAO_0000218,,
10609,Intermediate,50597,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,1,1,,CHEMBL625202,,BAO_0000218,,
10610,Intermediate,50597,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,N,1,1,,CHEMBL625203,,BAO_0000218,,
10611,Intermediate,50597,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,N,1,1,,CHEMBL625204,,BAO_0000218,,
10612,Intermediate,50597,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,N,1,1,,CHEMBL625205,,BAO_0000218,,
10613,Intermediate,50597,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,N,1,1,,CHEMBL625206,,BAO_0000218,,
10614,Autocuration,22224,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",U,0,1,,CHEMBL625207,,BAO_0000019,,
10615,Autocuration,22224,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,U,0,1,,CHEMBL625208,,BAO_0000019,,
10616,Intermediate,50587,,,In vivo absorption in Caco-2 cell line monolayers was determined,N,1,1,,CHEMBL625209,495.0,BAO_0000218,,
10617,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625210,,BAO_0000100,,
10618,Intermediate,50597,,,Area under curve was determine after peroral administration at 10 mpk in Rat,N,1,1,,CHEMBL625211,,BAO_0000218,,
10619,Intermediate,50797,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,N,1,1,,CHEMBL625212,,BAO_0000218,,
10620,Intermediate,50597,,,Area under curve was determine after peroral administration at 160 mpk in Rat,N,1,1,,CHEMBL625213,,BAO_0000218,,
10621,Intermediate,50597,,,Area under curve was determine after peroral administration at 20 mpk in Rat,N,1,1,,CHEMBL625214,,BAO_0000218,,
10622,Intermediate,50597,,,Area under curve was determine after peroral administration at 50 mpk in Rat,N,1,1,,CHEMBL874542,,BAO_0000218,,
10623,Autocuration,22229,,,Calculated partition coefficient (clogP) (AlogP),U,0,1,,CHEMBL625215,,BAO_0000100,,
10624,Autocuration,22224,,,Activated partial thromboplastin time measured,U,0,1,,CHEMBL625216,,BAO_0000019,,
10625,Autocuration,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),U,0,1,,CHEMBL625217,,BAO_0000100,,
10626,Autocuration,22224,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),U,0,1,,CHEMBL625218,,BAO_0000100,,
10627,Intermediate,50588,Plasma,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,N,1,1,,CHEMBL622864,,BAO_0000218,1969.0,
10628,Intermediate,50597,Plasma,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,N,1,1,,CHEMBL622865,,BAO_0000218,1969.0,
10629,Intermediate,50597,Plasma,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,N,1,1,,CHEMBL622866,,BAO_0000218,1969.0,
10630,Intermediate,50588,Plasma,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,N,1,1,,CHEMBL622867,,BAO_0000218,1969.0,
10631,Intermediate,50512,Plasma,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,N,1,1,,CHEMBL876808,,BAO_0000218,1969.0,
10632,Autocuration,22224,Brain,,AUC in brain,U,0,1,,CHEMBL627725,,BAO_0000019,955.0,
10633,Autocuration,22224,Serum,,AUC in serum,U,0,1,,CHEMBL627726,,BAO_0000019,1977.0,
10634,Autocuration,22224,Plasma,,AUC was determined,U,0,1,,CHEMBL627727,,BAO_0000019,1969.0,
10635,Autocuration,22224,Plasma,,AUC of the compound.,U,0,1,,CHEMBL627728,,BAO_0000019,1969.0,
10636,Autocuration,22224,Plasma,,AUC value (0-4 hr),U,0,1,,CHEMBL627729,,BAO_0000019,1969.0,
10637,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",U,0,1,,CHEMBL627730,,BAO_0000019,1969.0,
10638,Autocuration,22224,Plasma,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,U,0,1,,CHEMBL627731,,BAO_0000019,1969.0,
10639,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",U,0,1,,CHEMBL627732,,BAO_0000019,1969.0,
10640,Autocuration,22224,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",U,0,1,,CHEMBL627733,,BAO_0000019,1969.0,
10641,Intermediate,50597,Plasma,,AUC(area under curve) was determined after intravenous administration in rats,N,1,1,,CHEMBL627734,,BAO_0000218,1969.0,
10642,Intermediate,50597,Plasma,,AUC(area under curve) was determined after oral administration in rats,N,1,1,,CHEMBL627735,,BAO_0000218,1969.0,
10643,Intermediate,50512,Plasma,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,N,1,1,,CHEMBL627736,,BAO_0000218,1969.0,
10644,Intermediate,50597,Plasma,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,N,1,1,,CHEMBL876809,,BAO_0000218,1969.0,
10645,Autocuration,22224,,,Area Under Curve after oral dosing of 100 uM/Kg,U,0,1,,CHEMBL627737,,BAO_0000019,,
10646,Autocuration,22224,,,Area Under Curve after oral dosing of 30 uM/Kg,U,0,1,,CHEMBL627738,,BAO_0000019,,
10647,Autocuration,22224,,,Area Under Curve was measured by ploting the graph between concentration verses time,U,0,1,,CHEMBL627739,,BAO_0000019,,
10648,Intermediate,50588,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,N,1,1,,CHEMBL626143,,BAO_0000218,,
10649,Autocuration,22224,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,U,0,1,,CHEMBL626144,,BAO_0000218,,
10650,Intermediate,50592,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,N,1,1,,CHEMBL626145,,BAO_0000218,,
10651,Intermediate,50597,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,N,1,1,,CHEMBL626146,,BAO_0000218,,
10652,Intermediate,50597,Blood,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,N,1,1,,CHEMBL626147,,BAO_0000218,178.0,
10653,Autocuration,22224,,,Area under curve (AUC) was determined,U,0,1,,CHEMBL626148,,BAO_0000019,,
10654,Autocuration,22224,,,Area under curve (AUC) following ip administration at 1 mg/kg,U,0,1,,CHEMBL626149,,BAO_0000218,,
10655,Autocuration,22224,,,Area under curve (AUC) was determined; ND is Not determined,U,0,1,,CHEMBL626150,,BAO_0000019,,
10656,Intermediate,50588,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,N,1,1,,CHEMBL626151,,BAO_0000218,,
10657,Intermediate,50588,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,N,1,1,,CHEMBL626152,,BAO_0000218,,
10658,Intermediate,50588,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,N,1,1,,CHEMBL626153,,BAO_0000218,,
10659,Autocuration,22224,,,Area under curve (AUR) was determined,U,0,1,,CHEMBL626154,,BAO_0000019,,
10660,Autocuration,22224,,,Area under curve at 1 uM/dg administered intravenously,U,0,1,,CHEMBL626155,,BAO_0000019,,
10661,Autocuration,22224,,,Area under curve at 10 uM/dg administered perorally,U,0,1,,CHEMBL626156,,BAO_0000019,,
10662,Autocuration,22224,,,Area under curve at 2 uM/dg administered intravenously,U,0,1,,CHEMBL626157,,BAO_0000019,,
10663,Autocuration,22224,,,Area under curve at 20 uM/dg administered perorally,U,0,1,,CHEMBL626158,,BAO_0000019,,
10664,Intermediate,50588,,,Area under curve at a peroral dose of 3 mg/kg in dog,N,1,1,,CHEMBL626159,,BAO_0000218,,
10665,Intermediate,50597,,,Area under curve at a peroral dose of 3 mg/kg in rat,N,1,1,,CHEMBL626160,,BAO_0000218,,
10666,Intermediate,50588,,,Area under curve at an iv dose of 1 mg/kg in dog,N,1,1,,CHEMBL626161,,BAO_0000218,,
10667,Intermediate,50597,,,Area under curve at an iv dose of 1 mg/kg in rat,N,1,1,,CHEMBL626162,,BAO_0000218,,
10668,Autocuration,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,U,0,1,,CHEMBL626163,,BAO_0000019,,
10669,Autocuration,22224,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,U,0,1,,CHEMBL626164,,BAO_0000019,,
10670,Intermediate,50594,,,Area under curve measured as conc vs time after intravenous administration to mice.,N,1,1,,CHEMBL626165,,BAO_0000218,,
10671,Intermediate,50594,,,Area under curve measured as conc vs time after peroral administration to mice.,N,1,1,,CHEMBL626166,,BAO_0000218,,
10672,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,1,1,,CHEMBL626167,,BAO_0000218,,
10673,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,N,1,1,,CHEMBL626168,,BAO_0000218,,
10674,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,N,1,1,,CHEMBL877463,,BAO_0000218,,
10675,Intermediate,50588,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,N,1,1,,CHEMBL626169,,BAO_0000218,,
10676,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL626170,,BAO_0000218,948.0,
10677,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL626171,,BAO_0000218,948.0,
10678,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL626172,,BAO_0000218,948.0,
10679,Intermediate,50597,Heart,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL626173,,BAO_0000218,948.0,
10680,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,N,1,1,,CHEMBL626174,,BAO_0000218,2113.0,
10681,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL626175,,BAO_0000218,2113.0,
10682,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL626176,,BAO_0000218,2113.0,
10683,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL626177,,BAO_0000218,2113.0,
10684,Intermediate,50597,Kidney,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622499,,BAO_0000218,2113.0,
10685,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,N,1,1,,CHEMBL622500,,BAO_0000218,2107.0,
10686,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622501,,BAO_0000218,2107.0,
10687,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL622502,,BAO_0000218,2107.0,
10688,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL622503,,BAO_0000218,2107.0,
10689,Intermediate,50597,Liver,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL877614,,BAO_0000218,2107.0,
10690,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL624839,,BAO_0000218,2048.0,
10691,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL624840,,BAO_0000218,2048.0,
10692,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL624841,,BAO_0000218,2048.0,
10693,Intermediate,50597,Lung,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL624842,,BAO_0000218,2048.0,
10694,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL624843,,BAO_0000218,2385.0,
10695,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,N,1,1,,CHEMBL624844,,BAO_0000218,2385.0,
10696,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,N,1,1,,CHEMBL624845,,BAO_0000218,2385.0,
10697,Intermediate,50597,Muscle tissue,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,N,1,1,,CHEMBL621904,,BAO_0000218,2385.0,
10698,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,N,1,1,,CHEMBL621905,,BAO_0000218,178.0,
10699,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,N,1,1,,CHEMBL874382,,BAO_0000218,178.0,
10700,Intermediate,50597,Blood,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,N,1,1,,CHEMBL621906,,BAO_0000218,178.0,
10701,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,N,1,1,,CHEMBL621907,,BAO_0000218,955.0,
10702,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,N,1,1,,CHEMBL622096,,BAO_0000218,955.0,
10703,Intermediate,50597,Brain,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,N,1,1,,CHEMBL622097,,BAO_0000218,955.0,
10704,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,N,1,1,,CHEMBL622098,,BAO_0000218,948.0,
10705,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,N,1,1,,CHEMBL622099,,BAO_0000218,948.0,
10706,Intermediate,50597,Heart,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,N,1,1,,CHEMBL622100,,BAO_0000218,948.0,
10707,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,N,1,1,,CHEMBL622101,,BAO_0000218,2113.0,
10708,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,N,1,1,,CHEMBL622102,,BAO_0000218,2113.0,
10709,Intermediate,50597,Kidney,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,N,1,1,,CHEMBL622103,,BAO_0000218,2113.0,
10710,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,N,1,1,,CHEMBL622104,,BAO_0000218,2107.0,
10711,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,N,1,1,,CHEMBL622105,,BAO_0000218,2107.0,
10712,Intermediate,50597,Liver,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,N,1,1,,CHEMBL622106,,BAO_0000218,2107.0,
10713,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,N,1,1,,CHEMBL622107,,BAO_0000218,2048.0,
10714,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,N,1,1,,CHEMBL622108,,BAO_0000218,2048.0,
10715,Intermediate,50597,Lung,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,N,1,1,,CHEMBL622109,,BAO_0000218,2048.0,
10716,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,N,1,1,,CHEMBL622110,,BAO_0000218,2385.0,
10717,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,N,1,1,,CHEMBL622111,,BAO_0000218,2385.0,
10718,Intermediate,50597,Muscle tissue,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,N,1,1,,CHEMBL874383,,BAO_0000218,2385.0,
10719,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,N,1,1,,CHEMBL622112,,BAO_0000218,14.0,
10720,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,N,1,1,,CHEMBL622113,,BAO_0000218,14.0,
10721,Intermediate,50597,Zone of skin,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,N,1,1,,CHEMBL622114,,BAO_0000218,14.0,
10722,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,N,1,1,,CHEMBL622115,,BAO_0000218,2106.0,
10723,Intermediate,50597,Spleen,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,N,1,1,,CHEMBL622116,,BAO_0000218,2106.0,
10724,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622117,,BAO_0000218,,
10725,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622118,,BAO_0000218,,
10726,Intermediate,50597,,,Oral bioavailability in rats at 6 mg/kg,N,1,1,,CHEMBL622119,,BAO_0000218,,
10727,Intermediate,50597,,,Oral bioavailability in rat (dose 6 mg/kg),N,1,1,,CHEMBL622120,,BAO_0000218,,
10728,Intermediate,50597,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,N,1,1,,CHEMBL622121,,BAO_0000218,,
10729,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622122,,BAO_0000218,,
10730,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622123,,BAO_0000218,,
10731,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL622124,,BAO_0000218,,
10732,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL622125,,BAO_0000218,,
10733,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL622126,,BAO_0000218,,
10734,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,1,1,,CHEMBL620455,,BAO_0000218,,
10735,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620456,,BAO_0000218,,
10736,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620457,,BAO_0000218,,
10737,Intermediate,50597,,,Oral bioavailability was evaluated; Not tested,N,1,1,,CHEMBL620458,,BAO_0000218,,
10738,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL620459,,BAO_0000218,,
10739,Intermediate,50597,,,Oral bioavailability in rat by oral dosing,N,1,1,,CHEMBL620460,,BAO_0000218,,
10740,Intermediate,50597,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,1,1,,CHEMBL620461,,BAO_0000218,,
10741,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley),N,1,1,,CHEMBL620462,,BAO_0000218,,
10742,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,1,1,,CHEMBL620463,,BAO_0000218,,
10743,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,1,1,,CHEMBL620464,,BAO_0000218,,
10744,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,1,1,,CHEMBL620465,,BAO_0000218,,
10745,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),N,1,1,,CHEMBL620466,,BAO_0000218,,
10746,Intermediate,50597,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,N,1,1,,CHEMBL620467,,BAO_0000218,,
10747,Intermediate,50597,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,N,1,1,,CHEMBL620468,,BAO_0000218,,
10748,Intermediate,50597,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,N,1,1,,CHEMBL620469,,BAO_0000218,,
10749,Intermediate,50597,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,N,1,1,,CHEMBL620470,,BAO_0000218,,
10750,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620471,,BAO_0000218,,
10751,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620472,,BAO_0000218,,
10752,Intermediate,50597,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,N,1,1,,CHEMBL620473,,BAO_0000218,,
10753,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620474,,BAO_0000218,,
10754,Intermediate,50597,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),N,1,1,,CHEMBL620475,,BAO_0000218,,
10755,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620476,,BAO_0000218,,
10756,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL620477,,BAO_0000218,,
10757,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,N,1,1,,CHEMBL620478,,BAO_0000218,,
10758,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,N,1,1,,CHEMBL618768,,BAO_0000218,,
10759,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,N,1,1,,CHEMBL618769,,BAO_0000218,,
10760,Intermediate,50597,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,N,1,1,,CHEMBL618770,,BAO_0000218,,
10761,Intermediate,50597,,,Oral bioavailability (dose 20 mg/kg p.o.),N,1,1,,CHEMBL618771,,BAO_0000218,,
10762,Intermediate,50597,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,N,1,1,,CHEMBL618772,,BAO_0000218,,
10763,Intermediate,50597,,,Oral bioavailability in rat at 10 mg/kg of the compound,N,1,1,,CHEMBL618773,,BAO_0000218,,
10764,Intermediate,50597,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,1,1,,CHEMBL875842,,BAO_0000218,,
10765,Intermediate,50597,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,1,1,,CHEMBL618774,,BAO_0000218,,
10766,Intermediate,50597,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,1,1,,CHEMBL618775,,BAO_0000218,,
10767,Intermediate,50597,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,1,1,,CHEMBL618776,,BAO_0000218,,
10768,Intermediate,50597,,,Percent bioavailability (F) in rats after iv administration,N,1,1,,CHEMBL618777,,BAO_0000218,,
10769,Intermediate,50597,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,N,1,1,,CHEMBL618778,,BAO_0000218,,
10770,Intermediate,50597,,,Bioavailability in rat (dose 5 uM/kg p.o.),N,1,1,,CHEMBL618779,,BAO_0000218,,
10771,Intermediate,50597,,,Oral bioavailability,N,1,1,,CHEMBL618780,,BAO_0000218,,
10772,Intermediate,50597,,,Bioavailability in rat (dose 2 mg/kg p.o.),N,1,1,,CHEMBL618781,,BAO_0000218,,
10773,Intermediate,50597,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,N,1,1,,CHEMBL618782,,BAO_0000218,,
10774,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg),N,1,1,,CHEMBL618783,,BAO_0000218,,
10775,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618784,,BAO_0000218,,
10776,Intermediate,50597,,,Percent oral bioavailability evaluated in rat,N,1,1,,CHEMBL618785,,BAO_0000218,,
10777,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618786,,BAO_0000218,,
10778,Intermediate,50597,,,Percent oral bioavailability in rat; Not determined,N,1,1,,CHEMBL618787,,BAO_0000218,,
10779,Intermediate,50597,,,Oral bioavailability in rat,N,1,1,,CHEMBL618788,,BAO_0000218,,
10780,Intermediate,50597,,,Bioavailability in rat,N,1,1,,CHEMBL618789,,BAO_0000218,,
10781,Intermediate,50597,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),N,1,1,,CHEMBL618790,,BAO_0000218,,
10782,Intermediate,50597,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),N,1,1,,CHEMBL618791,,BAO_0000218,,
10783,Intermediate,50597,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,N,1,1,,CHEMBL875843,,BAO_0000218,,
10784,Intermediate,50597,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),N,1,1,,CHEMBL618792,,BAO_0000218,,
10785,Intermediate,50597,,,Cmax at a dose of 30 mg/kg in rat,N,1,1,,CHEMBL623395,,BAO_0000218,,
10786,Autocuration,22224,,,Cmax in monkeys at a dose of 1 mg/kg,U,0,1,,CHEMBL623396,,BAO_0000218,,
10787,Intermediate,50597,,,Cmax in rat,N,1,1,,CHEMBL623397,,BAO_0000218,,
10788,Intermediate,50597,,,Cmax in rats at a dose of 1 mg/kg,N,1,1,,CHEMBL623398,,BAO_0000218,,
10789,Intermediate,50594,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,N,1,1,,CHEMBL623399,,BAO_0000218,,
10790,Autocuration,22224,,,"Cmax value at a dose of 12.7 uM/kg, po",U,0,1,,CHEMBL623400,,BAO_0000218,,
10791,Autocuration,22224,,,"Cmax value at a dose of 6.3 uM/kg, iv",U,0,1,,CHEMBL623401,,BAO_0000218,,
10792,Autocuration,22224,,,"Cmax value at a dose of 7.1 uM/kg, iv",U,0,1,,CHEMBL623402,,BAO_0000218,,
10793,Autocuration,22224,,,Cmax value of compound was determined after 1 hr,U,0,1,,CHEMBL623403,,BAO_0000218,,
10794,Autocuration,22224,,,Cmax value of the compound,U,0,1,,CHEMBL623404,,BAO_0000218,,
10795,Intermediate,50597,,,Cmax value administered intraintestinal in rats.,N,1,1,,CHEMBL625997,,BAO_0000218,,
10796,Intermediate,50597,,,Cmax value administered perorally was determined in rat; Not determined,N,1,1,,CHEMBL625998,,BAO_0000218,,
10797,Autocuration,22224,,,Cmax value at the dose of 2.3 mg/kg,U,0,1,,CHEMBL625999,,BAO_0000218,,
10798,Autocuration,22224,,,Cmax value at the dose of 5 mg/kg,U,0,1,,CHEMBL626000,,BAO_0000218,,
10799,Autocuration,22224,,,Cmax value in the period of 8 hr after dosing. ,U,0,1,,CHEMBL626001,,BAO_0000218,,
10800,Autocuration,22224,,,Cmax value at a oral dose of 20 mg/kg; Not tested,U,0,1,,CHEMBL626002,,BAO_0000218,,
10801,Autocuration,22224,,,Cmax value at a oral dose of 20 mg/kg,U,0,1,,CHEMBL626003,,BAO_0000218,,
10802,Intermediate,50597,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,1,1,,CHEMBL626004,,BAO_0000218,,
10803,Intermediate,50512,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,N,1,1,,CHEMBL626005,,BAO_0000218,,
10804,Intermediate,50597,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,N,1,1,,CHEMBL626006,,BAO_0000218,,
10805,Intermediate,50597,Plasma,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,N,1,1,,CHEMBL626007,,BAO_0000218,1969.0,
10806,Intermediate,50594,Plasma,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,1,1,,CHEMBL626008,,BAO_0000218,1969.0,
10807,Intermediate,50588,Liver,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,N,1,1,,CHEMBL626009,,BAO_0000218,2107.0,
10808,Intermediate,50588,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,N,1,1,,CHEMBL626010,,BAO_0000218,,
10809,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,N,1,1,,CHEMBL626011,,BAO_0000218,178.0,
10810,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,N,1,1,,CHEMBL626012,,BAO_0000218,178.0,
10811,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,N,1,1,,CHEMBL626013,,BAO_0000218,178.0,
10812,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,N,1,1,,CHEMBL626014,,BAO_0000218,178.0,
10813,Intermediate,50594,Blood,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,N,1,1,,CHEMBL877496,,BAO_0000218,178.0,
10814,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,N,1,1,,CHEMBL626015,,BAO_0000218,,
10815,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,N,1,1,,CHEMBL626016,,BAO_0000218,,
10816,Intermediate,50588,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,N,1,1,,CHEMBL626017,,BAO_0000218,,
10817,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs,N,1,1,,CHEMBL626018,,BAO_0000218,1969.0,
10818,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs,N,1,1,,CHEMBL626692,,BAO_0000218,1969.0,
10819,Intermediate,50597,Plasma,,Bioavailability as maximal plasma concentration in rats,N,1,1,,CHEMBL626693,,BAO_0000218,1969.0,
10820,Autocuration,22224,Plasma,,Bioavailability as maximal plasma concentration in rats,U,0,1,,CHEMBL626694,,BAO_0000218,1969.0,
10821,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,1,1,,CHEMBL626695,,BAO_0000218,178.0,
10822,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,1,1,,CHEMBL626696,,BAO_0000218,178.0,
10823,Intermediate,50588,Blood,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,1,1,,CHEMBL626697,,BAO_0000218,178.0,
10824,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,N,1,1,,CHEMBL626859,,BAO_0000218,178.0,
10825,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,1,1,,CHEMBL626860,,BAO_0000218,178.0,
10826,Intermediate,50588,Blood,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,1,1,,CHEMBL626861,,BAO_0000218,178.0,
10827,Intermediate,50597,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,1,1,,CHEMBL626296,,BAO_0000218,,
10828,Autocuration,22224,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,U,0,1,,CHEMBL626297,,BAO_0000218,,
10829,Autocuration,22224,Plasma,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,U,0,1,,CHEMBL626298,,BAO_0000218,1969.0,
10830,Intermediate,50597,Plasma,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",N,1,1,,CHEMBL626299,,BAO_0000218,1969.0,
10831,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,N,1,1,,CHEMBL626300,,BAO_0000218,1969.0,
10832,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,N,1,1,,CHEMBL626301,,BAO_0000218,1969.0,
10833,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,N,1,1,,CHEMBL626962,,BAO_0000218,1969.0,
10834,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,N,1,1,,CHEMBL626963,,BAO_0000218,1969.0,
10835,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,N,1,1,,CHEMBL626964,,BAO_0000218,1969.0,
10836,Intermediate,100710,Plasma,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,N,1,1,,CHEMBL626965,,BAO_0000218,1969.0,
10837,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL626966,,BAO_0000218,1969.0,
10838,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL626967,,BAO_0000218,1969.0,
10839,Intermediate,100710,Plasma,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,N,1,1,,CHEMBL626968,,BAO_0000218,1969.0,
10840,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,N,1,1,,CHEMBL626969,,BAO_0000218,948.0,
10841,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,N,1,1,,CHEMBL627126,,BAO_0000218,948.0,
10842,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,N,1,1,,CHEMBL631276,,BAO_0000218,948.0,
10843,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,N,1,1,,CHEMBL631277,,BAO_0000218,948.0,
10844,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,N,1,1,,CHEMBL631278,,BAO_0000218,948.0,
10845,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,N,1,1,,CHEMBL874457,,BAO_0000218,948.0,
10846,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,N,1,1,,CHEMBL631279,,BAO_0000218,948.0,
10847,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,N,1,1,,CHEMBL631280,,BAO_0000218,948.0,
10848,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,N,1,1,,CHEMBL631281,,BAO_0000218,948.0,
10849,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,N,1,1,,CHEMBL631968,,BAO_0000218,948.0,
10850,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,N,1,1,,CHEMBL631969,,BAO_0000218,948.0,
10851,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,N,1,1,,CHEMBL631970,,BAO_0000218,948.0,
10852,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,N,1,1,,CHEMBL631971,,BAO_0000218,948.0,
10853,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,N,1,1,,CHEMBL631972,,BAO_0000218,948.0,
10854,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,N,1,1,,CHEMBL630435,,BAO_0000218,948.0,
10855,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,N,1,1,,CHEMBL630436,,BAO_0000218,948.0,
10856,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,N,1,1,,CHEMBL630437,,BAO_0000218,948.0,
10857,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,N,1,1,,CHEMBL630438,,BAO_0000218,948.0,
10858,Intermediate,50597,Heart,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,N,1,1,,CHEMBL630439,,BAO_0000218,948.0,
10859,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,N,1,1,,CHEMBL630440,,BAO_0000218,2113.0,
10860,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,N,1,1,,CHEMBL630441,,BAO_0000218,2113.0,
10861,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,N,1,1,,CHEMBL630442,,BAO_0000218,2113.0,
10862,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,N,1,1,,CHEMBL625234,,BAO_0000218,2113.0,
10863,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,N,1,1,,CHEMBL625235,,BAO_0000218,2113.0,
10864,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,N,1,1,,CHEMBL625236,,BAO_0000218,2113.0,
10865,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,N,1,1,,CHEMBL625237,,BAO_0000218,2113.0,
10866,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,N,1,1,,CHEMBL626125,,BAO_0000218,2113.0,
10867,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,N,1,1,,CHEMBL626126,,BAO_0000218,2113.0,
10868,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,N,1,1,,CHEMBL626127,,BAO_0000218,2113.0,
10869,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,N,1,1,,CHEMBL626128,,BAO_0000218,2113.0,
10870,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,N,1,1,,CHEMBL626129,,BAO_0000218,2113.0,
10871,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,N,1,1,,CHEMBL626130,,BAO_0000218,2113.0,
10872,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,N,1,1,,CHEMBL626131,,BAO_0000218,2113.0,
10873,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,N,1,1,,CHEMBL626132,,BAO_0000218,2113.0,
10874,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,N,1,1,,CHEMBL626752,,BAO_0000218,2113.0,
10875,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,N,1,1,,CHEMBL626753,,BAO_0000218,2113.0,
10876,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,N,1,1,,CHEMBL626754,,BAO_0000218,2113.0,
10877,Intermediate,50597,Kidney,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,N,1,1,,CHEMBL626755,,BAO_0000218,2113.0,
10878,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,N,1,1,,CHEMBL626756,,BAO_0000218,2107.0,
10879,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,N,1,1,,CHEMBL626757,,BAO_0000218,2107.0,
10880,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,N,1,1,,CHEMBL626758,,BAO_0000218,2107.0,
10881,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,N,1,1,,CHEMBL626759,,BAO_0000218,2107.0,
10882,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,N,1,1,,CHEMBL626760,,BAO_0000218,2107.0,
10883,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL626394,,BAO_0000218,,
10884,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,N,1,1,,CHEMBL626395,,BAO_0000218,,
10885,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL626396,,BAO_0000218,,
10886,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL626397,,BAO_0000218,,
10887,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL626398,,BAO_0000218,,
10888,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL626399,,BAO_0000218,,
10889,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,N,1,1,,CHEMBL874653,,BAO_0000218,,
10890,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL626400,,BAO_0000218,,
10891,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL626401,,BAO_0000218,,
10892,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL626402,,BAO_0000218,,
10893,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL626403,,BAO_0000218,,
10894,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL626404,,BAO_0000218,,
10895,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,N,1,1,,CHEMBL626405,,BAO_0000218,,
10896,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625529,,BAO_0000218,,
10897,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL625530,,BAO_0000218,,
10898,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL625531,,BAO_0000218,,
10899,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL625532,,BAO_0000218,,
10900,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625533,,BAO_0000218,,
10901,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,N,1,1,,CHEMBL875474,,BAO_0000218,,
10902,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625534,,BAO_0000218,,
10903,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL625535,,BAO_0000218,,
10904,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL625536,,BAO_0000218,,
10905,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL625537,,BAO_0000218,,
10906,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625538,,BAO_0000218,,
10907,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,N,1,1,,CHEMBL625539,,BAO_0000218,,
10908,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625540,,BAO_0000218,,
10909,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL625541,,BAO_0000218,,
10910,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL625542,,BAO_0000218,,
10911,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL625543,,BAO_0000218,,
10912,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL625544,,BAO_0000218,,
10913,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,N,1,1,,CHEMBL625545,,BAO_0000218,,
10914,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL625546,,BAO_0000218,,
10915,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,N,1,1,,CHEMBL625547,,BAO_0000218,,
10916,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL625548,,BAO_0000218,,
10917,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL625549,,BAO_0000218,,
10918,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL625550,,BAO_0000218,,
10919,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL625551,,BAO_0000218,,
10920,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL875475,,BAO_0000218,,
10921,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL625552,,BAO_0000218,,
10922,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL625553,,BAO_0000218,,
10923,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL625554,,BAO_0000218,,
10924,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL625555,,BAO_0000218,,
10925,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL625556,,BAO_0000218,,
10926,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,N,1,1,,CHEMBL624986,,BAO_0000218,,
10927,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL624987,,BAO_0000218,,
10928,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL624988,,BAO_0000218,,
10929,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,N,1,1,,CHEMBL624989,,BAO_0000218,1637.0,
10930,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,N,1,1,,CHEMBL624990,,BAO_0000218,1637.0,
10931,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,N,1,1,,CHEMBL874391,,BAO_0000218,1637.0,
10932,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,N,1,1,,CHEMBL624991,,BAO_0000218,1637.0,
10933,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,N,1,1,,CHEMBL624992,,BAO_0000218,1637.0,
10934,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,N,1,1,,CHEMBL624993,,BAO_0000218,1637.0,
10935,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,N,1,1,,CHEMBL624994,,BAO_0000218,1637.0,
10936,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,N,1,1,,CHEMBL624995,,BAO_0000218,1637.0,
10937,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,N,1,1,,CHEMBL624996,,BAO_0000218,1637.0,
10938,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,N,1,1,,CHEMBL624997,,BAO_0000218,1637.0,
10939,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,N,1,1,,CHEMBL624998,,BAO_0000218,1637.0,
10940,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,N,1,1,,CHEMBL624999,,BAO_0000218,1637.0,
10941,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,N,1,1,,CHEMBL882955,,BAO_0000218,1637.0,
10942,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,N,1,1,,CHEMBL625000,,BAO_0000218,1637.0,
10943,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,N,1,1,,CHEMBL625001,,BAO_0000218,1637.0,
10944,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,N,1,1,,CHEMBL625089,,BAO_0000218,1637.0,
10945,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,N,1,1,,CHEMBL625090,,BAO_0000218,1637.0,
10946,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,N,1,1,,CHEMBL625091,,BAO_0000218,1637.0,
10947,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,N,1,1,,CHEMBL625092,,BAO_0000218,1637.0,
10948,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,N,1,1,,CHEMBL625093,,BAO_0000218,1637.0,
10949,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,N,1,1,,CHEMBL625094,,BAO_0000218,1637.0,
10950,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,N,1,1,,CHEMBL625095,,BAO_0000218,1637.0,
10951,Intermediate,50588,,,Compound was evaluated for its bioavailability in the dogs,N,1,1,,CHEMBL625096,,BAO_0000218,,
10952,Intermediate,50597,,,Compound was evaluated for its bioavailability in the rats,N,1,1,,CHEMBL625097,,BAO_0000218,,
10953,Autocuration,22224,,,Compound was evaluated for oral bioavailability,U,0,1,,CHEMBL882956,,BAO_0000218,,
10954,Intermediate,50597,,,Compound was evaluated for percentage of Oral bioavailability in rats,N,1,1,,CHEMBL625098,,BAO_0000218,,
10955,Autocuration,22224,,,Bioavailability in guinea pig,U,0,1,,CHEMBL625099,,BAO_0000218,,
10956,Intermediate,50597,,,Compound was evaluated for the oral bioavailability in rat,N,1,1,,CHEMBL625100,,BAO_0000218,,
10957,Intermediate,50588,,,Compound was evaluated for the oral bioavailability in dog,N,1,1,,CHEMBL625101,,BAO_0000218,,
10958,Intermediate,50597,,,Compound was evaluated for the oral bioavailability in rat,N,1,1,,CHEMBL874396,,BAO_0000218,,
10959,Autocuration,22224,,,Bioavailability in dog (dosed i.v.),U,0,1,,CHEMBL625102,,BAO_0000218,,
10960,Intermediate,50588,,,Compound was tested for in vivo bioavailability in dog,N,1,1,,CHEMBL625103,,BAO_0000218,,
10961,Intermediate,100712,,,Compound was tested for in vivo bioavailability in hamsters,N,1,1,,CHEMBL625104,,BAO_0000218,,
10962,Autocuration,22224,,,Compound was tested for in vivo bioavailability in monkey,U,0,1,,CHEMBL625105,,BAO_0000218,,
10963,Intermediate,50597,,,Compound was tested for in vivo bioavailability in rat,N,1,1,,CHEMBL625106,,BAO_0000218,,
10964,Autocuration,22224,,,Oral bioavailability in mouse,U,0,1,,CHEMBL625107,,BAO_0000218,,
10965,Intermediate,50594,,,Compound was tested for percent of oral bioavailability in mice; 56-74,N,1,1,,CHEMBL625108,,BAO_0000218,,
10966,Autocuration,22224,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),U,0,1,,CHEMBL625109,,BAO_0000218,,
10967,Autocuration,22224,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),U,0,1,,CHEMBL625110,,BAO_0000218,,
10968,Autocuration,22224,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),U,0,1,,CHEMBL625111,,BAO_0000218,,
10969,Intermediate,50594,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),N,1,1,,CHEMBL625112,,BAO_0000218,,
10970,Intermediate,50594,,,Oral bioavailability in nude mice,N,1,1,,CHEMBL875334,,BAO_0000218,,
10971,Autocuration,22224,,,Bioavailability in monkey (i.d. dosing),U,0,1,,CHEMBL628617,,BAO_0000218,,
10972,Autocuration,22224,,,Bioavailability in rat,U,0,1,,CHEMBL628618,,BAO_0000218,,
10973,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,U,0,1,,CHEMBL628619,,BAO_0000218,,
10974,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,U,0,1,,CHEMBL628620,,BAO_0000218,,
10975,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,1,1,,CHEMBL628621,,BAO_0000218,,
10976,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,1,1,,CHEMBL628622,,BAO_0000218,,
10977,Intermediate,100710,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,1,1,,CHEMBL628623,,BAO_0000218,,
10978,Intermediate,100710,Plasma,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,N,1,1,,CHEMBL628624,,BAO_0000218,1969.0,
10979,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL628625,,BAO_0000218,1969.0,
10980,Intermediate,100710,Plasma,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,N,1,1,,CHEMBL628626,,BAO_0000218,1969.0,
10981,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL627041,,BAO_0000218,1969.0,
10982,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL627042,,BAO_0000218,1969.0,
10983,Intermediate,50594,Plasma,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,1,1,,CHEMBL627043,,BAO_0000218,1969.0,
10984,Autocuration,22224,Plasma,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,U,0,1,,CHEMBL627044,,BAO_0000218,1969.0,
10985,Intermediate,50594,Plasma,,Cmax in mouse plasma,N,1,1,,CHEMBL627045,,BAO_0000218,1969.0,
10986,Autocuration,22224,Plasma,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,U,0,1,,CHEMBL627046,,BAO_0000218,1969.0,
10987,Intermediate,50597,Plasma,,Maximal plasma concentration in rat,N,1,1,,CHEMBL627047,,BAO_0000218,1969.0,
10988,Intermediate,50597,Plasma,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,N,1,1,,CHEMBL627048,,BAO_0000218,1969.0,
10989,Intermediate,50597,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,N,1,1,,CHEMBL627049,,BAO_0000218,,
10990,Intermediate,50597,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,N,1,1,,CHEMBL627050,,BAO_0000218,,
10991,Intermediate,50597,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,N,1,1,,CHEMBL627051,,BAO_0000218,,
10992,Intermediate,50597,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,N,1,1,,CHEMBL627052,,BAO_0000218,,
10993,Intermediate,50597,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,N,1,1,,CHEMBL627053,,BAO_0000218,,
10994,Intermediate,50597,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,N,1,1,,CHEMBL627054,,BAO_0000218,,
10995,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627055,,BAO_0000218,,
10996,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627056,,BAO_0000218,,
10997,Intermediate,50594,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,1,1,,CHEMBL627057,,BAO_0000218,,
10998,Intermediate,50594,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL627058,,BAO_0000218,,
10999,Intermediate,50594,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,1,1,,CHEMBL626211,,BAO_0000218,,
11000,Autocuration,22224,,,Maximum Concentration of the compound.,U,0,1,,CHEMBL626212,,BAO_0000218,,
11001,Intermediate,50588,,,Maximum Concentration was measured after iv administration into Beagle dog,N,1,1,,CHEMBL626213,,BAO_0000218,,
11002,Intermediate,50588,,,Maximum Concentration was measured after iv administration into Beagle dog.,N,1,1,,CHEMBL626214,,BAO_0000218,,
11003,Intermediate,50588,,,Maximum Concentration was measured after po administration into Beagle dog,N,1,1,,CHEMBL626215,,BAO_0000218,,
11004,Intermediate,50588,,,Maximum Concentration was measured after po administration into Beagle dog.,N,1,1,,CHEMBL626216,,BAO_0000218,,
11005,Autocuration,22224,Blood,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,U,0,1,,CHEMBL626217,,BAO_0000218,178.0,
11006,Autocuration,22224,Blood,,Maximum blood level reached after an iv dose of 12.2 uM/kg,U,0,1,,CHEMBL626218,,BAO_0000218,178.0,
11007,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,U,0,1,,CHEMBL626219,,BAO_0000218,178.0,
11008,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,U,0,1,,CHEMBL626220,,BAO_0000218,178.0,
11009,Autocuration,22224,Blood,,Maximum blood level reached after an oral dose of 5.0 mg/kg,U,0,1,,CHEMBL626221,,BAO_0000218,178.0,
11010,Autocuration,22224,Blood,,Maximum blood level reached at dose of 10.6 uM/kg orally,U,0,1,,CHEMBL626222,,BAO_0000218,178.0,
11011,Intermediate,50512,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,N,1,1,,CHEMBL626223,,BAO_0000218,,
11012,Intermediate,50512,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,N,1,1,,CHEMBL626224,,BAO_0000218,,
11013,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,N,1,1,,CHEMBL626225,,BAO_0000218,955.0,
11014,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,N,1,1,,CHEMBL626226,,BAO_0000218,955.0,
11015,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,N,1,1,,CHEMBL626227,,BAO_0000218,955.0,
11016,Intermediate,50597,Brain,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,N,1,1,,CHEMBL626228,,BAO_0000218,955.0,
11017,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,1,1,,CHEMBL626229,,BAO_0000218,,
11018,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,N,1,1,,CHEMBL626921,,BAO_0000218,,
11019,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,N,1,1,,CHEMBL876793,,BAO_0000218,,
11020,Intermediate,50597,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,N,1,1,,CHEMBL625309,,BAO_0000218,,
11021,Intermediate,50278,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,1,1,,CHEMBL625310,,BAO_0000218,,
11022,Autocuration,22224,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,U,0,1,,CHEMBL625311,,BAO_0000218,,
11023,Intermediate,50597,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,N,1,1,,CHEMBL625312,,BAO_0000218,,
11024,Autocuration,22224,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,U,0,1,,CHEMBL625313,,BAO_0000218,,
11025,Intermediate,50594,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,N,1,1,,CHEMBL625314,,BAO_0000218,,
11026,Intermediate,50597,,,Maximum concentration in male rats after iv administration of 20 mg/kg,N,1,1,,CHEMBL625315,,BAO_0000218,,
11027,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,N,1,1,,CHEMBL625316,,BAO_0000218,2107.0,
11028,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,N,1,1,,CHEMBL625317,,BAO_0000218,2107.0,
11029,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,N,1,1,,CHEMBL625318,,BAO_0000218,2107.0,
11030,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,N,1,1,,CHEMBL625319,,BAO_0000218,2107.0,
11031,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,N,1,1,,CHEMBL625320,,BAO_0000218,2107.0,
11032,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,N,1,1,,CHEMBL625321,,BAO_0000218,2107.0,
11033,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,N,1,1,,CHEMBL625322,,BAO_0000218,2107.0,
11034,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,N,1,1,,CHEMBL876801,,BAO_0000218,2107.0,
11035,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,N,1,1,,CHEMBL625323,,BAO_0000218,2107.0,
11036,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,N,1,1,,CHEMBL625324,,BAO_0000218,2107.0,
11037,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,N,1,1,,CHEMBL625325,,BAO_0000218,2107.0,
11038,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,N,1,1,,CHEMBL625326,,BAO_0000218,2107.0,
11039,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,N,1,1,,CHEMBL625327,,BAO_0000218,2107.0,
11040,Intermediate,50597,Liver,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,N,1,1,,CHEMBL625328,,BAO_0000218,2107.0,
11041,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,N,1,1,,CHEMBL625329,,BAO_0000218,2048.0,
11042,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,N,1,1,,CHEMBL625330,,BAO_0000218,2048.0,
11043,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,N,1,1,,CHEMBL627774,,BAO_0000218,2048.0,
11044,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,N,1,1,,CHEMBL627775,,BAO_0000218,2048.0,
11045,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,N,1,1,,CHEMBL627949,,BAO_0000218,2048.0,
11046,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,N,1,1,,CHEMBL627950,,BAO_0000218,2048.0,
11047,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,N,1,1,,CHEMBL627951,,BAO_0000218,2048.0,
11048,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,N,1,1,,CHEMBL627952,,BAO_0000218,2048.0,
11049,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,N,1,1,,CHEMBL627953,,BAO_0000218,2048.0,
11050,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,N,1,1,,CHEMBL627954,,BAO_0000218,2048.0,
11051,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,N,1,1,,CHEMBL627955,,BAO_0000218,2048.0,
11052,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,N,1,1,,CHEMBL627956,,BAO_0000218,2048.0,
11053,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,N,1,1,,CHEMBL876802,,BAO_0000218,2048.0,
11054,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,N,1,1,,CHEMBL627957,,BAO_0000218,2048.0,
11055,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,N,1,1,,CHEMBL627958,,BAO_0000218,2048.0,
11056,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,N,1,1,,CHEMBL627959,,BAO_0000218,2048.0,
11057,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,N,1,1,,CHEMBL627960,,BAO_0000218,2048.0,
11058,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,N,1,1,,CHEMBL627961,,BAO_0000218,2048.0,
11059,Intermediate,50597,Lung,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,N,1,1,,CHEMBL627962,,BAO_0000218,2048.0,
11060,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,1,1,,CHEMBL627963,,BAO_0000218,,
11061,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624759,,BAO_0000218,,
11062,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624760,,BAO_0000218,,
11063,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624761,,BAO_0000218,,
11064,Intermediate,50597,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL877607,,BAO_0000218,,
11065,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,1,1,,CHEMBL624762,,BAO_0000218,2107.0,
11066,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624763,,BAO_0000218,2107.0,
11067,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624764,,BAO_0000218,2107.0,
11068,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624765,,BAO_0000218,2107.0,
11069,Intermediate,50597,Liver,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL624766,,BAO_0000218,2107.0,
11070,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL624767,,BAO_0000218,,
11071,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,N,1,1,,CHEMBL624768,,BAO_0000218,,
11072,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL624769,,BAO_0000218,,
11073,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL624770,,BAO_0000218,,
11074,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL624771,,BAO_0000218,,
11075,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL624772,,BAO_0000218,,
11076,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,N,1,1,,CHEMBL624773,,BAO_0000218,,
11077,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL624774,,BAO_0000218,,
11078,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL624775,,BAO_0000218,,
11079,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL624776,,BAO_0000218,,
11080,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL624777,,BAO_0000218,,
11081,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL624778,,BAO_0000218,,
11082,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,N,1,1,,CHEMBL624779,,BAO_0000218,,
11083,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL624780,,BAO_0000218,,
11084,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL624781,,BAO_0000218,,
11085,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL877608,,BAO_0000218,,
11086,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL624782,,BAO_0000218,,
11087,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL624783,,BAO_0000218,,
11088,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,N,1,1,,CHEMBL624784,,BAO_0000218,,
11089,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL624785,,BAO_0000218,,
11090,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL624786,,BAO_0000218,,
11091,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL624787,,BAO_0000218,,
11092,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL628676,,BAO_0000218,,
11093,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,N,1,1,,CHEMBL621842,,BAO_0000218,,
11094,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL621843,,BAO_0000218,,
11095,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL623873,,BAO_0000218,,
11096,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL623874,,BAO_0000218,,
11097,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL623875,,BAO_0000218,,
11098,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL623876,,BAO_0000218,,
11099,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,N,1,1,,CHEMBL623877,,BAO_0000218,,
11100,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL623878,,BAO_0000218,,
11101,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,N,1,1,,CHEMBL623879,,BAO_0000218,,
11102,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL623880,,BAO_0000218,,
11103,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL623881,,BAO_0000218,,
11104,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL623957,,BAO_0000218,,
11105,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL623958,,BAO_0000218,,
11106,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL623959,,BAO_0000218,,
11107,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL623960,,BAO_0000218,,
11108,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL623961,,BAO_0000218,,
11109,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL623962,,BAO_0000218,,
11110,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL624676,,BAO_0000218,,
11111,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL624677,,BAO_0000218,,
11112,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,N,1,1,,CHEMBL624678,,BAO_0000218,,
11113,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL624679,,BAO_0000218,,
11114,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL624680,,BAO_0000218,,
11115,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,U,0,1,,CHEMBL624849,,BAO_0000218,,
11116,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,U,0,1,,CHEMBL624850,,BAO_0000218,,
11117,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,U,0,1,,CHEMBL874399,,BAO_0000218,,
11118,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,U,0,1,,CHEMBL624851,,BAO_0000218,,
11119,Autocuration,22224,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,U,0,1,,CHEMBL624852,,BAO_0000218,,
11120,Autocuration,22224,,,Oral bioavailability in rat (dose 10 mg/kg),U,0,1,,CHEMBL624853,,BAO_0000218,,
11121,Autocuration,22224,,,Oral bioavailability in rat (Sprague-Dawley),U,0,1,,CHEMBL624854,,BAO_0000218,,
11122,Autocuration,22224,,,Oral bioavailability in rat,U,0,1,,CHEMBL624855,,BAO_0000218,,
11123,Autocuration,22224,,,Oral bioavailability in rats was determined in vivo,U,0,1,,CHEMBL624856,,BAO_0000218,,
11124,Autocuration,22224,,,Oral bioavailability in dog,U,0,1,,CHEMBL882957,,BAO_0000218,,
11125,Autocuration,22224,,,Oral bioavailability of compound in monkey,U,0,1,,CHEMBL624857,,BAO_0000218,,
11126,Intermediate,50597,,,Oral bioavailability of compound in rat,N,1,1,,CHEMBL622202,,BAO_0000218,,
11127,Autocuration,22224,,,Bioavailability in rat of PMEA prodrug,U,0,1,,CHEMBL622203,,BAO_0000218,,
11128,Intermediate,50597,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,N,1,1,,CHEMBL625522,,BAO_0000218,,
11129,Autocuration,22224,,,Serum conc at 3 hours following 25 mg/kg dose,U,0,1,,CHEMBL622868,,BAO_0000218,,
11130,Autocuration,22224,Urine,,Urine conc 0-5 hours following 25 mg/kg dose,U,0,1,,CHEMBL622869,,BAO_0000218,1088.0,
11131,Autocuration,22224,Urine,,Urine conc 0-24 hours following 25 mg/kg dose,U,0,1,,CHEMBL622870,,BAO_0000218,1088.0,
11132,Autocuration,22224,,,Oral bioavailability in African green monkeys; 20-25,U,0,1,,CHEMBL622871,,BAO_0000218,,
11133,Intermediate,100710,,,Oral bioavailability in cynomolgus monkey.,N,1,1,,CHEMBL620560,,BAO_0000218,,
11134,Autocuration,22224,,,Oral bioavailability in dog,U,0,1,,CHEMBL620561,,BAO_0000218,,
11135,Intermediate,50588,,,Oral bioavailability in dog at 10 mg/kg oral dose,N,1,1,,CHEMBL620562,,BAO_0000218,,
11136,Intermediate,100712,,,Oral bioavailability in hamster at 10 mg/kg oral dose,N,1,1,,CHEMBL620563,,BAO_0000218,,
11137,Intermediate,50597,,,Oral bioavailability in rat at 10 mg/kg oral dose,N,1,1,,CHEMBL620564,,BAO_0000218,,
11138,Autocuration,22224,,,Oral bioavailability in rat,U,0,1,,CHEMBL872265,,BAO_0000218,,
11139,Autocuration,22224,,,Oral bioavailability in rat,U,0,1,,CHEMBL620565,,BAO_0000218,,
11140,Autocuration,22224,,,Oral bioavailability,U,0,1,,CHEMBL620566,,BAO_0000218,,
11141,Autocuration,22224,,,Oral bioavailability was determined; range 49-102%,U,0,1,,CHEMBL620567,,BAO_0000218,,
11142,Intermediate,50588,,,Oral bioavailability was determined in dogs,N,1,1,,CHEMBL620568,,BAO_0000218,,
11143,Autocuration,22224,,,Oral bioavailability in rat,U,0,1,,CHEMBL620569,,BAO_0000218,,
11144,Autocuration,22224,,,Oral bioavailability,U,0,1,,CHEMBL620570,,BAO_0000218,,
11145,Autocuration,22224,,,Oral bioavailability was determined; Not orally available,U,0,1,,CHEMBL620571,,BAO_0000218,,
11146,Intermediate,50594,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),N,1,1,,CHEMBL620572,,BAO_0000218,,
11147,Autocuration,22224,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),U,0,1,,CHEMBL620573,,BAO_0000218,,
11148,Autocuration,22224,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,U,0,1,,CHEMBL620574,,BAO_0000218,,
11149,Autocuration,22224,,,Oral bioavailability in Rhesus monkey,U,0,1,,CHEMBL620575,,BAO_0000218,,
11150,Autocuration,22224,,,Oral bioavailability in dog (female mongrel),U,0,1,,CHEMBL620576,,BAO_0000218,,
11151,Autocuration,22224,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,U,0,1,,CHEMBL875846,,BAO_0000218,,
11152,Autocuration,22224,,,Oral bioavailability in dog,U,0,1,,CHEMBL620577,,BAO_0000218,,
11153,Autocuration,22224,,,Percentage Bioavailability was evaluated.,U,0,1,,CHEMBL620578,,BAO_0000218,,
11154,Autocuration,22224,,,Bioavailability in rat administered i.d.,U,0,1,,CHEMBL620579,,BAO_0000218,,
11155,Autocuration,22224,,,Bioavailability,U,0,1,,CHEMBL621248,,BAO_0000218,,
11156,Autocuration,22224,,,Bioavailability in dog (male Beagle) i.v. administration,U,0,1,,CHEMBL625390,,BAO_0000218,,
11157,Autocuration,22224,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",U,0,1,,CHEMBL625391,,BAO_0000218,,
11158,Autocuration,22224,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),U,0,1,,CHEMBL872266,,BAO_0000218,,
11159,Autocuration,22224,,,Oral bioavailability in rat (Sprague-Dawley) (male),U,0,1,,CHEMBL625392,,BAO_0000218,,
11160,Intermediate,50597,,,The oral bioavailability was measured on rats after oral administration,N,1,1,,CHEMBL625393,,BAO_0000218,,
11161,Intermediate,50597,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,1,1,,CHEMBL625394,,BAO_0000218,,
11162,Intermediate,50797,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,1,1,,CHEMBL625395,,BAO_0000218,,
11163,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,0,1,,CHEMBL625396,,BAO_0000218,,
11164,Autocuration,22224,,,Bioavailability in dog (male Beagle) i.v. administration,U,0,1,,CHEMBL625397,,BAO_0000218,,
11165,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625398,,BAO_0000218,,
11166,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625399,,BAO_0000218,178.0,
11167,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL626074,,BAO_0000218,2037.0,
11168,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL626075,,BAO_0000218,,
11169,Intermediate,50597,Plasma,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,1,1,,CHEMBL626076,,BAO_0000218,1969.0,
11170,Intermediate,50797,Plasma,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,1,1,,CHEMBL626077,,BAO_0000218,1969.0,
11171,Intermediate,50597,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),N,1,1,,CHEMBL626078,,BAO_0000218,178.0,
11172,Autocuration,22224,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),U,0,1,,CHEMBL625846,,BAO_0000218,178.0,
11173,Autocuration,22224,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),U,0,1,,CHEMBL625847,,BAO_0000218,178.0,
11174,Expert,50597,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,N,1,1,,CHEMBL625848,,BAO_0000218,,
11175,Intermediate,50597,Plasma,,Maximum concentration of compound in plasma administered orally to rats,N,1,1,,CHEMBL625849,,BAO_0000218,1969.0,
11176,Intermediate,50588,Plasma,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",N,1,1,,CHEMBL626023,,BAO_0000218,1969.0,
11177,Intermediate,50588,Plasma,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",N,1,1,,CHEMBL626024,,BAO_0000218,1969.0,
11178,Intermediate,50588,Plasma,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",N,1,1,,CHEMBL626025,,BAO_0000218,1969.0,
11179,Autocuration,22224,,,Maximum concentration after 10 mg/kg by oral administration,U,0,1,,CHEMBL626026,,BAO_0000218,,
11180,Autocuration,22224,,,Maximum concentration at a dose of 1.5 mg/kg,U,0,1,,CHEMBL626027,,BAO_0000218,,
11181,Autocuration,22224,,,Maximum concentration at a dose of 2.0 mg/kg,U,0,1,,CHEMBL626028,,BAO_0000218,,
11182,Intermediate,50588,Plasma,,Maximum concentration in dog plasma,N,1,1,,CHEMBL626029,,BAO_0000218,1969.0,
11183,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,U,0,1,,CHEMBL626030,,BAO_0000218,1969.0,
11184,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,U,0,1,,CHEMBL626031,,BAO_0000218,1969.0,
11185,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,U,0,1,,CHEMBL626032,,BAO_0000218,1969.0,
11186,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,U,0,1,,CHEMBL626033,,BAO_0000218,1969.0,
11187,Autocuration,22224,Plasma,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,U,0,1,,CHEMBL626034,,BAO_0000218,1969.0,
11188,Intermediate,50588,Plasma,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),N,1,1,,CHEMBL626035,,BAO_0000218,1969.0,
11189,Autocuration,22224,Plasma,,Maximum concentration in plasma at Tmax,U,0,1,,CHEMBL626036,,BAO_0000218,1969.0,
11190,Expert,50588,Plasma,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,N,1,1,,CHEMBL626037,,BAO_0000218,1969.0,
11191,Intermediate,100712,Plasma,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,N,1,1,,CHEMBL626038,,BAO_0000218,1969.0,
11192,Intermediate,50597,Plasma,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,N,1,1,,CHEMBL626039,,BAO_0000218,1969.0,
11193,Intermediate,50597,Plasma,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,N,1,1,,CHEMBL626040,,BAO_0000218,1969.0,
11194,Intermediate,50592,Plasma,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,N,1,1,,CHEMBL626041,,BAO_0000218,1969.0,
11195,Autocuration,22224,,,Maximum concentration was calculated,U,0,1,,CHEMBL626042,,BAO_0000218,,
11196,Autocuration,22224,,,Maximum concentration was calculated.,U,0,1,,CHEMBL626043,,BAO_0000218,,
11197,Autocuration,22224,,,Maximum concentration at a peroral dose of 10 mg/kg,U,0,1,,CHEMBL626044,,BAO_0000218,,
11198,Autocuration,22224,,,Maximum concentration of the drug at 10 uM/dg administered perorally,U,0,1,,CHEMBL626045,,BAO_0000218,,
11199,Autocuration,22224,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,U,0,1,,CHEMBL626046,,BAO_0000218,,
11200,Intermediate,50588,Plasma,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",N,1,1,,CHEMBL626047,,BAO_0000218,1969.0,
11201,Intermediate,100712,Plasma,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",N,1,1,,CHEMBL626048,,BAO_0000218,1969.0,
11202,Intermediate,50597,Plasma,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",N,1,1,,CHEMBL626049,,BAO_0000218,1969.0,
11203,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,N,1,1,,CHEMBL626050,,BAO_0000218,1969.0,
11204,Intermediate,50588,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,N,1,1,,CHEMBL874541,,BAO_0000218,1969.0,
11205,Intermediate,100712,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,N,1,1,,CHEMBL622826,,BAO_0000218,1969.0,
11206,Intermediate,100712,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,N,1,1,,CHEMBL622827,,BAO_0000218,1969.0,
11207,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,N,1,1,,CHEMBL622828,,BAO_0000218,1969.0,
11208,Intermediate,50597,Plasma,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,N,1,1,,CHEMBL622829,,BAO_0000218,1969.0,
11209,Intermediate,50597,,,Maximum concentration reached following intravenous administration in male rat,N,1,1,,CHEMBL876806,,BAO_0000218,,
11210,Intermediate,50588,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,N,1,1,,CHEMBL622830,,BAO_0000218,,
11211,Intermediate,50597,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,N,1,1,,CHEMBL622831,,BAO_0000218,,
11212,Intermediate,50588,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,N,1,1,,CHEMBL626794,,BAO_0000218,,
11213,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL626795,,BAO_0000218,,
11214,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL626796,,BAO_0000218,,
11215,Intermediate,50597,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL626797,,BAO_0000218,,
11216,Intermediate,50597,,,Maximum drug concentration is determined after oral dosing in rats.,N,1,1,,CHEMBL626798,,BAO_0000218,,
11217,Intermediate,50588,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,N,1,1,,CHEMBL626799,,BAO_0000218,,
11218,Intermediate,50588,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,N,1,1,,CHEMBL626800,,BAO_0000218,,
11219,Autocuration,22224,Plasma,,Maximum plasma concentration,U,0,1,,CHEMBL626801,,BAO_0000218,1969.0,
11220,Intermediate,50597,Plasma,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,N,1,1,,CHEMBL876816,,BAO_0000218,1969.0,
11221,Intermediate,50597,Plasma,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,N,1,1,,CHEMBL626802,,BAO_0000218,1969.0,
11222,Intermediate,50588,Plasma,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,N,1,1,,CHEMBL626803,,BAO_0000218,1969.0,
11223,Autocuration,22224,Plasma,,Maximum plasma concentration following oral administration of 30 umol/kg,U,0,1,,CHEMBL626804,,BAO_0000218,1969.0,
11224,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,N,1,1,,CHEMBL626805,,BAO_0000218,1969.0,
11225,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,1,1,,CHEMBL626309,,BAO_0000218,1969.0,
11226,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626310,,BAO_0000218,1969.0,
11227,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626311,,BAO_0000218,1969.0,
11228,Intermediate,50597,Plasma,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626312,,BAO_0000218,1969.0,
11229,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626313,,BAO_0000218,995.0,
11230,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,1,1,,CHEMBL626314,,BAO_0000218,995.0,
11231,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626315,,BAO_0000218,995.0,
11232,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626316,,BAO_0000218,995.0,
11233,Intermediate,50597,Uterus,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,1,1,,CHEMBL626317,,BAO_0000218,995.0,
11234,Intermediate,50597,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626318,,BAO_0000218,,
11235,Intermediate,50597,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL626319,,BAO_0000218,,
11236,Intermediate,50597,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626320,,BAO_0000218,,
11237,Intermediate,50597,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL875053,,BAO_0000218,,
11238,Intermediate,50597,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626321,,BAO_0000218,,
11239,Intermediate,50597,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL626322,,BAO_0000218,,
11240,Intermediate,50597,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626323,,BAO_0000218,,
11241,Intermediate,50597,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL626324,,BAO_0000218,,
11242,Intermediate,50597,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626325,,BAO_0000218,,
11243,Intermediate,50597,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL626326,,BAO_0000218,,
11244,Intermediate,50597,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),N,1,1,,CHEMBL626327,,BAO_0000218,,
11245,Intermediate,50597,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),N,1,1,,CHEMBL626328,,BAO_0000218,,
11246,Intermediate,50597,Blood,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626329,,BAO_0000218,178.0,
11247,Intermediate,50597,Blood,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626330,,BAO_0000218,178.0,
11248,Intermediate,50597,Blood,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626331,,BAO_0000218,178.0,
11249,Intermediate,50597,Blood,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626332,,BAO_0000218,178.0,
11250,Intermediate,50597,Blood,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626333,,BAO_0000218,178.0,
11251,Intermediate,50597,Blood,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626334,,BAO_0000218,178.0,
11252,Intermediate,50597,Blood,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL626335,,BAO_0000218,178.0,
11253,Intermediate,50597,Blood,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624798,,BAO_0000218,178.0,
11254,Intermediate,50597,Brain,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624799,,BAO_0000218,955.0,
11255,Intermediate,50597,Brain,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624800,,BAO_0000218,955.0,
11256,Intermediate,50597,Brain,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624801,,BAO_0000218,955.0,
11257,Intermediate,50597,Brain,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624802,,BAO_0000218,955.0,
11258,Intermediate,50597,Brain,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624803,,BAO_0000218,955.0,
11259,Intermediate,50597,Brain,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624804,,BAO_0000218,955.0,
11260,Intermediate,50597,Brain,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624805,,BAO_0000218,955.0,
11261,Intermediate,50597,Brain,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",N,1,1,,CHEMBL624806,,BAO_0000218,955.0,
11262,Intermediate,50597,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624807,,BAO_0000218,,
11263,Intermediate,50597,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624808,,BAO_0000218,,
11264,Intermediate,50597,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624809,,BAO_0000218,,
11265,Intermediate,50597,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624810,,BAO_0000218,,
11266,Intermediate,50597,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL877618,,BAO_0000218,,
11267,Intermediate,50597,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624811,,BAO_0000218,,
11268,Intermediate,50597,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624812,,BAO_0000218,,
11269,Intermediate,50597,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624813,,BAO_0000218,,
11270,Intermediate,50597,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624814,,BAO_0000218,,
11271,Intermediate,50597,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624815,,BAO_0000218,,
11272,Intermediate,50597,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624816,,BAO_0000218,,
11273,Intermediate,50597,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624817,,BAO_0000218,,
11274,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL624818,,BAO_0000218,,
11275,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,N,1,1,,CHEMBL624819,,BAO_0000218,,
11276,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL624820,,BAO_0000218,,
11277,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL624821,,BAO_0000218,,
11278,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL624822,,BAO_0000218,,
11279,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL624823,,BAO_0000218,,
11280,Intermediate,50212,,,Observed diffusion coefficient in organic solvent for Escherichia coli,N,1,1,,CHEMBL624824,,BAO_0000218,,
11281,Intermediate,50597,Blood,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624825,,BAO_0000218,178.0,
11282,Intermediate,50597,Blood,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624826,,BAO_0000218,178.0,
11283,Intermediate,50597,Cardiac atrium,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL876817,,BAO_0000218,2081.0,
11284,Intermediate,50597,Cardiac atrium,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624827,,BAO_0000218,2081.0,
11285,Intermediate,50597,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624828,,BAO_0000218,,
11286,Intermediate,50597,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624829,,BAO_0000218,,
11287,Intermediate,50597,Liver,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624830,,BAO_0000218,2107.0,
11288,Intermediate,50597,Liver,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624831,,BAO_0000218,2107.0,
11289,Intermediate,50597,Cardiac atrium,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624832,,BAO_0000218,2081.0,
11290,Intermediate,50597,Cardiac atrium,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624833,,BAO_0000218,2081.0,
11291,Intermediate,50597,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624834,,BAO_0000218,,
11292,Intermediate,50597,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624835,,BAO_0000218,,
11293,Intermediate,50597,Spleen,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,1,1,,CHEMBL624836,,BAO_0000218,2106.0,
11294,Intermediate,50597,Spleen,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,1,1,,CHEMBL624837,,BAO_0000218,2106.0,
11295,Intermediate,50597,Blood,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL624838,,BAO_0000218,178.0,
11296,Intermediate,50597,Blood,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,N,1,1,,CHEMBL622188,,BAO_0000218,178.0,
11297,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL622189,,BAO_0000218,948.0,
11298,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,N,1,1,,CHEMBL622190,,BAO_0000218,948.0,
11299,Intermediate,50597,Heart,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,N,1,1,,CHEMBL625170,,BAO_0000218,948.0,
11300,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL625171,,BAO_0000218,2113.0,
11301,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL625172,,BAO_0000218,2113.0,
11302,Intermediate,50597,Kidney,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,N,1,1,,CHEMBL625173,,BAO_0000218,2113.0,
11303,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL625174,,BAO_0000218,2107.0,
11304,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,N,1,1,,CHEMBL625175,,BAO_0000218,2107.0,
11305,Intermediate,50597,Liver,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,N,1,1,,CHEMBL625176,,BAO_0000218,2107.0,
11306,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL625177,,BAO_0000218,2048.0,
11307,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,N,1,1,,CHEMBL625178,,BAO_0000218,2048.0,
11308,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,N,1,1,,CHEMBL625179,,BAO_0000218,2048.0,
11309,Intermediate,50597,Lung,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,1,1,,CHEMBL625180,,BAO_0000218,2048.0,
11310,Autocuration,22224,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",U,0,1,,CHEMBL625181,,BAO_0000218,,
11311,Intermediate,50594,Urine,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,N,1,1,,CHEMBL625182,,BAO_0000218,1088.0,
11312,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL625183,,BAO_0000218,,
11313,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,1,1,,CHEMBL875848,,BAO_0000218,,
11314,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL622260,,BAO_0000218,,
11315,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,1,1,,CHEMBL622261,,BAO_0000218,,
11316,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL622262,,BAO_0000218,,
11317,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,1,1,,CHEMBL622263,,BAO_0000218,2113.0,
11318,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL622418,,BAO_0000218,2113.0,
11319,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,1,1,,CHEMBL622419,,BAO_0000218,2107.0,
11320,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623388,,BAO_0000218,,
11321,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623389,,BAO_0000218,2107.0,
11322,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623390,,BAO_0000218,,
11323,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623391,,BAO_0000218,,
11324,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623392,,BAO_0000218,178.0,
11325,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623393,,BAO_0000218,2037.0,
11326,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL623394,,BAO_0000218,,
11327,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL618885,,BAO_0000218,,
11328,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL618886,,BAO_0000218,2107.0,
11329,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL618887,,BAO_0000218,,
11330,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619535,,BAO_0000218,,
11331,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619536,,BAO_0000218,178.0,
11332,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619537,,BAO_0000218,2037.0,
11333,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619705,,BAO_0000218,,
11334,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619706,,BAO_0000218,,
11335,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619707,,BAO_0000218,2107.0,
11336,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL619708,,BAO_0000218,,
11337,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625219,,BAO_0000218,,
11338,Intermediate,50594,Blood,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625220,,BAO_0000218,178.0,
11339,Intermediate,50594,Cerebellum,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625221,,BAO_0000218,2037.0,
11340,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625222,,BAO_0000218,,
11341,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625223,,BAO_0000218,,
11342,Intermediate,50594,Liver,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625224,,BAO_0000218,2107.0,
11343,Intermediate,50594,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,1,1,,CHEMBL625225,,BAO_0000218,,
11344,Intermediate,50597,Blood,,Biodistribution in Rat blood after 24 hours of iv administration,N,1,1,,CHEMBL625226,,BAO_0000218,178.0,
11345,Intermediate,50597,Blood,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,N,1,1,,CHEMBL625227,,BAO_0000218,178.0,
11346,Intermediate,50597,Blood,,Biodistribution in Rat blood after 30 minutes of iv administration,N,1,1,,CHEMBL625228,,BAO_0000218,178.0,
11347,Intermediate,50597,Blood,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL875354,,BAO_0000218,178.0,
11348,Intermediate,50597,Blood,,Biodistribution in Rat blood after 5 minutes of iv administration,N,1,1,,CHEMBL625229,,BAO_0000218,178.0,
11349,Intermediate,50597,Blood,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL625230,,BAO_0000218,178.0,
11350,Intermediate,50597,Heart,,Biodistribution in Rat heart after 24 hours of iv administration,N,1,1,,CHEMBL625231,,BAO_0000218,948.0,
11351,Intermediate,50597,Heart,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,N,1,1,,CHEMBL625900,,BAO_0000218,948.0,
11352,Intermediate,50597,Heart,,Biodistribution in Rat heart after 30 minutes of iv administration,N,1,1,,CHEMBL625901,,BAO_0000218,948.0,
11353,Intermediate,50597,Heart,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL625902,,BAO_0000218,948.0,
11354,Intermediate,50597,Heart,,Biodistribution in Rat heart after 5 minutes of iv administration,N,1,1,,CHEMBL625903,,BAO_0000218,948.0,
11355,Intermediate,50597,Heart,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL625904,,BAO_0000218,948.0,
11356,Intermediate,50597,Liver,,Biodistribution in Rat liver after 24 hours of iv administration,N,1,1,,CHEMBL625905,,BAO_0000218,2107.0,
11357,Intermediate,50597,Liver,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,N,1,1,,CHEMBL627861,,BAO_0000218,2107.0,
11358,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration,N,1,1,,CHEMBL627862,,BAO_0000218,2107.0,
11359,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL627863,,BAO_0000218,2107.0,
11360,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration,N,1,1,,CHEMBL627769,,BAO_0000218,2107.0,
11361,Intermediate,50588,Plasma,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,1,1,,CHEMBL627770,,BAO_0000218,1969.0,
11362,Intermediate,100710,,,Cmax in cynomolgus monkey (PO dose),N,1,1,,CHEMBL627771,,BAO_0000218,,
11363,Intermediate,50597,,,Cmax in rat (PO dose),N,1,1,,CHEMBL627772,,BAO_0000218,,
11364,Intermediate,50597,,,Cmax in rat (PO dose),N,1,1,,CHEMBL627773,,BAO_0000218,,
11365,Intermediate,50597,Plasma,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,N,1,1,,CHEMBL621922,,BAO_0000218,1969.0,
11366,Intermediate,50597,Plasma,,Cmax in rat plasma after oral dose (10 mg/kg),N,1,1,,CHEMBL621923,,BAO_0000218,1969.0,
11367,Autocuration,22224,Plasma,,Cmax in plasma after oral dose (10 mg/kg),U,0,1,,CHEMBL621924,,BAO_0000218,1969.0,
11368,Intermediate,50588,Plasma,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,N,1,1,,CHEMBL621925,,BAO_0000218,1969.0,
11369,Autocuration,22224,Plasma,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,U,0,1,,CHEMBL621926,,BAO_0000218,1969.0,
11370,Intermediate,50592,Plasma,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,N,1,1,,CHEMBL621927,,BAO_0000218,1969.0,
11371,Intermediate,50597,Plasma,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,N,1,1,,CHEMBL621928,,BAO_0000218,1969.0,
11372,Intermediate,50597,Plasma,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,N,1,1,,CHEMBL621929,,BAO_0000218,1969.0,
11373,Intermediate,50594,Plasma,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,N,1,1,,CHEMBL621930,,BAO_0000218,1969.0,
11374,Intermediate,50597,Plasma,,Maximum plasma concentration after oral dosing in rat,N,1,1,,CHEMBL621931,,BAO_0000218,1969.0,
11375,Autocuration,22224,Plasma,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621932,,BAO_0000218,1969.0,
11376,Autocuration,22224,Plasma,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621933,,BAO_0000218,1969.0,
11377,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,N,1,1,,CHEMBL621934,,BAO_0000218,1969.0,
11378,Intermediate,50588,Plasma,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,N,1,1,,CHEMBL621935,,BAO_0000218,1969.0,
11379,Intermediate,50597,Plasma,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,N,1,1,,CHEMBL621936,,BAO_0000218,1969.0,
11380,Autocuration,22224,Plasma,,Maximum plasma concentration was determined,U,0,1,,CHEMBL621937,,BAO_0000218,1969.0,
11381,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621938,,BAO_0000218,1969.0,
11382,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621939,,BAO_0000218,1969.0,
11383,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621940,,BAO_0000218,1969.0,
11384,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621941,,BAO_0000218,1969.0,
11385,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL621942,,BAO_0000218,1969.0,
11386,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL626178,,BAO_0000218,1969.0,
11387,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL626179,,BAO_0000218,1969.0,
11388,Autocuration,22224,Plasma,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL626180,,BAO_0000218,1969.0,
11389,Intermediate,50597,Plasma,,Plasma Cmax in rat (PO dose),N,1,1,,CHEMBL626181,,BAO_0000218,1969.0,
11390,Intermediate,50597,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,N,1,1,,CHEMBL626182,,BAO_0000218,,
11391,Intermediate,50597,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,N,1,1,,CHEMBL626183,,BAO_0000218,,
11392,Intermediate,50597,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,N,1,1,,CHEMBL626184,,BAO_0000218,,
11393,Intermediate,50597,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,N,1,1,,CHEMBL626185,,BAO_0000218,,
11394,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,N,1,1,,CHEMBL626186,,BAO_0000218,1969.0,
11395,Intermediate,50588,Plasma,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,N,1,1,,CHEMBL877589,,BAO_0000218,1969.0,
11396,Autocuration,22224,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,U,0,1,,CHEMBL626187,,BAO_0000218,,
11397,Autocuration,22224,,,Maximum concentration of the drug at 20 uM/dg administered perorally,U,0,1,,CHEMBL626188,,BAO_0000218,,
11398,Autocuration,22224,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,U,0,1,,CHEMBL626189,,BAO_0000218,,
11399,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL626855,,BAO_0000218,178.0,
11400,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL623781,,BAO_0000218,178.0,
11401,Autocuration,22224,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL623782,,BAO_0000218,178.0,
11402,Intermediate,50597,Plasma,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,N,1,1,,CHEMBL623783,,BAO_0000218,1969.0,
11403,Intermediate,50588,Plasma,,Cmax in dog plasma after 1mg/kg oral dose,N,1,1,,CHEMBL623784,,BAO_0000218,1969.0,
11404,Intermediate,50588,Plasma,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,N,1,1,,CHEMBL623785,,BAO_0000218,1969.0,
11405,Intermediate,50597,Plasma,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,N,1,1,,CHEMBL623786,,BAO_0000218,1969.0,
11406,Intermediate,50597,,,Oral maximum concentration in rat,N,1,1,,CHEMBL623787,,BAO_0000218,,
11407,Intermediate,50597,,,Oral maximum concentration in rat,N,1,1,,CHEMBL623788,,BAO_0000218,,
11408,Intermediate,50594,Plasma,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,N,1,1,,CHEMBL623789,,BAO_0000218,1969.0,
11409,Intermediate,50594,Blood,,Peak concentration in blood after intravenous administration to mice,N,1,1,,CHEMBL623790,,BAO_0000218,178.0,
11410,Intermediate,50594,Blood,,Peak concentration in blood after peroral administration to mice,N,1,1,,CHEMBL623791,,BAO_0000218,178.0,
11411,Intermediate,50597,Plasma,,Peak concentration in rat plasma was determined,N,1,1,,CHEMBL623792,,BAO_0000218,1969.0,
11412,Autocuration,22224,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,U,0,1,,CHEMBL623793,,BAO_0000218,1969.0,
11413,Intermediate,50594,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,N,1,1,,CHEMBL623794,,BAO_0000218,1969.0,
11414,Intermediate,50597,Plasma,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,N,1,1,,CHEMBL623795,,BAO_0000218,1969.0,
11415,Intermediate,50597,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623796,,BAO_0000218,,
11416,Intermediate,50597,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623797,,BAO_0000218,,
11417,Intermediate,50597,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623798,,BAO_0000218,,
11418,Intermediate,50597,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623799,,BAO_0000218,,
11419,Intermediate,50597,Intestine,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624490,,BAO_0000218,160.0,
11420,Intermediate,50597,Intestine,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624491,,BAO_0000218,160.0,
11421,Intermediate,50597,Intestine,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624492,,BAO_0000218,160.0,
11422,Intermediate,50597,Intestine,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624493,,BAO_0000218,160.0,
11423,Intermediate,50597,Intestine,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL877595,,BAO_0000218,160.0,
11424,Intermediate,50597,Intestine,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624494,,BAO_0000218,160.0,
11425,Intermediate,50597,Intestine,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624495,,BAO_0000218,160.0,
11426,Intermediate,50597,Intestine,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624681,,BAO_0000218,160.0,
11427,Intermediate,50597,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624682,,BAO_0000218,,
11428,Intermediate,50597,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624683,,BAO_0000218,,
11429,Intermediate,50597,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624684,,BAO_0000218,,
11430,Intermediate,50597,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624685,,BAO_0000218,,
11431,Intermediate,50597,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624686,,BAO_0000218,,
11432,Intermediate,50597,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624687,,BAO_0000218,,
11433,Intermediate,50597,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624688,,BAO_0000218,,
11434,Intermediate,50597,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL627161,,BAO_0000218,,
11435,Intermediate,50597,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL622127,,BAO_0000218,,
11436,Intermediate,50597,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL622128,,BAO_0000218,,
11437,Intermediate,50597,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL874384,,BAO_0000218,,
11438,Intermediate,50597,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624898,,BAO_0000218,,
11439,Intermediate,50597,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624899,,BAO_0000218,,
11440,Intermediate,50597,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624900,,BAO_0000218,,
11441,Intermediate,50597,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624901,,BAO_0000218,,
11442,Intermediate,50597,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624902,,BAO_0000218,,
11443,Intermediate,50597,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624903,,BAO_0000218,,
11444,Intermediate,50597,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624904,,BAO_0000218,,
11445,Intermediate,50597,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624905,,BAO_0000218,,
11446,Intermediate,50597,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624906,,BAO_0000218,,
11447,Intermediate,50597,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624907,,BAO_0000218,,
11448,Intermediate,50597,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624908,,BAO_0000218,,
11449,Intermediate,50597,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624909,,BAO_0000218,,
11450,Intermediate,50597,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624910,,BAO_0000218,,
11451,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624911,,BAO_0000218,2385.0,
11452,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL874388,,BAO_0000218,2385.0,
11453,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL624912,,BAO_0000218,2385.0,
11454,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL622930,,BAO_0000218,2385.0,
11455,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623121,,BAO_0000218,2385.0,
11456,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623122,,BAO_0000218,2385.0,
11457,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623123,,BAO_0000218,2385.0,
11458,Intermediate,50597,Muscle tissue,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623124,,BAO_0000218,2385.0,
11459,Intermediate,50597,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623125,,BAO_0000218,,
11460,Intermediate,50597,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623126,,BAO_0000218,,
11461,Intermediate,50597,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623127,,BAO_0000218,,
11462,Intermediate,50597,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623128,,BAO_0000218,,
11463,Intermediate,50597,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623129,,BAO_0000218,,
11464,Intermediate,50597,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623130,,BAO_0000218,,
11465,Intermediate,50597,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623131,,BAO_0000218,,
11466,Intermediate,50597,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL623132,,BAO_0000218,,
11467,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623133,,BAO_0000218,2107.0,
11468,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623134,,BAO_0000218,,
11469,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL874389,,BAO_0000218,,
11470,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,1,1,,CHEMBL623135,,BAO_0000218,,
11471,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623136,,BAO_0000218,,
11472,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,1,1,,CHEMBL623137,,BAO_0000218,,
11473,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623138,,BAO_0000218,,
11474,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,1,1,,CHEMBL623139,,BAO_0000218,2113.0,
11475,Intermediate,50597,Kidney,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623140,,BAO_0000218,2113.0,
11476,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,1,1,,CHEMBL623141,,BAO_0000218,2107.0,
11477,Intermediate,50597,Liver,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623142,,BAO_0000218,2107.0,
11478,Intermediate,50597,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL623143,,BAO_0000218,,
11479,Intermediate,50594,Urine,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,N,1,1,,CHEMBL623144,,BAO_0000218,1088.0,
11480,Intermediate,50597,Urine,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,N,1,1,,CHEMBL623405,,BAO_0000218,1088.0,
11481,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624074,,BAO_0000218,,
11482,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,1,1,,CHEMBL624075,,BAO_0000218,,
11483,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624076,,BAO_0000218,,
11484,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,1,1,,CHEMBL624077,,BAO_0000218,,
11485,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624078,,BAO_0000218,,
11486,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,1,1,,CHEMBL624079,,BAO_0000218,2113.0,
11487,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624261,,BAO_0000218,2113.0,
11488,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,1,1,,CHEMBL624262,,BAO_0000218,,
11489,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624263,,BAO_0000218,,
11490,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624264,,BAO_0000218,,
11491,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624265,,BAO_0000218,,
11492,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,1,1,,CHEMBL624266,,BAO_0000218,,
11493,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624267,,BAO_0000218,,
11494,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,1,1,,CHEMBL624268,,BAO_0000218,,
11495,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL875227,,BAO_0000218,,
11496,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,1,1,,CHEMBL624269,,BAO_0000218,2113.0,
11497,Intermediate,50597,Kidney,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624270,,BAO_0000218,2113.0,
11498,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,1,1,,CHEMBL624271,,BAO_0000218,,
11499,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624272,,BAO_0000218,,
11500,Intermediate,50597,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,1,1,,CHEMBL624273,,BAO_0000218,,
11501,Intermediate,50597,Urine,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,N,1,1,,CHEMBL624274,,BAO_0000218,1088.0,
11502,Intermediate,50597,Urine,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,N,1,1,,CHEMBL624275,,BAO_0000218,1088.0,
11503,Intermediate,50597,Urine,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,N,1,1,,CHEMBL624276,,BAO_0000218,1088.0,
11504,Intermediate,50597,Urine,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,N,1,1,,CHEMBL624277,,BAO_0000218,1088.0,
11505,Autocuration,22224,,,% dose converted to 2-amino-5-chlorophenyl sulfate,U,0,1,,CHEMBL624278,,BAO_0000019,,
11506,Autocuration,22224,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),U,0,1,,CHEMBL624279,,BAO_0000019,,
11507,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,1,1,,CHEMBL624280,,BAO_0000218,1988.0,
11508,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,1,1,,CHEMBL624281,,BAO_0000218,1988.0,
11509,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,1,1,,CHEMBL622933,,BAO_0000218,1988.0,
11510,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,1,1,,CHEMBL622934,,BAO_0000218,1988.0,
11511,Intermediate,50597,Liver,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL622935,,BAO_0000218,2107.0,
11512,Intermediate,50597,Liver,,Biodistribution in Rat liver after 5 minutes of iv administration,N,1,1,,CHEMBL622936,,BAO_0000218,2107.0,
11513,Intermediate,50597,Liver,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL875228,,BAO_0000218,2107.0,
11514,Intermediate,50597,Lung,,Biodistribution in Rat lung after 24 hours of iv administration,N,1,1,,CHEMBL622937,,BAO_0000218,2048.0,
11515,Intermediate,50597,Lung,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,N,1,1,,CHEMBL622938,,BAO_0000218,2048.0,
11516,Intermediate,50597,Lung,,Biodistribution in Rat lung after 30 minutes of iv administration,N,1,1,,CHEMBL619736,,BAO_0000218,2048.0,
11517,Intermediate,50597,Lung,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL625117,,BAO_0000218,2048.0,
11518,Intermediate,50597,Lung,,Biodistribution in Rat lung after 5 minutes of iv administration,N,1,1,,CHEMBL625118,,BAO_0000218,2048.0,
11519,Intermediate,50597,Lung,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,N,1,1,,CHEMBL625119,,BAO_0000218,2048.0,
11520,Intermediate,50597,Cerebellum,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",N,1,1,,CHEMBL625120,,BAO_0000218,2037.0,
11521,Intermediate,50597,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",N,1,1,,CHEMBL625121,,BAO_0000218,,
11522,Intermediate,50597,Thalamus,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",N,1,1,,CHEMBL625122,,BAO_0000218,10000006.0,
11523,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL622204,,BAO_0000218,178.0,
11524,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL877503,,BAO_0000218,178.0,
11525,Intermediate,50597,Blood,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL627127,,BAO_0000218,178.0,
11526,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,U,0,1,,CHEMBL627128,,BAO_0000218,10000000.0,
11527,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,U,0,1,,CHEMBL627129,,BAO_0000218,10000000.0,
11528,Autocuration,22224,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,U,0,1,,CHEMBL627130,,BAO_0000218,10000000.0,
11529,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL627131,,BAO_0000218,955.0,
11530,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL627132,,BAO_0000218,955.0,
11531,Intermediate,50597,Brain,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL627133,,BAO_0000218,955.0,
11532,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL627134,,BAO_0000218,2037.0,
11533,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL627135,,BAO_0000218,2037.0,
11534,Intermediate,50597,Cerebellum,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL627136,,BAO_0000218,2037.0,
11535,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL628435,,BAO_0000218,,
11536,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL628436,,BAO_0000218,,
11537,Intermediate,50597,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL628437,,BAO_0000218,,
11538,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL628438,,BAO_0000218,948.0,
11539,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL628439,,BAO_0000218,948.0,
11540,Intermediate,50597,Heart,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL628440,,BAO_0000218,948.0,
11541,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL628441,,BAO_0000218,10000000.0,
11542,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL628442,,BAO_0000218,10000000.0,
11543,Intermediate,50597,Hippocampus,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL628443,,BAO_0000218,10000000.0,
11544,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL628444,,BAO_0000218,2113.0,
11545,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL628445,,BAO_0000218,2113.0,
11546,Intermediate,50597,Kidney,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL877504,,BAO_0000218,2113.0,
11547,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL628446,,BAO_0000218,2107.0,
11548,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL626874,,BAO_0000218,2107.0,
11549,Intermediate,50597,Liver,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL626875,,BAO_0000218,2107.0,
11550,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL626876,,BAO_0000218,2048.0,
11551,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL626877,,BAO_0000218,2048.0,
11552,Intermediate,50597,Lung,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL626878,,BAO_0000218,2048.0,
11553,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL626879,,BAO_0000218,2385.0,
11554,Autocuration,22224,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,U,0,1,,CHEMBL626880,,BAO_0000218,1969.0,
11555,Intermediate,50594,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,N,1,1,,CHEMBL626881,,BAO_0000218,1969.0,
11556,Intermediate,50597,Plasma,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,N,1,1,,CHEMBL626882,,BAO_0000218,1969.0,
11557,Intermediate,50588,Plasma,,Peak plasma concentration was measured in dogs,N,1,1,,CHEMBL626883,,BAO_0000218,1969.0,
11558,Intermediate,50597,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL626884,,BAO_0000218,,
11559,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,1,1,,CHEMBL626885,,BAO_0000218,,
11560,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,1,1,,CHEMBL626886,,BAO_0000218,,
11561,Intermediate,50597,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,1,1,,CHEMBL626887,,BAO_0000218,,
11562,Intermediate,50597,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL626888,,BAO_0000218,,
11563,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,N,1,1,,CHEMBL626889,,BAO_0000218,,
11564,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,U,0,1,,CHEMBL626761,,BAO_0000218,,
11565,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,N,1,1,,CHEMBL626762,,BAO_0000218,,
11566,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,N,1,1,,CHEMBL626763,,BAO_0000218,,
11567,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,N,1,1,,CHEMBL626764,,BAO_0000218,,
11568,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,N,1,1,,CHEMBL626765,,BAO_0000218,,
11569,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,N,1,1,,CHEMBL626766,,BAO_0000218,,
11570,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,N,1,1,,CHEMBL626767,,BAO_0000218,,
11571,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,N,1,1,,CHEMBL626768,,BAO_0000218,,
11572,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,N,1,1,,CHEMBL626769,,BAO_0000218,,
11573,Intermediate,50588,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,N,1,1,,CHEMBL874463,,BAO_0000218,,
11574,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,U,0,1,,CHEMBL626770,,BAO_0000218,,
11575,Autocuration,22224,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,U,0,1,,CHEMBL626771,,BAO_0000218,,
11576,Intermediate,50597,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,N,1,1,,CHEMBL626772,,BAO_0000218,,
11577,Intermediate,100710,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,1,1,,CHEMBL626773,,BAO_0000218,,
11578,Intermediate,50594,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,N,1,1,,CHEMBL626774,,BAO_0000218,,
11579,Intermediate,50588,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,1,1,,CHEMBL626775,,BAO_0000218,,
11580,Intermediate,50588,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,1,1,,CHEMBL626776,,BAO_0000218,,
11581,Intermediate,50597,,,Maximum concentration (Cmax) in rat when administered orally,N,1,1,,CHEMBL626777,,BAO_0000218,,
11582,Autocuration,22224,Plasma,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,U,0,1,,CHEMBL626778,,BAO_0000218,1969.0,
11583,Autocuration,22224,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",U,0,1,,CHEMBL626779,,BAO_0000218,,
11584,Autocuration,22224,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",U,0,1,,CHEMBL626780,,BAO_0000218,,
11585,Autocuration,22224,Plasma,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,U,0,1,,CHEMBL626781,,BAO_0000218,1969.0,
11586,Intermediate,50597,,,Pharmacokinetic profile Cmax was evaluated in rats,N,1,1,,CHEMBL632164,,BAO_0000218,,
11587,Intermediate,50588,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),N,1,1,,CHEMBL632165,,BAO_0000218,,
11588,Intermediate,50594,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),N,1,1,,CHEMBL632166,,BAO_0000218,,
11589,Intermediate,50588,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),N,1,1,,CHEMBL632167,,BAO_0000218,,
11590,Intermediate,50594,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),N,1,1,,CHEMBL632168,,BAO_0000218,,
11591,Autocuration,22224,Plasma,,Cmax in rat plasma,U,0,1,,CHEMBL632169,,BAO_0000218,1969.0,
11592,Intermediate,50588,Plasma,,Cmax in dog plasma after 30mg/kg oral dose,N,1,1,,CHEMBL632170,,BAO_0000218,1969.0,
11593,Intermediate,50597,Plasma,,Cmax in rat plasma after 30mg/kg oral dose,N,1,1,,CHEMBL632171,,BAO_0000218,1969.0,
11594,Intermediate,50597,Plasma,,Plasma level in rats at 30 mg/kg,N,1,1,,CHEMBL632172,,BAO_0000218,1969.0,
11595,Intermediate,50594,Plasma,,Tested for maximum plasma concentration in mice,N,1,1,,CHEMBL632173,,BAO_0000218,1969.0,
11596,Intermediate,50597,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL632174,,BAO_0000218,,
11597,Intermediate,50597,,,The Cmax values in female wistar rats.,N,1,1,,CHEMBL632175,,BAO_0000218,,
11598,Intermediate,50588,Plasma,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,N,1,1,,CHEMBL632176,,BAO_0000218,1969.0,
11599,Intermediate,50597,Plasma,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,N,1,1,,CHEMBL632177,,BAO_0000218,1969.0,
11600,Intermediate,50597,Plasma,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,N,1,1,,CHEMBL632178,,BAO_0000218,1969.0,
11601,Intermediate,50597,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,N,1,1,,CHEMBL632179,,BAO_0000218,,
11602,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,N,1,1,,CHEMBL632180,,BAO_0000218,178.0,
11603,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,N,1,1,,CHEMBL632181,,BAO_0000218,178.0,
11604,Intermediate,50597,Blood,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,N,1,1,,CHEMBL632182,,BAO_0000218,178.0,
11605,Autocuration,22224,Blood,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,U,0,1,,CHEMBL632183,,BAO_0000218,178.0,
11606,Intermediate,50588,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,N,1,1,,CHEMBL632184,,BAO_0000218,,
11607,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,N,1,1,,CHEMBL874470,,BAO_0000218,,
11608,Intermediate,50597,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631302,,BAO_0000218,,
11609,Intermediate,50597,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631303,,BAO_0000218,,
11610,Intermediate,50597,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631304,,BAO_0000218,,
11611,Intermediate,50597,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631305,,BAO_0000218,,
11612,Intermediate,50597,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631306,,BAO_0000218,,
11613,Intermediate,50597,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631307,,BAO_0000218,,
11614,Intermediate,50597,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL631308,,BAO_0000218,,
11615,Intermediate,50597,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625557,,BAO_0000218,,
11616,Intermediate,50597,Spleen,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625558,,BAO_0000218,2106.0,
11617,Intermediate,50597,Spleen,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625559,,BAO_0000218,2106.0,
11618,Intermediate,50597,Spleen,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625560,,BAO_0000218,2106.0,
11619,Intermediate,50597,Spleen,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625561,,BAO_0000218,2106.0,
11620,Intermediate,50597,Spleen,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625562,,BAO_0000218,2106.0,
11621,Intermediate,50597,Spleen,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL875320,,BAO_0000218,2106.0,
11622,Intermediate,50597,Spleen,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625563,,BAO_0000218,2106.0,
11623,Intermediate,50597,Spleen,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625564,,BAO_0000218,2106.0,
11624,Intermediate,50597,Uterus,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625565,,BAO_0000218,995.0,
11625,Intermediate,50597,Uterus,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625566,,BAO_0000218,995.0,
11626,Intermediate,50597,Uterus,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625567,,BAO_0000218,995.0,
11627,Intermediate,50597,Uterus,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL625568,,BAO_0000218,995.0,
11628,Intermediate,50597,Uterus,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL628217,,BAO_0000218,995.0,
11629,Intermediate,50597,Uterus,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",N,1,1,,CHEMBL628218,,BAO_0000218,995.0,
11630,Intermediate,50597,Uterus,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL628219,,BAO_0000218,995.0,
11631,Intermediate,50597,Uterus,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",N,1,1,,CHEMBL628220,,BAO_0000218,995.0,
11632,Autocuration,22224,,,Distribution in the blood after 120 min of intravenous administration,U,0,1,,CHEMBL628221,,BAO_0000019,,
11633,Autocuration,22224,,,Distribution in the blood after 15 min of intravenous administration,U,0,1,,CHEMBL628222,,BAO_0000019,,
11634,Autocuration,22224,,,Distribution in the blood after 30 min of intravenous administration,U,0,1,,CHEMBL628223,,BAO_0000019,,
11635,Autocuration,22224,,,Distribution in the blood after 5 min of intravenous administration,U,0,1,,CHEMBL628224,,BAO_0000019,,
11636,Autocuration,22224,,,Distribution in the blood after 60 min of intravenous administration,U,0,1,,CHEMBL628225,,BAO_0000019,,
11637,Autocuration,22224,,,Distribution in the blood after 90 min of intravenous administration,U,0,1,,CHEMBL628226,,BAO_0000019,,
11638,Autocuration,22224,,,Distribution in the bone after 120 min of intravenous administration,U,0,1,,CHEMBL628227,,BAO_0000019,,
11639,Autocuration,22224,,,Distribution in the bone after 15 min of intravenous administration,U,0,1,,CHEMBL875481,,BAO_0000019,,
11640,Autocuration,22224,,,Distribution in the bone after 30 min of intravenous administration,U,0,1,,CHEMBL628228,,BAO_0000019,,
11641,Autocuration,22224,,,Distribution in the bone after 5 min of intravenous administration,U,0,1,,CHEMBL628229,,BAO_0000019,,
11642,Autocuration,22224,,,Distribution in the bone after 60 min of intravenous administration,U,0,1,,CHEMBL628230,,BAO_0000019,,
11643,Autocuration,22224,,,Distribution in the bone after 90 min of intravenous administration,U,0,1,,CHEMBL628231,,BAO_0000019,,
11644,Autocuration,22224,,,Distribution in the heart after 120 min of intravenous administration,U,0,1,,CHEMBL628232,,BAO_0000019,,
11645,Autocuration,22224,,,Distribution in the heart after 15 min of intravenous administration,U,0,1,,CHEMBL628233,,BAO_0000019,,
11646,Autocuration,22224,,,Distribution in the heart after 30 min of intravenous administration,U,0,1,,CHEMBL628234,,BAO_0000019,,
11647,Autocuration,22224,,,Distribution in the heart after 5 min of intravenous administration,U,0,1,,CHEMBL628235,,BAO_0000019,,
11648,Autocuration,22224,,,Distribution in the heart after 60 min of intravenous administration,U,0,1,,CHEMBL628236,,BAO_0000019,,
11649,Autocuration,22224,,,Distribution in the heart after 90 min of intravenous administration,U,0,1,,CHEMBL628237,,BAO_0000019,,
11650,Autocuration,22224,,,Distribution in the kidneys after 120 min of intravenous administration,U,0,1,,CHEMBL628238,,BAO_0000019,,
11651,Autocuration,22224,,,Distribution in the kidneys after 15 min of intravenous administration,U,0,1,,CHEMBL628239,,BAO_0000019,,
11652,Autocuration,22224,,,Distribution in the kidneys after 30 min of intravenous administration,U,0,1,,CHEMBL628240,,BAO_0000019,,
11653,Autocuration,22224,,,Distribution in the kidneys after 5 min of intravenous administration,U,0,1,,CHEMBL628241,,BAO_0000019,,
11654,Autocuration,22224,,,Distribution in the kidneys after 60 min of intravenous administration,U,0,1,,CHEMBL628242,,BAO_0000019,,
11655,Autocuration,22224,,,Distribution in the kidneys after 90 min of intravenous administration,U,0,1,,CHEMBL875482,,BAO_0000019,,
11656,Autocuration,22224,,,Distribution in the liver after 120 min of intravenous administration,U,0,1,,CHEMBL628243,,BAO_0000019,,
11657,Autocuration,22224,,,Distribution in the liver after 15 min of intravenous administration,U,0,1,,CHEMBL628244,,BAO_0000019,,
11658,Autocuration,22224,,,Distribution in the liver after 30 min of intravenous administration,U,0,1,,CHEMBL628245,,BAO_0000019,,
11659,Autocuration,22224,,,Distribution in the liver after 5 min of intravenous administration,U,0,1,,CHEMBL628246,,BAO_0000019,,
11660,Autocuration,22224,,,Distribution in the liver after 60 min of intravenous administration,U,0,1,,CHEMBL628247,,BAO_0000019,,
11661,Autocuration,22224,,,Distribution in the liver after 90 min of intravenous administration,U,0,1,,CHEMBL628248,,BAO_0000019,,
11662,Autocuration,22224,,,Distribution in the lung after 120 min of intravenous administration,U,0,1,,CHEMBL628249,,BAO_0000019,,
11663,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",N,1,1,,CHEMBL625452,,BAO_0000218,,
11664,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",N,1,1,,CHEMBL625453,,BAO_0000218,,
11665,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",N,1,1,,CHEMBL625454,,BAO_0000218,,
11666,Intermediate,50594,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",N,1,1,,CHEMBL623844,,BAO_0000218,,
11667,Intermediate,50597,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,N,1,1,,CHEMBL623845,,BAO_0000218,,
11668,Intermediate,50597,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,N,1,1,,CHEMBL623846,,BAO_0000218,,
11669,Autocuration,22224,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,U,0,1,,CHEMBL623847,,BAO_0000218,,
11670,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,1,1,,CHEMBL623848,,BAO_0000218,,
11671,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,1,1,,CHEMBL623849,,BAO_0000218,,
11672,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,1,1,,CHEMBL623850,,BAO_0000218,,
11673,Intermediate,100710,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,1,1,,CHEMBL623851,,BAO_0000218,,
11674,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,0,1,,CHEMBL623852,,BAO_0000218,,
11675,Intermediate,50506,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,1,1,,CHEMBL624551,,BAO_0000218,,
11676,Intermediate,50506,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,1,1,,CHEMBL624552,,BAO_0000218,,
11677,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,0,1,,CHEMBL624553,,BAO_0000218,,
11678,Autocuration,22224,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,U,0,1,,CHEMBL624554,,BAO_0000218,,
11679,Intermediate,50597,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,1,1,,CHEMBL624555,,BAO_0000218,,
11680,Intermediate,50597,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,1,1,,CHEMBL624741,,BAO_0000218,,
11681,Intermediate,50588,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",N,1,1,,CHEMBL624742,,BAO_0000218,,
11682,Intermediate,100712,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",N,1,1,,CHEMBL624743,,BAO_0000218,,
11683,Intermediate,50597,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",N,1,1,,CHEMBL877606,,BAO_0000218,,
11684,Autocuration,22224,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,U,0,1,,CHEMBL624744,,BAO_0000218,,
11685,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL624745,,BAO_0000218,178.0,
11686,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL624746,,BAO_0000218,178.0,
11687,Autocuration,22224,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,0,1,,CHEMBL624747,,BAO_0000218,178.0,
11688,Autocuration,22224,,,Oral absorption expressed as Area under curve was determined,U,0,1,,CHEMBL624748,,BAO_0000019,,
11689,Intermediate,50588,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,N,1,1,,CHEMBL622504,,BAO_0000218,,
11690,Intermediate,50588,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",N,1,1,,CHEMBL622505,,BAO_0000218,,
11691,Intermediate,100712,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,1,1,,CHEMBL622506,,BAO_0000218,,
11692,Intermediate,100712,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,1,1,,CHEMBL622507,,BAO_0000218,,
11693,Intermediate,50597,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",N,1,1,,CHEMBL622508,,BAO_0000218,,
11694,Autocuration,22224,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,U,0,1,,CHEMBL622509,,BAO_0000019,,
11695,Intermediate,50597,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL622510,,BAO_0000218,,
11696,Intermediate,50597,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),N,1,1,,CHEMBL622511,,BAO_0000218,,
11697,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,1,1,,CHEMBL622512,,BAO_0000218,,
11698,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,1,1,,CHEMBL622513,,BAO_0000218,,
11699,Intermediate,100710,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,N,1,1,,CHEMBL622514,,BAO_0000218,,
11700,Intermediate,50588,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,1,1,,CHEMBL622515,,BAO_0000218,,
11701,Intermediate,50588,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,N,1,1,,CHEMBL622516,,BAO_0000218,,
11702,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,1,1,,CHEMBL622517,,BAO_0000218,,
11703,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,N,1,1,,CHEMBL622518,,BAO_0000218,,
11704,Intermediate,50597,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,N,1,1,,CHEMBL622519,,BAO_0000218,,
11705,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL622520,,BAO_0000218,2385.0,
11706,Intermediate,50597,Muscle tissue,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL622521,,BAO_0000218,2385.0,
11707,Intermediate,50594,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL625113,,BAO_0000218,14.0,
11708,Intermediate,50597,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL625114,,BAO_0000218,14.0,
11709,Intermediate,50597,Zone of skin,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL874397,,BAO_0000218,14.0,
11710,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL625115,,BAO_0000218,2106.0,
11711,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL625116,,BAO_0000218,2106.0,
11712,Intermediate,50597,Spleen,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL623932,,BAO_0000218,2106.0,
11713,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL623933,,BAO_0000218,2435.0,
11714,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL623934,,BAO_0000218,2435.0,
11715,Intermediate,50597,Striatum,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL623935,,BAO_0000218,2435.0,
11716,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,1,1,,CHEMBL623936,,BAO_0000218,2046.0,
11717,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,1,1,,CHEMBL623937,,BAO_0000218,2046.0,
11718,Intermediate,50597,Thyroid gland,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,1,1,,CHEMBL623938,,BAO_0000218,2046.0,
11719,Intermediate,50594,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL623939,,BAO_0000218,,
11720,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,1,1,,CHEMBL623940,,BAO_0000218,,
11721,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,1,1,,CHEMBL623941,,BAO_0000218,,
11722,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL627216,,BAO_0000218,,
11723,Intermediate,50594,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL623942,,BAO_0000218,,
11724,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL618793,,BAO_0000218,955.0,
11725,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618794,,BAO_0000218,955.0,
11726,Intermediate,50594,Brain,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618795,,BAO_0000218,955.0,
11727,Intermediate,50594,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618796,,BAO_0000218,,
11728,Intermediate,50594,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618797,,BAO_0000218,,
11729,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,1,1,,CHEMBL618798,,BAO_0000218,2113.0,
11730,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL618799,,BAO_0000218,2113.0,
11731,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,1,1,,CHEMBL618800,,BAO_0000218,2113.0,
11732,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,1,1,,CHEMBL618801,,BAO_0000218,2113.0,
11733,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618802,,BAO_0000218,2113.0,
11734,Intermediate,50594,Kidney,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618803,,BAO_0000218,2113.0,
11735,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,1,1,,CHEMBL618804,,BAO_0000218,2107.0,
11736,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL618805,,BAO_0000218,2107.0,
11737,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,1,1,,CHEMBL618806,,BAO_0000218,2107.0,
11738,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,1,1,,CHEMBL618807,,BAO_0000218,2107.0,
11739,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618808,,BAO_0000218,2107.0,
11740,Intermediate,50594,Liver,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618809,,BAO_0000218,2107.0,
11741,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL618810,,BAO_0000218,2385.0,
11742,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,1,1,,CHEMBL618811,,BAO_0000218,2385.0,
11743,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,1,1,,CHEMBL875844,,BAO_0000218,2385.0,
11744,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618812,,BAO_0000218,2385.0,
11745,Intermediate,50594,Muscle tissue,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618813,,BAO_0000218,2385.0,
11746,Intermediate,50594,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL618814,,BAO_0000218,,
11747,Intermediate,50594,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618815,,BAO_0000218,,
11748,Intermediate,50594,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL618816,,BAO_0000218,,
11749,Intermediate,50594,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL618817,,BAO_0000218,,
11750,Intermediate,50594,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL620544,,BAO_0000218,,
11751,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,N,1,1,,CHEMBL626230,,BAO_0000218,,
11752,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,N,1,1,,CHEMBL626231,,BAO_0000218,,
11753,Intermediate,50597,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,N,1,1,,CHEMBL626232,,BAO_0000218,,
11754,Intermediate,50588,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,N,1,1,,CHEMBL626233,,BAO_0000218,1969.0,
11755,Intermediate,50597,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,N,1,1,,CHEMBL626234,,BAO_0000218,1969.0,
11756,Intermediate,50597,Plasma,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,N,1,1,,CHEMBL875341,,BAO_0000218,1969.0,
11757,Intermediate,50587,Plasma,,The maximum plasma concentration (100 mg/kg) administered orally in human,N,1,1,,CHEMBL626235,,BAO_0000218,1969.0,
11758,Autocuration,22224,Plasma,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,U,0,1,,CHEMBL626236,,BAO_0000218,1969.0,
11759,Autocuration,22224,Plasma,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,U,0,1,,CHEMBL626237,,BAO_0000218,1969.0,
11760,Intermediate,50588,Plasma,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,N,1,1,,CHEMBL626238,,BAO_0000218,1969.0,
11761,Intermediate,50587,Plasma,,The maximum plasma concentration (200 mg/kg) administered orally in human,N,1,1,,CHEMBL622412,,BAO_0000218,1969.0,
11762,Intermediate,50597,Plasma,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,N,1,1,,CHEMBL623114,,BAO_0000218,1969.0,
11763,Autocuration,22224,Plasma,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,U,0,1,,CHEMBL623115,,BAO_0000218,1969.0,
11764,Autocuration,22224,Plasma,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,U,0,1,,CHEMBL623116,,BAO_0000218,1969.0,
11765,Autocuration,22224,Plasma,,The maximum plasma concentration (30 mg/kg) administered orally in dog,U,0,1,,CHEMBL623117,,BAO_0000218,1969.0,
11766,Intermediate,50587,Plasma,,The maximum plasma concentration (400 mg/kg) administered orally in human,N,1,1,,CHEMBL623118,,BAO_0000218,1969.0,
11767,Intermediate,50597,Plasma,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,N,1,1,,CHEMBL623119,,BAO_0000218,1969.0,
11768,Intermediate,50597,Plasma,,The maximum plasma concentration (50 mg/kg) administered orally in rat,N,1,1,,CHEMBL623120,,BAO_0000218,1969.0,
11769,Intermediate,50587,Plasma,,The maximum plasma concentration (800 mg/kg) administered orally in human,N,1,1,,CHEMBL623286,,BAO_0000218,1969.0,
11770,Intermediate,50597,Plasma,,The maximum plasma concentration was measured on rats,N,1,1,,CHEMBL623287,,BAO_0000218,1969.0,
11771,Intermediate,50597,Plasma,,The maximum plasma concentration was measured on rats after oral administration,N,1,1,,CHEMBL623288,,BAO_0000218,1969.0,
11772,Intermediate,50597,Plasma,,Plasma drug Cmax in rat (PO dose),N,1,1,,CHEMBL623289,,BAO_0000218,1969.0,
11773,Autocuration,22224,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,U,0,1,,CHEMBL623290,,BAO_0000218,,
11774,Intermediate,50588,Plasma,,maximum Plasma concentration in Dog was determined after Peroral administration,N,1,1,,CHEMBL623291,,BAO_0000218,1969.0,
11775,Intermediate,50597,Plasma,,maximum Plasma concentration in Rats was determined after Peroral administration,N,1,1,,CHEMBL623292,,BAO_0000218,1969.0,
11776,Intermediate,50588,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,1,1,,CHEMBL623293,,BAO_0000218,1969.0,
11777,Autocuration,22224,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,0,1,,CHEMBL623294,,BAO_0000218,1969.0,
11778,Intermediate,50597,Plasma,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,1,1,,CHEMBL623295,,BAO_0000218,1969.0,
11779,Intermediate,50594,,,maximum concentration was measured when administered through oral route in mice,N,1,1,,CHEMBL623296,,BAO_0000218,,
11780,Intermediate,50594,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,N,1,1,,CHEMBL875349,,BAO_0000218,,
11781,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,U,0,1,,CHEMBL623297,,BAO_0000019,,
11782,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,U,0,1,,CHEMBL623298,,BAO_0000019,,
11783,Autocuration,22224,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,U,0,1,,CHEMBL623299,,BAO_0000019,,
11784,Intermediate,50597,,,Pharmacokinetic parameter was evaluated in rats,N,1,1,,CHEMBL623300,,BAO_0000218,,
11785,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,1,1,,CHEMBL623301,,BAO_0000218,,
11786,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,N,1,1,,CHEMBL623302,,BAO_0000218,,
11787,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,1,1,,CHEMBL623303,,BAO_0000218,,
11788,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,N,1,1,,CHEMBL623304,,BAO_0000218,,
11789,Intermediate,50594,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,N,1,1,,CHEMBL623305,,BAO_0000218,,
11790,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,N,1,1,,CHEMBL623306,,BAO_0000218,1969.0,
11791,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,N,1,1,,CHEMBL623307,,BAO_0000218,1969.0,
11792,Intermediate,50597,Plasma,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,N,1,1,,CHEMBL623308,,BAO_0000218,1969.0,
11793,Intermediate,50594,Plasma,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,N,1,1,,CHEMBL623309,,BAO_0000218,1969.0,
11794,Intermediate,50594,,,Plasma Concentration after 120 min of oral administration to mice,N,1,1,,CHEMBL623310,,BAO_0000218,,
11795,Intermediate,50594,,,Plasma Concentration after 30 min of oral administration to mice,N,1,1,,CHEMBL623311,,BAO_0000218,,
11796,Intermediate,100710,,,Plasma Concentration after 60 min of oral administration to mice,N,1,1,,CHEMBL623312,,BAO_0000218,,
11797,Intermediate,50594,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,N,1,1,,CHEMBL875350,,BAO_0000218,,
11798,Intermediate,50594,,,Plasma Concentration after 90 min of oral administration to mice,N,1,1,,CHEMBL628635,,BAO_0000218,,
11799,Intermediate,50597,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,N,1,1,,CHEMBL628636,,BAO_0000218,,
11800,Intermediate,50597,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,N,1,1,,CHEMBL628637,,BAO_0000218,,
11801,Intermediate,50597,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,N,1,1,,CHEMBL628058,,BAO_0000218,,
11802,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,N,1,1,,CHEMBL628059,,BAO_0000218,,
11803,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,N,1,1,,CHEMBL628060,,BAO_0000218,,
11804,Autocuration,22224,,,Distribution in the lung after 15 min of intravenous administration,U,0,1,,CHEMBL628061,,BAO_0000019,,
11805,Autocuration,22224,,,Distribution in the lung after 30 min of intravenous administration,U,0,1,,CHEMBL628062,,BAO_0000019,,
11806,Autocuration,22224,,,Distribution in the lung after 5 min of intravenous administration,U,0,1,,CHEMBL628063,,BAO_0000019,,
11807,Autocuration,22224,,,Distribution in the lung after 60 min of intravenous administration,U,0,1,,CHEMBL628064,,BAO_0000019,,
11808,Autocuration,22224,,,Distribution in the lung after 90 min of intravenous administration,U,0,1,,CHEMBL628065,,BAO_0000019,,
11809,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 120 min of intravenous administration,U,0,1,,CHEMBL628066,,BAO_0000019,2385.0,
11810,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 15 min of intravenous administration,U,0,1,,CHEMBL628067,,BAO_0000019,2385.0,
11811,Intermediate,50594,Muscle tissue,,Distribution in the muscle after 30 min of intravenous administration,N,1,1,,CHEMBL874646,,BAO_0000218,2385.0,
11812,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 5 min of intravenous administration,U,0,1,,CHEMBL628068,,BAO_0000019,2385.0,
11813,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 60 min of intravenous administration,U,0,1,,CHEMBL628069,,BAO_0000019,2385.0,
11814,Autocuration,22224,Muscle tissue,,Distribution in the muscle after 90 min of intravenous administration,U,0,1,,CHEMBL628070,,BAO_0000019,2385.0,
11815,Autocuration,22224,Spleen,,Distribution in the spleen after 120 min of intravenous administration,U,0,1,,CHEMBL628071,,BAO_0000019,2106.0,
11816,Autocuration,22224,Spleen,,Distribution in the spleen after 15 min of intravenous administration,U,0,1,,CHEMBL628072,,BAO_0000019,2106.0,
11817,Autocuration,22224,Spleen,,Distribution in the spleen after 30 min of intravenous administration,U,0,1,,CHEMBL628073,,BAO_0000019,2106.0,
11818,Autocuration,22224,Spleen,,Distribution in the spleen after 5 min of intravenous administration,U,0,1,,CHEMBL628074,,BAO_0000019,2106.0,
11819,Autocuration,22224,Spleen,,Distribution in the spleen after 60 min of intravenous administration,U,0,1,,CHEMBL628075,,BAO_0000019,2106.0,
11820,Autocuration,22224,Spleen,,Distribution in the spleen after 90 min of intravenous administration,U,0,1,,CHEMBL628076,,BAO_0000019,2106.0,
11821,Intermediate,50597,Adrenal cortex,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,1,1,,CHEMBL628077,,BAO_0000218,1235.0,
11822,Intermediate,50597,Blood,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,N,1,1,,CHEMBL628078,,BAO_0000218,178.0,
11823,Intermediate,50597,Liver,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,N,1,1,,CHEMBL628079,,BAO_0000218,2107.0,
11824,Intermediate,50597,Female gonad,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,N,1,1,,CHEMBL628080,,BAO_0000218,992.0,
11825,Intermediate,50597,Thyroid gland,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,N,1,1,,CHEMBL628081,,BAO_0000218,2046.0,
11826,Intermediate,50597,Adrenal cortex,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,1,1,,CHEMBL628082,,BAO_0000218,1235.0,
11827,Intermediate,50597,Blood,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,N,1,1,,CHEMBL874647,,BAO_0000218,178.0,
11828,Intermediate,50597,Liver,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,N,1,1,,CHEMBL626406,,BAO_0000218,2107.0,
11829,Intermediate,50597,Female gonad,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,N,1,1,,CHEMBL626407,,BAO_0000218,992.0,
11830,Intermediate,50597,Thyroid gland,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,N,1,1,,CHEMBL626408,,BAO_0000218,2046.0,
11831,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",N,1,1,,CHEMBL626409,,BAO_0000218,178.0,
11832,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",N,1,1,,CHEMBL626410,,BAO_0000218,178.0,
11833,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",N,1,1,,CHEMBL626411,,BAO_0000218,178.0,
11834,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",N,1,1,,CHEMBL626412,,BAO_0000218,178.0,
11835,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",N,1,1,,CHEMBL626413,,BAO_0000218,178.0,
11836,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",N,1,1,,CHEMBL626414,,BAO_0000218,178.0,
11837,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",N,1,1,,CHEMBL626415,,BAO_0000218,178.0,
11838,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",N,1,1,,CHEMBL626416,,BAO_0000218,178.0,
11839,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",N,1,1,,CHEMBL627062,,BAO_0000218,178.0,
11840,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",N,1,1,,CHEMBL627063,,BAO_0000218,178.0,
11841,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",N,1,1,,CHEMBL627064,,BAO_0000218,178.0,
11842,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",N,1,1,,CHEMBL627227,,BAO_0000218,178.0,
11843,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",N,1,1,,CHEMBL627228,,BAO_0000218,178.0,
11844,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",N,1,1,,CHEMBL627229,,BAO_0000218,178.0,
11845,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",N,1,1,,CHEMBL625792,,BAO_0000218,178.0,
11846,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",N,1,1,,CHEMBL625793,,BAO_0000218,178.0,
11847,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",N,1,1,,CHEMBL625794,,BAO_0000218,178.0,
11848,Intermediate,50597,Blood,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",N,1,1,,CHEMBL625795,,BAO_0000218,178.0,
11849,Intermediate,50594,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,N,1,1,,CHEMBL625796,,BAO_0000218,,
11850,Intermediate,50588,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,1,1,,CHEMBL625797,,BAO_0000218,,
11851,Intermediate,50588,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,1,1,,CHEMBL625798,,BAO_0000218,,
11852,Autocuration,22224,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL875613,,BAO_0000218,,
11853,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL625799,,BAO_0000218,,
11854,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,U,0,1,,CHEMBL625800,,BAO_0000218,,
11855,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL625801,,BAO_0000218,,
11856,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL625802,,BAO_0000218,,
11857,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL625803,,BAO_0000218,,
11858,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,U,0,1,,CHEMBL625804,,BAO_0000019,,
11859,Autocuration,22224,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,U,0,1,,CHEMBL622530,,BAO_0000218,,
11860,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,N,1,1,,CHEMBL622531,,BAO_0000218,,
11861,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,1,1,,CHEMBL622532,,BAO_0000218,,
11862,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,1,1,,CHEMBL623176,,BAO_0000218,,
11863,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,1,1,,CHEMBL623177,,BAO_0000218,,
11864,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,1,1,,CHEMBL623178,,BAO_0000218,,
11865,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,N,1,1,,CHEMBL623179,,BAO_0000218,,
11866,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,1,1,,CHEMBL623180,,BAO_0000218,,
11867,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,1,1,,CHEMBL623181,,BAO_0000218,,
11868,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,1,1,,CHEMBL624131,,BAO_0000218,,
11869,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),N,1,1,,CHEMBL624132,,BAO_0000218,,
11870,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,1,1,,CHEMBL624133,,BAO_0000218,,
11871,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,N,1,1,,CHEMBL624846,,BAO_0000218,,
11872,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,1,1,,CHEMBL624847,,BAO_0000218,,
11873,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,1,1,,CHEMBL624848,,BAO_0000218,,
11874,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,1,1,,CHEMBL625012,,BAO_0000218,,
11875,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,1,1,,CHEMBL625013,,BAO_0000218,,
11876,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,N,1,1,,CHEMBL625014,,BAO_0000218,,
11877,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),N,1,1,,CHEMBL625015,,BAO_0000218,,
11878,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,1,1,,CHEMBL625016,,BAO_0000218,,
11879,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,N,1,1,,CHEMBL625017,,BAO_0000218,,
11880,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,1,1,,CHEMBL625018,,BAO_0000218,,
11881,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),N,1,1,,CHEMBL625019,,BAO_0000218,,
11882,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),N,1,1,,CHEMBL625020,,BAO_0000218,,
11883,Intermediate,50594,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,N,1,1,,CHEMBL625021,,BAO_0000218,,
11884,Intermediate,50597,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL625022,,BAO_0000218,,
11885,Intermediate,50594,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,N,1,1,,CHEMBL625023,,BAO_0000218,,
11886,Intermediate,100710,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,N,1,1,,CHEMBL625024,,BAO_0000218,,
11887,Intermediate,100710,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,1,1,,CHEMBL627626,,BAO_0000218,,
11888,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,0,1,,CHEMBL627627,,BAO_0000218,955.0,
11889,Autocuration,22224,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,U,0,1,,CHEMBL627628,,BAO_0000218,1977.0,
11890,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,0,1,,CHEMBL627629,,BAO_0000218,955.0,
11891,Autocuration,22224,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,U,0,1,,CHEMBL627630,,BAO_0000218,1977.0,
11892,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),U,0,1,,CHEMBL627631,,BAO_0000019,,
11893,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),U,0,1,,CHEMBL629515,,BAO_0000218,,
11894,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL629516,,BAO_0000218,2106.0,
11895,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL629517,,BAO_0000218,2106.0,
11896,Intermediate,50594,Spleen,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL629518,,BAO_0000218,2106.0,
11897,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,1,1,,CHEMBL877499,,BAO_0000218,,
11898,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,1,1,,CHEMBL629519,,BAO_0000218,,
11899,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,1,1,,CHEMBL629520,,BAO_0000218,,
11900,Intermediate,50594,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,1,1,,CHEMBL629521,,BAO_0000218,,
11901,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),N,1,1,,CHEMBL629522,,BAO_0000218,,
11902,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),N,1,1,,CHEMBL629523,,BAO_0000218,,
11903,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),N,1,1,,CHEMBL629524,,BAO_0000218,,
11904,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),N,1,1,,CHEMBL629525,,BAO_0000218,,
11905,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),N,1,1,,CHEMBL629526,,BAO_0000218,,
11906,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),N,1,1,,CHEMBL629527,,BAO_0000218,,
11907,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),N,1,1,,CHEMBL629528,,BAO_0000218,,
11908,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),N,1,1,,CHEMBL629529,,BAO_0000218,,
11909,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),N,1,1,,CHEMBL629530,,BAO_0000218,,
11910,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),N,1,1,,CHEMBL629531,,BAO_0000218,,
11911,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),N,1,1,,CHEMBL628656,,BAO_0000218,,
11912,Intermediate,50594,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),N,1,1,,CHEMBL628657,,BAO_0000218,,
11913,Intermediate,50597,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL628658,,BAO_0000218,,
11914,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL628659,,BAO_0000218,,
11915,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL877500,,BAO_0000218,,
11916,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL628660,,BAO_0000218,,
11917,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL628661,,BAO_0000218,,
11918,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL628662,,BAO_0000218,,
11919,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL628663,,BAO_0000218,,
11920,Intermediate,50597,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL628664,,BAO_0000218,,
11921,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL628665,,BAO_0000218,178.0,
11922,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL628666,,BAO_0000218,178.0,
11923,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL628667,,BAO_0000218,178.0,
11924,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL628668,,BAO_0000218,178.0,
11925,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL628669,,BAO_0000218,178.0,
11926,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL628670,,BAO_0000218,178.0,
11927,Intermediate,50597,Blood,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL628671,,BAO_0000218,178.0,
11928,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL628672,,BAO_0000218,10000001.0,
11929,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL630300,,BAO_0000218,10000001.0,
11930,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL629787,,BAO_0000218,10000001.0,
11931,Intermediate,50597,Bone,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL629788,,BAO_0000218,10000001.0,
11932,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL629789,,BAO_0000218,955.0,
11933,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL629790,,BAO_0000218,955.0,
11934,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL629791,,BAO_0000218,955.0,
11935,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL629792,,BAO_0000218,955.0,
11936,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL629793,,BAO_0000218,955.0,
11937,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL629794,,BAO_0000218,955.0,
11938,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,N,1,1,,CHEMBL874459,,BAO_0000218,,
11939,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,N,1,1,,CHEMBL629795,,BAO_0000218,,
11940,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,N,1,1,,CHEMBL629796,,BAO_0000218,,
11941,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,N,1,1,,CHEMBL629797,,BAO_0000218,,
11942,Intermediate,50597,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,N,1,1,,CHEMBL629798,,BAO_0000218,,
11943,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629799,,BAO_0000218,2369.0,
11944,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629800,,BAO_0000218,2369.0,
11945,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629801,,BAO_0000218,2369.0,
11946,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,N,1,1,,CHEMBL629802,,BAO_0000218,2369.0,
11947,Intermediate,50597,Adrenal gland,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629803,,BAO_0000218,2369.0,
11948,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629804,,BAO_0000218,178.0,
11949,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629805,,BAO_0000218,178.0,
11950,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629806,,BAO_0000218,178.0,
11951,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629807,,BAO_0000218,178.0,
11952,Intermediate,50597,Blood,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629808,,BAO_0000218,178.0,
11953,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629809,,BAO_0000218,955.0,
11954,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629810,,BAO_0000218,955.0,
11955,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629811,,BAO_0000218,955.0,
11956,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629812,,BAO_0000218,955.0,
11957,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629813,,BAO_0000218,955.0,
11958,Intermediate,50597,Brain,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL874460,,BAO_0000218,955.0,
11959,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629814,,BAO_0000218,,
11960,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629815,,BAO_0000218,,
11961,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629816,,BAO_0000218,,
11962,Intermediate,50597,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL629817,,BAO_0000218,,
11963,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626643,,BAO_0000218,2113.0,
11964,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626644,,BAO_0000218,2113.0,
11965,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626806,,BAO_0000218,2113.0,
11966,Intermediate,50597,Kidney,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626807,,BAO_0000218,2113.0,
11967,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627261,,BAO_0000218,2107.0,
11968,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627262,,BAO_0000218,2107.0,
11969,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627263,,BAO_0000218,2107.0,
11970,Intermediate,50597,Liver,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627264,,BAO_0000218,2107.0,
11971,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627265,,BAO_0000218,2048.0,
11972,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627266,,BAO_0000218,2048.0,
11973,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627267,,BAO_0000218,2048.0,
11974,Intermediate,50597,Lung,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627268,,BAO_0000218,2048.0,
11975,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627269,,BAO_0000218,2385.0,
11976,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627270,,BAO_0000218,2385.0,
11977,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",N,1,1,,CHEMBL627271,,BAO_0000218,,
11978,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",N,1,1,,CHEMBL627946,,BAO_0000218,,
11979,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",N,1,1,,CHEMBL875472,,BAO_0000218,,
11980,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",N,1,1,,CHEMBL627947,,BAO_0000218,,
11981,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",N,1,1,,CHEMBL627948,,BAO_0000218,,
11982,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",N,1,1,,CHEMBL628113,,BAO_0000218,,
11983,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",N,1,1,,CHEMBL628114,,BAO_0000218,,
11984,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",N,1,1,,CHEMBL628115,,BAO_0000218,,
11985,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",N,1,1,,CHEMBL628116,,BAO_0000218,,
11986,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",N,1,1,,CHEMBL628117,,BAO_0000218,,
11987,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",N,1,1,,CHEMBL628118,,BAO_0000218,,
11988,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",N,1,1,,CHEMBL628119,,BAO_0000218,,
11989,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",N,1,1,,CHEMBL628120,,BAO_0000218,,
11990,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",N,1,1,,CHEMBL628121,,BAO_0000218,,
11991,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",N,1,1,,CHEMBL628122,,BAO_0000218,,
11992,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",N,1,1,,CHEMBL627297,,BAO_0000218,,
11993,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",N,1,1,,CHEMBL627298,,BAO_0000218,,
11994,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",N,1,1,,CHEMBL627299,,BAO_0000218,,
11995,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",N,1,1,,CHEMBL627300,,BAO_0000218,,
11996,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",N,1,1,,CHEMBL627301,,BAO_0000218,,
11997,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",N,1,1,,CHEMBL627302,,BAO_0000218,,
11998,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",N,1,1,,CHEMBL627303,,BAO_0000218,,
11999,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",N,1,1,,CHEMBL627304,,BAO_0000218,,
12000,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",N,1,1,,CHEMBL627305,,BAO_0000218,,
12001,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,1,1,,CHEMBL627306,,BAO_0000218,,
12002,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",N,1,1,,CHEMBL623982,,BAO_0000218,,
12003,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",N,1,1,,CHEMBL623983,,BAO_0000218,,
12004,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",N,1,1,,CHEMBL623984,,BAO_0000218,,
12005,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",N,1,1,,CHEMBL623985,,BAO_0000218,,
12006,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",N,1,1,,CHEMBL623986,,BAO_0000218,,
12007,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",N,1,1,,CHEMBL623987,,BAO_0000218,,
12008,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",N,1,1,,CHEMBL623988,,BAO_0000218,,
12009,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",N,1,1,,CHEMBL623989,,BAO_0000218,,
12010,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",N,1,1,,CHEMBL622215,,BAO_0000218,,
12011,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",N,1,1,,CHEMBL622216,,BAO_0000218,,
12012,Intermediate,50597,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",N,1,1,,CHEMBL877481,,BAO_0000218,,
12013,Autocuration,22224,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),U,0,1,,CHEMBL622217,,BAO_0000218,,
12014,Intermediate,50594,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,1,1,,CHEMBL622218,,BAO_0000218,,
12015,Intermediate,50597,,,Pharmacokinetic profile AUC was evaluated in rats,N,1,1,,CHEMBL622219,,BAO_0000218,,
12016,Autocuration,22224,,,Pharmacokinetic property (Area under curve),U,0,1,,CHEMBL622220,,BAO_0000019,,
12017,Intermediate,50588,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",N,1,1,,CHEMBL622221,,BAO_0000218,,
12018,Intermediate,50594,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",N,1,1,,CHEMBL622222,,BAO_0000218,,
12019,Intermediate,50588,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",N,1,1,,CHEMBL622223,,BAO_0000218,,
12020,Intermediate,50594,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",N,1,1,,CHEMBL622224,,BAO_0000218,,
12021,Autocuration,22224,,,Plasma concentration (AUC) was determined,U,0,1,,CHEMBL622225,,BAO_0000019,,
12022,Autocuration,22224,,,Plasma concentration (AUC) was determined; Not detectable,U,0,1,,CHEMBL622226,,BAO_0000019,,
12023,Intermediate,50512,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),N,1,1,,CHEMBL624154,,BAO_0000218,,
12024,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,N,1,1,,CHEMBL624155,,BAO_0000218,,
12025,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,1,1,,CHEMBL624156,,BAO_0000218,,
12026,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,N,1,1,,CHEMBL624157,,BAO_0000218,,
12027,Intermediate,50597,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,N,1,1,,CHEMBL624158,,BAO_0000218,,
12028,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,N,1,1,,CHEMBL624159,,BAO_0000218,,
12029,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,N,1,1,,CHEMBL624160,,BAO_0000218,,
12030,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,N,1,1,,CHEMBL624161,,BAO_0000218,,
12031,Intermediate,50597,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,N,1,1,,CHEMBL624162,,BAO_0000218,,
12032,Intermediate,50588,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,N,1,1,,CHEMBL624163,,BAO_0000218,,
12033,Intermediate,50597,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL624164,,BAO_0000218,,
12034,Intermediate,50597,,,The AUC(0-infinity) values in female wistar rats.,N,1,1,,CHEMBL624165,,BAO_0000218,,
12035,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL624166,,BAO_0000218,,
12036,Intermediate,50597,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",N,1,1,,CHEMBL624167,,BAO_0000218,,
12037,Intermediate,50597,,,The AUC(0-t)values in female wistar rats.,N,1,1,,CHEMBL624168,,BAO_0000218,,
12038,Intermediate,50597,,,The Area under the concentration time curve of compound was measured on rats,N,1,1,,CHEMBL624169,,BAO_0000218,,
12039,Intermediate,50587,,,The area under curve (100 mg/kg) administered orally in humans,N,1,1,,CHEMBL624170,,BAO_0000218,,
12040,Autocuration,22224,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,U,0,1,,CHEMBL624171,,BAO_0000218,,
12041,Autocuration,22224,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,U,0,1,,CHEMBL624172,,BAO_0000218,,
12042,Intermediate,50588,,,The area under curve (15 mg/kg) administered intravenously in dog,N,1,1,,CHEMBL624173,,BAO_0000218,,
12043,Intermediate,50587,,,The area under curve (200 mg/kg) administered orally in humans,N,1,1,,CHEMBL877488,,BAO_0000218,,
12044,Intermediate,50597,,,The area under curve (25 mg/kg) administered intravenously in rat,N,1,1,,CHEMBL624174,,BAO_0000218,,
12045,Autocuration,22224,,,The area under curve (25 mg/kg) administered orally in marmoset,U,0,1,,CHEMBL624175,,BAO_0000218,,
12046,Autocuration,22224,,,The area under curve (25 mg/kg) administered orally in monkey,U,0,1,,CHEMBL624176,,BAO_0000218,,
12047,Intermediate,50588,,,The area under curve (30 mg/kg) administered orally in dog,N,1,1,,CHEMBL624177,,BAO_0000218,,
12048,Intermediate,50587,,,The area under curve (400 mg/kg) administered orally in humans,N,1,1,,CHEMBL624178,,BAO_0000218,,
12049,Intermediate,50597,,,The area under curve (50 mg/kg) administered orally in fasted rat,N,1,1,,CHEMBL624179,,BAO_0000218,,
12050,Intermediate,50597,,,The area under curve (50 mg/kg) administered orally in rat,N,1,1,,CHEMBL627689,,BAO_0000218,,
12051,Intermediate,50587,,,The area under curve (800 mg/kg) administered orally in humans,N,1,1,,CHEMBL627690,,BAO_0000218,,
12052,Autocuration,22224,,,The compound was evaluated for area under the curve,U,0,1,,CHEMBL627691,,BAO_0000019,,
12053,Autocuration,22224,,,The compound was evaluated for area under the curve in marmosets,U,0,1,,CHEMBL627692,,BAO_0000019,,
12054,Autocuration,22224,,,The compound was evaluated for area under the curve in marmosets,U,0,1,,CHEMBL627693,,BAO_0000019,,
12055,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,1,1,,CHEMBL627694,,BAO_0000218,,
12056,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,N,1,1,,CHEMBL627695,,BAO_0000218,,
12057,Autocuration,22224,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),U,0,1,,CHEMBL627696,,BAO_0000218,,
12058,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,1,1,,CHEMBL627697,,BAO_0000218,,
12059,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,1,1,,CHEMBL627698,,BAO_0000218,,
12060,Intermediate,50597,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,N,1,1,,CHEMBL627699,,BAO_0000218,,
12061,Intermediate,50597,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,N,1,1,,CHEMBL627700,,BAO_0000218,,
12062,Intermediate,50597,,,Total drug exposure is determined after oral dosing in rats.,N,1,1,,CHEMBL627701,,BAO_0000218,,
12063,Autocuration,22224,,,Total drug exposure (5 mg/kg) when administered intravenously,U,0,1,,CHEMBL627702,,BAO_0000218,,
12064,Autocuration,22224,,,Total drug exposure (5 mg/kg) when administered orally,U,0,1,,CHEMBL627703,,BAO_0000218,,
12065,Autocuration,22224,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,0,1,,CHEMBL626873,,BAO_0000218,,
12066,Intermediate,50597,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,1,1,,CHEMBL629583,,BAO_0000218,,
12067,Intermediate,50588,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,1,1,,CHEMBL629584,,BAO_0000218,,
12068,Intermediate,50588,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,1,1,,CHEMBL629585,,BAO_0000218,,
12069,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL629586,,BAO_0000218,955.0,
12070,Intermediate,50597,Brain,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL629587,,BAO_0000218,955.0,
12071,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL629588,,BAO_0000218,,
12072,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL629589,,BAO_0000218,,
12073,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL629590,,BAO_0000218,,
12074,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL629591,,BAO_0000218,,
12075,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL629592,,BAO_0000218,,
12076,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL629593,,BAO_0000218,,
12077,Intermediate,50597,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL629594,,BAO_0000218,,
12078,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL629595,,BAO_0000218,948.0,
12079,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL630290,,BAO_0000218,948.0,
12080,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL627137,,BAO_0000218,948.0,
12081,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL627138,,BAO_0000218,948.0,
12082,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL627139,,BAO_0000218,948.0,
12083,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL627140,,BAO_0000218,948.0,
12084,Intermediate,50597,Heart,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL627141,,BAO_0000218,948.0,
12085,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL627142,,BAO_0000218,2113.0,
12086,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL627143,,BAO_0000218,2113.0,
12087,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL874449,,BAO_0000218,2113.0,
12088,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL627144,,BAO_0000218,2113.0,
12089,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL627145,,BAO_0000218,2113.0,
12090,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL627146,,BAO_0000218,2113.0,
12091,Intermediate,50597,Kidney,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL627147,,BAO_0000218,2113.0,
12092,Intermediate,50597,Liver,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL627148,,BAO_0000218,2107.0,
12093,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL627149,,BAO_0000218,2048.0,
12094,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL632160,,BAO_0000218,2048.0,
12095,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL632161,,BAO_0000218,2048.0,
12096,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL632162,,BAO_0000218,2048.0,
12097,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL632163,,BAO_0000218,2048.0,
12098,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL874469,,BAO_0000218,2048.0,
12099,Intermediate,50597,Lung,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL627182,,BAO_0000218,2048.0,
12100,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,1,1,,CHEMBL627183,,BAO_0000218,2385.0,
12101,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL627184,,BAO_0000218,2385.0,
12102,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL627185,,BAO_0000218,2385.0,
12103,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL627186,,BAO_0000218,2385.0,
12104,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL627187,,BAO_0000218,2385.0,
12105,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL627188,,BAO_0000218,2385.0,
12106,Intermediate,50597,Muscle tissue,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL627189,,BAO_0000218,2385.0,
12107,Intermediate,50597,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL627190,,BAO_0000218,,
12108,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,1,1,,CHEMBL627191,,BAO_0000218,2107.0,
12109,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,1,1,,CHEMBL627192,,BAO_0000218,2107.0,
12110,Intermediate,50597,Liver,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,1,1,,CHEMBL627193,,BAO_0000218,2107.0,
12111,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL874590,,BAO_0000218,2385.0,
12112,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627194,,BAO_0000218,2385.0,
12113,Intermediate,50597,Muscle tissue,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627195,,BAO_0000218,2385.0,
12114,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627196,,BAO_0000218,992.0,
12115,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627197,,BAO_0000218,992.0,
12116,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627198,,BAO_0000218,992.0,
12117,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,N,1,1,,CHEMBL627199,,BAO_0000218,992.0,
12118,Intermediate,50597,Female gonad,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627200,,BAO_0000218,992.0,
12119,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627201,,BAO_0000218,1969.0,
12120,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627202,,BAO_0000218,1969.0,
12121,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627203,,BAO_0000218,1969.0,
12122,Intermediate,50597,Plasma,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627204,,BAO_0000218,1969.0,
12123,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627205,,BAO_0000218,2106.0,
12124,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627206,,BAO_0000218,2106.0,
12125,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627207,,BAO_0000218,2106.0,
12126,Intermediate,50597,Spleen,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627208,,BAO_0000218,2106.0,
12127,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627209,,BAO_0000218,2046.0,
12128,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627210,,BAO_0000218,2046.0,
12129,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627211,,BAO_0000218,2046.0,
12130,Intermediate,50597,Thyroid gland,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627212,,BAO_0000218,2046.0,
12131,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL627213,,BAO_0000218,995.0,
12132,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626599,,BAO_0000218,995.0,
12133,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626600,,BAO_0000218,995.0,
12134,Intermediate,50597,Uterus,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,1,1,,CHEMBL626601,,BAO_0000218,995.0,
12135,Autocuration,22224,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,U,0,1,,CHEMBL627484,,BAO_0000019,,
12136,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),N,1,1,,CHEMBL627485,,BAO_0000218,1969.0,
12137,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,N,1,1,,CHEMBL628147,,BAO_0000218,1969.0,
12138,Intermediate,100710,Plasma,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,N,1,1,,CHEMBL628148,,BAO_0000218,1969.0,
12139,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),N,1,1,,CHEMBL628149,,BAO_0000218,1969.0,
12140,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,N,1,1,,CHEMBL628150,,BAO_0000218,1969.0,
12141,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,N,1,1,,CHEMBL628318,,BAO_0000218,1969.0,
12142,Intermediate,50588,Plasma,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,N,1,1,,CHEMBL628319,,BAO_0000218,1969.0,
12143,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,1,1,,CHEMBL875609,,BAO_0000218,,
12144,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,U,0,1,,CHEMBL628320,,BAO_0000019,,
12145,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,U,0,1,,CHEMBL628321,,BAO_0000019,,
12146,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,U,0,1,,CHEMBL628322,,BAO_0000019,,
12147,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,U,0,1,,CHEMBL628323,,BAO_0000019,,
12148,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,U,0,1,,CHEMBL628324,,BAO_0000019,,
12149,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,U,0,1,,CHEMBL628325,,BAO_0000019,,
12150,Autocuration,22224,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,U,0,1,,CHEMBL628326,,BAO_0000019,,
12151,Intermediate,50588,Adrenal medulla,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",N,1,1,,CHEMBL628327,,BAO_0000218,1236.0,
12152,Intermediate,50588,Adrenal medulla,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",N,1,1,,CHEMBL628328,,BAO_0000218,1236.0,
12153,Intermediate,50588,Blood,,"Concentration of compound in blood of dog 1, after administering intravenously",N,1,1,,CHEMBL628329,,BAO_0000218,178.0,
12154,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",N,1,1,,CHEMBL628330,,BAO_0000218,2107.0,
12155,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",N,1,1,,CHEMBL628331,,BAO_0000218,2107.0,
12156,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",N,1,1,,CHEMBL628332,,BAO_0000218,2107.0,
12157,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",N,1,1,,CHEMBL628333,,BAO_0000218,2107.0,
12158,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",N,1,1,,CHEMBL628334,,BAO_0000218,2107.0,
12159,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",N,1,1,,CHEMBL628335,,BAO_0000218,2107.0,
12160,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",N,1,1,,CHEMBL628336,,BAO_0000218,2107.0,
12161,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,1,1,,CHEMBL628337,,BAO_0000218,2107.0,
12162,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",N,1,1,,CHEMBL628338,,BAO_0000218,2107.0,
12163,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",N,1,1,,CHEMBL875610,,BAO_0000218,2107.0,
12164,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",N,1,1,,CHEMBL628339,,BAO_0000218,2107.0,
12165,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",N,1,1,,CHEMBL628340,,BAO_0000218,2107.0,
12166,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",N,1,1,,CHEMBL628341,,BAO_0000218,2107.0,
12167,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",N,1,1,,CHEMBL622214,,BAO_0000218,2107.0,
12168,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",N,1,1,,CHEMBL623167,,BAO_0000218,2107.0,
12169,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",N,1,1,,CHEMBL623168,,BAO_0000218,2107.0,
12170,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",N,1,1,,CHEMBL623169,,BAO_0000218,2107.0,
12171,Intermediate,50597,Liver,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",N,1,1,,CHEMBL623170,,BAO_0000218,2107.0,
12172,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",N,1,1,,CHEMBL627224,,BAO_0000218,2048.0,
12173,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",N,1,1,,CHEMBL875634,,BAO_0000218,2048.0,
12174,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",N,1,1,,CHEMBL627225,,BAO_0000218,2048.0,
12175,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",N,1,1,,CHEMBL627226,,BAO_0000218,2048.0,
12176,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",N,1,1,,CHEMBL626083,,BAO_0000218,2048.0,
12177,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",N,1,1,,CHEMBL626084,,BAO_0000218,2048.0,
12178,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",N,1,1,,CHEMBL626085,,BAO_0000218,2048.0,
12179,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",N,1,1,,CHEMBL626086,,BAO_0000218,2048.0,
12180,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",N,1,1,,CHEMBL626087,,BAO_0000218,2048.0,
12181,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",N,1,1,,CHEMBL626088,,BAO_0000218,2048.0,
12182,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",N,1,1,,CHEMBL626089,,BAO_0000218,2048.0,
12183,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",N,1,1,,CHEMBL626090,,BAO_0000218,2048.0,
12184,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",N,1,1,,CHEMBL626091,,BAO_0000218,2048.0,
12185,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",N,1,1,,CHEMBL626092,,BAO_0000218,2048.0,
12186,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",N,1,1,,CHEMBL626093,,BAO_0000218,2048.0,
12187,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",N,1,1,,CHEMBL626094,,BAO_0000218,2048.0,
12188,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",N,1,1,,CHEMBL626095,,BAO_0000218,2048.0,
12189,Intermediate,50597,Lung,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",N,1,1,,CHEMBL626096,,BAO_0000218,2048.0,
12190,Autocuration,22224,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,0,1,,CHEMBL626097,,BAO_0000218,,
12191,Intermediate,50597,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,1,1,,CHEMBL626098,,BAO_0000218,,
12192,Autocuration,22224,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,U,0,1,,CHEMBL626099,,BAO_0000218,1969.0,
12193,Autocuration,22224,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,U,0,1,,CHEMBL626100,,BAO_0000218,1969.0,
12194,Intermediate,50588,Plasma,,AUC 0-inf in dog,N,1,1,,CHEMBL626101,,BAO_0000218,1969.0,
12195,Intermediate,50512,Plasma,,AUC 0-inf in guinea pig,N,1,1,,CHEMBL626102,,BAO_0000218,1969.0,
12196,Intermediate,50588,Plasma,,AUC 0-t in dog,N,1,1,,CHEMBL626103,,BAO_0000218,1969.0,
12197,Intermediate,50512,Plasma,,AUC 0-t in guinea pig,N,1,1,,CHEMBL628391,,BAO_0000218,1969.0,
12198,Intermediate,50597,,,The compound was tested for brain to plasma partition in rat,N,1,1,,CHEMBL628392,,BAO_0000218,,
12199,Intermediate,50597,,,The compound was tested for brain to plasma partition in rat.,N,1,1,,CHEMBL628393,,BAO_0000218,,
12200,Autocuration,22224,Blood,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,U,0,1,,CHEMBL628394,,BAO_0000019,178.0,
12201,Intermediate,50588,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL628395,,BAO_0000218,,
12202,Autocuration,22224,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,U,0,1,,CHEMBL628396,,BAO_0000218,,
12203,Intermediate,50592,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL628397,,BAO_0000218,,
12204,Intermediate,50597,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL628398,,BAO_0000218,,
12205,Intermediate,50797,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,N,1,1,,CHEMBL628399,,BAO_0000218,,
12206,Intermediate,50588,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,N,1,1,,CHEMBL628400,,BAO_0000218,,
12207,Intermediate,50597,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,N,1,1,,CHEMBL874907,,BAO_0000218,,
12208,Autocuration,22224,,,Area under curve of the compound was determined,U,0,1,,CHEMBL628401,,BAO_0000019,,
12209,Autocuration,22224,Plasma,,AUC in monkeys at a dose of 1 mg/kg,U,0,1,,CHEMBL628402,,BAO_0000218,1969.0,
12210,Intermediate,50597,Plasma,,AUC in rats at a dose of 1 mg/kg,N,1,1,,CHEMBL628403,,BAO_0000218,1969.0,
12211,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 2,U,0,1,,CHEMBL628404,,BAO_0000019,,
12212,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 4,U,0,1,,CHEMBL628405,,BAO_0000019,,
12213,Autocuration,22224,,,Compound was evaluated for the overall absorbance loss at pH of 7,U,0,1,,CHEMBL628406,,BAO_0000019,,
12214,Intermediate,50597,,,Compound was evaluated for its absorption in the rats,N,1,1,,CHEMBL628407,,BAO_0000218,,
12215,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,1,1,,CHEMBL628408,,BAO_0000218,1088.0,
12216,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,N,1,1,,CHEMBL629171,,BAO_0000218,1088.0,
12217,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,1,1,,CHEMBL629172,,BAO_0000218,1088.0,
12218,Intermediate,50597,Urine,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,N,1,1,,CHEMBL629173,,BAO_0000218,1088.0,
12219,Intermediate,50597,,,In vitro percent permeability into rat ileum,N,1,1,,CHEMBL629174,,BAO_0000218,,
12220,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-17,N,1,1,,CHEMBL629175,,BAO_0000218,,
12221,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-18,N,1,1,,CHEMBL629176,,BAO_0000218,,
12222,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 10-19,N,1,1,,CHEMBL629177,,BAO_0000218,,
12223,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 12-15,N,1,1,,CHEMBL629178,,BAO_0000218,,
12224,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 13-19,N,1,1,,CHEMBL631869,,BAO_0000218,,
12225,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 14-17,N,1,1,,CHEMBL631870,,BAO_0000218,,
12226,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 15-18,N,1,1,,CHEMBL631871,,BAO_0000218,,
12227,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 2-5,N,1,1,,CHEMBL631872,,BAO_0000218,,
12228,Autocuration,22224,Ileum,,In vitro percent permeability into rat ileum; Range is 23-42,U,0,1,,CHEMBL875775,,BAO_0000221,2116.0,
12229,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 28-36,N,1,1,,CHEMBL631873,,BAO_0000218,,
12230,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 29-35,N,1,1,,CHEMBL631874,,BAO_0000218,,
12231,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 46-66,N,1,1,,CHEMBL631875,,BAO_0000218,,
12232,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 50-68,N,1,1,,CHEMBL631876,,BAO_0000218,,
12233,Intermediate,50597,,,In vitro percent permeability into rat ileum; Range is 78-81,N,1,1,,CHEMBL631877,,BAO_0000218,,
12234,Intermediate,50597,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,N,1,1,,CHEMBL631878,,BAO_0000218,,
12235,Intermediate,50597,,,In vitro percent permeability into rat ileum; nd indicates not detected,N,1,1,,CHEMBL631879,,BAO_0000218,,
12236,Intermediate,50597,,,In vitro percent permeability into rat ileum; nt indicates not detected,N,1,1,,CHEMBL631880,,BAO_0000218,,
12237,Intermediate,50597,,,In vitro percent permeability into rat ileum; nt indicates not tested,N,1,1,,CHEMBL631881,,BAO_0000218,,
12238,Intermediate,50597,,,Compound was tested for oral absorption in bile-duct cannulated rats,N,1,1,,CHEMBL631882,,BAO_0000218,,
12239,Intermediate,50597,,,Compound was tested for oral absorption in bile-duct cannulated rats.,N,1,1,,CHEMBL630749,,BAO_0000218,,
12240,Intermediate,50587,,,Oral absorption using Caco-2 cell monolayers.,N,1,1,,CHEMBL630750,,BAO_0000218,,
12241,Intermediate,50587,,,Percent of the drug absorbed after administration to humans was determined,N,1,1,,CHEMBL630253,,BAO_0000218,,
12242,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,1,1,,CHEMBL630254,,BAO_0000218,1969.0,
12243,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,1,1,,CHEMBL630255,,BAO_0000218,1969.0,
12244,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,1,1,,CHEMBL630256,,BAO_0000218,1969.0,
12245,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,1,1,,CHEMBL875781,,BAO_0000218,2107.0,
12246,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,1,1,,CHEMBL630257,,BAO_0000218,2107.0,
12247,Intermediate,50597,Liver,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,1,1,,CHEMBL630258,,BAO_0000218,2107.0,
12248,Intermediate,50597,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",N,1,1,,CHEMBL630259,,BAO_0000218,,
12249,Intermediate,50597,Striatum,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",N,1,1,,CHEMBL630260,,BAO_0000218,2435.0,
12250,Intermediate,50597,Striatum,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",N,1,1,,CHEMBL630261,,BAO_0000218,2435.0,
12251,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,N,1,1,,CHEMBL630262,,BAO_0000218,,
12252,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,N,1,1,,CHEMBL630263,,BAO_0000218,,
12253,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,N,1,1,,CHEMBL630264,,BAO_0000218,,
12254,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,N,1,1,,CHEMBL630265,,BAO_0000218,,
12255,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,N,1,1,,CHEMBL630266,,BAO_0000218,,
12256,Intermediate,50597,Kidney,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,N,1,1,,CHEMBL630267,,BAO_0000218,2113.0,
12257,Intermediate,50597,Kidney,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,N,1,1,,CHEMBL630268,,BAO_0000218,2113.0,
12258,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,N,1,1,,CHEMBL630269,,BAO_0000218,,
12259,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,N,1,1,,CHEMBL630270,,BAO_0000218,,
12260,Intermediate,50597,Lung,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,N,1,1,,CHEMBL630141,,BAO_0000218,2048.0,
12261,Intermediate,50597,Lung,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,N,1,1,,CHEMBL630142,,BAO_0000218,2048.0,
12262,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,N,1,1,,CHEMBL630143,,BAO_0000218,2385.0,
12263,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,N,1,1,,CHEMBL630144,,BAO_0000218,2385.0,
12264,Intermediate,50597,Prostate gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,N,1,1,,CHEMBL630145,,BAO_0000218,2367.0,
12265,Intermediate,50597,Prostate gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,N,1,1,,CHEMBL630146,,BAO_0000218,2367.0,
12266,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,N,1,1,,CHEMBL630147,,BAO_0000218,,
12267,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,N,1,1,,CHEMBL630148,,BAO_0000218,,
12268,Intermediate,50597,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,N,1,1,,CHEMBL630149,,BAO_0000218,,
12269,Intermediate,50597,Spleen,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,N,1,1,,CHEMBL630150,,BAO_0000218,2106.0,
12270,Intermediate,50597,Spleen,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,N,1,1,,CHEMBL630151,,BAO_0000218,2106.0,
12271,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,N,1,1,,CHEMBL632031,,BAO_0000218,2046.0,
12272,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,N,1,1,,CHEMBL632032,,BAO_0000218,2046.0,
12273,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,N,1,1,,CHEMBL632033,,BAO_0000218,,
12274,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,N,1,1,,CHEMBL632034,,BAO_0000218,,
12275,Intermediate,50597,Muscle tissue,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,N,1,1,,CHEMBL632035,,BAO_0000218,2385.0,
12276,Intermediate,50597,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,N,1,1,,CHEMBL632036,,BAO_0000218,,
12277,Intermediate,50597,Thyroid gland,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,N,1,1,,CHEMBL632037,,BAO_0000218,2046.0,
12278,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,1,1,,CHEMBL632038,,BAO_0000218,178.0,
12279,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,1,1,,CHEMBL632039,,BAO_0000218,178.0,
12280,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,1,1,,CHEMBL632040,,BAO_0000218,178.0,
12281,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,1,1,,CHEMBL632041,,BAO_0000218,178.0,
12282,Intermediate,50588,Blood,,"Concentration of compound in blood of dog 2, after administering intravenously",N,1,1,,CHEMBL632042,,BAO_0000218,178.0,
12283,Intermediate,50588,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",N,1,1,,CHEMBL632043,,BAO_0000218,,
12284,Intermediate,50588,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",N,1,1,,CHEMBL632044,,BAO_0000218,,
12285,Intermediate,50588,Liver,,"Concentration of compound in liver of dog 1, after administering intravenously",N,1,1,,CHEMBL632045,,BAO_0000218,2107.0,
12286,Intermediate,50588,Liver,,"Concentration of compound in liver of dog 2, after administering intravenously",N,1,1,,CHEMBL632046,,BAO_0000218,2107.0,
12287,Intermediate,50588,Lung,,"Concentration of compound in lung of dog 1, after administering intravenously",N,1,1,,CHEMBL632047,,BAO_0000218,2048.0,
12288,Intermediate,50588,Lung,,"Concentration of compound in lung of dog 2, after administering intravenously",N,1,1,,CHEMBL632048,,BAO_0000218,2048.0,
12289,Intermediate,50588,Muscle tissue,,"Concentration of compound in muscle of dog 1, after administering intravenously",N,1,1,,CHEMBL632049,,BAO_0000218,2385.0,
12290,Intermediate,50588,Muscle tissue,,"Concentration of compound in muscle of dog 2, after administering intravenously",N,1,1,,CHEMBL876418,,BAO_0000218,2385.0,
12291,Intermediate,50588,Spleen,,"Concentration of compound in spleen of dog 1,after administering intravenously",N,1,1,,CHEMBL632050,,BAO_0000218,2106.0,
12292,Intermediate,50588,Spleen,,"Concentration of compound in spleen of dog 2, after administering intravenously",N,1,1,,CHEMBL632051,,BAO_0000218,2106.0,
12293,Autocuration,22224,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,U,0,1,,CHEMBL632052,,BAO_0000218,,
12294,Autocuration,22224,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,U,0,1,,CHEMBL632053,,BAO_0000218,,
12295,Autocuration,22224,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,0,1,,CHEMBL632054,,BAO_0000218,,
12296,Autocuration,22224,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,0,1,,CHEMBL632055,,BAO_0000218,,
12297,Autocuration,22224,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,U,0,1,,CHEMBL631181,,BAO_0000218,,
12298,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,U,0,1,,CHEMBL631182,,BAO_0000218,,
12299,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,0,1,,CHEMBL631183,,BAO_0000218,,
12300,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL631184,,BAO_0000218,,
12301,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL629774,,BAO_0000218,,
12302,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL629775,,BAO_0000218,,
12303,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL876549,,BAO_0000218,,
12304,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL628172,,BAO_0000218,,
12305,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL628173,,BAO_0000218,,
12306,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,U,0,1,,CHEMBL628174,,BAO_0000218,,
12307,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,U,0,1,,CHEMBL628175,,BAO_0000218,,
12308,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL628176,,BAO_0000218,,
12309,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL628177,,BAO_0000218,,
12310,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL628178,,BAO_0000218,,
12311,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL628179,,BAO_0000218,,
12312,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,0,1,,CHEMBL628180,,BAO_0000218,,
12313,Autocuration,22224,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,U,0,1,,CHEMBL628181,,BAO_0000218,,
12314,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL628182,,BAO_0000218,,
12315,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL628183,,BAO_0000218,,
12316,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,U,0,1,,CHEMBL628184,,BAO_0000218,,
12317,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL628185,,BAO_0000218,,
12318,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL875617,,BAO_0000218,,
12319,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,0,1,,CHEMBL628186,,BAO_0000218,,
12320,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL628187,,BAO_0000218,,
12321,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL628188,,BAO_0000218,,
12322,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL628189,,BAO_0000218,,
12323,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,U,0,1,,CHEMBL628190,,BAO_0000218,,
12324,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL628191,,BAO_0000218,,
12325,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,U,0,1,,CHEMBL626513,,BAO_0000218,,
12326,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",N,1,1,,CHEMBL626514,,BAO_0000218,2046.0,
12327,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",N,1,1,,CHEMBL626515,,BAO_0000218,2046.0,
12328,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",N,1,1,,CHEMBL626516,,BAO_0000218,2046.0,
12329,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",N,1,1,,CHEMBL626517,,BAO_0000218,2046.0,
12330,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",N,1,1,,CHEMBL626518,,BAO_0000218,2046.0,
12331,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",N,1,1,,CHEMBL626519,,BAO_0000218,2046.0,
12332,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",N,1,1,,CHEMBL626520,,BAO_0000218,2046.0,
12333,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",N,1,1,,CHEMBL626521,,BAO_0000218,2046.0,
12334,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",N,1,1,,CHEMBL626522,,BAO_0000218,2046.0,
12335,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",N,1,1,,CHEMBL626523,,BAO_0000218,2046.0,
12336,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",N,1,1,,CHEMBL626524,,BAO_0000218,2046.0,
12337,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",N,1,1,,CHEMBL626688,,BAO_0000218,2046.0,
12338,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",N,1,1,,CHEMBL626689,,BAO_0000218,2046.0,
12339,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",N,1,1,,CHEMBL626690,,BAO_0000218,2046.0,
12340,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",N,1,1,,CHEMBL626691,,BAO_0000218,2046.0,
12341,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",N,1,1,,CHEMBL627319,,BAO_0000218,2046.0,
12342,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",N,1,1,,CHEMBL624052,,BAO_0000218,2046.0,
12343,Intermediate,50597,Thyroid gland,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",N,1,1,,CHEMBL624053,,BAO_0000218,2046.0,
12344,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL624054,,BAO_0000218,,
12345,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL624055,,BAO_0000218,,
12346,Intermediate,50597,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL624056,,BAO_0000218,,
12347,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL624057,,BAO_0000218,995.0,
12348,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622281,,BAO_0000218,995.0,
12349,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622282,,BAO_0000218,995.0,
12350,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622283,,BAO_0000218,995.0,
12351,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622284,,BAO_0000218,995.0,
12352,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622285,,BAO_0000218,995.0,
12353,Intermediate,50597,Uterus,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,1,1,,CHEMBL622286,,BAO_0000218,995.0,
12354,Autocuration,22224,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,U,0,1,,CHEMBL622287,,BAO_0000100,,
12355,Intermediate,50594,,,Partition coefficient (logD7.4),N,1,1,,CHEMBL622288,,BAO_0000218,,
12356,Intermediate,50594,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,1,1,,CHEMBL622289,,BAO_0000218,,
12357,Intermediate,50594,Brain,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,1,1,,CHEMBL622290,,BAO_0000218,955.0,
12358,Intermediate,50594,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,1,1,,CHEMBL622291,,BAO_0000218,,
12359,Intermediate,50594,Brain,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,1,1,,CHEMBL622292,,BAO_0000218,955.0,
12360,Intermediate,50594,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,1,1,,CHEMBL622293,,BAO_0000218,,
12361,Intermediate,50594,Brain,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,1,1,,CHEMBL622294,,BAO_0000218,955.0,
12362,Intermediate,50594,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,1,1,,CHEMBL622295,,BAO_0000218,,
12363,Intermediate,50597,Brain,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,1,1,,CHEMBL622296,,BAO_0000218,955.0,
12364,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,N,1,1,,CHEMBL874409,,BAO_0000218,1969.0,
12365,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,1,1,,CHEMBL622297,,BAO_0000218,1969.0,
12366,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,1,1,,CHEMBL622298,,BAO_0000218,1969.0,
12367,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,1,1,,CHEMBL622299,,BAO_0000218,1969.0,
12368,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,1,1,,CHEMBL622300,,BAO_0000218,1969.0,
12369,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,1,1,,CHEMBL622301,,BAO_0000218,1969.0,
12370,Intermediate,50597,Plasma,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,1,1,,CHEMBL622302,,BAO_0000218,1969.0,
12371,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,1,1,,CHEMBL622303,,BAO_0000218,1969.0,
12372,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,1,1,,CHEMBL622304,,BAO_0000218,1969.0,
12373,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,N,1,1,,CHEMBL622305,,BAO_0000218,1969.0,
12374,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,1,1,,CHEMBL622306,,BAO_0000218,1969.0,
12375,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,N,1,1,,CHEMBL626864,,BAO_0000218,1969.0,
12376,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,1,1,,CHEMBL626865,,BAO_0000218,1969.0,
12377,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,N,1,1,,CHEMBL626866,,BAO_0000218,1969.0,
12378,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,1,1,,CHEMBL626867,,BAO_0000218,1969.0,
12379,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,1,1,,CHEMBL626868,,BAO_0000218,1969.0,
12380,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,N,1,1,,CHEMBL626869,,BAO_0000218,1969.0,
12381,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,1,1,,CHEMBL626870,,BAO_0000218,1969.0,
12382,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,N,1,1,,CHEMBL626871,,BAO_0000218,1969.0,
12383,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,1,1,,CHEMBL626872,,BAO_0000218,1969.0,
12384,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,1,1,,CHEMBL632185,,BAO_0000218,1969.0,
12385,Intermediate,50597,Plasma,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,N,1,1,,CHEMBL632186,,BAO_0000218,1969.0,
12386,Autocuration,22224,,,Amount of acetic acid produced by the compound,U,0,1,,CHEMBL629310,,BAO_0000019,,
12387,Autocuration,22224,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,U,0,1,,CHEMBL629311,,BAO_0000019,,
12388,Intermediate,50597,,,Log of (Cbrain/Cblood) in rats,N,1,1,,CHEMBL629312,,BAO_0000218,,
12389,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,0,1,,CHEMBL629313,,BAO_0000221,,
12390,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629314,,BAO_0000221,,
12391,Autocuration,22224,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,0,1,,CHEMBL629315,,BAO_0000221,,
12392,Autocuration,22224,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),U,0,1,,CHEMBL629316,,BAO_0000219,,
12393,Autocuration,22224,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629317,,BAO_0000221,,
12394,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,0,1,,CHEMBL629318,,BAO_0000019,,
12395,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),U,0,1,,CHEMBL877497,,BAO_0000019,,
12396,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),U,0,1,,CHEMBL629319,,BAO_0000019,,
12397,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629320,,BAO_0000019,,
12398,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),U,0,1,,CHEMBL629496,,BAO_0000019,,
12399,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629497,,BAO_0000019,,
12400,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),U,0,1,,CHEMBL629498,,BAO_0000019,,
12401,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629499,,BAO_0000019,,
12402,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,0,1,,CHEMBL629500,,BAO_0000019,,
12403,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),U,0,1,,CHEMBL629501,,BAO_0000019,,
12404,Autocuration,22224,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),U,0,1,,CHEMBL629502,,BAO_0000019,,
12405,Autocuration,22224,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,U,0,1,,CHEMBL629503,,BAO_0000218,,
12406,Intermediate,50588,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,N,1,1,,CHEMBL629504,,BAO_0000218,,
12407,Autocuration,22224,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,U,0,1,,CHEMBL629505,,BAO_0000019,,
12408,Autocuration,22224,,,Compound was evaluated for total body clearance,U,0,1,,CHEMBL629506,,BAO_0000019,,
12409,Autocuration,22224,,,Compound was evaluated for volume of distribution at steady state,U,0,1,,CHEMBL629507,,BAO_0000019,,
12410,Autocuration,22224,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,U,0,1,,CHEMBL877498,,BAO_0000019,,
12411,Autocuration,22224,,,Percentage of the diamine which is monoprotonated at pH 7.4,U,0,1,,CHEMBL629508,,BAO_0000019,,
12412,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,U,0,1,,CHEMBL629509,,BAO_0000019,,
12413,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,1,1,,CHEMBL629510,,BAO_0000218,178.0,
12414,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,1,1,,CHEMBL629511,,BAO_0000218,178.0,
12415,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,1,1,,CHEMBL629512,,BAO_0000218,178.0,
12416,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,1,1,,CHEMBL629513,,BAO_0000218,178.0,
12417,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,1,1,,CHEMBL629514,,BAO_0000218,178.0,
12418,Intermediate,50597,Blood,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,1,1,,CHEMBL628447,,BAO_0000218,178.0,
12419,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,1,1,,CHEMBL628448,,BAO_0000218,178.0,
12420,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,1,1,,CHEMBL628449,,BAO_0000218,178.0,
12421,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,1,1,,CHEMBL631119,,BAO_0000218,178.0,
12422,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,1,1,,CHEMBL631120,,BAO_0000218,178.0,
12423,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,1,1,,CHEMBL631121,,BAO_0000218,178.0,
12424,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,N,1,1,,CHEMBL874458,,BAO_0000218,178.0,
12425,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,1,1,,CHEMBL631122,,BAO_0000218,178.0,
12426,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,1,1,,CHEMBL631123,,BAO_0000218,178.0,
12427,Intermediate,50597,Blood,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,1,1,,CHEMBL631124,,BAO_0000218,178.0,
12428,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,1,1,,CHEMBL631125,,BAO_0000218,178.0,
12429,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,1,1,,CHEMBL631290,,BAO_0000218,178.0,
12430,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,1,1,,CHEMBL631291,,BAO_0000218,178.0,
12431,Intermediate,50597,Blood,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,1,1,,CHEMBL631292,,BAO_0000218,178.0,
12432,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,1,1,,CHEMBL631293,,BAO_0000218,178.0,
12433,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,1,1,,CHEMBL631294,,BAO_0000218,178.0,
12434,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,1,1,,CHEMBL631295,,BAO_0000218,178.0,
12435,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,1,1,,CHEMBL631296,,BAO_0000218,178.0,
12436,Intermediate,50597,Blood,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,1,1,,CHEMBL631297,,BAO_0000218,178.0,
12437,Autocuration,22224,,,Maximum biodistribution (Bmax) was determined.,U,0,1,,CHEMBL631298,,BAO_0000218,,
12438,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,N,1,1,,CHEMBL631299,,BAO_0000218,,
12439,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,N,1,1,,CHEMBL631300,,BAO_0000218,,
12440,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,N,1,1,,CHEMBL631301,,BAO_0000218,,
12441,Intermediate,50594,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,N,1,1,,CHEMBL630291,,BAO_0000218,,
12442,Autocuration,22224,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,U,0,1,,CHEMBL630292,,BAO_0000218,,
12443,Autocuration,22224,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,U,0,1,,CHEMBL630293,,BAO_0000218,,
12444,Autocuration,22224,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,U,0,1,,CHEMBL630294,,BAO_0000218,,
12445,Autocuration,22224,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,U,0,1,,CHEMBL630295,,BAO_0000218,,
12446,Autocuration,22224,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,U,0,1,,CHEMBL630296,,BAO_0000218,,
12447,Autocuration,22224,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,U,0,1,,CHEMBL626782,,BAO_0000218,,
12448,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,U,0,1,,CHEMBL626783,,BAO_0000218,,
12449,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,U,0,1,,CHEMBL626784,,BAO_0000218,,
12450,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,U,0,1,,CHEMBL626785,,BAO_0000218,,
12451,Autocuration,22224,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,U,0,1,,CHEMBL626786,,BAO_0000218,,
12452,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL626787,,BAO_0000218,,
12453,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,0,1,,CHEMBL626788,,BAO_0000218,,
12454,Autocuration,22224,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL625927,,BAO_0000218,,
12455,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL625928,,BAO_0000218,178.0,
12456,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL625929,,BAO_0000218,178.0,
12457,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,1,1,,CHEMBL625930,,BAO_0000218,178.0,
12458,Intermediate,50597,Blood,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",N,1,1,,CHEMBL625931,,BAO_0000218,178.0,
12459,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,N,1,1,,CHEMBL627230,,BAO_0000218,178.0,
12460,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627231,,BAO_0000218,178.0,
12461,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL627232,,BAO_0000218,178.0,
12462,Intermediate,50597,Blood,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,1,1,,CHEMBL627233,,BAO_0000218,178.0,
12463,Intermediate,50597,Blood,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL875470,,BAO_0000218,178.0,
12464,Intermediate,50597,Blood,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627234,,BAO_0000218,178.0,
12465,Intermediate,50597,Blood,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627235,,BAO_0000218,178.0,
12466,Intermediate,50597,Blood,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627236,,BAO_0000218,178.0,
12467,Intermediate,50597,Blood,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627237,,BAO_0000218,178.0,
12468,Intermediate,50597,Blood,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627238,,BAO_0000218,178.0,
12469,Intermediate,50597,Blood,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627239,,BAO_0000218,178.0,
12470,Intermediate,50597,Blood,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627240,,BAO_0000218,178.0,
12471,Intermediate,50597,Blood,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627241,,BAO_0000218,178.0,
12472,Intermediate,50597,Blood,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627242,,BAO_0000218,178.0,
12473,Intermediate,50597,Blood,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,N,1,1,,CHEMBL627243,,BAO_0000218,178.0,
12474,Intermediate,50597,Blood,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL627244,,BAO_0000218,178.0,
12475,Intermediate,50597,Blood,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627245,,BAO_0000218,178.0,
12476,Intermediate,50597,Blood,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627246,,BAO_0000218,178.0,
12477,Intermediate,50597,Blood,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627247,,BAO_0000218,178.0,
12478,Intermediate,50597,Blood,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627248,,BAO_0000218,178.0,
12479,Intermediate,50597,Blood,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627249,,BAO_0000218,178.0,
12480,Intermediate,50597,Blood,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL625569,,BAO_0000218,178.0,
12481,Intermediate,50597,Blood,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL625570,,BAO_0000218,178.0,
12482,Intermediate,50597,Blood,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL625571,,BAO_0000218,178.0,
12483,Intermediate,50597,Blood,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL625572,,BAO_0000218,178.0,
12484,Intermediate,50597,Blood,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL625573,,BAO_0000218,178.0,
12485,Intermediate,50597,Blood,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,N,1,1,,CHEMBL625574,,BAO_0000218,178.0,
12486,Intermediate,50597,Blood,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,1,1,,CHEMBL626245,,BAO_0000218,178.0,
12487,Intermediate,50597,Blood,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL626246,,BAO_0000218,178.0,
12488,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL626247,,BAO_0000218,,
12489,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL626248,,BAO_0000218,,
12490,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,0,1,,CHEMBL626249,,BAO_0000218,,
12491,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL626420,,BAO_0000218,,
12492,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,0,1,,CHEMBL626421,,BAO_0000218,,
12493,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL626422,,BAO_0000218,,
12494,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL626423,,BAO_0000218,,
12495,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL626424,,BAO_0000218,,
12496,Intermediate,50588,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,N,1,1,,CHEMBL626425,,BAO_0000218,,
12497,Intermediate,50597,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,N,1,1,,CHEMBL875476,,BAO_0000218,,
12498,Intermediate,100710,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,N,1,1,,CHEMBL626426,,BAO_0000218,,
12499,Autocuration,22224,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,U,0,1,,CHEMBL626427,,BAO_0000100,,
12500,Autocuration,22224,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,U,0,1,,CHEMBL626428,,BAO_0000100,,
12501,Autocuration,22224,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,U,0,1,,CHEMBL626429,,BAO_0000019,,
12502,Autocuration,22224,Urine,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,U,0,1,,CHEMBL625025,,BAO_0000019,1088.0,
12503,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL625026,,BAO_0000218,178.0,
12504,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL625027,,BAO_0000218,178.0,
12505,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL874410,,BAO_0000218,178.0,
12506,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL625028,,BAO_0000218,178.0,
12507,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL625029,,BAO_0000218,178.0,
12508,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL625030,,BAO_0000218,178.0,
12509,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL625031,,BAO_0000218,178.0,
12510,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL625032,,BAO_0000218,178.0,
12511,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL625033,,BAO_0000218,178.0,
12512,Intermediate,50597,Blood,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL625034,,BAO_0000218,178.0,
12513,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624872,,BAO_0000218,948.0,
12514,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL624873,,BAO_0000218,948.0,
12515,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624874,,BAO_0000218,948.0,
12516,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL624875,,BAO_0000218,948.0,
12517,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL624876,,BAO_0000218,948.0,
12518,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624877,,BAO_0000218,948.0,
12519,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624878,,BAO_0000218,948.0,
12520,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624879,,BAO_0000218,948.0,
12521,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624880,,BAO_0000218,948.0,
12522,Intermediate,50597,Heart,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,N,1,1,,CHEMBL624881,,BAO_0000218,948.0,
12523,Intermediate,50597,Heart,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",N,1,1,,CHEMBL624882,,BAO_0000218,948.0,
12524,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624883,,BAO_0000218,2113.0,
12525,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624884,,BAO_0000218,2113.0,
12526,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624885,,BAO_0000218,2113.0,
12527,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL624886,,BAO_0000218,2113.0,
12528,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL624887,,BAO_0000218,2113.0,
12529,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624888,,BAO_0000218,2113.0,
12530,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624889,,BAO_0000218,2113.0,
12531,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624890,,BAO_0000218,2113.0,
12532,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL621964,,BAO_0000218,2113.0,
12533,Intermediate,50597,Kidney,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL621965,,BAO_0000218,2113.0,
12534,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL621966,,BAO_0000218,2107.0,
12535,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL621967,,BAO_0000218,2107.0,
12536,Intermediate,50597,Liver,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL622164,,BAO_0000218,2107.0,
12537,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),U,0,1,,CHEMBL623097,,BAO_0000019,,
12538,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),U,0,1,,CHEMBL623098,,BAO_0000019,,
12539,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,U,0,1,,CHEMBL623099,,BAO_0000019,,
12540,Autocuration,22224,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,U,0,1,,CHEMBL623100,,BAO_0000019,,
12541,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",N,1,1,,CHEMBL628673,,BAO_0000218,,
12542,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",N,1,1,,CHEMBL628674,,BAO_0000218,,
12543,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",N,1,1,,CHEMBL628675,,BAO_0000218,,
12544,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",N,1,1,,CHEMBL627644,,BAO_0000218,,
12545,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",N,1,1,,CHEMBL627645,,BAO_0000218,,
12546,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",N,1,1,,CHEMBL627646,,BAO_0000218,,
12547,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",N,1,1,,CHEMBL627647,,BAO_0000218,,
12548,Intermediate,50597,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",N,1,1,,CHEMBL627648,,BAO_0000218,,
12549,Intermediate,50597,,,Free level in rat plasma,N,1,1,,CHEMBL627649,,BAO_0000218,,
12550,Autocuration,22224,,,Level reaching in blood plasma of rat or human was determined,U,0,1,,CHEMBL628313,,BAO_0000019,,
12551,Intermediate,50597,,,Log (Cbrain/Cblood) in rats,N,1,1,,CHEMBL628314,,BAO_0000218,,
12552,Autocuration,22224,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,U,0,1,,CHEMBL628315,,BAO_0000019,,
12553,Autocuration,22224,,,Mean percentage of compound transport through membrane; expressed as membrane transport,U,0,1,,CHEMBL628316,,BAO_0000019,,
12554,Autocuration,22224,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,U,0,1,,CHEMBL628317,,BAO_0000218,,
12555,Autocuration,22224,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,U,0,1,,CHEMBL628473,,BAO_0000019,,
12556,Autocuration,22224,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",U,0,1,,CHEMBL628474,,BAO_0000019,,
12557,Autocuration,22224,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,U,0,1,,CHEMBL628475,,BAO_0000019,,
12558,Autocuration,22224,,,Net water uptake by a carrier mediated transport (%cm) mechanism,U,0,1,,CHEMBL628476,,BAO_0000019,,
12559,Autocuration,22224,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,0,1,,CHEMBL628477,,BAO_0000218,,
12560,Intermediate,50506,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,1,1,,CHEMBL628478,,BAO_0000218,,
12561,Intermediate,50506,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,1,1,,CHEMBL628479,,BAO_0000218,,
12562,Autocuration,22224,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,0,1,,CHEMBL628480,,BAO_0000218,,
12563,Autocuration,22224,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",U,0,1,,CHEMBL628481,,BAO_0000218,,
12564,Intermediate,50597,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,1,1,,CHEMBL628482,,BAO_0000218,,
12565,Intermediate,50597,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,1,1,,CHEMBL628483,,BAO_0000218,,
12566,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,1,1,,CHEMBL628484,,BAO_0000218,1969.0,
12567,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,1,1,,CHEMBL628485,,BAO_0000218,1969.0,
12568,Intermediate,100710,Plasma,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",N,1,1,,CHEMBL628486,,BAO_0000218,1969.0,
12569,Intermediate,50587,Plasma,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",N,1,1,,CHEMBL628487,,BAO_0000218,1969.0,
12570,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,1,1,,CHEMBL628488,,BAO_0000218,1969.0,
12571,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,1,1,,CHEMBL628489,,BAO_0000218,1969.0,
12572,Intermediate,50597,Plasma,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,1,1,,CHEMBL628490,,BAO_0000218,1969.0,
12573,Intermediate,100710,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,1,1,,CHEMBL628491,,BAO_0000218,,
12574,Intermediate,100710,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,1,1,,CHEMBL877507,,BAO_0000218,,
12575,Autocuration,22224,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,U,0,1,,CHEMBL628492,,BAO_0000218,,
12576,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),U,0,1,,CHEMBL628493,,BAO_0000019,,
12577,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),U,0,1,,CHEMBL628494,,BAO_0000019,,
12578,Autocuration,22224,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),U,0,1,,CHEMBL628495,,BAO_0000019,,
12579,Intermediate,50587,,,Permeability in Caco-2 assay at 10E-6,N,1,1,,CHEMBL628496,,BAO_0000218,,
12580,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,0,1,,CHEMBL628497,,BAO_0000218,955.0,
12581,Autocuration,22224,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,0,1,,CHEMBL628498,,BAO_0000218,955.0,
12582,Autocuration,22224,,,Plasma protein binding was determined,U,0,1,,CHEMBL628499,,BAO_0000019,,
12583,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,U,0,1,,CHEMBL627656,,BAO_0000218,,
12584,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,U,0,1,,CHEMBL627657,,BAO_0000218,,
12585,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,U,0,1,,CHEMBL626808,,BAO_0000218,,
12586,Autocuration,22224,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,U,0,1,,CHEMBL626809,,BAO_0000218,,
12587,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,U,0,1,,CHEMBL626810,,BAO_0000218,,
12588,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,U,0,1,,CHEMBL626811,,BAO_0000218,,
12589,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,U,0,1,,CHEMBL874465,,BAO_0000218,,
12590,Autocuration,22224,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,U,0,1,,CHEMBL626812,,BAO_0000218,,
12591,Autocuration,22224,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,U,0,1,,CHEMBL626813,,BAO_0000218,,
12592,Autocuration,22224,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,U,0,1,,CHEMBL626814,,BAO_0000218,,
12593,Autocuration,22224,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,U,0,1,,CHEMBL626815,,BAO_0000019,,
12594,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL628566,,BAO_0000019,,
12595,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,0,1,,CHEMBL628567,,BAO_0000100,,
12596,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL628568,,BAO_0000100,,
12597,Intermediate,50588,,,C max in dog,N,1,1,,CHEMBL628569,,BAO_0000218,,
12598,Intermediate,50512,,,C max in guinea pig,N,1,1,,CHEMBL628570,,BAO_0000218,,
12599,Autocuration,22224,,,C max value was evaluated,U,0,1,,CHEMBL628571,,BAO_0000218,,
12600,Autocuration,22224,,,Cmax value after oral dose of 0.1 mg//kg,U,0,1,,CHEMBL628572,,BAO_0000218,,
12601,Autocuration,22224,,,Cmax value after oral dose of 0.3 mg/kg,U,0,1,,CHEMBL628573,,BAO_0000218,,
12602,Autocuration,22224,,,Cmax value after oral dose of 1 mg/kg,U,0,1,,CHEMBL628574,,BAO_0000218,,
12603,Autocuration,22224,,,Cmax value after oral dose of 10 mg/kg,U,0,1,,CHEMBL628575,,BAO_0000218,,
12604,Autocuration,22224,,,Cmax value after oral dose of 23.4 mg/kg,U,0,1,,CHEMBL628576,,BAO_0000218,,
12605,Autocuration,22224,,,Cmax value after oral dose of 3 mg/kg,U,0,1,,CHEMBL628577,,BAO_0000218,,
12606,Autocuration,22224,,,Cmax value after oral dose of 3.87 mg/kg,U,0,1,,CHEMBL628578,,BAO_0000218,,
12607,Intermediate,50588,,,Cmax value in female Beagle dogs,N,1,1,,CHEMBL874466,,BAO_0000218,,
12608,Intermediate,50597,,,Cmax value in male rats,N,1,1,,CHEMBL628579,,BAO_0000218,,
12609,Intermediate,50597,Plasma,,Cmax value in rat plasma when administered 20 mg/kg perorally,N,1,1,,CHEMBL628580,,BAO_0000218,1969.0,
12610,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,1,1,,CHEMBL628581,,BAO_0000218,1969.0,
12611,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,1,1,,CHEMBL628582,,BAO_0000218,1969.0,
12612,Intermediate,50588,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL628583,,BAO_0000218,,
12613,Autocuration,22224,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,U,0,1,,CHEMBL625782,,BAO_0000218,,
12614,Intermediate,50592,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL625783,,BAO_0000218,,
12615,Intermediate,50597,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL625784,,BAO_0000218,,
12616,Intermediate,50797,Plasma,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,N,1,1,,CHEMBL625785,,BAO_0000218,1969.0,
12617,Intermediate,50597,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,N,1,1,,CHEMBL625786,,BAO_0000218,,
12618,Autocuration,22224,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,U,0,1,,CHEMBL874467,,BAO_0000019,,
12619,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,1,1,,CHEMBL625787,,BAO_0000218,,
12620,Intermediate,50677,,,cytotoxicity against HIV protease enzyme.,N,1,1,,CHEMBL625964,,BAO_0000218,,
12621,Intermediate,50594,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,N,1,1,,CHEMBL625965,,BAO_0000218,,
12622,Intermediate,50594,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,N,1,1,,CHEMBL625966,,BAO_0000218,,
12623,Intermediate,50588,Plasma,,The plasma clearance in dog.,N,1,1,,CHEMBL625967,,BAO_0000218,1969.0,
12624,Intermediate,50597,Plasma,,The plasma clearance in rat.,N,1,1,,CHEMBL625968,,BAO_0000218,1969.0,
12625,Intermediate,50597,Plasma,,Clearance from plasma in male Sprague-Dawley rats,N,1,1,,CHEMBL625969,,BAO_0000218,1969.0,
12626,Intermediate,100710,Plasma,,Clearance from plasma in male cynomolgus monkeys,N,1,1,,CHEMBL625970,,BAO_0000218,1969.0,
12627,Intermediate,50588,Plasma,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",N,1,1,,CHEMBL625971,,BAO_0000218,1969.0,
12628,Intermediate,50588,Plasma,,Clearance of compound in dog plasma,N,1,1,,CHEMBL625972,,BAO_0000218,1969.0,
12629,Intermediate,50587,Plasma,,Clearance of compound in human plasma,N,1,1,,CHEMBL625973,,BAO_0000218,1969.0,
12630,Intermediate,50588,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,N,1,1,,CHEMBL625974,,BAO_0000218,,
12631,Intermediate,50588,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,N,1,1,,CHEMBL625975,,BAO_0000218,,
12632,Intermediate,50588,Plasma,,"Clearance (10 mg/kg, intravenously) in dog plasma",N,1,1,,CHEMBL625976,,BAO_0000218,1969.0,
12633,Intermediate,50588,,,Clearance value in dog,N,1,1,,CHEMBL625977,,BAO_0000218,,
12634,Intermediate,50512,,,Clearance value in guinea pig,N,1,1,,CHEMBL625978,,BAO_0000218,,
12635,Intermediate,50597,,,Clearance values in rats after iv administration.,N,1,1,,CHEMBL874468,,BAO_0000218,,
12636,Autocuration,22224,Plasma,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,U,0,1,,CHEMBL625421,,BAO_0000218,1969.0,
12637,Intermediate,50592,,,In vivo clearance (5 mg/kg) was determined in rabbits,N,1,1,,CHEMBL625422,,BAO_0000218,,
12638,Intermediate,50597,,,Plasma Clearance rate was determined for the compound in rats,N,1,1,,CHEMBL625423,,BAO_0000218,,
12639,Autocuration,22224,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,U,0,1,,CHEMBL625424,,BAO_0000218,,
12640,Intermediate,50597,,,Plasma clearance in rat,N,1,1,,CHEMBL625425,,BAO_0000218,,
12641,Autocuration,22224,,,Plasma clearance of the compound,U,0,1,,CHEMBL625426,,BAO_0000218,,
12642,Intermediate,50512,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,N,1,1,,CHEMBL625427,,BAO_0000218,,
12643,Intermediate,50512,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,N,1,1,,CHEMBL625428,,BAO_0000218,,
12644,Autocuration,22224,,,Plasma clearance was determined,U,0,1,,CHEMBL625429,,BAO_0000218,,
12645,Intermediate,50588,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,N,1,1,,CHEMBL625430,,BAO_0000218,,
12646,Intermediate,50597,,,Plasma clearance rate was determined for the compound in rats,N,1,1,,CHEMBL625431,,BAO_0000218,,
12647,Autocuration,22224,,,Plasma clearance rate was determined for the compound in squirrel monkeys,U,0,1,,CHEMBL627307,,BAO_0000218,,
12648,Autocuration,22224,,,Slow clearance (CL) was determined,U,0,1,,CHEMBL627308,,BAO_0000218,,
12649,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL627309,,BAO_0000218,,
12650,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,0,1,,CHEMBL627310,,BAO_0000218,,
12651,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,0,1,,CHEMBL627311,,BAO_0000218,,
12652,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL627312,,BAO_0000218,,
12653,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,0,1,,CHEMBL627313,,BAO_0000218,,
12654,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL627314,,BAO_0000218,,
12655,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL627315,,BAO_0000218,,
12656,Autocuration,22224,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL627316,,BAO_0000218,,
12657,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,0,1,,CHEMBL627317,,BAO_0000218,,
12658,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL627318,,BAO_0000218,,
12659,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,0,1,,CHEMBL627999,,BAO_0000218,,
12660,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,0,1,,CHEMBL628000,,BAO_0000218,,
12661,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,0,1,,CHEMBL628001,,BAO_0000218,,
12662,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL628002,,BAO_0000218,,
12663,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL625610,,BAO_0000218,,
12664,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL625611,,BAO_0000218,,
12665,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,0,1,,CHEMBL625612,,BAO_0000218,,
12666,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,0,1,,CHEMBL625613,,BAO_0000218,,
12667,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,0,1,,CHEMBL875479,,BAO_0000218,,
12668,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,0,1,,CHEMBL625614,,BAO_0000218,,
12669,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,0,1,,CHEMBL625615,,BAO_0000218,,
12670,Autocuration,22224,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,0,1,,CHEMBL626302,,BAO_0000218,,
12671,Intermediate,50597,Blood,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL626303,,BAO_0000218,178.0,
12672,Intermediate,50597,Blood,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,1,1,,CHEMBL627420,,BAO_0000218,178.0,
12673,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,N,1,1,,CHEMBL627421,,BAO_0000218,,
12674,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,N,1,1,,CHEMBL625695,,BAO_0000218,,
12675,Intermediate,50597,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,N,1,1,,CHEMBL625696,,BAO_0000218,,
12676,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 1 hr,N,1,1,,CHEMBL875606,,BAO_0000218,955.0,
12677,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 24 hr r,N,1,1,,CHEMBL625697,,BAO_0000218,955.0,
12678,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 2 hr,N,1,1,,CHEMBL625698,,BAO_0000218,955.0,
12679,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 3 hr,N,1,1,,CHEMBL625699,,BAO_0000218,955.0,
12680,Intermediate,50594,Brain,,Distribution of compound in mice brain was measured after 6 hr,N,1,1,,CHEMBL625700,,BAO_0000218,955.0,
12681,Intermediate,50594,,,Distribution of compound in mice liver was measured after 1 hr,N,1,1,,CHEMBL625701,,BAO_0000218,,
12682,Intermediate,50594,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,N,1,1,,CHEMBL625702,,BAO_0000218,,
12683,Intermediate,50594,,,Distribution of compound in mice liver was measured after 2 hr,N,1,1,,CHEMBL625703,,BAO_0000218,,
12684,Intermediate,50594,,,Distribution of compound in mice liver was measured after 3 hr,N,1,1,,CHEMBL625704,,BAO_0000218,,
12685,Intermediate,50594,,,Distribution of compound in mice liver was measured after 6 hr,N,1,1,,CHEMBL625705,,BAO_0000218,,
12686,Intermediate,50588,Adrenal medulla,,Distribution in dog adrenal medulla 30 min after administration.,N,1,1,,CHEMBL625706,,BAO_0000218,1236.0,
12687,Intermediate,50588,Adrenal medulla,,Distribution in dog adrenal medulla 72 hours after administration.,N,1,1,,CHEMBL625707,,BAO_0000218,1236.0,
12688,Intermediate,50588,,,Distribution in female dog Ovary 24 hours after administration.,N,1,1,,CHEMBL625708,,BAO_0000218,,
12689,Intermediate,50588,,,Distribution in female dog Ovary 72 hours after administration.,N,1,1,,CHEMBL625709,,BAO_0000218,,
12690,Intermediate,50588,,,Distribution in female dog adipose 24 hours after administration.,N,1,1,,CHEMBL624180,,BAO_0000218,,
12691,Intermediate,50588,,,Distribution in female dog adipose 72 hours after administration.,N,1,1,,CHEMBL624181,,BAO_0000218,,
12692,Intermediate,50588,Adrenal cortex,,Distribution in female dog adrenal cortex 72 hours after administration.,N,1,1,,CHEMBL624182,,BAO_0000218,1235.0,
12693,Intermediate,50588,Adrenal cortex,,Distribution in female dog adrenal cortex 72 hours after administration.,N,1,1,,CHEMBL624183,,BAO_0000218,1235.0,
12694,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL624184,,BAO_0000218,2107.0,
12695,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL877489,,BAO_0000218,2107.0,
12696,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624185,,BAO_0000218,2107.0,
12697,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624186,,BAO_0000218,2107.0,
12698,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624187,,BAO_0000218,2107.0,
12699,Intermediate,50597,Liver,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624188,,BAO_0000218,2107.0,
12700,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624189,,BAO_0000218,2048.0,
12701,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624190,,BAO_0000218,2048.0,
12702,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624191,,BAO_0000218,2048.0,
12703,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624192,,BAO_0000218,2048.0,
12704,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL624193,,BAO_0000218,2048.0,
12705,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL624194,,BAO_0000218,2048.0,
12706,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624891,,BAO_0000218,2048.0,
12707,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL624892,,BAO_0000218,2048.0,
12708,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL624893,,BAO_0000218,2048.0,
12709,Intermediate,50597,Lung,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627632,,BAO_0000218,2048.0,
12710,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627633,,BAO_0000218,,
12711,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627634,,BAO_0000218,,
12712,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL627635,,BAO_0000218,,
12713,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627636,,BAO_0000218,,
12714,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL626816,,BAO_0000218,,
12715,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL626817,,BAO_0000218,,
12716,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL626818,,BAO_0000218,,
12717,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626819,,BAO_0000218,,
12718,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL626820,,BAO_0000218,,
12719,Intermediate,50597,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626821,,BAO_0000218,,
12720,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626822,,BAO_0000218,2046.0,
12721,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626823,,BAO_0000218,2046.0,
12722,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL626824,,BAO_0000218,2046.0,
12723,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626825,,BAO_0000218,2046.0,
12724,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,1,1,,CHEMBL626826,,BAO_0000218,2046.0,
12725,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,1,1,,CHEMBL626827,,BAO_0000218,2046.0,
12726,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL626828,,BAO_0000218,2046.0,
12727,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626829,,BAO_0000218,2046.0,
12728,Intermediate,50597,Thyroid gland,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL626830,,BAO_0000218,2046.0,
12729,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL627150,,BAO_0000218,,
12730,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627151,,BAO_0000218,,
12731,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,1,1,,CHEMBL627152,,BAO_0000218,,
12732,Intermediate,50597,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,1,1,,CHEMBL627153,,BAO_0000218,,
12733,Autocuration,22224,,,Rate of acetate production by the compound was determined,U,0,1,,CHEMBL627154,,BAO_0000019,,
12734,Autocuration,22224,,,Rate of acetate production by the compound was determined; Not determined,U,0,1,,CHEMBL627155,,BAO_0000019,,
12735,Autocuration,22224,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,U,0,1,,CHEMBL627156,,BAO_0000019,,
12736,Autocuration,22224,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,U,0,1,,CHEMBL627157,,BAO_0000019,,
12737,Intermediate,50592,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,1,1,,CHEMBL627158,,BAO_0000218,,
12738,Intermediate,50592,Plasma,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,1,1,,CHEMBL627159,,BAO_0000218,1969.0,
12739,Intermediate,50594,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,1,1,,CHEMBL627160,,BAO_0000218,,
12740,Intermediate,50597,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,1,1,,CHEMBL628540,,BAO_0000218,,
12741,Intermediate,50597,Plasma,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,1,1,,CHEMBL628541,,BAO_0000218,1969.0,
12742,Intermediate,50597,Plasma,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,1,1,,CHEMBL628542,,BAO_0000218,1969.0,
12743,Autocuration,22229,,,Solubility after at a pH 1.2,U,0,1,,CHEMBL628543,,BAO_0000100,,
12744,Autocuration,22229,,,Solubility after at pH 1.2,U,0,1,,CHEMBL628544,,BAO_0000100,,
12745,Autocuration,22229,,,Solubility after injection of water,U,0,1,,CHEMBL628545,,BAO_0000100,,
12746,Autocuration,22224,,,Statistical significance of IC 50 values; Expressed as R value,U,0,1,,CHEMBL628546,,BAO_0000019,,
12747,Autocuration,22224,,,Systemic availability with respect to methyldopa was determined,U,0,1,,CHEMBL874455,,BAO_0000019,,
12748,Intermediate,50597,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,N,1,1,,CHEMBL628547,,BAO_0000218,,
12749,Intermediate,50597,Plasma,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,N,1,1,,CHEMBL628548,,BAO_0000218,1969.0,
12750,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",N,1,1,,CHEMBL628549,,BAO_0000218,1988.0,
12751,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",N,1,1,,CHEMBL628550,,BAO_0000218,1988.0,
12752,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",N,1,1,,CHEMBL628551,,BAO_0000218,1988.0,
12753,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",N,1,1,,CHEMBL628552,,BAO_0000218,1088.0,
12754,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",N,1,1,,CHEMBL628553,,BAO_0000218,1088.0,
12755,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",N,1,1,,CHEMBL628554,,BAO_0000218,1088.0,
12756,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",N,1,1,,CHEMBL628555,,BAO_0000218,1088.0,
12757,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",N,1,1,,CHEMBL628556,,BAO_0000218,1088.0,
12758,Intermediate,50592,Kidney,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",N,1,1,,CHEMBL628557,,BAO_0000218,2113.0,
12759,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",N,1,1,,CHEMBL628558,,BAO_0000218,1988.0,
12760,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",N,1,1,,CHEMBL628559,,BAO_0000218,1988.0,
12761,Intermediate,50592,Feces,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",N,1,1,,CHEMBL628560,,BAO_0000218,1988.0,
12762,Intermediate,50592,Urine,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",N,1,1,,CHEMBL874456,,BAO_0000218,1088.0,
12763,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",N,1,1,,CHEMBL628561,,BAO_0000218,1988.0,
12764,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",N,1,1,,CHEMBL628562,,BAO_0000218,1988.0,
12765,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",N,1,1,,CHEMBL628563,,BAO_0000218,1088.0,
12766,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",N,1,1,,CHEMBL628564,,BAO_0000218,1088.0,
12767,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",N,1,1,,CHEMBL628565,,BAO_0000218,1088.0,
12768,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",N,1,1,,CHEMBL631248,,BAO_0000218,1088.0,
12769,Intermediate,50592,Urine,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",N,1,1,,CHEMBL631249,,BAO_0000218,1088.0,
12770,Intermediate,50592,Kidney,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",N,1,1,,CHEMBL627214,,BAO_0000218,2113.0,
12771,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",N,1,1,,CHEMBL874591,,BAO_0000218,1988.0,
12772,Intermediate,50592,Feces,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",N,1,1,,CHEMBL627215,,BAO_0000218,1988.0,
12773,Intermediate,50592,Feces,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,N,1,1,,CHEMBL625471,,BAO_0000218,1988.0,
12774,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,N,1,1,,CHEMBL625472,,BAO_0000218,,
12775,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,N,1,1,,CHEMBL625473,,BAO_0000218,,
12776,Intermediate,50588,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,N,1,1,,CHEMBL625474,,BAO_0000218,,
12777,Intermediate,50588,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,N,1,1,,CHEMBL625475,,BAO_0000218,,
12778,Intermediate,50597,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,N,1,1,,CHEMBL625476,,BAO_0000218,,
12779,Intermediate,50597,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,N,1,1,,CHEMBL625477,,BAO_0000218,,
12780,Intermediate,50597,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,N,1,1,,CHEMBL625478,,BAO_0000218,,
12781,Intermediate,50597,esophageal tunica muscularis mucosae,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,N,1,1,,CHEMBL625479,,BAO_0000218,,
12782,Intermediate,50597,esophageal tunica muscularis mucosae,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,N,1,1,,CHEMBL625480,,BAO_0000218,,
12783,Intermediate,50597,Plasma,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,N,1,1,,CHEMBL625481,,BAO_0000218,1969.0,
12784,Intermediate,50597,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,N,1,1,,CHEMBL625482,,BAO_0000218,,
12785,Intermediate,50597,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,N,1,1,,CHEMBL625483,,BAO_0000218,,
12786,Intermediate,50597,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,N,1,1,,CHEMBL625484,,BAO_0000218,,
12787,Intermediate,50597,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,N,1,1,,CHEMBL625485,,BAO_0000218,,
12788,Intermediate,50588,Plasma,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,N,1,1,,CHEMBL625486,,BAO_0000218,1969.0,
12789,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL625487,,BAO_0000218,1969.0,
12790,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL625488,,BAO_0000218,1969.0,
12791,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL625489,,BAO_0000218,1969.0,
12792,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL625490,,BAO_0000218,1969.0,
12793,Intermediate,50588,Plasma,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,N,1,1,,CHEMBL625491,,BAO_0000218,1969.0,
12794,Intermediate,50597,Plasma,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,N,1,1,,CHEMBL625492,,BAO_0000218,1969.0,
12795,Intermediate,50587,Plasma,,plasma clearance in human,N,1,1,,CHEMBL625493,,BAO_0000218,1969.0,
12796,Intermediate,50597,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,1,1,,CHEMBL625494,,BAO_0000218,,
12797,Intermediate,50597,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,1,1,,CHEMBL625495,,BAO_0000218,,
12798,Intermediate,50597,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,1,1,,CHEMBL625496,,BAO_0000218,,
12799,Autocuration,22229,,,1-Octanol/water partition coefficient measured at 7.4,U,0,1,,CHEMBL625497,,BAO_0000100,,
12800,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625498,,BAO_0000100,,
12801,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL625499,,BAO_0000019,,
12802,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625500,,BAO_0000100,,
12803,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625501,,BAO_0000100,,
12804,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625502,,BAO_0000100,,
12805,Autocuration,22229,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),U,0,1,,CHEMBL625503,,BAO_0000100,,
12806,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625504,,BAO_0000100,,
12807,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625505,,BAO_0000100,,
12808,Autocuration,22229,,,Calculated partition coefficient of the compound,U,0,1,,CHEMBL625506,,BAO_0000100,,
12809,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL625507,,BAO_0000019,,
12810,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625508,,BAO_0000100,,
12811,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625509,,BAO_0000100,,
12812,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625510,,BAO_0000100,,
12813,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL883125,,BAO_0000100,,
12814,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625511,,BAO_0000100,,
12815,Autocuration,22224,,,Partition coefficient of the compound,U,0,1,,CHEMBL874650,,BAO_0000019,,
12816,Autocuration,22224,,,Partition coefficient of the compound,U,0,1,,CHEMBL625512,,BAO_0000019,,
12817,Autocuration,22224,,,Partition coefficient of compound was determined,U,0,1,,CHEMBL625513,,BAO_0000019,,
12818,Autocuration,22224,,,Partition coefficient was determined,U,0,1,,CHEMBL625514,,BAO_0000019,,
12819,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625515,,BAO_0000100,,
12820,Autocuration,22229,,,partition coefficient of compound was determined,U,0,1,,CHEMBL625516,,BAO_0000100,,
12821,Intermediate,50588,,,The total body administered intravenously in dog,N,1,1,,CHEMBL625517,,BAO_0000218,,
12822,Intermediate,50597,,,The total body administered intravenously in rats,N,1,1,,CHEMBL625518,,BAO_0000218,,
12823,Intermediate,50594,,,Time taken for the administration to female NIH mice weighing 25-30 g.,N,1,1,,CHEMBL625519,,BAO_0000218,,
12824,Autocuration,22224,,,Time taken for the administration,U,0,1,,CHEMBL625520,,BAO_0000019,,
12825,Intermediate,50588,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL874651,,BAO_0000218,,
12826,Autocuration,22224,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,U,0,1,,CHEMBL625521,,BAO_0000218,,
12827,Intermediate,50592,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL623171,,BAO_0000218,,
12828,Intermediate,50597,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,N,1,1,,CHEMBL623853,,BAO_0000218,,
12829,Autocuration,22224,,,Plasma clearance for the compound was determined.,U,0,1,,CHEMBL623854,,BAO_0000019,,
12830,Autocuration,22224,,,CLog P value of the compound,U,0,1,,CHEMBL874405,,BAO_0000100,,
12831,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL623855,,BAO_0000100,,
12832,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL623856,,BAO_0000100,,
12833,Autocuration,22224,,,ClogP value of the compound; nd ='no data',U,0,1,,CHEMBL623857,,BAO_0000100,,
12834,Autocuration,22224,,,ClogP value of the compound; nd ='not determined',U,0,1,,CHEMBL623858,,BAO_0000100,,
12835,Autocuration,22224,,,CLog P was determined,U,0,1,,CHEMBL623859,,BAO_0000100,,
12836,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL839829,,BAO_0000100,,
12837,Autocuration,22224,,,CLogP was calculated,U,0,1,,CHEMBL623860,,BAO_0000019,,
12838,Autocuration,22224,,,CLogP value was determined,U,0,1,,CHEMBL623861,,BAO_0000019,,
12839,Autocuration,22224,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,U,0,1,,CHEMBL623862,,BAO_0000019,,
12840,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL874406,,BAO_0000100,,
12841,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL623863,,BAO_0000100,,
12842,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624021,,BAO_0000100,,
12843,Intermediate,50588,Adrenal medulla,,Distribution in female dog adrenal medulla 24 hours after administration.,N,1,1,,CHEMBL624022,,BAO_0000218,1236.0,
12844,Intermediate,50588,Adrenal medulla,,Distribution in female dog adrenal medulla 72 hours after administration.,N,1,1,,CHEMBL624023,,BAO_0000218,1236.0,
12845,Intermediate,50588,,,Distribution in female dog bile 24 hours after administration.,N,1,1,,CHEMBL624024,,BAO_0000218,,
12846,Intermediate,50588,,,Distribution in female dog bile 72 hr after administration.,N,1,1,,CHEMBL624025,,BAO_0000218,,
12847,Intermediate,50588,,,Distribution in female dog blood 24 hours after administration.,N,1,1,,CHEMBL624026,,BAO_0000218,,
12848,Intermediate,50588,,,Distribution in female dog blood 72 hours after administration.,N,1,1,,CHEMBL624027,,BAO_0000218,,
12849,Intermediate,50588,,,Distribution in female dog heart 24 hours after administration.,N,1,1,,CHEMBL624028,,BAO_0000218,,
12850,Intermediate,50588,,,Distribution in female dog heart 72 hours after administration.,N,1,1,,CHEMBL624029,,BAO_0000218,,
12851,Intermediate,50588,,,Distribution in female dog kidney 24 hours after administration.,N,1,1,,CHEMBL624030,,BAO_0000218,,
12852,Intermediate,50588,,,Distribution in female dog kidney 72 hours after administration.,N,1,1,,CHEMBL624031,,BAO_0000218,,
12853,Intermediate,50588,Intestine,,Distribution in female dog large intestine 24 hours after administration.,N,1,1,,CHEMBL624032,,BAO_0000218,160.0,
12854,Intermediate,50588,Intestine,,Distribution in female dog large intestine 72 hours after administration.,N,1,1,,CHEMBL874407,,BAO_0000218,160.0,
12855,Intermediate,50588,,,Distribution in female dog liver 24 hours after administration.,N,1,1,,CHEMBL624033,,BAO_0000218,,
12856,Intermediate,50588,,,Distribution in female dog liver 72 hours after administration.,N,1,1,,CHEMBL624034,,BAO_0000218,,
12857,Intermediate,50588,,,Distribution in female dog lung 24 hours after administration.,N,1,1,,CHEMBL624035,,BAO_0000218,,
12858,Intermediate,50588,,,Distribution in female dog lung 72 hours after administration.,N,1,1,,CHEMBL624036,,BAO_0000218,,
12859,Intermediate,50588,Muscle tissue,,Distribution in female dog muscle 24 hours after administration.,N,1,1,,CHEMBL624037,,BAO_0000218,2385.0,
12860,Intermediate,50588,Muscle tissue,,Distribution in female dog muscle 72 hours after administration.,N,1,1,,CHEMBL624038,,BAO_0000218,2385.0,
12861,Intermediate,50588,,,Distribution in female dog pancreas 24 hours after administration.,N,1,1,,CHEMBL624039,,BAO_0000218,,
12862,Intermediate,50588,,,Distribution in female dog pancreas 72 hours after administration.,N,1,1,,CHEMBL624040,,BAO_0000218,,
12863,Intermediate,50588,Intestine,,Distribution in female dog small intestine 24 hours after administration.,N,1,1,,CHEMBL624041,,BAO_0000218,160.0,
12864,Intermediate,50588,Intestine,,Distribution in female dog small intestine 72 hours after administration.,N,1,1,,CHEMBL624042,,BAO_0000218,160.0,
12865,Intermediate,50588,Spleen,,Distribution in female dog spleen 24 hours after administration.,N,1,1,,CHEMBL624043,,BAO_0000218,2106.0,
12866,Intermediate,50588,Spleen,,Distribution in female dog spleen 72 hours after administration.,N,1,1,,CHEMBL624044,,BAO_0000218,2106.0,
12867,Intermediate,50588,Stomach,,Distribution in female dog stomach 24 hours after administration.,N,1,1,,CHEMBL624045,,BAO_0000218,945.0,
12868,Intermediate,50588,Stomach,,Distribution in female dog stomach 72 hours after administration.,N,1,1,,CHEMBL624046,,BAO_0000218,945.0,
12869,Intermediate,50588,Thyroid gland,,Distribution in female dog thyroid 24 hours after administration.,N,1,1,,CHEMBL624047,,BAO_0000218,2046.0,
12870,Intermediate,50588,Thyroid gland,,Distribution in female dog thyroid 72 hours after administration.,N,1,1,,CHEMBL624048,,BAO_0000218,2046.0,
12871,Intermediate,50588,Urine,,Distribution in female dog urine 24 hours after administration.,N,1,1,,CHEMBL874408,,BAO_0000218,1088.0,
12872,Intermediate,50588,Urine,,Distribution in female dog urine 72 hr after administration.,N,1,1,,CHEMBL624049,,BAO_0000218,1088.0,
12873,Autocuration,22224,Plasma,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,U,0,1,,CHEMBL624050,,BAO_0000218,1969.0,
12874,Autocuration,22224,,,Plasma concentration at 7 hr after intravenous dosing,U,0,1,,CHEMBL624051,,BAO_0000019,,
12875,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,N,1,1,,CHEMBL623278,,BAO_0000218,,
12876,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,N,1,1,,CHEMBL623279,,BAO_0000218,,
12877,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,N,1,1,,CHEMBL623280,,BAO_0000218,,
12878,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,N,1,1,,CHEMBL623963,,BAO_0000218,,
12879,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,N,1,1,,CHEMBL623964,,BAO_0000218,,
12880,Intermediate,50597,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,N,1,1,,CHEMBL623965,,BAO_0000218,,
12881,Intermediate,50597,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,N,1,1,,CHEMBL623966,,BAO_0000218,,
12882,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,N,1,1,,CHEMBL874415,,BAO_0000218,,
12883,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,N,1,1,,CHEMBL623967,,BAO_0000218,,
12884,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,N,1,1,,CHEMBL623968,,BAO_0000218,,
12885,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,N,1,1,,CHEMBL623969,,BAO_0000218,,
12886,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,N,1,1,,CHEMBL628409,,BAO_0000218,,
12887,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,N,1,1,,CHEMBL628410,,BAO_0000218,,
12888,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,N,1,1,,CHEMBL628411,,BAO_0000218,,
12889,Intermediate,50597,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,N,1,1,,CHEMBL628412,,BAO_0000218,,
12890,Autocuration,22224,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,U,0,1,,CHEMBL628413,,BAO_0000019,,
12891,Autocuration,22224,Plasma,,The concentration in plasmat; Not determined,U,0,1,,CHEMBL628414,,BAO_0000019,1969.0,
12892,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in blood,N,1,1,,CHEMBL628415,,BAO_0000218,,
12893,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,N,1,1,,CHEMBL628416,,BAO_0000218,,
12894,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in heart,N,1,1,,CHEMBL628417,,BAO_0000218,,
12895,Intermediate,50597,Liver,,Tissue level at 10 mg/kg/po in wistar rats in liver,N,1,1,,CHEMBL874908,,BAO_0000218,2107.0,
12896,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,N,1,1,,CHEMBL628418,,BAO_0000218,,
12897,Intermediate,50597,Muscle tissue,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,N,1,1,,CHEMBL628419,,BAO_0000218,2385.0,
12898,Intermediate,50597,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,N,1,1,,CHEMBL628420,,BAO_0000218,,
12899,Autocuration,22224,,,Water solubility at 37 degree C.,U,0,1,,CHEMBL628421,,BAO_0000019,,
12900,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,0,1,,CHEMBL626726,,BAO_0000100,,
12901,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,0,1,,CHEMBL626727,,BAO_0000100,,
12902,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626728,,BAO_0000218,178.0,
12903,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626729,,BAO_0000218,178.0,
12904,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626730,,BAO_0000218,178.0,
12905,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626731,,BAO_0000218,178.0,
12906,Intermediate,50597,Blood,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626732,,BAO_0000218,178.0,
12907,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626733,,BAO_0000218,948.0,
12908,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626734,,BAO_0000218,948.0,
12909,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626735,,BAO_0000218,948.0,
12910,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL874909,,BAO_0000218,948.0,
12911,Intermediate,50597,Heart,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626736,,BAO_0000218,948.0,
12912,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL626737,,BAO_0000218,2113.0,
12913,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630999,,BAO_0000218,2113.0,
12914,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631000,,BAO_0000218,2113.0,
12915,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631001,,BAO_0000218,2113.0,
12916,Intermediate,50597,Kidney,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631002,,BAO_0000218,2113.0,
12917,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631003,,BAO_0000218,2107.0,
12918,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631004,,BAO_0000218,2107.0,
12919,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631005,,BAO_0000218,2107.0,
12920,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631006,,BAO_0000218,2107.0,
12921,Intermediate,50597,Liver,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631007,,BAO_0000218,2107.0,
12922,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631008,,BAO_0000218,2048.0,
12923,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631009,,BAO_0000218,2048.0,
12924,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631010,,BAO_0000218,2048.0,
12925,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631011,,BAO_0000218,2048.0,
12926,Intermediate,50597,Lung,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL631012,,BAO_0000218,2048.0,
12927,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630271,,BAO_0000218,2046.0,
12928,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630272,,BAO_0000218,2046.0,
12929,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630273,,BAO_0000218,2046.0,
12930,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630274,,BAO_0000218,2046.0,
12931,Intermediate,50597,Thyroid gland,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630275,,BAO_0000218,2046.0,
12932,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL875782,,BAO_0000218,,
12933,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630276,,BAO_0000218,,
12934,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630277,,BAO_0000218,,
12935,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630278,,BAO_0000218,,
12936,Intermediate,50597,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,N,1,1,,CHEMBL630279,,BAO_0000218,,
12937,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,U,0,1,,CHEMBL630280,,BAO_0000019,,
12938,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,0,1,,CHEMBL630281,,BAO_0000019,,
12939,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,N,1,1,,CHEMBL630282,,BAO_0000218,,
12940,Intermediate,50592,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,N,1,1,,CHEMBL630283,,BAO_0000218,,
12941,Autocuration,22224,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),U,0,1,,CHEMBL630284,,BAO_0000019,,
12942,Autocuration,22224,,,Alkylating activity was determined,U,0,1,,CHEMBL630285,,BAO_0000019,,
12943,Autocuration,22224,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),U,0,1,,CHEMBL630286,,BAO_0000251,,
12944,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",N,1,1,,CHEMBL630069,,BAO_0000218,,
12945,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",N,1,1,,CHEMBL630070,,BAO_0000218,,
12946,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",N,1,1,,CHEMBL630071,,BAO_0000218,,
12947,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",N,1,1,,CHEMBL630072,,BAO_0000218,,
12948,Intermediate,50592,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",N,1,1,,CHEMBL875110,,BAO_0000218,,
12949,Intermediate,50597,,,Compound was tested for antidiuretic activity in rats,N,1,1,,CHEMBL630073,,BAO_0000218,,
12950,Autocuration,22224,,,Compound was tested for inactivation kinetic values,U,0,1,,CHEMBL630074,,BAO_0000019,,
12951,Autocuration,22224,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,U,0,1,,CHEMBL630075,,BAO_0000218,,
12952,Autocuration,22224,,,Dissociation rate calculated from the first-order equation using the t1/2 value,U,0,1,,CHEMBL630076,,BAO_0000019,,
12953,Autocuration,22229,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,U,0,1,,CHEMBL630077,,BAO_0000100,,
12954,Autocuration,22229,,,Aqueous solubility was measured,U,0,1,,CHEMBL630078,,BAO_0000100,,
12955,Autocuration,22229,,,Aqueous solubility was measured at a pH 4,U,0,1,,CHEMBL630079,,BAO_0000100,,
12956,Autocuration,22229,,,Aqueous solubility (pH 7),U,0,1,,CHEMBL630080,,BAO_0000100,,
12957,Autocuration,22229,,,Aqueous solubility was measured at a pH 9,U,0,1,,CHEMBL630081,,BAO_0000100,,
12958,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",U,0,1,,CHEMBL630082,,BAO_0000019,,
12959,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,0,1,,CHEMBL630083,,BAO_0000019,,
12960,Autocuration,22224,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,0,1,,CHEMBL630084,,BAO_0000019,,
12961,Autocuration,22229,,,Aqueous solubility of the compound,U,0,1,,CHEMBL629198,,BAO_0000100,,
12962,Autocuration,22229,,,Aqueous solubility at 37 degree Celsius at pH 7.38,U,0,1,,CHEMBL629199,,BAO_0000100,,
12963,Autocuration,22229,,,Aqueous solubility in pH 7.4 phosphate buffer,U,0,1,,CHEMBL629200,,BAO_0000100,,
12964,Intermediate,50588,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,N,1,1,,CHEMBL629201,,BAO_0000218,,
12965,Intermediate,50588,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,N,1,1,,CHEMBL629202,,BAO_0000218,,
12966,Intermediate,50587,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,N,1,1,,CHEMBL875111,,BAO_0000218,,
12967,Intermediate,50587,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,N,1,1,,CHEMBL629203,,BAO_0000218,,
12968,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,N,1,1,,CHEMBL629204,,BAO_0000218,,
12969,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,N,1,1,,CHEMBL629205,,BAO_0000218,,
12970,Intermediate,50587,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,N,1,1,,CHEMBL629206,,BAO_0000218,,
12971,Autocuration,22224,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,U,0,1,,CHEMBL631185,,BAO_0000019,,
12972,Intermediate,50597,,,Compound was evaluated for the average bile flow rat in rats,N,1,1,,CHEMBL631186,,BAO_0000218,,
12973,Intermediate,50592,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,1,1,,CHEMBL631187,,BAO_0000218,,
12974,Intermediate,50592,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,1,1,,CHEMBL631188,,BAO_0000218,,
12975,Autocuration,22224,,,Average half life period was determined,U,0,1,,CHEMBL876419,,BAO_0000019,,
12976,Autocuration,22224,,,Average half life period was determined,U,0,1,,CHEMBL631189,,BAO_0000019,,
12977,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,1,1,,CHEMBL631190,,BAO_0000218,,
12978,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,1,1,,CHEMBL631191,,BAO_0000218,,
12979,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,N,1,1,,CHEMBL631192,,BAO_0000218,,
12980,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,N,1,1,,CHEMBL632400,,BAO_0000218,,
12981,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,1,1,,CHEMBL630564,,BAO_0000218,,
12982,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,1,1,,CHEMBL630565,,BAO_0000218,,
12983,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,N,1,1,,CHEMBL630566,,BAO_0000218,,
12984,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,N,1,1,,CHEMBL631229,,BAO_0000218,,
12985,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,N,1,1,,CHEMBL631230,,BAO_0000218,,
12986,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL876428,,BAO_0000100,,
12987,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631231,,BAO_0000100,,
12988,Autocuration,22229,,,Calculated partition coefficient (clogP) (MacLogP),U,0,1,,CHEMBL631232,,BAO_0000100,,
12989,Autocuration,22224,,,Hydrophilicity was determined,U,0,1,,CHEMBL631233,,BAO_0000019,,
12990,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631234,,BAO_0000100,,
12991,Autocuration,22224,,,Increased absorption was determined,U,0,1,,CHEMBL883126,,BAO_0000019,,
12992,Autocuration,22224,,,Lipophilicity value was evaluated,U,0,1,,CHEMBL631235,,BAO_0000100,,
12993,Autocuration,22224,,,Log P value of the compound.,U,0,1,,CHEMBL631236,,BAO_0000100,,
12994,Autocuration,22224,,,Partition coefficient of compound was determined,U,0,1,,CHEMBL631237,,BAO_0000019,,
12995,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631238,,BAO_0000100,,
12996,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL876429,,BAO_0000100,,
12997,Autocuration,22224,,,Partition coefficient was measured by medchem software; Not calculated,U,0,1,,CHEMBL631414,,BAO_0000019,,
12998,Autocuration,22224,,,Partition coefficient was measured by octanol-water using standard shake-flask method,U,0,1,,CHEMBL631415,,BAO_0000100,,
12999,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631416,,BAO_0000100,,
13000,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL631417,,BAO_0000019,,
13001,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631418,,BAO_0000100,,
13002,Autocuration,22229,,,The Octanol/Water partition coefficient CLogP,U,0,1,,CHEMBL631419,,BAO_0000100,,
13003,Autocuration,22224,,,The pharmacokinetic parameter C Log p was reported,U,0,1,,CHEMBL631420,,BAO_0000019,,
13004,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631421,,BAO_0000100,,
13005,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631422,,BAO_0000100,,
13006,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL631423,,BAO_0000100,,
13007,Intermediate,50597,Plasma,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,1,1,,CHEMBL876430,,BAO_0000218,1969.0,
13008,Intermediate,50597,Plasma,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,N,1,1,,CHEMBL631424,,BAO_0000218,1969.0,
13009,Intermediate,50588,Plasma,,Compound was administered intravenously in dog to evaluate plasma clearance values,N,1,1,,CHEMBL631425,,BAO_0000218,1969.0,
13010,Autocuration,22224,Plasma,,Compound was administered intravenously in monkey to evaluate plasma clearance values,U,0,1,,CHEMBL631426,,BAO_0000218,1969.0,
13011,Intermediate,50594,Plasma,,Compound was administered intravenously in mouse to evaluate plasma clearance values,N,1,1,,CHEMBL631427,,BAO_0000218,1969.0,
13012,Intermediate,50588,Plasma,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,N,1,1,,CHEMBL631428,,BAO_0000218,1969.0,
13013,Intermediate,50797,Liver,,Intrinsic clearance in Rhesus liver microsome,N,1,1,,CHEMBL631429,,BAO_0000218,2107.0,
13014,Intermediate,50588,Liver,,Intrinsic clearance in dog liver microsome,N,1,1,,CHEMBL631430,,BAO_0000218,2107.0,
13015,Intermediate,50597,Liver,,Intrinsic clearance in rat liver microsome,N,1,1,,CHEMBL631431,,BAO_0000218,2107.0,
13016,Intermediate,50797,Plasma,,Low plasma clearance was calculated in rhesus monkey,N,1,1,,CHEMBL631432,,BAO_0000218,1969.0,
13017,Intermediate,50588,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,1,1,,CHEMBL631433,,BAO_0000218,,
13018,Autocuration,22224,,,Plasma clearance after intravenous dose of 0.3 mg/kg,U,0,1,,CHEMBL631434,,BAO_0000218,,
13019,Autocuration,22224,,,Plasma clearance after intravenous dose of 1 mg/kg,U,0,1,,CHEMBL631435,,BAO_0000218,,
13020,Autocuration,22224,,,Plasma clearance after intravenous dose of 3 mg/kg,U,0,1,,CHEMBL631436,,BAO_0000218,,
13021,Autocuration,22224,,,Plasma clearance after intravenous dose of 3.87 mg/kg,U,0,1,,CHEMBL631437,,BAO_0000218,,
13022,Intermediate,50597,,,Plasma clearance after peroral administration at 10 mpk in Rat,N,1,1,,CHEMBL631438,,BAO_0000218,,
13023,Intermediate,50797,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,N,1,1,,CHEMBL876431,,BAO_0000218,,
13024,Intermediate,50588,,,Plasma clearance after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL631439,,BAO_0000218,,
13025,Intermediate,50597,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,N,1,1,,CHEMBL631440,,BAO_0000218,,
13026,Autocuration,22224,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),U,0,1,,CHEMBL631441,,BAO_0000019,,
13027,Autocuration,22224,,,Critical Micellar concentration was determined,U,0,1,,CHEMBL631442,,BAO_0000019,,
13028,Autocuration,22224,,,Critical Micellar concentration of the compound. was determined,U,0,1,,CHEMBL626525,,BAO_0000019,,
13029,Autocuration,22224,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,U,0,1,,CHEMBL627168,,BAO_0000019,,
13030,Autocuration,22224,,,Critical micellar concentration was measured in water by the dye solubilization method,U,0,1,,CHEMBL875618,,BAO_0000019,,
13031,Autocuration,22224,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,U,0,1,,CHEMBL626612,,BAO_0000019,,
13032,Autocuration,22224,,,CMR value (relative to BAY K 8644),U,0,1,,CHEMBL626613,,BAO_0000019,,
13033,Autocuration,22224,,,Carbamoylating activity was determined,U,0,1,,CHEMBL626614,,BAO_0000019,,
13034,Autocuration,22224,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,U,0,1,,CHEMBL626615,,BAO_0000218,,
13035,Autocuration,22224,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,U,0,1,,CHEMBL626616,,BAO_0000019,,
13036,Autocuration,22224,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,U,0,1,,CHEMBL626617,,BAO_0000019,,
13037,Intermediate,50588,Plasma,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,N,1,1,,CHEMBL626618,,BAO_0000218,1969.0,
13038,Intermediate,50597,Plasma,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,N,1,1,,CHEMBL626619,,BAO_0000218,1969.0,
13039,Intermediate,50588,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",N,1,1,,CHEMBL626620,,BAO_0000218,,
13040,Intermediate,50597,,,"Clearance rate at 5.5 mg/kg, iv, in rat",N,1,1,,CHEMBL626621,,BAO_0000218,,
13041,Intermediate,100710,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,1,1,,CHEMBL626622,,BAO_0000218,,
13042,Intermediate,100710,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,1,1,,CHEMBL626623,,BAO_0000218,,
13043,Intermediate,50588,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,1,1,,CHEMBL626624,,BAO_0000218,,
13044,Intermediate,50597,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,1,1,,CHEMBL626625,,BAO_0000218,,
13045,Intermediate,50597,Liver,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,1,1,,CHEMBL626626,,BAO_0000218,2107.0,
13046,Autocuration,22224,,,Tested for the total clearance of the compound,U,0,1,,CHEMBL626627,,BAO_0000218,,
13047,Intermediate,50588,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,N,1,1,,CHEMBL626628,,BAO_0000218,,
13048,Autocuration,22224,,,Total body clearance was determined,U,0,1,,CHEMBL626629,,BAO_0000218,,
13049,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,1,1,,CHEMBL626630,,BAO_0000218,,
13050,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,1,1,,CHEMBL626631,,BAO_0000218,,
13051,Autocuration,22229,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,0,1,,CHEMBL626632,,BAO_0000100,,
13052,Autocuration,22229,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,0,1,,CHEMBL626633,,BAO_0000100,,
13053,Autocuration,22229,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,U,0,1,,CHEMBL626634,,BAO_0000100,,
13054,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,0,1,,CHEMBL626635,,BAO_0000100,,
13055,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,0,1,,CHEMBL626636,,BAO_0000100,,
13056,Autocuration,22229,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,0,1,,CHEMBL626637,,BAO_0000100,,
13057,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),N,1,1,,CHEMBL626638,,BAO_0000218,,
13058,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,N,1,1,,CHEMBL626639,,BAO_0000218,,
13059,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,N,1,1,,CHEMBL626640,,BAO_0000218,,
13060,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,N,1,1,,CHEMBL626641,,BAO_0000218,,
13061,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,N,1,1,,CHEMBL627272,,BAO_0000218,,
13062,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,N,1,1,,CHEMBL627273,,BAO_0000218,,
13063,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),N,1,1,,CHEMBL627441,,BAO_0000218,,
13064,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),N,1,1,,CHEMBL628355,,BAO_0000218,,
13065,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),N,1,1,,CHEMBL628356,,BAO_0000218,,
13066,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),N,1,1,,CHEMBL628357,,BAO_0000218,,
13067,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),N,1,1,,CHEMBL628358,,BAO_0000218,,
13068,Intermediate,50339,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),N,1,1,,CHEMBL622307,,BAO_0000218,,
13069,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,U,0,1,,CHEMBL622527,,BAO_0000019,,
13070,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,U,0,1,,CHEMBL622528,,BAO_0000019,,
13071,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,U,0,1,,CHEMBL622529,,BAO_0000019,,
13072,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,U,0,1,,CHEMBL622992,,BAO_0000019,,
13073,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,U,0,1,,CHEMBL622993,,BAO_0000019,,
13074,Autocuration,22224,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,U,0,1,,CHEMBL622994,,BAO_0000019,,
13075,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",N,1,1,,CHEMBL622995,,BAO_0000218,,
13076,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",N,1,1,,CHEMBL622996,,BAO_0000218,,
13077,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",N,1,1,,CHEMBL622997,,BAO_0000218,,
13078,Intermediate,50597,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",N,1,1,,CHEMBL622998,,BAO_0000218,,
13079,Autocuration,22224,,,Cp max following ip administration at 1 mg/kg,U,0,1,,CHEMBL622999,,BAO_0000218,,
13080,Autocuration,22224,Plasma,,Maximum concentration in plasma was reported at 0.5 hour,U,0,1,,CHEMBL623000,,BAO_0000218,1969.0,
13081,Autocuration,22224,Plasma,,Maximum concentration in plasma was reported at 2 hour,U,0,1,,CHEMBL623001,,BAO_0000218,1969.0,
13082,Intermediate,50594,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,N,1,1,,CHEMBL623002,,BAO_0000218,,
13083,Autocuration,22229,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),U,0,1,,CHEMBL623003,,BAO_0000100,,
13084,Autocuration,22224,,,Steady state concentration was evaluated,U,0,1,,CHEMBL623004,,BAO_0000019,,
13085,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL623005,,BAO_0000019,,
13086,Autocuration,22224,,,Partition coefficient (logD7.4),U,0,1,,CHEMBL623006,,BAO_0000019,,
13087,Intermediate,50597,Liver,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,N,1,1,,CHEMBL623007,,BAO_0000218,2107.0,
13088,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,N,1,1,,CHEMBL623008,,BAO_0000218,10000001.0,
13089,Intermediate,50597,Cerebellum,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,1,1,,CHEMBL876654,,BAO_0000218,2037.0,
13090,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,N,1,1,,CHEMBL623009,,BAO_0000218,,
13091,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,N,1,1,,CHEMBL623010,,BAO_0000218,,
13092,Intermediate,50597,Heart,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,N,1,1,,CHEMBL623011,,BAO_0000218,948.0,
13093,Intermediate,50597,Intestine,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,N,1,1,,CHEMBL623012,,BAO_0000218,160.0,
13094,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,U,0,1,,CHEMBL623013,,BAO_0000019,,
13095,Autocuration,22224,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,0,1,,CHEMBL623014,,BAO_0000019,,
13096,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,U,0,1,,CHEMBL623015,,BAO_0000019,1088.0,
13097,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,U,0,1,,CHEMBL623016,,BAO_0000019,1088.0,
13098,Autocuration,22224,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,U,0,1,,CHEMBL624858,,BAO_0000019,1088.0,
13099,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,N,1,1,,CHEMBL624859,,BAO_0000218,,
13100,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,1,1,,CHEMBL624860,,BAO_0000218,,
13101,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,1,1,,CHEMBL624861,,BAO_0000218,,
13102,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,N,1,1,,CHEMBL624862,,BAO_0000218,,
13103,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,N,1,1,,CHEMBL624863,,BAO_0000218,,
13104,Intermediate,50597,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,1,1,,CHEMBL876655,,BAO_0000218,,
13105,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,1,1,,CHEMBL624864,,BAO_0000218,,
13106,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,1,1,,CHEMBL624865,,BAO_0000218,,
13107,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,1,1,,CHEMBL624866,,BAO_0000218,,
13108,Expert,50588,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,N,1,1,,CHEMBL624867,,BAO_0000218,,
13109,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,1,1,,CHEMBL624868,,BAO_0000218,,
13110,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,N,1,1,,CHEMBL628450,,BAO_0000218,,
13111,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,1,1,,CHEMBL628451,,BAO_0000218,,
13112,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,1,1,,CHEMBL628452,,BAO_0000218,,
13113,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,1,1,,CHEMBL628453,,BAO_0000218,,
13114,Intermediate,50588,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,N,1,1,,CHEMBL628454,,BAO_0000218,,
13115,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,1,1,,CHEMBL628455,,BAO_0000218,,
13116,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,1,1,,CHEMBL628456,,BAO_0000218,,
13117,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,1,1,,CHEMBL628457,,BAO_0000218,,
13118,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,N,1,1,,CHEMBL877505,,BAO_0000218,,
13119,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,N,1,1,,CHEMBL628458,,BAO_0000218,,
13120,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,1,1,,CHEMBL628459,,BAO_0000218,,
13121,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,1,1,,CHEMBL628460,,BAO_0000218,,
13122,Intermediate,50588,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,1,1,,CHEMBL628461,,BAO_0000218,,
13123,Autocuration,22224,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",U,0,1,,CHEMBL628462,,BAO_0000218,,
13124,Intermediate,50588,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,1,1,,CHEMBL628463,,BAO_0000218,,
13125,Expert,50597,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",N,1,1,,CHEMBL625666,,BAO_0000218,,
13126,Autocuration,22224,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,U,0,1,,CHEMBL625667,,BAO_0000218,,
13127,Expert,50597,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,1,1,,CHEMBL625668,,BAO_0000218,,
13128,Intermediate,50597,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,1,1,,CHEMBL625669,,BAO_0000218,,
13129,Autocuration,22224,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,U,0,1,,CHEMBL625670,,BAO_0000019,,
13130,Intermediate,50597,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,N,1,1,,CHEMBL625671,,BAO_0000218,,
13131,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,N,1,1,,CHEMBL625672,,BAO_0000218,,
13132,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,N,1,1,,CHEMBL625673,,BAO_0000218,,
13133,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,N,1,1,,CHEMBL625674,,BAO_0000218,,
13134,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,N,1,1,,CHEMBL625675,,BAO_0000218,,
13135,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,1,1,,CHEMBL627637,,BAO_0000218,,
13136,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,N,1,1,,CHEMBL627638,,BAO_0000218,,
13137,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,N,1,1,,CHEMBL627639,,BAO_0000218,,
13138,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,N,1,1,,CHEMBL627640,,BAO_0000218,,
13139,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,N,1,1,,CHEMBL627641,,BAO_0000218,,
13140,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,1,1,,CHEMBL627642,,BAO_0000218,,
13141,Intermediate,50602,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,1,1,,CHEMBL877506,,BAO_0000218,,
13142,Intermediate,50594,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,1,1,,CHEMBL627275,,BAO_0000218,,
13143,Intermediate,50506,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",N,1,1,,CHEMBL627643,,BAO_0000218,,
13144,Intermediate,50506,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,1,1,,CHEMBL631246,,BAO_0000218,,
13145,Intermediate,50506,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,1,1,,CHEMBL631247,,BAO_0000218,,
13146,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,1,1,,CHEMBL629532,,BAO_0000218,,
13147,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,N,1,1,,CHEMBL629533,,BAO_0000218,,
13148,Intermediate,50506,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,1,1,,CHEMBL629534,,BAO_0000218,,
13149,Intermediate,50506,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,N,1,1,,CHEMBL629535,,BAO_0000218,,
13150,Autocuration,22224,,,Pharmacokinetic parameter :drug bound to plasma was reported,U,0,1,,CHEMBL625932,,BAO_0000019,,
13151,Autocuration,22224,,,compound was evaluated for drug bound in plasma,U,0,1,,CHEMBL625933,,BAO_0000019,,
13152,Intermediate,50597,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,N,1,1,,CHEMBL625934,,BAO_0000218,,
13153,Autocuration,22224,,,Bioavailability,U,0,1,,CHEMBL625935,,BAO_0000218,,
13154,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,N,1,1,,CHEMBL625936,,BAO_0000218,,
13155,Intermediate,50597,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,N,1,1,,CHEMBL625937,,BAO_0000218,,
13156,Intermediate,50588,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,1,1,,CHEMBL625938,,BAO_0000218,,
13157,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,N,1,1,,CHEMBL625939,,BAO_0000218,1970.0,
13158,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,N,1,1,,CHEMBL625940,,BAO_0000218,1970.0,
13159,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,N,1,1,,CHEMBL874464,,BAO_0000218,1970.0,
13160,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,N,1,1,,CHEMBL625941,,BAO_0000218,1970.0,
13161,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,N,1,1,,CHEMBL625942,,BAO_0000218,1970.0,
13162,Intermediate,50597,Bile,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,N,1,1,,CHEMBL625943,,BAO_0000218,1970.0,
13163,Intermediate,50587,Serum,,In vitro protein binding in human serum at 5 ug/ml,N,1,1,,CHEMBL625944,,BAO_0000218,1977.0,
13164,Autocuration,22224,,,Serum protein binding ability was measured,U,0,1,,CHEMBL625945,,BAO_0000019,,
13165,Autocuration,22224,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,0,1,,CHEMBL625946,,BAO_0000019,,
13166,Autocuration,22224,,,Oral bioavailability in dog,U,0,1,,CHEMBL625947,,BAO_0000218,,
13167,Intermediate,50597,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,N,1,1,,CHEMBL625948,,BAO_0000218,,
13168,Autocuration,22224,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,U,0,1,,CHEMBL625949,,BAO_0000218,,
13169,Autocuration,22224,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,U,0,1,,CHEMBL625950,,BAO_0000218,,
13170,Autocuration,22224,,,Oral bioavailability (dose 15 mg/kg i.v.),U,0,1,,CHEMBL625951,,BAO_0000218,,
13171,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,U,0,1,,CHEMBL625952,,BAO_0000218,,
13172,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,U,0,1,,CHEMBL625953,,BAO_0000218,,
13173,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,U,0,1,,CHEMBL625954,,BAO_0000218,,
13174,Autocuration,22224,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,U,0,1,,CHEMBL882959,,BAO_0000218,,
13175,Intermediate,50588,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,N,1,1,,CHEMBL625955,,BAO_0000218,,
13176,Autocuration,22224,,,Bioavailability in ferret,U,0,1,,CHEMBL625956,,BAO_0000218,,
13177,Intermediate,100710,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,N,1,1,,CHEMBL625957,,BAO_0000218,,
13178,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,1,1,,CHEMBL625958,,BAO_0000218,,
13179,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,1,1,,CHEMBL625959,,BAO_0000218,,
13180,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,1,1,,CHEMBL626642,,BAO_0000218,,
13181,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,1,1,,CHEMBL631330,,BAO_0000218,,
13182,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,1,1,,CHEMBL631331,,BAO_0000218,,
13183,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,1,1,,CHEMBL631332,,BAO_0000218,,
13184,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,1,1,,CHEMBL631333,,BAO_0000218,,
13185,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,1,1,,CHEMBL632018,,BAO_0000218,,
13186,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,1,1,,CHEMBL632019,,BAO_0000218,,
13187,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,1,1,,CHEMBL632020,,BAO_0000218,,
13188,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,1,1,,CHEMBL632021,,BAO_0000218,,
13189,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,1,1,,CHEMBL632022,,BAO_0000218,,
13190,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,1,1,,CHEMBL632023,,BAO_0000218,,
13191,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,1,1,,CHEMBL632024,,BAO_0000218,,
13192,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,1,1,,CHEMBL874472,,BAO_0000218,,
13193,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,1,1,,CHEMBL632025,,BAO_0000218,,
13194,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,1,1,,CHEMBL632026,,BAO_0000218,,
13195,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,1,1,,CHEMBL632027,,BAO_0000218,,
13196,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,1,1,,CHEMBL632028,,BAO_0000218,,
13197,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,1,1,,CHEMBL626430,,BAO_0000218,,
13198,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,1,1,,CHEMBL626431,,BAO_0000218,,
13199,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,1,1,,CHEMBL626432,,BAO_0000218,,
13200,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,1,1,,CHEMBL626433,,BAO_0000218,,
13201,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,1,1,,CHEMBL626434,,BAO_0000218,,
13202,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,1,1,,CHEMBL627280,,BAO_0000218,,
13203,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,1,1,,CHEMBL627281,,BAO_0000218,,
13204,Intermediate,50597,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,1,1,,CHEMBL627282,,BAO_0000218,,
13205,Autocuration,22224,,,Total body clearance was measured at given dose,U,0,1,,CHEMBL627283,,BAO_0000019,,
13206,Autocuration,22224,,,Total body clearance was measured at given dose.,U,0,1,,CHEMBL627284,,BAO_0000218,,
13207,Intermediate,50597,,,Metabolic clearance from the body in rat,N,1,1,,CHEMBL627285,,BAO_0000218,,
13208,Autocuration,22224,,,Renal clearance from the body,U,0,1,,CHEMBL627286,,BAO_0000218,,
13209,Intermediate,50597,,,Renal clearance from the body in rat,N,1,1,,CHEMBL875477,,BAO_0000218,,
13210,Intermediate,50597,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,N,1,1,,CHEMBL627287,,BAO_0000218,,
13211,Intermediate,50588,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,N,1,1,,CHEMBL627288,,BAO_0000218,,
13212,Intermediate,50597,,,Total clearance from the body in rat,N,1,1,,CHEMBL627289,,BAO_0000218,,
13213,Intermediate,50597,Plasma,,Clearance into cortex from rat plasma or PBS,N,1,1,,CHEMBL627290,,BAO_0000218,1969.0,
13214,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,U,0,1,,CHEMBL627291,,BAO_0000218,,
13215,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,U,0,1,,CHEMBL627292,,BAO_0000218,,
13216,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,U,0,1,,CHEMBL627293,,BAO_0000218,,
13217,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,U,0,1,,CHEMBL627294,,BAO_0000218,,
13218,Autocuration,22224,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,U,0,1,,CHEMBL875478,,BAO_0000218,,
13219,Autocuration,22224,,,Clearance was determined,U,0,1,,CHEMBL627295,,BAO_0000218,,
13220,Intermediate,50594,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,N,1,1,,CHEMBL627296,,BAO_0000218,,
13221,Intermediate,50592,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,N,1,1,,CHEMBL626119,,BAO_0000218,,
13222,Intermediate,50597,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,N,1,1,,CHEMBL626120,,BAO_0000218,,
13223,Intermediate,50597,,,Clearance in rat after iv dose (100 ug/kg),N,1,1,,CHEMBL626121,,BAO_0000218,,
13224,Autocuration,22224,,,Clearance in guinea pig,U,0,1,,CHEMBL626122,,BAO_0000218,,
13225,Intermediate,50597,,,Compound was evaluated for clearance in rat,N,1,1,,CHEMBL626123,,BAO_0000218,,
13226,Intermediate,50588,,,Compound was evaluated for the clearance in dog,N,1,1,,CHEMBL623456,,BAO_0000218,,
13227,Intermediate,50597,,,Compound was evaluated for the clearance in rat,N,1,1,,CHEMBL623457,,BAO_0000218,,
13228,Intermediate,50597,,,Compound was tested in vivo for clearance after iv administration in the rat,N,1,1,,CHEMBL623458,,BAO_0000218,,
13229,Autocuration,22224,,,IV clearance determined at an iv dose of 14 mg/kg,U,0,1,,CHEMBL623459,,BAO_0000218,,
13230,Autocuration,22224,,,IV clearance determined at an iv dose of 15.2 mg/kg,U,0,1,,CHEMBL875484,,BAO_0000218,,
13231,Autocuration,22224,,,IV clearance determined at an iv dose of 15 mg/kg,U,0,1,,CHEMBL623460,,BAO_0000218,,
13232,Autocuration,22224,,,IV clearance determined at an peroral dose of 30 mg/kg.,U,0,1,,CHEMBL623461,,BAO_0000218,,
13233,Autocuration,22224,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,U,0,1,,CHEMBL623462,,BAO_0000218,,
13234,Autocuration,22224,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,U,0,1,,CHEMBL627386,,BAO_0000218,,
13235,Intermediate,50597,Kidney,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,N,1,1,,CHEMBL627387,,BAO_0000218,2113.0,
13236,Intermediate,50597,Liver,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,N,1,1,,CHEMBL627388,,BAO_0000218,2107.0,
13237,Intermediate,50597,Lung,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,N,1,1,,CHEMBL627389,,BAO_0000218,2048.0,
13238,Intermediate,50597,Muscle tissue,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,N,1,1,,CHEMBL627390,,BAO_0000218,2385.0,
13239,Intermediate,50597,Plasma,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,N,1,1,,CHEMBL627391,,BAO_0000218,1969.0,
13240,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,1,1,,CHEMBL627392,,BAO_0000218,,
13241,Intermediate,50597,Spleen,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,N,1,1,,CHEMBL627393,,BAO_0000218,2106.0,
13242,Intermediate,50597,Trachea,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,N,1,1,,CHEMBL627394,,BAO_0000218,3126.0,
13243,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,N,1,1,,CHEMBL627395,,BAO_0000218,10000001.0,
13244,Intermediate,50597,Cerebellum,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,1,1,,CHEMBL875485,,BAO_0000218,2037.0,
13245,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,N,1,1,,CHEMBL627396,,BAO_0000218,,
13246,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,N,1,1,,CHEMBL627397,,BAO_0000218,,
13247,Intermediate,50597,Heart,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,N,1,1,,CHEMBL627398,,BAO_0000218,948.0,
13248,Intermediate,50597,Bone,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,N,1,1,,CHEMBL627399,,BAO_0000218,10000001.0,
13249,Intermediate,50597,Kidney,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,N,1,1,,CHEMBL627400,,BAO_0000218,2113.0,
13250,Intermediate,50597,Liver,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,N,1,1,,CHEMBL627401,,BAO_0000218,2107.0,
13251,Intermediate,50597,Lung,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,N,1,1,,CHEMBL627402,,BAO_0000218,2048.0,
13252,Intermediate,50597,Muscle tissue,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,N,1,1,,CHEMBL627403,,BAO_0000218,2385.0,
13253,Intermediate,50597,Plasma,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,N,1,1,,CHEMBL627404,,BAO_0000218,1969.0,
13254,Intermediate,50597,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,1,1,,CHEMBL623101,,BAO_0000218,,
13255,Intermediate,50597,Spleen,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,N,1,1,,CHEMBL877480,,BAO_0000218,2106.0,
13256,Intermediate,50597,Trachea,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,N,1,1,,CHEMBL623102,,BAO_0000218,3126.0,
13257,Intermediate,50597,Bone,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,N,1,1,,CHEMBL623103,,BAO_0000218,10000001.0,
13258,Intermediate,50597,Cerebellum,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,1,1,,CHEMBL623104,,BAO_0000218,2037.0,
13259,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,N,1,1,,CHEMBL623105,,BAO_0000218,,
13260,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,N,1,1,,CHEMBL623106,,BAO_0000218,,
13261,Intermediate,50597,Heart,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,N,1,1,,CHEMBL623107,,BAO_0000218,948.0,
13262,Intermediate,50597,Intestine,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,N,1,1,,CHEMBL623108,,BAO_0000218,160.0,
13263,Intermediate,50597,Kidney,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,N,1,1,,CHEMBL623109,,BAO_0000218,2113.0,
13264,Intermediate,50597,Liver,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,N,1,1,,CHEMBL623110,,BAO_0000218,2107.0,
13265,Intermediate,50597,Lung,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,N,1,1,,CHEMBL623111,,BAO_0000218,2048.0,
13266,Intermediate,50597,Muscle tissue,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,N,1,1,,CHEMBL625060,,BAO_0000218,2385.0,
13267,Intermediate,50597,Plasma,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,N,1,1,,CHEMBL625061,,BAO_0000218,1969.0,
13268,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,1,1,,CHEMBL625062,,BAO_0000218,,
13269,Intermediate,50597,Spleen,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,N,1,1,,CHEMBL625063,,BAO_0000218,2106.0,
13270,Intermediate,50597,Trachea,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,N,1,1,,CHEMBL625064,,BAO_0000218,3126.0,
13271,Intermediate,50597,Bone,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,N,1,1,,CHEMBL625065,,BAO_0000218,10000001.0,
13272,Intermediate,50597,Cerebellum,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,1,1,,CHEMBL625066,,BAO_0000218,2037.0,
13273,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,N,1,1,,CHEMBL625067,,BAO_0000218,,
13274,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,N,1,1,,CHEMBL625068,,BAO_0000218,,
13275,Intermediate,50597,Heart,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,N,1,1,,CHEMBL622159,,BAO_0000218,948.0,
13276,Intermediate,50597,Intestine,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,N,1,1,,CHEMBL622160,,BAO_0000218,160.0,
13277,Intermediate,50597,Kidney,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,N,1,1,,CHEMBL622161,,BAO_0000218,2113.0,
13278,Intermediate,50597,Lung,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,N,1,1,,CHEMBL622162,,BAO_0000218,2048.0,
13279,Intermediate,50597,Muscle tissue,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,N,1,1,,CHEMBL622163,,BAO_0000218,2385.0,
13280,Intermediate,50597,Plasma,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,N,1,1,,CHEMBL622313,,BAO_0000218,1969.0,
13281,Intermediate,50597,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,1,1,,CHEMBL622314,,BAO_0000218,,
13282,Intermediate,50597,Spleen,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,N,1,1,,CHEMBL622315,,BAO_0000218,2106.0,
13283,Intermediate,50597,Trachea,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,N,1,1,,CHEMBL622316,,BAO_0000218,3126.0,
13284,Intermediate,50212,,,Normal diffusion coefficient in water for Escherichia coli,N,1,1,,CHEMBL877486,,BAO_0000218,,
13285,Autocuration,22224,,,Average max percent decrease in RVR (renal vascular resistance) was determined,U,0,1,,CHEMBL622317,,BAO_0000019,,
13286,Autocuration,22224,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,U,0,1,,CHEMBL622318,,BAO_0000019,,
13287,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,U,0,1,,CHEMBL622319,,BAO_0000019,,
13288,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,U,0,1,,CHEMBL622320,,BAO_0000019,,
13289,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,U,0,1,,CHEMBL622321,,BAO_0000019,,
13290,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,U,0,1,,CHEMBL622322,,BAO_0000019,,
13291,Autocuration,22224,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,U,0,1,,CHEMBL622323,,BAO_0000019,,
13292,Intermediate,50597,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,N,1,1,,CHEMBL622324,,BAO_0000218,,
13293,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,1,1,,CHEMBL622325,,BAO_0000218,1088.0,
13294,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,1,1,,CHEMBL622326,,BAO_0000218,1088.0,
13295,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",N,1,1,,CHEMBL877487,,BAO_0000218,1088.0,
13296,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,1,1,,CHEMBL622327,,BAO_0000218,1088.0,
13297,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",N,1,1,,CHEMBL622328,,BAO_0000218,1088.0,
13298,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,1,1,,CHEMBL622329,,BAO_0000218,1088.0,
13299,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,1,1,,CHEMBL622330,,BAO_0000218,1088.0,
13300,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,1,1,,CHEMBL622331,,BAO_0000218,1088.0,
13301,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,1,1,,CHEMBL622332,,BAO_0000218,1088.0,
13302,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",N,1,1,,CHEMBL622333,,BAO_0000218,1088.0,
13303,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,0,1,,CHEMBL627658,,BAO_0000218,1088.0,
13304,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",U,0,1,,CHEMBL630428,,BAO_0000218,1088.0,
13305,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,0,1,,CHEMBL630429,,BAO_0000218,1088.0,
13306,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",U,0,1,,CHEMBL630430,,BAO_0000218,1088.0,
13307,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",U,0,1,,CHEMBL630431,,BAO_0000218,1088.0,
13308,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,1,1,,CHEMBL630432,,BAO_0000218,1088.0,
13309,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,1,1,,CHEMBL630433,,BAO_0000218,1088.0,
13310,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,1,1,,CHEMBL630434,,BAO_0000218,1088.0,
13311,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,1,1,,CHEMBL629372,,BAO_0000218,1088.0,
13312,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",N,1,1,,CHEMBL629553,,BAO_0000218,1088.0,
13313,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,1,1,,CHEMBL629554,,BAO_0000218,1088.0,
13314,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,1,1,,CHEMBL874447,,BAO_0000218,1088.0,
13315,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,1,1,,CHEMBL629555,,BAO_0000218,1088.0,
13316,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,1,1,,CHEMBL629556,,BAO_0000218,1088.0,
13317,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",N,1,1,,CHEMBL629557,,BAO_0000218,1088.0,
13318,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,1,1,,CHEMBL629558,,BAO_0000218,1088.0,
13319,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,1,1,,CHEMBL629559,,BAO_0000218,1088.0,
13320,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,1,1,,CHEMBL629560,,BAO_0000218,1088.0,
13321,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,1,1,,CHEMBL629561,,BAO_0000218,1088.0,
13322,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,1,1,,CHEMBL629562,,BAO_0000218,1088.0,
13323,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,1,1,,CHEMBL629563,,BAO_0000218,1088.0,
13324,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,1,1,,CHEMBL629564,,BAO_0000218,1088.0,
13325,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,1,1,,CHEMBL629565,,BAO_0000218,1088.0,
13326,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,1,1,,CHEMBL629566,,BAO_0000218,1088.0,
13327,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,1,1,,CHEMBL629567,,BAO_0000218,1088.0,
13328,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,1,1,,CHEMBL629568,,BAO_0000218,1088.0,
13329,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",N,1,1,,CHEMBL629569,,BAO_0000218,1088.0,
13330,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,1,1,,CHEMBL629570,,BAO_0000218,1088.0,
13331,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,0,1,,CHEMBL629571,,BAO_0000218,1088.0,
13332,Autocuration,22224,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,0,1,,CHEMBL629572,,BAO_0000218,,
13333,Autocuration,22224,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,0,1,,CHEMBL629573,,BAO_0000218,,
13334,Autocuration,22224,,,Bioavailability (dose 20 mg/kg),U,0,1,,CHEMBL629574,,BAO_0000218,,
13335,Autocuration,22224,,,Bioavailability in dog,U,0,1,,CHEMBL629575,,BAO_0000218,,
13336,Autocuration,22224,,,Bioavailability in rat (Sprague-Dawley) (male),U,0,1,,CHEMBL874448,,BAO_0000218,,
13337,Autocuration,22224,,,Bioavailability in monkey (dose 10 mg/kg i.d.),U,0,1,,CHEMBL629576,,BAO_0000218,,
13338,Autocuration,22224,,,Bioavailability in rat,U,0,1,,CHEMBL629577,,BAO_0000218,,
13339,Autocuration,22224,,,Bioavailability in rat,U,0,1,,CHEMBL629578,,BAO_0000218,,
13340,Autocuration,22224,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),U,0,1,,CHEMBL629579,,BAO_0000218,,
13341,Autocuration,22224,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,U,0,1,,CHEMBL882958,,BAO_0000218,,
13342,Intermediate,50505,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,N,1,1,,CHEMBL629580,,BAO_0000218,,
13343,Autocuration,22224,,,Bioavailability,U,0,1,,CHEMBL629581,,BAO_0000218,,
13344,Autocuration,22224,,,Bioavailability in squirrel monkey,U,0,1,,CHEMBL629582,,BAO_0000218,,
13345,Intermediate,50588,,,Bioavailability was evaluated in dog,N,1,1,,CHEMBL628522,,BAO_0000218,,
13346,Intermediate,100712,,,Bioavailability was evaluated in hamster,N,1,1,,CHEMBL625432,,BAO_0000218,,
13347,Autocuration,22224,,,Bioavailability in rat,U,0,1,,CHEMBL625433,,BAO_0000218,,
13348,Intermediate,50597,Plasma,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,1,1,,CHEMBL625434,,BAO_0000218,1969.0,
13349,Intermediate,50597,Plasma,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,N,1,1,,CHEMBL625435,,BAO_0000218,1969.0,
13350,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg p.o.),U,0,1,,CHEMBL625436,,BAO_0000218,,
13351,Intermediate,100710,,,Bioavailability was measured in cynomolgus monkeys.,N,1,1,,CHEMBL874588,,BAO_0000218,,
13352,Intermediate,50594,,,Bioavailability was measured in nude mice.,N,1,1,,CHEMBL625437,,BAO_0000218,,
13353,Autocuration,22224,,,Bioavailability in ferret (dose 10 mg/kg i.d.),U,0,1,,CHEMBL625438,,BAO_0000218,,
13354,Autocuration,22224,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),U,0,1,,CHEMBL625439,,BAO_0000218,,
13355,Autocuration,22224,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",U,0,1,,CHEMBL625440,,BAO_0000218,,
13356,Autocuration,22224,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),U,0,1,,CHEMBL625441,,BAO_0000218,,
13357,Autocuration,22224,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,0,1,,CHEMBL625442,,BAO_0000218,,
13358,Intermediate,50597,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,1,1,,CHEMBL625443,,BAO_0000218,,
13359,Autocuration,22224,,,Bioavailability was determined; extremely poor,U,0,1,,CHEMBL625444,,BAO_0000218,,
13360,Intermediate,50594,,,% bioavailability in mice after oral administration of prodrug,N,1,1,,CHEMBL625445,,BAO_0000218,,
13361,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,N,1,1,,CHEMBL625446,,BAO_0000218,,
13362,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,N,1,1,,CHEMBL882960,,BAO_0000218,,
13363,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,N,1,1,,CHEMBL625447,,BAO_0000218,,
13364,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,N,1,1,,CHEMBL625448,,BAO_0000218,,
13365,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,N,1,1,,CHEMBL625449,,BAO_0000218,,
13366,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),N,1,1,,CHEMBL874589,,BAO_0000218,,
13367,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,N,1,1,,CHEMBL625450,,BAO_0000218,,
13368,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,N,1,1,,CHEMBL625451,,BAO_0000218,,
13369,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,N,1,1,,CHEMBL626584,,BAO_0000218,,
13370,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,N,1,1,,CHEMBL626585,,BAO_0000218,,
13371,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,N,1,1,,CHEMBL626586,,BAO_0000218,,
13372,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,N,1,1,,CHEMBL626587,,BAO_0000218,,
13373,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,N,1,1,,CHEMBL626588,,BAO_0000218,,
13374,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,N,1,1,,CHEMBL626589,,BAO_0000218,,
13375,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,N,1,1,,CHEMBL626590,,BAO_0000218,,
13376,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,N,1,1,,CHEMBL626591,,BAO_0000218,,
13377,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,N,1,1,,CHEMBL627181,,BAO_0000218,,
13378,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,N,1,1,,CHEMBL628083,,BAO_0000218,,
13379,Autocuration,22224,,,IV clearance determined at an peroral dose of 15 mg/kg.,U,0,1,,CHEMBL628084,,BAO_0000218,,
13380,Expert,50064,,,Mouse oral clearance was measured against Hymenolepiasis nana.,N,1,1,,CHEMBL628085,,BAO_0000218,,
13381,Expert,50545,,,Mouse oral clearance was measured against Nematospiroides dubius,N,1,1,,CHEMBL628086,,BAO_0000218,,
13382,Autocuration,22224,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,U,0,1,,CHEMBL628087,,BAO_0000218,,
13383,Intermediate,50594,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,N,1,1,,CHEMBL628088,,BAO_0000218,,
13384,Autocuration,22224,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,U,0,1,,CHEMBL628089,,BAO_0000218,,
13385,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL628090,,BAO_0000218,,
13386,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL628091,,BAO_0000218,,
13387,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL628092,,BAO_0000218,,
13388,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL628093,,BAO_0000218,,
13389,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL875607,,BAO_0000218,,
13390,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL625710,,BAO_0000218,,
13391,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL625711,,BAO_0000218,,
13392,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL625712,,BAO_0000218,,
13393,Autocuration,22224,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,U,0,1,,CHEMBL625713,,BAO_0000218,,
13394,Intermediate,50588,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,N,1,1,,CHEMBL625714,,BAO_0000218,,
13395,Intermediate,50797,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,N,1,1,,CHEMBL625715,,BAO_0000218,,
13396,Intermediate,50597,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,N,1,1,,CHEMBL625716,,BAO_0000218,,
13397,Intermediate,50597,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,N,1,1,,CHEMBL625717,,BAO_0000218,,
13398,Intermediate,50597,,,Plasma clearance was determined for the compound in rats,N,1,1,,CHEMBL625718,,BAO_0000218,,
13399,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,N,1,1,,CHEMBL625719,,BAO_0000218,,
13400,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,N,1,1,,CHEMBL625720,,BAO_0000218,,
13401,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,N,1,1,,CHEMBL625721,,BAO_0000218,,
13402,Intermediate,50597,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,N,1,1,,CHEMBL625722,,BAO_0000218,,
13403,Intermediate,50597,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,N,1,1,,CHEMBL625723,,BAO_0000218,,
13404,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,N,1,1,,CHEMBL625724,,BAO_0000218,,
13405,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,N,1,1,,CHEMBL625725,,BAO_0000218,,
13406,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,N,1,1,,CHEMBL625726,,BAO_0000218,,
13407,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,N,1,1,,CHEMBL875608,,BAO_0000218,,
13408,Intermediate,50545,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,N,1,1,,CHEMBL625727,,BAO_0000218,,
13409,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,U,0,1,,CHEMBL625728,,BAO_0000218,1088.0,
13410,Autocuration,22224,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,0,1,,CHEMBL625729,,BAO_0000218,,
13411,Autocuration,22224,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,U,0,1,,CHEMBL625730,,BAO_0000218,,
13412,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,0,1,,CHEMBL625731,,BAO_0000218,1088.0,
13413,Autocuration,22224,Urine,,Urinary clearance was determined in rat at 25 mg/kg os dosage,U,0,1,,CHEMBL626417,,BAO_0000218,1088.0,
13414,Intermediate,50587,Urine,,Urinary clearance was determined at 100 mg/kg oral dosage in human,N,1,1,,CHEMBL626418,,BAO_0000218,1088.0,
13415,Intermediate,50588,Urine,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,N,1,1,,CHEMBL626419,,BAO_0000218,1088.0,
13416,Intermediate,50588,Plasma,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,1,1,,CHEMBL626592,,BAO_0000218,1969.0,
13417,Intermediate,50597,Plasma,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,1,1,,CHEMBL626593,,BAO_0000218,1969.0,
13418,Intermediate,50597,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,1,1,,CHEMBL626594,,BAO_0000218,,
13419,Intermediate,50588,,,Clearance rate in dogs,N,1,1,,CHEMBL625035,,BAO_0000218,,
13420,Autocuration,22224,,,Compound was measured for intrinsic clearance,U,0,1,,CHEMBL625036,,BAO_0000019,,
13421,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625037,,BAO_0000100,,
13422,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625038,,BAO_0000100,,
13423,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625039,,BAO_0000100,,
13424,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625040,,BAO_0000100,,
13425,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625041,,BAO_0000100,,
13426,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625042,,BAO_0000100,,
13427,Autocuration,22224,,,Partition coefficient of the compound,U,0,1,,CHEMBL874411,,BAO_0000019,,
13428,Autocuration,22224,,,Permeability,U,0,1,,CHEMBL625043,,BAO_0000019,,
13429,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625044,,BAO_0000100,,
13430,Autocuration,22224,,,Partition coefficient (logD),U,0,1,,CHEMBL625045,,BAO_0000019,,
13431,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,0,1,,CHEMBL625046,,BAO_0000100,,
13432,Autocuration,22229,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,0,1,,CHEMBL625047,,BAO_0000100,,
13433,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625048,,BAO_0000100,,
13434,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625049,,BAO_0000100,,
13435,Autocuration,22229,,,Calculated logarithm of partition coefficient (P) was determined,U,0,1,,CHEMBL625050,,BAO_0000100,,
13436,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625051,,BAO_0000100,,
13437,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL874412,,BAO_0000100,,
13438,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625052,,BAO_0000100,,
13439,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL625053,,BAO_0000100,,
13440,Autocuration,22224,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,U,0,1,,CHEMBL623250,,BAO_0000019,,
13441,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,U,0,1,,CHEMBL623251,,BAO_0000019,,
13442,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,U,0,1,,CHEMBL623252,,BAO_0000019,,
13443,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,U,0,1,,CHEMBL623253,,BAO_0000019,,
13444,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,U,0,1,,CHEMBL623254,,BAO_0000019,,
13445,Autocuration,22224,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,U,0,1,,CHEMBL623255,,BAO_0000019,,
13446,Autocuration,22224,,,Percent degradation of compound at a pH of 1 over a 18 hr period,U,0,1,,CHEMBL626831,,BAO_0000019,,
13447,Autocuration,22224,,,Percent degradation of compound at pH of 1 over an 18 hr period,U,0,1,,CHEMBL877494,,BAO_0000019,,
13448,Autocuration,22224,,,Delta Logarithm of Partition Coefficient value was determined.,U,0,1,,CHEMBL626832,,BAO_0000019,,
13449,Autocuration,22224,,,Delta logPoct-cyc,U,0,1,,CHEMBL626833,,BAO_0000019,,
13450,Autocuration,22224,,,Lipophilicity estimated on reversed phase TLC,U,0,1,,CHEMBL626834,,BAO_0000100,,
13451,Autocuration,22224,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,U,0,1,,CHEMBL626835,,BAO_0000019,,
13452,Autocuration,22224,,,Delta logPoct-cyc,U,0,1,,CHEMBL626836,,BAO_0000019,,
13453,Autocuration,22229,,,Change in logarithm of partition coefficient of the compound,U,0,1,,CHEMBL626837,,BAO_0000100,,
13454,Autocuration,22224,,,Delta logD (pH 6.5),U,0,1,,CHEMBL626838,,BAO_0000019,,
13455,Autocuration,22224,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",U,0,1,,CHEMBL626839,,BAO_0000100,,
13456,Autocuration,22224,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,U,0,1,,CHEMBL626840,,BAO_0000019,,
13457,Autocuration,22224,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),U,0,1,,CHEMBL626841,,BAO_0000019,,
13458,Autocuration,22224,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,U,0,1,,CHEMBL626842,,BAO_0000219,,
13459,Autocuration,22224,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,U,0,1,,CHEMBL626843,,BAO_0000219,,
13460,Intermediate,50597,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,N,1,1,,CHEMBL626844,,BAO_0000218,,
13461,Intermediate,50597,,,Amount of deuterium retained was reported after normal workup in rats,N,1,1,,CHEMBL877495,,BAO_0000218,,
13462,Intermediate,50597,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,N,1,1,,CHEMBL626845,,BAO_0000218,,
13463,Intermediate,50597,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,N,1,1,,CHEMBL626846,,BAO_0000218,,
13464,Intermediate,50597,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,1,1,,CHEMBL626847,,BAO_0000218,,
13465,Intermediate,50597,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,1,1,,CHEMBL628677,,BAO_0000218,,
13466,Intermediate,50597,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,N,1,1,,CHEMBL628678,,BAO_0000218,,
13467,Autocuration,22224,,,Compound was subjected to electrochemical oxidation,U,0,1,,CHEMBL628679,,BAO_0000019,,
13468,Autocuration,22224,,,Compound was subjected to photochemical oxidation,U,0,1,,CHEMBL628680,,BAO_0000019,,
13469,Autocuration,22224,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,U,0,1,,CHEMBL628681,,BAO_0000019,,
13470,Autocuration,22224,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,U,0,1,,CHEMBL628682,,BAO_0000019,,
13471,Autocuration,22224,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,U,0,1,,CHEMBL628683,,BAO_0000019,,
13472,Intermediate,50597,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,N,1,1,,CHEMBL628684,,BAO_0000218,,
13473,Autocuration,22229,,,Dissociation constant (pKa),U,0,1,,CHEMBL877501,,BAO_0000100,,
13474,Autocuration,22224,,,Dissociation constant value of the compound; ND means not determined.,U,0,1,,CHEMBL628685,,BAO_0000100,,
13475,Intermediate,50597,Blood,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,N,1,1,,CHEMBL628686,,BAO_0000218,178.0,
13476,Intermediate,50597,Blood,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,1,1,,CHEMBL628687,,BAO_0000218,178.0,
13477,Intermediate,50597,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,N,1,1,,CHEMBL628688,,BAO_0000218,,
13478,Intermediate,50597,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,1,1,,CHEMBL628689,,BAO_0000218,,
13479,Intermediate,50597,Liver,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,N,1,1,,CHEMBL628690,,BAO_0000218,2107.0,
13480,Intermediate,50597,Liver,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,1,1,,CHEMBL629363,,BAO_0000218,2107.0,
13481,Intermediate,50597,Spleen,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,N,1,1,,CHEMBL629364,,BAO_0000218,2106.0,
13482,Intermediate,50597,Spleen,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,1,1,,CHEMBL629365,,BAO_0000218,2106.0,
13483,Intermediate,50597,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,N,1,1,,CHEMBL629366,,BAO_0000218,,
13484,Intermediate,50597,Urine,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,N,1,1,,CHEMBL629367,,BAO_0000218,1088.0,
13485,Intermediate,50597,Feces,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,1,1,,CHEMBL629368,,BAO_0000218,1988.0,
13486,Intermediate,50597,Urine,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,1,1,,CHEMBL877502,,BAO_0000218,1088.0,
13487,Intermediate,50594,Cerebellum,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,N,1,1,,CHEMBL629369,,BAO_0000218,2037.0,
13488,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,N,1,1,,CHEMBL629370,,BAO_0000218,955.0,
13489,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",U,0,1,,CHEMBL629371,,BAO_0000218,1088.0,
13490,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,0,1,,CHEMBL626276,,BAO_0000218,1088.0,
13491,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,0,1,,CHEMBL626277,,BAO_0000218,1088.0,
13492,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,0,1,,CHEMBL631250,,BAO_0000218,1088.0,
13493,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,1,1,,CHEMBL631251,,BAO_0000218,1088.0,
13494,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,1,1,,CHEMBL631252,,BAO_0000218,1088.0,
13495,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",N,1,1,,CHEMBL631253,,BAO_0000218,1088.0,
13496,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,1,1,,CHEMBL631254,,BAO_0000218,1088.0,
13497,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,1,1,,CHEMBL631255,,BAO_0000218,1088.0,
13498,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,1,1,,CHEMBL631256,,BAO_0000218,1088.0,
13499,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,1,1,,CHEMBL631257,,BAO_0000218,1088.0,
13500,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",N,1,1,,CHEMBL628009,,BAO_0000218,1088.0,
13501,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,1,1,,CHEMBL628010,,BAO_0000218,1088.0,
13502,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,1,1,,CHEMBL628011,,BAO_0000218,1088.0,
13503,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",N,1,1,,CHEMBL628012,,BAO_0000218,1088.0,
13504,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,1,1,,CHEMBL628013,,BAO_0000218,1088.0,
13505,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,1,1,,CHEMBL628014,,BAO_0000218,1088.0,
13506,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",N,1,1,,CHEMBL628015,,BAO_0000218,1088.0,
13507,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,1,1,,CHEMBL628016,,BAO_0000218,1088.0,
13508,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",N,1,1,,CHEMBL874461,,BAO_0000218,1088.0,
13509,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,1,1,,CHEMBL628017,,BAO_0000218,1088.0,
13510,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,1,1,,CHEMBL628018,,BAO_0000218,1088.0,
13511,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,1,1,,CHEMBL628019,,BAO_0000218,1088.0,
13512,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,1,1,,CHEMBL628020,,BAO_0000218,1088.0,
13513,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,1,1,,CHEMBL628021,,BAO_0000218,1088.0,
13514,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,1,1,,CHEMBL628022,,BAO_0000218,1088.0,
13515,Intermediate,50588,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,1,1,,CHEMBL628023,,BAO_0000218,1088.0,
13516,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,0,1,,CHEMBL628024,,BAO_0000218,1088.0,
13517,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",U,0,1,,CHEMBL628025,,BAO_0000218,1088.0,
13518,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,0,1,,CHEMBL628026,,BAO_0000218,1088.0,
13519,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,0,1,,CHEMBL628027,,BAO_0000218,1088.0,
13520,Autocuration,22224,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,0,1,,CHEMBL628028,,BAO_0000218,1088.0,
13521,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,1,1,,CHEMBL628029,,BAO_0000218,1088.0,
13522,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",N,1,1,,CHEMBL628030,,BAO_0000218,1088.0,
13523,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,1,1,,CHEMBL628031,,BAO_0000218,1088.0,
13524,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",N,1,1,,CHEMBL628032,,BAO_0000218,1088.0,
13525,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,1,1,,CHEMBL628033,,BAO_0000218,1088.0,
13526,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",N,1,1,,CHEMBL628034,,BAO_0000218,1088.0,
13527,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,1,1,,CHEMBL628035,,BAO_0000218,1088.0,
13528,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",N,1,1,,CHEMBL628036,,BAO_0000218,1088.0,
13529,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,1,1,,CHEMBL874462,,BAO_0000218,1088.0,
13530,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,N,1,1,,CHEMBL628037,,BAO_0000218,,
13531,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,N,1,1,,CHEMBL628123,,BAO_0000218,,
13532,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,N,1,1,,CHEMBL628124,,BAO_0000218,,
13533,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,N,1,1,,CHEMBL628125,,BAO_0000218,,
13534,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,N,1,1,,CHEMBL628126,,BAO_0000218,,
13535,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),N,1,1,,CHEMBL628127,,BAO_0000218,,
13536,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,N,1,1,,CHEMBL628128,,BAO_0000218,,
13537,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,N,1,1,,CHEMBL628129,,BAO_0000218,,
13538,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,N,1,1,,CHEMBL628130,,BAO_0000218,,
13539,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,N,1,1,,CHEMBL628131,,BAO_0000218,,
13540,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,N,1,1,,CHEMBL628132,,BAO_0000218,,
13541,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,N,1,1,,CHEMBL628133,,BAO_0000218,,
13542,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,N,1,1,,CHEMBL628134,,BAO_0000218,,
13543,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,N,1,1,,CHEMBL628135,,BAO_0000218,,
13544,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,N,1,1,,CHEMBL628136,,BAO_0000218,,
13545,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,N,1,1,,CHEMBL628137,,BAO_0000218,,
13546,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,N,1,1,,CHEMBL628138,,BAO_0000218,,
13547,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,N,1,1,,CHEMBL628139,,BAO_0000218,,
13548,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,N,1,1,,CHEMBL628140,,BAO_0000218,,
13549,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,N,1,1,,CHEMBL628141,,BAO_0000218,,
13550,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,N,1,1,,CHEMBL628142,,BAO_0000218,,
13551,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,N,1,1,,CHEMBL628143,,BAO_0000218,,
13552,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,N,1,1,,CHEMBL628144,,BAO_0000218,,
13553,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,N,1,1,,CHEMBL628145,,BAO_0000218,,
13554,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,N,1,1,,CHEMBL628146,,BAO_0000218,,
13555,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,N,1,1,,CHEMBL625355,,BAO_0000218,,
13556,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,N,1,1,,CHEMBL625356,,BAO_0000218,,
13557,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,N,1,1,,CHEMBL625357,,BAO_0000218,,
13558,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,N,1,1,,CHEMBL625527,,BAO_0000218,,
13559,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),N,1,1,,CHEMBL875473,,BAO_0000218,,
13560,Intermediate,50588,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,N,1,1,,CHEMBL625528,,BAO_0000218,,
13561,Intermediate,50597,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,N,1,1,,CHEMBL626304,,BAO_0000218,,
13562,Intermediate,50588,Artery,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,N,1,1,,CHEMBL624138,,BAO_0000218,1637.0,
13563,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624139,,BAO_0000100,,
13564,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624140,,BAO_0000100,,
13565,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624141,,BAO_0000100,,
13566,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624142,,BAO_0000100,,
13567,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624143,,BAO_0000100,,
13568,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624144,,BAO_0000100,,
13569,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624145,,BAO_0000100,,
13570,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624146,,BAO_0000100,,
13571,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624147,,BAO_0000100,,
13572,Autocuration,22229,,,Calculated partition coefficient (clogP) (MacLogP),U,0,1,,CHEMBL883123,,BAO_0000100,,
13573,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL624148,,BAO_0000019,,
13574,Autocuration,22224,,,Kinetic parameter was determined,U,0,1,,CHEMBL874416,,BAO_0000019,,
13575,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624149,,BAO_0000100,,
13576,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL624150,,BAO_0000100,,
13577,Autocuration,22224,,,Lipophilicity was determined,U,0,1,,CHEMBL624151,,BAO_0000100,,
13578,Autocuration,22224,,,Lipophilicity was determined,U,0,1,,CHEMBL624152,,BAO_0000100,,
13579,Autocuration,22224,,,Lipophilicity was determined,U,0,1,,CHEMBL622139,,BAO_0000100,,
13580,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL622140,,BAO_0000100,,
13581,Autocuration,22224,,,Lipophilicity was determined,U,0,1,,CHEMBL622141,,BAO_0000100,,
13582,Autocuration,22224,,,Lipophilicity in octanol-water,U,0,1,,CHEMBL622142,,BAO_0000100,,
13583,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL622143,,BAO_0000100,,
13584,Autocuration,22229,,,Octanol-water partition coefficient was determined,U,0,1,,CHEMBL622144,,BAO_0000100,,
13585,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL877473,,BAO_0000019,,
13586,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL622145,,BAO_0000100,,
13587,Autocuration,22224,,,Partition coefficient was determined; ND means not determined,U,0,1,,CHEMBL622146,,BAO_0000019,,
13588,Autocuration,22229,,,Calculated partition coefficient (clogP),U,0,1,,CHEMBL622147,,BAO_0000100,,
13589,Autocuration,22224,,,Partition coefficient of the compound,U,0,1,,CHEMBL622148,,BAO_0000019,,
13590,Autocuration,22224,,,Permeability was determined,U,0,1,,CHEMBL883124,,BAO_0000019,,
13591,Autocuration,22229,,,The compound was evaluated for the partition coefficient,U,0,1,,CHEMBL622149,,BAO_0000100,,
13592,Autocuration,22224,,,Partition coefficient (logP),U,0,1,,CHEMBL622150,,BAO_0000019,,
13593,Autocuration,22224,,,The lipophilicity was reported,U,0,1,,CHEMBL622151,,BAO_0000100,,
13594,Autocuration,22229,,,logarithm of the octanol-water partition coefficient for the compound,U,0,1,,CHEMBL622152,,BAO_0000100,,
13595,Autocuration,22224,,,Clogp value was determined,U,0,1,,CHEMBL622153,,BAO_0000019,,
13596,Autocuration,22224,,,Clp at a dose of 1.5 mg/kg,U,0,1,,CHEMBL877474,,BAO_0000218,,
13597,Autocuration,22224,,,Clp at a dose of 2.0 mg/kg,U,0,1,,CHEMBL622154,,BAO_0000218,,
13598,Autocuration,22224,Plasma,,"Clp, plasma clearance at a dose of 10 mg/kg",U,0,1,,CHEMBL622155,,BAO_0000218,1969.0,
13599,Autocuration,22224,Plasma,,"Clp, plasma clearance at a dose of 50 mg/kg",U,0,1,,CHEMBL622156,,BAO_0000218,1969.0,
13600,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat,N,1,1,,CHEMBL622157,,BAO_0000218,1969.0,
13601,Intermediate,50597,Plasma,,Compound was tested for plasma clearance in rat; Not determined,N,1,1,,CHEMBL622158,,BAO_0000218,1969.0,
13602,Intermediate,50597,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,N,1,1,,CHEMBL622807,,BAO_0000218,,
13603,Intermediate,50797,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,N,1,1,,CHEMBL622808,,BAO_0000218,,
13604,Autocuration,22224,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,U,0,1,,CHEMBL622809,,BAO_0000218,,
13605,Autocuration,22224,,,Plasma clearance determined,U,0,1,,CHEMBL622810,,BAO_0000218,,
13606,Intermediate,100712,,,Plasma clearance after iv administration at 3 mg/kg in hamster,N,1,1,,CHEMBL876653,,BAO_0000218,,
13607,Intermediate,100712,,,Plasma clearance after iv administration at 4 mg/kg in hamster,N,1,1,,CHEMBL622811,,BAO_0000218,,
13608,Intermediate,50597,,,Rate of clearance in rat was determined,N,1,1,,CHEMBL622986,,BAO_0000218,,
13609,Intermediate,50597,Plasma,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,N,1,1,,CHEMBL622987,,BAO_0000218,1969.0,
13610,Intermediate,50597,Plasma,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,N,1,1,,CHEMBL622988,,BAO_0000218,1969.0,
13611,Intermediate,50597,Plasma,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,N,1,1,,CHEMBL622989,,BAO_0000218,1969.0,
13612,Intermediate,50597,Plasma,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,N,1,1,,CHEMBL622990,,BAO_0000218,1969.0,
13613,Autocuration,22224,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,0,1,,CHEMBL622991,,BAO_0000218,1969.0,
13614,Intermediate,50597,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,1,1,,CHEMBL622227,,BAO_0000218,1969.0,
13615,Intermediate,50588,Plasma,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,1,1,,CHEMBL622228,,BAO_0000218,1969.0,
13616,Intermediate,50597,,,Clpl value in rat,N,1,1,,CHEMBL622229,,BAO_0000218,,
13617,Intermediate,50512,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,N,1,1,,CHEMBL622230,,BAO_0000218,,
13618,Intermediate,50597,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,N,1,1,,CHEMBL622231,,BAO_0000218,,
13619,Intermediate,100710,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,N,1,1,,CHEMBL622232,,BAO_0000218,,
13620,Autocuration,22224,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,U,0,1,,CHEMBL622233,,BAO_0000218,,
13621,Autocuration,22224,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,U,0,1,,CHEMBL622234,,BAO_0000218,,
13622,Autocuration,22224,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,U,0,1,,CHEMBL622235,,BAO_0000218,,
13623,Autocuration,22224,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,U,0,1,,CHEMBL622236,,BAO_0000218,,
13624,Autocuration,22224,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,U,0,1,,CHEMBL622237,,BAO_0000218,,
13625,Autocuration,22224,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,U,0,1,,CHEMBL877482,,BAO_0000218,,
13626,Autocuration,22224,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,U,0,1,,CHEMBL622238,,BAO_0000218,,
13627,Autocuration,22224,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,U,0,1,,CHEMBL622239,,BAO_0000218,,
13628,Autocuration,22224,Blood,,Cmax was calculated as maximum concentration reached in the blood,U,0,1,,CHEMBL622240,,BAO_0000218,178.0,
13629,Autocuration,22224,Blood,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,U,0,1,,CHEMBL622241,,BAO_0000218,178.0,
13630,Intermediate,50597,,,Cmax was determine after peroral administration at 10 mpk in Rat,N,1,1,,CHEMBL631013,,BAO_0000218,,
13631,Intermediate,50797,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,N,1,1,,CHEMBL631014,,BAO_0000218,,
13632,Intermediate,50588,,,Cmax was determine after peroral administration at 10 mpk in dog,N,1,1,,CHEMBL631015,,BAO_0000218,,
13633,Intermediate,50597,,,Cmax was determine after peroral administration at 160 mpk in Rat,N,1,1,,CHEMBL631016,,BAO_0000218,,
13634,Intermediate,50597,,,Cmax was determine after peroral administration at 20 mpk in Rat,N,1,1,,CHEMBL631017,,BAO_0000218,,
13635,Intermediate,50597,,,Cmax was determine after peroral administration at 50 mpk in Rat,N,1,1,,CHEMBL631018,,BAO_0000218,,
13636,Autocuration,22224,,,Cmax was determined,U,0,1,,CHEMBL631019,,BAO_0000218,,
13637,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,N,1,1,,CHEMBL875761,,BAO_0000218,955.0,
13638,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,N,1,1,,CHEMBL631020,,BAO_0000218,955.0,
13639,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,N,1,1,,CHEMBL631669,,BAO_0000218,955.0,
13640,Intermediate,50594,Brain,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,N,1,1,,CHEMBL631670,,BAO_0000218,955.0,
13641,Intermediate,50594,Striatum,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,N,1,1,,CHEMBL631671,,BAO_0000218,2435.0,
13642,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,N,1,1,,CHEMBL631672,,BAO_0000218,178.0,
13643,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,N,1,1,,CHEMBL631673,,BAO_0000218,178.0,
13644,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,N,1,1,,CHEMBL631856,,BAO_0000218,178.0,
13645,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,N,1,1,,CHEMBL631857,,BAO_0000218,178.0,
13646,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,N,1,1,,CHEMBL631858,,BAO_0000218,178.0,
13647,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,N,1,1,,CHEMBL631859,,BAO_0000218,178.0,
13648,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,N,1,1,,CHEMBL631860,,BAO_0000218,178.0,
13649,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,N,1,1,,CHEMBL631861,,BAO_0000218,178.0,
13650,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,N,1,1,,CHEMBL631862,,BAO_0000218,178.0,
13651,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,N,1,1,,CHEMBL631863,,BAO_0000218,178.0,
13652,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,N,1,1,,CHEMBL631864,,BAO_0000218,178.0,
13653,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,N,1,1,,CHEMBL631865,,BAO_0000218,178.0,
13654,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,N,1,1,,CHEMBL631866,,BAO_0000218,178.0,
13655,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,N,1,1,,CHEMBL629360,,BAO_0000218,178.0,
13656,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,N,1,1,,CHEMBL629361,,BAO_0000218,178.0,
13657,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,N,1,1,,CHEMBL629362,,BAO_0000218,178.0,
13658,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,N,1,1,,CHEMBL630740,,BAO_0000218,178.0,
13659,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,N,1,1,,CHEMBL630741,,BAO_0000218,178.0,
13660,Intermediate,50597,Blood,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,N,1,1,,CHEMBL630742,,BAO_0000218,178.0,
13661,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,N,1,1,,CHEMBL630743,,BAO_0000218,,
13662,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,N,1,1,,CHEMBL630744,,BAO_0000218,,
13663,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,N,1,1,,CHEMBL630745,,BAO_0000218,,
13664,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,N,1,1,,CHEMBL630746,,BAO_0000218,,
13665,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,N,1,1,,CHEMBL630747,,BAO_0000218,,
13666,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,N,1,1,,CHEMBL630748,,BAO_0000218,,
13667,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,N,1,1,,CHEMBL632056,,BAO_0000218,,
13668,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,N,1,1,,CHEMBL632057,,BAO_0000218,,
13669,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,N,1,1,,CHEMBL632058,,BAO_0000218,,
13670,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,N,1,1,,CHEMBL632059,,BAO_0000218,,
13671,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,N,1,1,,CHEMBL632060,,BAO_0000218,,
13672,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,N,1,1,,CHEMBL632061,,BAO_0000218,,
13673,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,N,1,1,,CHEMBL629207,,BAO_0000218,,
13674,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,N,1,1,,CHEMBL629208,,BAO_0000218,,
13675,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,N,1,1,,CHEMBL629209,,BAO_0000218,,
13676,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,N,1,1,,CHEMBL629210,,BAO_0000218,,
13677,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,N,1,1,,CHEMBL629211,,BAO_0000218,,
13678,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,N,1,1,,CHEMBL629212,,BAO_0000218,,
13679,Intermediate,50597,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,N,1,1,,CHEMBL629213,,BAO_0000218,,
13680,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,1,1,,CHEMBL629214,,BAO_0000218,1088.0,
13681,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",N,1,1,,CHEMBL629215,,BAO_0000218,1088.0,
13682,Intermediate,50597,Urine,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",N,1,1,,CHEMBL635154,,BAO_0000218,1088.0,
13683,Intermediate,50597,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL629216,,BAO_0000218,,
13684,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,N,1,1,,CHEMBL629217,,BAO_0000218,,
13685,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL629218,,BAO_0000218,,
13686,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL629219,,BAO_0000218,,
13687,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL629220,,BAO_0000218,,
13688,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL629221,,BAO_0000218,,
13689,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631127,,BAO_0000218,,
13690,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,N,1,1,,CHEMBL631128,,BAO_0000218,,
13691,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631129,,BAO_0000218,,
13692,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL631130,,BAO_0000218,,
13693,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL631131,,BAO_0000218,,
13694,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL631132,,BAO_0000218,,
13695,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631133,,BAO_0000218,,
13696,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,N,1,1,,CHEMBL631134,,BAO_0000218,,
13697,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL875120,,BAO_0000218,,
13698,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL631135,,BAO_0000218,,
13699,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL631136,,BAO_0000218,,
13700,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL631137,,BAO_0000218,,
13701,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631138,,BAO_0000218,,
13702,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,N,1,1,,CHEMBL631139,,BAO_0000218,,
13703,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631140,,BAO_0000218,,
13704,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,1,1,,CHEMBL631141,,BAO_0000218,,
13705,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,1,1,,CHEMBL631142,,BAO_0000218,,
13706,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,1,1,,CHEMBL631143,,BAO_0000218,,
13707,Intermediate,50597,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,1,1,,CHEMBL631144,,BAO_0000218,,
13708,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,N,1,1,,CHEMBL631145,,BAO_0000218,,
13709,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL631146,,BAO_0000218,,
13710,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,N,1,1,,CHEMBL631147,,BAO_0000218,,
13711,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631148,,BAO_0000218,,
13712,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631149,,BAO_0000218,,
13713,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL631150,,BAO_0000218,,
13714,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631151,,BAO_0000218,,
13715,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631152,,BAO_0000218,,
13716,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631443,,BAO_0000218,,
13717,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL631444,,BAO_0000218,,
13718,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL631445,,BAO_0000218,,
13719,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,1,1,,CHEMBL631446,,BAO_0000218,,
13720,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),N,1,1,,CHEMBL631447,,BAO_0000218,,
13721,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,1,1,,CHEMBL631448,,BAO_0000218,,
13722,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,N,1,1,,CHEMBL631449,,BAO_0000218,,
13723,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,1,1,,CHEMBL631450,,BAO_0000218,,
13724,Intermediate,50588,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,1,1,,CHEMBL629724,,BAO_0000218,,
13725,Intermediate,50594,Zone of skin,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL629725,,BAO_0000218,14.0,
13726,Intermediate,50594,Zone of skin,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL629726,,BAO_0000218,14.0,
13727,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL629727,,BAO_0000218,2106.0,
13728,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630404,,BAO_0000218,2106.0,
13729,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630405,,BAO_0000218,2106.0,
13730,Intermediate,50594,Spleen,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630406,,BAO_0000218,2106.0,
13731,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630407,,BAO_0000218,945.0,
13732,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630573,,BAO_0000218,945.0,
13733,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630574,,BAO_0000218,945.0,
13734,Intermediate,50594,Stomach,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630575,,BAO_0000218,945.0,
13735,Intermediate,50594,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630576,,BAO_0000218,,
13736,Intermediate,50594,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630577,,BAO_0000218,,
13737,Intermediate,50594,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630578,,BAO_0000218,,
13738,Intermediate,50594,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,1,1,,CHEMBL630579,,BAO_0000218,,
13739,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),N,1,1,,CHEMBL630580,,BAO_0000218,2113.0,
13740,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,N,1,1,,CHEMBL630581,,BAO_0000218,2113.0,
13741,Intermediate,50594,Kidney,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),N,1,1,,CHEMBL630582,,BAO_0000218,2113.0,
13742,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,N,1,1,,CHEMBL630583,,BAO_0000218,,
13743,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),N,1,1,,CHEMBL630584,,BAO_0000218,,
13744,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,N,1,1,,CHEMBL630585,,BAO_0000218,,
13745,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),N,1,1,,CHEMBL630586,,BAO_0000218,,
13746,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,N,1,1,,CHEMBL630587,,BAO_0000218,,
13747,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),N,1,1,,CHEMBL630588,,BAO_0000218,,
13748,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,N,1,1,,CHEMBL630589,,BAO_0000218,,
13749,Intermediate,50594,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),N,1,1,,CHEMBL630590,,BAO_0000218,,
13750,Autocuration,22224,Feces,,Removal of 238-Plutonium(IV) in feces at 24 h,U,0,1,,CHEMBL630591,,BAO_0000019,1988.0,
13751,Autocuration,22224,Feces,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),U,0,1,,CHEMBL630592,,BAO_0000019,1988.0,
13752,Autocuration,22224,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,U,0,1,,CHEMBL630593,,BAO_0000019,,
13753,Autocuration,22224,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),U,0,1,,CHEMBL630594,,BAO_0000019,,
13754,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),U,0,1,,CHEMBL630595,,BAO_0000019,1088.0,
13755,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),U,0,1,,CHEMBL630596,,BAO_0000019,1088.0,
13756,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 h,U,0,1,,CHEMBL630597,,BAO_0000019,1088.0,
13757,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),U,0,1,,CHEMBL630598,,BAO_0000019,1088.0,
13758,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 h,U,0,1,,CHEMBL630599,,BAO_0000019,1088.0,
13759,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),U,0,1,,CHEMBL630600,,BAO_0000019,1088.0,
13760,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 h,U,0,1,,CHEMBL630601,,BAO_0000019,1088.0,
13761,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),U,0,1,,CHEMBL630602,,BAO_0000019,1088.0,
13762,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),U,0,1,,CHEMBL630603,,BAO_0000019,1088.0,
13763,Autocuration,22224,Urine,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),U,0,1,,CHEMBL630604,,BAO_0000019,1088.0,
13764,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL624869,,BAO_0000218,178.0,
13765,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL624870,,BAO_0000218,178.0,
13766,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL623189,,BAO_0000218,178.0,
13767,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623190,,BAO_0000218,178.0,
13768,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623191,,BAO_0000218,178.0,
13769,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623192,,BAO_0000218,,
13770,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623193,,BAO_0000218,,
13771,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL623194,,BAO_0000218,,
13772,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623195,,BAO_0000218,,
13773,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623196,,BAO_0000218,,
13774,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,N,1,1,,CHEMBL623197,,BAO_0000218,,
13775,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623198,,BAO_0000218,,
13776,Intermediate,50597,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,1,1,,CHEMBL623199,,BAO_0000218,,
13777,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623200,,BAO_0000218,2385.0,
13778,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623201,,BAO_0000218,2385.0,
13779,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623202,,BAO_0000218,2385.0,
13780,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623203,,BAO_0000218,2385.0,
13781,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623204,,BAO_0000218,2385.0,
13782,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,N,1,1,,CHEMBL623205,,BAO_0000218,2385.0,
13783,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623206,,BAO_0000218,2385.0,
13784,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,N,1,1,,CHEMBL623207,,BAO_0000218,2385.0,
13785,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,N,1,1,,CHEMBL623208,,BAO_0000218,2385.0,
13786,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623209,,BAO_0000218,2385.0,
13787,Intermediate,50597,Muscle tissue,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,1,1,,CHEMBL623210,,BAO_0000218,2385.0,
13788,Intermediate,50597,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623211,,BAO_0000218,,
13789,Intermediate,50597,Uterus,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,1,1,,CHEMBL623212,,BAO_0000218,995.0,
13790,Autocuration,22224,,,Tested in vitro for intrinsic activity relative to quinpirole,U,0,1,,CHEMBL623213,,BAO_0000019,,
13791,Autocuration,22224,,,"Relative ion enhancement, determined in pulsed ultrafiltration",U,0,1,,CHEMBL623214,,BAO_0000019,,
13792,Autocuration,22224,,,% ionization at the pH 7.4 at 37 degree Centigrade,U,0,1,,CHEMBL623215,,BAO_0000019,,
13793,Autocuration,22224,,,Percentage ionization was measured,U,0,1,,CHEMBL623216,,BAO_0000019,,
13794,Intermediate,50591,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,N,1,1,,CHEMBL623217,,BAO_0000218,,
13795,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,U,0,1,,CHEMBL623218,,BAO_0000019,,
13796,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,U,0,1,,CHEMBL623913,,BAO_0000019,,
13797,Autocuration,22224,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,U,0,1,,CHEMBL623914,,BAO_0000019,,
13798,Autocuration,22229,,,Compound was evaluated for the partition coefficient in octanol/water,U,0,1,,CHEMBL623915,,BAO_0000100,,
13799,Autocuration,22229,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),U,0,1,,CHEMBL624080,,BAO_0000100,,
13800,Autocuration,22224,,,Equilibrium constant measured by the pulse radiolysis at pH 7,U,0,1,,CHEMBL624081,,BAO_0000019,,
13801,Intermediate,50587,,,In vitro hydrolytic rate constant determined in human blood,N,1,1,,CHEMBL624082,,BAO_0000218,,
13802,Intermediate,50587,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,N,1,1,,CHEMBL625054,,BAO_0000218,,
13803,Autocuration,22224,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,U,0,1,,CHEMBL877485,,BAO_0000019,,
13804,Intermediate,50594,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,N,1,1,,CHEMBL625055,,BAO_0000218,,
13805,Intermediate,50594,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,N,1,1,,CHEMBL625056,,BAO_0000218,,
13806,Intermediate,50587,,,In vitro oxidation of compound in presence of human plasma,N,1,1,,CHEMBL625057,,BAO_0000218,,
13807,Autocuration,22224,,,In vitro oxidation of compound in presence of hydrogen peroxide,U,0,1,,CHEMBL625058,,BAO_0000019,,
13808,Intermediate,50594,,,In vitro oxidation of compound in presence of mouse brain homogenate,N,1,1,,CHEMBL625059,,BAO_0000218,,
13809,Intermediate,50594,,,In vitro oxidation of compound in presence of mouse liver homogenate,N,1,1,,CHEMBL629536,,BAO_0000218,,
13810,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,1,1,,CHEMBL629537,,BAO_0000218,,
13811,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,1,1,,CHEMBL629538,,BAO_0000218,,
13812,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,1,1,,CHEMBL629539,,BAO_0000218,,
13813,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,1,1,,CHEMBL874445,,BAO_0000218,,
13814,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,1,1,,CHEMBL629540,,BAO_0000218,,
13815,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,1,1,,CHEMBL629541,,BAO_0000218,,
13816,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,1,1,,CHEMBL629542,,BAO_0000218,,
13817,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,1,1,,CHEMBL630243,,BAO_0000218,,
13818,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,1,1,,CHEMBL630244,,BAO_0000218,,
13819,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,1,1,,CHEMBL630245,,BAO_0000218,,
13820,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,1,1,,CHEMBL630246,,BAO_0000218,,
13821,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,1,1,,CHEMBL630247,,BAO_0000218,,
13822,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,1,1,,CHEMBL630248,,BAO_0000218,,
13823,Intermediate,50597,Blood,,Biodistribution in rat blood at 240 minutes after dose administration.,N,1,1,,CHEMBL630249,,BAO_0000218,178.0,
13824,Intermediate,50597,Blood,,Biodistribution in rat blood at 30 minutes after dose administration.,N,1,1,,CHEMBL630250,,BAO_0000218,178.0,
13825,Intermediate,50597,Blood,,Biodistribution in rat blood at 360 minutes after dose administration.,N,1,1,,CHEMBL630251,,BAO_0000218,178.0,
13826,Intermediate,50597,Blood,,Biodistribution in rat blood at 3 hr after dose administration.,N,1,1,,CHEMBL630252,,BAO_0000218,178.0,
13827,Intermediate,50597,Blood,,Biodistribution in rat blood at 60 minutes after dose administration.,N,1,1,,CHEMBL630408,,BAO_0000218,178.0,
13828,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,N,1,1,,CHEMBL630409,,BAO_0000218,2037.0,
13829,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,N,1,1,,CHEMBL874446,,BAO_0000218,2037.0,
13830,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,N,1,1,,CHEMBL630410,,BAO_0000218,2037.0,
13831,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,N,1,1,,CHEMBL630411,,BAO_0000218,2037.0,
13832,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,N,1,1,,CHEMBL630412,,BAO_0000218,2037.0,
13833,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,N,1,1,,CHEMBL630413,,BAO_0000218,2037.0,
13834,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 3 hr after dose administration.,N,1,1,,CHEMBL630414,,BAO_0000218,2037.0,
13835,Intermediate,50597,Cerebellum,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,N,1,1,,CHEMBL630415,,BAO_0000218,2037.0,
13836,Intermediate,50597,,,Biodistribution in rat cortex at 120 minutes after dose administration.,N,1,1,,CHEMBL630416,,BAO_0000218,,
13837,Intermediate,50597,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,N,1,1,,CHEMBL630417,,BAO_0000218,,
13838,Intermediate,50597,,,Biodistribution in rat cortex at 15 minutes after dose administration.,N,1,1,,CHEMBL630418,,BAO_0000218,,
13839,Intermediate,50597,,,Biodistribution in rat cortex at 240 minutes after dose administration.,N,1,1,,CHEMBL630419,,BAO_0000218,,
13840,Intermediate,50597,,,Biodistribution in rat cortex at 30 minutes after dose administration.,N,1,1,,CHEMBL630420,,BAO_0000218,,
13841,Intermediate,50597,,,Biodistribution in rat cortex at 360 minutes after dose administration.,N,1,1,,CHEMBL630421,,BAO_0000218,,
13842,Intermediate,50597,,,Biodistribution in rat cortex at 3 hr after dose administration.,N,1,1,,CHEMBL630422,,BAO_0000218,,
13843,Intermediate,50597,,,Biodistribution in rat cortex at 60 minutes after dose administration.,N,1,1,,CHEMBL630423,,BAO_0000218,,
13844,Intermediate,50597,Heart,,Biodistribution in rat heart at 120 minutes after dose administration.,N,1,1,,CHEMBL630424,,BAO_0000218,948.0,
13845,Intermediate,50597,Heart,,Biodistribution in rat heart at 15 minutes after dose administration.,N,1,1,,CHEMBL630425,,BAO_0000218,948.0,
13846,Intermediate,50597,Heart,,Biodistribution in rat heart at 240 minutes after dose administration.,N,1,1,,CHEMBL629462,,BAO_0000218,948.0,
13847,Intermediate,50597,Heart,,Biodistribution in rat heart at 30 minutes after dose administration.,N,1,1,,CHEMBL630426,,BAO_0000218,948.0,
13848,Intermediate,50597,Heart,,Biodistribution in rat heart at 360 minutes after dose administration.,N,1,1,,CHEMBL630427,,BAO_0000218,948.0,
13849,Intermediate,50597,Heart,,Biodistribution in rat heart at 3 hr after dose administration.,N,1,1,,CHEMBL625877,,BAO_0000218,948.0,
13850,Intermediate,50597,Heart,,Biodistribution in rat heart at 60 minutes after dose administration.,N,1,1,,CHEMBL625878,,BAO_0000218,948.0,
13851,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,N,1,1,,CHEMBL625879,,BAO_0000218,10000000.0,
13852,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,N,1,1,,CHEMBL625880,,BAO_0000218,10000000.0,
13853,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,N,1,1,,CHEMBL625881,,BAO_0000218,10000000.0,
13854,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,N,1,1,,CHEMBL625882,,BAO_0000218,10000000.0,
13855,Intermediate,50597,Hippocampus,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,N,1,1,,CHEMBL625883,,BAO_0000218,10000000.0,
13856,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 120 minutes after dose administration.,N,1,1,,CHEMBL625884,,BAO_0000218,2113.0,
13857,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 1440 minutes after dose administration.,N,1,1,,CHEMBL625885,,BAO_0000218,2113.0,
13858,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 15 minutes after dose administration.,N,1,1,,CHEMBL628649,,BAO_0000218,2113.0,
13859,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 240 minutes after dose administration.,N,1,1,,CHEMBL628650,,BAO_0000218,2113.0,
13860,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 30 minutes after dose administration.,N,1,1,,CHEMBL628651,,BAO_0000218,2113.0,
13861,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 360 minutes after dose administration.,N,1,1,,CHEMBL628652,,BAO_0000218,2113.0,
13862,Intermediate,50597,Kidney,,Biodistribution in rat kidney at 60 minutes after dose administration.,N,1,1,,CHEMBL628653,,BAO_0000218,2113.0,
13863,Intermediate,50597,Liver,,Biodistribution in rat liver at 120 minutes after dose administration.,N,1,1,,CHEMBL628654,,BAO_0000218,2107.0,
13864,Intermediate,50597,Liver,,Biodistribution in rat liver at 1440 minutes after dose administration.,N,1,1,,CHEMBL628655,,BAO_0000218,2107.0,
13865,Intermediate,50597,Liver,,Biodistribution in rat liver at 15 minutes after dose administration.,N,1,1,,CHEMBL625238,,BAO_0000218,2107.0,
13866,Intermediate,50597,Liver,,Biodistribution in rat liver at 240 minutes after dose administration.,N,1,1,,CHEMBL625239,,BAO_0000218,2107.0,
13867,Intermediate,50597,Liver,,Biodistribution in rat liver at 30 minutes after dose administration.,N,1,1,,CHEMBL625240,,BAO_0000218,2107.0,
13868,Intermediate,50597,Liver,,Biodistribution in rat liver at 360 minutes after dose administration.,N,1,1,,CHEMBL625241,,BAO_0000218,2107.0,
13869,Intermediate,50597,Liver,,Biodistribution in rat liver at 60 minutes after dose administration.,N,1,1,,CHEMBL625242,,BAO_0000218,2107.0,
13870,Intermediate,50597,Lung,,Biodistribution in rat lung at 120 minutes after dose administration.,N,1,1,,CHEMBL874587,,BAO_0000218,2048.0,
13871,Intermediate,50597,Lung,,Biodistribution in rat lung at 1440 minutes after dose administration.,N,1,1,,CHEMBL625405,,BAO_0000218,2048.0,
13872,Intermediate,50597,Lung,,Biodistribution in rat lung at 15 minutes after dose administration.,N,1,1,,CHEMBL625406,,BAO_0000218,2048.0,
13873,Intermediate,50597,Lung,,Biodistribution in rat lung at 240 minutes after dose administration.,N,1,1,,CHEMBL625407,,BAO_0000218,2048.0,
13874,Intermediate,50597,Lung,,Biodistribution in rat lung at 30 minutes after dose administration.,N,1,1,,CHEMBL625408,,BAO_0000218,2048.0,
13875,Intermediate,50597,Lung,,Biodistribution in rat lung at 360 minutes after dose administration.,N,1,1,,CHEMBL625409,,BAO_0000218,2048.0,
13876,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,N,1,1,,CHEMBL625410,,BAO_0000218,1515.0,
13877,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,N,1,1,,CHEMBL625411,,BAO_0000218,1515.0,
13878,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,N,1,1,,CHEMBL625412,,BAO_0000218,1515.0,
13879,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,N,1,1,,CHEMBL625413,,BAO_0000218,1515.0,
13880,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,N,1,1,,CHEMBL625414,,BAO_0000218,1515.0,
13881,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,N,1,1,,CHEMBL625415,,BAO_0000218,1515.0,
13882,Intermediate,50597,Thoracic aorta,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,N,1,1,,CHEMBL625416,,BAO_0000218,1515.0,
13883,Intermediate,50597,Urine,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,N,1,1,,CHEMBL625417,,BAO_0000218,1088.0,
13884,Intermediate,50597,Feces,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,N,1,1,,CHEMBL625418,,BAO_0000218,1988.0,
13885,Intermediate,50597,Urine,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,N,1,1,,CHEMBL625419,,BAO_0000218,1088.0,
13886,Intermediate,50597,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,N,1,1,,CHEMBL625420,,BAO_0000218,,
13887,Intermediate,50597,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,N,1,1,,CHEMBL626996,,BAO_0000218,,
13888,Intermediate,50597,Feces,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",N,1,1,,CHEMBL626997,,BAO_0000218,1988.0,
13889,Intermediate,50597,Urine,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",N,1,1,,CHEMBL626998,,BAO_0000218,1088.0,
13890,Intermediate,50597,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",N,1,1,,CHEMBL626999,,BAO_0000218,,
13891,Intermediate,50594,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,N,1,1,,CHEMBL627000,,BAO_0000218,,
13892,Intermediate,50594,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,N,1,1,,CHEMBL627001,,BAO_0000218,,
13893,Intermediate,50594,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,N,1,1,,CHEMBL627002,,BAO_0000218,,
13894,Intermediate,50594,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,N,1,1,,CHEMBL627003,,BAO_0000218,,
13895,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,N,1,1,,CHEMBL627004,,BAO_0000218,1088.0,
13896,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,N,1,1,,CHEMBL627005,,BAO_0000218,1088.0,
13897,Intermediate,50594,Urine,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,N,1,1,,CHEMBL874594,,BAO_0000218,1088.0,
13898,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,N,1,1,,CHEMBL627006,,BAO_0000218,1088.0,
13899,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,N,1,1,,CHEMBL627007,,BAO_0000218,1088.0,
13900,Intermediate,50594,Urine,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,N,1,1,,CHEMBL627884,,BAO_0000218,1088.0,
13901,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,N,1,1,,CHEMBL627885,,BAO_0000218,1088.0,
13902,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,N,1,1,,CHEMBL627886,,BAO_0000218,1088.0,
13903,Intermediate,50594,Urine,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,N,1,1,,CHEMBL627887,,BAO_0000218,1088.0,
13904,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,N,1,1,,CHEMBL627888,,BAO_0000218,1088.0,
13905,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,N,1,1,,CHEMBL628057,,BAO_0000218,1088.0,
13906,Intermediate,50594,Urine,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,N,1,1,,CHEMBL627405,,BAO_0000218,1088.0,
13907,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,1,1,,CHEMBL627406,,BAO_0000218,1088.0,
13908,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,1,1,,CHEMBL627407,,BAO_0000218,1088.0,
13909,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,1,1,,CHEMBL627408,,BAO_0000218,1088.0,
13910,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,1,1,,CHEMBL627409,,BAO_0000218,1088.0,
13911,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,1,1,,CHEMBL875486,,BAO_0000218,1088.0,
13912,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL627410,,BAO_0000218,1088.0,
13913,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,1,1,,CHEMBL627411,,BAO_0000218,1088.0,
13914,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,1,1,,CHEMBL627412,,BAO_0000218,1088.0,
13915,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,1,1,,CHEMBL627413,,BAO_0000218,1088.0,
13916,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,1,1,,CHEMBL627414,,BAO_0000218,1088.0,
13917,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL627415,,BAO_0000218,1088.0,
13918,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,N,1,1,,CHEMBL627416,,BAO_0000218,1088.0,
13919,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL627417,,BAO_0000218,1088.0,
13920,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL627418,,BAO_0000218,1088.0,
13921,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL627419,,BAO_0000218,1088.0,
13922,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,1,1,,CHEMBL627320,,BAO_0000218,1088.0,
13923,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,1,1,,CHEMBL627321,,BAO_0000218,1088.0,
13924,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627322,,BAO_0000218,2113.0,
13925,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627323,,BAO_0000218,2113.0,
13926,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL627491,,BAO_0000218,2113.0,
13927,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627492,,BAO_0000218,2113.0,
13928,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627493,,BAO_0000218,2113.0,
13929,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627494,,BAO_0000218,2107.0,
13930,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627495,,BAO_0000218,2107.0,
13931,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL627496,,BAO_0000218,2107.0,
13932,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627497,,BAO_0000218,2107.0,
13933,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627498,,BAO_0000218,2107.0,
13934,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627499,,BAO_0000218,2048.0,
13935,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL627500,,BAO_0000218,2048.0,
13936,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL627501,,BAO_0000218,2048.0,
13937,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625616,,BAO_0000218,2048.0,
13938,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625617,,BAO_0000218,2048.0,
13939,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625618,,BAO_0000218,2385.0,
13940,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625619,,BAO_0000218,2385.0,
13941,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL625620,,BAO_0000218,2385.0,
13942,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625621,,BAO_0000218,2385.0,
13943,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625622,,BAO_0000218,2385.0,
13944,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625788,,BAO_0000218,2106.0,
13945,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625789,,BAO_0000218,2106.0,
13946,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL625790,,BAO_0000218,2106.0,
13947,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL625791,,BAO_0000218,2106.0,
13948,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL622334,,BAO_0000218,2106.0,
13949,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL622335,,BAO_0000218,2046.0,
13950,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL622336,,BAO_0000218,2046.0,
13951,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL622337,,BAO_0000218,2046.0,
13952,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL622338,,BAO_0000218,2046.0,
13953,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL622339,,BAO_0000218,2046.0,
13954,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL624153,,BAO_0000218,,
13955,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL628430,,BAO_0000218,,
13956,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL628431,,BAO_0000218,,
13957,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL628432,,BAO_0000218,,
13958,Intermediate,50597,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL628433,,BAO_0000218,,
13959,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL628434,,BAO_0000218,2106.0,
13960,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL626789,,BAO_0000218,2106.0,
13961,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",N,1,1,,CHEMBL626790,,BAO_0000218,2106.0,
13962,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL626791,,BAO_0000218,2106.0,
13963,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL626792,,BAO_0000218,2106.0,
13964,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL626793,,BAO_0000218,2106.0,
13965,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,1,1,,CHEMBL627436,,BAO_0000218,,
13966,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,1,1,,CHEMBL627437,,BAO_0000218,,
13967,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,1,1,,CHEMBL627438,,BAO_0000218,,
13968,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,1,1,,CHEMBL627439,,BAO_0000218,,
13969,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,1,1,,CHEMBL627440,,BAO_0000218,,
13970,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,1,1,,CHEMBL627602,,BAO_0000218,,
13971,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,1,1,,CHEMBL627603,,BAO_0000218,,
13972,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,1,1,,CHEMBL627604,,BAO_0000218,,
13973,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,1,1,,CHEMBL627605,,BAO_0000218,,
13974,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,1,1,,CHEMBL627606,,BAO_0000218,,
13975,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,1,1,,CHEMBL627607,,BAO_0000218,,
13976,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,1,1,,CHEMBL627608,,BAO_0000218,,
13977,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,1,1,,CHEMBL627609,,BAO_0000218,,
13978,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,1,1,,CHEMBL627610,,BAO_0000218,,
13979,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,1,1,,CHEMBL627611,,BAO_0000218,,
13980,Intermediate,50597,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,1,1,,CHEMBL627612,,BAO_0000218,,
13981,Autocuration,22229,,,Octanol:water partition coefficient is evaluated,U,0,1,,CHEMBL627613,,BAO_0000100,,
13982,Autocuration,22224,,,Partition coefficient in 1-octanol/water system,U,0,1,,CHEMBL627614,,BAO_0000100,,
13983,Autocuration,22224,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,U,0,1,,CHEMBL627615,,BAO_0000100,,
13984,Autocuration,22224,,,Partition coefficient in octanol/water system was determined,U,0,1,,CHEMBL627616,,BAO_0000100,,
13985,Autocuration,22224,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,U,0,1,,CHEMBL627617,,BAO_0000100,,
13986,Autocuration,22224,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,U,0,1,,CHEMBL627618,,BAO_0000019,,
13987,Autocuration,22224,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",U,0,1,,CHEMBL627619,,BAO_0000019,,
13988,Autocuration,22224,,,Pseudo-first-order rate constant of the compound,U,0,1,,CHEMBL627620,,BAO_0000019,,
13989,Autocuration,22224,,,Pseudo-first-order rate constant with 1-min time point,U,0,1,,CHEMBL627621,,BAO_0000019,,
13990,Autocuration,22224,,,Pseudo-first-order rate constant without 1-min time point,U,0,1,,CHEMBL627622,,BAO_0000019,,
13991,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,U,0,1,,CHEMBL627623,,BAO_0000019,,
13992,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,U,0,1,,CHEMBL627624,,BAO_0000019,,
13993,Autocuration,22224,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,U,0,1,,CHEMBL627625,,BAO_0000019,,
13994,Autocuration,22224,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,U,0,1,,CHEMBL628523,,BAO_0000019,,
13995,Autocuration,22224,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,U,0,1,,CHEMBL628524,,BAO_0000019,,
13996,Autocuration,22224,,,The efflux rate constant of the compound,U,0,1,,CHEMBL628525,,BAO_0000019,,
13997,Autocuration,22224,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,0,1,,CHEMBL625732,,BAO_0000019,,
13998,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,0,1,,CHEMBL625733,,BAO_0000019,,
13999,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,0,1,,CHEMBL625734,,BAO_0000019,,
14000,Autocuration,22224,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,U,0,1,,CHEMBL625913,,BAO_0000019,,
14001,Autocuration,22224,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,U,0,1,,CHEMBL625914,,BAO_0000019,,
14002,Autocuration,22224,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,U,0,1,,CHEMBL625915,,BAO_0000019,,
14003,Autocuration,22224,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,U,0,1,,CHEMBL625916,,BAO_0000019,,
14004,Autocuration,22224,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),U,0,1,,CHEMBL625917,,BAO_0000019,,
14005,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625918,,BAO_0000019,,
14006,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625919,,BAO_0000019,,
14007,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625920,,BAO_0000019,,
14008,Autocuration,22224,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL874453,,BAO_0000019,,
14009,Autocuration,22224,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625921,,BAO_0000019,,
14010,Autocuration,22224,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,U,0,1,,CHEMBL625922,,BAO_0000019,,
14011,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625923,,BAO_0000019,,
14012,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625924,,BAO_0000019,,
14013,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625925,,BAO_0000019,,
14014,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL625926,,BAO_0000019,,
14015,Intermediate,50597,Lung,,Biodistribution in rat lung at 60 minutes after dose administration.,N,1,1,,CHEMBL627704,,BAO_0000218,2048.0,
14016,Intermediate,50597,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,N,1,1,,CHEMBL627705,,BAO_0000218,,
14017,Intermediate,50597,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,N,1,1,,CHEMBL627706,,BAO_0000218,,
14018,Intermediate,50597,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,N,1,1,,CHEMBL627707,,BAO_0000218,,
14019,Intermediate,50597,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,N,1,1,,CHEMBL627708,,BAO_0000218,,
14020,Intermediate,50597,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,N,1,1,,CHEMBL628361,,BAO_0000218,,
14021,Intermediate,50597,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,N,1,1,,CHEMBL628362,,BAO_0000218,,
14022,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 120 minutes after dose administration.,N,1,1,,CHEMBL628363,,BAO_0000218,2435.0,
14023,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 1440 minutes after dose administration.,N,1,1,,CHEMBL628364,,BAO_0000218,2435.0,
14024,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 15 minutes after dose administration.,N,1,1,,CHEMBL628365,,BAO_0000218,2435.0,
14025,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 240 minutes after dose administration.,N,1,1,,CHEMBL874454,,BAO_0000218,2435.0,
14026,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 30 minutes after dose administration.,N,1,1,,CHEMBL628531,,BAO_0000218,2435.0,
14027,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 360 minutes after dose administration.,N,1,1,,CHEMBL628532,,BAO_0000218,2435.0,
14028,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 3 hr after dose administration.,N,1,1,,CHEMBL628533,,BAO_0000218,2435.0,
14029,Intermediate,50597,Striatum,,Biodistribution in rat striatum at 60 minutes after dose administration.,N,1,1,,CHEMBL628534,,BAO_0000218,2435.0,
14030,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 120 minutes after dose administration.,N,1,1,,CHEMBL628535,,BAO_0000218,2046.0,
14031,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,N,1,1,,CHEMBL628536,,BAO_0000218,2046.0,
14032,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 15 minutes after dose administration.,N,1,1,,CHEMBL628537,,BAO_0000218,2046.0,
14033,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 240 minutes after dose administration.,N,1,1,,CHEMBL628538,,BAO_0000218,2046.0,
14034,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 30 minutes after dose administration.,N,1,1,,CHEMBL628539,,BAO_0000218,2046.0,
14035,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 360 minutes after dose administration.,N,1,1,,CHEMBL630297,,BAO_0000218,2046.0,
14036,Intermediate,50597,Thyroid gland,,Biodistribution in rat thyroid at 60 minutes after dose administration.,N,1,1,,CHEMBL630298,,BAO_0000218,2046.0,
14037,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,N,1,1,,CHEMBL630299,,BAO_0000218,955.0,
14038,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,N,1,1,,CHEMBL628094,,BAO_0000218,955.0,
14039,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,N,1,1,,CHEMBL628095,,BAO_0000218,955.0,
14040,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,N,1,1,,CHEMBL874648,,BAO_0000218,955.0,
14041,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,N,1,1,,CHEMBL628096,,BAO_0000218,955.0,
14042,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,N,1,1,,CHEMBL628097,,BAO_0000218,955.0,
14043,Intermediate,50597,Brain,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,N,1,1,,CHEMBL628098,,BAO_0000218,955.0,
14044,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",U,0,1,,CHEMBL628099,,BAO_0000019,,
14045,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,0,1,,CHEMBL628100,,BAO_0000019,,
14046,Autocuration,22224,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),U,0,1,,CHEMBL628101,,BAO_0000019,,
14047,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",U,0,1,,CHEMBL628102,,BAO_0000019,,
14048,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",U,0,1,,CHEMBL628103,,BAO_0000019,,
14049,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,0,1,,CHEMBL628104,,BAO_0000019,,
14050,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",U,0,1,,CHEMBL628105,,BAO_0000019,,
14051,Autocuration,22224,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",U,0,1,,CHEMBL628106,,BAO_0000019,,
14052,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,N,1,1,,CHEMBL628107,,BAO_0000218,1088.0,
14053,Autocuration,22224,Urine,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,U,0,1,,CHEMBL628108,,BAO_0000218,1088.0,
14054,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,N,1,1,,CHEMBL628109,,BAO_0000218,1088.0,
14055,Autocuration,22224,Urine,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,U,0,1,,CHEMBL625299,,BAO_0000218,1088.0,
14056,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,N,1,1,,CHEMBL625300,,BAO_0000218,1088.0,
14057,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,N,1,1,,CHEMBL625301,,BAO_0000218,1088.0,
14058,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,N,1,1,,CHEMBL625302,,BAO_0000218,1088.0,
14059,Intermediate,50597,Urine,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,N,1,1,,CHEMBL874649,,BAO_0000218,1088.0,
14060,Intermediate,50597,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,N,1,1,,CHEMBL625303,,BAO_0000218,,
14061,Intermediate,50597,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,N,1,1,,CHEMBL625463,,BAO_0000218,,
14062,Intermediate,50587,Liver,,In vitro metabolism in human liver microsomes,N,1,1,,CHEMBL625464,,BAO_0000218,2107.0,
14063,Intermediate,50587,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,N,1,1,,CHEMBL625465,,BAO_0000218,,
14064,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,1,1,,CHEMBL625466,,BAO_0000218,1088.0,
14065,Intermediate,50588,Urine,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,1,1,,CHEMBL625467,,BAO_0000218,1088.0,
14066,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,1,1,,CHEMBL625468,,BAO_0000218,1088.0,
14067,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,N,1,1,,CHEMBL625469,,BAO_0000218,1088.0,
14068,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,1,1,,CHEMBL625470,,BAO_0000218,1088.0,
14069,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,1,1,,CHEMBL632418,,BAO_0000218,1088.0,
14070,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL627250,,BAO_0000218,1088.0,
14071,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,N,1,1,,CHEMBL627251,,BAO_0000218,1088.0,
14072,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,N,1,1,,CHEMBL627252,,BAO_0000218,1088.0,
14073,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,1,1,,CHEMBL627253,,BAO_0000218,1088.0,
14074,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,N,1,1,,CHEMBL627254,,BAO_0000218,1088.0,
14075,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,1,1,,CHEMBL875471,,BAO_0000218,1088.0,
14076,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,N,1,1,,CHEMBL627255,,BAO_0000218,1088.0,
14077,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,1,1,,CHEMBL627256,,BAO_0000218,1088.0,
14078,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,N,1,1,,CHEMBL627257,,BAO_0000218,1088.0,
14079,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,1,1,,CHEMBL627258,,BAO_0000218,1088.0,
14080,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,N,1,1,,CHEMBL627259,,BAO_0000218,1088.0,
14081,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,1,1,,CHEMBL627260,,BAO_0000218,1088.0,
14082,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,N,1,1,,CHEMBL623256,,BAO_0000218,1088.0,
14083,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,1,1,,CHEMBL874413,,BAO_0000218,1088.0,
14084,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,N,1,1,,CHEMBL623257,,BAO_0000218,1088.0,
14085,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,1,1,,CHEMBL623258,,BAO_0000218,1088.0,
14086,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,N,1,1,,CHEMBL623259,,BAO_0000218,1088.0,
14087,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,N,1,1,,CHEMBL623260,,BAO_0000218,1088.0,
14088,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,1,1,,CHEMBL623261,,BAO_0000218,1088.0,
14089,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,N,1,1,,CHEMBL623262,,BAO_0000218,1088.0,
14090,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,N,1,1,,CHEMBL623263,,BAO_0000218,1088.0,
14091,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,1,1,,CHEMBL623264,,BAO_0000218,1088.0,
14092,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,1,1,,CHEMBL623265,,BAO_0000218,1088.0,
14093,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,1,1,,CHEMBL623266,,BAO_0000218,1088.0,
14094,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,N,1,1,,CHEMBL623267,,BAO_0000218,1088.0,
14095,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,N,1,1,,CHEMBL623268,,BAO_0000218,1088.0,
14096,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL623269,,BAO_0000218,1088.0,
14097,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL623270,,BAO_0000218,1088.0,
14098,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,1,1,,CHEMBL623271,,BAO_0000218,1088.0,
14099,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,N,1,1,,CHEMBL623272,,BAO_0000218,1088.0,
14100,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,1,1,,CHEMBL623273,,BAO_0000218,1088.0,
14101,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,N,1,1,,CHEMBL623274,,BAO_0000218,1088.0,
14102,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,1,1,,CHEMBL874414,,BAO_0000218,1088.0,
14103,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,N,1,1,,CHEMBL623275,,BAO_0000218,1088.0,
14104,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,1,1,,CHEMBL629150,,BAO_0000218,1088.0,
14105,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL623276,,BAO_0000218,1088.0,
14106,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,1,1,,CHEMBL623277,,BAO_0000218,1088.0,
14107,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,N,1,1,,CHEMBL623112,,BAO_0000218,1088.0,
14108,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,N,1,1,,CHEMBL623113,,BAO_0000218,1088.0,
14109,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,1,1,,CHEMBL623800,,BAO_0000218,1088.0,
14110,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,1,1,,CHEMBL623801,,BAO_0000218,1088.0,
14111,Intermediate,50597,Spleen,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,1,1,,CHEMBL623802,,BAO_0000218,2106.0,
14112,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623803,,BAO_0000218,995.0,
14113,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623970,,BAO_0000218,995.0,
14114,Intermediate,50597,Uterus,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL623971,,BAO_0000218,995.0,
14115,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),N,1,1,,CHEMBL623972,,BAO_0000218,178.0,
14116,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),N,1,1,,CHEMBL623973,,BAO_0000218,178.0,
14117,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),N,1,1,,CHEMBL623974,,BAO_0000218,178.0,
14118,Intermediate,50597,Blood,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),N,1,1,,CHEMBL623975,,BAO_0000218,178.0,
14119,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),N,1,1,,CHEMBL623976,,BAO_0000218,955.0,
14120,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),N,1,1,,CHEMBL623977,,BAO_0000218,955.0,
14121,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),N,1,1,,CHEMBL623978,,BAO_0000218,955.0,
14122,Intermediate,50597,Brain,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),N,1,1,,CHEMBL623979,,BAO_0000218,955.0,
14123,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),N,1,1,,CHEMBL623980,,BAO_0000218,,
14124,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),N,1,1,,CHEMBL623981,,BAO_0000218,,
14125,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),N,1,1,,CHEMBL626278,,BAO_0000218,,
14126,Intermediate,50597,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),N,1,1,,CHEMBL626279,,BAO_0000218,,
14127,Intermediate,50594,,,Biodistribution in mice bladder plus excreted urine was determined,N,1,1,,CHEMBL626280,,BAO_0000218,,
14128,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",N,1,1,,CHEMBL626281,,BAO_0000218,,
14129,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",N,1,1,,CHEMBL626282,,BAO_0000218,,
14130,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",N,1,1,,CHEMBL626283,,BAO_0000218,,
14131,Intermediate,50594,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",N,1,1,,CHEMBL626284,,BAO_0000218,,
14132,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 10 minutes post injection",N,1,1,,CHEMBL626285,,BAO_0000218,955.0,
14133,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 30 minutes post injection",N,1,1,,CHEMBL626286,,BAO_0000218,955.0,
14134,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 5 minutes post injection",N,1,1,,CHEMBL626287,,BAO_0000218,955.0,
14135,Intermediate,50594,Brain,,"Percentage biodistribution in mouse brain, 60 minutes post injection",N,1,1,,CHEMBL626288,,BAO_0000218,955.0,
14136,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",N,1,1,,CHEMBL626289,,BAO_0000218,,
14137,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",N,1,1,,CHEMBL626290,,BAO_0000218,,
14138,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",N,1,1,,CHEMBL626291,,BAO_0000218,,
14139,Intermediate,50594,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",N,1,1,,CHEMBL839888,,BAO_0000218,,
14140,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",N,1,1,,CHEMBL626292,,BAO_0000218,160.0,
14141,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",N,1,1,,CHEMBL626293,,BAO_0000218,160.0,
14142,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",N,1,1,,CHEMBL626294,,BAO_0000218,160.0,
14143,Intermediate,50594,Intestine,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",N,1,1,,CHEMBL626295,,BAO_0000218,160.0,
14144,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 10 minutes post injection",N,1,1,,CHEMBL627659,,BAO_0000218,2107.0,
14145,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",N,1,1,,CHEMBL627660,,BAO_0000218,2107.0,
14146,Intermediate,50594,Liver,,"Percentage biodistribution in mouse liver, 5 minutes post injection",N,1,1,,CHEMBL627661,,BAO_0000218,2107.0,
14147,Intermediate,50594,Liver,,Biodistribution in mice liver at 60 minutes of post injection,N,1,1,,CHEMBL627662,,BAO_0000218,2107.0,
14148,Intermediate,50594,Lung,,Biodistribution in mice lungs at 10 min of post injection,N,1,1,,CHEMBL627663,,BAO_0000218,2048.0,
14149,Intermediate,50594,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",N,1,1,,CHEMBL627664,,BAO_0000218,,
14150,Intermediate,50594,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",N,1,1,,CHEMBL627665,,BAO_0000218,,
14151,Intermediate,50594,Lung,,Biodistribution in mice lungs at 60 min of post injection,N,1,1,,CHEMBL627666,,BAO_0000218,2048.0,
14152,Intermediate,50594,Spleen,,Percentage biodistribution in mouse spleen,N,1,1,,CHEMBL627667,,BAO_0000218,2106.0,
14153,Intermediate,50594,Stomach,,Percentage biodistribution in mouse stomach,N,1,1,,CHEMBL627668,,BAO_0000218,945.0,
14154,Intermediate,50594,Urine,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,N,1,1,,CHEMBL627669,,BAO_0000218,1088.0,
14155,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,U,0,1,,CHEMBL627670,,BAO_0000218,1255.0,
14156,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,U,0,1,,CHEMBL627671,,BAO_0000218,178.0,
14157,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,U,0,1,,CHEMBL627672,,BAO_0000218,1474.0,
14158,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,U,0,1,,CHEMBL627673,,BAO_0000218,,
14159,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,U,0,1,,CHEMBL627674,,BAO_0000218,2113.0,
14160,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,U,0,1,,CHEMBL627675,,BAO_0000218,2107.0,
14161,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,U,0,1,,CHEMBL627676,,BAO_0000218,2048.0,
14162,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,U,0,1,,CHEMBL627677,,BAO_0000218,2385.0,
14163,Autocuration,22224,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL627678,,BAO_0000019,,
14164,Intermediate,50597,Serum,,Affinity for protein binding expressed as association constant in fresh rat serum,N,1,1,,CHEMBL627679,,BAO_0000218,1977.0,
14165,Autocuration,22224,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,0,1,,CHEMBL627680,,BAO_0000019,,
14166,Autocuration,22224,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,0,1,,CHEMBL627681,,BAO_0000019,,
14167,Autocuration,22224,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,0,1,,CHEMBL627682,,BAO_0000019,,
14168,Autocuration,22224,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,0,1,,CHEMBL627683,,BAO_0000019,,
14169,Autocuration,22224,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,U,0,1,,CHEMBL627684,,BAO_0000019,,
14170,Autocuration,22224,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,0,1,,CHEMBL874441,,BAO_0000019,,
14171,Autocuration,22224,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,U,0,1,,CHEMBL627685,,BAO_0000019,,
14172,Autocuration,22224,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,0,1,,CHEMBL627686,,BAO_0000019,,
14173,Autocuration,22224,,,Apparent rate constant Koff for inactivation of dTMP synthase.,U,0,1,,CHEMBL627687,,BAO_0000019,,
14174,Autocuration,22224,,,The irreversible inhibitor activity by second order rate equation.,U,0,1,,CHEMBL627688,,BAO_0000019,,
14175,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,N,1,1,,CHEMBL628038,,BAO_0000218,,
14176,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,N,1,1,,CHEMBL628039,,BAO_0000218,,
14177,Intermediate,50597,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,N,1,1,,CHEMBL628040,,BAO_0000218,,
14178,Autocuration,22224,,,Dissociation rate calculated from the first-order equation using t1/2 value,U,0,1,,CHEMBL628041,,BAO_0000019,,
14179,Autocuration,22224,,,The compound was tested for Binding constant against DNA,U,0,1,,CHEMBL630226,,BAO_0000019,,
14180,Autocuration,22224,,,First order rate constant for cyclization of the compound,U,0,1,,CHEMBL628042,,BAO_0000019,,
14181,Autocuration,22224,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,0,1,,CHEMBL625232,,BAO_0000019,,
14182,Autocuration,22224,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,0,1,,CHEMBL625233,,BAO_0000019,,
14183,Autocuration,22224,,,Hydrolysis rate constant was determined,U,0,1,,CHEMBL625979,,BAO_0000019,,
14184,Autocuration,22224,,,Observed first order rate constant,U,0,1,,CHEMBL625980,,BAO_0000019,,
14185,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,0,1,,CHEMBL625981,,BAO_0000019,,
14186,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,0,1,,CHEMBL625982,,BAO_0000019,,
14187,Autocuration,22224,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,U,0,1,,CHEMBL625983,,BAO_0000019,,
14188,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625984,,BAO_0000019,,
14189,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625985,,BAO_0000019,,
14190,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625986,,BAO_0000019,,
14191,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625987,,BAO_0000019,,
14192,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625988,,BAO_0000019,,
14193,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625989,,BAO_0000019,,
14194,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625990,,BAO_0000019,,
14195,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625991,,BAO_0000019,,
14196,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625992,,BAO_0000019,,
14197,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL625993,,BAO_0000019,,
14198,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL631973,,BAO_0000019,,
14199,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632143,,BAO_0000019,,
14200,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632144,,BAO_0000019,,
14201,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632145,,BAO_0000019,,
14202,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632146,,BAO_0000019,,
14203,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632147,,BAO_0000019,,
14204,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632148,,BAO_0000019,,
14205,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632149,,BAO_0000019,,
14206,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632150,,BAO_0000019,,
14207,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL632151,,BAO_0000019,,
14208,Intermediate,50587,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,N,1,1,,CHEMBL632152,,BAO_0000218,,
14209,Intermediate,50587,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,1,1,,CHEMBL632153,,BAO_0000218,,
14210,Intermediate,50587,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,1,1,,CHEMBL632154,,BAO_0000218,,
14211,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL632155,,BAO_0000218,,
14212,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,N,1,1,,CHEMBL632156,,BAO_0000218,,
14213,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL632157,,BAO_0000218,,
14214,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL632158,,BAO_0000218,,
14215,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,N,1,1,,CHEMBL632159,,BAO_0000218,,
14216,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL626305,,BAO_0000218,,
14217,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,N,1,1,,CHEMBL626306,,BAO_0000218,,
14218,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL626307,,BAO_0000218,,
14219,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL626308,,BAO_0000218,,
14220,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL626479,,BAO_0000218,,
14221,Intermediate,50602,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,N,1,1,,CHEMBL626480,,BAO_0000218,,
14222,Autocuration,22229,,,Calculated partition coefficient (clogP) (MlogP),U,0,1,,CHEMBL626481,,BAO_0000100,,
14223,Autocuration,22224,,,Equipotent potent ratio relative to carbachol (nicotinic activity),U,0,1,,CHEMBL626482,,BAO_0000019,,
14224,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",N,1,1,,CHEMBL626483,,BAO_0000218,,
14225,Intermediate,50588,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",N,1,1,,CHEMBL626484,,BAO_0000218,,
14226,Autocuration,22229,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,U,0,1,,CHEMBL626485,,BAO_0000100,,
14227,Autocuration,22229,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,U,0,1,,CHEMBL626486,,BAO_0000100,,
14228,Autocuration,22229,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,U,0,1,,CHEMBL626487,,BAO_0000100,,
14229,Intermediate,50588,Plasma,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,1,1,,CHEMBL626488,,BAO_0000218,1969.0,
14230,Intermediate,50597,Serum,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,N,1,1,,CHEMBL626489,,BAO_0000218,1977.0,
14231,Autocuration,22224,,,Area under the MAP curve measured over 5 min; ND means Not determined,U,0,1,,CHEMBL626490,,BAO_0000019,,
14232,Autocuration,22224,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,U,0,1,,CHEMBL626491,,BAO_0000100,,
14233,Autocuration,22229,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,U,0,1,,CHEMBL626492,,BAO_0000100,,
14234,Autocuration,22224,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,U,0,1,,CHEMBL626493,,BAO_0000019,,
14235,Intermediate,50597,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,N,1,1,,CHEMBL626494,,BAO_0000218,,
14236,Autocuration,22224,,,Half life after oral tested,U,0,1,,CHEMBL626495,,BAO_0000218,,
14237,Intermediate,50597,Plasma,,Half life was determined in plasma of rat; NT indicates not tested,N,1,1,,CHEMBL626496,,BAO_0000218,1969.0,
14238,Intermediate,50597,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,N,1,1,,CHEMBL626497,,BAO_0000218,,
14239,Autocuration,22224,,,Oral bioavailability after oral tested,U,0,1,,CHEMBL626498,,BAO_0000218,,
14240,Intermediate,50597,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),N,1,1,,CHEMBL626499,,BAO_0000218,,
14241,Intermediate,50597,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),N,1,1,,CHEMBL626500,,BAO_0000218,,
14242,Intermediate,50597,Plasma,,half life was determined in plasma of rat; NT indicates not tested,N,1,1,,CHEMBL626501,,BAO_0000218,1969.0,
14243,Intermediate,50597,Plasma,,half life was determined in plasma of rat; NT means not tested,N,1,1,,CHEMBL626502,,BAO_0000218,1969.0,
14244,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,N,1,1,,CHEMBL626503,,BAO_0000218,,
14245,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,N,1,1,,CHEMBL626504,,BAO_0000218,,
14246,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,N,1,1,,CHEMBL626505,,BAO_0000218,,
14247,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,N,1,1,,CHEMBL626506,,BAO_0000218,,
14248,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,N,1,1,,CHEMBL626507,,BAO_0000218,,
14249,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,N,1,1,,CHEMBL626508,,BAO_0000218,,
14250,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,N,1,1,,CHEMBL626509,,BAO_0000218,,
14251,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,N,1,1,,CHEMBL875480,,BAO_0000218,,
14252,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,N,1,1,,CHEMBL626510,,BAO_0000218,,
14253,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,N,1,1,,CHEMBL626511,,BAO_0000218,,
14254,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,N,1,1,,CHEMBL626512,,BAO_0000218,,
14255,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,N,1,1,,CHEMBL628208,,BAO_0000218,,
14256,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,N,1,1,,CHEMBL628209,,BAO_0000218,,
14257,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,N,1,1,,CHEMBL628210,,BAO_0000218,,
14258,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,N,1,1,,CHEMBL628211,,BAO_0000218,,
14259,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,N,1,1,,CHEMBL628212,,BAO_0000218,,
14260,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,N,1,1,,CHEMBL628213,,BAO_0000218,,
14261,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,1,1,,CHEMBL628214,,BAO_0000218,1088.0,
14262,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,1,1,,CHEMBL628215,,BAO_0000218,1088.0,
14263,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,1,1,,CHEMBL628216,,BAO_0000218,1088.0,
14264,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,1,1,,CHEMBL626595,,BAO_0000218,1088.0,
14265,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,1,1,,CHEMBL626596,,BAO_0000218,1088.0,
14266,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,1,1,,CHEMBL626597,,BAO_0000218,1088.0,
14267,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,1,1,,CHEMBL626598,,BAO_0000218,1088.0,
14268,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,1,1,,CHEMBL622242,,BAO_0000218,1088.0,
14269,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,1,1,,CHEMBL622243,,BAO_0000218,1088.0,
14270,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,1,1,,CHEMBL622244,,BAO_0000218,1088.0,
14271,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,1,1,,CHEMBL622245,,BAO_0000218,1088.0,
14272,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,1,1,,CHEMBL622246,,BAO_0000218,1088.0,
14273,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,1,1,,CHEMBL622247,,BAO_0000218,1088.0,
14274,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,1,1,,CHEMBL622248,,BAO_0000218,1088.0,
14275,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,1,1,,CHEMBL877483,,BAO_0000218,1088.0,
14276,Intermediate,50597,Urine,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,1,1,,CHEMBL622249,,BAO_0000218,1088.0,
14277,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,1,1,,CHEMBL622250,,BAO_0000218,1088.0,
14278,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,1,1,,CHEMBL622251,,BAO_0000218,1088.0,
14279,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,1,1,,CHEMBL622252,,BAO_0000218,1088.0,
14280,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,1,1,,CHEMBL622253,,BAO_0000218,1088.0,
14281,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,1,1,,CHEMBL622254,,BAO_0000218,1088.0,
14282,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL622255,,BAO_0000218,1088.0,
14283,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,1,1,,CHEMBL622256,,BAO_0000218,1088.0,
14284,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,1,1,,CHEMBL622257,,BAO_0000218,1088.0,
14285,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,1,1,,CHEMBL622258,,BAO_0000218,1088.0,
14286,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,1,1,,CHEMBL622259,,BAO_0000218,1088.0,
14287,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL622927,,BAO_0000218,1088.0,
14288,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL622928,,BAO_0000218,1088.0,
14289,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL622929,,BAO_0000218,1088.0,
14290,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,1,1,,CHEMBL623182,,BAO_0000218,1088.0,
14291,Intermediate,50588,Urine,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,1,1,,CHEMBL623183,,BAO_0000218,1088.0,
14292,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,N,1,1,,CHEMBL623184,,BAO_0000218,1088.0,
14293,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,1,1,,CHEMBL623185,,BAO_0000218,1088.0,
14294,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,1,1,,CHEMBL877484,,BAO_0000218,1088.0,
14295,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL627274,,BAO_0000218,1088.0,
14296,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,N,1,1,,CHEMBL623186,,BAO_0000218,1088.0,
14297,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,N,1,1,,CHEMBL623187,,BAO_0000218,1088.0,
14298,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,1,1,,CHEMBL623188,,BAO_0000218,1088.0,
14299,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,N,1,1,,CHEMBL628055,,BAO_0000218,1088.0,
14300,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,1,1,,CHEMBL628056,,BAO_0000218,1088.0,
14301,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,N,1,1,,CHEMBL628200,,BAO_0000218,1088.0,
14302,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,1,1,,CHEMBL628201,,BAO_0000218,1088.0,
14303,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,N,1,1,,CHEMBL628202,,BAO_0000218,1088.0,
14304,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,1,1,,CHEMBL628203,,BAO_0000218,1088.0,
14305,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,N,1,1,,CHEMBL628204,,BAO_0000218,1088.0,
14306,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,1,1,,CHEMBL628205,,BAO_0000218,1088.0,
14307,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,N,1,1,,CHEMBL628206,,BAO_0000218,1088.0,
14308,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),U,0,1,,CHEMBL628207,,BAO_0000218,2367.0,
14309,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,U,0,1,,CHEMBL627220,,BAO_0000218,2367.0,
14310,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,U,0,1,,CHEMBL627221,,BAO_0000218,2385.0,
14311,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),U,0,1,,CHEMBL627222,,BAO_0000218,2367.0,
14312,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,U,0,1,,CHEMBL627223,,BAO_0000218,,
14313,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,U,0,1,,CHEMBL632062,,BAO_0000218,2385.0,
14314,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,U,0,1,,CHEMBL632063,,BAO_0000218,2106.0,
14315,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,U,0,1,,CHEMBL632064,,BAO_0000218,1255.0,
14316,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,U,0,1,,CHEMBL632065,,BAO_0000218,178.0,
14317,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,U,0,1,,CHEMBL632066,,BAO_0000218,1474.0,
14318,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,U,0,1,,CHEMBL632067,,BAO_0000218,,
14319,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,U,0,1,,CHEMBL629188,,BAO_0000218,2113.0,
14320,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,U,0,1,,CHEMBL629189,,BAO_0000218,2107.0,
14321,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,U,0,1,,CHEMBL629190,,BAO_0000218,2048.0,
14322,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,U,0,1,,CHEMBL629191,,BAO_0000218,2385.0,
14323,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),U,0,1,,CHEMBL629192,,BAO_0000218,2367.0,
14324,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,U,0,1,,CHEMBL629193,,BAO_0000218,2385.0,
14325,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),U,0,1,,CHEMBL629194,,BAO_0000218,2367.0,
14326,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,U,0,1,,CHEMBL629195,,BAO_0000218,,
14327,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,U,0,1,,CHEMBL629373,,BAO_0000218,2385.0,
14328,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,U,0,1,,CHEMBL629374,,BAO_0000218,2106.0,
14329,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,U,0,1,,CHEMBL629375,,BAO_0000218,2367.0,
14330,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,U,0,1,,CHEMBL629376,,BAO_0000218,1255.0,
14331,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,U,0,1,,CHEMBL629377,,BAO_0000218,178.0,
14332,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,U,0,1,,CHEMBL629378,,BAO_0000218,1474.0,
14333,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,U,0,1,,CHEMBL629379,,BAO_0000218,,
14334,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,U,0,1,,CHEMBL629151,,BAO_0000218,2113.0,
14335,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,U,0,1,,CHEMBL629152,,BAO_0000218,2107.0,
14336,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,U,0,1,,CHEMBL629153,,BAO_0000218,2048.0,
14337,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,U,0,1,,CHEMBL629154,,BAO_0000218,2385.0,
14338,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),U,0,1,,CHEMBL629155,,BAO_0000218,2367.0,
14339,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,U,0,1,,CHEMBL629156,,BAO_0000218,2367.0,
14340,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,U,0,1,,CHEMBL629157,,BAO_0000218,2385.0,
14341,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),U,0,1,,CHEMBL629158,,BAO_0000218,2367.0,
14342,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,U,0,1,,CHEMBL629159,,BAO_0000218,,
14343,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,U,0,1,,CHEMBL629160,,BAO_0000218,2385.0,
14344,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,U,0,1,,CHEMBL629161,,BAO_0000218,2106.0,
14345,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,U,0,1,,CHEMBL629162,,BAO_0000218,1255.0,
14346,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,U,0,1,,CHEMBL629163,,BAO_0000218,178.0,
14347,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,U,0,1,,CHEMBL629164,,BAO_0000218,1474.0,
14348,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,U,0,1,,CHEMBL629165,,BAO_0000218,,
14349,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,U,0,1,,CHEMBL629166,,BAO_0000218,2107.0,
14350,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,U,0,1,,CHEMBL629167,,BAO_0000218,2048.0,
14351,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,U,0,1,,CHEMBL629168,,BAO_0000218,2385.0,
14352,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,U,0,1,,CHEMBL629169,,BAO_0000019,,
14353,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,U,0,1,,CHEMBL629170,,BAO_0000019,,
14354,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,U,0,1,,CHEMBL631153,,BAO_0000019,,
14355,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,U,0,1,,CHEMBL875121,,BAO_0000019,,
14356,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,U,0,1,,CHEMBL631154,,BAO_0000019,,
14357,Autocuration,22224,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,U,0,1,,CHEMBL631155,,BAO_0000019,,
14358,Autocuration,22224,,,Hydrolysis rate constant was determined,U,0,1,,CHEMBL631156,,BAO_0000019,,
14359,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",U,0,1,,CHEMBL631157,,BAO_0000019,,
14360,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,0,1,,CHEMBL631158,,BAO_0000019,,
14361,Autocuration,22224,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,0,1,,CHEMBL631159,,BAO_0000019,,
14362,Autocuration,22224,,,Observed second order rate constant,U,0,1,,CHEMBL631160,,BAO_0000019,,
14363,Autocuration,22224,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,0,1,,CHEMBL631161,,BAO_0000019,,
14364,Autocuration,22224,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,0,1,,CHEMBL631162,,BAO_0000019,,
14365,Autocuration,22224,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,0,1,,CHEMBL630313,,BAO_0000019,,
14366,Autocuration,22224,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,0,1,,CHEMBL630314,,BAO_0000019,,
14367,Autocuration,22224,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,0,1,,CHEMBL630315,,BAO_0000019,,
14368,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630316,,BAO_0000019,,
14369,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630986,,BAO_0000019,,
14370,Autocuration,22224,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630987,,BAO_0000019,,
14371,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630988,,BAO_0000019,,
14372,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630989,,BAO_0000019,,
14373,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630990,,BAO_0000019,,
14374,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630991,,BAO_0000019,,
14375,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630992,,BAO_0000019,,
14376,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630993,,BAO_0000019,,
14377,Autocuration,22224,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,0,1,,CHEMBL630994,,BAO_0000019,,
14378,Intermediate,50597,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,N,1,1,,CHEMBL630995,,BAO_0000218,,
14379,Autocuration,22224,,,Association constant for compound at 31 degree C was determined,U,0,1,,CHEMBL629252,,BAO_0000019,,
14380,Autocuration,22224,,,Calculated antagonist equilibrium dissociation constant of the compound,U,0,1,,CHEMBL629253,,BAO_0000019,,
14381,Autocuration,22224,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,U,0,1,,CHEMBL629944,,BAO_0000019,,
14382,Intermediate,50512,Trachea,,Dissociation constants vs LTE4 on guinea pig trachea,N,1,1,,CHEMBL629945,,BAO_0000218,3126.0,
14383,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",U,0,1,,CHEMBL629946,,BAO_0000019,,
14384,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",U,0,1,,CHEMBL629947,,BAO_0000019,,
14385,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",U,0,1,,CHEMBL629948,,BAO_0000019,,
14386,Autocuration,22224,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",U,0,1,,CHEMBL856024,,BAO_0000019,,
14387,Autocuration,22224,,,Affinity constant KD value was derived from TMP,U,0,1,,CHEMBL629949,,BAO_0000019,,
14388,Autocuration,22224,,,Apparent dissociation (binding) rate constant was evaluated,U,0,1,,CHEMBL629950,,BAO_0000019,,
14389,Autocuration,22224,,,Dissociation constant (KD) of the compound,U,0,1,,CHEMBL630127,,BAO_0000100,,
14390,Autocuration,22224,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,U,0,1,,CHEMBL630128,,BAO_0000100,,
14391,Autocuration,22224,,,Dissociation constant from ESR titration experiments,U,0,1,,CHEMBL630129,,BAO_0000100,,
14392,Autocuration,22224,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),U,0,1,,CHEMBL630130,,BAO_0000019,,
14393,Autocuration,22224,,,Dissociation constant was evaluated.,U,0,1,,CHEMBL875234,,BAO_0000100,,
14394,Autocuration,22224,,,Dissociation constant was reported,U,0,1,,CHEMBL630131,,BAO_0000100,,
14395,Intermediate,50597,,,Dissociation constant was determined in rat pituitary cells.,N,1,1,,CHEMBL630132,,BAO_0000218,,
14396,Autocuration,22224,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,U,0,1,,CHEMBL630133,,BAO_0000019,,
14397,Autocuration,22224,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,U,0,1,,CHEMBL630134,,BAO_0000019,,
14398,Autocuration,22224,,,Equilibrium dissociation constant of the compound,U,0,1,,CHEMBL630135,,BAO_0000019,,
14399,Autocuration,22224,,,Equilibrium dissociation constant was determined,U,0,1,,CHEMBL630136,,BAO_0000019,,
14400,Autocuration,22224,,,Kinetic constant KD was evaluated,U,0,1,,CHEMBL630137,,BAO_0000019,,
14401,Autocuration,22224,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,U,0,1,,CHEMBL630138,,BAO_0000019,,
14402,Autocuration,22224,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,U,0,1,,CHEMBL630139,,BAO_0000019,,
14403,Autocuration,22224,,,Rate constant for hydrolysis in aqueous acetone.,U,0,1,,CHEMBL630140,,BAO_0000019,,
14404,Autocuration,22224,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,U,0,1,,CHEMBL875235,,BAO_0000019,,
14405,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,N,1,1,,CHEMBL876439,,BAO_0000218,,
14406,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,N,1,1,,CHEMBL630605,,BAO_0000218,,
14407,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,N,1,1,,CHEMBL630606,,BAO_0000218,,
14408,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,N,1,1,,CHEMBL630607,,BAO_0000218,,
14409,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,N,1,1,,CHEMBL630608,,BAO_0000218,,
14410,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,N,1,1,,CHEMBL630609,,BAO_0000218,,
14411,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,N,1,1,,CHEMBL630610,,BAO_0000218,,
14412,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,N,1,1,,CHEMBL630611,,BAO_0000218,,
14413,Intermediate,50597,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,N,1,1,,CHEMBL629552,,BAO_0000218,,
14414,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,1,1,,CHEMBL629733,,BAO_0000218,,
14415,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,1,1,,CHEMBL629734,,BAO_0000218,,
14416,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,1,1,,CHEMBL629735,,BAO_0000218,,
14417,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,1,1,,CHEMBL629736,,BAO_0000218,,
14418,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,1,1,,CHEMBL629737,,BAO_0000218,,
14419,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,1,1,,CHEMBL629738,,BAO_0000218,,
14420,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,1,1,,CHEMBL629739,,BAO_0000218,,
14421,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,1,1,,CHEMBL629740,,BAO_0000218,,
14422,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,1,1,,CHEMBL629741,,BAO_0000218,,
14423,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,1,1,,CHEMBL629742,,BAO_0000218,,
14424,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,1,1,,CHEMBL629743,,BAO_0000218,,
14425,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,1,1,,CHEMBL629744,,BAO_0000218,,
14426,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,1,1,,CHEMBL629745,,BAO_0000218,,
14427,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,1,1,,CHEMBL629746,,BAO_0000218,,
14428,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,1,1,,CHEMBL629747,,BAO_0000218,,
14429,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,1,1,,CHEMBL629748,,BAO_0000218,,
14430,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,1,1,,CHEMBL629749,,BAO_0000218,,
14431,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,1,1,,CHEMBL629750,,BAO_0000218,,
14432,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,1,1,,CHEMBL629751,,BAO_0000218,,
14433,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,1,1,,CHEMBL629752,,BAO_0000218,,
14434,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,1,1,,CHEMBL629753,,BAO_0000218,,
14435,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,1,1,,CHEMBL629754,,BAO_0000218,,
14436,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,1,1,,CHEMBL629755,,BAO_0000218,,
14437,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,1,1,,CHEMBL629756,,BAO_0000218,,
14438,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,1,1,,CHEMBL629757,,BAO_0000218,,
14439,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,1,1,,CHEMBL629758,,BAO_0000218,,
14440,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,1,1,,CHEMBL629759,,BAO_0000218,,
14441,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,1,1,,CHEMBL629760,,BAO_0000218,,
14442,Intermediate,50597,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,1,1,,CHEMBL876443,,BAO_0000218,,
14443,Intermediate,50588,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,N,1,1,,CHEMBL629761,,BAO_0000218,,
14444,Intermediate,50588,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,N,1,1,,CHEMBL629762,,BAO_0000218,,
14445,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,1,1,,CHEMBL629763,,BAO_0000218,,
14446,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,1,1,,CHEMBL629764,,BAO_0000218,,
14447,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,1,1,,CHEMBL629765,,BAO_0000218,,
14448,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,N,1,1,,CHEMBL629766,,BAO_0000218,,
14449,Intermediate,50594,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,1,1,,CHEMBL629767,,BAO_0000218,,
14450,Intermediate,50588,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,N,1,1,,CHEMBL629768,,BAO_0000218,,
14451,Intermediate,50594,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,N,1,1,,CHEMBL629769,,BAO_0000218,,
14452,Intermediate,50588,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,N,1,1,,CHEMBL629770,,BAO_0000218,,
14453,Intermediate,50588,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,N,1,1,,CHEMBL629771,,BAO_0000218,,
14454,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,1,1,,CHEMBL629772,,BAO_0000218,,
14455,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,1,1,,CHEMBL629773,,BAO_0000218,,
14456,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,1,1,,CHEMBL625455,,BAO_0000218,,
14457,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,N,1,1,,CHEMBL625456,,BAO_0000218,,
14458,Intermediate,50594,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,N,1,1,,CHEMBL625457,,BAO_0000218,,
14459,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,1,1,,CHEMBL625458,,BAO_0000218,1088.0,
14460,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,N,1,1,,CHEMBL625459,,BAO_0000218,1088.0,
14461,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,1,1,,CHEMBL875483,,BAO_0000218,1088.0,
14462,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,N,1,1,,CHEMBL634779,,BAO_0000218,1088.0,
14463,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,N,1,1,,CHEMBL625460,,BAO_0000218,1088.0,
14464,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,1,1,,CHEMBL626117,,BAO_0000218,1088.0,
14465,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,N,1,1,,CHEMBL626118,,BAO_0000218,1088.0,
14466,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,N,1,1,,CHEMBL628342,,BAO_0000218,1088.0,
14467,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,1,1,,CHEMBL628343,,BAO_0000218,1088.0,
14468,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,1,1,,CHEMBL628344,,BAO_0000218,1088.0,
14469,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,1,1,,CHEMBL628345,,BAO_0000218,1088.0,
14470,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,N,1,1,,CHEMBL628346,,BAO_0000218,1088.0,
14471,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,N,1,1,,CHEMBL628347,,BAO_0000218,1088.0,
14472,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL628348,,BAO_0000218,1088.0,
14473,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL628349,,BAO_0000218,1088.0,
14474,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,1,1,,CHEMBL875611,,BAO_0000218,1088.0,
14475,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,N,1,1,,CHEMBL628350,,BAO_0000218,1088.0,
14476,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,1,1,,CHEMBL628351,,BAO_0000218,1088.0,
14477,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,N,1,1,,CHEMBL628352,,BAO_0000218,1088.0,
14478,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,1,1,,CHEMBL628353,,BAO_0000218,1088.0,
14479,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,N,1,1,,CHEMBL628354,,BAO_0000218,1088.0,
14480,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,1,1,,CHEMBL626667,,BAO_0000218,1088.0,
14481,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL626668,,BAO_0000218,1088.0,
14482,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,1,1,,CHEMBL626669,,BAO_0000218,1088.0,
14483,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,N,1,1,,CHEMBL626670,,BAO_0000218,1088.0,
14484,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,N,1,1,,CHEMBL626671,,BAO_0000218,1088.0,
14485,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,1,1,,CHEMBL626672,,BAO_0000218,1088.0,
14486,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,N,1,1,,CHEMBL626673,,BAO_0000218,1088.0,
14487,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,1,1,,CHEMBL626674,,BAO_0000218,1088.0,
14488,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,1,1,,CHEMBL626675,,BAO_0000218,1088.0,
14489,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,N,1,1,,CHEMBL626676,,BAO_0000218,1088.0,
14490,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,N,1,1,,CHEMBL626677,,BAO_0000218,1088.0,
14491,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,1,1,,CHEMBL626678,,BAO_0000218,1088.0,
14492,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,1,1,,CHEMBL626679,,BAO_0000218,1088.0,
14493,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,1,1,,CHEMBL875612,,BAO_0000218,1088.0,
14494,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,1,1,,CHEMBL626680,,BAO_0000218,1088.0,
14495,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,1,1,,CHEMBL626681,,BAO_0000218,1088.0,
14496,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,1,1,,CHEMBL626682,,BAO_0000218,1088.0,
14497,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,1,1,,CHEMBL626683,,BAO_0000218,1088.0,
14498,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,1,1,,CHEMBL626684,,BAO_0000218,1088.0,
14499,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,1,1,,CHEMBL626685,,BAO_0000218,1088.0,
14500,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,1,1,,CHEMBL626686,,BAO_0000218,1088.0,
14501,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,1,1,,CHEMBL626687,,BAO_0000218,1088.0,
14502,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,1,1,,CHEMBL624978,,BAO_0000218,1088.0,
14503,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,1,1,,CHEMBL624979,,BAO_0000218,1088.0,
14504,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,1,1,,CHEMBL624980,,BAO_0000218,1088.0,
14505,Intermediate,50597,Urine,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,1,1,,CHEMBL624981,,BAO_0000218,1088.0,
14506,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,1,1,,CHEMBL624982,,BAO_0000218,1088.0,
14507,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),U,0,1,,CHEMBL627564,,BAO_0000218,2367.0,
14508,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),U,0,1,,CHEMBL627565,,BAO_0000218,2367.0,
14509,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,U,0,1,,CHEMBL627566,,BAO_0000218,,
14510,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,U,0,1,,CHEMBL627567,,BAO_0000218,2385.0,
14511,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,U,0,1,,CHEMBL627568,,BAO_0000218,2106.0,
14512,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,U,0,1,,CHEMBL627569,,BAO_0000218,2113.0,
14513,Autocuration,22224,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,U,0,1,,CHEMBL627570,,BAO_0000218,1255.0,
14514,Autocuration,22224,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,U,0,1,,CHEMBL627571,,BAO_0000218,178.0,
14515,Autocuration,22224,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,U,0,1,,CHEMBL627572,,BAO_0000218,1474.0,
14516,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,U,0,1,,CHEMBL627573,,BAO_0000218,,
14517,Autocuration,22224,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,U,0,1,,CHEMBL627574,,BAO_0000218,2113.0,
14518,Autocuration,22224,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,U,0,1,,CHEMBL627575,,BAO_0000218,2107.0,
14519,Autocuration,22224,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,U,0,1,,CHEMBL627576,,BAO_0000218,2048.0,
14520,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,U,0,1,,CHEMBL627577,,BAO_0000218,2385.0,
14521,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),U,0,1,,CHEMBL627578,,BAO_0000218,2367.0,
14522,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,U,0,1,,CHEMBL627579,,BAO_0000218,2367.0,
14523,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,U,0,1,,CHEMBL627580,,BAO_0000218,2385.0,
14524,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),U,0,1,,CHEMBL627581,,BAO_0000218,2367.0,
14525,Autocuration,22224,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,U,0,1,,CHEMBL627582,,BAO_0000218,,
14526,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,U,0,1,,CHEMBL627583,,BAO_0000218,2385.0,
14527,Autocuration,22224,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,U,0,1,,CHEMBL627584,,BAO_0000218,2106.0,
14528,Autocuration,22224,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,U,0,1,,CHEMBL627585,,BAO_0000218,2367.0,
14529,Autocuration,22224,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,U,0,1,,CHEMBL627586,,BAO_0000218,2385.0,
14530,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,N,1,1,,CHEMBL627587,,BAO_0000218,,
14531,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL627588,,BAO_0000218,,
14532,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,N,1,1,,CHEMBL628250,,BAO_0000218,,
14533,Intermediate,50597,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628251,,BAO_0000218,,
14534,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,N,1,1,,CHEMBL628252,,BAO_0000218,10000000.0,
14535,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628253,,BAO_0000218,10000000.0,
14536,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,N,1,1,,CHEMBL628254,,BAO_0000218,1898.0,
14537,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL877493,,BAO_0000218,1898.0,
14538,Intermediate,50597,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628255,,BAO_0000218,,
14539,Intermediate,50597,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628256,,BAO_0000218,,
14540,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628257,,BAO_0000218,10000000.0,
14541,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628258,,BAO_0000218,1898.0,
14542,Intermediate,50597,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628259,,BAO_0000218,,
14543,Intermediate,50597,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL628429,,BAO_0000218,,
14544,Intermediate,50597,Hippocampus,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,1,1,,CHEMBL626862,,BAO_0000218,10000000.0,
14545,Intermediate,50597,Hypothalamus,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,N,1,1,,CHEMBL626863,,BAO_0000218,1898.0,
14546,Intermediate,50597,Cerebellum,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,N,1,1,,CHEMBL625886,,BAO_0000218,2037.0,
14547,Intermediate,50597,Cerebellum,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,N,1,1,,CHEMBL625887,,BAO_0000218,2037.0,
14548,Intermediate,50597,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,N,1,1,,CHEMBL625888,,BAO_0000218,,
14549,Intermediate,50597,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,N,1,1,,CHEMBL625889,,BAO_0000218,,
14550,Intermediate,50597,Hippocampus,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,N,1,1,,CHEMBL625890,,BAO_0000218,10000000.0,
14551,Intermediate,50597,Hippocampus,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,N,1,1,,CHEMBL625891,,BAO_0000218,10000000.0,
14552,Intermediate,50597,Hypothalamus,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,N,1,1,,CHEMBL625892,,BAO_0000218,1898.0,
14553,Intermediate,50597,Hypothalamus,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,N,1,1,,CHEMBL625893,,BAO_0000218,1898.0,
14554,Intermediate,50597,Cerebellum,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,N,1,1,,CHEMBL625894,,BAO_0000218,2037.0,
14555,Intermediate,50597,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,N,1,1,,CHEMBL625895,,BAO_0000218,,
14556,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,0,1,,CHEMBL625896,,BAO_0000019,,
14557,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",U,0,1,,CHEMBL625897,,BAO_0000019,,
14558,Autocuration,22224,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,0,1,,CHEMBL625898,,BAO_0000019,,
14559,Autocuration,22224,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,0,1,,CHEMBL625899,,BAO_0000019,,
14560,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,0,1,,CHEMBL626124,,BAO_0000019,,
14561,Intermediate,50212,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,N,1,1,,CHEMBL628500,,BAO_0000218,,
14562,Intermediate,50597,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",N,1,1,,CHEMBL857856,,BAO_0000218,,
14563,Intermediate,50597,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",N,1,1,,CHEMBL628501,,BAO_0000218,,
14564,Autocuration,22224,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",U,0,1,,CHEMBL628502,,BAO_0000019,,
14565,Autocuration,22224,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,U,0,1,,CHEMBL628503,,BAO_0000019,,
14566,Autocuration,22224,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,U,0,1,,CHEMBL628504,,BAO_0000019,,
14567,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,0,1,,CHEMBL628505,,BAO_0000019,,
14568,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",U,0,1,,CHEMBL874452,,BAO_0000019,,
14569,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",U,0,1,,CHEMBL628506,,BAO_0000019,,
14570,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,0,1,,CHEMBL628507,,BAO_0000019,,
14571,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",U,0,1,,CHEMBL628508,,BAO_0000019,,
14572,Autocuration,22224,,,Michaelis constant (KM) was evaluated,U,0,1,,CHEMBL628509,,BAO_0000019,,
14573,Autocuration,22224,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,0,1,,CHEMBL628510,,BAO_0000019,,
14574,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,U,0,1,,CHEMBL628511,,BAO_0000019,,
14575,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,U,0,1,,CHEMBL628512,,BAO_0000019,,
14576,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,U,0,1,,CHEMBL628513,,BAO_0000019,,
14577,Autocuration,22224,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,U,0,1,,CHEMBL628514,,BAO_0000019,,
14578,Autocuration,22224,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,U,0,1,,CHEMBL628515,,BAO_0000019,,
14579,Autocuration,22224,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,U,0,1,,CHEMBL628516,,BAO_0000019,,
14580,Autocuration,22224,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,0,1,,CHEMBL628517,,BAO_0000019,,
14581,Autocuration,22224,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,0,1,,CHEMBL628518,,BAO_0000019,,
14582,Autocuration,22224,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,U,0,1,,CHEMBL628519,,BAO_0000019,,
14583,Autocuration,22224,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,U,0,1,,CHEMBL628520,,BAO_0000019,,
14584,Autocuration,22224,,,Binding constant was determined,U,0,1,,CHEMBL628521,,BAO_0000019,,
14585,Autocuration,22224,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,U,0,1,,CHEMBL630443,,BAO_0000019,,
14586,Autocuration,22224,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,U,0,1,,CHEMBL630444,,BAO_0000019,,
14587,Autocuration,22224,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,U,0,1,,CHEMBL857732,,BAO_0000019,,
14588,Autocuration,22224,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,U,0,1,,CHEMBL630445,,BAO_0000100,,
14589,Autocuration,22224,,,Catalytic rate constant of the compound,U,0,1,,CHEMBL630446,,BAO_0000019,,
14590,Autocuration,22224,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,U,0,1,,CHEMBL630447,,BAO_0000019,,
14591,Autocuration,22224,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),U,0,1,,CHEMBL630448,,BAO_0000019,,
14592,Autocuration,22224,,,Catalytic rate constant against phospholipase A2 was determined,U,0,1,,CHEMBL630449,,BAO_0000019,,
14593,Autocuration,22224,,,"Compound was evaluated for catalytic constant, Kcat",U,0,1,,CHEMBL630450,,BAO_0000019,,
14594,Autocuration,22224,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,U,0,1,,CHEMBL630451,,BAO_0000019,,
14595,Autocuration,22224,,,Kcat calculated from 0.693/T1/2,U,0,1,,CHEMBL630452,,BAO_0000019,,
14596,Autocuration,22224,,,Kcat was determined,U,0,1,,CHEMBL630453,,BAO_0000019,,
14597,Autocuration,22224,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,U,0,1,,CHEMBL630454,,BAO_0000019,,
14598,Autocuration,22224,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,U,0,1,,CHEMBL630455,,BAO_0000019,,
14599,Autocuration,22224,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,U,0,1,,CHEMBL631487,,BAO_0000019,,
14600,Autocuration,22224,,,Kcat value was determined,U,0,1,,CHEMBL631488,,BAO_0000019,,
14601,Autocuration,22224,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,U,0,1,,CHEMBL876440,,BAO_0000019,,
14602,Autocuration,22224,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,U,0,1,,CHEMBL631489,,BAO_0000019,,
14603,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,0,1,,CHEMBL857742,,BAO_0000019,,
14604,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,0,1,,CHEMBL631490,,BAO_0000019,,
14605,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",U,0,1,,CHEMBL631491,,BAO_0000019,,
14606,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,0,1,,CHEMBL631492,,BAO_0000019,,
14607,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,0,1,,CHEMBL631493,,BAO_0000019,,
14608,Autocuration,22224,,,Kinetic parameter for rate of conversion to PABA was determined,U,0,1,,CHEMBL631494,,BAO_0000019,,
14609,Autocuration,22224,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,0,1,,CHEMBL631495,,BAO_0000019,,
14610,Intermediate,50597,Feces,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,1,1,,CHEMBL631496,,BAO_0000218,1988.0,
14611,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,1,1,,CHEMBL631497,,BAO_0000218,1088.0,
14612,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,1,1,,CHEMBL631498,,BAO_0000218,1088.0,
14613,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,1,1,,CHEMBL629776,,BAO_0000218,1088.0,
14614,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,1,1,,CHEMBL629777,,BAO_0000218,1088.0,
14615,Intermediate,50597,Urine,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,1,1,,CHEMBL629778,,BAO_0000218,1088.0,
14616,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,N,1,1,,CHEMBL630456,,BAO_0000218,,
14617,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,N,1,1,,CHEMBL630457,,BAO_0000218,,
14618,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,N,1,1,,CHEMBL630458,,BAO_0000218,,
14619,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,N,1,1,,CHEMBL630459,,BAO_0000218,,
14620,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,N,1,1,,CHEMBL630460,,BAO_0000218,,
14621,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,N,1,1,,CHEMBL876550,,BAO_0000218,,
14622,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,N,1,1,,CHEMBL630461,,BAO_0000218,,
14623,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,N,1,1,,CHEMBL630462,,BAO_0000218,,
14624,Intermediate,50597,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,N,1,1,,CHEMBL630463,,BAO_0000218,,
14625,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,N,1,1,,CHEMBL630464,,BAO_0000218,,
14626,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,N,1,1,,CHEMBL630465,,BAO_0000218,,
14627,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,N,1,1,,CHEMBL630466,,BAO_0000218,,
14628,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,N,1,1,,CHEMBL630467,,BAO_0000218,,
14629,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,N,1,1,,CHEMBL630633,,BAO_0000218,,
14630,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,N,1,1,,CHEMBL630634,,BAO_0000218,,
14631,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,N,1,1,,CHEMBL630635,,BAO_0000218,,
14632,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,N,1,1,,CHEMBL630636,,BAO_0000218,,
14633,Intermediate,50597,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,N,1,1,,CHEMBL630637,,BAO_0000218,,
14634,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,1,1,,CHEMBL630638,,BAO_0000218,1988.0,
14635,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,1,1,,CHEMBL630639,,BAO_0000218,1988.0,
14636,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,1,1,,CHEMBL630640,,BAO_0000218,1988.0,
14637,Intermediate,50592,Feces,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,1,1,,CHEMBL876551,,BAO_0000218,1988.0,
14638,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",N,1,1,,CHEMBL630641,,BAO_0000218,1088.0,
14639,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,1,1,,CHEMBL630642,,BAO_0000218,1088.0,
14640,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,1,1,,CHEMBL630643,,BAO_0000218,1088.0,
14641,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,1,1,,CHEMBL630644,,BAO_0000218,1088.0,
14642,Intermediate,50592,Urine,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,1,1,,CHEMBL630645,,BAO_0000218,1088.0,
14643,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,1,1,,CHEMBL625599,,BAO_0000218,1988.0,
14644,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,1,1,,CHEMBL625600,,BAO_0000218,1988.0,
14645,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,1,1,,CHEMBL625601,,BAO_0000218,1988.0,
14646,Intermediate,50592,Feces,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,1,1,,CHEMBL625602,,BAO_0000218,1988.0,
14647,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",N,1,1,,CHEMBL627470,,BAO_0000218,1088.0,
14648,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,1,1,,CHEMBL627471,,BAO_0000218,1088.0,
14649,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,1,1,,CHEMBL627472,,BAO_0000218,1088.0,
14650,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,1,1,,CHEMBL627473,,BAO_0000218,1088.0,
14651,Intermediate,50592,Urine,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,1,1,,CHEMBL627474,,BAO_0000218,1088.0,
14652,Intermediate,50597,Blood,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL627475,,BAO_0000218,178.0,
14653,Intermediate,50597,Blood,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL627476,,BAO_0000218,178.0,
14654,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,1,1,,CHEMBL627477,,BAO_0000218,1088.0,
14655,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,1,1,,CHEMBL627478,,BAO_0000218,1088.0,
14656,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,1,1,,CHEMBL627479,,BAO_0000218,1088.0,
14657,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,1,1,,CHEMBL627480,,BAO_0000218,1088.0,
14658,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,1,1,,CHEMBL627481,,BAO_0000218,1088.0,
14659,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL627482,,BAO_0000218,1088.0,
14660,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,1,1,,CHEMBL627483,,BAO_0000218,1088.0,
14661,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,1,1,,CHEMBL875636,,BAO_0000218,1088.0,
14662,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,1,1,,CHEMBL625764,,BAO_0000218,1088.0,
14663,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL625765,,BAO_0000218,1088.0,
14664,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,N,1,1,,CHEMBL625766,,BAO_0000218,1088.0,
14665,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL625767,,BAO_0000218,1088.0,
14666,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL625768,,BAO_0000218,1088.0,
14667,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL625769,,BAO_0000218,1088.0,
14668,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,1,1,,CHEMBL625770,,BAO_0000218,1088.0,
14669,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,1,1,,CHEMBL625771,,BAO_0000218,1088.0,
14670,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,N,1,1,,CHEMBL625772,,BAO_0000218,1088.0,
14671,Intermediate,50588,Urine,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,1,1,,CHEMBL625773,,BAO_0000218,1088.0,
14672,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,1,1,,CHEMBL625774,,BAO_0000218,1088.0,
14673,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,N,1,1,,CHEMBL625775,,BAO_0000218,1088.0,
14674,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,1,1,,CHEMBL625776,,BAO_0000218,1088.0,
14675,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,1,1,,CHEMBL625777,,BAO_0000218,1088.0,
14676,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,1,1,,CHEMBL625778,,BAO_0000218,1088.0,
14677,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,N,1,1,,CHEMBL625779,,BAO_0000218,1088.0,
14678,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,N,1,1,,CHEMBL625780,,BAO_0000218,1088.0,
14679,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,1,1,,CHEMBL625781,,BAO_0000218,1088.0,
14680,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,N,1,1,,CHEMBL875637,,BAO_0000218,1088.0,
14681,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,1,1,,CHEMBL626473,,BAO_0000218,1088.0,
14682,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,N,1,1,,CHEMBL626474,,BAO_0000218,1088.0,
14683,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,1,1,,CHEMBL626475,,BAO_0000218,1088.0,
14684,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,N,1,1,,CHEMBL626476,,BAO_0000218,1088.0,
14685,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,1,1,,CHEMBL634397,,BAO_0000218,1088.0,
14686,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,N,1,1,,CHEMBL626477,,BAO_0000218,1088.0,
14687,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,1,1,,CHEMBL631069,,BAO_0000218,1088.0,
14688,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,N,1,1,,CHEMBL631070,,BAO_0000218,1088.0,
14689,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,1,1,,CHEMBL631071,,BAO_0000218,1088.0,
14690,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,N,1,1,,CHEMBL631072,,BAO_0000218,1088.0,
14691,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,1,1,,CHEMBL631073,,BAO_0000218,1088.0,
14692,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,N,1,1,,CHEMBL631074,,BAO_0000218,1088.0,
14693,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,N,1,1,,CHEMBL631075,,BAO_0000218,1088.0,
14694,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,1,1,,CHEMBL631725,,BAO_0000218,1088.0,
14695,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,N,1,1,,CHEMBL631726,,BAO_0000218,1088.0,
14696,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,N,1,1,,CHEMBL631727,,BAO_0000218,1088.0,
14697,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,1,1,,CHEMBL631728,,BAO_0000218,1088.0,
14698,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,1,1,,CHEMBL631729,,BAO_0000218,1088.0,
14699,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,N,1,1,,CHEMBL631730,,BAO_0000218,1088.0,
14700,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,N,1,1,,CHEMBL631731,,BAO_0000218,1088.0,
14701,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,1,1,,CHEMBL631910,,BAO_0000218,1088.0,
14702,Intermediate,50597,Hippocampus,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,N,1,1,,CHEMBL631911,,BAO_0000218,10000000.0,
14703,Intermediate,50597,Hypothalamus,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,N,1,1,,CHEMBL631912,,BAO_0000218,1898.0,
14704,Intermediate,50597,Hypothalamus,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,N,1,1,,CHEMBL631913,,BAO_0000218,1898.0,
14705,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631914,,BAO_0000218,178.0,
14706,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631915,,BAO_0000218,178.0,
14707,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL875778,,BAO_0000218,178.0,
14708,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631916,,BAO_0000218,178.0,
14709,Intermediate,50597,Blood,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631917,,BAO_0000218,178.0,
14710,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631918,,BAO_0000218,178.0,
14711,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631919,,BAO_0000218,178.0,
14712,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL631920,,BAO_0000218,178.0,
14713,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631921,,BAO_0000218,178.0,
14714,Intermediate,50597,Blood,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631922,,BAO_0000218,178.0,
14715,Intermediate,50597,Blood,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL631923,,BAO_0000218,178.0,
14716,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631924,,BAO_0000218,,
14717,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630234,,BAO_0000218,,
14718,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630235,,BAO_0000218,,
14719,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630236,,BAO_0000218,,
14720,Intermediate,50597,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630237,,BAO_0000218,,
14721,Intermediate,50597,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630238,,BAO_0000218,,
14722,Intermediate,50597,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630239,,BAO_0000218,,
14723,Intermediate,50597,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630303,,BAO_0000218,,
14724,Intermediate,50597,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630304,,BAO_0000218,,
14725,Intermediate,50597,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630305,,BAO_0000218,,
14726,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630306,,BAO_0000218,2113.0,
14727,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630307,,BAO_0000218,2113.0,
14728,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630308,,BAO_0000218,2113.0,
14729,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630309,,BAO_0000218,2113.0,
14730,Intermediate,50597,Kidney,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL629309,,BAO_0000218,2113.0,
14731,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL629993,,BAO_0000218,2113.0,
14732,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL629994,,BAO_0000218,2113.0,
14733,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL629995,,BAO_0000218,2113.0,
14734,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631993,,BAO_0000218,2113.0,
14735,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631994,,BAO_0000218,2113.0,
14736,Intermediate,50597,Kidney,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631995,,BAO_0000218,2113.0,
14737,Intermediate,50597,Liver,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL631996,,BAO_0000218,2107.0,
14738,Intermediate,50597,Liver,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631997,,BAO_0000218,2107.0,
14739,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631998,,BAO_0000218,2107.0,
14740,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631999,,BAO_0000218,2107.0,
14741,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL632000,,BAO_0000218,2107.0,
14742,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL632001,,BAO_0000218,2107.0,
14743,Intermediate,50597,Liver,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL874424,,BAO_0000218,2107.0,
14744,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL632002,,BAO_0000218,2107.0,
14745,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL632003,,BAO_0000218,2107.0,
14746,Autocuration,22224,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,0,1,,CHEMBL632004,,BAO_0000019,,
14747,Autocuration,22224,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,U,0,1,,CHEMBL632005,,BAO_0000019,,
14748,Autocuration,22224,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,U,0,1,,CHEMBL632006,,BAO_0000019,,
14749,Autocuration,22224,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,U,0,1,,CHEMBL632007,,BAO_0000019,,
14750,Autocuration,22224,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,U,0,1,,CHEMBL632008,,BAO_0000019,,
14751,Autocuration,22224,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,U,0,1,,CHEMBL632009,,BAO_0000019,,
14752,Autocuration,22224,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,U,0,1,,CHEMBL632010,,BAO_0000019,,
14753,Autocuration,22224,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,U,0,1,,CHEMBL857750,,BAO_0000019,,
14754,Autocuration,22224,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,U,0,1,,CHEMBL632011,,BAO_0000019,,
14755,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,0,1,,CHEMBL632012,,BAO_0000019,,
14756,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,0,1,,CHEMBL632013,,BAO_0000019,,
14757,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",U,0,1,,CHEMBL632014,,BAO_0000019,,
14758,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,0,1,,CHEMBL629622,,BAO_0000019,,
14759,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,0,1,,CHEMBL629623,,BAO_0000019,,
14760,Autocuration,22224,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",U,0,1,,CHEMBL629624,,BAO_0000019,,
14761,Autocuration,22224,,,Ratio of Kcat to that of Km was determined,U,0,1,,CHEMBL629625,,BAO_0000019,,
14762,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,0,1,,CHEMBL629626,,BAO_0000019,,
14763,Autocuration,22224,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,0,1,,CHEMBL629627,,BAO_0000019,,
14764,Autocuration,22224,,,"Compound was evaluated for constant, Kd",U,0,1,,CHEMBL629628,,BAO_0000019,,
14765,Autocuration,22224,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,U,0,1,,CHEMBL629629,,BAO_0000019,,
14766,Autocuration,22224,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,U,0,1,,CHEMBL629630,,BAO_0000019,,
14767,Autocuration,22224,,,Dissociation Constant of compound determined,U,0,1,,CHEMBL856030,,BAO_0000019,,
14768,Autocuration,22224,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,U,0,1,,CHEMBL629631,,BAO_0000019,,
14769,Autocuration,22224,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,U,0,1,,CHEMBL629632,,BAO_0000019,,
14770,Autocuration,22224,,,Dissociation constant of compound with Fructose was determined,U,0,1,,CHEMBL629633,,BAO_0000100,,
14771,Autocuration,22224,,,Dissociation constant of compound with Fructose was determined; Not determined,U,0,1,,CHEMBL629634,,BAO_0000100,,
14772,Autocuration,22224,,,Dissociation constant of compound with Lactulose was determined,U,0,1,,CHEMBL629635,,BAO_0000100,,
14773,Autocuration,22224,,,Dissociation constant of compound with Lactulose was determined; Not determined,U,0,1,,CHEMBL629636,,BAO_0000100,,
14774,Autocuration,22224,,,Dissociation constant of the Compound,U,0,1,,CHEMBL629637,,BAO_0000100,,
14775,Autocuration,22224,,,Dissociation constant by non-linear regression analysis,U,0,1,,CHEMBL629638,,BAO_0000100,,
14776,Autocuration,22224,,,Dissociation constant was determined,U,0,1,,CHEMBL629639,,BAO_0000100,,
14777,Autocuration,22224,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,U,0,1,,CHEMBL629640,,BAO_0000100,,
14778,Autocuration,22224,,,Dissociation constant was determined,U,0,1,,CHEMBL629641,,BAO_0000100,,
14779,Autocuration,22224,,,Dissociation constant was determined,U,0,1,,CHEMBL631344,,BAO_0000100,,
14780,Intermediate,50597,Muscle tissue,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,N,1,1,,CHEMBL631345,,BAO_0000218,2385.0,
14781,Autocuration,22224,,,The dissociation constant determined by fluorescence displacement assay,U,0,1,,CHEMBL631346,,BAO_0000019,,
14782,Autocuration,22224,,,kd value surface plasmon resonance (SPR) method,U,0,1,,CHEMBL631524,,BAO_0000019,,
14783,Intermediate,50597,Muscle tissue,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,N,1,1,,CHEMBL631525,,BAO_0000218,2385.0,
14784,Autocuration,22224,,,First dissociation constant of the binding of compound to V30M TTR,U,0,1,,CHEMBL631526,,BAO_0000019,,
14785,Autocuration,22224,,,Second dissociation constant of the binding of compound to V30M TTR,U,0,1,,CHEMBL631527,,BAO_0000019,,
14786,Autocuration,22224,,,"Compound was evaluated for equilibrium constant, Ke",U,0,1,,CHEMBL631528,,BAO_0000019,,
14787,Autocuration,22224,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,U,0,1,,CHEMBL631529,,BAO_0000019,1898.0,
14788,Autocuration,22224,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,U,0,1,,CHEMBL631530,,BAO_0000019,1898.0,
14789,Autocuration,22224,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,U,0,1,,CHEMBL631531,,BAO_0000019,,
14790,Autocuration,22224,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,0,1,,CHEMBL631532,,BAO_0000019,,
14791,Autocuration,22224,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,U,0,1,,CHEMBL631533,,BAO_0000019,,
14792,Intermediate,50594,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,1,1,,CHEMBL876552,,BAO_0000218,,
14793,Intermediate,50594,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,1,1,,CHEMBL631534,,BAO_0000218,,
14794,Intermediate,50594,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,1,1,,CHEMBL631535,,BAO_0000218,,
14795,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,1,1,,CHEMBL631536,,BAO_0000218,,
14796,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,N,1,1,,CHEMBL631537,,BAO_0000218,,
14797,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,1,1,,CHEMBL631538,,BAO_0000218,,
14798,Intermediate,50594,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,N,1,1,,CHEMBL631539,,BAO_0000218,,
14799,Intermediate,50594,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,1,1,,CHEMBL631540,,BAO_0000218,,
14800,Intermediate,50597,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL625637,,BAO_0000218,,
14801,Intermediate,50597,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,1,1,,CHEMBL625638,,BAO_0000218,,
14802,Intermediate,50597,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,1,1,,CHEMBL625639,,BAO_0000218,,
14803,Intermediate,50597,Brain,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625640,,BAO_0000218,955.0,
14804,Intermediate,50597,Brain,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625641,,BAO_0000218,955.0,
14805,Intermediate,50597,Heart,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625642,,BAO_0000218,948.0,
14806,Intermediate,50597,Heart,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625643,,BAO_0000218,948.0,
14807,Intermediate,50597,Kidney,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625644,,BAO_0000218,2113.0,
14808,Intermediate,50597,Kidney,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625645,,BAO_0000218,2113.0,
14809,Intermediate,50597,Liver,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625646,,BAO_0000218,2107.0,
14810,Intermediate,50597,Liver,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625647,,BAO_0000218,2107.0,
14811,Intermediate,50597,Lung,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625648,,BAO_0000218,2048.0,
14812,Intermediate,50597,Lung,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625649,,BAO_0000218,2048.0,
14813,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625650,,BAO_0000218,2385.0,
14814,Intermediate,50597,Muscle tissue,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625651,,BAO_0000218,2385.0,
14815,Intermediate,50597,Zone of skin,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625652,,BAO_0000218,14.0,
14816,Intermediate,50597,Zone of skin,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625653,,BAO_0000218,14.0,
14817,Intermediate,50597,Spleen,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625654,,BAO_0000218,2106.0,
14818,Intermediate,50597,Spleen,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,1,1,,CHEMBL625655,,BAO_0000218,2106.0,
14819,Intermediate,50597,Blood,,Biodistribution of Compound in rat blood after 15 minutes of administration,N,1,1,,CHEMBL625656,,BAO_0000218,178.0,
14820,Intermediate,50597,Blood,,Biodistribution of Compound in rat blood after 2 minutes of administration,N,1,1,,CHEMBL625657,,BAO_0000218,178.0,
14821,Intermediate,50597,Brain,,Biodistribution of Compound in rat brain after 15 minutes of administration,N,1,1,,CHEMBL625658,,BAO_0000218,955.0,
14822,Intermediate,50597,Brain,,Biodistribution of Compound in rat brain after 2 minutes of administration,N,1,1,,CHEMBL625659,,BAO_0000218,955.0,
14823,Intermediate,50597,Heart,,Biodistribution of Compound in rat heart after 15 minutes of administration,N,1,1,,CHEMBL625660,,BAO_0000218,948.0,
14824,Intermediate,50597,Heart,,Biodistribution of Compound in rat heart after 2 minutes of administration,N,1,1,,CHEMBL625661,,BAO_0000218,948.0,
14825,Intermediate,50597,Liver,,Biodistribution of Compound in rat liver after 15 minutes of administration,N,1,1,,CHEMBL625662,,BAO_0000218,2107.0,
14826,Intermediate,50597,Liver,,Biodistribution of Compound in rat liver after 2 minutes of administration,N,1,1,,CHEMBL625663,,BAO_0000218,2107.0,
14827,Intermediate,50597,Lung,,Biodistribution of Compound in rat lung after 15 minutes of administration,N,1,1,,CHEMBL875621,,BAO_0000218,2048.0,
14828,Intermediate,50597,Lung,,Biodistribution of Compound in rat lung after 2 minutes of administration,N,1,1,,CHEMBL628382,,BAO_0000218,2048.0,
14829,Intermediate,50597,Muscle tissue,,Biodistribution of Compound in rat muscle after 15 minutes of administration,N,1,1,,CHEMBL628383,,BAO_0000218,2385.0,
14830,Intermediate,50597,Muscle tissue,,Biodistribution of Compound in rat muscle after 2 minutes of administration,N,1,1,,CHEMBL628384,,BAO_0000218,2385.0,
14831,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,N,1,1,,CHEMBL628385,,BAO_0000218,,
14832,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,N,1,1,,CHEMBL875753,,BAO_0000218,,
14833,Intermediate,50597,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,N,1,1,,CHEMBL628386,,BAO_0000218,,
14834,Intermediate,50597,,,Organ distribution in rat blood 2 minutes after intravenous injection,N,1,1,,CHEMBL628387,,BAO_0000218,,
14835,Intermediate,50597,,,Organ distribution in rat blood 2 hr after intravenous injection,N,1,1,,CHEMBL628388,,BAO_0000218,,
14836,Intermediate,50597,,,Organ distribution in rat blood 30 minutes after intravenous injection,N,1,1,,CHEMBL628389,,BAO_0000218,,
14837,Intermediate,50597,,,Organ distribution in rat blood 30 min after intravenous injection,N,1,1,,CHEMBL632756,,BAO_0000218,,
14838,Intermediate,50597,,,Organ distribution in rat brain 2 minutes after intravenous injection,N,1,1,,CHEMBL628390,,BAO_0000218,,
14839,Intermediate,50597,,,Organ distribution in rat brain 2 hr after intravenous injection,N,1,1,,CHEMBL631811,,BAO_0000218,,
14840,Intermediate,50597,,,Organ distribution in rat brain 30 minutes after intravenous injection,N,1,1,,CHEMBL631812,,BAO_0000218,,
14841,Intermediate,50597,,,Organ distribution in rat heart 2 minutes after intravenous injection,N,1,1,,CHEMBL631813,,BAO_0000218,,
14842,Intermediate,50597,,,Organ distribution in rat heart 2 hr after intravenous injection,N,1,1,,CHEMBL631814,,BAO_0000218,,
14843,Intermediate,50597,,,Organ distribution in rat heart 30 minutes after intravenous injection,N,1,1,,CHEMBL631815,,BAO_0000218,,
14844,Intermediate,50597,,,Organ distribution in rat kidney 2 minutes after intravenous injection,N,1,1,,CHEMBL631816,,BAO_0000218,,
14845,Intermediate,50597,,,Organ distribution in rat kidney 2 hr after intravenous injection,N,1,1,,CHEMBL875758,,BAO_0000218,,
14846,Intermediate,50597,,,Organ distribution in rat kidney 30 minutes after intravenous injection,N,1,1,,CHEMBL631817,,BAO_0000218,,
14847,Intermediate,50597,Liver,,Organ distribution in rat liver 2 minutes after intravenous injection,N,1,1,,CHEMBL631818,,BAO_0000218,2107.0,
14848,Intermediate,50597,Liver,,Organ distribution in rat liver 2 hr after intravenous injection,N,1,1,,CHEMBL631819,,BAO_0000218,2107.0,
14849,Intermediate,50597,Liver,,Organ distribution in rat liver 30 minutes after intravenous injection,N,1,1,,CHEMBL631820,,BAO_0000218,2107.0,
14850,Intermediate,50597,,,Organ distribution in rat lung 2 minutes after intravenous injection,N,1,1,,CHEMBL631821,,BAO_0000218,,
14851,Intermediate,50597,,,Organ distribution in rat lung 2 hr after intravenous injection,N,1,1,,CHEMBL631822,,BAO_0000218,,
14852,Intermediate,50597,,,Organ distribution in rat lung 30 minutes after intravenous injection,N,1,1,,CHEMBL631823,,BAO_0000218,,
14853,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 2 minutes after intravenous injection,N,1,1,,CHEMBL631824,,BAO_0000218,2385.0,
14854,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 2 hr after intravenous injection,N,1,1,,CHEMBL631825,,BAO_0000218,2385.0,
14855,Intermediate,50597,Muscle tissue,,Organ distribution in rat muscle 30 minutes after intravenous injection,N,1,1,,CHEMBL631826,,BAO_0000218,2385.0,
14856,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),N,1,1,,CHEMBL631827,,BAO_0000218,,
14857,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),N,1,1,,CHEMBL631828,,BAO_0000218,,
14858,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),N,1,1,,CHEMBL631829,,BAO_0000218,,
14859,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,1,1,,CHEMBL875759,,BAO_0000218,1088.0,
14860,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,N,1,1,,CHEMBL631830,,BAO_0000218,1088.0,
14861,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,N,1,1,,CHEMBL631831,,BAO_0000218,1088.0,
14862,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,1,1,,CHEMBL631832,,BAO_0000218,1088.0,
14863,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,N,1,1,,CHEMBL631833,,BAO_0000218,1088.0,
14864,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,1,1,,CHEMBL631834,,BAO_0000218,1088.0,
14865,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,N,1,1,,CHEMBL631835,,BAO_0000218,1088.0,
14866,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,1,1,,CHEMBL631836,,BAO_0000218,1088.0,
14867,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,1,1,,CHEMBL631837,,BAO_0000218,1088.0,
14868,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,1,1,,CHEMBL631838,,BAO_0000218,1088.0,
14869,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,N,1,1,,CHEMBL631839,,BAO_0000218,1088.0,
14870,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,N,1,1,,CHEMBL631840,,BAO_0000218,1088.0,
14871,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,1,1,,CHEMBL631841,,BAO_0000218,1088.0,
14872,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,1,1,,CHEMBL631842,,BAO_0000218,1088.0,
14873,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,1,1,,CHEMBL631843,,BAO_0000218,1088.0,
14874,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,1,1,,CHEMBL631844,,BAO_0000218,1088.0,
14875,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,1,1,,CHEMBL631845,,BAO_0000218,1088.0,
14876,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,1,1,,CHEMBL631846,,BAO_0000218,1088.0,
14877,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,1,1,,CHEMBL875760,,BAO_0000218,1088.0,
14878,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,1,1,,CHEMBL632199,,BAO_0000218,1088.0,
14879,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,1,1,,CHEMBL631847,,BAO_0000218,1088.0,
14880,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,1,1,,CHEMBL631848,,BAO_0000218,1088.0,
14881,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,1,1,,CHEMBL628707,,BAO_0000218,1088.0,
14882,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,1,1,,CHEMBL628708,,BAO_0000218,1088.0,
14883,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,1,1,,CHEMBL628709,,BAO_0000218,1088.0,
14884,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,1,1,,CHEMBL628710,,BAO_0000218,1088.0,
14885,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,1,1,,CHEMBL628711,,BAO_0000218,1088.0,
14886,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,1,1,,CHEMBL628712,,BAO_0000218,1088.0,
14887,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,1,1,,CHEMBL628713,,BAO_0000218,1088.0,
14888,Intermediate,50597,Urine,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,1,1,,CHEMBL628714,,BAO_0000218,1088.0,
14889,Intermediate,50597,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",N,1,1,,CHEMBL628715,,BAO_0000218,,
14890,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,U,0,1,,CHEMBL629179,,BAO_0000019,,
14891,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,U,0,1,,CHEMBL629180,,BAO_0000019,,
14892,Autocuration,22224,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,U,0,1,,CHEMBL875108,,BAO_0000019,,
14893,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629181,,BAO_0000019,1235.0,
14894,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629182,,BAO_0000019,1235.0,
14895,Autocuration,22224,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,U,0,1,,CHEMBL629183,,BAO_0000019,,
14896,Autocuration,22224,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629184,,BAO_0000019,,
14897,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,0,1,,CHEMBL629185,,BAO_0000019,1235.0,
14898,Autocuration,22224,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629186,,BAO_0000019,1235.0,
14899,Autocuration,22224,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,U,0,1,,CHEMBL629187,,BAO_0000019,,
14900,Autocuration,22224,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,U,0,1,,CHEMBL629887,,BAO_0000019,,
14901,Autocuration,22224,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,U,0,1,,CHEMBL629888,,BAO_0000019,,
14902,Autocuration,22224,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629889,,BAO_0000019,,
14903,Autocuration,22224,Adrenal cortex,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,U,0,1,,CHEMBL629890,,BAO_0000019,1235.0,
14904,Autocuration,22224,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629891,,BAO_0000019,,
14905,Autocuration,22224,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,U,0,1,,CHEMBL629892,,BAO_0000019,,
14906,Autocuration,22224,Adrenal cortex,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,0,1,,CHEMBL629893,,BAO_0000019,1235.0,
14907,Autocuration,22224,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,U,0,1,,CHEMBL629894,,BAO_0000019,,
14908,Autocuration,22224,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,U,0,1,,CHEMBL629895,,BAO_0000019,,
14909,Autocuration,22224,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",U,0,1,,CHEMBL875109,,BAO_0000218,,
14910,Autocuration,22224,,,Absolute bioavailability in male cynomolgus monkeys,U,0,1,,CHEMBL629896,,BAO_0000218,,
14911,Autocuration,22224,,,Absolute bioavailability in maleSprague-Dawley rats,U,0,1,,CHEMBL629897,,BAO_0000218,,
14912,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL629898,,BAO_0000218,2107.0,
14913,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630057,,BAO_0000218,2107.0,
14914,Intermediate,50597,Liver,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630058,,BAO_0000218,2107.0,
14915,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630059,,BAO_0000218,2048.0,
14916,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630060,,BAO_0000218,2048.0,
14917,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630061,,BAO_0000218,2048.0,
14918,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630062,,BAO_0000218,2048.0,
14919,Intermediate,50597,Lung,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630063,,BAO_0000218,2048.0,
14920,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630064,,BAO_0000218,2048.0,
14921,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630065,,BAO_0000218,2048.0,
14922,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630066,,BAO_0000218,2048.0,
14923,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630067,,BAO_0000218,2048.0,
14924,Intermediate,50597,Lung,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630068,,BAO_0000218,2048.0,
14925,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631113,,BAO_0000218,2385.0,
14926,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631114,,BAO_0000218,2385.0,
14927,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL631115,,BAO_0000218,2385.0,
14928,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL631116,,BAO_0000218,2385.0,
14929,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630528,,BAO_0000218,2385.0,
14930,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630529,,BAO_0000218,2385.0,
14931,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630530,,BAO_0000218,2385.0,
14932,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630531,,BAO_0000218,2385.0,
14933,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630532,,BAO_0000218,2385.0,
14934,Intermediate,50597,Muscle tissue,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630533,,BAO_0000218,2385.0,
14935,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 120 hr,N,1,1,,CHEMBL630534,,BAO_0000218,178.0,
14936,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 24 hr,N,1,1,,CHEMBL630535,,BAO_0000218,178.0,
14937,Intermediate,50594,Blood,,Biodistribution in normal mice blood after 4 hr,N,1,1,,CHEMBL630536,,BAO_0000218,178.0,
14938,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 120 hr,N,1,1,,CHEMBL630537,,BAO_0000218,10000001.0,
14939,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 24 hr,N,1,1,,CHEMBL630538,,BAO_0000218,10000001.0,
14940,Intermediate,50594,Bone,,Biodistribution in normal mice bone after 4 hr,N,1,1,,CHEMBL630539,,BAO_0000218,10000001.0,
14941,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 120 hr,N,1,1,,CHEMBL630540,,BAO_0000218,948.0,
14942,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 24 hr,N,1,1,,CHEMBL630541,,BAO_0000218,948.0,
14943,Intermediate,50594,Heart,,Biodistribution in normal mice heart after 4 hr,N,1,1,,CHEMBL630542,,BAO_0000218,948.0,
14944,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 120 hr,N,1,1,,CHEMBL630543,,BAO_0000218,2113.0,
14945,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 24 hr,N,1,1,,CHEMBL630544,,BAO_0000218,2113.0,
14946,Intermediate,50594,Kidney,,Biodistribution in normal mice kidney after 4 hr,N,1,1,,CHEMBL630545,,BAO_0000218,2113.0,
14947,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 120 hr,N,1,1,,CHEMBL630546,,BAO_0000218,2107.0,
14948,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 24 hr,N,1,1,,CHEMBL630547,,BAO_0000218,2107.0,
14949,Intermediate,50594,Liver,,Biodistribution in normal mice liver after 4 hr,N,1,1,,CHEMBL630548,,BAO_0000218,2107.0,
14950,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 120 hr,N,1,1,,CHEMBL630549,,BAO_0000218,2106.0,
14951,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 24 hr,N,1,1,,CHEMBL630550,,BAO_0000218,2106.0,
14952,Intermediate,50594,Spleen,,Biodistribution in normal mice spleen after 4 hr,N,1,1,,CHEMBL876426,,BAO_0000218,2106.0,
14953,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630551,,BAO_0000218,2106.0,
14954,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630552,,BAO_0000218,2106.0,
14955,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630553,,BAO_0000218,2106.0,
14956,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630554,,BAO_0000218,2106.0,
14957,Intermediate,50597,Spleen,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630555,,BAO_0000218,2106.0,
14958,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630556,,BAO_0000218,2106.0,
14959,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630557,,BAO_0000218,2106.0,
14960,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,1,1,,CHEMBL630558,,BAO_0000218,2106.0,
14961,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630559,,BAO_0000218,2106.0,
14962,Intermediate,50597,Spleen,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL630560,,BAO_0000218,2106.0,
14963,Intermediate,50597,Thyroid gland,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,1,1,,CHEMBL876427,,BAO_0000218,2046.0,
14964,Intermediate,50597,,,The Kel values in female wistar rats.,N,1,1,,CHEMBL630561,,BAO_0000218,,
14965,Autocuration,22224,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,U,0,1,,CHEMBL630562,,BAO_0000019,,
14966,Autocuration,22224,,,Hydrolysis rate constant of the compound,U,0,1,,CHEMBL630563,,BAO_0000019,,
14967,Autocuration,22229,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,U,0,1,,CHEMBL629673,,BAO_0000100,,
14968,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",U,0,1,,CHEMBL629674,,BAO_0000019,,
14969,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",U,0,1,,CHEMBL629675,,BAO_0000019,,
14970,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",U,0,1,,CHEMBL629676,,BAO_0000019,,
14971,Autocuration,22224,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",U,0,1,,CHEMBL629677,,BAO_0000019,,
14972,Autocuration,22224,,,Apparent inactivation rate constant was evaluated,U,0,1,,CHEMBL629678,,BAO_0000019,,
14973,Autocuration,22224,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,U,0,1,,CHEMBL629679,,BAO_0000019,,
14974,Autocuration,22224,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,U,0,1,,CHEMBL629680,,BAO_0000019,,
14975,Autocuration,22224,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,U,0,1,,CHEMBL629681,,BAO_0000019,,
14976,Autocuration,22224,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,U,0,1,,CHEMBL629682,,BAO_0000019,,
14977,Autocuration,22224,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,U,0,1,,CHEMBL629683,,BAO_0000019,,
14978,Autocuration,22224,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,U,0,1,,CHEMBL629684,,BAO_0000019,,
14979,Autocuration,22224,,,Dissociation constant was determined,U,0,1,,CHEMBL629685,,BAO_0000100,,
14980,Autocuration,22224,,,Dissociation constant was determined,U,0,1,,CHEMBL629686,,BAO_0000100,,
14981,Autocuration,22224,,,Dissociation constant at pH 7.4,U,0,1,,CHEMBL872932,,BAO_0000100,,
14982,Autocuration,22224,,,Dissociation constant in presence of 1 mM dithiothreitol,U,0,1,,CHEMBL629687,,BAO_0000100,,
14983,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,0,1,,CHEMBL872931,,BAO_0000019,,
14984,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,0,1,,CHEMBL628151,,BAO_0000019,,
14985,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,0,1,,CHEMBL628152,,BAO_0000019,,
14986,Autocuration,22224,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,0,1,,CHEMBL628153,,BAO_0000019,,
14987,Autocuration,22224,,,Kinetic constant for aromatization of androstenedione,U,0,1,,CHEMBL628154,,BAO_0000019,,
14988,Autocuration,22224,,,Kinetic constant for aromatization of testosterone,U,0,1,,CHEMBL628155,,BAO_0000019,,
14989,Autocuration,22224,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,U,0,1,,CHEMBL628156,,BAO_0000019,,
14990,Autocuration,22224,,,Local inhibition constant was determined,U,0,1,,CHEMBL628157,,BAO_0000019,,
14991,Intermediate,50347,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,N,1,1,,CHEMBL857533,,BAO_0000218,,
14992,Autocuration,22224,,,Dissociation constant value of the compound,U,0,1,,CHEMBL628158,,BAO_0000100,,
14993,Autocuration,22224,Cornea,,In vitro permeability through cornea without epithelium,U,0,1,,CHEMBL628159,,BAO_0000019,964.0,
14994,Autocuration,22224,Cornea,,In vitro permeability through intact cornea,U,0,1,,CHEMBL875616,,BAO_0000019,964.0,
14995,Intermediate,50592,Cornea,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,N,1,1,,CHEMBL628160,,BAO_0000218,964.0,
14996,Autocuration,22224,,,Rate of enzyme inactivation for the compound was determined,U,0,1,,CHEMBL628161,,BAO_0000019,,
14997,Autocuration,22224,Cornea,,In vitro permeability through cornea without epithelium,U,0,1,,CHEMBL628162,,BAO_0000019,964.0,
14998,Autocuration,22224,Cornea,,In vitro permeability through intact cornea,U,0,1,,CHEMBL628163,,BAO_0000019,964.0,
14999,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628164,,BAO_0000019,,
15000,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628165,,BAO_0000019,,
15001,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628166,,BAO_0000019,,
15002,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628167,,BAO_0000019,,
15003,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628168,,BAO_0000019,,
15004,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628169,,BAO_0000019,,
15005,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628170,,BAO_0000019,,
15006,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628171,,BAO_0000019,,
15007,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL627434,,BAO_0000019,,
15008,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL627435,,BAO_0000019,,
15009,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628110,,BAO_0000019,,
15010,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628111,,BAO_0000019,,
15011,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628112,,BAO_0000019,,
15012,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628260,,BAO_0000019,,
15013,Autocuration,22224,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,0,1,,CHEMBL628261,,BAO_0000019,,
15014,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),N,1,1,,CHEMBL628262,,BAO_0000218,,
15015,Intermediate,50587,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,N,1,1,,CHEMBL628263,,BAO_0000218,,
15016,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),N,1,1,,CHEMBL628264,,BAO_0000218,,
15017,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),N,1,1,,CHEMBL628265,,BAO_0000218,,
15018,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),N,1,1,,CHEMBL628266,,BAO_0000218,,
15019,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),N,1,1,,CHEMBL628267,,BAO_0000218,,
15020,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,N,1,1,,CHEMBL628268,,BAO_0000218,,
15021,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),N,1,1,,CHEMBL628269,,BAO_0000218,,
15022,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),N,1,1,,CHEMBL628270,,BAO_0000218,,
15023,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),N,1,1,,CHEMBL628271,,BAO_0000218,,
15024,Intermediate,50594,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),N,1,1,,CHEMBL628272,,BAO_0000218,,
